PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kim, M; Chen, B; Hussey, RE; Chishti, Y; Montefiori, D; Hoxie, JA; Byron, O; Campbell, G; Harrison, SC; Reinherz, EL				Kim, M; Chen, B; Hussey, RE; Chishti, Y; Montefiori, D; Hoxie, JA; Byron, O; Campbell, G; Harrison, SC; Reinherz, EL			The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; SOLUBLE CD4; SYNERGISTIC NEUTRALIZATION; ATOMIC-STRUCTURE; HTLV-III/LAV; HIV-1 GP41; RECEPTOR-BINDING; CD4-BINDING SITE; GP120 MOLECULES	Human and simian immunodeficiency viruses infect host lymphoid cells by binding CD4 molecules via their gp160 envelope glycoproteins. Biochemical studies on recombinant SIVmac32H (pJ5) envelope ectodomain gp140 precursor protein show that the envelope is a trimer. Using size exclusion chromatography, quantitative amino acid analysis, analytical ultracentrifugation, and CD4-based competition assay, we demonstrate that the stoichiometry of CD4 receptor-oligomeric envelope interaction is 1:1. By contrast, Fab fragments of both neutralizing and non-neutralizing monoclonal antibodies bind at a 3:1 ratio. Thus, despite displaying equivalent CD4 binding sites on each of the three gp140 protomers within an uncleaved trimer, only one site binds the soluble 4-domain human CD4 extracellular segment. The anti-cooperativity and the faster k(off) of gp140 trimer:CD4 versus gp120 monomer:CD4 interaction suggest that CD4-induced conformational change is impeded in the intact envelope. The implications of these findings for immunity against human immunodeficiency virus and simian immunodeficiency virus are discussed.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Mol Med Lab, Boston, MA 02115 USA; Duke Univ, Sch Med, Dept Surg, Durham, NC 27710 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Duke University; University of Pennsylvania; University of Glasgow	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu		Byron, Olwyn/0000-0001-7857-4520	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI143649, P01AI043649, N01AI085343] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43649, AI85343] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; Burton DR, 2000, VIROLOGY, V270, P1, DOI 10.1006/viro.2000.0239; Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen B, 2000, J BIOL CHEM, V275, P34946, DOI 10.1074/jbc.M004905200; CHOI WS, 1994, J VIROL, V68, P5395, DOI 10.1128/JVI.68.9.5395-5402.1994; COHN EJ, 1943, AM CHEM SOC MONOGRAP; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1988, ANNU REV MICROBIOL, V42, P607, DOI 10.1146/annurev.mi.42.100188.003135; DSOUZA MP, 1993, AIDS RES HUM RETROV, V9, P415, DOI 10.1089/aid.1993.9.415; EARL PL, 1992, J VIROL, V66, P5610, DOI 10.1128/JVI.66.9.5610-5614.1992; Earl PL, 2001, J VIROL, V75, P645, DOI 10.1128/JVI.75.2.645-653.2001; Edinger AL, 2000, J VIROL, V74, P7922, DOI 10.1128/JVI.74.17.7922-7935.2000; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fouts TR, 1998, AIDS RES HUM RETROV, V14, P591, DOI 10.1089/aid.1998.14.591; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; JAVAHERIAN K, 1994, J VIROL, V68, P2624, DOI 10.1128/JVI.68.4.2624-2631.1994; JONES DH, 1994, VACCINE, V12, P250, DOI 10.1016/0264-410X(94)90202-X; KENT KA, 1992, AIDS RES HUM RETROV, V8, P1147, DOI 10.1089/aid.1992.8.1147; KENT KA, 1991, AIDS, V5, P829, DOI 10.1097/00002030-199107000-00006; KIM H, 1977, CHEM REV, V77, P659, DOI 10.1021/cr60309a002; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LAAL S, 1994, J VIROL, V68, P4001, DOI 10.1128/JVI.68.6.4001-4008.1994; Langlois AJ, 1998, J VIROL, V72, P6950, DOI 10.1128/JVI.72.8.6950-6955.1998; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MULLIGAN MJ, 1992, VIROLOGY, V187, P233, DOI 10.1016/0042-6822(92)90311-C; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Nyambi PN, 1998, J VIROL, V72, P9384, DOI 10.1128/JVI.72.11.9384-9391.1998; Parren PWHI, 1998, J VIROL, V72, P3512, DOI 10.1128/JVI.72.5.3512-3519.1998; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POLZIEN F, 1992, AIDS RES HUM RETROV, V8, P1171, DOI 10.1089/aid.1992.8.1171; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; Stamatatos L, 1997, VIROLOGY, V229, P360, DOI 10.1006/viro.1997.8443; Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; TILLEY SA, 1992, AIDS RES HUM RETROV, V8, P461, DOI 10.1089/aid.1992.8.461; VANCOTT TC, 1994, J IMMUNOL, V153, P449; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VijhWarrier S, 1996, J VIROL, V70, P4466, DOI 10.1128/JVI.70.7.4466-4473.1996; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000	70	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42667	42676		10.1074/jbc.M104166200	http://dx.doi.org/10.1074/jbc.M104166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544255	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000172169300006
J	Zhou, XB; Arntz, C; Kamm, S; Motejlek, K; Sausbier, U; Wang, GX; Ruth, P; Korth, M				Zhou, XB; Arntz, C; Kamm, S; Motejlek, K; Sausbier, U; Wang, GX; Ruth, P; Korth, M			A molecular switch for specific stimulation of the BKCa channel by cGMP and cAMP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CA2+-ACTIVATED K+ CHANNEL; ACTIVATED POTASSIUM CHANNELS; SMOOTH-MUSCLE; LARGE-CONDUCTANCE; BETA-SUBUNIT; PHOSPHORYLATION; MODULATION; CELLS; SEQUENCES	The cGMP and the cAMP pathways control smooth muscle tone by regulation of BKCa (BK) channel activity. BK channels show considerable diversity and plasticity in their regulation by cyclic nucleotide-dependent protein kinases. The underlying molecular mechanisms are unclear but may involve expression of splice variants of the BK channel a subunit. Three isoforms, BKA, BKB, and BKC, which were cloned from tracheal smooth muscle, differed only in their C terminus. When expressed in HEK293 cells, cGMP kinase (cGK) but not cAMP kinase (cAK) stimulated the activity of BKA and BKB by shifting the voltage dependence of the channel to more negative potentials. In contrast, BKC was exclusively stimulated by cAK. BKC lacks a C-terminal tandem phosphorylation motif for protein kinase C (PKC) with Ser(1151) and Ser(1154). Mutation of this motif in BKA switched channel regulation from cGK to cAK. Furthermore, inhibition of PKC in excised patches from cells expressing BKA abolished the stimulatory effect of cGK but allowed channel stimulation by cAK. cAK and cGK phosphorylated the channel at different sites. Thus, phosphorylation/dephosphorylation by PKC determines whether the BK channel is stimulated by cGK or cAK. The molecular mechanisms may be relevant for smooth muscle relaxation by cAMP and cGMP.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Hamburg, Hosp Eppendorf, Abt Pharmakol Pharmazeuten, D-20246 Hamburg, Germany	Technical University of Munich; University of Hamburg	Ruth, P (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteinerstr 29, D-80802 Munich, Germany.	peter.ruth@uni-tuebingen.de						Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; BIALECKI RA, 1995, AM J PHYSIOL-LUNG C, V268, pL152, DOI 10.1152/ajplung.1995.268.1.L152; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CLARK A, 1991, AM J PHYSIOL, V261, pC387; Dietrich RC, 1997, MOL CELL, V1, P151, DOI 10.1016/S1097-2765(00)80016-7; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Hall SK, 2000, J BIOL CHEM, V275, P3749, DOI 10.1074/jbc.275.6.3749; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRAMATSU T, 1994, CLIN EXP PHARMACOL P, V21, P367, DOI 10.1111/j.1440-1681.1994.tb02529.x; HUELSEMANN S, 1999, CLONING CHARACTERIZA; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; REINHART PH, 1995, J NEUROSCI, V15, P4572; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Ruth P, 1997, J BIOL CHEM, V272, P10522; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Schubert R, 1999, AM J PHYSIOL-CELL PH, V276, pC648, DOI 10.1152/ajpcell.1999.276.3.C648; Schubert R, 1996, AM J PHYSIOL-CELL PH, V271, pC1203; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Shipston MJ, 1996, J BIOL CHEM, V271, P9197, DOI 10.1074/jbc.271.16.9197; Stockand JD, 1996, AM J PHYSIOL-CELL PH, V271, pC1669, DOI 10.1152/ajpcell.1996.271.5.C1669; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wang J, 1999, J Neurosci, V19, pRC4; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; Zhou XB, 1998, PFLUG ARCH EUR J PHY, V436, P725, DOI 10.1007/s004240050695; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	44	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43239	43245		10.1074/jbc.M104202200	http://dx.doi.org/10.1074/jbc.M104202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11514553	hybrid			2022-12-25	WOS:000172169300079
J	Cheng, JZ; Sharma, R; Yang, YS; Singhal, SS; Sharma, A; Saini, MK; Singh, SV; Zimniak, P; Awasthi, S; Awasthi, YC				Cheng, JZ; Sharma, R; Yang, YS; Singhal, SS; Sharma, A; Saini, MK; Singh, SV; Zimniak, P; Awasthi, S; Awasthi, YC			Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; N-TERMINAL KINASE; LIPID-PEROXIDATION PRODUCT; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ATP-DEPENDENT TRANSPORT; HUMAN LEUKEMIA-CELLS; INDUCED APOPTOSIS; CONJUGATE TRANSPORTER; CASPASE ACTIVATION; SHOCK-PROTEIN	To explore the role of lipid peroxidation (LPG) products in the initial phase of stress mediated signaling, we studied the effect of mild, transient oxidative or heat stress on parameters that regulate the cellular concentration of 4-hydroxynonenal (4-HNE). When K562 cells were exposed to mild heat shock (42 degreesC, 30 min) or oxidative stress (50 mum H2O2,20 min) and allowed to recover for 2 h, there was a severalfold induction of hGST5.8, which catalyzes the formation of glutathione-4-HNE conjugate (GS-HNE), and RLIP76, which mediates the transport of GS-HNE from cells (Awasthi, S., Cheng, J., Singhal, S. S., Saini, M. K., Pandya, U., Pikula, S., Bandorowicz-Pikula, J., Singh, S. V., Zimniak, P., and Awasthi, Y. C. (2000) Biochemistry 39, 9327-9334). Enhanced LPO was observed in stressed cells, but the major antioxidant enzymes and HSP70 remained unaffected. The stressed cells showed higher GS-HNE-conjugating activity and increased efflux of GS-FINE. Stress-pre-conditioned cells with induced hGST5.8 and RLIP76 acquired resistance to 4-HNE and H2O2-mediated apoptosis by suppressing a sustained activation of c-Jun N-terminal kinase and caspase 3. The protective effect of stress pre-conditioning against apoptosis was abrogated by coating the cells with anti-RLIP76 IgG, which inhibited the efflux of GS-HNE from cells, indicating that the cells acquired resistance to apoptosis by metabolizing and excluding 4-HNE at a higher rate. Induction of hGST5.8 and RLIP76 by mild, transient stress and the resulting resistance of stress-pre-conditioned cells to apoptosis appears to be a general phenomenon since it was not limited to K562 cells but was also evident in lung cancer cells, H-69, H-226, human leukemia cells, HL-60, and human retinal pigmented epithelial cells. These results strongly suggest a role of LPO products, particularly 4-HNE, in the initial phase of stress mediated signaling.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Arlington; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Awasthi, YC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Biochem & Genet, 7-138 Med Res Bldg, Galveston, TX 77555 USA.		Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NCI NIH HHS [CA 76348, CA 27967, CA 77495] Funding Source: Medline; NEI NIH HHS [EY 04396] Funding Source: Medline; NIEHS NIH HHS [ES 07804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076348, R01CA077495, R01CA027967] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R55EY004396, R01EY004396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; AWASTHI S, 1994, J CLIN INVEST, V93, P958, DOI 10.1172/JCI117102; Awasthi S, 1998, BIOCHEMISTRY-US, V37, P5239, DOI 10.1021/bi972131r; Awasthi S, 1998, BIOCHEMISTRY-US, V37, P5231, DOI 10.1021/bi972130z; Awasthi S, 2001, BIOCHEMISTRY-US, V40, P4159, DOI 10.1021/bi002182f; AWASTHI YC, 1975, J BIOL CHEM, V250, P5144; BEERS RF, 1952, J BIOL CHEM, V195, P133; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Boon PJM, 1999, TOXICOL APPL PHARM, V159, P214, DOI 10.1006/taap.1999.8742; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; Chen YR, 2000, INT J ONCOL, V16, P651; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Desmots F, 2001, CHEM-BIOL INTERACT, V133, P315; Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hammer A, 1997, FREE RADICAL BIO MED, V23, P26, DOI 10.1016/S0891-5849(96)00630-2; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KERENDIAN J, 1992, CURR EYE RES, V11, P385, DOI 10.3109/02713689209001792; KONDO T, 1993, J BIOL CHEM, V268, P20366; Kruman I, 1997, J NEUROSCI, V17, P5089; Kwak HJ, 1998, CELL IMMUNOL, V187, P1, DOI 10.1006/cimm.1998.1309; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LEE YP, 1966, ANAL BIOCHEM, V14, P71, DOI 10.1016/0003-2697(66)90057-1; Liu SX, 1998, ARCH BIOCHEM BIOPHYS, V352, P306, DOI 10.1006/abbi.1998.0608; Liu W, 2000, J CELL SCI, V113, P635; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; PARADISI L, 1985, CHEM-BIOL INTERACT, V53, P209, DOI 10.1016/S0009-2797(85)80097-1; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Rinaldi M, 2000, BIOCHEM BIOPH RES CO, V272, P75, DOI 10.1006/bbrc.2000.2691; ROSSI MA, 1990, BIOCHEM PHARMACOL, V39, P1715, DOI 10.1016/0006-2952(90)90116-3; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Sharma R, 2001, ARCH BIOCHEM BIOPHYS, V391, P171, DOI 10.1006/abbi.2001.2395; Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652; SINGHAL SS, 1994, ARCH BIOCHEM BIOPHYS, V311, P242, DOI 10.1006/abbi.1994.1233; SINGHAL SS, 1994, BBA-PROTEIN STRUCT M, V1204, P279, DOI 10.1016/0167-4838(94)90019-1; Singhal SS, 1999, TOXICOL LETT, V109, P87, DOI 10.1016/S0378-4274(99)00124-1; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Song BJ, 2001, CHEM-BIOL INTERACT, V130, P943, DOI 10.1016/S0009-2797(00)00247-7; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Ullrich O, 1996, BIOCHEM J, V315, P705, DOI 10.1042/bj3150705; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; ZIMNIAK P, 1994, J BIOL CHEM, V269, P992	70	133	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41213	41223		10.1074/jbc.M106838200	http://dx.doi.org/10.1074/jbc.M106838200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522795	hybrid			2022-12-25	WOS:000171925600112
J	Guaiquil, VH; Vera, JC; Golde, DW				Guaiquil, VH; Vera, JC; Golde, DW			Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER ISOFORMS; MYELOID-LEUKEMIA CELLS; ASCORBIC-ACID; HYDROGEN-PEROXIDE; DEHYDROASCORBIC ACID; ENDOTHELIAL-CELLS; FACTORS SIGNAL; DNA-DAMAGE; APOPTOSIS; EXPRESSION	Vitamin C is a well known antioxidant whose precise role in protecting cells from oxidative challenge is uncertain. In vitro results have been confounded by prooxidant effects of ascorbic acid and an overlapping role of glutathione. We used HL-60 cells as a model to determine the precise and independent role of vitamin C in cellular protection against cell death induced by oxidative stress. HL-60 cells do not depend on glutathione to transport or reduce dehydroascorbic acid. Depletion of glutathione rendered the HL-60 cells highly sensitive to cell death induced by H2O2, an effect that was not mediated by changes in the activities of glutathione reductase, glutathione peroxidase, catalase, or superoxide dismutase. The increased sensitivity to oxidative stress was largely reversed when glutathione-depleted cells were preloaded with ascorbic acid by exposure to dehydroascorbic acid. Resistance to H2O2 treatment in cells loaded with vitamin C was accompanied by intracellular consumption of ascorbic acid, generation of dehydroascorbic acid, and a decrease in the cellular content of reactive oxygen species. Some of the dehydroascorbic acid generated was exported out of the cells via the glucose transporters. Our data indicate that vitamin C is an important independent antioxidant in protecting cells against death from oxidative stress.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Univ Concepcion, Dept Fisiopatol, Concepcion, Chile	Memorial Sloan Kettering Cancer Center; Universidad de Concepcion	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, 1275 York Ave, New York, NY 10021 USA.	d-golde@ski.mskcc.org			NCI NIH HHS [CA30388, CA08748] Funding Source: Medline; NHLBI NIH HHS [HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030388, R37CA030388, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agus DB, 1999, CANCER RES, V59, P4555; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BASS DA, 1983, J IMMUNOL, V130, P1910; Binder C, 1997, ANTICANCER RES, V17, P4299; BRUNK UT, 1995, FREE RADICAL BIO MED, V19, P813, DOI 10.1016/0891-5849(95)02001-Q; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; Fujibayashi Y, 1997, RADIAT RES, V147, P729, DOI 10.2307/3579487; GerardMonnier D, 1996, PATHOL BIOL, V44, P77; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; HIRAISHI H, 1993, GASTROENTEROL JPN, V28, P132, DOI 10.1007/BF02989224; Kawamura T, 2001, CANCER-AM CANCER SOC, V92, P634, DOI 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X; Kurata T, 1999, JPN J CANCER RES, V90, P1238, DOI 10.1111/j.1349-7006.1999.tb00702.x; Li X, 2001, ARCH BIOCHEM BIOPHYS, V387, P143, DOI 10.1006/abbi.2000.2245; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MALINS DC, 1993, CANCER-AM CANCER SOC, V71, P3036, DOI 10.1002/1097-0142(19930515)71:10<3036::AID-CNCR2820711025>3.0.CO;2-P; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MEISTER A, 1994, CANCER RES, V54, pS1969; Mendiratta S, 1998, FREE RADICAL BIO MED, V24, P789, DOI 10.1016/S0891-5849(97)00351-1; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Sattler M, 1999, BLOOD, V93, P2928; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Sweetman SF, 1997, NUTR CANCER, V27, P122, DOI 10.1080/01635589709514513; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Vera JC, 1998, BLOOD, V91, P2536, DOI 10.1182/blood.V91.7.2536.2536_2536_2546; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Vethanayagam JGG, 1999, FREE RADICAL BIO MED, V26, P1591, DOI 10.1016/S0891-5849(99)00031-3; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; Witenberg B, 1999, BIOCHEM PHARMACOL, V57, P823, DOI 10.1016/S0006-2952(98)00351-7; Witenberg B, 1999, RADIAT RES, V152, P468, DOI 10.2307/3580142	41	105	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40955	40961		10.1074/jbc.M106878200	http://dx.doi.org/10.1074/jbc.M106878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533037	hybrid			2022-12-25	WOS:000171925600078
J	Huang, S; Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK				Huang, S; Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK			Chemoattractant-stimulated NF-kappa B activation is dependent on the low molecular weight GTPase RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; PERIPHERAL-BLOOD MONOCYTES; FMET-LEU-PHE; PHOSPHATIDYLINOSITOL 3-KINASE; ADP-RIBOSYLATION; GENE-EXPRESSION; PEPTIDE RECEPTOR; CELLS; TRANSCRIPTION; PATHWAY	Chemoattractants bind to seven transmembrane-spanning, G-protein-coupled receptors on monocytes and neutrophils and induce a variety of functional responses, including activation of the transcription factor NF-kappaB. The signaling mechanisms utilized by chemoattractants to activate NF-kappaB in human peripheral blood monocytes are poorly defined. We previously demonstrated that fMet-Leu-Phe (fMLP) stimulates NF-kappaB activation, and this function of fMLP requires phosphatidylinositol 3-kinase (PI3K). Here we present evidence that fMLP activates RhoA and that fMLP-induced NF-kappaB activation requires this small GTPase. Stimulation of monocytes with fMLP rapidly activated RhoA as well as NF-kappaB, and their activation was markedly reduced by pertussis toxin treatment. Pretreatment of monocyte with a RhoA inhibitor, C3 transferase from Clostridium botulinum, effectively blocked fMLP-induced NF-kappaB activation as well as interleukin-1 beta gene expression. A dominant negative form of RhoA (T19N) also inhibited fMLP-stimulated reporter gene expression in a KB-dependent manner. Cotransfection of the monocytic THP1 cells with a constitutively active form of RhoA (Q63L) with the promoter reporter plasmid results in a marked increase in NF-kappaB-mediated reporter gene expression. Furthermore, the PI3K inhibitors wortmannin and LY294002 block RhoA activation induced by fMLP. These results demonstrate that low molecular weight GTPase RhoA is a novel signal transducer for fMLP-induced NF-kappaB activation and G alpha (i) or G alpha (o) class of heterotrimeric G proteins likely mediate RhoA activation via PI3K in human peripheral blood monocytes.	Scripps Res Inst, Dept Mol & Expt Med, Dept Immunol, La Jolla, CA 92037 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Scripps Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pan, ZXK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	zkpan@scripps.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [T32 AI 07469, AI43524] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524, T32AI007469, R56AI043524] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Arbour N, 1996, CYTOKINE, V8, P468, DOI 10.1006/cyto.1996.0063; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; BURNETTE WN, 1994, STRUCTURE, V2, P151, DOI 10.1016/S0969-2126(00)00017-4; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Gomez J, 1997, J IMMUNOL, V158, P1516; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MARI B, 1994, J BIOL CHEM, V269, P8517; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	43	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40977	40981		10.1074/jbc.M105242200	http://dx.doi.org/10.1074/jbc.M105242200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533055	hybrid			2022-12-25	WOS:000171925600081
J	Kavakli, IH; Park, JS; Slattery, CJ; Salamone, PR; Frohlick, J; Okita, TW				Kavakli, IH; Park, JS; Slattery, CJ; Salamone, PR; Frohlick, J; Okita, TW			Analysis of allosteric effector binding sites of potato ADP-glucose pyrophosphorylase through reverse genetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAF ADPGLUCOSE PYROPHOSPHORYLASE; STARCH-DEFICIENT MUTANT; ARABIDOPSIS-THALIANA; CATALYTIC-PROPERTIES; SMALL-SUBUNIT; MUTAGENESIS; SEQUENCES; ENDOSPERM; TUBER; 3-PHOSPHOGLYCERATE	ADP-glucose pyrophosphorylase (AGPase) is a key regulatory enzyme of bacterial glycogen and plant starch synthesis as it controls carbon flux via its allosteric regulatory behavior. Unlike the bacterial enzyme that is composed of a single subunit type, the plant AGPase is a heterotetrameric enzyme (alpha (2)beta (2)) with distinct roles for each subunit type. The large subunit (LS) is involved mainly in allosteric regulation through its interaction with the catalytic small subunit (SS). The LS modulates the catalytic activity of the SS by increasing the allosteric regulatory response of the hetero-oligomeric enzyme. To identify regions of the LS involved in binding of effector molecules, a reverse genetics approach was employed. A potato (Solanum tuberosum L.) AGPase LS down-regulatory mutant (E38A) was subjected to random mutagenesis using error-prone polymerise chain reaction and screened for the capacity to form an enzyme capable of restoring glycogen production in glgC(-) Escherichia coli. Dominant mutations were identified by their capacity to restore glycogen production when the LS containing only the second site mutations was co-expressed with the wild-type SS. Sequence analysis showed that most of the mutations were decidedly nonrandom and were clustered at conserved N- and C-terminal regions. Kinetic analysis of the dominant mutant enzymes indicated that the K-m values for cofactor and substrates were comparable with the wildtype AGPase, whereas the affinities for activator and inhibitor were altered appreciably. These AGPase variants displayed increased resistance to P-i inhibition and/or greater sensitivity toward 3-phosphoglyceric acid activation. Further studies of Lys-197, Pro-261, and Lys-420, residues conserved in AGPase sequences, by site-directed mutagenesis suggested that the effectors 3-phosphoglyceric acid and PI interact at two closely located binding sites.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Okita, TW (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	okita@wsu.edu	Kavakli, Ibrahim/AAF-5468-2020	Kavakli, Ibrahim/0000-0001-6624-3505; Okita, Tom/0000-0002-2246-0599				BALL K, 1994, J BIOL CHEM, V269, P24706; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; BALLICORA MA, 1996, 5 NIAR COE INT S REG, P5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; Giroux MJ, 1996, P NATL ACAD SCI USA, V93, P5824, DOI 10.1073/pnas.93.12.5824; GOVONS S, 1969, J BACTERIOL, V97, P970, DOI 10.1128/JB.97.2.970-972.1969; Greene TW, 1996, PLANT PHYSIOL, V112, P1315, DOI 10.1104/pp.112.3.1315; Greene TW, 1998, P NATL ACAD SCI USA, V95, P10322, DOI 10.1073/pnas.95.17.10322; Greene TW, 1996, P NATL ACAD SCI USA, V93, P1509, DOI 10.1073/pnas.93.4.1509; Kavakli IH, 2001, BIOCHEM BIOPH RES CO, V281, P783, DOI 10.1006/bbrc.2001.4416; Kavakli IH, 2000, AUST J PLANT PHYSIOL, V27, P561, DOI 10.1071/PP99176; KLECZKOWSKI LA, 1993, PLANT PHYSIOL, V101, P179, DOI 10.1104/pp.101.1.179; Laughlin MJ, 1998, PHYTOCHEMISTRY, V47, P621, DOI 10.1016/S0031-9422(97)00578-5; Laughlin MJ, 1998, PLANT J, V14, P159, DOI 10.1046/j.1365-313X.1998.00102.x; LI L, 1992, CARBOHYD RES, V227, P227, DOI 10.1016/0008-6215(92)85074-A; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; MORELL M, 1988, J BIOL CHEM, V263, P633; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NAKATA PA, 1991, PLANT MOL BIOL, V17, P1089, DOI 10.1007/BF00037149; OKITA TW, 1992, PLANT PHYSIOL, V100, P560, DOI 10.1104/pp.100.2.560; Okita TW, 1998, PORTL PR P, V14, P99; OLIVE MR, 1989, PLANT MOL BIOL, V12, P525, DOI 10.1007/BF00036967; PLAXTON WC, 1987, PLANT PHYSIOL, V83, P105, DOI 10.1104/pp.83.1.105; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; PREISS J, 1991, BIOCHEM SOC T, V19, P539, DOI 10.1042/bst0190539; Preiss J., 1996, PHOTOASSIMILATE DIST, P63; PREISS J, 1994, P IMPR CER QUAL GEN, P115; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Salamone PR, 2000, FEBS LETT, V482, P113, DOI 10.1016/S0014-5793(00)01985-2; Slattery CJ, 2000, TRENDS PLANT SCI, V5, P291, DOI 10.1016/S1360-1385(00)01657-5; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; WEBER H, 1995, PLANTA, V195, P352, DOI 10.1007/BF00202592	35	29	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40834	40840		10.1074/jbc.M106310200	http://dx.doi.org/10.1074/jbc.M106310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524424	hybrid			2022-12-25	WOS:000171925600062
J	Verhees, CH; Huynen, MA; Ward, DE; Schiltz, E; de Vos, WM; van der Oost, J				Verhees, CH; Huynen, MA; Ward, DE; Schiltz, E; de Vos, WM; van der Oost, J			The phosphoglucose isomerase from the hyperthermophilic archaeon Pyrococcus furiosus is a unique glycolytic enzyme that belongs to the cupin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBDEN-MEYERHOF PATHWAY; DEPENDENT PHOSPHOFRUCTOKINASE; SUGAR FERMENTATION; PURIFICATION; EVOLUTION; GLYCERALDEHYDE-3-PHOSPHATE; ALIGNMENT; OPERATION; SEQUENCE; KINASES	Pyrococcus furiosus uses a variant of the Embden-Meyerhof pathway during growth on sugars. All but one of the genes that encode the glycolytic enzymes of P. furiosus have previously been identified, either by homology searching of its genome or by reversed genetics. We here report the isolation of the missing link of the pyrococcal glycolysis, the phosphoglucose isomerase (PGI), which was purified to homogeneity from P. furiosus and biochemically characterized. The P. furiosus PGI, a dimer of identical 23.5-kDa subunits, catalyzes the reversible isomerization of glucose 6-phosphate to fructose 6-phosphate, with K, values of 1.99 and 0.63 mm, respectively. An optimum pH of 7.0 has been determined in both directions, and at its optimum temperature of 90 degreesC the enzyme has a half-life of 2.4 h. The N-terminal sequence was used for the identification of the pgiA gene in the P. furiosus genome. The pgiA transcription start site has been determined, and a monocistronic messenger was detected in P. furiosus during growth on maltose and pyruvate. The pgiA gene was functionally expressed in Escherichia coli BL21(DE3). The deduced amino acid sequence of this first archaeal PGI revealed that it is not related to its bacterial and eukaryal counterparts. In contrast, this archaeal PGI shares similarity with the cupin superfamily that consists of a variety of proteins that are generally involved in sugar metabolism in both prokaryotes and eukaryotes. As for the P. furiosus PGI, distinct phylogenetic origins have previously been reported for other enzymes from the pyrococcal glycolytic pathway. Apparently, convergent evolution by recruitment of several unique enzymes has resulted in the unique Pyrococcus glycolysis.	Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Freiburg, D-79104 Freiburg, Germany	Wageningen University & Research; European Molecular Biology Laboratory (EMBL); University of Freiburg	Verhees, CH (corresponding author), Univ Wageningen & Res Ctr, Microbiol Lab, Hesselink Van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.		van+der+Oost, John/Y-2548-2019; Huynen, Martijn A/A-1530-2014; Huijnen, M.A./H-8051-2014	Huynen, Martijn A/0000-0001-6189-5491; 				Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; BORK P, 1993, PROTEIN SCI, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Galperin MY, 2000, FEMS MICROBIOL LETT, V183, P259, DOI 10.1016/S0378-1097(99)00612-6; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; Huynen MA, 1999, TRENDS MICROBIOL, V7, P281, DOI 10.1016/S0966-842X(99)01539-5; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; Ko TP, 2000, ACTA CRYSTALLOGR D, V56, P411, DOI 10.1107/S0907444900002237; Li XC, 2000, BBA-PROTEIN STRUCT M, V1476, P363, DOI 10.1016/S0167-4838(99)00258-7; LOWE SL, 1975, J BIOL CHEM, V250, P94; MARCHAND M, 1989, EUR J BIOCHEM, V184, P455, DOI 10.1111/j.1432-1033.1989.tb15038.x; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; NATAKE M, 1964, AGR BIOL CHEM TOKYO, V28, P510; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; ROBINSON KA, 1994, GENE, V151, P173, DOI 10.1016/0378-1119(94)90651-3; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruijter GJG, 1999, BIOCHIMIE, V81, P267, DOI 10.1016/S0300-9084(99)80061-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHREYER R, 1980, ARCH MICROBIOL, V127, P289, DOI 10.1007/BF00427206; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Siebers B, 2001, J BIOL CHEM, V276, P28710, DOI 10.1074/jbc.M103447200; TAKAMA M, 1980, J BIOCHEM, V87, P1821, DOI 10.1093/oxfordjournals.jbchem.a132927; THOMAS DA, 1981, J GEN MICROBIOL, V124, P403; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; van der Oost J, 1998, J BIOL CHEM, V273, P28149, DOI 10.1074/jbc.273.43.28149; Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000	36	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40926	40932		10.1074/jbc.M104603200	http://dx.doi.org/10.1074/jbc.M104603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533028	hybrid, Green Published			2022-12-25	WOS:000171925600074
J	Jodo, S; Xiao, S; Hohlbaum, A; Strehlow, D; Marshak-Rothstein, A; Ju, ST				Jodo, S; Xiao, S; Hohlbaum, A; Strehlow, D; Marshak-Rothstein, A; Ju, ST			Apoptosis-inducing membrane vesicles - A novel agent with unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MEDIATED CYTOTOXICITY; FAS LIGAND EXPRESSION; T-CELLS; MONOCLONAL-ANTIBODY; RETROVIRAL VECTORS; DOWN-REGULATION; GENE-TRANSFER; CD95 LIGAND; B-CELLS; ANTIGEN	The CD95 ligand (FasL) transmembrane protein is found on activated T cells and cells outside the immune system. A well-known turnover process of membrane FasL is mediated by matrix metalloproteinase, which generates soluble FasL (sFasL). Here, we demonstrate that membrane FasL turnover occurs effectively through the release of membrane vesicles. Quantitative analysis indicates that this process is as effective as sFasL release for FasL-3T3 cells but somewhat less effective for FasL-expressing T cells. The apoptosis-inducing membrane vesicles display unique properties not found in FasL-expressing cells and sFasL. Unlike sFasL, vesicle-associated FasL remained bioactive, killing the same panel of targets that are susceptible to FasL-expressing cells. In contrast to FasL-expressing T cells, FasL-mediated killing by vesicles do not involve LFA-1/ICAM interaction and do not depend on de novo protein synthesis. These observations indicate that the release of FasL-bearing vesicles contributes to the turnover of cell-associated FasL, but the impact of the bioactive FasL-expressing vesicles on the function of cell-associated FasL is different from that of sFasL.	Boston Univ, Ctr Arthrit, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Ctr Arthrit, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University; Boston University	Ju, ST (corresponding author), Boston Univ, Ctr Arthrit, Sch Med, Dept Med, 715 Albany St,Med Campus K508, Boston, MA 02118 USA.				NATIONAL CANCER INSTITUTE [R01CA090691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES010244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058724] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90691] Funding Source: Medline; NIAID NIH HHS [AI 36938] Funding Source: Medline; NIEHS NIH HHS [ES 10244] Funding Source: Medline; NIGMS NIH HHS [GM 58724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese J, 1998, BLOOD, V91, P3862; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; Aoki K, 2001, NAT IMMUNOL, V2, P333, DOI 10.1038/86336; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett MW, 1998, J IMMUNOL, V160, P5669; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; DAVIDSON WF, 1986, J IMMUNOL, V136, P4075; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ETTINGER R, 1995, J IMMUNOL, V154, P4302; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; French LE, 1997, J IMMUNOL, V159, P2196; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hahne M, 1996, EUR J IMMUNOL, V26, P721, DOI 10.1002/eji.1830260332; Jodo S, 2000, J IMMUNOL, V165, P5487, DOI 10.4049/jimmunol.165.10.5487; Jodo S, 2000, J IMMUNOL, V164, P5062, DOI 10.4049/jimmunol.164.10.5062; JONES B, 1986, J IMMUNOL, V136, P348; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kojima H, 1997, J IMMUNOL, V159, P2728; Lu LN, 1997, J IMMUNOL, V158, P5676; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Moller P, 1996, AM J PATHOL, V149, P9; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OZDEMIRLI M, 1992, J IMMUNOL, V149, P1889; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; STALDER T, 1994, J IMMUNOL, V152, P1127; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strehlow D, 2000, P NATL ACAD SCI USA, V97, P4209, DOI 10.1073/pnas.070049197; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang J, 1997, J EXP MED, V186, P1171, DOI 10.1084/jem.186.7.1171; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	54	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39938	39944		10.1074/jbc.M107005200	http://dx.doi.org/10.1074/jbc.M107005200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546786	hybrid			2022-12-25	WOS:000171789200059
J	Stafford, JM; Wilkinson, JC; Beechem, JM; Granner, DK				Stafford, JM; Wilkinson, JC; Beechem, JM; Granner, DK			Accessory factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NUCLEAR FACTOR-3; RESPONSE UNIT; IN-VIVO; SEQUENCE SPECIFICITY; TRANSCRIPTION FACTOR; DNA; PROTEIN; COMPLEX; INSULIN; SITES	Glucocorticoid induction of the phosphoenolpyruvate carboxykinase (PEPCK) gene requires a glucocorticoid response unit (GRU) comprised of two non-consensus glucocorticold receptor (GR) binding sites, GR1 and GR2, and at least three accessory factor elements (gAF1-3). DNA-binding accessory proteins are commonly required for the regulation of genes whose products play an important role in metabolism, development, and a variety of defense responses, but little is known about why they are necessary. Quantitative, real time homogenous assays of cooperative protein-DNA interactions in complex media (e.g. nuclear extracts) have not previously been reported. Here we perform quantitative, real time equilibrium and stopped-flow fluorescence anisotropy measurements of protein-DNA interactions in nuclear extracts to demonstrate that GR binds to the GR1-GR2 elements poorly as compared with a palindromic or consensus glucocorticoid response element (GRE). Inclusion of either the gAF1 or gAF2 element with GR1-GR2, however, creates a high affinity binding environment for GR. GR can undergo multiple rounds of binding and dissociation to the palindromic GRE in less than 100 ms at nanomolar concentrations. The dissociation rate of GR is differentially slowed by the gAF1 or gAF2 elements that bind two functionally distinct accessory factors, COUP-TF/HNF4 and HNF3, respectively.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biol Sci, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 707 Light Hall, Nashville, TN 37232 USA.		Stafford, John/K-7763-2017	Stafford, John/0000-0001-6527-959X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P60DK020593, R37DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35107, DK 20593] Funding Source: Medline; NIGMS NIH HHS [GM 55056, GM 07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; Dunkak KS, 1996, ANAL BIOCHEM, V243, P234, DOI 10.1006/abio.1996.0511; FABER S, 1993, J BIOL CHEM, V268, P24976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LABAER J, 1994, J MOL BIOL, V239, P664, DOI 10.1006/jmbi.1994.1405; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Lehmann M, 1996, EMBO J, V15, P4825, DOI 10.1002/j.1460-2075.1996.tb00863.x; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PAYVAR F, 1981, P NATL ACAD SCI-BIOL, V78, P6628, DOI 10.1073/pnas.78.11.6628; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHMIDT TJ, 1985, J BIOL CHEM, V260, P6255; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Steiner RF, 1991, TOPICS FLUORESCENCE, V2; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WRANGE O, 1989, J BIOL CHEM, V264, P5253; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zimmermann PL, 1997, DNA CELL BIOL, V16, P713, DOI 10.1089/dna.1997.16.713	37	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39885	39891		10.1074/jbc.M105370200	http://dx.doi.org/10.1074/jbc.M105370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518712	hybrid			2022-12-25	WOS:000171789200052
J	Brusselmans, K; Bono, F; Maxwell, P; Dor, Y; Dewerchin, M; Collen, D; Herbert, JM; Carmeliet, P				Brusselmans, K; Bono, F; Maxwell, P; Dor, Y; Dewerchin, M; Collen, D; Herbert, JM; Carmeliet, P			Hypoxia-inducible factor-2 alpha (HIF-2 alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; NEONATAL HYPOGLYCEMIA; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; MICE LACKING; SOLID TUMORS; FACTOR-I; FACTOR-1-ALPHA; ANGIOGENESIS	Deprivation of oxygen (hypoxia) and/or glucose (hypoglycemia) represents a serious stress that affects cellular survival. The hypoxia-inducible transcription factor-1 alpha (HIF-1 alpha), which has been implicated in the cellular response to hypoxia (Semenza, G. L. (1999) Annu. Rev. Cell Dev. Biol. 15, 551-578), mediates apoptosis during hypoxia (Halterman, M. W., Miller, C. C., and Federoff, H. J. (1999) J. Neurosci. 19,6818-6824 and Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Ahramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. (1998) Nature 394, 485-490), but the function of its homologue HIF-2 alpha remains unknown. Therefore, the role of HIF-2 alpha in cellular survival was studied by targeted inactivation of the HIF-2 alpha gene (HIF-2 alpha (-/-)) in murine embryonic stem (ES) cells. In contrast to HIF-1 alpha deficiency, loss of HIF-2 alpha did not protect ES cells against apoptosis during hypoxia. Both HIF-1 alpha (-/-) and HIF-2 alpha (-/-) ES cells were, however, resistant to apoptosis in response to hypoglycemia. When co-cultured with wild type ES cells, HIF-2 alpha (-/-) ES cells became rapidly and progressively enriched in hypoglycemia but not in hypoxia. Thus, HIF-1 alpha and HIF-2 alpha may have distinct roles in responses to environmental stress, and despite its name, HIF-2 alpha may be more important in the survival response to environmental variables other than the level of oxygen.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Sanofi Synthelabo Rech, Cardiovasc Thrombosis Res Dept, F-31036 Toulouse, France; Wellcome Trust Ctr Human Genet, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 7BN, England; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Flanders Institute for Biotechnology (VIB); KU Leuven; Sanofi-Aventis; Sanofi France; University of Oxford; Wellcome Centre for Human Genetics; Hebrew University of Jerusalem	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; Maxwell, Patrick H/C-5557-2008; Dor, Yuval/C-2405-2011	Carmeliet, Peter/0000-0001-7961-1821; Maxwell, Patrick H/0000-0002-0338-2679; 				AKAZAWA S, 1987, DIABETOLOGIA, V30, P791; Akeno N, 2001, ENDOCRINOLOGY, V142, P959, DOI 10.1210/en.142.2.959; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Duvanel CB, 1999, J PEDIATR-US, V134, P492, DOI 10.1016/S0022-3476(99)70209-X; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Favier J, 1999, FEBS LETT, V462, P19, DOI 10.1016/S0014-5793(99)01476-3; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Smoak IW, 1997, REPROD TOXICOL, V11, P495, DOI 10.1016/S0890-6238(97)00016-6; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Tkacs NC, 2000, DIABETES, V49, P820, DOI 10.2337/diabetes.49.5.820; Traill Z, 1998, ARCH DIS CHILD-FETAL, V79, pF145, DOI 10.1136/fn.79.2.F145; Vincent KA, 2000, CIRCULATION, V102, P2255; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Williams AF, 1997, B WORLD HEALTH ORGAN, V75, P261	33	88	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39192	39196		10.1074/jbc.C100428200	http://dx.doi.org/10.1074/jbc.C100428200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11546756	hybrid			2022-12-25	WOS:000171673200113
J	Missiaen, L; Van Acker, K; Parys, JB; De Smedt, H; Van Baelen, K; Weidema, AF; Vanoevelen, J; Raeymaekers, L; Renders, J; Callewaert, G; Rizzuto, R; Wuytack, F				Missiaen, L; Van Acker, K; Parys, JB; De Smedt, H; Van Baelen, K; Weidema, AF; Vanoevelen, J; Raeymaekers, L; Renders, J; Callewaert, G; Rizzuto, R; Wuytack, F			Baseline cytosolic Ca2+ oscillations derived from a non-endoplasmic reticulum Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE CELLS; BASOPHILIC LEUKEMIA-CELLS; GOLGI-APPARATUS; CALCIUM-RELEASE; ADENINE-NUCLEOTIDES; LUMINAL CA2+; PROPERTIES DISTINCT; PLASMA-MEMBRANE; TRISPHOSPHATE	Cytosolic Ca2+ oscillations can be due to cycles of release and re-uptake of internally stored Ca2+. To investigate the nature of these Ca2+ stores, we expressed the Pmr1 Ca2+ pump of Caenorhabditis elegans in COS-1 cells and pretreated the cells with thapsigargin to prevent Ca2+ uptake by the sarco(endo)plasmic reticulum Ca2+-ATPase. Pmr1 co-localized with the Golgi-specific 58K protein and was targeted to a Ca2+ store that was less leaky for Ca2+ than the endoplasmic reticulum and whose inositol trisphosphate receptors were less sensitive to inositol trisphosphate and ATP than those in the endoplasmic reticulum. ATP-stimulated Pmr1-overexpressing cells responded after a latency to extracellular Ca2+ with a regenerative Ca2+ signal, which could be prevented by caffeine. They also produced very stable ilimaquinone-sensitive baseline Ca2+ spikes, even in the presence of thapsigargin. Such responses never occurred in non-transfected cells or in cells that overexpressed the type-1 sarco(endo)plasmic reticulum Ca(2+-)ATPase. Abortive Ca2+ spikes also occurred in histamine-stimulated untransfected HeLa cells pretreated with thapsigargin, and they too were inhibited by ilimaquinone. We conclude that the Pmr1-induced Ca2+ store, which probably corresponds to the Golgi compartment, can play a crucial role in setting up baseline Ca2+ spiking.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	KU Leuven; University of Ferrara	Missiaen, L (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.	Ludwig.Missiaen@med.kuleuven.ac.be	Vanoevelen, Jo M/F-2686-2013; Rizzuto, Rosario/B-6312-2008	Vanoevelen, Jo M/0000-0003-1830-8858; Rizzuto, Rosario/0000-0001-7044-5097; Parys, Jan/0000-0002-3591-4967				ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CHANDRA S, 1991, J CELL SCI, V100, P747; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DeSmedt H, 1997, BIOCHEM J, V322, P575; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HIROSE K, 1993, BIOCHEM BIOPH RES CO, V194, P726, DOI 10.1006/bbrc.1993.1882; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Maes K, 2001, J BIOL CHEM, V276, P3492, DOI 10.1074/jbc.M006082200; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Sorin A, 1997, J BIOL CHEM, V272, P9895; Surroca A, 2000, J MEMBRANE BIOL, V177, P243, DOI 10.1007/s002320010008; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; YOSHIMOTO A, 1990, CELL BIOCHEM FUNCT, V8, P191, DOI 10.1002/cbf.290080402; ZHAO X, 1995, AM J PHYSIOL, V268, pC1133	51	50	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39161	39170		10.1074/jbc.M104044200	http://dx.doi.org/10.1074/jbc.M104044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514551	hybrid			2022-12-25	WOS:000171673200109
J	Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS				Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS			Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; KIF1B gene; 1p36; kinesin superfamily	MOTOR PROTEIN; MOLECULAR-BIOLOGY; MONOMERIC MOTOR; KINESIN; TRANSPORT; REGION; HETEROZYGOSITY; IDENTIFICATION; CELLS; PROGRESSION	In order to clone candidate tumor suppressor genes whose loss contributes to the pathogenesis of neuroblastoma (NB), we performed polymerase chain reaction (PCR) screening using a high-density sequence tagged site-content map within a commonly deleted region (chromosome band 1p36) in 24 NB cell lines. We found a similar to 480 kb homozygously deleted region at chromosome band 1p36.2 in one of the 24 NB cell lines, NB-1, and cloned the human homologue (KIF1B-beta) of the mouse-Kif1B-beta gene in this region. The KIF1B-beta gene had at least 47 exons, all of which had a classic exon-intron boundary structure. Mouse Kif1B is a microtubule-based putative anterograde motor protein for the transport of mitochondria in neural cells. We performed mutational analysis of the KIF1B-beta gene in 23 cell lines using 46 sets of primers and also an allelic imbalance (Al) analysis of KIF1B-beta in 50 fresh NB samples. A missense mutation at codon 1554, GTG (Gly) to ATG (Met), silent mutations at codon 409 (ACG to ACA) and codon 1721 (ACC to ACT), and polymorphisms at codon 170, GAT (Asp) to GAA (Glu), and at codon 1087, TAT (Tyr), to TGT (Cys), were all identified, although their functional significances remain to be determined. The Al for KIF1B-beta was slightly higher (38%) than those for the other two markers (D1S244, D1S1350) (35 and 32%) within the commonly deleted region (1p36). Reverse transcriptase-PCR analysis of the KIF-IB-fl gene revealed obvious expression in all NB cell lines except NB-1, although decreased expression of the KIF1B-beta gene was found in a subset of early- and advanced-stage NBs. These results suggest that the KIF1B-beta gene may not be a candidate for tumor suppressor gene of NB.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	University of Tokyo; RIKEN	Hayashi, YS (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chen YZ, 2001, GENOMICS, V74, P55, DOI 10.1006/geno.2001.6511; CHEN YZ, 2001, IN PRESS GENES CHROM, V31; Conforti L, 1999, MAMM GENOME, V10, P617, DOI 10.1007/s003359901056; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Furlong RA, 1996, GENOMICS, V33, P421, DOI 10.1006/geno.1996.0217; Gong TWL, 1999, GENE, V239, P117, DOI 10.1016/S0378-1119(99)00370-4; Greene MH, 1999, CANCER-AM CANCER SOC, V86, P2464, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOMURO H, 1993, CANCER RES, V53, P5284; Kong XT, 1997, CANCER RES, V57, P3772; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Leek JP, 1997, CYTOGENET CELL GENET, V79, P212, DOI 10.1159/000134725; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakagawa T, 1998, MOL BIOL CELL, V9, p393A; NAKAGAWA T, 1999, GENBANK ACCESSION; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Saito M, 1997, NEUROLOGY, V49, P1630, DOI 10.1212/WNL.49.6.1630; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Yang HW, 2000, INT J MOL MED, V5, P379; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	47	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5075	5083		10.1038/sj.onc.1204456	http://dx.doi.org/10.1038/sj.onc.1204456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526494				2022-12-25	WOS:000170439800019
J	Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM				Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM			Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding	ONCOGENE			English	Article						BRCA1; retinoblastoma; RB; p107; p130; p300	TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HISTONE DEACETYLASE; ALPHA-SUBUNIT; APOPTOSIS; P53; TRANSCRIPTION; EXPRESSION; INTERACT	The tumor suppressor activity of the BRCA1 gene product is due, in part, to functional interactions with other tumor suppressors, including p53 and the retinoblastoma (RB) protein. RB binding sites on BRCA1 were identified in the C-terminal BRCT domain (Yarden and Brody, 1999) and in the N-terminus (aa 304-394) (Aprelikova et al., 1999). The N-terminal site contains a consensus RB binding motif, LXCXE (aa 358-362), but the role of this motif in RB binding and BRCA1 functional activity is unclear. In both in vitro and in vivo assays, we found that the BRCA1:RB interaction does not require the BRCA1 LXCXE motif, nor does it require an intact A/B binding pocket of RB. In addition, nuclear co-localization of the endogenous BRCA1 and RB proteins was observed. Over-expression of wild-type BRCA1 (wtBRCA1) did not cause cell cycle arrest but did cause down-regulation of expression of RB, p107, p130, and other proteins (e.g., p300), associated with increased sensitivity to DNA-damaging agents. In contrast, expression of a full-length BRCA1 with an LXCXE inactivating mutation (LXCXE-->RXRXH) failed to down-regulate RB, blocked the down-regulation of RB by wtBRCA1, induced chemoresistance, and abrogated the ability of BRCA1 to mediate tumor growth suppression of DU-145 prostate cancer cells. wtBRCA1-induced chemosensitivity was partially reversed by expression of either Rb or p300 and fully reversed by co-expression of Rb plus p300. Our findings suggest that: (I) disruption of the LXCXE motif within the N-terminal RB binding region alters the biologic function of BRCA1; and (2) over-expression of BRCA1 inhibits the expression of RB and RB family (p107 and p130) proteins.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fan, SJ (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	fan@lij.edu; erosen@lij.edu	Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA82599, R01-CA80000] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	51	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4827	4841		10.1038/sj.onc.1204666	http://dx.doi.org/10.1038/sj.onc.1204666			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521194				2022-12-25	WOS:000170271800007
J	Escobar-Henriques, M; Balguerie, A; Monribot, C; Boucherie, H; Daignan-Fornier, B				Escobar-Henriques, M; Balguerie, A; Monribot, C; Boucherie, H; Daignan-Fornier, B			Proteome analysis and morphological studies reveal multiple effects of the immunosuppressive drug mycophenolic acid specifically resulting from guanylic nucleotide depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; CDC37; PROGRESSION; MECHANISM; CHAPERONE; MUTANTS; COMPLEX; GENES	Mycophenolic acid (NMA), one of the most promising immunosuppressive drugs recently developed, is a potent inhibitor of IMP dehydrogenase, the first committed step toward GMP synthesis. We found that all the drug effects on yeast cells were prevented by bypassing GMP synthesis, thus confirming the high specificity of MPA. Although the primary target of MPA is clearly identified, we aimed to further understand how GTP depletion leads to growth arrest and developed a new approach based on proteome analysis combined with overexpression studies. Essential proteins down-expressed in the presence of NMA were identified by protein two-dimensional gel analysis and subsequently overexpressed in yeast. Two such proteins, Cdc37p and Sup45p, when overexpressed allowed partial relief of MPA toxicity, strongly suggesting that their lower amount after MPA treatment significantly contributed to the MPA effect. These conserved proteins involved in cell cycle progression and translation are therefore important secondary targets for MPA. Our data establish that NEPA effects occur through inhibition of a unique primary target resulting in guanine nucleotides depletion, thereby affecting multiple cellular processes.	CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Daignan-Fornier, B (corresponding author), CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	B.Daigman-Fornier@ibgc.u-bordeaux2.fr		Escobar-Henriques, Mafalda/0000-0002-0879-3119				Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0; Balguerie A, 1999, J CELL SCI, V112, P2529; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P1523, DOI 10.1074/jbc.M007926200; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Guetsova ML, 1997, GENETICS, V147, P383; Hashimoto H, 1997, J BIOL CHEM, V272, P16308, DOI 10.1074/jbc.272.26.16308; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Lin P, 1997, P NATL ACAD SCI USA, V94, P10780, DOI 10.1073/pnas.94.20.10780; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pruyne D, 2000, J CELL SCI, V113, P365; Qiu Y, 2000, TRANSPLANTATION, V69, P890; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000	24	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46237	46242		10.1074/jbc.M103416200	http://dx.doi.org/10.1074/jbc.M103416200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11535588	hybrid			2022-12-25	WOS:000172573100102
J	Shakkottai, VG; Regaya, I; Wulff, H; Fajloun, Z; Tomita, H; Fathallah, M; Cahalan, MD; Gargus, JJ; Sabatier, JM; Chandy, KG				Shakkottai, VG; Regaya, I; Wulff, H; Fajloun, Z; Tomita, H; Fathallah, M; Cahalan, MD; Gargus, JJ; Sabatier, JM; Chandy, KG			Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-LYMPHOCYTES; POTASSIUM CHANNELS; SCORPION TOXIN; STRUCTURAL CONSERVATION; LEIUROTOXIN-I; APAMIN; CELLS; PHARMACOLOGY; AFFINITY; BRAIN	Apamin-sensitive small conductance calcium-activated potassium channels (SKCa1-3) mediate the slow afterhyperpolarization in neurons, but the molecular identity of the channel has not been defined because of the lack of specific inhibitors. Here we describe the structure-based design of a selective inhibitor of SKCa2. Leiurotoxin I (Lei) and PO5, peptide toxins that share the RXCQ motif, potently blocked human SKCa2 and SKCa3 but not SKCa1, whereas maurotoxin, Pi1, Tsk, and PO1 were ineffective. Lei blocked these channels more potently than PO5 because of the presence of Ala(1), Phe(2), and Met(7). By replacing Met(7) in the RXCQ motif of Lei with the shorter, unnatural, positively charged diaminobutanoic acid (Dab), we generated Lei-Dab(7), a selective SKCa2 inhibitor (K-d = 3.8 nM) that interacts with residues in the external vestibule of the channel. SKCa3 was rendered sensitive to Lei-Dab(7) by replacing His(521) with the corresponding SKCa2 residue (Asn(367)). Intracerebroventricular injection of Lei-Dab(7) into mice resulted in no gross central nervous system toxicity at concentrations that specifically blocked SKCa2 homotetramers. Lei-Dab(7) will be a useful tool to investigate the functional role of SKCa2 in mammalian tissues.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Fac Med Nord, CNRS, Unite Mixte Rech 6560, F-13014 Marseille, France; Hop St Marguerite, INSERM, Assistance Publ Hop Marseille, CIC 9502, F-13009 Marseille, France	University of California System; University of California Irvine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Shakkottai, VG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Rm 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.	vshakkot@uci.edu	Fajloun, Ziad/AAO-8595-2021; wulff, Heike/Z-2056-2019; Regaya, Imed/L-7899-2018	Tomita, Hiroaki/0000-0003-2628-880X; SABATIER, Jean-Marc/0000-0002-9040-5647; Regaya, Imed/0000-0001-8671-5186	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NIMH NIH HHS [MH59222] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; Behrens B., 1934, ARCH EXP PATHOL PH, V177, P379; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Empson RM, 2001, NEUROSCIENCE, V102, P297, DOI 10.1016/S0306-4522(00)00494-2; Fajloun Z, 2000, EUR J BIOCHEM, V267, P5149, DOI 10.1046/j.1432-1327.2000.01577.x; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hanselmann C, 1996, J PHYSIOL-LONDON, V496, P627, DOI 10.1113/jphysiol.1996.sp021714; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hirschberg B, 1998, J GEN PHYSIOL, V111, P565, DOI 10.1085/jgp.111.4.565; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; JENKINSON DH, 1983, CELL CALCIUM, V4, P429, DOI 10.1016/0143-4160(83)90019-2; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kimura T, 2000, NEUROSCI LETT, V295, P93, DOI 10.1016/S0304-3940(00)01598-6; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MCCOWN TJ, 1990, EUR J PHARMACOL, V187, P49, DOI 10.1016/0014-2999(90)90339-8; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mourre C, 1997, BRAIN RES, V778, P405, DOI 10.1016/S0006-8993(97)01165-7; Nagayama T, 2000, AM J PHYSIOL-REG I, V279, pR1731, DOI 10.1152/ajpregu.2000.279.5.R1731; Paolocci N, 2001, CIRCULATION, V103, P119; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; Rajamohan F, 1996, P NATL ACAD SCI USA, V93, P14338, DOI 10.1073/pnas.93.25.14338; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Rimini R, 2000, MOL BRAIN RES, V85, P218, DOI 10.1016/S0169-328X(00)00255-2; SABATIER JM, 1994, INT J PEPT PROT RES, V43, P486; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	50	95	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43145	43151		10.1074/jbc.M106981200	http://dx.doi.org/10.1074/jbc.M106981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11527975	hybrid			2022-12-25	WOS:000172169300067
J	Sokal, I; Li, N; Klug, CS; Filipek, S; Hubbell, WL; Baehr, W; Palczewski, K				Sokal, I; Li, N; Klug, CS; Filipek, S; Hubbell, WL; Baehr, W; Palczewski, K			Calcium-sensitive regions of GCAP1 as observed by chemical modifications, fluorescence, and EPR spectroscopies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEIN; PHOTORECEPTOR GUANYLATE-CYCLASE; OXIDASE SUBUNIT P47(PHOX); DOMINANT CONE DYSTROPHY; CENTRAL-NERVOUS-SYSTEM; RABBIT PSOAS MUSCLE; LOOP-GAP RESONATOR; BINDING PROTEIN; CONFORMATIONAL-CHANGES; ACETYLCHOLINE-RECEPTOR	Guanylyl cyclase-activating proteins are EF-hand Ca2+-binding proteins that belong to the calmodulin superfamily. They are involved in the regulation of photoreceptor membrane-associated guanylyl cyclases that produce cGMP, a second messenger of vertebrate vision. Here, we investigated changes in GCAP1 structure using mutagenesis, chemical modifications, and spectroscopic methods. Two Cys residues of GCAP1 situated in spatially distinct regions of the N-terminal domain (positions 18 and 29) and two Cys residues located within the C-terminal lobe (positions 106 and 125) were employed to detect conformational changes upon Ca2+ binding. GCAP1 mutants with only a single Cys residue at each of these positions, modified with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine, an environmentally sensitive fluorophore, and with (1-oxy-2,2,5,5-tetramethylpyrroline-3-methyl)methanethiosulfonate, a spin label reagent, were studied using fluorescence and EPR spectroscopy, respectively. Only minor structural changes around Cys(18), Cys(29), Cys(106), and Cys(125) were observed as a function of Ca2+ concentration. No Ca2+-dependent oligomerization of GCAP1 was observed at physiologically relevant Ca2+ concentrations, in contrast to the observation reported by others for GCAP2. Based on these results and previous studies, we propose a photoreceptor activation model that assumes changes within the flexible central helix upon Ca2+ dissociation, causing relative reorientation of two structural domains containing a pair of EF-hand motifs and thus switching its partner, guanylyl cyclase, from an inactive (or low activity) to an active conformation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Warsaw, Dept Chem, PL-02093 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Warsaw	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY008123, R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008123, R01 EY008061, EY08061, EY08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AJTAI K, 1989, BIOCHEMISTRY-US, V28, P2204, DOI 10.1021/bi00431a035; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P9586, DOI 10.1021/bi00451a006; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; ANDLEY UP, 1985, CURR EYE RES, V4, P831, DOI 10.3109/02713688509095249; Bobkova EA, 1999, BIOPHYS J, V76, P1001, DOI 10.1016/S0006-3495(99)77264-4; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner B, 1999, BIOPHYS J, V77, P2677, DOI 10.1016/S0006-3495(99)77102-X; Brenner B, 1999, BIOPHYS J, V77, P2692, DOI 10.1016/S0006-3495(99)77103-1; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8608, DOI 10.1021/bi00084a031; DUNN SMJ, 1983, BIOCHEMISTRY-US, V22, P2512, DOI 10.1021/bi00279a031; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FRONCISZ W, 1982, J MAGN RESON, V47, P515, DOI 10.1016/0022-2364(82)90221-9; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; GILARDI G, 1994, ANAL CHEM, V66, P3840, DOI 10.1021/ac00093a047; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Gordon AM, 1997, J MUSCLE RES CELL M, V18, P643, DOI 10.1023/A:1018631806182; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; GREENE LE, 1986, J BIOL CHEM, V261, P1279; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HATAKENAKA S, 1985, BRAIN RES, V331, P209, DOI 10.1016/0006-8993(85)91546-X; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HIDAKA H, 1993, NEUROSCI RES, V16, P73, DOI 10.1016/0168-0102(93)90074-Z; HUANG MJ, 1994, J AM CHEM SOC, V116, P2515; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; KATAOKA M, 1993, J BIOCHEM-TOKYO, V114, P535, DOI 10.1093/oxfordjournals.jbchem.a124212; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; Kawamura S, 1996, J BIOL CHEM, V271, P21359, DOI 10.1074/jbc.271.35.21359; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; KOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V196, P1017, DOI 10.1006/bbrc.1993.2351; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; Kojima K, 2001, J BIOL CHEM, V276, P2115, DOI 10.1074/jbc.M003111200; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LI N, 2001, IN PRESS BIOL CHEM; LIANG JN, 1987, EXP EYE RES, V45, P197, DOI 10.1016/S0014-4835(87)80143-4; LIANG JN, 1987, CURR EYE RES, V6, P351, DOI 10.3109/02713688709025187; Lucas KA, 2000, PHARMACOL REV, V52, P375; MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V790, P275, DOI 10.1016/0167-4838(84)90032-3; Moon C, 1998, J NEUROSCI, V18, P3195; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park HS, 1999, BIOCHEM BIOPH RES CO, V259, P38, DOI 10.1006/bbrc.1999.0721; Park HS, 1998, ARCH BIOCHEM BIOPHYS, V360, P165, DOI 10.1006/abbi.1998.0938; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; POLANS AS, 1995, P NATL ACAD SCI USA, V92, P9176, DOI 10.1073/pnas.92.20.9176; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SempleRowland SL, 1996, FEBS LETT, V385, P47, DOI 10.1016/0014-5793(96)00345-6; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; Sokal I, 2000, BBA-MOL CELL RES, V1498, P233, DOI 10.1016/S0167-4889(00)00099-9; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; TAKAMATSU K, 1993, NEUROSCI RES, V17, P291, DOI 10.1016/0168-0102(93)90112-4; TAKAMI K, 1985, NEUROSCIENCE, V15, P667, DOI 10.1016/0306-4522(85)90068-5; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	87	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43361	43373		10.1074/jbc.M103614200	http://dx.doi.org/10.1074/jbc.M103614200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11524415	Green Accepted, hybrid			2022-12-25	WOS:000172169300095
J	Stephens, LR; Anderson, KE; Hawkins, PT				Stephens, LR; Anderson, KE; Hawkins, PT			Src family kinases mediate receptor-stimulated, phosphoinositide 3-kinase-dependent, tyrosine phosphorylation of dual adaptor for phosphotyrosine and 3-phosphoinositides-1 in endothelial and B cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; SYK; PROTEIN; EXPRESSION; PRODUCTS; INSULIN; PATHWAY; DOMAINS	DAPP-1 ((d) under bar ual-(a) under bar daptor for (p) under bar hosphotyrosine and 3-(p) under bar hosphoinositides-(1) under bar) is a broadly distributed pleckstrin homology (PH) and Src homology 2 domain containing protein that can bind phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) and can be phosphorylated on tyrosine 139 and internalised in response to activation of type I phosphoinositide 3-kinases (PI3K). Tyrosine phosphorylation of DAPP-1 appears important for appropriate intracellular targeting and creates a potential binding site for Src homology 2 domain-containing proteins. In endothelial cells overexpressing wild-type platelet-derived growth factor beta (PDGF beta) receptors, which express Bmx and Src as their major Btk ((B) under bar ruton's (t) under bar yrosine (k) under bar inase) family and Src family tyrosine kinases, respectively, PDGF can stimulate PI3K-dependent tyrosine phosphorylation of DAPP-1. Transient overexpression of Src most effectively, compared with Bmx and Syk, augments basal and PDGF-stimulated tyrosine phosphorylation of DAPP-1, whereas overexpression of dominant-negative Src, but not dominant-negative Bmx, inhibits PDGF-stimulated phosphorylation of DAPP-1. Cells expressing mutant PDGF beta (Y579F/Y581F) receptors (which fail to bind and activate Src-type kinases) fail to tyrosine phosphorylate DAPP-1 in response to PDGF. We show that in DT40 chicken B cell lines, antibody stimulation leads to PI3K-dependent tyrosine phosphorylation of DAPP-1 that is lost in Lyn- or Syk-deficient cell lines but not Btk-deficient cell lines. PI3K-dependent activation of PKB is only lost in Syk-deficient lines. Finally, in vitro we find lipid-modified Src to be the most effective DAPP-1 tyrosine kinase (versus Syk, Lyn, Btk, and Bmx); phosphorylation of DAPP-1 but not Src autophosphorylation is stimulated similar to 10-fold by PtdIns(3,4,5)P-3 (IC50 = 150 nM) and phosphatidylinositol 3,4-bisphosphate but not by their nonbiological diastereoisomers and depends on PH domain mediated binding of DAPP-1 to PtdIns(3,4,5)P-3-containing membranes. We conclude that Src family kinases are responsible for tyrosine phosphorylation of DAPP-1 in vivo and that PI3K regulation is at the level of PH domain-mediated translocation of DAPP-1 to PI3K products in the membrane.	Babraham Inst, Signalling Program, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Stephens, LR (corresponding author), Babraham Inst, Signalling Program, Inositide Lab, Cambridge CB2 4AT, England.			Hawkins, Phillip/0000-0002-6979-0464; Anderson, Karen/0000-0002-7394-6660; stephens, len/0000-0002-2771-3487				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 2000, CURR BIOL, V10, P1403, DOI 10.1016/S0960-9822(00)00794-6; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Dowler S, 2000, BIOCHEM J, V349, P605, DOI 10.1042/0264-6021:3490605; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Gold MR, 1999, J IMMUNOL, V163, P1894; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KHARLUND JK, 1998, J BIOL CHEM, V273, P1859; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Painter GF, 1999, J CHEM SOC PERK T 1, P923, DOI 10.1039/a900278b; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X	29	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42767	42773		10.1074/jbc.M107194200	http://dx.doi.org/10.1074/jbc.M107194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11524430	hybrid			2022-12-25	WOS:000172169300019
J	Gumbiowski, K; Cherepanov, D; Muller, M; Panke, O; Promto, P; Winkler, S; Junge, W; Engelbrecht, S				Gumbiowski, K; Cherepanov, D; Muller, M; Panke, O; Promto, P; Winkler, S; Junge, W; Engelbrecht, S			F-ATPase: Forced full rotation of the rotor despite covalent cross-link with the stator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; C-SUBUNIT OLIGOMER; COUPLING FACTOR-I; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; GAMMA-SUBUNIT; EPSILON-SUBUNIT; SYNTHASE; F-1-ATPASE; F1-ATPASE	In ATP synthase (F0F1-ATPase) ion flow through the membrane-intrinsic portion, Fo, drives the central "rotor", subunits c(10)epsilon gamma, relative to the "stator" ab(2)delta(alpha beta)(3). This converts ADP and P-i into ATP. Vice versa, ATP hydrolysis drives the rotation backwards. Covalent cross-links between rotor and stator subunits have been shown to inhibit these activities. Aiming at the rotary compliance of subunit gamma we introduced disulfide bridges between gamma (rotor) and a or beta (stator). We engineered cysteine residues into positions located roughly at the "top," "center," and "bottom" parts of the coiled-coil portion of gamma and suitable residues on alpha or beta. This part of gamma is located at the center of the (alpha beta)(3) domain with its C-terminal part at the top of F-1 and the bottom part close to the F-0 complex. Disulfide bridge formation under oxidizing conditions was quantitative as shown by SDS-polyacrylamide gel electrophoresis and immunoblotting. As expected both the ATPase activities and the yield of rotating subunits gamma dropped to zero when the cross-link was formed at the center (gamma L262C <----> alpha A334C) and bottom (,gamma Cys(87) <----> beta D380C) positions. But much to our surprise disulfide bridging impaired neither ATP hydrolysis activity nor the full rotation of gamma and the enzyme-generated torque of oxidized F-1, which had been engineered at the top position (gamma A285C <----> alpha P280C). Apparently the high torque of this rotary engine uncoiled the a-helix and forced amino acids at the C-terminal portion of gamma into full rotation around their dihedral (Ramachandran) angles. This conclusion was supported by molecular dynamics simulations: If gamma Cys(285)-Val(286) are attached covalently to (alpha beta )3 and gamma Ala(1)-Ser(281) is forced to rotate, gamma GlY(282)-Ala(284) can serve as cardan shaft.	Univ Osnabruck, FB Biol, Abt Biophys, D-49069 Osnabruck, Germany	University Osnabruck	Engelbrecht, S (corresponding author), Univ Osnabruck, FB Biol, Abt Biophys, Barbarastr 11, D-49069 Osnabruck, Germany.		Cherepanov, Dmitry A./R-8391-2016	Cherepanov, Dmitry A./0000-0001-6286-4638				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, X PLOR VERSION 3 1; Cherepanov DA, 2001, BIOPHYS J, V81, P1234, DOI 10.1016/S0006-3495(01)75781-5; Dalke A, 1997, Pac Symp Biocomput, P85; DARAGAN VA, 1993, BIOCHEMISTRY-US, V32, P11488, DOI 10.1021/bi00094a004; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 2000, NAT STRUCT BIOL, V7, P1002, DOI 10.1038/80902; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KRAUSE I, 1987, 5 MINUTE SILVER STAI; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; RANKIN W, 2001, IN PRESS I EL EL ENG; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHREIBER H, 1992, BIOCHEMISTRY-US, V31, P5856, DOI 10.1021/bi00140a022; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WISE JG, 1990, J BIOL CHEM, V265, P10403; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	42	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42287	42292		10.1074/jbc.M106884200	http://dx.doi.org/10.1074/jbc.M106884200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533065	hybrid			2022-12-25	WOS:000172450400099
J	Liberati, C; Cera, MR; Secco, P; Santoro, C; Mantovani, R; Ottolenghi, S; Ronchi, A				Liberati, C; Cera, MR; Secco, P; Santoro, C; Mantovani, R; Ottolenghi, S; Ronchi, A			Cooperation and competition between the binding of COUP-TFII and NF-Y on human epsilon- and gamma-globin gene promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL CCAAT BOX; GREEK HEREDITARY PERSISTENCE; NUCLEAR FACTOR-Y; MHC CLASS-II; FETAL HEMOGLOBIN; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; ACTIVE REPRESSION; ERYTHROID-CELLS; POINT MUTATION	The nuclear receptor COUP-TFII was recently shown to bind to the promoter of the epsilon- and gamma -globin genes and was identified as the nuclear factor NF-E3. Transgenic experiments and genetic evidence from humans affected with hereditary persistence of fetal hemoglobin suggest that NF-E3 may be a repressor of adult epsilon and gamma expression. We show that, on the epsilon -promoter, recombinant COUP-TFII binds to two sites, the more downstream of which overlaps with an NF-Y binding CCAAT box. Binding occurs efficiently to either the 5' or the 3' COUP-TFII site but not to both sites simultaneously. However, adding recombinant NF-Y induces the formation of a stable COUP-(TFIINF)-N-.-Y-promoter complex at concentrations of COUP-TFII that would not give significant binding in the absence of NF-Y. Mutations of the promoter indicate that COUP-TFII cooperates with NF-Y when bound to the 5' site, whereas binding at the 3' site is mutually exclusive. Likewise, in the gamma -promoter, COUP-TFII binds to a site overlapping the distal member of a duplicated CCAAT box, competing with NF-Y binding. Transfections in K562 cells show that both the mutation of the 5' COUP-TFII or of the NF-Y site on the epsilon -promoter decrease the activity of a luciferase reporter; the mutation of the 3' COUP-TFII site has little effect. These results, together with transgenic experiments suggesting a repressive activity of COUP-TFII on the epsilon -promoter and the observation that, on the 3' site, COUP-TFII and NF-Y binding is mutually exclusive, suggest that COUP-TFII may exert different effects on epsilon transcription depending on whether it binds to the 5' or to the 3' site. At the 5' site, COUP-TFII might cooperate with NF-Y, forming a stable complex, and stimulate transcription; at the 3' site, COUP-TFII might compete for binding with NF-Y and, directly or indirectly, decrease gene activity.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy; Univ Modena, Dipartimento Biol Anim, I-41100 Modena, Italy	University of Milano-Bicocca; University of Eastern Piedmont Amedeo Avogadro; Universita di Modena e Reggio Emilia	Ronchi, A (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy.		santoro, claudio/G-6819-2012		Telethon [E.0596] Funding Source: Medline	Telethon(Fondazione Telethon)		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Caretti G, 2000, J MOL BIOL, V302, P539, DOI 10.1006/jmbi.2000.4028; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; Falck J, 1999, J BIOL CHEM, V274, P18753, DOI 10.1074/jbc.274.26.18753; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; Forget BG, 1998, ANN NY ACAD SCI, V850, P38, DOI 10.1111/j.1749-6632.1998.tb10460.x; FUCHAROEN S, 1990, NUCLEIC ACIDS RES, V18, P5245, DOI 10.1093/nar/18.17.5245; GE RW, 1994, J BIOL CHEM, V269, P13185; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GILMAN JG, 1988, NUCLEIC ACIDS RES, V16, P10635, DOI 10.1093/nar/16.22.10635; Glass CK, 2000, GENE DEV, V14, P121; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; INDRAK K, 1991, ANN HEMATOL, V63, P1; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jackson SM, 1998, J LIPID RES, V39, P767; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Leng X, 1996, MOL CELL BIOL, V16, P2332; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liberati C, 1999, J MOL BIOL, V285, P1441, DOI 10.1006/jmbi.1998.2384; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MOTUM PI, 1994, BRIT J HAEMATOL, V86, P219, DOI 10.1111/j.1365-2141.1994.tb03284.x; NEY P, 1990, GENE DEV, V4, P93; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OTTOLENGHI S, 1989, HEMOGLOBIN, V13, P523, DOI 10.3109/03630268908993104; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PERKINS AC, 1995, NATURE, V375, P318; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Power SC, 1996, MOL CELL BIOL, V16, P778; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; Tanimoto K, 2000, GENE DEV, V14, P2778, DOI 10.1101/gad.822500; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; Villard J, 2000, MOL CELL BIOL, V20, P3364, DOI 10.1128/MCB.20.10.3364-3376.2000; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Weatherall DJ, 1981, THALASSEMIA SYNDROME; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zertal-Zidani S, 1999, HEMOGLOBIN, V23, P159, DOI 10.3109/03630269908996160	58	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41700	41709		10.1074/jbc.M102987200	http://dx.doi.org/10.1074/jbc.M102987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11544252	hybrid, Green Published			2022-12-25	WOS:000172450400023
J	Senoo-Matsuda, N; Yasuda, K; Tsuda, M; Ohkubo, T; Yoshimura, S; Nakazawa, H; Hartman, PS; Ishii, N				Senoo-Matsuda, N; Yasuda, K; Tsuda, M; Ohkubo, T; Yoshimura, S; Nakazawa, H; Hartman, PS; Ishii, N			A defect in the cytochrome b large subunit in complex II causes both superoxide anion overproduction and abnormal energy metabolism in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; ONSET OPTIC ATROPHY; OXIDATIVE STRESS; SUCCINATE-DEHYDROGENASE; SENSITIVE MUTANT; DEFICIENCY; OXYGEN; MUTATION; GENE; PARAGANGLIOMA	A mev-1(kn1) mutant of the nematode Caenorhabditis elegans is defective in the cytochrome b large subunit (Cyt-1/ceSDHC) in complex II of the mitochondrial electron transport chain. We have previously shown that a mutation in mev-1 causes shortened life span and rapid accumulation of aging markers such as fluorescent materials and protein carbonyls in an oxygen-dependent fashion. However, it remains unclear as to whether this hypersensitivity is caused by direct toxicity of the exogenous oxygen or by the damage of endogenous reactive oxygen species derived from mitochondria. Here we report important biochemical changes in mev-1 animals that serve to explain their abnormalities under normoxic conditions: (i) an overproduction of superoxide anion from mitochondria; and (ii) a reciprocal reduction in glutathione content even under atmospheric oxygen. In addition, unlike wild type, the levels of superoxide anion production from mev-1 mitochondria were significantly elevated under hyperoxia. Under normal circumstances, it is well known that superoxide anion is produced at complexes I and III in the electron transport system. Our data suggest that the mev-1(kn1) mutation increases superoxide anion production at complex II itself rather than at complexes I and III. The mev-1 mutant also had a lactate level 2-fold higher than wild type, indicative of lactic acidosis, a hallmark of human mitochondrial diseases. These data indicate that Cyt-1/ceSDHC plays an important role not only in energy metabolism but also in superoxide anion production that is critically involved in sensitivity to atmospheric oxygen.	Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan; Tokai Univ, Sch Med, Dept Physiol, Kanagawa 2591193, Japan; Texas Christian Univ, Dept Biol, Ft Worth, TX 76129 USA	Tokai University; Tokai University; Texas Christian University	Ishii, N (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan.		Yasuda, Kayo/ABA-5867-2021	Yasuda, Kayo/0000-0002-6205-9249				Adachi H, 1998, J GERONTOL A-BIOL, V53, pB240, DOI 10.1093/gerona/53A.4.B240; ANDERSON AE, 1985, HDB METHODS OXYGEN R, P317; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A; BOURGEOIS M, 1992, BRAIN DEV-JPN, V14, P404, DOI 10.1016/S0387-7604(12)80349-4; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; DiMauro S, 1998, BBA-BIOENERGETICS, V1366, P199, DOI 10.1016/S0005-2728(98)00113-3; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; HALL RE, 1993, J CLIN INVEST, V92, P2660, DOI 10.1172/JCI116882; HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; Howell N, 1999, INT REV CYTOL, V186, P49; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; MARTIN JJ, 1988, J NEUROL SCI, V84, P189, DOI 10.1016/0022-510X(88)90124-4; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48; RIVNER MH, 1989, NEUROLOGY, V39, P693, DOI 10.1212/WNL.39.5.693; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916	31	209	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41553	41558		10.1074/jbc.M104718200	http://dx.doi.org/10.1074/jbc.M104718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527963	hybrid			2022-12-25	WOS:000172450400004
J	Stromhaug, PE; Bevan, A; Dunn, WA				Stromhaug, PE; Bevan, A; Dunn, WA			GSA11 encodes a unique 208-kDa protein required for pexophagy and autophagy in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HANSENULA-POLYMORPHA; PEROXISOME-DEFICIENT MUTANTS; VACUOLE TARGETING PATHWAY; ISOLATED RAT HEPATOCYTES; SACCHAROMYCES-CEREVISIAE; SELECTIVE INACTIVATION; CONJUGATION SYSTEM; VESICLE FORMATION; CVT PATHWAY; DEGRADATION	Cells are capable of adapting to changes in their environment by synthesizing needed proteins and degrading superfluous ones. Pichia pastoris synthesizes peroxisomal enzymes to grow in methanol medium. Upon adapting from methanol medium to one containing glucose, this yeast rapidly and selectively degrades peroxisomes by an autophagic process referred to as pexophagy. In this study, we have utilized a novel approach to identify genes required for this degradative pathway. Our approach involves the random integration of a vector containing the Zeocin resistance gene into the yeast genome by restriction enzyme-mediated integration. Cells unable to degrade peroxisomes during glucose adaptation were isolated, and the genes that were disrupted by the insertion of the vector were determined by sequencing. By using this approach, we have identified a number of genes required for glucose-induced selective autophagy of peroxisomes (GSA genes). We report here the characterization of Gsa11, a unique 208-kDa protein. We found that this protein is required for glucose-induced pexophagy and starvation-induced autophagy. Gsa11 is a cytosolic protein that becomes associated with one or more structures situated near the vacuole during glucose adaptation. The punctate localization of Gsa11 was not observed in gsa10, gsa12, gsa14, and gsa19 mutants. We have previously shown that Gsa9 appears to relocate from a compartment at the vacuole surface to regions between the vacuole and the peroxisomes being sequestered. In the gsa11 mutants, the vacuole only partially surrounded the peroxisomes, but Gsa9 was still distributed around the peroxisome cluster. This suggests that Gsa9 binds to the peroxisomes independent of the vacuole. The data also indicate that Gsa11 is not necessary for Gsa9 to interact with peroxisomes but acts at an intermediate event required for the vacuole to engulf the peroxisomes.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Norwegian Radium Hosp, Dept Cell Biol, Inst Canc Res, N-0310 Oslo, Norway	State University System of Florida; University of Florida; University of Oslo	Bevan, A (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.							Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; Holtzman E, 1989, LYSOSOMES; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kiel JAKW, 1999, YEAST, V15, P741, DOI 10.1002/(SICI)1097-0061(19990630)15:9<741::AID-YEA416>3.0.CO;2-O; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 1997, J MEMBRANE BIOL, V157, P105, DOI 10.1007/s002329900220; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LUIKEN JJFP, 1992, FEBS LETT, V304, P93, DOI 10.1016/0014-5793(92)80596-9; Marzella L, 1987, LYSOSOMES THEIR ROLE, P319; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; MORTIMORE GE, 1983, P NATL ACAD SCI-BIOL, V80, P2179, DOI 10.1073/pnas.80.8.2179; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saiz JE, 1999, YEAST, V15, P155, DOI 10.1002/(SICI)1097-0061(19990130)15:2<155::AID-YEA342>3.0.CO;2-U; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Sears IB, 1998, YEAST, V14, P783, DOI 10.1002/(SICI)1097-0061(19980615)14:8<783::AID-YEA272>3.0.CO;2-Y; Seglen PO, 1996, ADV EXP MED BIOL, V389, P103; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stasyk OV, 1999, CURR GENET, V36, P262, DOI 10.1007/s002940050499; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; TUTTLE DL, 1995, J CELL SCI, V108, P25; VANDERKLEI IJ, 1991, YEAST, V7, P813, DOI 10.1002/yea.320070806; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; Veenhuis M, 2000, MICROSC RES TECHNIQ, V51, P584, DOI 10.1002/1097-0029(20001215)51:6<584::AID-JEMT8>3.0.CO;2-W; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Yuan WP, 1997, J CELL SCI, V110, P1935; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	71	52	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42422	42435		10.1074/jbc.M104087200	http://dx.doi.org/10.1074/jbc.M104087200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533052	hybrid			2022-12-25	WOS:000172450400114
J	Hickox, JR; Bi, M; Hardy, DM				Hickox, JR; Bi, M; Hardy, DM			Heterogeneous processing and zona pellucida binding activity of pig zonadhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; SPERM MEMBRANE-PROTEIN; VONWILLEBRAND-FACTOR; MULTIPLE FORMS; EXTRACELLULAR-MATRIX; POLYACRYLAMIDE GELS; D-DOMAINS; HYALURONIDASE; RAM; MULTIMERIZATION	Zonadhesin is a mosaic protein in sperm membrane fractions that binds directly and in a species-specific manner to the extracellular matrix (zona pellucida) of the oocyte. The active form of pig zonadhesin from capacitated, epididymal spermatozoa comprises two covalently associated polypeptide chains of M-r 105,000 (p105) and M-r 45,000 (p45). Here we report detection and characterization of multiple zonadhesin isoforms in freshly ejaculated cells. Antibodies to the predicted von Willebrand D0-D1, D1, and D3 domains of pig zonadhesin recognized p105, p45, and additional M-r 60,000-90,000 polypeptides in particulate fractions of uncapacitated cells. Although the p105/45 form constituted a minority of all zonadhesin forms in sperm membrane fractions, it was the predominant form capable of binding to the pig zona pellucida. Zonadhesin-binding sites were distributed over the entire zona pellucida. Anion exchange chromatography resolved active, p105/45 zonadhesin from the p60-90 inactive forms. Without disulfide bond reduction some zonadhesin was M-r greater than or equal to 300,000, including M-r 300,000 and 900,000 proteins comprising in part multimers of p105/45. The multimeric forms did not bind the zona pellucida as avidly as did the p105/45 monomer. Expressed Dl and D3 domain fragments containing the CG(L/V)CG sequence motif spontaneously formed multimers at -246 mV E-h in vitro. Double Cys --> Ser mutants of the D1 fragment formed multimers with the same apparent kinetics as the wild type protein. Zonadhesin localized to the apical head of pig spermatozoa. We conclude that a heterogeneous combination of specific proteolysis and intermolecular disulfide bond formation in the sperm head generates multiple forms of zonadhesin with differing avidities for the zona pellucida.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Hardy, DM (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.		Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD035166] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-35166] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BI M, 2002, IN PRESS FERTILIZATI; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; Haden NP, 2000, BIOL REPROD, V63, P1839, DOI 10.1095/biolreprod63.6.1839; HARDY DM, 1987, BIOL REPROD, V37, P189, DOI 10.1095/biolreprod37.1.189; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HARRISON RAP, 1988, BIOCHEM J, V252, P865, DOI 10.1042/bj2520865; HARRISON RAP, 1988, J REPROD FERTIL, V82, P777, DOI 10.1530/jrf.0.0820777; HARRISON RAP, 1988, BIOCHEM J, V252, P875, DOI 10.1042/bj2520875; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; JAISWAL BS, 2002, FERTILIZATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wilson MD, 2001, NUCLEIC ACIDS RES, V29, P1352, DOI 10.1093/nar/29.6.1352; Yanagimachi R., 1994, P189	29	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41502	41509		10.1074/jbc.M106795200	http://dx.doi.org/10.1074/jbc.M106795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526117	hybrid			2022-12-25	WOS:000171925600148
J	Segarini, PR; Nesbitt, JE; Li, DX; Hays, LG; Yates, JR; Carmichael, DF				Segarini, PR; Nesbitt, JE; Li, DX; Hays, LG; Yates, JR; Carmichael, DF			The low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor is a receptor for connective tissue growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; VASCULAR ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E RECEPTORS; COMPLEMENT-TYPE REPEATS; HUMAN SKIN FIBROBLASTS; FACTOR-BETA; ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND-BINDING; PROTEIN LRP; TYROSINE PHOSPHORYLATION	Connective tissue growth factor (CTGF) expression is regulated by transforming growth factor-beta (TGF-beta) and strong up-regulation occurs during wound healing; in situ hybridization data indicate that there are high levels of CTGF expression in fibrotic lesions. Recently the binding parameters of CTGF to both high and lower affinity cell surface binding components have been characterized. Affinity cross-linking and SDS-polyacrylamide gel electrophoresis analysis demonstrated the binding of CTGF to a cell surface protein with a mass of similar to 620 kDa. We report here the purification of this protein by affinity chromatography on CTGF coupled to Sepharose and sequence information obtained by mass spectroscopy. The binding protein was identified as the multiligand receptor, low density lipoprotein receptor-related protein/alpha (2)-macroglobulin receptor (LRP). The identification of LRP as a receptor for CTGF was validated by several studies: 1) binding competition with many ligands that bind to LRP, including receptor-associated protein; 2) immunoprecipitation of CTGF-receptor complex with LRP antibodies; and 3) cells that are genetically deficient for LRP were unable to bind CTGF. Last, CTGF is rapidly internalized and degraded and this process is LRP-dependent. In summary, our data indicate that LRP is a receptor for CTGF, and may play an important role in mediating CTGF biology.	FibroGen Inc, San Francisco, CA 94080 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	FibroGen; University of Washington; University of Washington Seattle	Nesbitt, JE (corresponding author), FibroGen Inc, San Francisco, CA 94080 USA.	jnesbitt@fibrogen.com						Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Atkinson P H, 1973, Methods Cell Biol, V7, P157; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Chambers RC, 2000, J BIOL CHEM, V275, P35584, DOI 10.1074/jbc.M003188200; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; COUKOS G, 1994, AM J PATHOL, V144, P383; Crisp RJ, 2000, J BIOL CHEM, V275, P19628, DOI 10.1074/jbc.M909172199; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fan WH, 2000, EUR J CELL BIOL, V79, P915, DOI 10.1078/0171-9335-00122; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Gliemann J, 1998, BIOL CHEM, V379, P951; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hahn A, 2000, J BIOL CHEM, V275, P37429, DOI 10.1074/jbc.M000976200; Handschug K, 1998, J MOL MED-JMM, V76, P596, DOI 10.1007/s001090050255; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kasza A, 1997, EUR J BIOCHEM, V248, P270, DOI 10.1111/j.1432-1033.1997.00270.x; KIKUCHI K, 1995, J INVEST DERMATOL, V105, P128, DOI 10.1111/1523-1747.ep12313452; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; LAMARRE J, 1991, LAB INVEST, V65, P3; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Oemar BS, 1997, CIRCULATION, V95, P831; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Schwab JM, 2000, NEUROPATH APPL NEURO, V26, P434, DOI 10.1046/j.1365-2990.2000.00271.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Surveyor GA, 1998, BIOL REPROD, V59, P1207, DOI 10.1095/biolreprod59.5.1207; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Teesalu T, 1996, MECH DEVELOP, V56, P103, DOI 10.1016/0925-4773(96)00515-1; Thal DR, 1997, BRAIN RES, V777, P223, DOI 10.1016/S0006-8993(97)01021-4; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; van Goor H, 1999, EXP NEPHROL, V7, P35; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Wunderlich K, 2000, GRAEF ARCH CLIN EXP, V238, P910, DOI 10.1007/s004170000199; Wunderlich K, 2000, CURR EYE RES, V21, P627, DOI 10.1076/0271-3683(200008)21:2;1-V;FT627; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	84	177	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40659	40667		10.1074/jbc.M105180200	http://dx.doi.org/10.1074/jbc.M105180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518710	hybrid			2022-12-25	WOS:000171925600039
J	LaFleur, DW; Nardelli, B; Tsareva, T; Mather, D; Feng, P; Semenuk, M; Taylor, K; Buergin, M; Chinchilla, D; Roshke, V; Chen, GX; Ruben, SM; Pitha, PM; Coleman, TA; Moore, PA				LaFleur, DW; Nardelli, B; Tsareva, T; Mather, D; Feng, P; Semenuk, M; Taylor, K; Buergin, M; Chinchilla, D; Roshke, V; Chen, GX; Ruben, SM; Pitha, PM; Coleman, TA; Moore, PA			Interferon-kappa, a novel type I interferon expressed in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INTERFERON; BETA; RECEPTOR; CELLS; GENE; IDENTIFICATION; CYTOKINE; SUBUNIT; CLONING; PATHWAY	High throughput cDNA sequencing has led to the identification of interferon-kappa, a novel subclass of type I interferon that displays similar to 30% homology to other family members. Interferon-kappa consists of 207 amino acids, including a 27-amino acid signal peptide and a series of cysteines conserved in type I interferons. The gene encoding interferon-kappa is located on the short arm of chromosome 9 adjacent to the type I interferon gene cluster and is selectively expressed in epidermal keratinocytes. Expression of interferon-kappa is significantly enhanced in keratinocytes upon viral infection, upon exposure to double-stranded RNA, or upon treatment with either interferon-gamma or interferon-beta. Administration of interferon-kappa recombinant protein imparts cellular protection against viral infection in a species-specific manner. Interferon-kappa activates the interferon-stimulated response element signaling pathway and a panel of genes similar to those regulated by other type I interferons including anti-viral mediators and transcriptional regulators. An antibody that neutralizes the type I interferon receptor completely blocks interferon-kappa signaling, demonstrating that interferon-kappa utilizes the same receptor as other type I interferons. Interferon-kappa therefore defines a novel subclass of type I interferon that is expressed in keratinocytes and expands the repertoire of known proteins mediating host defense.	Human Genome Sci, Rockville, MD 20850 USA; Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA	GlaxoSmithKline; Human Genome Sciences Inc; Johns Hopkins University	Moore, PA (corresponding author), Human Genome Sci, Rockville, MD 20850 USA.							ADOLF GR, 1995, MULT SCLER, V1, P44; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P4415, DOI 10.1073/pnas.74.10.4415; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DIAZ MO, 1994, GENOMICS, V22, P540, DOI 10.1006/geno.1994.1427; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; Fujisawa H, 1997, J INTERF CYTOK RES, V17, P721, DOI 10.1089/jir.1997.17.721; Gao YN, 1999, MOL CELL BIOL, V19, P7305; GENTZ RL, 2001, Patent No. 6194168; GREINER JW, 1987, SCIENCE, V235, P895, DOI 10.1126/science.3580039; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LIN LS, 1986, METHOD ENZYMOL, V119, P183; MAEYER ED, 1998, CYTOKINE HDB, P491; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Oritani K, 2000, NAT MED, V6, P659, DOI 10.1038/76233; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; Roberts RM, 1999, PLACENTA, V20, P259, DOI 10.1053/plac.1998.0381; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SENDA T, 1995, J MOL BIOL, V253, P187, DOI 10.1006/jmbi.1995.0544; SOH JM, 1994, J BIOL CHEM, V269, P18102; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAAR M, 1986, J CELL BIOL, V103, P1349, DOI 10.1083/jcb.103.4.1349	38	200	225	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39765	39771		10.1074/jbc.M102502200	http://dx.doi.org/10.1074/jbc.M102502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514542	hybrid			2022-12-25	WOS:000171789200035
J	Rui, LY; Fisher, TL; Thomas, J; White, MF				Rui, LY; Fisher, TL; Thomas, J; White, MF			Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; MAMMALIAN TARGET; KAPPA-B; 3T3-L1 ADIPOCYTES; MICE LACKING; IN-VITRO; RESISTANCE; PATHWAY; RAPAMYCIN; ALPHA	Insulin and insulin-like growth factor-1 (IGF-1) regulate metabolism and body growth through homologous receptor tyrosine kinases that phosphorylate the insulin receptor substrate (IRS) proteins. IRS-2 is an important IRS protein, as it mediates peripheral insulin action and beta -cell survival. In this study, we show that insulin, IGF-1, or osmotic stress promoted ubiquitin/proteasome-mediated degradation of IRS-2 in 3T3-L1 cells, Fao hepatoma, cells and mouse embryo fibroblasts; however, insulin/IGF-1 did not promote degradation of IRS-1 in 3T3-L1 preadipocytes or mouse embryo fibroblasts. MG132 or lactacystin, specific inhibitors of 26S proteasome, blocked insulin/IGF-1-induced degradation of IRS-2 and enhanced the detection of ubiquitinated IRS-2. Insulin/IGF1-induced ubiquitination and degradation of IRS-2 was blocked by inhibitors of phosphatidylinositol 3-kinase (wortmannin or LY294002) or mTOR (rapamycin). Chronic insulin or IGF-1 treatment of IRS-1-deficient mouse embryo fibroblasts inhibited IRS-2-mediated activation of Akt and ERK1/2, which was reversed by lactacystin pretreatment. By contrast, IRS-I activation of Akt and ERK1/2 was not inhibited by chronic insulin/IGF-1 stimulation in IRS-2-deficient mouse embryo fibroblasts. Thus, we identified a novel negative feedback mechanism by which the ubiquitin/proteasome-mediated degradation of IRS-2 limits the magnitude and duration of the response to insulin or IGF-1.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, MF (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, 1 Joslin Pl, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu			NIDDK NIH HHS [DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; DeFronzo RA, 1997, DIABETES REV, V5, P177; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Goldberg AL, 2001, SCI AM, V284, P68, DOI 10.1038/scientificamerican0101-68; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kirschner M, 1999, TRENDS CELL BIOL, V9, pM42, DOI 10.1016/S0962-8924(99)01666-9; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Merforth S, 1999, MOL BIOL REP, V26, P83, DOI 10.1023/A:1006966005662; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wojcik C, 1999, DRUG DISCOV TODAY, V4, P188; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	41	163	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40362	40367		10.1074/jbc.M105332200	http://dx.doi.org/10.1074/jbc.M105332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546773	hybrid			2022-12-25	WOS:000171789200114
J	Kawakami, M; Sekiguchi, M; Sato, K; Kozaki, S; Takahashi, M				Kawakami, M; Sekiguchi, M; Sato, K; Kozaki, S; Takahashi, M			Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; RAT HIPPOCAMPAL; PROTEIN HORMONE; BRAIN ISCHEMIA; NEURONS; TARGETS	Erythropoietin (EPO) reduced Ca2+-induced glutamate (Glu) release from cultured cerebellar granule neurons. Inhibition was also produced by EPO mimetic peptide 1 (EMP1), a small synthetic peptide agonist of EPO receptor (EPO-R), but not by iEMP1, an inactive analogue of EMP1. EPO and EMP1 induced autophosphorylation of Janus kinase 2 (JAK2), a tyrosine kinase that associates with EPO-R. Furthermore, genistein, but not genistin, antagonized both the phosphorylation of JAK2 and the suppression of Glu release induced by EPO and EMP1. During chemical ischemia, substantial amounts of Glu were released from cultured cerebellar and hippocampal neurons by at least two distinct mechanisms. In the early phase, Glu release occurred by exocytosis of synaptic vesicle contents, because it was abolished by botulinum type B neurotoxin (BoNT/B). In contrast, the later phase of Glu release mainly involved a BoNT/B-insensitive non-exocytotic pathway. EMP1 inhibited Glu release only during the early exocytotic phase. A 20-min exposure of hippocampal slices to chemical ischemia induced neuronal cell death, especially in the CA1 region and the dentate gyrus, which was suppressed by EMP1 but not iEMP1. However, EMP1 did not attenuate neuronal cell death induced by exogenously applied Glu. These results suggest that activation of EPO-R suppresses ischemic cell death by inhibiting the exocytosis of Glu.	Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Biol, Tokyo 1538902, Japan; Osaka Prefecture Univ, Coll Agr, Dept Vet Sci, Sakai, Osaka 593, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo; Osaka Metropolitan University	Takahashi, M (corresponding author), Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan.	masami@libra.ls.m-kagaku.co.jp						BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; DUFFY KR, 1988, METABOLISM, V37, P136, DOI 10.1016/S0026-0495(98)90007-5; FORAN P, 1995, BIOCHEMISTRY-US, V34, P5494, DOI 10.1021/bi00016a021; GODEL H, 1984, J CHROMATOGR, V297, P49, DOI 10.1016/S0021-9673(01)89028-2; Gottschalk WA, 1999, LEARN MEMORY, V6, P243; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hirasawa T, 2000, BRIT J PHARMACOL, V129, P21, DOI 10.1038/sj.bjp.0702949; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Kawakami M, 2000, BIOCHEM BIOPH RES CO, V279, P293, DOI 10.1006/bbrc.2000.3926; KOZAKI S, 1974, INFECT IMMUN, V10, P750, DOI 10.1128/IAI.10.4.750-756.1974; KRANTZ SB, 1991, BLOOD, V77, P419; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Pardridge WM, 1997, J CEREBR BLOOD F MET, V17, P713, DOI 10.1097/00004647-199707000-00001; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; POCOCK JM, 1993, NEUROPHARMACOLOGY, V32, P1185, DOI 10.1016/0028-3908(93)90012-R; Pocock JM, 1998, J NEUROCHEM, V70, P806; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; SAKAGUCHI T, 1994, NEUROSCI RES, V20, P157, DOI 10.1016/0168-0102(94)90033-7; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; VonLubitz DKJE, 1996, EUR J PHARMACOL, V316, P171, DOI 10.1016/S0014-2999(96)00667-X; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	37	202	224	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39469	39475		10.1074/jbc.M105832200	http://dx.doi.org/10.1074/jbc.M105832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504731	hybrid			2022-12-25	WOS:000171673200148
J	Linseman, DA; Laessig, T; Meintzer, MK; McClure, M; Barth, H; Aktories, K; Heidenreich, KA				Linseman, DA; Laessig, T; Meintzer, MK; McClure, M; Barth, H; Aktories, K; Heidenreich, KA			An essential role for Rac/Cdc42 GTPases in cerebellar granule neuron survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; GTP-BINDING PROTEINS; RHO-FAMILY GTPASES; N-TERMINAL KINASE; DIFFICILE TOXIN-B; C-JUN; CLOSTRIDIUM-DIFFICILE; GROWTH-FACTOR; SYMPATHETIC NEURONS; INDUCED APOPTOSIS	Rho family GTPases are critical molecular switches that regulate the actin cytoskeleton and cell function. In the current study, we investigated the involvement of Rho GTPases in regulating neuronal survival using primary cerebellar granule neurons. Clostridium difficile toxin B, a specific inhibitor of Rho, Rac, and Cdc42, induced apoptosis of granule neurons characterized by c-Jun phosphorylation, caspase-3 activation, and nuclear condensation. Serum and depolarization-dependent survival signals could not compensate for the loss of GTPase function. Unlike trophic factor withdrawal, toxin B did not affect the antiapoptotic kinase Akt or its target glycogen synthase kinase-3 beta. The proapoptotic effects of toxin B were mimicked by Clostridium sordellii lethal toxin, a selective inhibitor of Rac/Cdc42. Although Rac/Cdc42 GTPase inhibition led to F-actin disruption, direct cytoskeletal disassembly with Clostridium botulinum C2 toxin was insufficient to induce c-Jun phosphorylation or apoptosis. Granule neurons expressed high basal JNK and low p38 mitogen-activated protein kinase activities that were unaffected by toxin B. However, pyridyl imidazole inhibitors of JNK/p38 attenuated c-Jun phosphorylation. Moreover, both pyridyl imidazoles and adenoviral dominant-negative c-Jun attenuated apoptosis, suggesting that JNK/c-Jun signaling was required for cell death. The results indicate that Rac/Cdc42 GTPases, in addition to trophic factors, are critical for survival of cerebellar granule neurons.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80220 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Freiburg	Linseman, DA (corresponding author), Denver VAMC 111H, 1055 Clermont St, Denver, CO 80220 USA.		Core, Vector/CAF-4832-2022; Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022; Linseman, Daniel/L-3846-2019	Aktories, Klaus/0000-0002-5397-0436; 				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Carpenter CL, 1996, SEMIN CELL DEV BIOL, V7, P691, DOI 10.1006/scdb.1996.0085; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Coffey ET, 2000, J NEUROSCI, V20, P7602; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eilers A, 1998, J NEUROSCI, V18, P1713; Eldadah BA, 2000, J NEUROSCI, V20, P179, DOI 10.1523/JNEUROSCI.20-01-00179.2000; Embade N, 2000, MOL BIOL CELL, V11, P4347, DOI 10.1091/mbc.11.12.4347; Fiorentini C, 1997, BIOCHEM BIOPH RES CO, V241, P341, DOI 10.1006/bbrc.1997.7723; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 1998, INFECT IMMUN, V66, P2660, DOI 10.1128/IAI.66.6.2660-2665.1998; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; GALLI C, 1995, J NEUROSCI, V15, P1172; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Garcia-Roman N, 2001, MOL CELL NEUROSCI, V17, P329, DOI 10.1006/mcne.2000.0904; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Hetman M, 2000, J NEUROSCI, V20, P2567; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Iimura O, 1997, KIDNEY INT, V52, P962, DOI 10.1038/ki.1997.418; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kumar S, 1997, INT J BIOCHEM CELL B, V29, P393, DOI 10.1016/S1357-2725(96)00146-X; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; MILLER TM, 1997, J BIOL CHEM, V272, P9487; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Suria H, 1999, LIFE SCI, V65, P2697, DOI 10.1016/S0024-3205(99)00538-X; Tanaka T, 2000, J NEUROSCI, V20, P2852; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; Wadsworth SA, 1999, J PHARMACOL EXP THER, V291, P680; Watson A, 1998, J NEUROSCI, V18, P751; Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970; Zawada WM, 2001, BRAIN RES, V891, P185	57	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39123	39131		10.1074/jbc.M103959200	http://dx.doi.org/10.1074/jbc.M103959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509562	hybrid			2022-12-25	WOS:000171673200104
J	Mikhailenko, I; Battey, FD; Migliorini, M; Ruiz, JF; Argraves, K; Moayeri, M; Strickland, DK				Mikhailenko, I; Battey, FD; Migliorini, M; Ruiz, JF; Argraves, K; Moayeri, M; Strickland, DK			Recognition of alpha(2)-macroglobulin by the low density lipoprotein receptor-related protein requires the cooperation of two ligand binding cluster regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; ALZHEIMERS-DISEASE; PSEUDOMONAS EXOTOXIN; CLEARANCE; LRP; COMPLEX; PROUROKINASE; DEGRADATION; DISSECTION	The low density lipoprotein receptor-related protein (LRP) is a scavenger receptor that binds several ligands including the activated form of the pan-proteinase inhibitor alpha (2)-macroglobulin (alpha M-2*) and amyloid precursor protein, two ligands genetically linked to Alzheimer's disease. To delineate the contribution of LRP to this disease, it will be necessary to identify the sites on this receptor which are responsible for recognizing these and other ligands to assist in the development of specific inhibitors. Structurally, LRP contains four clusters of cysteine-rich repeats, yet studies thus far suggest that only two of these clusters (clusters II and IV) bind ligands. Identifying binding sites within LRP for certain ligands, such as alpha M-2*, has proven to be difficult. To accomplish this, we mapped the binding site on LRP for two inhibitors of alpha M-2* uptake, monoclonal antibody 8G1 and an amino-terminal fragment of receptor-associated protein (RAP D1D2). Surprisingly, the inhibitors recognized different clusters of ligand binding repeats: 8G1 bound to repeats within cluster I, whereas the RAP fragment bound to repeats within cluster II. A recombinant LRP mini-receptor containing the repeats from cluster I along with three ligand binding repeats from cluster II was effective in mediating the internalization of I-125-labeled alpha M-2*. Together, these studies indicate that ligand binding repeats from both cluster I and II cooperate to generate a high affinity binding site for alpha M-2*, and they suggest a strategy for developing specific inhibitors to block alpha M-2* binding to LRP by identifying molecules capable of binding repeats in cluster I.	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	American Red Cross	Mikhailenko, I (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	mikhaile@usa.redcross.org			NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen OM, 2000, BIOCHEMISTRY-US, V39, P10627, DOI 10.1021/bi000498h; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HORN IR, 1995, J BIOL CHEM, V270, P11770, DOI 10.1074/jbc.270.20.11770; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	35	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39484	39491		10.1074/jbc.M104382200	http://dx.doi.org/10.1074/jbc.M104382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507091	hybrid			2022-12-25	WOS:000171673200150
J	Wilson, GM; Sutphen, K; Moutafis, M; Sinha, S; Brewer, G				Wilson, GM; Sutphen, K; Moutafis, M; Sinha, S; Brewer, G			Structural remodeling of an A + U-rich RNA element by cation or AUF1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; A+U-RICH ELEMENTS; MESSENGER-RNA DEGRADATION; TRANSFER RIBONUCLEIC-ACID; FLUORESCENCE ANISOTROPY; TERTIARY STRUCTURE; MAMMALIAN-CELLS; BINDING PROTEIN; AUF1; DESTABILIZATION	Association of AUF1 with A + U-rich elements (AREs) induces rapid cytoplasmic degradation of mRNAs containing these sequences, involving the recruitment or assembly of multisubunit trans-acting complexes on the mRNA. Recently, we reported that Mg2+-induced conformational changes in the ARE from tumor necrosis factor a mRNA inhibited AUF1 binding and oligomerization activities on this substrate (Wilson, G. M., Sutphen, K., Chuang, K., and Brewer, G. (2001) J. Biol. Chem. 276, 8695-8704). In this study, resonance energy transfer was employed to characterize structural changes in RNA substrates in response to cation- and AUF1-binding events. An RNA substrate containing the tumor necrosis factor a ARE displayed a weak conformational transition in the absence of added cations but was cooperatively stabilized by Mg2+. Additional assays demonstrated a strong preference for small, multivalent cations, suggesting that the folded RNA structure was stabilized by counterion neutralization at discrete regions of high negative charge density. Association of AUF1 with cognate RNA substrates also induced formation of condensed RNA structures, although distinct from the folded structure stabilized by multivalent cations. Taken together, these experiments indicate that association of AUF1 with an ARE may function to remodel local RNA structures, which may be a prerequisite for subsequent recruitment of additional transacting factors.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.	brewerga@umdnj.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Bassi GS, 1997, EMBO J, V16, P7481, DOI 10.1093/emboj/16.24.7481; Basu S, 2001, METHODS, V23, P264, DOI 10.1006/meth.2000.1137; Bouvet P, 2001, J MOL BIOL, V309, P763, DOI 10.1006/jmbi.2001.4691; Brannvall M, 2001, NUCLEIC ACIDS RES, V29, P1426, DOI 10.1093/nar/29.7.1426; Breslauer KJ, 1995, METHOD ENZYMOL, V259, P221; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FASMAN GD, 1976, CRC HDB BIOCH MOL BI, P589; Gonzalez RL, 1999, J MOL BIOL, V289, P1267, DOI 10.1006/jmbi.1999.2841; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Heilman-Miller SL, 2001, J MOL BIOL, V306, P1157, DOI 10.1006/jmbi.2001.4437; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Klostermeier D, 2001, METHODS, V23, P240, DOI 10.1006/meth.2000.1135; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LAING LG, 1994, J MOL BIOL, V237, P577, DOI 10.1006/jmbi.1994.1256; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LEROY JL, 1977, EUR J BIOCHEM, V74, P567, DOI 10.1111/j.1432-1033.1977.tb11426.x; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; LYNCH DC, 1974, BIOCHEMISTRY-US, V13, P1841, DOI 10.1021/bi00706a012; Maguire JL, 2001, J MOL BIOL, V309, P45, DOI 10.1006/jmbi.2001.4625; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Pan J, 1999, P NATL ACAD SCI USA, V96, P6149, DOI 10.1073/pnas.96.11.6149; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Walter F, 1998, BIOCHEMISTRY-US, V37, P17629, DOI 10.1021/bi9821115; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	56	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38400	38409		10.1074/jbc.M106509200	http://dx.doi.org/10.1074/jbc.M106509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514570	hybrid			2022-12-25	WOS:000171673200012
J	Shahin, V; Danker, T; Enss, K; Ossig, R; Oberleithner, H				Shahin, V; Danker, T; Enss, K; Ossig, R; Oberleithner, H			Evidence for Ca2+- and ATP-sensitive peripheral channels in nuclear pore complexes	FASEB JOURNAL			English	Article						nuclear hourglass technique; Ca2+ stores; nuclear envelope; atomic force microscopy	IONIC PERMEABILITY; DEPLETION; ENVELOPE; CALCIUM; CA2+; ALDOSTERONE; DIFFUSION; MYOSIN; ACTIN	In eukaryotic cells the nuclear envelope (NE) serves as a functional barrier between cytosol and nucleoplasm perforated by nuclear pore complexes (NPCs). Both active and passive transport of ions and macromolecules are thought to be mediated by the centrally located large NPC channel. However, 3-dimensional imaging of NPCs based on electron microscopy indicates the existence of additional small channels of unknown function located in the NPC periphery. By means of the recently developed nuclear hourglass technique that measures NE electrical conductance, we evaluated passive electrically driven transport through NPCs. In isolated Xenopus laevis oocyte nuclei, we varied ambient Ca2+ and ATP in the cytosolic solution and/or chelated Ca2+ in the perinuclear stores in order to assess the role of Ca2+ in regulating passive ion transport. We noticed that NE electrical conductance is large under conditions where macromolecule permeability is known to be low. In addition, atomic force microscopy applied to native NPCs detects multiple small pores in the NPC periphery consistent with channel openings. Peripheral pores were detectable only in the presence of ATP. We conclude that NPC transport of ions and macromolecules occurs through different routes. We present a model in which NE ion flux does not occur through the central NPC channel but rather through Ca2+ - and ATP-activated peripheral channels of individual NPCs.	Univ Munster, Dept Physiol, D-48149 Munster, Germany	University of Munster	Oberleithner, H (corresponding author), Univ Munster, Dept Physiol, Robert Koch Str 27A, D-48149 Munster, Germany.	oberlei@uni-muenster.de						Aebi U, 1992, VERH DTSCH ZOOL GES, V85, P285; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CALLAN HG, 1949, NATURE, V163, P280, DOI 10.1038/163280a0; Danker T, 1999, P NATL ACAD SCI USA, V96, P13530, DOI 10.1073/pnas.96.23.13530; Danker T, 1997, CELL BIOL INT, V21, P747, DOI 10.1006/cbir.1997.0219; Draguhn A, 1997, J MEMBRANE BIOL, V158, P159, DOI 10.1007/s002329900253; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; LOEWENSTEIN WR, 1962, NATURE, V195, P462, DOI 10.1038/195462a0; LOEWENSTEIN WR, 1964, PROTOPLASMATOLOGIA, V5, P26; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; Mazzanti M, 2001, PHYSIOL REV, V81, P1, DOI 10.1152/physrev.2001.81.1.1; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Oberleithner H, 1999, STEROIDS, V64, P42, DOI 10.1016/S0039-128X(98)00090-7; OBERLEITHNER H, 1994, P NATL ACAD SCI USA, V91, P9784, DOI 10.1073/pnas.91.21.9784; Pante N, 1996, CRIT REV BIOCHEM MOL, V31, P153, DOI 10.3109/10409239609106583; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Petersen OH, 1998, CELL CALCIUM, V23, P87, DOI 10.1016/S0143-4160(98)90106-3; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC1532, DOI 10.1152/ajpcell.1996.270.5.C1532; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; Wang HW, 1999, BIOPHYS J, V77, P241, DOI 10.1016/S0006-3495(99)76885-2	33	55	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1895	1901		10.1096/fj.00-0838com	http://dx.doi.org/10.1096/fj.00-0838com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532969				2022-12-25	WOS:000171372700004
J	Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L				Morali, OG; Delmas, V; Moore, R; Jeanney, C; Thiery, JP; Larue, L			IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition	ONCOGENE			English	Article						cadherin; catenin; insulin-like growth factor; epithelium to mesenchyme transition	MOUSE EMBRYONIC-DEVELOPMENT; EPIDERMAL GROWTH-FACTOR; CELL-CELL-ADHESION; PROTEIN-KINASE-B; E-CADHERIN; TRANSCRIPTIONAL ACTIVITY; CYTOPLASMIC DOMAIN; DROSOPHILA HOMOLOG; FACTOR RECEPTOR; INSULIN	The epithelium to mesenchyme transition is thought to play a fundamental role during embryonic development and tumor progression. Loss of cell-cell adhesion and modification of both cell morphology and gene expression are the main events associated with this transition. There is a large amount of evidence suggesting that growth factors can initiate these events. Yet, the connection from growth factor induction to changes in cell adhesion and morphology is largely unknown. To elucidate this connection, we have investigated the action of IGF-II on E-eadherin/beta -catenin complex-mediated cell-cell adhesion and on beta -catenin/TCF-3 mediated gene expression. We can show that (1) IGF-II induces a rapid epithelium to mesenchymal transition; (2) IGF1R, the receptor for IGF-II, belongs to the same membrane complex as E-cadherin and beta -catenin; (3) IGF-II induces a redistribution of beta -catenin from the plasma membrane to the nucleus and an intracellular sequestration and degradation of E-cadherin; (4) IGF-II induces the transcription of beta -catenin/TCF-3 target genes. Based on the given case of IGF-II and E-eadherin/beta -catenin complex, this study reveals the backbone of a cascade connecting growth factor signaling with cell-cell adhesion during EMT.	Inst Curie, UMR 146 CNRS, F-91405 Orsay, France; Inst Curie, UMR 144 CNRS, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Larue, L (corresponding author), Inst Curie, UMR 146 CNRS, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Delmas, veronique/0000-0001-7368-3664				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, J CELL BIOCHEM, P68; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Birchmeier C, 1996, ACTA ANAT, V156, P217; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLAKESLEY VA, 1999, CONT ENDOCRINOLOGY I, V7, P143; BOYER B, 1992, EXP CELL RES, V201, P347, DOI 10.1016/0014-4827(92)90283-E; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Butz S, 1995, CELL ADHES COMMUN, V3, P337, DOI 10.3109/15419069509081018; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delmas V, 1999, DEV BIOL, V216, P491, DOI 10.1006/dbio.1999.9517; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; Greaves S, 1999, GENETICS, V153, P1753; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Larue L, 1996, DEVELOPMENT, V122, P3185; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yagi T, 2000, GENE DEV, V14, P1169	48	212	218	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4942	4950		10.1038/sj.onc.1204660	http://dx.doi.org/10.1038/sj.onc.1204660			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526479				2022-12-25	WOS:000170439800004
J	Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K				Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K			Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus	ONCOGENE			English	Article						Wnt pathway; human polyomavirus; T-antigen; JCV; medulloblastoma	CADHERIN-CATENIN COMPLEX; TRANSGENIC MICE; BETA-CATENIN; EARLY PROTEIN; CELL-CYCLE; TUMORS; POLYOMAVIRUS; TRANSDUCTION; EXPRESSION; MUTATION	By using the early genome of the human neurotropic polyomavirus, JCV, we have created transgenic animals that develop cerebellar primitive neuroectodermal tumors which model human medulloblastoma. Expression of T-antigen was found in some, but not all, tumor cells, and examination of the clonal cell lines derived from the tumor population showed enhanced tumorigenicity of cells expressing T-antigen in comparison to T-antigen negative cells. Considering the earlier notion on the potential involvement of beta -catenin with human medulloblastoma, we investigated various components of the Wnt signaling pathway including beta -catenin, its partner transcription factor, LEF-1, and their downstream target gene c-myc in these two cell populations. Immunohistochemical staining of the cells revealed enhanced nuclear appearance of beta -catenin in T-antigen positive cells. Results from Western blot showed higher levels of beta -catenin and LEF-1 in T-antigen positive cells in comparison to those in T-antigen negative cells. The enhanced level of LEF-1 expression correlated with the increase in DNA binding activity of this protein in nuclear extracts of T-antigen positive cells. Results from Northern and Western blot analyses revealed that the level of c-myc expression is augmented both at the RNA and protein levels in T-antigen positive cells. These observations corroborated results from transfection studies indicating the ability of JCV T-antigen to stimulate c-myc promoter activity. Further, co-transfection experiments revealed that the amount of c-myc and T-antigen protein in tumor cells may dictate the activity of JCV early promoter in these cells. These observations are interesting in light of recent discoveries on the association of JCV with human medulloblastoma and suggest that communication between JCV and the Wnt pathway may be an important event in the genesis of these tumors.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Rabin Med Ctr, Felsenstein Res Ctr, Lab Tumor Immunol, Petah Tiqwa, Israel	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Rabin Medical Center	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010; Del Valle, Luis/J-4085-2015	Giordano, Antonio/0000-0002-5959-016X; Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Franks RR, 1996, ONCOGENE, V12, P2573; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Howard CM, 2000, CANCER RES, V60, P2737; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marino S, 2000, GENE DEV, V14, P994; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TAGUCHI F, 1982, MICROBIOL IMMUNOL, V26, P1057, DOI 10.1111/j.1348-0421.1982.tb00254.x; WALKER DL, 1983, POLYOMAVIRUSES HUMAN, P99	29	57	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4864	4870		10.1038/sj.onc.1204670	http://dx.doi.org/10.1038/sj.onc.1204670			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521197				2022-12-25	WOS:000170271800010
J	Glaser, T; Wagenknecht, B; Weller, M				Glaser, T; Wagenknecht, B; Weller, M			Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; p21; CD95; cytochrome c	CYTOCHROME-C RELEASE; 3/P21 COMPLEX-FORMATION; DEATH RECEPTORS; CASPASE CASCADE; ACTIVATION; PROTEIN; CLEAVAGE; MITOCHONDRIA; INHIBITOR; BCL-2	Human glioma cell lines differ in their requirement for the inhibition of protein synthesis to activate the CD95-dependent killing pathway. CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX). These biochemical changes were observed in LN-229 cells only in the presence of CHX. The viral caspase inhibitor, cytokine response modifier (crm)-A, inhibited mitochondrial cytochrome c release, caspase processing and cell death under all conditions. Ectopic expression of BCL-X-L prevented processing of caspase 8 in LN-18 cells but not in LN-229 cells. Thus, caspase 8 activation is amplified through the release of cytochrome c in LN-18 cells but occurs mainly at the receptor in LN-229 cells. In contrast to BCL-2, BCL-X-L, X-linked inhibitor-of-apoptosis protein (XIAP) and FLICE-inhibitory protein (FLIP), the levels of the cyclin-dependent kinase (CDK) inhibitor, p21(Waf/Cip1), rapidly decreased in response to CHX. P21 antisense oligonucleotides promoted caspase activation and mitochondrial cytochrome c release and induced strong sensitization to CD95-mediated apoptosis. These data place potentiating effects of CHX (i) to the activation of caspase 8 at the receptor in LN-229 cells as well as (ii) to a down-stream target at least in LN-18 cells, but probably both cell lines, that may be identical with p21(Waf/Cip1).	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Fulda S, 2000, CANCER RES, V60, P3947; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leverkus M, 2000, CANCER RES, V60, P553; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Ruan S, 1998, CANCER RES, V58, P1538; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang ZL, 1999, CANCER RES, V59, P1259; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WELLER M, 1995, CANCER RES, V55, P2963; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	59	47	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4757	4767		10.1038/sj.onc.1204498	http://dx.doi.org/10.1038/sj.onc.1204498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521188				2022-12-25	WOS:000170271800001
J	Kitzing, K; Macheroux, P; Amrhein, N				Kitzing, K; Macheroux, P; Amrhein, N			Spectroscopic and kinetic characterization of the bifunctional chorismate synthase from Neurospora crassa - Evidence for a common binding site for 5-enolpyruvylshikimate 3-phosphate and NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOGS PROVIDE EVIDENCE; SACCHAROMYCES-CEREVISIAE; FLAVIN REDUCTASE; RAPID REACTION; INTERMEDIATE; PURIFICATION; SUBSTRATE; MECHANISM; HYDROXYLASE; PROTEINS	Chorismate synthase catalyzes the anti-1,4-elimination of the phosphate group and the C-(6proR) hydrogen from 5-enolpyruvylshikimate 3-phosphate to yield chorismate, a central building block in aromatic amino acid biosynthesis. The enzyme has an absolute requirement for reduced FMN, which in the case of the fungal chorismate synthases is supplied by an intrinsic FMN: NADPH oxidoreductase activity, i.e. these enzymes have an additional catalytic activity. Therefore, these fungal enzymes have been termed "bifunctional." We have cloned chorismate synthase from the common bread mold Neurospora crassa, expressed it heterologously in Escherichia coli, and purified it in a three-step purification procedure to homogeneity. Recombinant IV. crassa chorismate synthase has a diaphorase activity, i.e. it catalyzes the reduction of oxidized FMN at the expense of NADPH. Using NADPH as a reductant, a reduced Ravin intermediate was observed under single and multiple turnover conditions with spectral features similar to those reported for monofunctional chorismate synthases, thus demonstrating that the intermediate is common to the chorismate synthase-catalyzed reaction. Furthermore, multiple turnover experiments in the presence of oxygen have provided evidence that NADPH binds in or near the substrate (5-enolpyruvylshikimate 3-phosphate) binding site, suggesting that NADPH binding to bifunctional chorismate synthases is embedded in the general protein structure and a special NADPH binding domain is not required to generate the intrinsic oxidoreductase activity.	Swiss Fed Inst Technol, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Amrhein, N (corresponding author), Swiss Fed Inst Technol, Inst Pflanzenwissensch, Univ Str 2, CH-8092 Zurich, Switzerland.	nikolaus.amrhein@ipw.biol.ethz.ch	Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Fitzpatrick TB, 2001, J BIOL CHEM, V276, P18052, DOI 10.1074/jbc.M100867200; FLOSS HG, 1972, J BIOL CHEM, V247, P736; GAERTNER FH, 1973, J BIOL CHEM, V248, P4602; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; Henstrand JM, 1996, MOL MICROBIOL, V22, P859, DOI 10.1046/j.1365-2958.1996.01534.x; HESSING HGM, 1987, MOL GEN GENET, V210, P256, DOI 10.1007/BF00325691; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; ITO J, 1969, J BACTERIOL, V97, P725, DOI 10.1128/JB.97.2.725-733.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MACHEROUX P, 1991, BIOCHEMISTRY-US, V30, P4612, DOI 10.1021/bi00232a036; Maniatis T., 1982, MOL CLONING LAB MANU; MORELL H, 1967, J BIOL CHEM, V242, P82; NEGRI A, 1988, J BIOL CHEM, V263, P13557; Osborne A, 2000, J BIOL CHEM, V275, P35825, DOI 10.1074/jbc.M005796200; POWLOWSKI J, 1989, J BIOL CHEM, V264, P16008; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHALLER A, 1990, ARCH BIOCHEM BIOPHYS, V282, P437, DOI 10.1016/0003-9861(90)90141-K; STOTT K, 1993, J BIOL CHEM, V268, P6097; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313	28	15	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42658	42666		10.1074/jbc.M107249200	http://dx.doi.org/10.1074/jbc.M107249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11526120	hybrid			2022-12-25	WOS:000172169300005
J	He, JQ; Lau, AG; Yaffe, MB; Hall, RA				He, JQ; Lau, AG; Yaffe, MB; Hall, RA			Phosphorylation and cell cycle-dependent regulation of Na+/H+ exchanger regulatory factor-1 by Cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PEPTIDYL-PROLYL ISOMERASE; CAMP-MEDIATED INHIBITION; NHE-RF; BETA(2)-ADRENERGIC RECEPTOR; SUBSTRATE RECOGNITION; NA/H EXCHANGER; PROTEIN; ASSOCIATION; BINDING	Na+/H+ exchanger regulatory factor (NHERF)-1 is a PDZ domain-containing adaptor protein known to bind to various receptors, channels, cytoskeletal elements, and cytoplasmic signaling proteins. We report here that the phosphorylation state of NHERF-1 is profoundly regulated by the cell cycle: NHERF-1 in HeLa cells is hyperphosphorylated in mitosis phase and much less phosphorylated at other points of the cell cycle. This mitosis phase-dependent phosphorylation of NHERF-1 could be blocked by roscovitine, consistent with phosphorylation by cyclin-dependent kinases. In vitro studies with purified NHERF-1 fusion proteins and purified kinases revealed that NHERF-1 was robustly phosphorylated by the cyclin-dependent kinase Cdc2. In contrast, the NHERF-1 relative NHERF-2 was not phosphorylated at all by Cdc2. NHERF-1 possesses two serines (Ser(279) and Ser(301)) that conform to the SPX(K/R) motif preferred for phosphorylation by Cdc2. Mutation of either of these serines reduced Cdc2-mediated phosphorylation of NHERF-1 in vitro, and mutation of both residues together completely abolished Cdc2-mediated phosphorylation. When the S279A/S301A NHERF-1 mutant was expressed in cells, it failed to exhibit the mitosis phase-dependent phosphorylation observed with wild-type NHERF-1. Mutation of both Ser(279) and Ser(301) to aspartate, to mimic Cdc2 phosphorylation of NHERF-1, resulted in a NHERF-1 mutant with a markedly impaired ability to oligomerize in vitro. Similarly, endogenous NHERF-1 from lysates of mitosis phase HeLa cells exhibited a markedly reduced ability to oligomerize relative to endogenous NHERF-1 from lysates of interphase HeLa cells. Mitosis phase NHERF-1 furthermore exhibited the ability to associate with Pint, a WW domain-containing peptidylprolyl isomerase that does not detectably bind to NHERF-1 in interphase lysates. The association of NHERF-1 with Pint facilitated dephosphorylation of NHERF-1, as shown in experiments in which cellular Pin1 activity was blocked by the selective inhibitor juglone. These data reveal that cellular NHERF-1 is phosphorylated during mitosis phase by Cdc2 at Ser(279) and Ser(301) and that this phosphorylation regulates NHERF-1 oligomerization and association with Pin1.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, Atlanta, GA 30322 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Emory University; Massachusetts Institute of Technology (MIT)	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.			Hall, Randy/0000-0002-8318-8728	NHLBI NIH HHS [R01-HL64713] Funding Source: Medline; NIGMS NIH HHS [R01-GM60594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardo AA, 1999, J CLIN INVEST, V104, P195, DOI 10.1172/JCI5344; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Gerez L, 2000, MOL BIOL CELL, V11, P2201, DOI 10.1091/mbc.11.7.2201; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	51	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41559	41565		10.1074/jbc.M106859200	http://dx.doi.org/10.1074/jbc.M106859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533036	hybrid			2022-12-25	WOS:000172450400005
J	Weinman, EJ; Evangelista, CM; Steplock, D; Liu, MZ; Shenolikar, S; Bernardo, A				Weinman, EJ; Evangelista, CM; Steplock, D; Liu, MZ; Shenolikar, S; Bernardo, A			Essential role for NHERF in cAMP-mediated inhibition of the Na+-HCO3- co-transporter in BSC-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; PROTEIN-KINASE-A; PARATHYROID-HORMONE; PROXIMAL TUBULE; PHOSPHORYLATION; EXPRESSION; CLONING; NHE-3	Prior studies have indicated a requirement for the PDZ domain-containing protein, Na+/H+ Exchanger Regulatory Factor (NHERF), for protein kinase A (PKA)mediated inhibition of the renal basolateral Na+-HCO3- co-transporter (NBC). The present studies explore the potential mechanisms by which NHERF transduces cAMP signals to inhibit NBC. In BSC-1 cells, cells that express NBC but lack NHERF, 8-bromo-cAMP (100 mum for 15 min) failed to inhibit transport until wild-type mNHERF-(1-355) was expressed. mNHERF-(116-355) containing PDZ II and C-terminal ezrin-binding sequences or a mutant unphosphorylated form of rabbit NHERF effectively transduced the cAMP signals that inhibited NBC. By contrast, mNHERF-(1-126) encompassing N-terminal PDZ I and mNDERF-(1-325), which lacks ezrin-binding, failed to support cAMP inhibition of NBC activity. NBC and NHERF did not associate with each other in yeast two-hybrid or co-immunoprecipitation assays, and confocal microscopy indicated distinct subcellular localization of the two proteins. NBC was phosphorylated in BSC-1 cells, but its phosphorylation was not increased by cAMP nor was immunoprecipitated NBC phosphorylated by PKA in vitro. Acute exposure of mNHERF-(1-355)-expressing BSC-1 cells to cAMP did not change cell surface expression of NBC. Although these results established an essential role for NHERF in cAMP-mediated inhibition of NBC in BSC-1 cells, they also suggest a novel mechanism for NHERF-mediated signal transduction distinct from that previously characterized from studies of other NHERF targets.	Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Med Serv, Baltimore, MD 21201 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Illinois, Dept Med, Nephrol Sect, Chicago, IL 60612 USA; Chicago Vet Affairs Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Weinman, EJ (corresponding author), Univ Maryland, Sch Med, Dept Med, 22 S Greene St,Rm N3W143, Baltimore, MD 21201 USA.	eweinman@medicine.umaryland.edu			NIDDK NIH HHS [DK 55881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIBA T, 1986, J CLIN INVEST, V78, P1472, DOI 10.1172/JCI112738; Bernardo AA, 1999, J CLIN INVEST, V104, P195, DOI 10.1172/JCI5344; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; GEIBEL J, 1990, P NATL ACAD SCI USA, V87, P7917, DOI 10.1073/pnas.87.20.7917; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; JENTSCH TJ, 1986, J BIOL CHEM, V261, P2120; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; PASTORIZAMUNOZ E, 1992, J CLIN INVEST, V89, P1485, DOI 10.1172/JCI115739; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; RUIZ OS, 1989, AM J PHYSIOL, V256, pF414, DOI 10.1152/ajprenal.1989.256.3.F414; RUIZ OS, 1992, AM J PHYSIOL, V262, pF560, DOI 10.1152/ajprenal.1992.262.4.F560; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	23	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42339	42346		10.1074/jbc.M106153200	http://dx.doi.org/10.1074/jbc.M106153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535598	hybrid			2022-12-25	WOS:000172450400105
J	Ballou, LM; Tian, PY; Lin, HY; Jiang, YP; Lin, RZ				Ballou, LM; Tian, PY; Lin, HY; Jiang, YP; Lin, RZ			Dual regulation of glycogen synthase kinase-3 beta by the alpha(1A)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-FATE SPECIFICATION; P70 S6 KINASE; DIFFERENTIAL REGULATION; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; ALPHA-1-ADRENERGIC RECEPTORS; SIGNALING PATHWAY; COUPLED RECEPTORS; POTENTIAL ROLE	Catecholamines, acting through adrenergic receptors, play an important role in modulating the effects of insulin on glucose metabolism. Insulin activation of glycogen synthesis is mediated in part by the inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3). In this study, catecholamine regulation of GSK-3 beta was investigated in Rat-1 fibroblasts stably expressing the alpha (1A)-adrenergic receptor. Treatment of these cells with either insulin or phenylephrine (PE), an al-adrenergic receptor agonist, induced Ser-9 phosphorylation of GSK-3 beta and inhibited GSK-3 beta activity. Insulin-induced GSK-3 beta phosphorylation is mediated by the phosphatidylinositol 3-kinase/Akt signaling pathway. PE treatment does not activate phosphatidylinositol 3-kinase or Akt (Ballou, L. M., Cross, M. E., Huang, S., McReynolds, E. M., Zhang, B. X., and Lin, R. Z. (2000) J. Biol. Chem. 275, 4803-4809), but instead inhibits insulin-induced Akt activation and GSK-3 beta phosphorylation. Experiments using protein kinase C (PKC) inhibitors suggest that phorbol ester-sensitive novel PKC and Go 6983-sensitive atypical PKC isoforms are involved in the PE-induced phosphorylation of GSK-3 beta. Indeed, PE treatment of Rat-1 cells increased the activity of atypical PKC zeta, and expression of PKC zeta in COS-7 cells stimulated GSK-3 beta Ser-9 phosphorylation. In addition, PE-induced GSK-3 beta phosphorylation was reduced in Rat-1 cells treated with a cell-permeable PKC zeta pseudosubstrate peptide inhibitor. These results suggest that the alpha (1A)-adrenergic receptor regulates GSK-3 beta through two signaling pathways. One pathway inhibits insulin-induced GSK-3 beta phosphorylation by blocking insulin activation of Akt. The second pathway stimulates Ser-9 phosphorylation of GSK3 beta, probably via PKC.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Audie L Murphy Vet Affairs Med Ctr, Res Serv, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276				Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BOUSCAREL B, 1986, BIOCHIM BIOPHYS ACTA, V888, P126, DOI 10.1016/0167-4889(86)90078-9; BOUSCAREL B, 1988, BIOCHEM J, V251, P47, DOI 10.1042/bj2510047; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Exton J H, 1975, Adv Cyclic Nucleotide Res, V5, P519; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUTSON NJ, 1976, J BIOL CHEM, V251, P5200; Isagawa T, 2000, BIOCHEM BIOPH RES CO, V273, P209, DOI 10.1006/bbrc.2000.2926; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Lin RZ, 1998, J BIOL CHEM, V273, P30033, DOI 10.1074/jbc.273.45.30033; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weeks G, 2000, CURR OPIN MICROBIOL, V3, P625, DOI 10.1016/S1369-5274(00)00151-X; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WU DQ, 1992, J BIOL CHEM, V267, P25798; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YANG SD, 1994, J CELL BIOCHEM, V56, P550, DOI 10.1002/jcb.240560416	50	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40910	40916		10.1074/jbc.M103480200	http://dx.doi.org/10.1074/jbc.M103480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533051	hybrid			2022-12-25	WOS:000171925600072
J	Conti, LR; Radeke, CM; Shyng, SL; Vandenberg, CA				Conti, LR; Radeke, CM; Shyng, SL; Vandenberg, CA			Transmembrane topology of the sulfonylurea receptor SUR1.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; RESISTANCE-ASSOCIATED PROTEIN; MEMBRANE TOPOLOGY; EPITOPE INSERTION; P-GLYCOPROTEIN; INSULIN-SECRETION; SUBUNIT; GLYCOSYLATION; REGULATOR; OPENERS	Sulfonylurea receptors (SURx) are multi-spanning transmembrane proteins of the ATP-binding cassette (ABC) family, which associate with Kir6.x to form ATP-sensitive potassium channels. Two models, with 13-17 transmembrane segments, have been proposed for SURx topologies. Recently, we demonstrated that the aminoterminal region of SUR1 contains 5 transmembrane segments, supporting the 17-transmembrane model. To investigate the topology of the complete full-length SUR1, two strategies were employed. Topology was probed by accessibility of introduced cysteines to a membrane-impermeable biotinylating reagent, biotin maleimide. Amino acid positions 6/26, 99, 159, 337, 567, 1051, and 1274 were accessible, therefore extracellular, whereas many endogenous and some introduced cysteines were inaccessible, thus likely cytoplasmic or intramembrane. These sites correspond to extracellular loops 1-3, 5-6, and 8 and the NH2 terminus, and intracellular loops 3-8 and COOH terminus in the 17-transmembrane model. Immunofluorescence was used to determine accessibility of epitope-tagged SUR1 in intact and permeabilized cells. Epitopes at positions 337 and 1050 (putative external loops 3 and 6) were labeled in intact cells, therefore external, whereas positions 485 and 1119 (putative internal loops 5 and 7) only were accessible after permeabilization and therefore internal. These results are compatible with the 17-transmembrane model with two pairs of transmembrane segments as possible reentrant loops.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Oregon Health & Science University	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NHLBI NIH HHS [HL 41656] Funding Source: Medline; NIDDK NIH HHS [R01 DK057699, DK 57699] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041656, R01HL041656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Fujita A, 2000, PHARMACOL THERAPEUT, V85, P39, DOI 10.1016/S0163-7258(99)00050-9; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Moreau C, 2000, EMBO J, V19, P6644, DOI 10.1093/emboj/19.24.6644; Nasonkin I, 1999, J BIOL CHEM, V274, P29420, DOI 10.1074/jbc.274.41.29420; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	32	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41270	41278		10.1074/jbc.M106555200	http://dx.doi.org/10.1074/jbc.M106555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546780	hybrid			2022-12-25	WOS:000171925600119
J	de la Serna, IL; Roy, K; Carlson, KA; Imbalzano, AN				de la Serna, IL; Roy, K; Carlson, KA; Imbalzano, AN			MyoD can induce cell cycle arrest but not muscle differentiation in the presence of dominant negative SWI/SNF chromatin remodeling enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; SKELETAL-MUSCLE; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; DEPENDENT KINASES; DNA-BINDING; MICE LEADS	Cell cycle arrest is critical for muscle differentiation, and the two processes are closely coordinated but temporally separable. SWI/SNF complexes are ATP-dependent chromatin-remodeling enzymes that have been shown to be required for muscle differentiation in cell culture and have also been reported to be required for Rb-mediated cell cycle arrest. We therefore looked more closely at how SWI/SNF enzymes affect the events that occur during MyoD-induced myogenesis, namely, cell cycle regulation and muscle-specific gene expression, in cells that inducibly express dominant negative versions of Brahma (BRM) and Brahma-related gene 1 (BRG1), the ATPase subunits of two distinct SWI/SNF complexes. Although dominant negative BRM and BRG1 inhibited expression of every muscle-specific regulator and structural gene assayed, there was no effect on MyoD-induced activation of cell cycle regulatory proteins, and thus, cells arrested normally. In particular, in the presence or absence of dominant negative BRM or BRG1, MyoD was able to activate expression of p21, cyclin D3, and Rb, all of which are critical for cell cycle withdrawal in the G(1)/G(0) phase of the cell cycle. These findings suggest that at least one basis for the distinct mechanisms that regulate cessation of cell proliferation and muscle-specific gene expression during muscle differentiation is that SWI/SNF-mediated chromatin-remodeling enzymes are required only for the latter.	Univ Massachusetts, Dept Cell Biol, Sch Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Imbalzano, AN (corresponding author), Univ Massachusetts, Dept Cell Biol, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020371, R01GM056244] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056244, F32GM20371, GM56244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; MARTELLI F, 1994, ONCOGENE, V9, P3579; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTARRAS D, 1991, NEW BIOL, V3, P592; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Valdez MR, 2000, DEV BIOL, V219, P287, DOI 10.1006/dbio.2000.9621; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	65	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41486	41491		10.1074/jbc.M107281200	http://dx.doi.org/10.1074/jbc.M107281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522799	hybrid			2022-12-25	WOS:000171925600146
J	Stipp, CS; Kolesnikova, TV; Hemler, ME				Stipp, CS; Kolesnikova, TV; Hemler, ME			EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; FELINE IMMUNODEFICIENCY VIRUS; DIPHTHERIA-TOXIN RECEPTOR; MHC CLASS-II; TRANSMEMBRANE-4 SUPERFAMILY; CELL MOTILITY; GROWTH-FACTOR; T-CELLS; IMMUNOGLOBULIN SUPERFAMILY; MEMBRANE-PROTEIN	A novel Ig superfamily protein, EWI-2, was co-purified with tetraspanin protein CD81 under relatively stringent Brij 96 detergent conditions and identified by mass spectrometric protein sequencing. EWI-2 associated specifically with CD9 and CD81 but not with other tetraspanins or with integrins. Immunodepletion experiments indicated that EWI-2-CD9/CD81 interactions are highly stoichiometric, with similar to 70% of CD9 and CD81 associated with EWI-2 in an embryonic kidney cell line. The EWI-2 molecule was covalently cross-linked (in separate complexes) to both CD81 and CD9, suggesting that association is direct. EWI-2 is part of a novel Ig subfamily that includes EWI-F (F2 alpha receptor regulatory protein (FPRP), CD9P-1), EWI-3 (IgSF3), and EWI-101 (CD101). All four members of this Ig subfamily contain a Glu-Trp-Ile (EWI) motif not seen in other Ig proteins. As shown previously, the EWI-F molecule likewise forms highly proximal, specific, and stoichiometric complexes with CD9 and CD81. Human and murine EWI-2 protein sequences are 91% identical, and transcripts in the two species are expressed in virtually every tissue tested. Thus, EWI-2 potentially contributes to a variety of CD9 and CD81 functions seen in different cell and tissue types.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allander T, 2000, VIROLOGY, V277, P358, DOI 10.1006/viro.2000.0617; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Cajot JF, 1997, CANCER RES, V57, P2593; Cha JH, 2000, J BIOL CHEM, V275, P6901, DOI 10.1074/jbc.275.10.6901; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; deParseval A, 1997, J VIROL, V71, P5742, DOI 10.1128/JVI.71.8.5742-5749.1997; Domanico SZ, 1997, MOL BIOL CELL, V8, P2253, DOI 10.1091/mbc.8.11.2253; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Germi R, 2001, J MED VIROL, V64, P6, DOI 10.1002/jmv.1010; GOUTTEFANGEAS C, 1994, INT IMMUNOL, V6, P423, DOI 10.1093/intimm/6.3.423; Greene NDE, 1998, MECH DEVELOP, V73, P59, DOI 10.1016/S0925-4773(98)00029-X; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hasegawa H, 1998, J IMMUNOL, V161, P3087; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; Kelic S, 2001, MOL CELL NEUROSCI, V17, P551, DOI 10.1006/mcne.2000.0955; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1998, P NATL ACAD SCI USA, V95, P2458, DOI 10.1073/pnas.95.5.2458; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Meola A, 2000, J VIROL, V74, P5933, DOI 10.1128/JVI.74.13.5933-5938.2000; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyake M, 1996, CANCER RES, V56, P1244; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; Mori M, 1998, CLIN CANCER RES, V4, P1507; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PESANDO JM, 1986, J IMMUNOL, V136, P2709; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Saupe S, 1998, GENOMICS, V52, P305, DOI 10.1006/geno.1998.5439; SCHICK MR, 1993, J IMMUNOL, V151, P4090; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Shimotohno K, 2000, SEMIN CANCER BIOL, V10, P233, DOI 10.1006/scbi.2000.0322; Sincock PM, 1999, J CELL SCI, V112, P833; Skubitz KM, 1996, J IMMUNOL, V157, P3617; Skubitz KM, 2000, FEBS LETT, V469, P52, DOI 10.1016/S0014-5793(00)01240-0; Stipp CS, 2000, J CELL SCI, V113, P1871; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Szollosi J, 1996, J IMMUNOL, V157, P2939; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Tsitsikov EN, 1997, P NATL ACAD SCI USA, V94, P10844, DOI 10.1073/pnas.94.20.10844; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Underhill DA, 2000, MAMM GENOME, V11, P633, DOI 10.1007/s003350010118; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Willett B, 1997, J GEN VIROL, V78, P611, DOI 10.1099/0022-1317-78-3-611; WILLETT BJ, 1994, IMMUNOLOGY, V81, P228; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	86	166	174	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40545	40554		10.1074/jbc.M107338200	http://dx.doi.org/10.1074/jbc.M107338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11504738	hybrid			2022-12-25	WOS:000171925600025
J	Hanna, IH; Krauser, JA; Cai, HL; Kim, MS; Guengerich, FP				Hanna, IH; Krauser, JA; Cai, HL; Kim, MS; Guengerich, FP			Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6 - Lack of an allosteric role of nadph-cytochrome P450 reductase in catalytic regioselectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; CUMENE HYDROPEROXIDE; ESCHERICHIA-COLI; DRUG OXIDATION; ACTIVE-SITE; DEBRISOQUINE 4-HYDROXYLATION; BUFURALOL HYDROXYLATION; ELECTRON-TRANSFER; METABOLISM; PURIFICATION	Cytochrome P450 (P450) 2D6 was first identified as the polymorphic human debrisoquine hydroxylase and subsequently shown to catalyze the oxidation of a variety of drugs containing a basic nitrogen. Differences in the regioselectivity of oxidation products formed in systems containing NADPH-P450 reductase/NADPH and the model oxidant cumene hydroperoxide have been proposed by others to be due to an allosteric influence of the reductase on P450 2D6 (Modi, S., Gilham, D. E., Sutcliffe, M. J., Lian, L.-Y., Primrose, W. U., Wolf, C. R., and Roberts, G. C. K. (1997) Biochemistry 36, 4461-4470). We examined the differences in the formation of oxidation products of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, metoprolol, and bufuralol between reductase-, cumene hydroperoxide-, and iodosylbenzene-supported systems. Catalytic regioselectivity was not influenced by the presence of the reductase in any of the systems supported by model oxidants, ruling out allosteric influences. The presence of the reductase had little effect on the affinity of P450 2D6 for any of these three substrates. The addition of the reaction remnants of the model oxidants (cumyl alcohol and iodobenzene) to the reductase-supported system did not affect reaction patterns, arguing against steric influences of these products on catalytic regioselectivity. Label from (H2O)-O-18 was quantitatively incorporated into 1'-hydroxybufuralol in the iodosylbenzene- but not in the reductase- or cumene hydroperoxide-supported reactions. We conclude that the P450 systems utilizing NADPH-P450 reductase, cumene hydroperoxide, and iodosylbenzene use similar but distinct chemical mechanisms. These differences are the basis for the variable product distributions, not an allosteric influence of the reductase.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638B Robinson Res Bldg,Med Res Bldg 1,23rd & Pier, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R35CA044353, F32CA079162, R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA79162, R01 CA90426, R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267, T32 ES07028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Barr DP, 1996, CHEM RES TOXICOL, V9, P318, DOI 10.1021/tx9501501; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BLAKE RC, 1981, J BIOL CHEM, V256, P5755; BURKA LT, 1980, J AM CHEM SOC, V102, P7615, DOI 10.1021/ja00545a062; CAPDEVILA J, 1980, ARCH BIOCHEM BIOPHYS, V200, P186, DOI 10.1016/0003-9861(80)90345-8; CRESPI CL, 1995, PHARMACOGENETICS, V5, P234, DOI 10.1097/00008571-199508000-00007; Daly AK, 1996, PHARMACOGENETICS, V6, P193, DOI 10.1097/00008571-199606000-00001; DAYER P, 1982, EUR J DRUG METAB PH, V7, P73, DOI 10.1007/BF03189547; DAYER P, 1986, BIOCHEM PHARMACOL, V34, P399; deGroot MJ, 1997, CHEM RES TOXICOL, V10, P41, DOI 10.1021/tx960129f; deGroot MJ, 1996, CHEM RES TOXICOL, V9, P1079, DOI 10.1021/tx960003i; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; EICHELBAUM M, 1979, EUR J CLIN PHARMACOL, V16, P189, DOI 10.1007/BF00562060; Ekins S, 2001, DRUG METAB DISPOS, V29, P936; ELLIS SW, 1995, J BIOL CHEM, V270, P29055, DOI 10.1074/jbc.270.49.29055; Ellis SW, 1996, BIOCHEM J, V316, P647, DOI 10.1042/bj3160647; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; FASCO MJ, 1979, BIOCHEM PHARMACOL, V28, P97, DOI 10.1016/0006-2952(79)90276-4; FRANCIS RJ, 1976, EUR J DRUG METAB PH, P113; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich F. Peter, 1995, P473; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P413, DOI 10.1021/tx00022a003; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1997, BIOTRANSFORMATION, V3, P37; GUSTAFSSON JA, 1979, BIOCHEMISTRY-US, V18, P865, DOI 10.1021/bi00572a020; GUT J, 1984, FEBS LETT, V173, P287, DOI 10.1016/0014-5793(84)80792-9; GUT J, 1986, J BIOL CHEM, V261, P1734; Hanna IH, 2000, ARCH BIOCHEM BIOPHYS, V376, P206, DOI 10.1006/abbi.2000.1708; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; Hanna IH, 2001, ARCH BIOCHEM BIOPHYS, V393, P255, DOI 10.1006/abbi.2001.2510; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; Hayhurst GP, 2001, BIOCHEM J, V355, P373, DOI 10.1042/0264-6021:3550373; HEIMBROOK DC, 1981, BIOCHEM BIOPH RES CO, V99, P530, DOI 10.1016/0006-291X(81)91777-0; Hiroi T, 2001, ENDOCRINOLOGY, V142, P3901, DOI 10.1210/en.142.9.3901; HIROI T, 2000, FRONT SCI SER, V29, P417; HIROI T, 2000, 13 INT S MICR DRUG O, P113; HOCH H, 1944, CHEM BER, V77, P257; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; ISLAM SA, 1991, CARCINOGENESIS, V12, P2211, DOI 10.1093/carcin/12.12.2211; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; KOOP DR, 1980, J BIOL CHEM, V255, P9685; KOYMANS L, 1992, CHEM RES TOXICOL, V5, P211, DOI 10.1021/tx00026a010; KROEMER HK, 1995, LIFE SCI, V56, P2285, DOI 10.1016/0024-3205(95)00223-S; KRONBACH T, 1987, ANAL BIOCHEM, V162, P24, DOI 10.1016/0003-2697(87)90006-6; Kusano K, 1999, ARCH BIOCHEM BIOPHYS, V367, P129, DOI 10.1006/abbi.1999.1248; LENN, 1982, BR J PHARM, V16, pP572; Lightfoot T, 2000, XENOBIOTICA, V30, P219, DOI 10.1080/004982500237622; Loughran PA, 2001, ARCH BIOCHEM BIOPHYS, V385, P311, DOI 10.1006/abbi.2000.2136; MACDONALD TL, 1982, BIOCHEM BIOPH RES CO, V104, P620, DOI 10.1016/0006-291X(82)90682-9; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; MATELES RJ, 1993, CHEM ENG NEWS, V71, P5; MCCARTHY MB, 1983, J BIOL CHEM, V258, P9153; MCCARTHY MB, 1983, J BIOL CHEM, V258, P1610; MCELVAIN SM, 1955, J AM CHEM SOC, V77, P2848, DOI 10.1021/ja01615a054; MEYER UA, 1986, XENOBIOTICA, V16, P449, DOI 10.3109/00498258609050251; Miller GP, 2001, BIOCHEMISTRY-US, V40, P7262, DOI 10.1021/bi010402z; Modi S, 1996, BIOCHEMISTRY-US, V35, P4540, DOI 10.1021/bi952742o; Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p; NAGATA K, 1986, DRUG METAB DISPOS, V14, P559; Niwa T, 1998, XENOBIOTICA, V28, P539, DOI 10.1080/004982598239290; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; Ortiz de Montellano P. R., 1995, CYTOCHROME P450 STRU, P245; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PALMER G, 1992, J BIOL CHEM, V267, P665; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RETTIE AE, 1987, SCIENCE, V235, P890, DOI 10.1126/science.3101178; Saltzman H., 1973, ORG SYNTH, P658; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHINKA T, 1987, J CHROMATOGR, V398, P279, DOI 10.1016/S0021-9673(01)96513-6; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; STROBL GR, 1993, J MED CHEM, V36, P1136, DOI 10.1021/jm00061a004; THOMPSON JA, 1989, DRUG METAB REV, V20, P365, DOI 10.3109/03602538909103548; THOMPSON JA, 1985, J BIOL CHEM, V260, P637; Toy PH, 1998, J AM CHEM SOC, V120, P9718, DOI 10.1021/ja981990f; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; WOLFF T, 1985, CANCER RES, V45, P2116; YAMAZAKI H, 1994, MOL PHARMACOL, V46, P568; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yamazaki H, 2001, J BIOL CHEM, V276, P30885, DOI 10.1074/jbc.M105011200; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256	86	42	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39553	39561		10.1074/jbc.M106841200	http://dx.doi.org/10.1074/jbc.M106841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509577	hybrid			2022-12-25	WOS:000171789200009
J	Lawson, TG; Sweep, ME; Schlax, PE; Bohnsack, RN; Haas, AL				Lawson, TG; Sweep, ME; Schlax, PE; Bohnsack, RN; Haas, AL			Kinetic analysis of the conjugation of ubiquitin to picornavirus 3C proteases catalyzed by the mammalian ubiquitin-protein ligase E3 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; HEPATITIS-A VIRUS; MEDIATED PROTEOLYTIC SYSTEM; BINDING-SITES; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; CARRIER PROTEIN; G-ALPHA; DEGRADATION; PATHWAY	The 3C proteases of the encephalomyocarditis virus and the hepatitis A virus are both type III substrates for the mammalian ubiquitin-protein ligase E3 alpha. The conjugation of ubiquitin to these proteins requires internal ten-amino acid-long protein destruction signal sequences. To evaluate how these destruction signals modulate interactions that must occur between E3a and the 3C proteases, we have kinetically analyzed the formation of ubiquitin-3C protease conjugates in a reconstituted system of purified E1, HsUbc2b/E2(14Kb), and human E3a. Our measurements show that the encephalomyocarditis virus 3C protease is ubiquitinated in this system with K-m = 42 +/- 11 muM and V-max = 0.051 +/- 0.01 pmol/min whereas the parameters for the ubiquitination of the hepatitis A virus 3C protease are K-m = 20 +/- 5 muM and V-max = 0.018 +/- 0.003 pmol/min. Mutations in the destruction signal sequences resulted in changes in the rate at which E3a conjugates ubiquitin to the altered 3C protease proteins. The K-m and V-max values for these reactions change proportionally in the same direction. These results suggest differences in rates of conjugation of ubiquitin to 3C proteases are primarily a k(cat) effect. Replacing specific encephalomyocarditis virus 3C protease lysine residues with arginine residues was found to increase, rather than decrease, the rate of ubiquitin conjugation, and the K,, and V.. values for these reactions are both higher than for the wild type protein. The ability of E3a to catalyze the conjugation of ubiquitin to both 3C proteases was found to be inhibited by lysylalanine and phenylalanylalanine, demonstrating that the same sites on E3a that bind destabilizing N-terminal amino acids in type I and 11 substrates also interact with the 3C proteases.	Bates Coll, Dept Chem, Lewiston, ME 04240 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Lawson, TG (corresponding author), Bates Coll, Dept Chem, Lewiston, ME 04240 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANCHORDOGUY TJ, 1995, J EXP BIOL, V198, P1299; Baboshina OV, 2001, J BIOL CHEM, V276, P39428, DOI 10.1074/jbc.M106967200; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; Bergmann EM, 1997, J VIROL, V71, P2436, DOI 10.1128/JVI.71.3.2436-2448.1997; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gladding RL, 1997, BIOCHEM BIOPH RES CO, V238, P119, DOI 10.1006/bbrc.1997.7251; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LAWSON TG, 1994, J BIOL CHEM, V269, P28429; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; PAUL AV, 1987, VIRUS RES, V8, P153, DOI 10.1016/0168-1702(87)90026-8; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WING SS, 1992, J BIOL CHEM, V267, P6494; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	35	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39629	39637		10.1074/jbc.M102659200	http://dx.doi.org/10.1074/jbc.M102659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11526102	hybrid			2022-12-25	WOS:000171789200018
J	Magne, S; Couchie, D; Pecker, F; Pavoine, C				Magne, S; Couchie, D; Pecker, F; Pavoine, C			beta(2)-adrenergic receptor agonists increase intracellular free Ca2+ concentration cycling in ventricular cardiomyocytes through p38 and p42/44 MAPK-mediated cytosolic phospholipase A(2) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE; PHOSPHORYLATION SITES; NUCLEAR-ENVELOPE; SMOOTH-MUSCLE; MINI-GLUCAGON; CARDIAC-CELLS; G(I) PROTEINS; CALCIUM; TRANSLOCATION	We have recently reported that arachidonic acid mediates beta (2)-adrenergic receptor (AR) stimulation of [Ca2+](i) cycling and cell contraction in embryonic chick ventricular cardiomyocytes (Pavoine, C., Magne, S., Sauvadet, A., and Pecker, F. (1999) J. Biol. Chem.. 274, 628-637). In the present work, we demonstrate that beta (2)-AR agonists trigger arachidonic acid release via translocation and activation of cytosolic phospholipase A. (cPLA(2)) and increase caffeine-releasable Ca2+ pools from Fura-2-loaded cells. We also show that beta (2)-AR agonists trigger a rapid and dose-dependent phosphorylation of both p38 and p42/44 MAPKs. Translocation and activation of ePLA(2), as well as Ca2+ accumulation in sarcoplasmic reticulum stores sensitive to caffeine and amplification of [Ca2+](i) cycling in response to beta (2)-AR agonists, were blocked by inhibitors of the p38 or p42/44 MAPK pathway (SB203580 and PD98059, respectively), suggesting a role of both MAPK subtypes in beta (2)-AR stimulation. In contrast, beta (1)-AP. stimulation of [Ca2+](i) cycling was rather limited by the MAPKs, clearly proving the divergence between beta (2)-AR and beta (1)-AR signaling systems. This study presents the first evidence for the coupling of beta (2)-AR to cardiac ePLA(2) and points out the key role of the MAPK pathway in the intracellular signaling elicited by positive inotropic beta (2)-AR agonists in heart.	Hop Henri Mondor, INSERM Unite 99, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pavoine, C (corresponding author), Hop Henri Mondor, INSERM Unite 99, F-94010 Creteil, France.		Couchie, Dominique/D-4895-2017; Pavoine, Catherine/N-4405-2018	Pavoine, Catherine/0000-0002-0598-5545				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 2000, ADV ENZYME REGUL, V40, P255, DOI 10.1016/S0065-2571(99)00031-X; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; Kaumann AJ, 1997, TRENDS PHARMACOL SCI, V18, P70, DOI 10.1016/S0165-6147(96)01033-4; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Murthy KS, 1998, J BIOL CHEM, V273, P34519, DOI 10.1074/jbc.273.51.34519; ONEILL SC, 1990, J PHYSIOL-LONDON, V430, P519, DOI 10.1113/jphysiol.1990.sp018305; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Sauvadet A, 1997, J BIOL CHEM, V272, P12437, DOI 10.1074/jbc.272.19.12437; Sauvadet A, 1996, CIRC RES, V78, P102, DOI 10.1161/01.RES.78.1.102; SAUVADET A, 1995, CELL CALCIUM, V18, P76, DOI 10.1016/0143-4160(95)90047-0; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Steinberg SF, 1999, CIRC RES, V85, P1101; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1996, UNCOUPLING BETA2 ADR, P291; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	47	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39539	39548		10.1074/jbc.M100954200	http://dx.doi.org/10.1074/jbc.M100954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11507087	hybrid			2022-12-25	WOS:000171789200007
J	Masumiya, H; Li, P; Zhang, L; Chen, SRW				Masumiya, H; Li, P; Zhang, L; Chen, SRW			Ryanodine sensitizes the Ca2+ release channel (ryanodine receptor) to Ca2+ activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL TERMINAL CISTERNAE; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; BINDING-SITES; LOCALIZATION; COMPLEX; PURIFICATION; PHARMACOLOGY; MODULATION	Ryanodine, a plant alkaloid, is one of the most widely used pharmacological probes for intracellular Ca2+ signaling in a variety of muscle and non-muscle cells. Upon binding to the Ca2+ release channel (ryanodine receptor), ryanodine causes two major changes in the channel: a reduction in single-channel conductance and a marked increase in open probability. The molecular mechanisms underlying these alterations are not well understood. In the present study, we investigated the gating behavior and Ca2+ dependence of the wild type (wt) and a mutant cardiac ryanodine receptor (RyR2) after being modified by ryanodine. Single-channel studies revealed that the ryanodine-modified wt RyR2 channel was sensitive to inhibition by Mg2+ and to activation by caffeine and ATP. In the presence of Mg2+, the ryanodine-modified single wt RyR2 channel displayed a Sigmoidal Ca2+ dependence with an EC50 value of 110 nm, whereas the ryanodine-unmodified single wt channel exhibited an EC50 of 120 muM for Ca2+ activation, indicating that ryanodine is able to increase the sensitivity of the wt RyR2 channel to Ca2+ activation by similar to1,000-fold. Furthermore, ryanodine is able to restore Ca2+ activation and ligand response of the E3987A mutant RyR2 channel that has been shown to exhibit similar to1,000-fold reduction in Ca2+ sensitivity to activation. The E3987A mutation, however, affects neither [H-3]ryanodine binding to nor the stimulatory and inhibitory effects of ryanodine on the RyR2 channel. These results demonstrate that ryanodine does not "lock" the RyR channel into an open state as generally believed; rather, it sensitizes dramatically the channel to activation by Ca2+.	Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca						BAUS E, 1994, J IMMUNOL METHODS, V173, P41, DOI 10.1016/0022-1759(94)90281-X; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHU A, 1990, MOL PHARMACOL, V37, P735; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; LINDSAY ARG, 1994, J GEN PHYSIOL, V104, P425, DOI 10.1085/jgp.104.3.425; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Tinker A, 1996, BIOPHYS J, V70, P2110, DOI 10.1016/S0006-3495(96)79777-1; WANG JP, 1993, J BIOL CHEM, V268, P20974; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; Xu L, 1998, ANN NY ACAD SCI, V853, P130; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; Zucchi R, 1997, PHARMACOL REV, V49, P1	35	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39727	39735		10.1074/jbc.M106557200	http://dx.doi.org/10.1074/jbc.M106557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11507100	hybrid			2022-12-25	WOS:000171789200030
J	Nelsestuen, GL; Stone, M; Martinez, MB; Harvey, SB; Foster, D; Kisiel, W				Nelsestuen, GL; Stone, M; Martinez, MB; Harvey, SB; Foster, D; Kisiel, W			Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes - Behavior in a diffusion-limited reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PERIPLASM; K-DEPENDENT PROTEINS; TISSUE FACTOR; FACTOR-X; ALKALINE-PHOSPHATASE; ACTIVATION; BINDING; ENZYME; PROTHROMBIN; SITE	Blood clotting factor VIIa is involved in the first step of the blood coagulation cascade, as a membrane-associated enzyme in complex with tissue factor (TF). Factor VIIa is also an important therapeutic agent for hemophilia where its function may include TF-independent as well as TF-dependent mechanisms. This study compared the activity of wild type factor VIIa (WT-VIIa) with that of a mutant with elevated affinity for membrane (P10Q/Q32E, QE-VIIa). Phospholipid and cell-based assays showed the mutant to have up to 40-fold higher function than WT-VIIa in both TF-dependent and TF-independent reactions. Tissue factor-dependent reactions displayed the maximum enhancement when binding had reached equilibrium in competition with another TF-binding protein. In liposome-based assays, the association rate of WT-VIIa with TF occurred at a physical maximum and could not be improved by site-directed mutagenesis. A practical consequence was identical function of WT-VIIa and QE-VIIa in assays that depended entirely on assembly kinetics. Thus, factor VIIa mutants provided unique reagents for probing the mechanism of factor VIIa action. They may also offer superior agents for therapy.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA; Zymogenet Inc, Seattle, WA 98102 USA; Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA	University of Minnesota System; University of Minnesota Twin Cities; Zymogenet Inc.; University of New Mexico	Nelsestuen, GL (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.	nelsc002@tc.umn.edu			NHLBI NIH HHS [HL 60859] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060859] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1988, FASEB J, V2, P2858, DOI 10.1096/fasebj.2.13.2844615; ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; BILLY D, 1995, J BIOL CHEM, V270, P1029, DOI 10.1074/jbc.270.3.1029; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Hedner U, 1996, HAEMOSTASIS, V26, P102; Hedner Ulla, 1993, Transfusion Medicine Reviews, V7, P78, DOI 10.1016/S0887-7963(93)70126-1; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; LE DT, 1992, J BIOL CHEM, V267, P15447; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8193, DOI 10.1021/bi960280o; MARTINEZ MB, 1992, BIOCHEMISTRY-US, V31, P11500, DOI 10.1021/bi00161a031; Martinez MB, 1996, BIOCHEMISTRY-US, V35, P1179, DOI 10.1021/bi951955a; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; MORRISSEY JH, 1993, BLOOD, V81, P734; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; Nelsestuen GL, 1997, BIOCHEMISTRY-US, V36, P9081, DOI 10.1021/bi970720r; Nelsestuen GL, 1999, CHEM PHYS LIPIDS, V101, P37, DOI 10.1016/S0009-3084(99)00053-5; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; QUICK AJ, 1959, HEMORRHAGIC DISEASES, P376; RAO LVM, 1990, BLOOD, V75, P1069; Shah AM, 1998, P NATL ACAD SCI USA, V95, P4229, DOI 10.1073/pnas.95.8.4229; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; TIMMONS S, 1989, METHOD ENZYMOL, V169, P11; Vergne I, 1999, EUR J BIOCHEM, V264, P369, DOI 10.1046/j.1432-1327.1999.00651.x; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015	32	20	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39825	39831		10.1074/jbc.M104896200	http://dx.doi.org/10.1074/jbc.M104896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517221	hybrid			2022-12-25	WOS:000171789200043
J	DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI				DiNardo, DNM; Butcher, DT; Robinson, DP; Archer, TK; Rodenhiser, DI			Functional analysis of CpG methylation in the BRCA1 promoter region	ONCOGENE			English	Article						BRCA1; methylation; expression; CREB	CANCER SUSCEPTIBILITY GENE; SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR GENE; OVARIAN-CANCER; DNA METHYLATION; MESSENGER-RNA; ISLAND; ESTROGEN; BINDING; TRANSCRIPTION	Understanding the role for DNA methylation in tumorigenesis has evolved from defining the location and extent of methylation in a variety of cancer-related genes to clarifying the functional and site-specific effects of aberrant methylation on gene expression, Our objectives were to characterize the functional effects of DNA methylation in the BRCA1 promoter and to clarify the functional status of the BRCA1 CRE (cAMP response element) motif Luciferase reporter assays confirm that an intact CRE is important for BRCA1 expression in transient transfections. Luciferase activities were decreased in constructs where the CRE recognition sequence was altered and when constructs were methylated in vitro. Gel mobility shift and competition assays identified a DNA-protein complex recognizing the CRE motif that we were able to supershift using CREB-specific antibody. Furthermore this CRE is methylation sensitive, and we localized this methylation effect to a CpG dinucleotide within the BRCA1 CRE motif. The consequences of aberrant DNA methylation at specific transcription factor motifs, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, paint a complex picture where both genetic and epigenetic changes contribute to tumour formation.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room 4068,790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Baldwin RL, 2000, CANCER RES, V60, P5329; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Dobrovic A, 1997, CANCER RES, V57, P3347; Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Maesawa C, 1996, CANCER RES, V56, P3875; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okuse K, 1997, MOL BRAIN RES, V46, P197, DOI 10.1016/S0169-328X(96)00302-6; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rodenhiser D, 1996, ONCOGENE, V12, P2623; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; SAKAI T, 1991, AM J HUM GENET, V48, P888; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHATTUCKEIDENS E, 1995, JAMA-J AM MED ASSOC, V273, P535; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	45	46	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5331	5340		10.1038/sj.onc.1204697	http://dx.doi.org/10.1038/sj.onc.1204697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536045				2022-12-25	WOS:000170575500008
J	Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC				Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC			P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?	ONCOGENE			English	Article						p73; differentiation; carcinogenesis; head and neck tissues	TUMOR-SUPPRESSOR GENE; WILD-TYPE P73; P53-RELATED PROTEIN; BREAST CANCERS; CELL CARCINOMA; HOMOLOG; OVEREXPRESSION; NEUROBLASTOMA; HETEROZYGOSITY; INACTIVATION	P73, a p53-homologue gene, has been studied for its possible role in head and neck squamous epithelium (HNSE) differentiation and carcinogenesis. P73 RNA and protein were analysed in 50 biopsies, including well- and moderately-differentiated carcinomas, and 21 matched normal adjacent tissues. P73 immunohistochemical analyses revealed intense p73 nuclear staining in basal and parabasal cells of normal squamous epithelium, in contrast with complete absence of staining in the more superficial cell layers. Moderately-differentiated carcinomas demonstrated homogeneous and diffuse staining in all tumour cells, while only basal cells were stained in well-differentiated carcinomas as in normal tissue. No correlation was observed between p73 and p53 protein expression. Immunostaining for p63, another p53-related protein previously described as being involved in HNSE morphogenesis and overexpressed in head and neck squamous cell carcinomas (HNSCC), was found to be similar to p73 labelling in carcinomas, but spread to the more differentiated layers in normal epithelium. Biallelic expression of p73 was found in tumours as well as in matched normal tissues. Comparison of p73 transcript levels between tumours and normal tissues showed decreased mRNA expression in 5/17 (30%) tumours independently of the differentiation status. Mutation and loss of heterozygosity analyses of the p73 gene revealed wild type status and no deletion. Our results strongly suggest that: (i) p73 is associated with homeostasis and control of differentiation of head and neck squamous epithelium probably in concert with p53 and p63; (ii) down-regulation of p73 expression could participate in HNSE carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Anat Pathol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Chirurg Cervicofaciale, F-94805 Villejuif, France; UPJV, Fac Pharm, F-80037 Amiens, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Picardie Universites; Universite de Picardie Jules Verne (UPJV); Sanofi-Aventis; Sanofi France	Ahomadegbe, JC (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France.		AMSELLEM, Sophie/B-3645-2012					Ahomadegbe JC, 2000, ONCOGENE, V19, P5413, DOI 10.1038/sj.onc.1203914; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; Brash DE, 1998, CANCER SURV, V32, P69; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Liefer KM, 2000, CANCER RES, V60, P4016; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	42	39	43	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5302	5312		10.1038/sj.onc.1204687	http://dx.doi.org/10.1038/sj.onc.1204687			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536043				2022-12-25	WOS:000170575500006
J	Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH				Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH			Evidence for the transforming activity of a truncated Int6 gene, in vitro	ONCOGENE			English	Article						Int6; eIF3-p48; transformation; mammary gland; epithelial cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; HTLV-I TAX; RNA 5' CAP; TRANSLATION INITIATION; GROWTH-FACTOR; TUMOR VIRUS; MALIGNANT TRANSFORMATION; TRANSGENIC MICE; PROSTATE-CANCER	Int6/eIF3-p48 was first identified as a common integration site for MMTV in mouse mammary tumors. In all cases, the MMTV integration event resulted in an interruption of the normal Int6 transcript from one allele leaving the second allele intact and operative. We hypothesize that insertion of MMTV into Int6 results in a mutated allele that encodes a shortened Int6 mRNA and protein (Int6sh), which either modifies normal Int6 function or possesses a new independent function. To confirm the transforming potential of the mutation and its dominant function, we transfected two mammary epithelial cell lines, MCF10A (human), and HC11 (mouse), with Int6sh under the control of the elongation factor-la (eEF1A) promoter. Expression of Int6sh in MCF10A and HC11 mammary epithelial cells leads to anchorage-independent growth in soft agar indicative of a transformed phenotype. Colonies selected from agar exhibited high levels of mutated Int6sh and wild type Int6 RNA transcripts by RT-PCR and Northern blot analysis. In addition, Int6sh transformed MCF10A and HC11 cells formed nodular growths, in vivo, in immune compromised hosts. NIH3T3 cells, mouse embryo fibroblasts, were also transformed to anchorage-independent growth in vitro by Int6sh expression. These observations provide direct evidence that the Int6 mutations observed in MMTV-induced tumors and hyperplasia contribute to the malignant transformation of the mammary epithelial cells.	NCI, NIH, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA; Acad Nacl Med Buenos Aires, Buenos Aires, DF, Argentina	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Buenos Aires National Academy of Medicine	Smith, GH (corresponding author), NCI, NIH, Tumor Immunol & Biol Lab, 10 Center Dr,Room 8B07, Bethesda, MD 20892 USA.							Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Girard L, 1998, ONCOGENE, V16, P517, DOI 10.1038/sj.onc.1201562; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Methot N, 1996, MOL CELL BIOL, V16, P5328; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MIYAZAKI S, 1995, GENOMICS, V27, P420, DOI 10.1006/geno.1995.1072; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Pauley R J, 1993, Eur J Cancer Prev, V2 Suppl 3, P67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Sambrook J., 2002, MOL CLONING LAB MANU; SOULE HD, 1990, CANCER RES, V50, P6075; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WEN JY, 1995, MOL REPROD DEV, V41, P399, DOI 10.1002/mrd.1080410402	41	58	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5291	5301		10.1038/sj.onc.1204624	http://dx.doi.org/10.1038/sj.onc.1204624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536042				2022-12-25	WOS:000170575500005
J	Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N				Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N			Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells	ONCOGENE			English	Article						p53; apoptosis; FLIP; ubiquitin-proteasome; colon cancer	NF-KAPPA-B; DEATH RECEPTOR; P53; GENE; EXPRESSION; KILLER/DR5; SYSTEM; FADD; MODULATION; FAS	Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DR5-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transfer.	Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, Okayama 7008558, Japan; Shiga Univ Med Sci, Dept Surg 1, Otsu, Shiga 5202192, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Okayama University; Shiga University of Medical Science; University of Texas System; UTMD Anderson Cancer Center; University of Lausanne	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Fukazawa, Takuya/GLR-7099-2022; Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kataoka T, 1998, J IMMUNOL, V161, P3936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MEDEMA JP, 1997, EMBO J, V16, P2749; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheikh MS, 1998, CANCER RES, V58, P1593; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	23	119	119	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5225	5231		10.1038/sj.onc.1204673	http://dx.doi.org/10.1038/sj.onc.1204673			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526513				2022-12-25	WOS:000170464000018
J	Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H				Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H			Germline SDHD mutation in paraganglioma of the spinal cord	ONCOGENE			English	Article						SDHD; germline mutation; paraganglioma; cauda equina	FAMILIAL NONCHROMAFFIN PARAGANGLIOMAS; AUTOSOMAL-DOMINANT PARAGANGLIOMA; SUCCINATE-UBIQUINONE REDUCTASE; HEREDITARY PARAGANGLIOMAS; IMPRINTED GENE; GLOMUS TUMORS; CHROMOSOME; OXIDOREDUCTASE; CLONING; DOMAIN	Hereditary paraganglioma of the head and neck is associated with germline mutations in the SDHD gene, which encodes a mitochondrial respirator), chain protein. Paragangliomas of the central nervous system are very rare, occur almost exclusively in the cauda equina of the spinal cord and are considered non-familial. In the present study, we screened 22 apparently sporadic paragangliomas of the cauda equina for SDHD mutations. One spinal paraganglioma and similar cerebellar tumours that developed 22 years later in the same patient contained a missense mutation at codon 12 (GGT --> AGT, Gly --> Ser) and a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). There was no family history of paragangliomas but DNA from white blood cells of this patient showed the same sequence alterations, indicating the presence of a germline mutation. All other cases of spinal paraganglioma had the wild-type SDHD sequence, except one case with a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). This is the first observation indicating that inherited SDHD mutations may occasionally cause the development of paragangliomas in the central nervous system.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Hosp, Neuropathol Lab, F-69003 Lyon, France; Fed Univ Rio De Janeiro, Univ Hosp, Div Pathol, BR-21941590 Rio De Janeiro, Brazil; Victor Segalen Univ, Neuropathol Lab, F-33076 Bordeaux, France; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Univ Munster, Inst Neuropathol, D-48129 Munster, Germany	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; CHU Lyon; Universidade Federal do Rio de Janeiro; UDICE-French Research Universities; Universite de Bordeaux; Hebrew University of Jerusalem; University of Munster	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342				Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BRODEUR GM, 1998, PHEOCHROMOCYTOMAS PA, P535; GRUFFERMAN S, 1980, CANCER, V46, P2116, DOI 10.1002/1097-0142(19801101)46:9<2116::AID-CNCR2820460934>3.0.CO;2-S; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Heutink Peter, 1994, European Journal of Human Genetics, V2, P148; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075; Niemann S, 1999, NEUROGENETICS, V2, P167, DOI 10.1007/s100480050078; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SOFFER D, 2000, WHO CLASSIFICATION T, P112; SPECTOR GJ, 1975, LARYNGOSCOPE, V85, P1066, DOI 10.1288/00005537-197506000-00016; STROMMER KN, 1995, J NEUROSURG, V83, P166, DOI 10.3171/jns.1995.83.1.0166; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANBAARS F, 1982, HUM GENET, V60, P305, DOI 10.1007/BF00569208; VANDERMEY AGL, 1989, LANCET, V2, P1291; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x	24	24	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5084	5086		10.1038/sj.onc.1204579	http://dx.doi.org/10.1038/sj.onc.1204579			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526495				2022-12-25	WOS:000170439800020
J	Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW				Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW			Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; Kruppel-like factor 4; colon cancer; CDX2; adenomatous polyposis coli; dominant negative	MULTIPLE INTESTINAL NEOPLASIA; HOMEOBOX GENE; EPITHELIAL-CELLS; COLORECTAL-CANCER; BETA-CATENIN; EMBRYONIC INTESTINE; PROMOTER ACTIVITY; CYCLIN D1; DIFFERENTIATION; IDENTIFICATION	Gut-enriched Kruppel-like factor (GKLF or KLF4) is a zinc finger-containing, epithelial-specific transcription factor, that functions as a suppressor of cell proliferation. We previously showed that GKLF expression is decreased in intestinal and colonic adenomas, respectively, from multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients. This study shows that GKLF is induced upon activation of the adenomatous polyposis coli (APC) gene. However, among several human colon cancer cell lines surveyed, expression of GKLF is lowest in RKO, a line with wildtype APC and beta -catenin. RKO contains a mutated allele that encodes the putative tumor suppressor homeodomain protein, CDX2. We show that wild-type CDX2 activates the GKLF promoter and that the mutated CDX2 has a dominant negative effect on wild-type function. Our results may help explain the exceedingly low levels of GKLF expression detected in this cell line, which may in turn contribute to the tumor phenotype.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA084197-02, R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [F32 DK010020, DK10020, R01 DK052230-04, DK52230, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010020, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Polakis P, 2000, GENE DEV, V14, P1837; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Tamai Y, 1999, CANCER RES, V59, P2965; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	45	108	117	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4884	4890		10.1038/sj.onc.1204645	http://dx.doi.org/10.1038/sj.onc.1204645			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521200	Green Accepted			2022-12-25	WOS:000170271800013
J	Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A				Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A			Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract	ONCOGENE			English	Article						urothelial carcinoma; upper and lower urinary tract; LOH; oligoclonality; p53 mutation	TRANSITIONAL-CELL CARCINOMA; MICROSATELLITE INSTABILITY; BLADDER-CANCER; FIELD CANCERIZATION; CLONAL ORIGIN; P53 MUTATION; LOW-GRADE; DELETION	Multifocality and recurrence of urothelial carcinoma may result from either the field effect of carcinogens leading to oligoclonal tumors or monoclonal tumor spread. Previous molecular studies, favoring the monoclonality hypothesis, are mostly limited to the urinary bladder. We investigated genetic alterations in a total of 94 synchronous or metachronous multifocal tumors from 19 patients with at least one tumor both in the upper and lower urinary tract. Loss of heterozygosity (LOH) was determined using eight markers on chromosome 9 and one marker on 17p13 (p53). Microsatellite instability was investigated at six loci and protein expression of MSH2 and MLH1 was evaluated by immunohistochemistry. In addition, exons 5-9 of the p53 gene were sequenced. Deletions at chromosome 9 were found in 73% of tumors and at 17p13 in 18% of tumors. There was no significant difference in the frequency of LOH in the upper and lower urinary tract. Deletions at 9p21 were significantly correlated with invasive tumor growth. The pattern of deletion revealed monoclonality of all tumors in nine patients. In five patients there were at least two tumor clones with different genetic alterations. In four of these patients the different clones occured in the bladder and subsequently in the ureter and renal pelvis. All four patients with p53 mutations revealed identical mutations in all tumors. Thus, multifocal urothelial carcinomas are frequently monoclonal, whereas others show oligoclonality, providing molecular evidence for field cancerization. Intraluminal tumor cell seeding appears to be an important mechanism of multifocal occurence and recurrence of urothelial carcinomas.	Univ Regensburg, Inst Pathol, D-93042 Regensburg, Germany; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	University of Regensburg; Mayo Clinic	Hartmann, A (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	arndt.hartmann@klinik.uni-regensburg.de						Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bender CM, 1998, MED RAD DIA IMG, P37; Boland CR, 1998, CANCER RES, V58, P5248; Dietmaier W, 1999, AM J PATHOL, V154, P83, DOI 10.1016/S0002-9440(10)65254-6; Dietmaier W, 1997, CANCER RES, V57, P4749; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; HABUCHI T, 1993, LANCET, V342, P1087, DOI 10.1016/0140-6736(93)92066-3; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; Hartmann A, 2000, LAB INVEST, V80, P709, DOI 10.1038/labinvest.3780074; HENEY NM, 1978, J UROLOGY, V120, P559, DOI 10.1016/S0022-5347(17)57275-4; HERMANEK P, 1998, TNM CLASSIFICATION M; Li MM, 1999, HUM PATHOL, V30, P1197, DOI 10.1016/S0046-8177(99)90037-0; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Paiss Thomas, 1997, Journal of Urology, V157, P161; Partridge M, 1997, ORAL ONCOL, V33, P332; RADOVANOVIC Z, 1985, J CANCER RES CLIN, V110, P181, DOI 10.1007/BF00402737; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Simon R, 2001, CANCER RES, V61, P355; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Takahashi T, 2001, J UROLOGY, V165, P672, DOI 10.1097/00005392-200102000-00092; Takahashi T, 1998, CANCER RES, V58, P5835; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Xu XH, 1996, CLIN CANCER RES, V2, P1795; Yamamoto S, 1998, CARCINOGENESIS, V19, P855, DOI 10.1093/carcin/19.5.855	28	129	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4910	4915		10.1038/sj.onc.1204671	http://dx.doi.org/10.1038/sj.onc.1204671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521204				2022-12-25	WOS:000170271800017
J	Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X				Parreno, M; Garriga, J; Limon, A; Albrecht, JH; Grana, X			E1A modulates phosphorylation of p130 and p107 by differentially regulating the activity of G1/S cyclin/CDK complexes	ONCOGENE			English	Article						large T antigen (TAg); cyclins; cyclin dependent kinase (CDK); adenovirus; retinoblastoma protein	CELL-CYCLE CONTROL; CDC2-RELATED KINASE PITALRE; LARGE T-ANTIGEN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; ADENOVIRUS E1A; PRB; INHIBITOR; CDK2; GROWTH	We have previously shown that the adenoviral 12S E1A protein modulates the phosphorylation status of p130 and p107 without apparent changes in the cell cycle dependent phosphorylation of the retinoblastoma protein. Here we report on the mechanisms by which E1A modifies differentially the phosphorylation status of pocket proteins. In human U-2 OS osteosarcoma cells transiently expressing E1A, ectopic expression of D-type cyclins alone or combined, but not cyclins E and/or A, fully rescues EIA-mediated block in hyperphosphorylation of p130 to form 3. However, cyclins E and A, individually or together, induce hyperphosphorylation of p130 to species with intermediate mobility. Phosphopeptide maps indicate that E1A inhibits phosphorylation of sites phosphorylatable by CDKs. One of these sites is Ser-1044. The effects of blocking the activities of endogenous and exogenous cyclins with p16 and dominant negative CDK2 in E1A expressing cells further indicate that p130 is phosphorylated by both D-type cyclin and cyclin E/CDK complexes and that E1A modulates the activity of these G1/S CDKs by independent mechanisms. Stable expression of E1A in MC3T3-E1 cells leads to downregulation of D-type cyclins, and upregulation of cyclins E and A. This is accompanied by increased CDK2 kinase activity. Downregulation of D-type cyclins in these cells correlates with a block on both p130 hyperphosphorylation to form 3 and hyperphosphorylation of p107. This is rescued by D-type cyclins but not by cyclin E. In addition, we show that the upregulation of cyclins E and A is at least partially dependent on an intact pocket protein/E2F pathway, but downregulation of D-type cyclins is not. Moreover, we provide evidence that while the lack of a functional pRB pathway also results in a block on hyperphosphorylation of p130 to form 3, this is not sufficient to induce constitutive expression of p130 form 2b.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hennepin County Medical Center	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St, Philadelphia, PA 19140 USA.	xavier@unix.temple.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045450, K02AI001823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO;2-A; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MAYOL X, 1997, PROGR CELL CYCLE RES, P157; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; YEAGER T, 1995, CANCER RES, V55, P493; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	50	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4793	4806		10.1038/sj.onc.1204644	http://dx.doi.org/10.1038/sj.onc.1204644			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521191				2022-12-25	WOS:000170271800004
J	Webb, HM; Ruddock, LW; Marchant, RJ; Jonas, K; Klappa, P				Webb, HM; Ruddock, LW; Marchant, RJ; Jonas, K; Klappa, P			Interaction of the periplasmic peptidylprolyl cis-trans isomerase SurA with model peptides - The N-terminal region of SurA is essential and sufficient for peptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; PROLYL CIS/TRANS ISOMERASES; ESCHERICHIA-COLI SURA; TRIGGER FACTOR; CIS,TRANS-ISOMERASE FKPA; PRESECRETORY PROTEINS; MISFOLDED PROTEINS; STATIONARY-PHASE; CATALYSIS; RECOGNITION	One of the rate-limiting steps in protein folding has been shown to be the cis-trans isomerization of proline residues, which is catalyzed by a range of peptidylprolyl cis-trans isomerases. To characterize the interaction between model peptides and the periplasmic peptidylprolyl cis-trans isomerase SurA from E. coli, we employed a chemical cross-linking strategy that has been used previously to elucidate the interaction of substrates with other folding catalysts. The interaction between purified SurA and model peptides was significant in that it showed saturation and was abolished by denaturation of SurA; however the interaction was independent of the presence of proline residues in the model peptides. From results obtained by limited proteolysis we conclude that an N-terminal fragment of SurA, comprising 150 amino acids that do not contain the active sites involved in the peptidylprolyl cis-trans isomerization, is essential for the binding of peptides by SurA. This was confirmed by probing the interaction of the model peptide with the recombinant N-terminal fragment, expressed in Escherichia coli. Hence we propose that, similar to protein disulfide isomerase and other folding catalysts, SurA exhibits a modular architecture composed of a substrate binding domain and distinct catalytically active domains.	Univ Kent, Canterbury CT2 7NJ, Kent, England; Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	University of Kent; Finland National Institute for Health & Welfare; University of Oulu	Klappa, P (corresponding author), Univ Kent, Canterbury CT2 7NJ, Kent, England.			Ruddock, Lloyd/0000-0002-6247-686X; Jonas, Kim/0000-0003-1891-2617				Bang N, 2000, EUR J BIOCHEM, V267, P3270, DOI 10.1046/j.1432-1327.2000.01355.x; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bothmann H, 2000, J BIOL CHEM, V275, P17100, DOI 10.1074/jbc.M910233199; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; FREEDMAN RB, 1999, MOL CHAPERONES PROTE, P437; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1996, EUR J BIOCHEM, V239, P509, DOI 10.1111/j.1432-1033.1996.0509u.x; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; Klappa P, 1998, EUR J BIOCHEM, V254, P63, DOI 10.1046/j.1432-1327.1998.2540063.x; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; Lazar SW, 1998, J BACTERIOL, V180, P5704, DOI 10.1128/JB.180.21.5704-5711.1998; Maruyama T, 2000, FRONT BIOSCI-LANDMRK, V5, pD821, DOI 10.2741/maruyama; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; Ramm K, 2000, J BIOL CHEM, V275, P17106, DOI 10.1074/jbc.M910234199; Ruddock LW, 2000, PROTEIN SCI, V9, P758; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; TORMO A, 1990, J BACTERIOL, V172, P4339, DOI 10.1128/jb.172.8.4339-4347.1990; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206	26	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45622	45627		10.1074/jbc.M107508200	http://dx.doi.org/10.1074/jbc.M107508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11546789	Green Accepted, hybrid			2022-12-25	WOS:000172573100019
J	Gooch, JL; Tang, YP; Ricono, JM; Abboud, HE				Gooch, JL; Tang, YP; Ricono, JM; Abboud, HE			Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY ALBUMIN EXCRETION; MESANGIAL CELLS; CARDIAC-HYPERTROPHY; TRANSGENIC MICE; HORMONE; RECEPTOR; EXPRESSION; SYSTEM; NFAT	Insulin-like growth factor-I (IGF-I) may play an important role in the development of renal hypertrophy. In this study we determined the effect of IGF-I on cultured mesangial cells (MCs) and examined activation of key signaling pathways. IGF-I induced hypertrophy as determined by an increase in cell size and an increase in protein to DNA ratio and increased accumulation of extracellular matrix (ECM) proteins. IGF-I also activated both Erk1/Erk2 MAPK and phosphatidylinositol 3-kinase (PI3K) in MCs. Inhibition of either MAPK or PI3K, however, had no effect on IGF-I-induced hypertrophy or ECM production. Next, we examined the effect of IGF-I on activation of the calcium-dependent phosphatase calcineurin. IGF-I treatment stimulated calcineurin activity and increased the protein levels of calcineurin and the calcineurin binding protein, calmodulin. Cyclosporin A, an inhibitor of calcineurin, blocked both IGF-I-mediated hypertrophy and up-regulation of ECM. In addition, calcineurin resulted in sustained Akt activation, indicating possible cross-talk with other signaling pathways. Finally, IGF-I treatment resulted in the calcineurindependent nuclear localization of NFATc1. Therefore, IGF-I induces hypertrophy and increases ECM accumulation in MCs. IGF-I-mediated hypertrophy is associated with activation of Erk1/Erk2 MAPK and PI3K but does not require either of these pathways. Instead, IGF-I mediates hypertrophy via a calcineurin-dependent pathway.	Univ Texas, Hlth Sci Ctr, Dept Med Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Gooch, JL (corresponding author), Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	gooch@uthscsa.edu						Abboud HE, 1997, KIDNEY INT, pS3; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CHOI ME, 1993, KIDNEY INT, V44, P948, DOI 10.1038/ki.1993.336; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; DIMARI J, 1999, AM J PHYSIOL, V2777, pF195; DOI T, 1988, AM J PATHOL, V131, P398; Feld S, 1996, ENDOCR REV, V17, P423, DOI 10.1210/er.17.5.423; FLED SA, 1995, KIDNEY INT, V48, P45; FLYVBJERG A, 1992, KIDNEY INT, V41, P805, DOI 10.1038/ki.1992.124; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Flyvbjerg A, 1997, KIDNEY INT S, V60, pS12; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; Grellier P, 1996, KIDNEY INT, V49, P1071, DOI 10.1038/ki.1996.156; GROMBAEK H, 1997, AM J PHYSIOL, V272, pE918; Horney MJ, 1998, AM J PHYSIOL-RENAL, V274, pF1045, DOI 10.1152/ajprenal.1998.274.6.F1045; LIM HW, 1999, CIRCULATION, P2431; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Murat A, 2000, J BIOL CHEM, V275, P40867, DOI 10.1074/jbc.M008071200; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pricci F, 1996, ENDOCRINOLOGY, V137, P879, DOI 10.1210/en.137.3.879; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER BD, 1995, CLIN NEPHROL, V43, P368; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; Sugimoto H, 1996, NEPHRON, V72, P648, DOI 10.1159/000188954; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Tumlin JA, 1997, AM J KIDNEY DIS, V30, P884, DOI 10.1016/S0272-6386(97)90100-1; Verrotti A, 1999, DIABETES NUTR METAB, V12, P271; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X	36	60	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42492	42500		10.1074/jbc.M102994200	http://dx.doi.org/10.1074/jbc.M102994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11509557	hybrid			2022-12-25	WOS:000172450400122
J	Nilsson, IM; Ohvo-Rekila, H; Slotte, JP; Johnson, AE; von Heijne, G				Nilsson, IM; Ohvo-Rekila, H; Slotte, JP; Johnson, AE; von Heijne, G			Inhibition of protein translocation across the endoplasmic reticulum membrane by sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ANISOTROPY DECAY; HIGHER-ORDER ANALYSIS; PLASMA-MEMBRANE; CHOLESTEROL ACYLTRANSFERASE; INTRACELLULAR CHOLESTEROL; HUMAN-FIBROBLASTS; SIGNAL SEQUENCE; RAT-LIVER; ACYL-COA; CULTURED FIBROBLASTS	Cholesterol and related sterols are known to modulate the physical properties of biological membranes and can affect the activities of membrane-bound protein complexes. Here, we report that an early step in protein translocation across the endoplasmic reticulum (ER) membrane is reversibly inhibited by cholesterol levels significantly lower than those found in the plasma membrane. By UV-induced chemical cross-linking we further show that high cholesterol levels prevent cross-linking between ribosome-nascent chain complexes and components of the Sec61 translocon, but have no effect on cross-linking to the signal recognition particle. The inhibiting effect on translocation is different between different sterols. Our data suggest that the protein translocation machinery may be sensitive to changes in cholesterol levels in the ER membrane.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Stockholm University; Abo Akademi University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.		Johnson, Arthur E/G-3457-2012; von Heijne, Gunnar/AAH-9389-2019; Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENYASHAR V, 1989, BIOCHIM BIOPHYS ACTA, V985, P271, DOI 10.1016/0005-2736(89)90412-4; BILLHEIMER JT, 1985, METHOD ENZYMOL, V111, P286; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Brown MS, 1998, NUTR REV, V56, pS1; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Christian AE, 1997, J LIPID RES, V38, P2264; CLEJAN S, 1981, BIOCHEMISTRY-US, V20, P2200, DOI 10.1021/bi00511a019; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Field FJ, 1998, J LIPID RES, V39, P333; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Finegold L., 1993, CHOLESTEROL MEMBRANE; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Greenfield JJA, 1999, J CELL SCI, V112, P1477; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUDCHODKAR BJ, 1983, ATHEROSCLEROSIS, V46, P353, DOI 10.1016/0021-9150(83)90184-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1998, CURR OPIN STRUC BIOL, V8, P435, DOI 10.1016/S0959-440X(98)80119-X; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1991, J LIPID RES, V32, P329; Lange Y, 1999, J LIPID RES, V40, P2264; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LAU WF, 1995, EXPERIENTIA, V51, P731, DOI 10.1007/BF01941271; Leppimaki P, 2000, EUR J BIOCHEM, V267, P6385, DOI 10.1046/j.1432-1327.2000.01726.x; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILJESTROM P, 1991, J VIROL, V65, P147; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; OKWU AK, 1994, J LIPID RES, V35, P644; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RANADIVE GN, 1987, BIOCHEMISTRY-US, V26, P2426, DOI 10.1021/bi00383a005; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROTHBLAT GH, 1971, J LIPID RES, V12, P647; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7196; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STRAUME M, 1988, BIOCHEMISTRY-US, V27, P7723, DOI 10.1021/bi00420a022; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; TAVANI DM, 1982, J LIPID RES, V23, P774; Urich, 1994, COMP ANIMAL BIOCH, P624, DOI DOI 10.1007/978-3-662-06303-3_16; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; XU XX, 1991, J BIOL CHEM, V266, P17040; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	71	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41748	41754		10.1074/jbc.M105823200	http://dx.doi.org/10.1074/jbc.M105823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535595	hybrid			2022-12-25	WOS:000172450400029
J	Shima, T; Okumura, N; Takao, T; Satomi, Y; Yagi, T; Okada, M; Nagai, K				Shima, T; Okumura, N; Takao, T; Satomi, Y; Yagi, T; Okada, M; Nagai, K			Interaction of the SH2 domain of Fyn with a cytoskeletal protein beta-adducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEFICIENT MICE; TYROSINE-PHOSPHORYLATED PROTEINS; FOCAL ADHESION KINASE; SRC-FAMILY KINASES; INCREASED FEARFULNESS; MEMBRANE SKELETON; PLASMA-MEMBRANE; BINDING-PROTEIN; RHO-KINASE; ASSOCIATION	Fyn is a Src family tyrosine kinase expressed abundantly in neurons and believed to have specific functions in the brain. To understand the function of Fyn tyrosine kinase, we attempted to identify Fyn Src homology 2 (SH2) domain-binding proteins from a Nonidet P-40-insoluble fraction of the mouse brain. beta -Adducin, an actin filament-associated cytoskeletal protein, was isolated by two-dimensional gel electrophoresis and identified by tandem mass spectrometry. beta -Adducin was tyrosine phosphorylated by coexpression with wild type but not with a kinase-negative form of Fyn in COS-7 cells. Cell staining analysis showed that coexpression of beta -adducin with Fyn induced translocation of beta -adducin from the cytoplasm to the periphery of the cells where it was colocalized with actin filaments and Fyn. These findings suggest that tyrosine-phosphorylated beta -adducin associates with the SH2 domain of Fyn and colocalizes under plasma membranes.	Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Organ Chem, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Div Mol Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Okumura, N (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Metab, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	taisha@protein.osaka-u.ac.jp		Satomi, Yoshinori/0000-0002-8991-1040				ALLAND L, 1994, J BIOL CHEM, V269, P16701; BARE DJ, 1993, ONCOGENE, V8, P1429; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BIANCHI G, 1994, P NATL ACAD SCI USA, V91, P3999, DOI 10.1073/pnas.91.9.3999; BIXBY JL, 1993, J NEUROSCI, V13, P3421; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Fernandez-de-Cossio J, 2000, ELECTROPHORESIS, V21, P1694, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1694::AID-ELPS1694>3.0.CO;2-W; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; ICHIHARA Y, 2000, NATURE, V408, P448; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KIPROV D, 1980, COR VASA, V22, P116; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LING E, 1986, J BIOL CHEM, V261, P13875; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Miyakawa T, 1996, MOL BRAIN RES, V37, P145; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; MIYAKAWA T, 1995, MOL BRAIN RES, V28, P349, DOI 10.1016/0169-328X(94)00251-9; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; NADA S, 1994, ONCOGENE, V9, P3571; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Shima T, 2000, BRAIN RES, V870, P36, DOI 10.1016/S0006-8993(00)02399-4; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343	46	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42233	42240		10.1074/jbc.M102699200	http://dx.doi.org/10.1074/jbc.M102699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11526103	hybrid			2022-12-25	WOS:000172450400093
J	Hanada, T; Yoshida, T; Kinjyo, I; Minoguchi, S; Yasukawa, H; Kato, S; Mimata, H; Nomura, Y; Seki, Y; Kubo, M; Yoshimura, A				Hanada, T; Yoshida, T; Kinjyo, I; Minoguchi, S; Yasukawa, H; Kato, S; Mimata, H; Nomura, Y; Seki, Y; Kubo, M; Yoshimura, A			A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING SUPPRESSOR; STAT3 ACTIVATION; T-CELLS; LIVER; APOPTOSIS; BINDING; GAMMA; DIFFERENTIATION; ELONGATION; REGULATOR	Cytokines exert biological functions by activating Janus tyrosine kinases (JAKs), and JAR inhibitors JAB (also referred to as SOCS1 and SSI1) and CIS3 (SOCS3) play an essential role in the negative regulation of cytokine signaling. We have found that transgenic (Tg) mice expressing a mutant JAB (F59D-JAB) exhibited a more potent STAT3 activation and a more severe colitis than did wild-type littermates after treatment with dextran sulfate sodium. We now find that there is a prolonged activation of JAKs and STATs in response to a number of cytokines in T cells from Tg mice with lek promoter-driven F59D-JAB. Overexpression of F59D-JAB also sustained activation of JAK2 in Ba/F3 cells. These data suggested that F59D-JAB up-regulated STAT activity by sustaining JAK activation. To elucidate molecular mechanisms related to F59D-JAB, we analyzed the effects of F59D-JAB on the JAK/STAT pathway using the 293 cell transient expression system. We found that the C-terminal SOCS-box played an essential role in augmenting cytokine signaling by F59D-JAB. The SOCS-box interacted with the Elongin BC complex, and this interaction stabilized JAB. F59D-JAB induced destabilization of wild-type JAB, whereas overexpression of Elongin BC canceled this effect. Levels of endogenous JAB and CIS3 in T cells from F59D-JAB Tg-mouse were lower than in wild-type mice. We propose that F59D-JAB destabilizes wild-type, endogenous JAB and CIS3 by chelating the Elongin BC complex, thereby sustaining JAK activation.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Oita Med Univ, Dept Urol, Oita 8795593, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Dept Pathol, Kurume, Fukuoka 8300011, Japan; Tokyo Univ Sci, Res Inst Biol Sci, Div Immunobiol, Noda, Chiba 2780022, Japan	Kyushu University; Oita University; Kurume University; Kurume University; Tokyo University of Science	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Kinjyo, Ichiko/0000-0001-7051-3790				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kaneko Y, 2000, J EXP MED, V191, P105, DOI 10.1084/jem.191.1.105; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kusters S, 1996, GASTROENTEROLOGY, V111, P462, DOI 10.1053/gast.1996.v111.pm8690213; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Tagawa Y, 1997, J IMMUNOL, V159, P1418; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	35	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40746	40754		10.1074/jbc.M106139200	http://dx.doi.org/10.1074/jbc.M106139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522790	hybrid			2022-12-25	WOS:000171925600051
J	Hoffmann, J; Haendeler, J; Zeiher, AM; Dimmeler, S				Hoffmann, J; Haendeler, J; Zeiher, AM; Dimmeler, S			TNF alpha and oxLDL reduce protein S-nitrosylation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; APOPTOSIS; NO; NITROSOGLUTATHIONE; NITROSATION; SUPPRESSION; GLUTATHIONE; ACTIVATION; CASPASE-3; ENZYME	Nitric oxide (NO) plays an important role in the regulation of the functional integrity of the endothelium. The intracellular reaction of NO with reactive cysteine groups leads to the formation of S-nitrosothiols. To investigate the regulation of S-nitrosothiols in endothelial cells, we first analyzed the composition of the S-nitrosylated molecules in endothelial cells. Gel filtration revealed that more than 95% of the detected S-nitrosothiols had a molecular mass of more than 5000 Da. Moreover, inhibition of de novo synthesis of glutathione using N-butyl-sulfoximine did not diminish the overall cellular S-NO content suggesting that S-nitrosylated glutathione quantitatively plays only a minor role in endothelial cells. Having demonstrated that most of the S-nitrosothiols are proteins, we determined the regulation of the S-nitrosylation by pro-inflammatory and proatherogenic factors, such as TNF alpha and mildly oxidized low density lipoprotein (oxLDL). TNF alpha and oxLDL induced denitrosylation of various proteins as assessed by Saville-Griess assay, by immunostaining with an anti-S-nitrosocysteine antibody, and by a Western blot approach. Furthermore, the caspase-3 p17 subunit, which has previously been shown to be S-nitrosylated and thereby inhibited, was denitrosylated by TNFa treatment suggesting that S-nitrosylation and denitrosylation are important regulatory mechanisms in endothelial cells contributing to the integrity of the endothelial cell monolayer.	Goethe Univ Frankfurt, Dept Internal Med 4, D-6000 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-6000 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436; Haendeler, Judith/0000-0001-8507-4540				Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; De Frutos T, 1999, AM J PHYSIOL-HEART C, V277, pH1317, DOI 10.1152/ajpheart.1999.277.4.H1317; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, CIRCULATION, V95, P1760; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Peterson TE, 1999, CIRC RES, V85, P29; Rossig L, 2000, J BIOL CHEM, V275, P25502, DOI 10.1074/jbc.M002283200; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Tsao PS, 1998, J CARDIOVASC PHARM, V32, pS48; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731	33	71	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41383	41387		10.1074/jbc.M107566200	http://dx.doi.org/10.1074/jbc.M107566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524431	hybrid			2022-12-25	WOS:000171925600133
J	Mao, Y; Desai, SD; Ting, CY; Hwang, JL; Liu, LF				Mao, Y; Desai, SD; Ting, CY; Hwang, JL; Liu, LF			26 S proteasome-mediated degradation of topoisomerase II cleavable complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING ANTITUMOR DRUGS; ACUTE MYELOID-LEUKEMIA; KAPPA-B ACTIVATION; DNA TOPOISOMERASE; SECONDARY LEUKEMIAS; SUMO-1 CONJUGATION; CELLS; BETA; ALPHA; GENE	DNA topoisomerase II (TOP2) cleavable complexes represent an unusual type of DNA damage characterized by reversible TOP2-DNA cross-links and DNA double strand breaks. Many antitumor drugs and physiological stresses are known to induce TOP2 cleavable complexes leading to apoptotic cell death and genomic instability. However, the molecular mechanism(s) for repair of TOP2 cleavable complexes remains unclear. In the current studies, we show that TOP2 cleavable complexes induced by the prototypic TOP2 poison VM-26 are proteolytically degraded by the ubiquitin/26 S proteasome pathway. Surprisingly the TOP2 beta isozyme is preferentially degraded over TOP2 alpha isozyme. In addition, transcription inhibitors such as 5,6-dichlorobenzimidazole riboside and camptothecin can substantially block VM-26-induced TOP2 beta degradation. These results are consistent with a model in which the repair of TOP2 beta cleavable complexes may involve transcription-dependent proteolysis of TOP2 beta to reveal the protein-concealed double strand breaks.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Academia Sinica - Taiwan	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.		Ting, chun-yuan/F-6448-2013	Ting, chun-yuan/0000-0002-2302-4203; Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauman ME, 1997, MODERN PATHOL, V10, P168; BODLEY AL, 1993, MOL CELL BIOL, V13, P6190, DOI 10.1128/MCB.13.10.6190; Boland MP, 2000, J BIOL CHEM, V275, P25231, DOI 10.1074/jbc.275.33.25231; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; CHARCOSSET JY, 1993, B CANCER, V80, P923; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; D'Arpa P, 1994, Adv Pharmacol, V29B, P127; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; Errington F, 1999, MOL PHARMACOL, V56, P1309, DOI 10.1124/mol.56.6.1309; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOVONI M, 1995, BIOCHEM BIOPH RES CO, V213, P282, DOI 10.1006/bbrc.1995.2127; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hiom K, 1999, CURR BIOL, V9, pR446, DOI 10.1016/S0960-9822(99)80278-4; Hsu CT, 2000, CANCER RES, V60, P3701; HUNGER SP, 1993, BLOOD, V81, P3197; HWANG JL, 1989, CANCER RES, V49, P958; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; KUMAR A, 1973, J MOL BIOL, V80, P265, DOI 10.1016/0022-2836(73)90172-1; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu LF, 1996, ANN NY ACAD SCI, V803, P44, DOI 10.1111/j.1749-6632.1996.tb26375.x; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Long B H, 1992, Semin Oncol, V19, P3; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Moreland N, 1997, EUR J CANCER, V33, P1668, DOI 10.1016/S0959-8049(97)00165-2; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NAMBI P, 1989, BIOCHEM J, V262, P485, DOI 10.1042/bj2620485; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1992, CANCER RES, V52, P4467; POMMIER Y, 1988, CANCER RES, V48, P512; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; SANDER M, 1983, J BIOL CHEM, V258, P8421; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Sumner AT, 1996, CHROMOSOME RES, V4, P5, DOI 10.1007/BF02254938; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; TAN KB, 1992, CANCER RES, V52, P231; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; Tsutsui K, 2001, J COMP NEUROL, V431, P228, DOI 10.1002/1096-9861(20010305)431:2<228::AID-CNE1067>3.0.CO;2-M; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Watanabe K, 2000, BIOCHEM PHARMACOL, V60, P823, DOI 10.1016/S0006-2952(00)00387-7; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	58	157	159	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40652	40658		10.1074/jbc.M104009200	http://dx.doi.org/10.1074/jbc.M104009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546768	hybrid			2022-12-25	WOS:000171925600038
J	Peng, YH; Chen, LH; Li, CG; Lu, WG; Chen, JD				Peng, YH; Chen, LH; Li, CG; Lu, WG; Chen, JD			Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; FUNCTION MUTATIONS; GENE-EXPRESSION; TERMINAL DOMAIN; FEEDBACK LOOP; CELL-LINES; PROTEIN; ASSOCIATION; GELDANAMYCIN; GAIN	Stabilization and overexpression are hallmarks of mutant p53 found in nearly 50% of human tumors. Mutations in the conformation-sensitive core domain of p53 often lead to association with molecular chaperones such as hsp70 and hsp90. Inhibition of hsp90 function accelerates mutant p53 degradation. We recently found that expression of p53 core domain mutants inhibits MDM2 degradation, suggesting that mutant p53 can modulate MDM2 functions. In this report, we show that mutant p53 mediates formation of MDM2-p53-hsp90 complexes. Release of MDM2 from the p53-hsp90 complex after DNA damage restores MDM2 but not p53 turnover, whereas dissociation of hsp90 by geldanamycin increases the degradation of both MDM2 and mutant p53. Mutant p53 degradation after hsp90 inhibition requires MDM2 expression. The interaction between MDM2 and hsp90 is disrupted by the 2A10 antibody, which recognizes a site on MDM2 important for binding to alternative reading frame (ARF). Expression of mutant p53 prevents MDM2 from binding ARF and accumulating in the nucleolus in an hsp90-dependent fashion. These results suggest that hsp90 recruited by mutant p53 conceals the ARF-binding site on MDM2 and inhibits its ubiquitin-protein isopeptide ligase function, resulting in the stabilization of both mutant p53 and MDM2.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HSIAO M, 1994, AM J PATHOL, V145, P702; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; OLSON DC, 1993, ONCOGENE, V8, P2353; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Prives C, 1999, J PATHOL, V187, P112; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	43	134	139	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40583	40590		10.1074/jbc.M102817200	http://dx.doi.org/10.1074/jbc.M102817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11507088	hybrid			2022-12-25	WOS:000171925600029
J	Tarui, T; Miles, LA; Takada, Y				Tarui, T; Miles, LA; Takada, Y			Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V BETA 3; KRINGLE DOMAINS; LIGAND-BINDING; TUMOR-GROWTH; PLASMINOGEN BINDING; FIBRINOGEN GAMMA; POTENT INHIBITOR; ANGIOGENESIS; IDENTIFICATION; SITES	Angiostatin, the N-terminal four kringles (K1-4) of plasminogen, blocks tumor-mediated angiogenesis and has great therapeutic potential. However, angiostatin's mechanism of anti-angiogenic action is unclear. We found that bovine arterial endothelial (BAE) cells adhere to angiostatin in an integrin-dependent manner and that integrins alpha (v)beta (3), alpha (9)beta (1), and to a lesser extent alpha (4)beta (1) specifically bind to angiostatin. alpha (v)beta (3) is a predominant receptor for angiostatin on BAE cells, since a function-blocking antibody to alpha (v)beta (3) effectively blocks adhesion of BAE cells to angiostatin, but an antibody to alpha (9)beta (1) does not. e-Aminocaproic acid, a Lys analogue, effectively blocks angiostatin binding to BAE cells, indicating that an unoccupied Lys-binding site of the kringles may be required for integrin binding. It is known that other plasminogen fragments containing three or five kringles (K1-3 or K1-5) have an anti-angiogenic effect, but plasminogen itself does not. We found that K1-3 and K1-5 bind to alpha (v)beta (3), but plasminogen does not. These results suggest that the anti-angiogenic action of angiostatin may be mediated via interaction with alpha (v)beta (3). Angiostatin binding to alpha (v)beta (3) does not strongly induce stress-fiber formation, suggesting that angiostatin may prevent angiogenesis by perturbing the alpha (v)beta (3)-mediated signal transduction that may be necessary for angiogenesis.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, CAL-10,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu	Tarui, Takehiko/L-4778-2019	Tarui, Takehiko/0000-0002-2519-7052; takada, yoshikazu/0000-0001-5481-9589	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038272, R29HL038272, R01HL045934] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38272, HL 45934] Funding Source: Medline; NIGMS NIH HHS [GM 49899] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Castellino FJ, 1997, CIBA F SYMP, V212, P46; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, MOL MED, V1, P120, DOI 10.1007/BF03401559; Gamble J, 1999, ENDOTHELIUM-NEW YORK, V7, P23, DOI 10.3109/10623329909165309; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shahan TA, 1999, CANCER RES, V59, P4584; Shin EY, 1999, MOL CELLS, V9, P138; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	58	172	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39562	39568		10.1074/jbc.M101815200	http://dx.doi.org/10.1074/jbc.M101815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514539	hybrid			2022-12-25	WOS:000171789200010
J	Wang, Y; Shao, L; Shi, SL; Harris, RJ; Spellman, MW; Stanley, P; Haltiwanger, RS				Wang, Y; Shao, L; Shi, SL; Harris, RJ; Spellman, MW; Stanley, P; Haltiwanger, RS			Modification of epidermal growth factor-like repeats with O-fucose - Molecular cloning and expression of a novel GDP-fucose protein O-fucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; LINKED FUCOSE; GLYCOSYLATION PATHWAY; STRUCTURAL-ANALYSIS; NOTCH; FRINGE; GLYCOSYLTRANSFERASES; IDENTIFICATION; TRANSFERASE; UROKINASE	The O-fucose modification is found on epidermal growth factor-like repeats of a number of cell surface and secreted proteins. O-Fucose glycans play important roles in ligand-induced receptor signaling. For example, elongation of O-fucose on Notch by the beta1,3-N-acetylglucosaminyltransferase Fringe modulates the ability of Notch to respond to its ligands. The enzyme that adds O-fucose to epidermal growth factor-like repeats, GDP-fucose protein O-fucosyltransferase (O-FucT-1), was purified previously from Chinese hamster ovary (CHO) cells. Here we report the isolation of a cDNA that encodes human O-FucT-1. A probe deduced from N-terminal sequence analysis of purified CHO O-FucT-1 was used to screen a human heart cDNA library and expressed sequence tag and genomic data bases. The cDNA contains an open reading frame encoding a protein of 388 amino acids with a predicted N-terminal transmembrane sequence typical of a type H membrane orientation. Likewise, the mouse homolog obtained from an expressed sequence tag and 5'-rapid amplification of cDNA ends of a mouse liver cDNA library encodes a type H transmembrane protein of 393 amino acids with 90.4% identity to human O-FucT-1. Homologs were also found in Drosophila and Caenorhabditis elegans with 41.2 and 29.4% identity to human O-FucT-1, respectively. The human gene (POFUT1) is on chromosome 20 between PLAGL2 and KIF3B, near the centromere at 20p11. The mouse gene (Pofut1) maps near Plagl2 on a homologous region of mouse chromosome 2. POFUT1 gene transcripts were expressed in all tissues examined, consistent with the widespread localization of the modification. Expression of a soluble form of human O-FucT-1 in insect cells yielded a protein of the predicted molecular weight with O-FucT-1 kinetic and enzymatic properties similar to those of O-FucT-1 purified from CHO cells. The identification of the gene encoding protein O-fucosyltransferase I now makes possible mutational strategies to examine the functions of the unusual O-fucose post-translational modification.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Genentech Inc, Dept Metab & Pharmacokinet, S San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, S San Francisco, CA 94080 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Roche Holding; Genentech; Roche Holding; Genentech; Yeshiva University; Albert Einstein College of Medicine; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.			Stanley, Pamela/0000-0001-5704-3747	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061126, GM 61126] Funding Source: Medline; PHS HHS [NC 30645] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams JC, 2000, DEV DYNAM, V218, P280; APPELLA E, 1987, J BIOL CHEM, V262, P4437; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Becker DJ, 1999, BBA-MOL BASIS DIS, V1455, P193, DOI 10.1016/S0925-4439(99)00071-X; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Kao YH, 1999, BIOCHEMISTRY-US, V38, P7097, DOI 10.1021/bi990234z; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; Kikuno R, 2000, NUCLEIC ACIDS RES, V28, P331, DOI 10.1093/nar/28.1.331; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	34	196	208	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40338	40345		10.1074/jbc.M107849200	http://dx.doi.org/10.1074/jbc.M107849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11524432	hybrid			2022-12-25	WOS:000171789200111
J	Riquet, FB; Tan, LJ; Choy, BK; Osaki, M; Karsenty, G; Osborne, TF; Auron, PE; Goldring, MB				Riquet, FB; Tan, LJ; Choy, BK; Osaki, M; Karsenty, G; Osborne, TF; Auron, PE; Goldring, MB			YY1 is a positive regulator of transcription of the Col1a1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELEMENT-BINDING PROTEIN; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; NUCLEAR-FACTOR; YANG 1; ADENOVIRUS E1A; PROMOTER; ACTIVATION; REPRESSION	Both cell-specific and ubiquitous transcription factors in fibroblasts have been identified as critical for expression of the Colla1 gene, which encodes the alpha1 chain of type I collagen. Here, we report that Yin Yang 1 (YY1) binds to the Colla1 promoter immediately upstream of the TATA box, and we examine the functional implications of YY1 binding for regulation of Colla1 gene expression in BALBc/3T3 fibroblasts. The Colla1 promoter region spanning base pairs (bp) -56 to -9 bound purified recombinant YY1 and the corresponding binding activity in nuclear extracts was supershifted using a YY1-specific antibody. Mutation of the TATA box to TgTA enhanced YY1 complex formation. Mutation analysis revealed two YY1 core binding sites at -40/-37 by (YY1A) and, on the reverse strand, at -32/-29 by (YY1B) immediately adjacent to the TATA box. In transfections using Colla1-luciferase constructs, mutation of YY1A decreased activity completely (wild-type p350 (p350wt), -222/+113 bp) or partially (p130wt, -84 bp/+13 bp), whereas mutation of YY1B blocked the expression of both promoter constructs. Cotransfection with pCMV-YY1 increased p350wt and p130wt activities by as much as 10-fold, whereas antisense YY1 decreased constitutive expression and blocked the increased activity due to pCMV-YY1 overexpression. The mTgTA constructs were devoid of activity, arguing for a requirement for cognate binding of the TATA box-binding protein (TBP). Electrophoretic mobility shift assays performed under conditions permitting TBP binding showed that recombinant TBP/TFIID and YY1 could bind to the -56/-9 by fragment and that YY1B was the preferred site for YY1 binding. Our results indicate that YY1 binds to the Colla1 proximal promoter and functions as a positive regulator of constitutive activity in fibroblasts. Although YY1 is not sufficient for transcriptional initiation, it is a required component of the transcription machinery in this promoter.	Havard Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Baylor College of Medicine; University of California System; University of California Irvine	Goldring, MB (corresponding author), Havard Inst Med, New England Baptist Bone & Joint Inst, Rm 246,4 Blackfan Circle, Boston, MA 02115 USA.	mgoldrin@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378, P01AR003564] Funding Source: NIH RePORTER; NCI NIH HHS [CA68544] Funding Source: Medline; NIAMS NIH HHS [P01-AR03564, R01-AR45378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Bilezikian, 1999, DYNAMICS BONE CARTIL, P3; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GREENWEL P, 2000, MOL CELL BIOL, P20; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Last TJ, 1999, J CELL BIOCHEM, V72, P507, DOI 10.1002/(SICI)1097-4644(19990315)72:4<507::AID-JCB6>3.0.CO;2-5; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mayne R., 1997, ARTHRITIS ALLIED CON, P207; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; Miao K, 1999, ARCH BIOCHEM BIOPHYS, V361, P7, DOI 10.1006/abbi.1998.0977; Mori K, 1996, BIOCHEM J, V319, P811, DOI 10.1042/bj3190811; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Patten M, 1996, J BIOL CHEM, V271, P21134, DOI 10.1074/jbc.271.35.21134; Patten M, 2000, J MOL CELL CARDIOL, V32, P1341, DOI 10.1006/jmcc.2000.1169; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Riquet FB, 2000, MOL MED, V6, P705, DOI 10.1007/BF03402050; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Ye JP, 1996, MOL CELL BIOL, V16, P4744; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	54	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38665	38672		10.1074/jbc.M009881200	http://dx.doi.org/10.1074/jbc.M009881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514536	hybrid			2022-12-25	WOS:000171673200046
J	Watanabe, D; Hashimoto, S; Ishiai, M; Matsushita, M; Baba, Y; Kishimoto, T; Kurosaki, T; Tsukada, S				Watanabe, D; Hashimoto, S; Ishiai, M; Matsushita, M; Baba, Y; Kishimoto, T; Kurosaki, T; Tsukada, S			Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; MEDIATED ACTIVATION; CUTTING EDGE; CATALYTIC ACTIVITY; ADAPTER PROTEIN; LINKER PROTEIN; LYMPHOCYTES-B; SH2 DOMAIN; BLNK; KINASE	Activation of phospholipase C-gamma2 (PLC gamma2) is the critical step in B cell antigen receptor (BCR)-coupled calcium signaling. Although genetic dissection experiments on B cells have demonstrated that Bruton's tyrosine kinase (Btk) and Syk are required for activating PLC gamma2, the exact activation mechanism of PLC gamma2 by these kinases has not been established. We identify the tyrosine residues 753, 759, 1197, and 1217 in rat PLC gamma2 as Btk-dependent phosphorylation sites by using an in vitro kinase assay. To evaluate the role of these tyrosine residues in phosphorylation-dependent activation of PLC gamma2, PLC gamma2-deficient DT40 cells were reconstituted with a series of mutant PLC gamma 2s in which the phenylalanine was substituted for tyrosine. Substitution of all four tyrosine residues almost completely eliminated the BCR-induced PLC gamma2 phosphorylation, indicating that these residues include the major phosphorylation sites upon BCR engagement. Cells expressing PLC gamma2 with a single substitution exhibited some extent of reduction in calcium mobilization, whereas those expressing quadruple mutant PLC gamma2 showed greatly reduced calcium response. These findings indicate that the phosphorylations of the tyrosine residues 753, 759, 1197, and 1217, which have been identified as Btk-dependent phosphorylation sites in vitro, coordinately contribute to BCR-induced activation of PLC gamma2.	Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Kansai Med Sch, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Osaka University; Kansai Medical University	Tsukada, S (corresponding author), Osaka Univ, Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kishimoto, Tadamitsu/C-8470-2009; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 1998, J IMMUNOL, V161, P5804; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hashimoto A, 2000, J IMMUNOL, V165, P1738, DOI 10.4049/jimmunol.165.4.1738; Hashimoto S, 1996, BLOOD, V88, P561, DOI 10.1182/blood.V88.2.561.bloodjournal882561; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Justement LB, 2000, CURR TOP MICROBIOL, V245, P1; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Law CL, 1996, MOL CELL BIOL, V16, P1305; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wienands J, 2000, CURR TOP MICROBIOL, V245, P53; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397	55	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38595	38601		10.1074/jbc.M103675200	http://dx.doi.org/10.1074/jbc.M103675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507089	hybrid			2022-12-25	WOS:000171673200037
J	Yuan, JZ; Slice, LW; Rozengurt, E				Yuan, JZ; Slice, LW; Rozengurt, E			Activation of protein kinase D by signaling through Rho and the alpha subunit of the heterotrimeric G protein G(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAPID ACTIVATION; PHORBOL ESTERS; INTACT-CELLS; P115 RHOGEF; EXCHANGE; PHOSPHORYLATION; DIACYLGLYCEROL; TARGET; STIMULATION	Protein kinase D (PKD/PKC mu) immunoprecipitated from COS-7 cells transiently transfected with either a constitutively active mutant of Rho (RhoQ63L) or the Rho-specific guanine nucleotide exchange factor pOnco-Lbc (Lbc) exhibited a marked increase in basal activity. Addition of aluminum fluoride to cells co-transfected with PKD and wild type Gal, also induced PKD activation. Co-transfection of Clostridium botulinum C3 toxin blocked activation of PKD by RhoQ63L, Lbc, or aluminum fluoride-stimulated G alpha (13). Treatment with the protein kinase C inhibitors GF I or Ro 31-8220 prevented the increase in PKD activity induced by RhoQ63L, Lbc, or aluminum fluoride-stimulated G alpha (13). PKD activation in response to G alpha (13) signaling was also completely prevented by mutation of Ser-744 and Ser-748 to Ala in the kinase activation loop of PKD. Co-expression of C. botulinum C3 toxin and a COOH-terminal fragment of G alpha (q) that acts in a dominant-negative fashion blocked PKD activation in response to agonist stimulation of bombesin receptor. Expression of the COON-terminal region of G alpha (13) also attenuated PKD activation in response to bombesin receptor stimulation. Our results show that G alpha (13) contributes to PKD activation through a Rho- and protein kinase C-dependent signaling pathway and indicate that PKD activation is mediated by both G alpha (q) and G alpha (13) in response to bombesin receptor stimulation.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [P50 CA 90388-01, F32 CA84658-01A1] Funding Source: Medline; NIDDK NIH HHS [DK 17294, DK 55003, DK56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA084658, P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK056930, R01DK017294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Leung T, 1996, MOL CELL BIOL, V16, P5313; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Offermanns S, 1996, CANCER SURV, V27, P177; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Paolucci L, 1999, CANCER RES, V59, P572; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; WU DQ, 1992, J BIOL CHEM, V267, P1811; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	73	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38619	38627		10.1074/jbc.M105530200	http://dx.doi.org/10.1074/jbc.M105530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507098	hybrid			2022-12-25	WOS:000171673200040
J	Bessede, G; Miguet, C; Gambert, P; Neel, D; Lizard, G				Bessede, G; Miguet, C; Gambert, P; Neel, D; Lizard, G			Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to gamma-glutamyl transpeptidase activity	FASEB JOURNAL			English	Article						HUVECs; ECV304 cells; Hcy; gamma-GT	ENDOTHELIAL-CELL INJURY; SMOOTH-MUSCLE-CELLS; RISK-FACTOR; LYMPHOBLASTOID-CELLS; THROMBOGENIC AGENT; VASCULAR-DISEASE; REDOX STATUS; ACTIVATION; PROTEIN; GLUTATHIONE	Hyperhomocysteinemia represents an independent risk factor for atherosclerosis, but the mechanisms leading to cellular dysfunctions remain unknown. Using ECV304 cells, we found that homocysteine (Hcy) plus copper (Cu2+) induced cytotoxic effects: loss of cell adhesion, increased permeability to PI, and the occurrence of morphologically apoptotic cells. This form of apoptosis, inhibited by Z-VAD-fmk, was associated with a loss of mitochondrial potential, a cytosolic release of cytochrome c, activation of caspase-3, degradation of poly( ADP-ribose) polymerase, and internucleosomal DNA fragmentation. However, the ability of Hcy plus Cu2+ to induce apoptosis decreased when the pretreatment culture time increased. As a positive correlation was found between the length of time of culture before treatment and the enhancement of gamma -glutamyl transpeptidase (gamma -GT) activity, we asked whether gamma -GT was involved in the control of Hcy plus Cu2+-induced apoptosis. Therefore, ECV304 cells were treated with either acivicin or dexamethasone, inhibiting and stimulating gamma -GT, respectively. In ECV304 cells and human umbilical venous endothelial cells, acivicin favored Hcy plus Cu2+-induced apoptosis whereas dexamethasone counteracted the apoptotic process. As acivicin and dexamethasone were also capable of modulating cell death in ECV304 cells treated with antitumoral drugs, our data emphasize that the involvement of gamma -GT in the control of apoptosis is not restricted to Hcy but also concerns other chemical compounds.	CHU, Hop Bocage, INSERM, U498,Lab Biochim Med, F-21034 Dijon, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lizard, G (corresponding author), CHU, Hop Bocage, INSERM, U498,Lab Biochim Med, BP 1542,2 Bd Marechal de Lattre de Tassigny, F-21034 Dijon, France.	Gerard.Lizard@u-bourgogne.fr	Lizard, Gerard/B-2439-2012	Carole, MIGUET-ALFONSI/0000-0002-3317-6454				AHMAD S, 1987, J CELL PHYSIOL, V131, P240, DOI 10.1002/jcp.1041310214; AUBELSADRON G, 1984, BIOCHIMIE, V66, P333, DOI 10.1016/0300-9084(84)90018-X; Causse E, 1998, J CHROMATOGR A, V817, P181, DOI 10.1016/S0021-9673(98)00363-X; Chango A, 1999, ANN BIOL CLIN-PARIS, V57, P37; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Dirks WG, 1999, IN VITRO CELL DEV-AN, V35, P558; DOROSZ P, 1995, GUIDE PRATIQUE MED, P1512; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; FAU D, 1988, J NUTR, V118, P128, DOI 10.1093/jn/118.1.128; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GRABER R, 1995, INT J CANCER, V62, P443, DOI 10.1002/ijc.2910620414; GRABER R, 1995, ANAL CELL PATHOL, V8, P159; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Halvorsen B, 1996, J LIPID RES, V37, P1591; Harada K, 1997, ATHEROSCLEROSIS, V135, P235, DOI 10.1016/S0021-9150(97)00167-6; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; Harrington EO, 2000, AM J PHYSIOL-LUNG C, V279, pL733, DOI 10.1152/ajplung.2000.279.4.L733; Hasdai D, 1999, ATHEROSCLEROSIS, V142, P317, DOI 10.1016/S0021-9150(98)00249-4; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; HULTBERG B, 1995, BBA-MOL CELL RES, V1269, P6, DOI 10.1016/0167-4889(95)00094-9; Hultberg B, 1997, CLIN CHIM ACTA, V262, P39, DOI 10.1016/S0009-8981(97)06531-5; Hultberg B, 2000, TOXICOLOGY, V147, P69, DOI 10.1016/S0300-483X(00)00189-X; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200; Kiessling F, 1999, CELL TISSUE RES, V297, P131, DOI 10.1007/s004410051340; Kinscherf R, 1999, ATHEROSCLEROSIS, V144, P33, DOI 10.1016/S0021-9150(99)00037-4; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Koch HG, 1998, EUR J PEDIATR, V157, pS102, DOI 10.1007/PL00014294; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Konecky N, 1997, AM HEART J, V133, P534, DOI 10.1016/S0002-8703(97)70148-0; KRISHNASWAMY K, 1977, ATHEROSCLEROSIS, V27, P253, DOI 10.1016/0021-9150(77)90033-8; Kullo IJ, 2000, MAYO CLIN PROC, V75, P369, DOI 10.4065/75.4.369; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Leveque D, 1996, B CANCER, V83, P176; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; LIZARD G, 1995, CYTOMETRY, V21, P275, DOI 10.1002/cyto.990210308; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; MAJNO G, 1995, AM J PATHOL, V146, P3; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; MCDONALD L, 1964, LANCET, V1, P745; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nishio E, 1997, BRIT J PHARMACOL, V122, P269, DOI 10.1038/sj.bjp.0701391; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; REED CJ, 1989, BIOCHEM BIOPH RES CO, V162, P1111, DOI 10.1016/0006-291X(89)90788-2; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TK, 1994, FASEB J, V8, P661, DOI 10.1096/fasebj.8.9.7911768; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Stehouwer CDA, 1998, EUR J PEDIATR, V157, pS107, DOI 10.1007/PL00014293; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Wills PW, 2000, CANCER CHEMOTH PHARM, V46, P193, DOI 10.1007/s002800000119; Xu D, 2000, FEBS LETT, V470, P20, DOI 10.1016/S0014-5793(00)01278-3; XUN L, 2000, EXP CELL RES, V257, P290; YEH CJG, 1981, J IMMUNOL METHODS, V43, P269, DOI 10.1016/0022-1759(81)90174-5	82	23	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1927	1940		10.1096/fj.00-0848com	http://dx.doi.org/10.1096/fj.00-0848com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532973				2022-12-25	WOS:000171372700008
J	Soler, C; Garcia-Manteiga, J; Valdes, R; Xaus, J; Comalda, M; Casado, FJ; Pastor-Anglada, M; Celada, A; Felipe, A				Soler, C; Garcia-Manteiga, J; Valdes, R; Xaus, J; Comalda, M; Casado, FJ; Pastor-Anglada, M; Celada, A; Felipe, A			Macrophages require different nucleoside transport systems for proliferation and activation	FASEB JOURNAL			English	Article						nucleoside uptake; interferon gamma; macrophage colony-stimulating factor	PROTEIN-KINASE PHOSPHATASE-1; RAT-LIVER; MOLECULAR-BIOLOGY; INTERFERON-GAMMA; B-LYMPHOCYTES; CELLS; EXPRESSION; RECEPTOR; MOUSE; LIPOPOLYSACCHARIDE	proliferation and activation, we studied the regulation of the nucleoside transport systems. In murine bone marrow-derived macrophages, the nucleosides required for DNA and RNA synthesis are recruited from the extracellular medium. M-CSF induced macrophage proliferation and DNA and RNA synthesis, whereas interferon gamma (IFN-gamma) led to activation, blocked proliferation, and induced only RNA synthesis. Macrophages express at least the concentrative systems N1 and N2 (CNT2 and CNT1 genes, respectively) and the equilibrative systems es and ei (ENT1 and ENT2 genes, respectively). Incubation with M-CSF only up-regulated the equilibrative system es. Inhibition of this transport system blocked M-CSF-dependent proliferation. Treatment with IFN-gamma only induced the concentrative N1 and N2 systems. IFN-gamma also down-regulated the increased expression of the es equilibrative system induced by M-CSF. Thus, macrophage proliferation and activation require selective regulation of nucleoside transporters and may respond to specific requirements for DNA and RNA synthesis. This report also shows that the nucleoside transporters are critical for macrophage proliferation and activation.	Univ Barcelona, Dept Bioquim & Biol Mol, Lab Fisiol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain; Univ Barcelona, Fdn August Pi I Sunyer, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Felipe, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Lab Fisiol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	afelipe@porthos.bio.ub.es	Soler, Concepció/L-1185-2014; Celada, Antonio/I-1714-2016; Felipe, Antonio/M-8297-2015; Manteiga, Jose Manuel Garcia/AAN-1954-2020	Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Manteiga, Jose Manuel Garcia/0000-0002-5481-040X; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171				Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BAER HP, 1990, BIOCHIM BIOPHYS ACTA, V1026, P241, DOI 10.1016/0005-2736(90)90070-5; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CELADA A, 1992, J IMMUNOL, V148, P1102; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FELIPE A, 1994, J BIOL CHEM, V269, P30125; Felipe A, 1997, BIOCHEM BIOPH RES CO, V233, P572, DOI 10.1006/bbrc.1997.6498; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; MECKLINGGILL KA, 1993, J CELL PHYSIOL, V155, P530, DOI 10.1002/jcp.1041550311; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Pastor-Anglada M, 1998, BIOCHEM CELL BIOL, V76, P771, DOI 10.1139/bcb-76-5-771; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; PLAGEMANN PGW, 1991, BIOCHEM PHARMACOL, V42, P247, DOI 10.1016/0006-2952(91)90710-M; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; Thomas R, 1998, SPRINGER SEMIN IMMUN, V20, P53, DOI 10.1007/BF00831999; Valledor AF, 1999, J IMMUNOL, V163, P2452; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; VANFURTH R, 1992, PRODUCTION MIGRATION, P3; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2000, BLOOD, V95, P3823; Xu YJ, 1999, MOL CELL BIOCHEM, V195, P183, DOI 10.1023/A:1006961330375	39	86	90	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1979	1988		10.1096/fj.01-0022com	http://dx.doi.org/10.1096/fj.01-0022com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532978				2022-12-25	WOS:000171372700013
J	Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C				Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C			Involvement of protein kinase C delta in contact-dependent inhibition of growth in human and murine fibroblasts	ONCOGENE			English	Article						contact-inhibition; PKC delta; fibroblast	HUMAN-DIPLOID FIBROBLASTS; PHORBOL ESTER; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; RAT FIBROBLASTS; PKC-DELTA; EXPRESSION; CELLS; SRC; ROTTLERIN	There is evidence that protein kinase C delta (PKC delta) is a tumor suppressor, although its physiological role has not been elucidated so far. Since important anti-proliferative signals are mediated by cell-cell contacts we studied whether PKC delta is involved in contact-dependent inhibition of growth in human (FH109) and murine (NIH3T3) fibroblasts. Cell-cell contacts were imitated by the addition of glutardialdehyde-fixed cells to sparsely seeded fibroblasts. Downregulation of the PKC isoforms alpha, delta, epsilon, and mu after prolonged treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA, 0.1 mum) resulted in a significant release from contact-inhibition in FH109 cells. Bryostatin I selectively prevented TPA-induced PKC delta -downregulation and reversed TPA-induced release from contact-inhibition arguing for a role of PKC delta in contact-inhibition. In accordance, the PKC delta specific inhibitor Rottlerin (1 mum) totally abolished contact-inhibition. Interestingly, immunofluorescence revealed a rapid translocation of PKC delta to the nucleus when cultures reached confluence with a peak in early-mid G1 phase. Nuclear translocation of PKC delta in response to cell-cell contacts could also be demonstrated after subcellular fractionation by Western blotting and by measuring PKC delta -activity after immunoprecipitation. Transient transfection of NIH3T3 cells with a dominant negative mutant of PKC delta induced a transformed phenotype. We conclude that PKC delta is involved in contact-dependent inhibition of growth.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	cdietric@mail.uni-mainz.de	Oesch, Franz/AAA-8746-2020					Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Guay J, 1997, J CELL SCI, V110, P357; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; LaPorta CAM, 1997, CARCINOGENESIS, V18, P715, DOI 10.1093/carcin/18.4.715; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; OESCH F, 1988, CARCINOGENESIS, V9, P1319, DOI 10.1093/carcin/9.7.1319; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	54	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5143	5154		10.1038/sj.onc.1204657	http://dx.doi.org/10.1038/sj.onc.1204657			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526503				2022-12-25	WOS:000170464000008
J	Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F				Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F			No evidence of somatic FGFR3 mutation in various types of carcinoma	ONCOGENE			English	Article						FGFR3; growth factor receptor; carcinoma; oncogene	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; ACTIVATING MUTATIONS; SKELETAL DISORDERS; FIBROBLAST; GENE; EXPRESSION; DYSPLASIA; BLADDER; CERVIX	Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Grenoble, Serv Pathol Cellulaire, F-38700 Grenoble, France; Inst Gustave Roussy, Dept Biol Clin, F-94800 Villejuif, France; Hop Beaujon, Serv Anat & Cytol Pathol, F-92110 Clichy, France; Univ Paris 05, Hop Ambroise Pare, Serv Anat & Cytol Pathol, F-92104 Boulogne, France; Univ Paris 05, Hop Ambroise Pare, Lab Biochim & Genet Mol, F-92104 Boulogne, France; CHRU Lille, Hop Claude Huriez, Serv Chirurg Digest & Transplantat, F-59037 Lille, France; Univ Paris 05, Hop Ambroise Pare, Federat Special Digest, F-92104 Boulogne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite	Thiery, JP (corresponding author), Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France.		gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; boileau, catherine/M-4482-2017; Brambilla, Elisabeth MP/L-8796-2013; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; boileau, catherine/0000-0002-0371-7539; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424; Anne, Couvelard/0000-0002-6316-1210				Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; COHEN SM, 1992, UROL CLIN N AM, V19, P421; Delezoide AL, 1998, MECH DEVELOP, V77, P19, DOI 10.1016/S0925-4773(98)00133-6; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; MURGUE B, 1994, CANCER RES, V54, P5206; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	17	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5059	5061		10.1038/sj.onc.1204651	http://dx.doi.org/10.1038/sj.onc.1204651			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526491				2022-12-25	WOS:000170439800016
J	Jahn, T; Seipel, P; Coutinho, S; Miething, C; Peschel, C; Duyster, J				Jahn, T; Seipel, P; Coutinho, S; Miething, C; Peschel, C; Duyster, J			Grb4/Nck beta acts as a nuclear repressor of v-Abl-induced transcription from c-jun/c-fos promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAINS; NF-KAPPA-B; ADAPTER PROTEIN; TYROSINE PHOSPHORYLATION; BINDING-PROTEIN; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; C/EBP-BETA; BCR-ABL	Grb4 is an adaptor protein consisting of three src homology (SH) 3 domains and a single SH2 domain. We previously cloned Grb4 as a direct interacting partner of Bcr-Abl and v-Abl via the Grb4 SH2 domain. We now show that overexpression of Grb4 results in significant inhibition of v-Abl-induced transcriptional activation from promitogenic enhancer elements such as activator protein 1 (AP-1) and serum-responsive element (SRE). We demonstrate that the inhibitory activity of Grb4 is independent of the direct interaction of v-Abl and Grb4: a Grb4 mutant that lacks a functional SH2 domain shows an even more pronounced inhibition of AP-1/SRE. Further mutational analysis revealed that the first two SH3 domains primarily mediate the inhibitory function. The inhibitory activity of Grb4 is specific for c-jun/c-fos-regulated promoter elements and is located downstream of MEKK1 and JNK because co-expression of Grb4 resulted in down-regulation of MEKK1-induced AP-1 activity without affecting JNK activity. Thus, the nuclear pool of Grb4 is likely to mediate this inhibition. Indeed, cell fractionation and fluorescence microscopy studies revealed that the stronger inhibitory potential of the Grb4 SH2 mutant occurred in conjunction with increased nuclear localization of this mutant. Our results suggest a novel role for Grb4 in the inhibition of promitogenic enhancer elements such as 12-O-tetradecanoylphorbol-13-acetate-responsive element and SRE.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany	Technical University of Munich; University of Munich	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Trogerstr 32, D-81675 Munich, Germany.		Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Coutinho S, 2000, BLOOD, V96, P618; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; HORI Y, 1990, ONCOGENE, V5, P1201; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Min W, 1996, MOL CELL BIOL, V16, P359; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	44	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43419	43427		10.1074/jbc.M107030200	http://dx.doi.org/10.1074/jbc.M107030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11514578	hybrid			2022-12-25	WOS:000172169300102
J	Niu, SL; Mitchell, DC; Litman, BJ				Niu, SL; Mitchell, DC; Litman, BJ			Optimization of receptor-G protein coupling by bilayer lipid composition II - Formation of metarhodopsin II-transducin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID DEFICIENCY; GTP-BINDING PROTEIN; DOCOSAHEXAENOIC ACID; CYTOPLASMIC LOOP; GAMMA-SUBUNITS; GUINEA-PIG; RHODOPSIN; MEMBRANES; CHOLESTEROL; EQUILIBRIUM	The visual transduction system was used as a model to investigate the effects of membrane lipid composition on receptor-G protein coupling. Rhodopsin was reconstituted into large, unilamellar phospholipid vesicles with varying acyl chain unsaturation, with and without cholesterol. The association constant (K-alpha) for metarhodopsin II (MII) and transducin (G(t)) binding was determined by monitoring MII-G(t) complex formation spectrophotometrically. At 20 degreesC, in pH 7.5 isotonic buffer, the strongest MII-G(t) binding was observed in 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0,22:6PC), whereas the weakest binding was in 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0,18:1PC) with 30 mol% cholesterol. Increasing acyl chain unsaturation from 18:0,18:1PC to 18:0,22:6PC resulted in a 3-fold increase in K-alpha. The inclusion of 30 mol% cholesterol in the membrane reduced K-alpha in both 18:0,22:6PC and 18:0,18:1PC. These findings demonstrate that membrane compositions can alter the signaling cascade by changing protein-protein interactions occurring predominantly in the hydrophilic region of the proteins, external to the lipid bilayer. These findings, if extended to other members of the superfamily of G protein-coupled receptors, suggest that a loss in efficiency of receptor-G protein binding is a contributing factor to the loss of cognitive skills, odor and spatial discrimination, and visual function associated with n-3 fatty acid deficiency.	NIAAA, Sect Fluorescence Studies, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), NIAAA, Sect Fluorescence Studies, Lab Membrane Biochem & Biophys, Pk 5,Rm 158,12420 Parklawn Dr, Rockville, MD 20852 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000072, Z01AA000105, Z01AA000080, ZIAAA000080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], [No title captured]; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HOFMANN KP, 1985, BIOCHIM BIOPHYS ACTA, V810, P278, DOI 10.1016/0005-2728(85)90143-4; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; LITMAN BJ, 1996, LIPIDS S, V31, P193; LITMAN BJ, 1996, BIOMEMBRANE, P1; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; OBRIEN DF, 1977, BIOCHEMISTRY-US, V16, P1295, DOI 10.1021/bi00626a009; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SanGiovanni JP, 2000, PEDIATRICS, V105, P1292, DOI 10.1542/peds.105.6.1292; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; Weisinger HS, 1996, LIPIDS, V31, P65, DOI 10.1007/BF02522413; Weisinger HS, 1999, INVEST OPHTH VIS SCI, V40, P327	38	91	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42807	42811		10.1074/jbc.M105778200	http://dx.doi.org/10.1074/jbc.M105778200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544259	hybrid			2022-12-25	WOS:000172169300024
J	Hilaire, S; Belanger, C; Bertrand, J; Laperriere, A; Foord, SM; Bouvier, M				Hilaire, S; Belanger, C; Bertrand, J; Laperriere, A; Foord, SM; Bouvier, M			Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; HORMONE RECEPTOR; COUPLED RECEPTORS; ADRENOMEDULLIN RECEPTORS; TERMINAL TAIL; DESENSITIZATION; ENDOCYTOSIS; BINDING; CELLS; LOCALIZATION	The calcitonin receptor-like receptor (CRLR) is a seven-transmembrane domain (7TM) protein that requires the receptor activity-modifying protein 1 (RAMP1) to be expressed at the cell surface as a functional calcitonin gene-related peptide (CGRP) receptor. Although dimerization between the two molecules is well established, very little is known concerning the trafficking of this heterodimer upon receptor activation. Also, the subcellular localization and biochemical state of this ubiquitously expressed protein, in the absence of CRLR, remains poorly characterized. Here we report that when expressed alone RAMP1 is retained inside the cells where it is found in the endoplasmic reticulum and the Golgi predominantly as a disulfide-linked homodimer. In contrast, when expressed with CRLR, it is targeted to the cell surface as a 1:1 heterodimer with the 7TM protein. Although heterodimer formation does not involve intermolecular disulfide bonds, RAMP-CRLR association promotes the formation of intramolecular disulfide bonds within RAMP1. CGRP binding and receptor activation lead to the phosphorylation of CRLR and the internalization of the receptor as a stable complex. The internalization was found to be both dynamin- and beta -arrestin-dependent, indicating that the formation of a ternary complex between CRLR, RAMP1, and beta -arrestin leads to clathrin-coated pit-mediated endocytosis. These results therefore indicate that although atypical by its heterodimeric composition and its targeting to the plasma membrane, the CGRP receptor shares endocytotic mechanisms that are common to most classical 7TM receptors.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Glaxo Wellcome Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England	Universite de Montreal; GlaxoSmithKline	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Bouvier@bcm.umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Drake WM, 1999, ENDOCRINOLOGY, V140, P533, DOI 10.1210/en.140.1.533; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Fullekrug J, 1999, J CELL SCI, V112, P2813; Gines S, 2001, MOL PHARMACOL, V59, P1314, DOI 10.1124/mol.59.5.1314; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; Haasemann M, 1998, J CELL SCI, V111, P917; Hauri HP, 2000, J CELL SCI, V113, P587; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leuthauser K, 2000, BIOCHEM J, V351, P347, DOI 10.1042/0264-6021:3510347; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mentlein R, 2001, CELL TISSUE RES, V303, P27, DOI 10.1007/s004410000302; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Poyner DR, 1997, BIOCHEM SOC T, V25, P1032, DOI 10.1042/bst0251032; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; WADA I, 1991, J BIOL CHEM, V266, P19599; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	113	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42182	42190		10.1074/jbc.M107323200	http://dx.doi.org/10.1074/jbc.M107323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535606	hybrid			2022-12-25	WOS:000172450400086
J	Jamali, M; Rogerson, PJ; Wilton, S; Skerjanc, IS				Jamali, M; Rogerson, PJ; Wilton, S; Skerjanc, IS			Nkx2-5 activity is essential for cardiomyogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BONE MORPHOGENETIC PROTEINS; CARDIAC GENE-EXPRESSION; TINMAN-RELATED GENES; DNA-BINDING TARGETS; ENHANCER FACTOR 2C; HEART DEVELOPMENT; SKELETAL-MUSCLE; P19 CELLS; TRANSCRIPTION FACTORS	The homeobox transcription factor tinman is essential for heart vessel formation in Drosophila. In contrast, mice lacking the murine homologue Nkx2-5 are defective in cardiac looping but not in cardiac myocyte development. The lack of an essential role for Nkx2-5 in cardiomyogenesis in mammalian systems is most likely the result of genetic redundancy with family members. In this study, we used a dominant negative mutant of Nkx2-5, created by fusing the repressor domain of engrailed 2 to the Nkx2-5 homeodomain, termed Nkx/EnR. Expression of Nkx/EnR inhibited Me2SO-induced cardiomyogenesis in P19 cells but not skeletal myogenesis. Nkx/EnR inhibited expression of cardiomyoblast markers, such as GATA-4 and MEF2C, but not of mesoderm markers, such as Brachyury T and Wnt5b, or of skeletal lineage markers, such as MyoD and Mox1. To identify the minimal region of Nkx2-5 that can trigger cardiomyogenesis, we analyzed the activity of various Nkx2-5 deletion mutants. The C-terminal domain was not necessary for the ability of Nkx2-5 to induce cardiomyogenesis and loss of this domain did not enhance myogenesis. Therefore, Nkx2-5 function is essential for commitment of mesoderm into the cardiac muscle lineage, and the N-terminal region, together with the homeodomain, is sufficient for cardiomyogenesis in P19 cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.		Skerjanc, Ilona/AAN-3318-2020					Andree B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925-4773(97)00186-X; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1993, DEVELOPMENT, V118, P719; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Cripps RM, 1999, DEV BIOL, V215, P420, DOI 10.1006/dbio.1999.9446; Davis DL, 2000, DEV BIOL, V217, P310, DOI 10.1006/dbio.1999.9561; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Fu YC, 1998, DEVELOPMENT, V125, P4439; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Gajewski K, 2001, DEV BIOL, V233, P425, DOI 10.1006/dbio.2001.0220; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Gofflot F, 1997, DEV DYNAM, V210, P431, DOI 10.1002/(SICI)1097-0177(199712)210:4<431::AID-AJA7>3.0.CO;2-H; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Jiang YM, 1999, DEV BIOL, V216, P57, DOI 10.1006/dbio.1999.9469; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Montross WT, 2000, J CELL SCI, V113, P1759; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Newman CS, 1998, DEV GENET, V22, P230; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shi YQ, 2000, DEV BIOL, V224, P226, DOI 10.1006/dbio.2000.9802; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; SKERJANC IS, 1994, MOL CELL BIOL, V1464, P8451; Tanaka M, 1999, DEVELOPMENT, V126, P1269; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	63	69	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42252	42258		10.1074/jbc.M107814200	http://dx.doi.org/10.1074/jbc.M107814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11526122	hybrid			2022-12-25	WOS:000172450400095
J	Li, ZY; Xi, XD; Du, XP				Li, ZY; Xi, XD; Du, XP			A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IB; VON-WILLEBRAND-FACTOR; RECEPTOR GAMMA-CHAIN; IX-V COMPLEX; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; CYTOPLASMIC DOMAIN; FIBRINOGEN BINDING; ADHESION RECEPTOR; IIB/IIIA COMPLEX	We have recently shown that the platelet integrin alpha (IIb)beta (3) is activated by von Willebrand factor (vWF) binding to its platelet receptor, glycoprotein Ib-IX (GPIb-IX, via the protein kinase G (PKG) signaling pathway. Here we show that GPIb-IX-mediated activation of integrin alpha (IIb)beta (3) is inhibited by dominant negative mutants of Raf-1 and MEK1 in a reconstituted integrin activation model in Chinese hamster ovary (CHO) cells and that the integrin-dependent platelet aggregation induced by either vWF or low dose thrombin is inhibited by MEK inhibitors PD98059 and U0126. Thus, mitogen-activated protein kinase MAPK) pathway is important in GPIb-IX-dependent activation of platelet integrin alpha (IIb)beta (3). Furthermore, vWF binding to GPIb-IX induces phosphorylation of Thr-202/Tyr-204 of extracellular signal-regulated kinase 2 (ERK2). GPIb-IX-induced ERK2 phosphorylation is inhibited by PKG inhibitors and enhanced by overexpression of recombinant PKG. PKG activators also induce ERK phosphorylation, indicating that activation of MAPK pathway is downstream from PKG. Thus, our data delineate a novel integrin activation pathway in which ligand binding to GPIb-IX activates PKG that stimulates MAPK pathway, leading to integrin activation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	xdu@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062350, R29HL052547] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL068819, HL62350, R01 HL062350, HL52547] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Canobbio I, 2001, J BIOL CHEM, V276, P26022, DOI 10.1074/jbc.M102639200; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Munday AD, 2000, BLOOD, V96, P577; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; OKUMURA T, 1976, THROMB RES, V8, P701, DOI 10.1016/0049-3848(76)90250-4; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; RUAN CG, 1987, BLOOD, V69, P570; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	49	112	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42226	42232		10.1074/jbc.M106129200	http://dx.doi.org/10.1074/jbc.M106129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11522789	hybrid			2022-12-25	WOS:000172450400092
J	Qian, YC; Commane, M; Ninomiya-Tsuji, J; Matsumoto, K; Li, XX				Qian, YC; Commane, M; Ninomiya-Tsuji, J; Matsumoto, K; Li, XX			IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of N-F kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; LYMPHOTOXIN-BETA-RECEPTOR; TRANSCRIPTION FACTOR; IKK-ALPHA; IL-1; SUBUNIT; MYD88; TAK1; MICE; MECHANISMS	The interleukin-1 (IL-1) receptor-associated kinase (IRAK) is required for the IL-1-induced activation of nuclear factor kappaB and c-Jun N-terminal kinase. The goal of this study was to understand how IRAK activates the intermediate proteins TRAF6, TAK1, TAB1, and TAB2. When IRAK is phosphorylated in response to IL-1, it binds to the membrane where it forms a complex with TRAF6; TRAF6 then dissociates and translocates to the cytosol. The membrane-bound IRAK similarly mediates the IL-1-induced translocation of TAB2 from the membrane to the cytosol. Different regions of IRAK are required for the translocation of TAB2 and TRAF6, suggesting that IRAK mediates the translocation of each protein separately. The translocation of TAB2 and TRAF6 is needed to form a TRAF6-TAK1-TAB1-TAB2 complex in the cytosol and thus activate TAK1. Our results show that IRAK is required for the IL-1-induced phosphorylation of TAK1, TAB1, and TAB2. The phosphorylation of these three proteins correlates strongly with the activation of nuclear factor kappaB but is not necessary to activate c-Jun N-terminal kinase.	Cleveland Clin Fdn, Dept Immunol NB30, Lerner Res Inst, Cleveland, OH 44195 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Cleveland Clinic Foundation; Nagoya University; Japan Science & Technology Agency (JST)	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol NB30, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	Lix@ccf.org		Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NIGMS NIH HHS [GM 600020] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	35	158	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41661	41667		10.1074/jbc.M102262200	http://dx.doi.org/10.1074/jbc.M102262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11518704	hybrid			2022-12-25	WOS:000172450400018
J	Baker, RP; Harreman, MT; Eccleston, JF; Corbett, AH; Stewart, M				Baker, RP; Harreman, MT; Eccleston, JF; Corbett, AH; Stewart, M			Interaction between Ran and Mog1 is required for efficient nuclear protein import.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT FACTOR-2 NTF2; GDP-BOUND FORM; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; CHROMOSOME CONDENSATION; DIFFRACTION ANALYSIS; NUCLEOTIDE EXCHANGE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MESSENGER-RNA	Mog1 is a nuclear protein that interacts with Ran, the Ras family GTPase that confers directionality to nuclear import and export pathways. Deletion of MOG1 in Saccharomyces cerevisiae (Delta mog1) causes temperature-sensitive growth and defects in nuclear protein import. Mog1 has previously been shown to stimulate GTP release from Ran and we demonstrate here that addition of Mog1 to either Ran-GTP or Ran-GDP results in nucleotide release and formation of a stable complex between Mog1 and nucleotide-free Ran. Moreover, MOG1 shows synthetic lethality with PRP20, the Ran guanine nucleotide exchange factor (RanGEF) that also binds nucleotide-free Ran. To probe the functional role of the Mog1-Ran interaction, we engineered mutants of yeast Mog1 and Ran that specifically disrupt their interaction both in vitro and in vivo. These mutants indicate that the interaction interface involves conserved Mog1p residues Asp(62) and Glu(65), and residue Lys(136) in yeast Ran. Mutations at these residues decrease the ability of Mog1 to bind and release nucleotide from Ran. Furthermore, the E65K-Mog1 and K136E-Ran mutations in yeast cause temperature sensitivity and mislocalization of a nuclear import reporter protein, similar to the phenotype observed for the Delta mog1 strain. Our results indicate that a primary function of Mog1 requires binding to Ran and that the Mog1-Ran interaction is necessary for efficient nuclear protein import in vivo.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, Atlanta, GA 30322 USA; Natl Inst Med Res, London NW7 1AA, England	MRC Laboratory Molecular Biology; Emory University; MRC National Institute for Medical Research	Stewart, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895; Baker, Rosanna/0000-0002-9970-6278	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Akhtar N, 2001, MOL GENET GENOMICS, V265, P851, DOI 10.1007/s004380100480; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Baker RP, 2000, ACTA CRYSTALLOGR D, V56, P229, DOI 10.1107/S0907444999016856; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Hayashi N, 1996, MOL GEN GENET, V253, P149, DOI 10.1007/s004380050307; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Kent HM, 1999, J MOL BIOL, V289, P565, DOI 10.1006/jmbi.1999.2775; Kent HM, 1996, J STRUCT BIOL, V116, P326, DOI 10.1006/jsbi.1996.0049; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marfatia KA, 2001, GENE, V266, P45, DOI 10.1016/S0378-1119(01)00364-X; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Murphy GA, 1997, MOL BIOL CELL, V8, P2591, DOI 10.1091/mbc.8.12.2591; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Oki M, 2000, J BIOL CHEM, V275, P32894, DOI 10.1074/jbc.M910251199; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2000, J MOL BIOL, V299, P213, DOI 10.1006/jmbi.2000.3733; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755	46	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41255	41262		10.1074/jbc.M106060200	http://dx.doi.org/10.1074/jbc.M106060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11509570	hybrid			2022-12-25	WOS:000171925600117
J	Jacobs, AR; LeRoith, D; Taylor, SI				Jacobs, AR; LeRoith, D; Taylor, SI			Insulin receptor substrate-1 pleckstrin homology and phosphotyrosine-binding domains are both involved in plasma membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; PROTEIN; DOWNSTREAM; ACTIVATION; IRS-1; COMPARTMENTALIZATION; PHOSPHORYLATION; LOCALIZATION; ASSOCIATION; DYNAMICS	The localization of insulin receptor substrate (IRS) molecules may be responsible for the differential biological activities of insulin and other peptides such as platelet-derived growth factor. The subcellular localization of IRS-1 is controversial, with some reports suggesting association with the cytoskeleton and other studies reporting membrane localization. In this study, we used immunofluorescence microscopy to define the localization of IRS-1. In the basal state, recombinant IRS-1 was localized predominantly in the cytoplasm. In response to insulin, recombinant IRS-1 translocated to the plasma membrane. We have also studied the localization of green fluorescent protein (GFP) fusion proteins. Unlike native IRS-1, a fusion protein containing GFP plus full-length IRS-1 appeared to localize in inclusion bodies. In contrast, when GFP was fused to the N terminus of IRS-1 (i.e. the pleckstrin homology and phosphotyrosine-binding domains), this fusion protein was targeted to the plasma membrane. Mutations of phosphoinositide-binding sites in both the pleckstrin homology and phosphotyrosine-binding domains significantly reduced the ability of Myc-tagged IRS-1 to translocate to the plasma membrane following insulin stimulation. However, these mutations did not cause a statistically significant impairment of tyrosine phosphorylation in response to insulin. This raises the possibility that IRS-1 tyrosine phosphorylation may occur prior to plasma membrane translocation.	NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); George Washington University	LeRoith, D (corresponding author), NIDDK, Clin Endocrinol Branch, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.	Derek@helix.nih.gov						Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Kriauciunas KM, 2000, MOL CELL BIOL, V20, P6849, DOI 10.1128/MCB.20.18.6849-6859.2000; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; QUON MJ, 1994, J BIOL CHEM, V269, P27920; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Takeuchi H, 1998, BIOCHEM J, V334, P211, DOI 10.1042/bj3340211; Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; VanRenterghem B, 1998, J BIOL CHEM, V273, P29942, DOI 10.1074/jbc.273.45.29942; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262	32	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40795	40802		10.1074/jbc.M105194200	http://dx.doi.org/10.1074/jbc.M105194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526109	hybrid			2022-12-25	WOS:000171925600057
J	Krasotkina, J; Walters, T; Maruya, KA; Ragsdale, SW				Krasotkina, J; Walters, T; Maruya, KA; Ragsdale, SW			Characterization of the B-12- and iron-sulfur-containing reductive dehalogenase from Desulfitobacterium chlororespirans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE; SP-NOV; HALOALKANE DEHALOGENASE; DESULFOMONILE-TIEDJEI; COENZYME-A; PURIFICATION; TETRACHLOROETHENE; DECHLORINATION; PROTEIN; ENZYME	The United Nations and the U.S. Environmental Protection Agency have identified a variety of chlorinated aromatics that constitute a significant health and environmental risk as "priority organic pollutants," the so-called "dirty dozen." Microbes have evolved the ability to utilize chlorinated aromatics as terminal electron acceptors in an energy-generating process called dehalorespiration. In this process, a reductive dehalogenase (CprA), couples the oxidation of an electron donor to the reductive elimination of chloride. We have characterized the B-12 and iron-sulfur cluster-containing 3-chloro-4-hydroxybenzoate reductive dehalogenase from Desulfitobacterium chlororespirans. By defining the substrate and inhibitor specificity for the dehalogenase, the enzyme was found to require an hydroxyl group ortho to the halide. Inhibition studies indicate that the hydroxyl group is required for substrate binding. The carboxyl group can be replaced by other functionalities, e.g. acetyl or halide groups, ortho or meta to the chloride to be eliminated. The purified D. chlororespirans enzyme could dechlorinate an hydroxylated PCB (3,3',5,5'-tetra-chloro-4,4'-biphenyldiol) at a rate about 1% of that with 3-chloro-4-hydroxybenzoate. Solvent deuterium isotope effect studies indicate that transfer of a single proton is partially rate-limiting in the dehalogenation reaction.	Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA; Skidaway Inst Oceanog, Savannah, GA 31411 USA	University of Nebraska System; University of Nebraska Lincoln; University System of Georgia; University of Georgia; Skidaway Institute of Oceanography	Ragsdale, SW (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr, Lincoln, NE 68588 USA.	sragsdale1@unl.edu						Alber BE, 1999, BIOCHEMISTRY-US, V38, P13119, DOI 10.1021/bi9828876; Anandarajah K, 2000, BIOCHEMISTRY-US, V39, P5303, DOI 10.1021/bi9923813; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bouchard B, 1996, INT J SYST BACTERIOL, V46, P1010, DOI 10.1099/00207713-46-4-1010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; Christiansen N, 1996, INT J SYST BACTERIOL, V46, P442, DOI 10.1099/00207713-46-2-442; Copley SD, 1998, CURR OPIN CHEM BIOL, V2, P613, DOI 10.1016/S1367-5931(98)80092-6; DOLFING J, 1987, ARCH MICROBIOL, V149, P102, DOI 10.1007/BF00425073; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; GRIFFITH GD, 1992, APPL ENVIRON MICROB, V58, P409, DOI 10.1128/AEM.58.1.409-411.1992; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Hurt JD, 1997, J BIOL CHEM, V272, P13512, DOI 10.1074/jbc.272.21.13512; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JOHANSSON IM, 1994, EUR J BIOCHEM, V224, P901, DOI 10.1111/j.1432-1033.1994.00901.x; KRAUTLER B, 1999, CHEM BIOCH B12, V1, P315; Krooshof GH, 1998, BIOCHEMISTRY-US, V37, P15013, DOI 10.1021/bi9815187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE SD, 1990, J BACTERIOL, V172, P164, DOI 10.1128/JB.172.1.164-171.1990; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LJUNGDAH.LG, 1973, BIOCHEMISTRY-US, V12, P1802, DOI 10.1021/bi00733a022; Loffler FE, 1996, APPL ENVIRON MICROB, V62, P3809, DOI 10.1128/AEM.62.10.3809-3813.1996; McCarthy DL, 1996, BIOCHEMISTRY-US, V35, P14634, DOI 10.1021/bi961730f; Messmer M, 1996, ARCH MICROBIOL, V165, P18, DOI 10.1007/s002030050291; Miller E, 1998, ARCH MICROBIOL, V169, P497, DOI 10.1007/s002030050602; Miller E, 1996, ARCH MICROBIOL, V166, P379, DOI 10.1007/BF01682983; MOHN WW, 1991, ARCH MICROBIOL, V157, P1; MORRIS PJ, 1992, APPL ENVIRON MICROB, V58, P3088, DOI 10.1128/AEM.58.9.3088-3094.1992; Neumann A, 1996, J BIOL CHEM, V271, P16515, DOI 10.1074/jbc.271.28.16515; NI SS, 1995, J BACTERIOL, V177, P5135, DOI 10.1128/jb.177.17.5135-5139.1995; QUENSEN JF, 1990, APPL ENVIRON MICROB, V56, P2360, DOI 10.1128/AEM.56.8.2360-2369.1990; Rabinowitz J C, 1978, Methods Enzymol, V53, P275; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1999, CHEM BIOCH B12, V1, P633; Sanford RA, 1996, APPL ENVIRON MICROB, V62, P3800, DOI 10.1128/AEM.62.10.3800-3808.1996; Schanstra JP, 1996, BIOCHEMISTRY-US, V35, P5624, DOI 10.1021/bi952904g; Schumacher W, 1997, FEBS LETT, V409, P421, DOI 10.1016/S0014-5793(97)00520-6; Schumacher W, 1996, J BACTERIOL, V178, P2328, DOI 10.1128/jb.178.8.2328-2333.1996; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; Smith KS, 2000, J BACTERIOL, V182, P6605, DOI 10.1128/JB.182.23.6605-6613.2000; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Wiegel J, 2000, FEMS MICROBIOL ECOL, V32, P1, DOI 10.1111/j.1574-6941.2000.tb00693.x; Wiegel J, 1999, APPL ENVIRON MICROB, V65, P2217; Wohlfarth G, 1997, CURR OPIN BIOTECH, V8, P290, DOI 10.1016/S0958-1669(97)80006-7	47	59	60	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40991	40997		10.1074/jbc.M106217200	http://dx.doi.org/10.1074/jbc.M106217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533062	hybrid			2022-12-25	WOS:000171925600083
J	Song, YL; Verkman, AS				Song, YL; Verkman, AS			Aquaporin-5 dependent fluid secretion in airway submucosal glands.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNELS; TRANSPORT; LUNG; EXPRESSION; TRACHEAL; LACKING; MICE; CLEARANCE; MUCUS; CFTR	Fluid and macromolecule secretion by submucosal glands in mammalian airways is believed to play an important role in airway defense and surface liquid homeostasis and in the pathogenesis of cystic fibrosis. Immunocytochemistry revealed strong expression of aquaporin water channel AQP5 at the luminal membrane of serous epithelial cells in submucosal glands throughout the mouse nasopharynx and upper airways and AQP4 at the contralateral basolateral membrane in some glands. Novel methods were applied to measure secretion rates and composition of gland fluid in wild type mice and knockout mice lacking AQP4 or AQP5. In mice breathing through a tracheotomy, total gland fluid output was measured from the dilution of a volume marker present in the fluid-filled nasopharynx and upper trachea. Pilocarpine-stimulated fluid secretion was 4.3 +/- 0.4 mul/min in wild type mice, 4.9 +/- 0.9 mul/min in AQP4 null mice, and 1.9.+/- 0.3 mul/min in AQP5 null mice (p < 0.001). Similar results were obtained when secreted fluid was collected in the oil-filled nasopharyngeal cavity. Real-time video imaging of fluid droplets secreted from individual submucosal glands near the larynx in living mice showed a 57 +/- 4% reduced fluid secretion rate in AQP5 null mice. Analysis of secreted fluid showed a 2.3 +/- 0.2-fold increase in total protein in AQP5 null mice and a smaller increase in [Cl-], suggesting intact protein and salt secretion across a relatively water impermeable epithelial barrier. Submucosal gland morphology and density did not differ significantly in wild type versus AQP5 null mice. These results indicate that AQP5 facilitates fluid secretion in submucosal glands and that the luminal membrane of gland epithelial cells is the rate-limiting barrier to water movement. Modulation of gland AQP5 expression or function might provide a novel approach to treat hyperviscous gland secretions in cystic fibrosis and excessive fluid secretions in infectious or allergic bronchitis/rhinitis.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BASBAUM CB, 1990, ANNU REV PHYSIOL, V52, P97; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Choi HK, 2000, J ANAT, V197, P361, DOI 10.1046/j.1469-7580.2000.19730361.x; FUNAKI H, 1997, AM J PHYSIOL, V272, pL203; GIROD S, 1992, EUR RESPIR J, V5, P477; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Inglis SK, 1997, AM J PHYSIOL-LUNG C, V272, pL203, DOI 10.1152/ajplung.1997.272.2.L203; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Kreda SM, 2001, AM J RESP CELL MOL, V24, P224, DOI 10.1165/ajrcmb.24.3.4367; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Moore M, 2000, EXP EYE RES, V70, P557, DOI 10.1006/exer.1999.0814; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PILEWSKI JM, 1999, PHYSIOL REV, V79, pS216; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SON GY, 2000, AM J PHYSIOL, V279, pC1744; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Song YL, 2000, J PHYSIOL-LONDON, V525, P771, DOI 10.1111/j.1469-7793.2000.00771.x; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF1030, DOI 10.1152/ajprenal.2000.278.6.F1030; Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Widdicombe JH, 2001, J ANAT, V198, P207, DOI 10.1046/j.1469-7580.2001.19820207.x; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140	33	169	200	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41288	41292		10.1074/jbc.M107257200	http://dx.doi.org/10.1074/jbc.M107257200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514581	hybrid			2022-12-25	WOS:000171925600121
J	Yamauchi, T; Kamon, J; Waki, H; Murakami, K; Motojima, K; Komeda, K; Ide, T; Kubota, N; Terauchi, Y; Tobe, K; Miki, H; Tsuchida, A; Akanuma, Y; Nagai, R; Kimura, S; Kadowaki, T				Yamauchi, T; Kamon, J; Waki, H; Murakami, K; Motojima, K; Komeda, K; Ide, T; Kubota, N; Terauchi, Y; Tobe, K; Miki, H; Tsuchida, A; Akanuma, Y; Nagai, R; Kimura, S; Kadowaki, T			Mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; GENE-EXPRESSION; PRO12ALA POLYMORPHISM; ALPHA; OBESITY; THIAZOLIDINEDIONES; RATS; MICE; ADIPOGENESIS; SENSITIVITY	Peroxisome proliferator-activated receptor (PPAR) gamma is a ligand-activated transcription factor and a member of the nuclear hormone receptor superfamily that is thought to be the master regulator of fat storage; however, the relationship between PPAR gamma and insulin sensitivity is highly controversial. We show here that supraphysiological activation of PPAR gamma by PPAR gamma agonist thiazolidinediones (TZD) markedly increases triglyceride (TG) content of white adipose tissue (WAT), thereby decreasing TG content of liver and muscle, leading to amelioration of insulin resistance at the expense of obesity. Moderate reduction of PPAR gamma activity by heterozygous PPAR gamma deficiency decreases TG content of WAT, skeletal muscle, and liver due to increased leptin expression and increase in fatty acid combustion and decrease in lipogenesis, thereby ameliorating high fat diet-induced obesity and insulin resistance. Moreover, although heterozygous PPAR gamma deficiency and TZD have opposite effects on total WAT mass, heterozygous PPAR gamma deficiency decreases lipogenesis in WAT, whereas TZD stimulate adipocyte differentiation and apoptosis, thereby both preventing adipocyte hypertrophy, which is associated with alleviation of insulin resistance presumably due to decreases in free fatty acids, and tumor necrosis factor a, and up-regulation of adiponectin, at least in part. We conclude that, although by different mechanisms, both heterozygous PPAR gamma deficiency and PPAR gamma agonist improve insulin resistance, which is associated with decreased TG content of muscle/liver and prevention of adipocyte hypertrophy.	Univ Tokyo, Dept Internal Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Tokyo Med Univ, Div Lab Anim Sci, Anim Res Ctr, Tokyo 1608402, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 1000005, Japan	University of Tokyo; Meiji Pharmaceutical University; Tokyo Medical University; Asahi Life Foundation	Kadowaki, T (corresponding author), Univ Tokyo, Dept Internal Med, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Kubota, Naoto/N-7892-2015; Terauchi, Yasuo/AAO-4347-2020; Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; ASKEW EW, 1975, J CLIN INVEST, V56, P521, DOI 10.1172/JCI108120; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bakopanos E, 2000, DIABETES, V49, P2108, DOI 10.2337/diabetes.49.12.2108; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gonzalez FJ, 1997, BIOCHIMIE, V79, P139, DOI 10.1016/S0300-9084(97)81506-4; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hara K, 2000, BIOCHEM BIOPH RES CO, V271, P212, DOI 10.1006/bbrc.2000.2605; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Kahn CR, 2000, J CLIN INVEST, V106, P1305, DOI 10.1172/JCI11705; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	34	524	549	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41245	41254		10.1074/jbc.M103241200	http://dx.doi.org/10.1074/jbc.M103241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533050	hybrid			2022-12-25	WOS:000171925600116
J	Blobe, GC; Liu, XD; Fang, SJJ; How, T; Lodish, HF				Blobe, GC; Liu, XD; Fang, SJJ; How, T; Lodish, HF			A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling - Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; DEPENDENT DEGRADATION; C-TERMINUS; KINASE; PATHWAY; CLONING; CELLS; BINDS; RESPONSIVENESS; ARREST	Transforming growth factor beta (TGF-beta) mediates its biological effects through three high-affinity cell surface receptors, the TGF-beta type I, type II, and type III receptors, and the Smad family of transcription factors. Although the functions of the type II and type I receptors are well established, the precise role of the type III receptor in TGF-beta signaling remains to be established. While expression cloning signaling molecules downstream of TGF-beta, we cloned GIPC (GAIP-interacting protein, C terminus), a PDZ domain-containing protein. GIPC binds a Class I PDZ binding motif in the cytoplasmic domain of the type III receptor resulting in regulation of expression of the type III receptor at the cell surface. Increased expression of the type III receptor mediated by GIPC enhanced cellular responsiveness to TGF-beta both in terms of inhibition of proliferation and in plasminogen-activating inhibitor (PAD-based promoter gene induction assays. In all cases, deletion of the Class I PDZ binding motif of the type III receptor prevented the type III receptor from binding to GIPC and abrogated the effects of GIPC on type III receptor expressing cells. These results establish, for the first time, a protein that interacts with the cytoplasmic domain of the type III receptor, determine that expression of the type III receptor is regulated at the protein level and that increased expression of the type III receptor is sufficient to enhance TGF-beta signaling. These results further support an essential, non-redundant role for the type I receptor in TGF-beta signaling.	Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Duke University; Duke University; University of Colorado System; University of Colorado Boulder; Massachusetts Institute of Technology (MIT); Whitehead Institute	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA.	blobe001@mc.duke.edu	Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; LIU, XUEDONG/0000-0001-7209-4964	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blain SW, 2000, J BIOL CHEM, V275, P32066, DOI 10.1074/jbc.M006496200; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Cai HB, 1999, J NEUROSCI, V19, P6519; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fink SP, 2001, CANCER RES, V61, P256; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; James P, 1996, GENETICS, V144, P1425; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu TF, 2001, J BIOL CHEM, V276, P35768, DOI 10.1074/jbc.M103585200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Onishi M, 1996, EXP HEMATOL, V24, P324; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tani TT, 2001, J BIOL CHEM, V276, P36535, DOI 10.1074/jbc.M105785200; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9	34	165	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39608	39617		10.1074/jbc.M106831200	http://dx.doi.org/10.1074/jbc.M106831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546783	hybrid			2022-12-25	WOS:000171789200016
J	Bulman, AL; Hubl, ST; Nelson, HCM				Bulman, AL; Hubl, ST; Nelson, HCM			The DNA-binding domain of yeast heat shock transcription factor independently regulates both the N- and C-terminal activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR CONTAINS; KEY FEATURES; TRIMERIZATION; EXPRESSION; GENE; HSF; TRANSIENT; PROTEIN	The expression of heat shock proteins in response to cellular stresses is dependent on the activity of the heat shock transcription factor (HSF). In yeast, HSF is constitutively bound to DNA, however, the mitigation of negative regulation in response to stress dramatically increases transcriptional activity. Through alanine-scanning mutagenesis of the surface residues of the DNA-binding domain, we have identified a large number of mutants with increased transcriptional activity. Six of the strongest mutations were selected for detailed study. Our studies suggest that the DNA-binding domain is involved in the negative regulation of both the N-terminal and C-terminal activation domains of HSF. These mutations do not significantly affect DNA binding. Circular dichroism analysis suggests that a subset of the mutants may have altered secondary structure, whereas a different subset has decreased thermal stability. Our findings suggest that the regulation of HSF transcriptional activity (under both constitutive and stressed conditions) may be partially dependent on the local topology of the DNA-binding domain. In addition, the DNA-binding domain may mediate key interactions with ancillary factors and/or other intramolecular regulatory regions in order to modulate the complex regulation of HSF's transcriptional activity.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California Berkeley	Nelson, HCM (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 813 Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	hnelson@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; Bonner JJ, 2000, J MOL BIOL, V302, P581, DOI 10.1006/jmbi.2000.4096; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; Bonner JJ, 2000, MOL BIOL CELL, V11, P1739, DOI 10.1091/mbc.11.5.1739; CHEN YQ, 1993, EMBO J, V12, P5007, DOI 10.1002/j.1460-2075.1993.tb06194.x; Cicero MP, 2001, NUCLEIC ACIDS RES, V29, P1715, DOI 10.1093/nar/29.8.1715; Drees BL, 1997, J MOL BIOL, V273, P61, DOI 10.1006/jmbi.1997.1283; FLICK KE, 1994, J BIOL CHEM, V269, P12475; Hardy JA, 2000, J MOL BIOL, V295, P393, DOI 10.1006/jmbi.1999.3357; Hardy JA, 2000, PROTEIN SCI, V9, P2128, DOI 10.1110/ps.9.11.2128; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hjorth-Sorensen B, 2001, MOL MICROBIOL, V39, P914, DOI 10.1046/j.1365-2958.2001.02279.x; HOJ A, 1994, EMBO J, V13, P2617; HUBL ST, 1994, NAT STRUCT BIOL, V1, P615, DOI 10.1038/nsb0994-615; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Moore DD, 1995, GLOB MOB SURV; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40254	40262		10.1074/jbc.M106301200	http://dx.doi.org/10.1074/jbc.M106301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509572	hybrid			2022-12-25	WOS:000171789200099
J	Tauhata, SBF; dos Santos, DV; Taylor, EW; Mooseker, MS; Larson, RE				Tauhata, SBF; dos Santos, DV; Taylor, EW; Mooseker, MS; Larson, RE			High affinity binding of brain myosin-Va to F-actin induced by calcium in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSINS; CALMODULIN-BINDING; PIGMENT TRANSPORT; PURIFICATION; MICROTUBULE; MOVEMENT; COMPLEX; MODEL; ADP	Brain myosin-Va consists of two heavy chains, each containing a neck domain with six tandem IQ motifs that bind four to five calmodulins and one to two essential light chains. Previous studies demonstrated that myosin-Va exhibits an unusually high affinity for F-actin in the presence of ATP and that its MgATPase activity is stimulated by micromolar Ca2+ in a highly cooperative manner. We demonstrate here that Ca2+ also induces myosin-Va binding to and cosedimentation with F-actin in the presence of ATP in a similar cooperative manner and calcium concentration range as that observed for the ATPase activity. Neither hydrolysis of ATP nor buildup of ADP was required for Ca2+-induced cosedimentation. The Ca2+-induced binding was inhibited by low temperature or by 0.6 m NaCl, but not by Triton X-100. Tight binding between myosin-Va and pyrene-labeled F-actin in the presence of ATP and Ca2+ was also detected by quenching of the pyrene fluorescence. Negatively stained preparations of actomyosin-Va under Ca2+-induced binding conditions showed tightly packed F-actin bundles cross-linked by myosin-Va. Our data demonstrate that high affinity binding of myosin-Va and F-actin in the presence of ATP or 5'-O-(thiotriphosphate) is induced by micromolar concentrations of Ca2+. Since Ca2+ regulates both the actin binding properties and actin-activated ATPase of myosin-Va over the same concentration range, we suggest that the calcium signal may regulate the mechanism of processivity of myosin Va.	Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Cellular & Mol Biol, BR-14049900 Ribeirao Preto, SP, Brazil; Marine Biol Lab, Woods Hole, MA 02543 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Yale Univ, Dept MCD Biol, New Haven, CT 06511 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06511 USA; Yale Univ, Dept Pathol, New Haven, CT 06511 USA	Universidade de Sao Paulo; Marine Biological Laboratory - Woods Hole; Northwestern University; Yale University; Yale University; Yale University	Larson, RE (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Cellular & Mol Biol, BR-14049900 Ribeirao Preto, SP, Brazil.	relarson@fmrp.usp.br		Tauhata, Sinji/0000-0002-6617-4244	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, P01DK055389, R37DK025387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25387, DK 55389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Brown SS, 1999, ANNU REV CELL DEV BI, V15, P63, DOI 10.1146/annurev.cellbio.15.1.63; Cameron LC, 1998, ARCH BIOCHEM BIOPHYS, V355, P35, DOI 10.1006/abbi.1998.0700; Castrucci A.M. de L., 1988, Progress in Clinical and Biological Research, V256, P547; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Costa MCR, 1999, J BIOL CHEM, V274, P15811, DOI 10.1074/jbc.274.22.15811; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Eggleston A, 2000, NAT CELL BIOL, V2, pE128; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; Evans LL, 1998, J CELL SCI, V111, P2055; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCNIVEN MA, 1988, J CELL BIOL, V106, P111, DOI 10.1083/jcb.106.1.111; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Provance DW, 1999, CELL MOL LIFE SCI, V56, P233, DOI 10.1007/s000180050425; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Tsakraklides V, 1999, J CELL SCI, V112, P2853; Tuma MC, 1999, PIGM CELL RES, V12, P283, DOI 10.1111/j.1600-0749.1999.tb00762.x; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	35	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39812	39818		10.1074/jbc.M102583200	http://dx.doi.org/10.1074/jbc.M102583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517216	hybrid			2022-12-25	WOS:000171789200041
J	Higuchi, H; Bronk, SF; Takikawa, Y; Werneburg, N; Takimoto, R; El-Deiry, W; Gores, GJ				Higuchi, H; Bronk, SF; Takikawa, Y; Werneburg, N; Takimoto, R; El-Deiry, W; Gores, GJ			The bile acid glycochenodeoxycholate induces TRAIL-receptor 2/DR5 expression and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE APOPTOSIS; URSODEOXYCHOLIC ACID; DIRECT ACTIVATION; NUCLEAR RECEPTOR; RAT HEPATOCYTES; KILLER/DR5 GENE; BINDING SITE; HUMAN LIVER; CELL-DEATH; FAS	Toxic bile salts induce hepatocyte apoptosis by both Fas-dependent and -independent mechanisms. In this study, we examined the cellular mechanisms responsible for Fas-independent, bile acid-mediated apoptosis. HuH-7 cells, which are known to be Fas deficient, were stably transfected with the sodium-dependent bile acid transporting polypeptide. The toxic bile acid glycochenodeoxycholate (GCDC)-induced apoptosis in these cells in a time- and concentration-dependent manner. Apoptosis and mitochondrial cytochrome c release were inhibited by transfection with dominant negative FADD, CrmA transfection, or treatment with the selective caspase 8 inhibitor IETD-CHO. These observations suggested the Fas-independent apoptosis was also death receptor mediated. Reverse transcriptase-polymerase chain reaction demonstrated tumor necrosis factor-R1, tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-R1/DR4, -R2/DR5, and TRAIL, but not tumor necrosis fator-alpha expression by these cells. GCDC treatment increased expression of TRAIL-R2/DR5 mRNA and protein 10-fold while expression of TRAIL-R1 was unchanged. Furthermore, aggregation of TRAIL-R2/DR5, but not TRAIL-R1/DR4 was observed following GCDC treatment of the cells. Induction of TRAIL-R2/DR5 expression and apoptosis by bile acids provides new insights into the mechanisms of hepatocyte apoptosis and the regulation of TRAIL-R2/DR5 expression.	Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA	Mayo Clinic; Howard Hughes Medical Institute; University of Pennsylvania	Gores, GJ (corresponding author), Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NIDDK NIH HHS [DK41876] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041876, R01DK041876, R29DK041876] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hao CH, 2001, CANCER RES, V61, P1162; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723; Kim K, 2001, INT J ONCOL, V18, P241; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Leverkus M, 2000, CANCER RES, V60, P553; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PATEL T, 1994, J CLIN INVEST, V94, P2183, DOI 10.1172/JCI117579; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702	48	152	157	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38610	38618		10.1074/jbc.M105300200	http://dx.doi.org/10.1074/jbc.M105300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507096	hybrid			2022-12-25	WOS:000171673200039
J	Krynetskaia, NF; Feng, JY; Krynetski, EY; Garcia, JV; Panetta, JC; Anderson, KS; Evans, WE				Krynetskaia, NF; Feng, JY; Krynetski, EY; Garcia, JV; Panetta, JC; Anderson, KS; Evans, WE			Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug	FASEB JOURNAL			English	Article						thiopurines; thioguanylated DNA; viral RNase H	HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-TRANSFER VECTORS; REVERSE-TRANSCRIPTASE; RNASE-H; LYMPHOBLASTIC-LEUKEMIA; DNA-POLYMERASES; 6-THIOGUANINE; CLEAVAGE; CHEMOTHERAPY; RESISTANCE	Inhibition of HIV-1 reverse transcriptase (RT) and HIV protease are effective mechanisms for anti-retroviral agents, and the combined use of mechanistically different medications has markedly improved the treatment of HIV infected patients. The active metabolite of mercaptopurine and thioguanine (TG), deoxythioguanosine triphosphate, was shown to be incorporated into DNA by the polymerase function of HIV-1 RT and then to abrogate RNA cleavage by HIV-1 RNaseH. Treatment of human lymphocyte cultures with thioguanine produced substantial inhibition of HIV replication (IC50 = 0.035 muM, IC95 = 515.4 muM), with minimal toxicity to host lymphocytes (<10% at 15.4 <mu>M TG, P<0.000005). Furthermore, low concentrations of TG and zidovudine were synergistic in inhibiting HIV replication in human lymphocytes (synergy volume=9 <mu>M-2 %), without additive cytotoxicity to host lymphocytes. Thus, thiopurines are novel anti-retroviral agents that alter the DNA-RNA substrates for HIV RNaseH, thereby abrogating early stages of HIV replication.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Texas, SW Med Ctr, Dallas, TX USA	St Jude Children's Research Hospital; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Evans, WE (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012; Panetta, John/AAY-3850-2021	Evans, William E./0000-0002-9333-5322; Panetta, John/0000-0003-1308-7208	NATIONAL CANCER INSTITUTE [R37CA036401, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, R37 CA36401] Funding Source: Medline; NIAID NIH HHS [AI39416] Funding Source: Medline; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; BUCKHEIT RW, 1991, AIDS RES HUM RETROV, V7, P295, DOI 10.1089/aid.1991.7.295; BUCKHEIT RW, 1994, ANTIVIR CHEM CHEMOTH, V5, P35, DOI 10.1177/095632029400500105; Budavari S., 1989, MERCK INDEX; CAMPISI J, 1981, J CELL PHYSIOL, V109, P469, DOI 10.1002/jcp.1041090313; D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; Douglas J, 1999, HUM GENE THER, V10, P935, DOI 10.1089/10430349950018337; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Evans JT, 1999, HUM GENE THER, V10, P1479, DOI 10.1089/10430349950017815; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gerondelis P, 1999, J VIROL, V73, P5803, DOI 10.1128/JVI.73.7.5803-5813.1999; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JacqzAigrain E, 1997, EUR J CLIN PHARMACOL, V53, P71, DOI 10.1007/s002280050339; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Krynetskaia NF, 1999, MOL PHARMACOL, V56, P841; Krynetskaia NF, 2000, FASEB J, V14, P2339, DOI 10.1096/fj.00-0089com; LEPAGE GA, 1963, CANCER RES, V23, P1202; LING YH, 1991, MOL PHARMACOL, V40, P508; LING YH, 1992, MOL PHARMACOL, V42, P802; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; MAYBAUM J, 1987, MOL PHARMACOL, V32, P606; MAYBAUM J, 1983, CANCER RES, V43, P3852; METELEV VG, 1988, FEBS LETT, V226, P232, DOI 10.1016/0014-5793(88)81429-7; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Skoog D.A, 1985, PRINCIPLE INSTRUMENT, Vthird, P7; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; Wodarz D, 2000, P NATL ACAD SCI USA, V97, P8193, DOI 10.1073/pnas.97.15.8193; XU YZ, 1992, TETRAHEDRON, V48, P1729, DOI 10.1016/S0040-4020(01)88731-7; YAMAMOTO K, 1988, ACTA VIROL, V32, P386; ZIMM S, 1983, NEW ENGL J MED, V308, P1005, DOI 10.1056/NEJM198304283081705	36	13	13	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1902	1908		10.1096/fj.01-0124com	http://dx.doi.org/10.1096/fj.01-0124com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532970				2022-12-25	WOS:000171372700005
J	Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK				Claudio, J; Zhu, YX; Benn, SJ; Shukla, AH; McGlade, CJ; Falcioni, N; Stewart, AK			HACS1 encodes a novel SM-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells	ONCOGENE			English	Article						myeloma; adaptor protein; hematopoietic; SAM domain; SH3 domain	TYROSINE KINASE; HUMAN LEUKEMIA; FUSION; TEL; ACTIVATION; FAMILY; DOMAIN; GENE	SH3 and SAM domains are protein interaction motifs that are predominantly seen in signaling molecules, adaptors, and scaffold proteins. We have identified a novel family of putative adaptor genes that includes HACS1. HACS1 encodes a 441 amino acid protein that is differentially expressed in hematopoietic cells and has restricted expression in human tissues. Its SH3 domain is most similar to the same motif in Crk and its SAM domain shares homology with a family of uncharacterized putative scaffold and adaptor proteins. HACS1 maps to human chromosome 21q11.2 in a region that is frequently disrupted by translocation events in hematopoietic malignancies. Polyclonal antibodies against HACS1 recognized a 49.5 kDa protein whose mRNA is expressed in human immune tissues, bone marrow, heart, lung, placenta and brain. Cell lines and primary cells from acute myeloid leukemias and multiple myeloma patients express HACS1. Immunostaining and cellular fractionation studies localized the HACS1 protein predominantly to the cytoplasm.	Toronto Gen Res Inst, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Canadian Blood Serv, Toronto Ctr, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Canadian Blood Services	Stewart, AK (corresponding author), Princess Margaret Hosp, 610 Univ Ave,Room 5-126, Toronto, ON M5G 2M9, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Claudio JO, 1998, GENOMICS, V50, P44, DOI 10.1006/geno.1998.5308; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 2000, J CELL SCI, V113, P1851; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876	17	48	50	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5373	5377		10.1038/sj.onc.1204698	http://dx.doi.org/10.1038/sj.onc.1204698			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536050				2022-12-25	WOS:000170575500013
J	Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C				Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C			Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy	ONCOGENE			English	Article						Ras; hepatectomy; liver regeneration; DNA synthesis; cyclin E	RETINOBLASTOMA GENE-PRODUCT; MITOGEN-ACTIVATED PROTEIN; CELL-CYCLE; LIVER-REGENERATION; DIFFERENTIAL REGULATION; DOWN-REGULATION; S PHASE; TRANSCRIPTION; BINDING; GROWTH	Ras-genes encode for proteins important for transmitting extracellular signals from the cytoplasm to the nucleus. In this study we investigated the impact of Ras on cell cycle progression after hepatectomy by using adenoviral vectors (adv) expressing beta -galactosidase (beta -gal), a dominant-negative (Ras N17) or a dominant-active (Ras 61L) form of H-Ras. Partial hepatectomy was performed in mice treated with the different adenoviruses and cell cycle progression was studied by analysing factors involved in cell cycle control during liver regeneration. After hepatectomy, adv Ras 61L increases DNA synthesis significantly in comparison to the other treatment groups. Higher Ras activity results in an early increase of transcriptional active E2F-3, which is associated with higher cyclin E, but almost unchanged cyclin D protein expression. However, Northern blot analysis and cyclin E promoter experiments indicate that, besides transcriptional mechanisms also post-transcriptional mechanisms are involved in regulating cyclin E protein expression after partial hepatectomy in mice treated with adv Ras 61L. Cyclin E phosphorylation studies demonstrate that adv Ras 61L results in hypophosphorylation of cyclin E compared to the control group at early time points after hepatectomy, when cyclin E protein expression strongly increases and there is only a minor effect on cyclin E mRNA levels. Our experiments indicate adv Ras 61L in vivo increases Cyclin E expression by higher transcription via E2F and a post-transcriptional mechanism. These mechanisms result in an earlier activation of an active CDK2/Cyclin E complex which, in turn, triggers DNA synthesis.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Trautwein, C (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Trautwein.christian@MH-Hannover.de	Liedtke, Christian/DTV-1874-2022; Luedde, Tom/AAE-9135-2022	Liedtke, Christian/0000-0003-4681-7887; Luedde, Tom/0000-0002-6288-8821				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BRENNER DA, 1998, GASTROENTEROL HEPATO, V13, P93; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hayder H, 1999, J IMMUNOL, V163, P1516; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Kim TH, 1997, HEPATOLOGY, V26, P896, DOI 10.1002/hep.510260415; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; Rudolph KL, 1999, HEPATOLOGY, V30, P1159, DOI 10.1002/hep.510300502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Trautwein C, 1999, ONCOGENE, V18, P6443, DOI 10.1038/sj.onc.1203045; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Winston JT, 1996, ONCOGENE, V12, P127; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	49	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5264	5278		10.1038/sj.onc.1204690	http://dx.doi.org/10.1038/sj.onc.1204690			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536040				2022-12-25	WOS:000170575500003
J	Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D				Jeronimo, C; Nomoto, S; Caballero, OL; Usadel, H; Henrique, R; Varzim, G; Oliveira, J; Lopes, C; Fliss, MS; Sidransky, D			Mitochondrial mutations in early stage prostate cancer and bodily fluids	ONCOGENE			English	Article						prostate cancer; prostate intraepithelial neoplasia; mitochondrial mutations; bodily fluids	MICROSATELLITE ANALYSIS; MOLECULAR-DETECTION; BLADDER-CANCER; DNA MUTATIONS; CARCINOMA; NUCLEAR; REPAIR; TUMORS; GENOME; CELLS	We recently demonstrated the existence of specific patterns of somatic mitochondrial DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of mtDNA mutations in prostate cancer an their paired PIN lesions. The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations were also identified in the PIN lesion from one patient. This patient with multiple point mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. Remarkably, identical mutations were also detected in all (3/3) matched urine and plasma samples obtained from these patients. Although mitochondrial mutations are less common in prostate adenocareinoma, they occur early in cancer progression and they can be detected in bodily fluids of early stage disease patients. The identification of MtDNA mutations may complement other early detection approaches for prostate cancer.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Pathol, Unit Mol Pathol, Oporto, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Reg Porto, Dept Urol, Oporto, Portugal	Johns Hopkins University; Portuguese Institute of Oncology; Portuguese Institute of Oncology	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Jerónimo, Carmen/H-3284-2013; Henrique, Rui Manuel Ferreira/I-2757-2013	Jerónimo, Carmen/0000-0003-4186-5345; Henrique, Rui Manuel Ferreira/0000-0003-3171-4666	NCI NIH HHS [R01 CA 77664, P01 CA 58184, UO1 CA 84986] Funding Source: Medline; NIDCR NIH HHS [R01 DE 012488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184, P01CA077664, U01CA084986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Cairns P, 1997, CANCER RES, V57, P4997; CAIRNS P, 2000, IN PRESS P AM ASS CA, V41, P241; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; ISAACS WB, 1996, PRINCIPLES PRACTICE, P403; JEN J, 1994, CANCER RES, V54, P5523; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4	20	193	208	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5195	5198		10.1038/sj.onc.1204646	http://dx.doi.org/10.1038/sj.onc.1204646			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526508				2022-12-25	WOS:000170464000013
J	Turenne, GA; Paul, P; Laflair, L; Price, BD				Turenne, GA; Paul, P; Laflair, L; Price, BD			Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53	ONCOGENE			English	Article						ATM; p53; chk2; phosphorylation; bleomycin	DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; CHECKPOINT PATHWAY; CELLULAR-RESPONSE; IN-VITRO; CDS1	The ATM protein kinase regulates the cell's response to DNA damage by regulating cell cycle checkpoints and DNA repair. ATM phosphorylates several proteins involved in the DNA-damage response, including p53. We have examined the mechanism by which ATM regulates p53's transcriptional activity. Here, we demonstrate that reintroduction of ATM into AT cells restores the activation of p53 by the radio-mimetic agent bleomycin. Further, p53 activation is lost when a kinase inactive ATM is used. or if the N-terminal of ATM is deleted. In addition, AT cells stably expressing ATM showed decreased sensitivity to Ionizing Radiation-induced cell killing, whereas cells expressing kinase inactive ATM or N-terminally deleted ATM were indistinguishable from AT cells. Finally, single point-mutations of serines 15, 20, 33 or 37 did not individually block the ATM-dependent activation of p53 transcriptional activity by bleomycin. However, double mutations of either serines 15 and 20 or serines 33 and 37 blocked the ability of ATM to activate p53. Our results indicate that the N-terminal of ATM and ATM's kinase activity are required for activation of p53's transcriptionl activity and restoration of normal sensitivity to DNA damage. In addition, activation of p53 by ATM requires multiple serine residues in p53's transactivation domain.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,D810A, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEBAB NH, 1999, P NATL ACAD SCI USA, V96, P13777; CHEBAB NH, 2000, GENE DEV, V14, P278; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jung M, 1997, INT J RADIAT ONCOL, V37, P417, DOI 10.1016/S0360-3016(96)00500-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; ONeill FJ, 1997, ONCOGENE, V14, P955, DOI 10.1038/sj.onc.1200913; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sheppard HM, 1999, ANTICANCER RES, V19, P2079; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TISHLER RB, 1993, CANCER RES, V53, P2212; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	62	75	79	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5100	5110		10.1038/sj.onc.1204665	http://dx.doi.org/10.1038/sj.onc.1204665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526498				2022-12-25	WOS:000170464000003
J	Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL				Heppner, C; Bilimoria, KY; Agarwal, SK; Kester, MB; Whitty, LJ; Guru, SC; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ; Burns, AL			The tumor suppressor protein menin interacts with NF-kappa B proteins and inhibits NF-kappa B-mediated transactivation	ONCOGENE			English	Article						MEN1; MEN1 gene; menin; NF-kappa B; transcriptional repression; oncogene; Rel-homology domain	JUND-ACTIVATED TRANSCRIPTION; GENE-MUTATIONS; P65; FAMILY; IDENTIFICATION; EXPRESSION; PRODUCT; SUBUNIT; CANCER; P300	Multiple endocrine neoplasia type I is an autosomal dominant tumor syndrome. Manifestations include neoplasms of the parathyroid glands, entero pancreatic neuroendocrine cells, and the anterior pituitary gland. The MEN1 tumor suppressor gene encodes menin, a 610 amino acid nuclear protein without sequence homology to other proteins. To elucidate menin function, we used immunoprecipitation to identify interacting proteins. The NF-kappaB proteins p50, p52 and p65 were found to interact specifically and directly with menin in vitro and in vivo. The region of NF-kappaB proteins sufficient for binding to menin is the N-terminus. Furthermore, amino acids 305-381 of menin are essential for this binding. Menin represses p65-mediated transcriptional activation on NF-kappaB sites in a dose-dependent and specific manner. Also, PMA (phorbol 12-myristate 13-acetate)-stimulated NF-kappaB activation is suppressed by menin. These observations suggest that menin's ability to interact with NF-kappaB proteins and its modulation of NF-kappaB transactivation contribute to menin's tumor suppressor function.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Burns, AL (corresponding author), Univ Klin Koln, Klin & Poliklin Innere Med 2, D-50924 Cologne, Germany.		Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIEDK043009, Z01DK043009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000062] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Goebel SU, 2000, J CLIN ENDOCR METAB, V85, P116, DOI 10.1210/jc.85.1.116; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Marx SJ, 2001, METABOLIC MOL BASES, P943; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ravi R, 1998, CANCER RES, V58, P4531; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VALLE MA, 2001, IN PRESS CYTOTECHNOL; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	38	201	209	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4917	4925		10.1038/sj.onc.1204529	http://dx.doi.org/10.1038/sj.onc.1204529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526476				2022-12-25	WOS:000170439800001
J	Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP				Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP			Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1	ONCOGENE			English	Article						Abelson murine leukemia virus; interacting protein	TYROSINE KINASE-ACTIVITY; LEUKEMIA-VIRUS VARIANTS; C-ABL; INDUCED ACTIVATION; BINDING; GROWTH; EPS8; RAS; ABL-INTERACTOR-1; IDENTIFICATION	The abi-1 gene encodes a protein that binds and is phosphorylated by the Abelson protein tyrosine kinase. Constructs expressing a full-length abi-1 cDNA, and a smaller cDNA arising from an alternatively spliced form, were generated and tested for their effect on transformation of NIH3T3 cells by the Abelson murine leukemia virus. Overexpression of both forms of the protein strongly inhibited transformation by the wild-type P160 strain of the virus, but not by the non-interacting mutant P90A strain. The inhibition required the SH3 domain of Abi-1, suggesting that a direct interaction was required for the effect. Rare breakthrough P160 transformants of the Abi-1 overexpressing lines were found to have downregulated Abi-1 protein levels by a post-transcriptional mechanism.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA 23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOFF SP, 1981, J VIROL, V38, P460, DOI 10.1128/JVI.38.2.460-468.1981; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Maniatis T., 1982, MOL CLONING LAB MANU; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NICHOLS GL, 1994, BLOOD, V84, P2912; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; So CW, 2000, LEUKEMIA, V14, P594, DOI 10.1038/sj.leu.2401692; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	29	21	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4926	4934		10.1038/sj.onc.1204502	http://dx.doi.org/10.1038/sj.onc.1204502			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526477				2022-12-25	WOS:000170439800002
J	Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S				Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S			Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo	ONCOGENE			English	Article						p53; p14ARF; Mdm2; ubiquitin; proteasome inhibition	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR P53; IN-VIVO; NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; STABILIZES P53; DEGRADATION; PROMOTES; P19(ARF); PROTEIN	Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Lain, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	s.lain@dundee.ac.uk	Lain, Sonia/B-6980-2014; Lane, David P/C-4920-2008	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; Xirodimas, Dimitris/0000-0001-9275-1140				An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	149	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4972	4983		10.1038/sj.onc.1204656	http://dx.doi.org/10.1038/sj.onc.1204656			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526482				2022-12-25	WOS:000170439800007
J	Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E				Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E			Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor	ONCOGENE			English	Article						amplification; GAS41; glioma; NuMA; ENL; KIAA1009; PFDN1; TFIIF	GENE AMPLIFICATION; MITOTIC SPINDLE; MATRIX; NUMA; OVEREXPRESSION; PREFOLDIN; COMPONENT; DOMAIN	The glioma amplified sequence 41 (GAS41) was previously isolated by microdissection mediated cDNA capture from the glioblastoma multiforme cell line TX3868 and shown to be frequently amplified in human gliomas. We determined the complete cDNA sequence of the GAS41 gene, demonstrated that the GAS41 protein is evolutionarily conserved, specifically at the N-terminus, and identified the yeast transcription factor tf2f domain within the GAS41 sequence. A human multiple-tissue Northern blot revealed ubiquitous expression of GAS41 with the highest expression in human brain. After generating polyclonal antibodies we found GAS41 protein expression in the nucleus of the TX3868 cell line by Western blot analysis and immunofluorescence microscopy. The nuclear localization was confirmed for several human tumors including gliomas of different grades of malignancy. In neuroblastoma however, GAS41 was found in the nucleoli but not in the nucleoplasm. Yeast two-hybrid screening of the TX3868 cell line identified the nuclear mitotic apparatus protein (NuMA), the KIAA1009 protein, and prefoldin subunit 1 (PFDN1) as potential interacting partners of GAS41. We generated a polyclonal antibody against the KIAA1009 protein and we demonstrated that the KIAA1009 protein is a nuclear protein, which appears to be co-localized with the GAS41 protein and NuMA.	Univ Saarlandes Kliniken, Inst Human Genet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	, PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Albrecht EB, 2000, MOL BIOL CELL, V11, P873, DOI 10.1091/mbc.11.3.873; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COMPTON DA, 1995, J CELL SCI, V108, P621; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; Harlow E., 1989, ANTIBODIES LAB MANUA; Heiskanen MA, 2000, CANCER RES, V60, P799; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSON BK, 1980, CELL               2, V22, P498; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RICHARD AW, 1997, NAT GENET, V17, P109; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Suzuki SO, 2000, MODERN PATHOL, V13, P548, DOI 10.1038/modpathol.3880095; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang ZH, 1999, ANTICANCER RES, V19, P5445; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M	37	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4853	4863		10.1038/sj.onc.1204650	http://dx.doi.org/10.1038/sj.onc.1204650			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521196				2022-12-25	WOS:000170271800009
J	Elmore, SP; Qian, T; Grissom, SF; Lemasters, JJ				Elmore, SP; Qian, T; Grissom, SF; Lemasters, JJ			The mitochondrial permeability transition initiates autophagy in rat hepatocytes	FASEB JOURNAL			English	Article						cyclosporin A; glucagon; tacrolimus	CELL-DEATH; AMINO-ACID; CONDUCTANCE CHANNEL; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; INNER MEMBRANE; LIVER; CYCLOSPORINE; INHIBITION; NECROSIS	Cells degrade excess and effete organelles by the process of autophagy. Autophagic stimulation of rat hepatocytes by serum deprivation and glucagon (1 muM) caused a fivefold increase of spontaneously depolarizing mitochondria to about 1.5% of total mitochondria after 90 min. Cyclosporin A (CsA, 5 muM), an immunosuppressant that blocks the mitochondrial permeability transition (MPT), prevented this depolarization. Depolarized mitochondria moved into acidic vacuoles labeled by LysoTracker Red. These autophagosomes also increased several-fold after autophagic stimulation. CsA blocked autophagosomal proliferation, whereas tacrolimus, an immunosuppressant that does not block the MPT, did not. In conclusion, the MPT initiates mitochondrial depolarization after autophagic stimulation and the subsequent sequestration of mitochondria into autophagosomes.	Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; Vrije Univ Amsterdam, Physiol Lab, NL-1081 BT Amsterdam, Netherlands	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Vrije Universiteit Amsterdam	Lemasters, JJ (corresponding author), Univ N Carolina, Sch Med, Dept Cell Biol & Anat, CB 7090,236 Taylor Hall, Chapel Hill, NC 27599 USA.	lemaster@med.unc.edu						ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARSTILA AU, 1972, LAB INVEST, V27, P317; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Christensen ST, 1998, CELL BIOL INT, V22, P591, DOI 10.1006/cbir.1998.0320; CROMPTON M, 1988, BIOCHEM J, V255, P357; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; ELMORE SP, 1998, TOXICOL SCI, V42, P370; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GRINDE B, 1983, BIOCHEM J, V216, P529, DOI 10.1042/bj2160529; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Lemasters JJ, 1999, METHOD ENZYMOL, V302, P341, DOI 10.1016/S0076-6879(99)02031-5; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NIEMINEN AL, 1994, AM J PHYSIOL, V267, pC67, DOI 10.1152/ajpcell.1994.267.1.C67; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; Prins JB, 1998, BIOSCIENCE REP, V18, P329, DOI 10.1023/A:1020261316486; SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4; SchulteHermann R, 1997, TOXICOL PATHOL, V25, P89, DOI 10.1177/019262339702500117; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SHELBURNE JD, 1973, AM J PATHOL, V72, P521; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; VARGAS JL, 1987, FEBS LETT, V224, P182, DOI 10.1016/0014-5793(87)80444-1; Vittorini S, 1999, J GERONTOL A-BIOL, V54, pB318, DOI 10.1093/gerona/54.8.B318; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; YU QC, 1988, LAB INVEST, V58, P643; Zhang Y.-Z., 1994, Molecular Biology of the Cell, V5, p113A	48	522	551	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2286	+		10.1096/fj.01-0206fje	http://dx.doi.org/10.1096/fj.01-0206fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511528				2022-12-25	WOS:000170809900016
J	Vohradsky, J; Ramsden, JJ				Vohradsky, J; Ramsden, JJ			Genome resource utilization during prokaryotic development	FASEB JOURNAL			English	Article						gene expression; proteome	STATISTICAL-ANALYSES	The distributions of synthesis rates of expressed proteins in a liquid batch culture of the prokaryote S. coelicolor during 3 days' growth have been analyzed by using a law governing the relation between the synthesis rates and the corresponding ranks in a list of rates (the so-called simplified canonical law, scl), which we have found previously to characterize the distribution of prokaryotic protein expression. The scl remains valid throughout development and the two parameters of the distribution, theta and rho, evolve in a highly characteristic and revealing way. theta is a measure of the degree to which available genomic resources are used, in the sense of exploiting their potential diversity. The passage from one developmental phase to another is marked by a sharp peak in theta, as these resources are fully mobilized to deal with a crisis (i.e., exhaustion of the habitual food supply). This is followed by an even more pronounced trough, as the organism briefly focuses its resources on synthesizing just those proteins most essential for survival, especially those hitherto unavailable and needed for metabolizing the new nutrient source. The parameter rho indicates redundancy among the most abundantly expressed proteins: higher rho corresponds to more diversity; i.e., less duplication of function, hence less robustness. This parameter is relatively steady throughout the development of the culture, except for a pronounced peak during the developmental phase transition. This corresponds to the "emergency mode" characterized by extremely low theta, during which a minimum repertoire of proteins is expressed.	Univ Basel, Biozentrum, Dept Microbiol, Basel, Switzerland; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Univ Basel, Biozentrum, Dept Biophys Chem, Basel, Switzerland; Inst Adv Study, Collegium Basilea, Basel, Switzerland	University of Basel; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Basel	Ramsden, JJ (corresponding author), Hochstr 51, CH-4053 Basel, Switzerland.	J.Ramsden@unibas.ch						GARRELS JI, 1989, J BIOL CHEM, V264, P5269; HOLT TG, 1992, MOL MICROBIOL, V6, P969, DOI 10.1111/j.1365-2958.1992.tb02163.x; Jollife I. T., 1986, PRINCIPAL COMPONENT; Mandelbrot B.B., 1952, PUBL I STAT U PARIS, V2, P1; Mandelbrot B, 1954, WORD, V10, P1; Neumann T, 1996, MICROBIOL-UK, V142, P1953, DOI 10.1099/13500872-142-8-1953; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PUGLIA AM, 1995, MOL MICROBIOL, V17, P737, DOI 10.1111/j.1365-2958.1995.mmi_17040737.x; Ramsden JJ, 1998, PHYS REV E, V58, P7777, DOI 10.1103/PhysRevE.58.7777; Ramsden JJ, 2000, PHYSICA A, V277, P220, DOI 10.1016/S0378-4371(99)00572-5; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; VanBogelen R A, 1995, Biotechnol Annu Rev, V1, P69, DOI 10.1016/S1387-2656(08)70048-6; Vohradsky J, 1997, ELECTROPHORESIS, V18, P1418, DOI 10.1002/elps.1150180817; Vohradsky J, 2000, J BACTERIOL, V182, P4979, DOI 10.1128/JB.182.17.4979-4986.2000; Wilkins M. R., 1997, PROTEOME RES NEW FRO	15	13	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2054	+		10.1096/fj.00-0889fje	http://dx.doi.org/10.1096/fj.00-0889fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511523				2022-12-25	WOS:000170318500011
J	Abbott, JJ; Pei, JM; Ford, JL; Qi, Y; Grishin, VN; Phillips, MA; Grishin, NV				Abbott, JJ; Pei, JM; Ford, JL; Qi, Y; Grishin, VN; Phillips, MA; Grishin, NV			Structure prediction and active site analysis of the metal binding determinants gamma-glutamyleysteine synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; COLI GLUTAMINE-SYNTHETASE; HIDDEN MARKOV-MODELS; GLUTAMYLCYSTEINE SYNTHETASE; ESCHERICHIA-COLI; PHOSPHORYL TRANSFER; PROTEINS; ENZYMES; GLUTATHIONE; MECHANISM	gamma -Glultamylcysteine synthetase (gamma -GCS) catalyzes the first step in the de novo biosynthesis of glutathione. In trypanosomes, glutathione is conjugated to spermidine to form a unique cofactor termed trypanothione, an essential cofactor for the maintenance of redox balance in the cell. Using extensive similarity searches and sequence motif analysis we detected homology between gamma -GCS and glutamine synthetase (GS), allowing these proteins to be unified into a superfamily of carboxylate-amine/ammonia ligases. The structure of gamma -GCS, which was previously poorly understood, was modeled using the known structure of GS. Two metal-binding sites, each ligated. by three conserved active site residues (nl: Glu-55, Glu-93, Glu-100; and n2: Glu-53, Gln-321, and Glu-489), are predicted to form the catalytic center of the active site, where the nl site is expected to bind free metal and the n2 site to interact with MgATP. To elucidate the roles of the metals and their ligands in catalysis, these six residues were mutated to alanine in the Trypanosoma brucei enzyme. All mutations caused a substantial loss of activity. Most notably, E93A was able to catalyze the L-Glu-dependent ATP hydrolysis but not the peptide bond ligation, suggesting that the nl metal plays an important role in positioning L-Glu for the reaction chemistry. The apparent K-m values for ATP were increased for both the E489A and Q321A mutant enzymes, consistent with a role for the n2 metal in ATP binding and phosphoryl transfer. Furthermore, the apparent K-d values for activation of E489A and Q321A by free Mg2+ increased. Finally, substitution of Mn2+ for Mg2+ in the reaction rescued the catalytic deficits caused by both mutations, demonstrating that the nature of the metal ligands plays an important role in metal specificity.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI34432] Funding Source: Medline; NIGMS NIH HHS [T32-GM08014] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abell LM, 1995, BIOCHEMISTRY-US, V34, P16695, DOI 10.1021/bi00051a018; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Fairlamb Alan H., 1997, P149; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Ginsburg A., 1972, ADV PROTEIN CHEM, V26, P1; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Henikoff JG, 1996, COMPUT APPL BIOSCI, V12, P135; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HUNT JB, 1975, ARCH BIOCHEM BIOPHYS, V166, P102, DOI 10.1016/0003-9861(75)90370-7; HUNT JB, 1980, J BIOL CHEM, V255, P590; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P675, DOI 10.1021/bi00169a007; LIU HJ, 1995, J AOAC INT, V78, P736; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; MAURIZI MR, 1987, BIOCHEMISTRY-US, V26, P5023, DOI 10.1021/bi00390a021; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; Meister A., 1989, METABOLISM FUNCTIONS, P367; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; NEWTON GL, 1985, J BACTERIOL, V161, P438, DOI 10.1128/JB.161.1.438-441.1985; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; ORLOWSKI M, 1971, BIOCHEMISTRY-US, V10, P372, DOI 10.1021/bi00779a003; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; WATANABE K, 1986, NUCLEIC ACIDS RES, V14, P4393, DOI 10.1093/nar/14.11.4393; WITMER MR, 1994, PROTEIN SCI, V3, P1746, DOI 10.1002/pro.5560031015; WOTTON JC, 1996, METHOD ENZYMOL, V266, P554	43	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42099	42107		10.1074/jbc.M104672200	http://dx.doi.org/10.1074/jbc.M104672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527962	hybrid			2022-12-25	WOS:000172450400076
J	Dellambra, E; Prislei, S; Salvati, AL; Madeddu, ML; Golisano, O; Siviero, E; Bondanza, S; Cicuzza, S; Orecchia, A; Giancotti, FG; Zambruno, G; De Luca, M				Dellambra, E; Prislei, S; Salvati, AL; Madeddu, ML; Golisano, O; Siviero, E; Bondanza, S; Cicuzza, S; Orecchia, A; Giancotti, FG; Zambruno, G; De Luca, M			Gene correction of integrin beta(4)-dependent pyloric atresia-functional epidermolysis bullosa keratinocytes establishes a role for beta(4) tyrosines 1422 and 1440 in hemidesmosome assembly.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL STEM-CELLS; ALPHA(6)BETA(4) INTEGRIN; BETA-4 SUBUNIT; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CLONAL ANALYSIS; CHAIN GENE; CYTOSKELETON; EXPRESSION; ADHESION	The cytoplasmic domain of beta (4) integrin contains two pairs of fibronectin-like repeats separated by a connecting segment. The connecting segment harbors a putative tyrosine activation motif in which tyrosines 1422 and 1440 are phosphorylated in response to alpha (6)beta (4) binding to laminin-5. Primary beta (4)-null keratinocytes, obtained from a newborn suffering from lethal junctional epidermolysis bullosa, were stably transduced with retroviruses carrying a full-length beta (4) cDNA or a beta (4) cDNA with phenylalanine substitutions at Tyr-1422 and Tyr-1440. Hemidesmosome assembly was evaluated on organotypic skin cultures. beta (4)-corrected keratinocytes were indistinguishable from normal cells in terms of alpha (6)beta (4) expression, the localization of hemidesmosome components, and hemidesmosome structure and density, suggesting full genetic and functional correction of beta (4)-null keratinocytes. In cultures generated from beta (Y1422F/Y1440F)(4) keratinocytes, beta (4) mutants as well as a, integrin, HD1/plectin, and BP180 were not concentrated at the dermal-epidermal junction. Furthermore, the number of hemidesmosomes was strikingly reduced as compared with beta (4)-corrected keratinocytes. The rare hemidesmosomes detected in beta (Y1422F/Y1440F)(4) cells were devoid of sub-basal dense plates and of inner cytoplasmic plaques with keratin filament insertion. Collectively, our data demonstrate that the beta (4) tyrosine activation motif is not required for the localization of alpha (6)beta (4) at the keratinocyte plasma membrane but is essential for optimal assembly of bona fide hemidesmosomes.	Ist Dermopat Immacolata, Lab Tissue Engn, I-00167 Rome, Italy; Ist Dermopat Immacolata, Mol & Cellular Biol Lab, I-00167 Rome, Italy; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituto Dermopatico dell'Immacolata (IDI); Memorial Sloan Kettering Cancer Center	De Luca, M (corresponding author), Ist Dermopat Immacolata, Lab Tissue Engn, Via Castelli Romani 83-85, I-00040 Pomezia, Italy.		Dellambra, Elena/A-4005-2014; Zambruno, Giavanna/K-2933-2018; De Luca, Michele/N-5883-2014	Dellambra, Elena/0000-0002-4329-3312; De Luca, Michele/0000-0002-0850-8445; Zambruno, Giovanna/0000-0002-1295-056X; Prislei, Silvia/0000-0003-1789-6002	Telethon [A.106] Funding Source: Medline	Telethon(Fondazione Telethon)		ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Aumailley M, 1996, J INVEST DERMATOL, V106, P209, DOI 10.1111/1523-1747.ep12340471; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Dellambra E, 1998, HUM GENE THER, V9, P1359, DOI 10.1089/hum.1998.9.9-1359; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Green H, 1980, Harvey Lect, V74, P101; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Niessen CM, 1997, J CELL SCI, V110, P1705; Niessen CM, 1996, J CELL SCI, V109, P1695; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769; Pellegrini G, 1999, TRANSPLANTATION, V68, P868, DOI 10.1097/00007890-199909270-00021; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REGNIER M, 1986, EXP CELL RES, V165, P63, DOI 10.1016/0014-4827(86)90533-1; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TIDMAN MJ, 1986, J INVEST DERMATOL, V86, P51, DOI 10.1111/1523-1747.ep12283807; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wiche G, 1998, J CELL SCI, V111, P2477; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	47	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41336	41342		10.1074/jbc.M103139200	http://dx.doi.org/10.1074/jbc.M103139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522777	hybrid			2022-12-25	WOS:000171925600127
J	Itoh, T; Kondo, M; Tanaka, Y; Kobayashi, M; Sasada, R; Igarashi, K; Suenaga, M; Koyama, N; Nishimura, O; Fujino, M				Itoh, T; Kondo, M; Tanaka, Y; Kobayashi, M; Sasada, R; Igarashi, K; Suenaga, M; Koyama, N; Nishimura, O; Fujino, M			Novel betacellulin derivatives - Separation of the differentiation activity from the mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECOMBINANT HUMAN BETACELLULIN; SITE-DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; EGF FAMILY; IN-VITRO; EXPRESSION; CELLS; RECEPTOR	Betacellulin (BTC) is a member of the epidermal growth factor family. It has two biological activities: mitogenic activity in fibroblasts and vascular smooth muscle cells, and differentiation activity for the differentiation of pancreatic acinar AR42J cells into insulin-secreting cells. The previous finding that recombinant BTC promotes the neogenesis of beta -cells in a mouse model supports the possibility that BTC is a therapeutic protein. However, the mitogenic activity of BTC may not be needed for differentiation into beta -cells and may cause a side effect in clinical use. We prepared several derivatives of BTC to segregate the two activities, to decrease the mitogenic activity, and to maintain the differentiation activity. We succeeded in obtaining BTC derivatives segregated by the two biological activities by preparing truncated-type derivatives. A derivative of BTC, BTC24-76, with a truncated N-terminal 23 amino acids and C-terminal 4 amino acids, was 2.5-fold more active in differentiation and had one-tenth of the mitogenic activity. The derivatives described in the present study should be helpful in future applications as therapeutic proteins and in basic research for discovery of a BTC-specific receptor.	Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Itoh, T (corresponding author), Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs 1, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.	Ito1_Takashi@takeda.co.jp						Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; CHAN SJ, 1979, P NATL ACAD SCI USA, V76, P5036, DOI 10.1073/pnas.76.10.5036; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; Dunbar AJ, 1999, BIOCHEM J, V344, P713, DOI 10.1042/0264-6021:3440713; Dunbar AJ, 2000, INT J BIOCHEM CELL B, V32, P805, DOI 10.1016/S1357-2725(00)00028-5; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; FEILD JA, 1992, BIOCHEM J, V283, P91, DOI 10.1042/bj2830091; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Huotari MA, 1998, ENDOCRINOLOGY, V139, P1494, DOI 10.1210/en.139.4.1494; Ishiyama N, 1998, DIABETOLOGIA, V41, P623, DOI 10.1007/s001250050959; Kallincos NC, 2000, GROWTH FACTORS, V18, P203, DOI 10.3109/08977190009003245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MASSAGUE J, 1983, J BIOL CHEM, V258, P3606; MATSUNAMI RK, 1991, J CELL BIOCHEM, P46242; Miyagawa J, 1999, ENDOCR J, V46, P755, DOI 10.1507/endocrj.46.755; Nishimura O, 1998, CHEM COMMUN, P1135, DOI 10.1039/a801297k; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; Riese DJ, 1996, ONCOGENE, V12, P345; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; Seno M, 1996, GROWTH FACTORS, V13, P181, DOI 10.3109/08977199609003220; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIMPSON RJ, 1985, EUR J BIOCHEM, V153, P629, DOI 10.1111/j.1432-1033.1985.tb09346.x; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; WATANABE T, 1994, J BIOL CHEM, V269, P9966; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YAMAGATA H, 1989, P NATL ACAD SCI USA, V86, P3589, DOI 10.1073/pnas.86.10.3589; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892; Yamamoto K, 2000, DIABETES, V49, P2021, DOI 10.2337/diabetes.49.12.2021	45	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40698	40703		10.1074/jbc.M106603200	http://dx.doi.org/10.1074/jbc.M106603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522793	hybrid			2022-12-25	WOS:000171925600044
J	Kim, KY; Rhim, T; Choi, I; Kim, SS				Kim, KY; Rhim, T; Choi, I; Kim, SS			N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR SP1; SIGNAL-REGULATED KINASE; FACTOR-KAPPA-B; ITO-CELLS; PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; REDOX REGULATION; GENE-EXPRESSION	Activation of hepatic stellate cells (HSC) has been identified as a critical step in hepatic fibrogenesis and is regulated by several factors including cytokines and oxidative stress. However, the molecular mechanism for HSC inactivation is not well understood. We investigated an N-acetyl-L-cysteine (NAC)-mediated signaling pathway involved in HSC inactivation. NAC, which acting through its reducing activity, induced cell arrest at Gl via the mitogen-activated protein kinase (MAPK) kinase (MEK)/ MAPK pathway in a Ras-independent manner. The sustained activation of this extracellular signal-regulated kinase induced the expression of p21(Cip/WAF1), a cell cycle-dependent kinase inhibitor, and mediated cell growth arrest through the Spl transcription activator-dependent mechanism. These effects of NAC were all reversed by treatment of HSC with MEK inhibitor PD98059 followed by culturing HSC on type I collagen-coated flasks. The collagen-mediated suppression of NAC-induced arrest may be due to an overriding of the cell cycle arrest through an acceleration of integrin-induced cell growth. NAC action is actually dependent on modulating the redox states of cysteine residues of target proteins such as Raf-1, MEK, and ERK. In conclusion, an understanding of the NAC signaling pathway in HSC should provide the theoretical basis for clinical approaches using antioxidant therapies in liver fibrosis.	Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea; Dobeel Corp, Seoul 135961, South Korea; Korea Res Inst Biosci & Biotechnol, Immunol Lab, Taejon 305333, South Korea	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, SS (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea.	kimss518@yonsei.ac.kr						ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1002/hep.1840200231; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Brown KE, 1997, AM J PHYSIOL-GASTR L, V272, pG116, DOI 10.1152/ajpgi.1997.272.1.G116; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURT AD, 1993, J PATHOL, V170, P105, DOI 10.1002/path.1711700203; CANO E, 1995, J CELL SCI, V108, P3599; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FAILLI P, 1995, AM J PHYSIOL-CELL PH, V269, pC1133, DOI 10.1152/ajpcell.1995.269.5.C1133; FERRARI G, 1995, J NEUROSCI, V15, P2857; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GRESSNER AM, 1995, J HEPATOL, V22, P28; Gressner AM, 1998, CELL TISSUE RES, V292, P447, DOI 10.1007/s004410051073; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; Houglum K, 1997, GASTROENTEROLOGY, V113, P1069, DOI 10.1053/gast.1997.v113.pm9322499; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kawada N, 1996, BIOCHEM BIOPH RES CO, V229, P238, DOI 10.1006/bbrc.1996.1786; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAXWELL SRJ, 1995, DRUGS, V49, P345, DOI 10.2165/00003495-199549030-00003; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pastor A, 1997, J HEPATOL, V27, P363, DOI 10.1016/S0168-8278(97)80183-3; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; PINZANI M, 1995, J HEPATOL, V22, P700, DOI 10.1016/0168-8278(95)80227-4; Pinzani M, 1998, LIVER, V18, P2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TSUKAMOTO H, 1995, J GASTROEN HEPATOL, V10, pS50, DOI 10.1111/j.1440-1746.1995.tb01798.x; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425	59	118	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40591	40598		10.1074/jbc.M100975200	http://dx.doi.org/10.1074/jbc.M100975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11509553	hybrid			2022-12-25	WOS:000171925600030
J	Rommelaere, H; De Neve, M; Neirynck, K; Peelaers, D; Waterschoot, D; Goethals, M; Fraeyman, N; Vandekerckhove, J; Ampe, A				Rommelaere, H; De Neve, M; Neirynck, K; Peelaers, D; Waterschoot, D; Goethals, M; Fraeyman, N; Vandekerckhove, J; Ampe, A			Prefoldin recognition motifs in the nonhomologous proteins of the actin and tubulin families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CHAPERONIN; UNFOLDED PROTEINS; GAMMA-TUBULIN; BINDING-SITES; YEAST ACTIN; BETA-ACTIN; COMPLEX; SUBUNITS; POLYPEPTIDE; MODEL	Nascent actin and tubulin molecules undergo a series of complex interactions with chaperones and are thereby guided to their native conformation. These cytoskeletal proteins have the initial part of the pathway in common: both interact with prefoldin and with the cytosolic chaperonin containing tailless complex polypeptide 1. Little is understood with regard to how these chaperones and, in particular, prefoldin recognize the non-native forms of these target proteins. Using mutagenesis, we provide evidence that beta -actin and alpha -tubulin each have two prefoldin interaction sites. The most amino-terminally located site of both proteins shows striking sequence similarity, although these proteins are nonhomologous. Very similar motifs are present in beta- and gamma -tubulin and in the newly identified prefoldin target protein actin-related protein 1. Actin-related proteins 2 and 3 have related motifs, but these have altered charge properties. The latter two proteins do not bind prefoldin, although we identify them here as target proteins for the cytosolic chaperonin. Actin fragments containing the two prefoldin interaction regions compete efficiently with actin for prefoldin binding. In addition, they also compete with tubulins, suggesting that these target proteins contact similar prefoldin subunits.	State Univ Ghent VIB, B-9000 Ghent, Belgium; State Univ Ghent VIB, B-9000 Ghent, Belgium; Univ Ghent, Fac Med, Dept Biochem, B-9000 Ghent, Belgium; Univ Ghent, Fac Med, Dept Pharmacol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University	Rommelaere, H (corresponding author), State Univ Ghent VIB, K L Ledeganckstr 35, B-9000 Ghent, Belgium.	Heidi.Rommelaere@rug.ac.be						Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; Dobrzynski JK, 2000, BIOCHEMISTRY-US, V39, P3988, DOI 10.1021/bi992110s; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hynes GM, 2000, J BIOL CHEM, V275, P18985, DOI 10.1074/jbc.M910297199; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kalhor HR, 1999, ARCH BIOCHEM BIOPHYS, V370, P105, DOI 10.1006/abbi.1999.1370; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2000, EMBO J, V19, P5971, DOI 10.1093/emboj/19.22.5971; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Ritco-Vonsovici M, 2000, J MOL BIOL, V304, P81, DOI 10.1006/jmbi.2000.4177; Rommelaere H, 1999, BIOCHEMISTRY-US, V38, P3246, DOI 10.1021/bi9815905; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	28	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41023	41028		10.1074/jbc.M106591200	http://dx.doi.org/10.1074/jbc.M106591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11535601	hybrid			2022-12-25	WOS:000171925600087
J	Shah, K; Vervoort, J; de Vries, SC				Shah, K; Vervoort, J; de Vries, SC			Role of threonines in the Arabidopsis thaliana somatic embryogenesis receptor kinase 1 activation loop in phosphorylation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; GENE ENCODES; TRANSMEMBRANE; PLANT; EXPRESSION	The Arabidopsis thaliana somatic embryogenesis receptor kinase 1 (AtSERK1) gene encodes a receptor-like protein kinase that is transiently expressed during embryogenesis. To determine the intrinsic biochemical properties of the AtSERK1 protein, we have expressed the intracellular catalytic domain as a glutathione S-transferase fusion protein in Escherichia coli. The AtSERK1-glutathione S-transferase fusion protein mainly autophosphorylates on threonine residues (K-m for ATP, 4 x 10(-6) M), and the reaction is Mg2+ dependent and inhibited by Mn2+. A K330E substitution in the kinase domain of AtSERK1 abolishes all kinase activity. The active AtSERK1(kin) can phosphorylate inactive AtSERK1(K330E) protein, suggesting an intermolecular mechanism of autophosphorylation. The AtSERK1 kinase protein was modeled using the insulin receptor kinase as a template. On the basis of this model, threonine residues in the AtSERK1 activation loop of catalytic subdomain VIII are potential targets for phosphorylation. AtSERK1 phosphorylation on myelin basic protein and casein showed tyrosine, serine, and threonine as targets, demonstrating that AtSERK1 is a dual specificity kinase. Replacing Thr-468 with either alanine or glutamic acid not only obliterated the ability of the AtSERK1 protein to be phosphorylated but also inhibited phosphorylation on myelin basic protein and casein, suggesting that Thr-468 is essential for AtSERK-mediated signaling.	Univ Wageningen & Res Ctr, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands; Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Shah, K (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, 149 E 13th St 6204, Charlestown, MA 02129 USA.	kshah@helix.mgh.harvard.edu						Baudino S, 2001, PLANTA, V213, P1, DOI 10.1007/s004250000471; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Coello P, 1999, PLANT SCI, V142, P83, DOI 10.1016/S0168-9452(98)00247-7; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Filippini F, 1996, NATURE, V379, P499, DOI 10.1038/379499a0; Francoijs CJJ, 2000, PROTEIN ENG, V13, P391, DOI 10.1093/protein/13.6.391; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Jin P, 2000, GENESIS, V27, P104, DOI 10.1002/1526-968X(200007)27:3<104::AID-GENE30>3.0.CO;2-I; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Lease K, 1998, CURR OPIN PLANT BIOL, V1, P388, DOI 10.1016/S1369-5266(98)80261-6; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MU JH, 1994, PLANT CELL, V6, P709, DOI 10.1105/tpc.6.5.709; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; Oh MH, 2000, PLANT PHYSIOL, V124, P751, DOI 10.1104/pp.124.2.751; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; SCHALLER GE, 1993, FEBS LETT, V333, P306, DOI 10.1016/0014-5793(93)80676-L; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; van der Knaap E, 1999, PLANT PHYSIOL, V120, P559, DOI 10.1104/pp.120.2.559	43	96	102	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41263	41269		10.1074/jbc.M102381200	http://dx.doi.org/10.1074/jbc.M102381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11509554	hybrid			2022-12-25	WOS:000171925600118
J	Song, JX; Chen, ZG; Xu, P; Gingras, R; Ng, A; Leberer, E; Thomas, DY; Ni, F				Song, JX; Chen, ZG; Xu, P; Gingras, R; Ng, A; Leberer, E; Thomas, DY; Ni, F			Molecular interactions of the G beta binding domain of the Ste20p/PAK family of protein kinases. An isolated but fully functional G beta binding domain from Ste20p is only partially folded as shown by heteronuclear NMR spectroscopy.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SIGMA FACTOR; C-TERMINAL HALF; SECONDARY STRUCTURE; PHEROMONE RESPONSE; BACKBONE DYNAMICS; SEQUENCE; YEAST; CONFORMATION; ASSIGNMENT; LYSOZYME	The transmission of the mating signal of the budding yeast Saccharomyces cerevisiae requires Ste20p, a member of the serine/threonine protein kinases of the Ste20p/PAK family, to link the G beta subunit of the heterotrimeric G protein to the mitogen-activated protein kinase cascades. The binding site of Ste20p to the G beta subunit was mapped to a consensus sequence of SSL phi PLI/VX phi phi beta (X for any residue; phi for A, I, L, S or T; beta for basic residues), which was shown to be a novel G beta binding (GBB) motif present only in the noncatalytic C-terminal domains of the Ste20p/PAK family of protein kinases (Leeuw, T., Wu, C., Schrag, J. D., Whiteway, M., Thomas, D. Y., and Leberer, E. (1998) Nature 391, 191-195; Leberer, E., Dignard, D., Thomas, D. Y., and Leeuw, T. (2000) Biol. Chem. 381, 427-431). Here, we report the results of an NMR study on two GBB motif peptides and the entire C-terminal domain derived from Ste20p. The NAM data show that the two peptide fragments are not uniquely structured in aqueous solution, but in the presence of 40% trifluoroethanol, the longer 37-residue peptide exhibited two well defined, but flexibly linked helical structure elements. Heteronuclear NMR data indicate that the fully functional 86-residue C-terminal domain of Ste20p is again unfolded in aqueous solution but has helical secondary structure preferences similar to those of the two peptide fragments. The NMR results on the two GBB peptides and the entire GBB domain all indicate that the two important binding residues, Ser(879) and Ser(880), are located at the junction between two helical segments. These experimental observations with the prototype GBB domain of a novel family of G beta -controlled effectors may have important implications in understanding the molecular mechanisms of the signal transduction from the heterotrimeric G protein to the mitogen-activated protein kinase cascade.	Natl Res Council Canada, Biotechnol Res Inst, Biomol NMR Grp, Biomol NMR Lab, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Ni, F (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Biomol NMR Grp, Biomol NMR Lab, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	Feng.Ni@nrc.ca	Song, Jianxing/J-3617-2013; Ni, Feng/AAN-6388-2020; Song, Jianxing/H-8026-2012; Ng, Andy/I-3060-2016; Thomas, David/M-7661-2017	Ng, Andy/0000-0003-3257-0801; Song, Jianxing/0000-0003-0224-6322; Thomas, David/0000-0002-8854-762X				Bai YW, 2001, PROTEIN SCI, V10, P1056, DOI 10.1110/ps.00601; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; CHOI KY, 1994, CELL, V78, P499; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Constantine KL, 1997, J MOL BIOL, V267, P1223, DOI 10.1006/jmbi.1997.0915; Daughdrill GW, 1998, BIOCHEMISTRY-US, V37, P1076, DOI 10.1021/bi971952t; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DUNKER AK, 1998, PAC S BIOCOMP, V3, P473; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Leberer E, 2000, BIOL CHEM, V381, P427, DOI 10.1515/BC.2000.055; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; Millet O, 2000, J AM CHEM SOC, V122, P2867, DOI 10.1021/ja993511y; Mulder FAA, 2001, J AM CHEM SOC, V123, P967, DOI 10.1021/ja003447g; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SEGAWA S, 1991, BIOPOLYMERS, V31, P497, DOI 10.1002/bip.360310505; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WUTHRICH K, 1994, EXS, V71, P261; Wuthrich K, 1986, NMR PROTEINS NUCL AC	47	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41205	41212		10.1074/jbc.M103449200	http://dx.doi.org/10.1074/jbc.M103449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11509560	Green Submitted, hybrid			2022-12-25	WOS:000171925600111
J	Takabe, W; Kodama, T; Hamakubo, T; Tanaka, K; Suzuki, T; Aburatani, H; Matsukawa, N; Noguchi, N				Takabe, W; Kodama, T; Hamakubo, T; Tanaka, K; Suzuki, T; Aburatani, H; Matsukawa, N; Noguchi, N			Anti-atherogenic antioxidants regulate the expression and function of proteasome alpha-type subunits in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; LOW-DENSITY-LIPOPROTEIN; E-DEFICIENT MICE; CORONARY ANGIOPLASTY; PROBUCOL TREATMENT; ATHEROSCLEROSIS; ADHESION; VCAM-1; PROGRESSION; RESTENOSIS	It has been proposed that phenolic antioxidants such as probucol exert their anti-atherogenic effects through scavenging lipid-derived radicals. In this study the potential for genomics to reveal unanticipated pharmacological properties of phenolic antioxidants is explored. It was found that two anti-atherogenic compounds, BO-653 and probucol, inhibited the expression of three alpha -type proteasome subunits, PMSA2, PMSA3, and PMSA4 in human umbilical vein endothelial cells. Here we report that both BO-653 and probucol caused not only inhibition of the mRNA levels of these three subunits but also inhibition of both the gene expression and protein synthesis of the alpha -type subunit, PMSA1. Other subunit components of the proteasome such as the beta -type subunits (PMSB1, PMSB7), the ATPase subunit of 19 S (PMSC6), the non-ATPase subunit of 19 S (PMSD1), and PA28 (PMSE2) were not significantly affected by treatment with these compounds. The specific inhibition of alpha -type subunit expression in response to these antioxidants resulted in functional alterations of the proteasome with suppression of degradation of multi-ubiquitinated proteins and I kappaB alpha. These results suggest that certain compounds previously classified solely as antioxidants are able to exert potentially important modulatory effects on proteasome function.	Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Tokyo 1538904, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Noguchi, N (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, 4-6-1 Komaba, Tokyo 1538904, Japan.			Suzuki, Toshiaki/0000-0002-0650-6251				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cynshi O, 1998, P NATL ACAD SCI USA, V95, P10123, DOI 10.1073/pnas.95.17.10123; Daida H, 2000, AM J CARDIOL, V86, P550, DOI 10.1016/S0002-9149(00)01013-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289; Fruebis J, 1999, J LIPID RES, V40, P1958; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOTOH N, 1992, BIOCHIM BIOPHYS ACTA, V1128, P147, DOI 10.1016/0005-2760(92)90300-K; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOCHSTRASSER M, 1996, ANNU REV GENET, V30, P415; Kalogeris TJ, 1999, AM J PHYSIOL-CELL PH, V276, pC856, DOI 10.1152/ajpcell.1999.276.4.C856; Kalogeris TJ, 1999, AM J PHYSIOL-LUNG C, V276, pL9, DOI 10.1152/ajplung.1999.276.1.L9; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; KUZUYA M, 1993, FREE RADICAL BIO MED, V14, P67, DOI 10.1016/0891-5849(93)90510-2; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MAO SJT, 1994, METHOD ENZYMOL, V234, P505; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Noguchi N, 1997, ARCH BIOCHEM BIOPHYS, V347, P141, DOI 10.1006/abbi.1997.0331; Noguchi N, 1997, ARCH BIOCHEM BIOPHYS, V342, P236, DOI 10.1006/abbi.1997.9994; Parola M, 1999, ANTIOXID REDOX SIGN, V1, P255, DOI 10.1089/ars.1999.1.3-255; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; TAKABE W, 2001, J ATHEROSCLER THROMB, V7, P223; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Thurberg BL, 1998, CURR OPIN LIPIDOL, V9, P387, DOI 10.1097/00041433-199810000-00002; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Umetani M, 2000, BIOCHEM BIOPH RES CO, V272, P370, DOI 10.1006/bbrc.2000.2784; Witting PK, 2000, ARTERIOSCL THROM VAS, V20, pE26, DOI 10.1161/01.ATV.20.8.e26; Zapolska-Downar D, 2001, ATHEROSCLEROSIS, V155, P123, DOI 10.1016/S0021-9150(00)00553-0; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	37	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40497	40501		10.1074/jbc.M104882200	http://dx.doi.org/10.1074/jbc.M104882200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533053	hybrid			2022-12-25	WOS:000171925600019
J	Xiao, B; Shi, GB; Gao, JH; Blaszczyk, J; Liu, Q; Ji, XH; Yan, HG				Xiao, B; Shi, GB; Gao, JH; Blaszczyk, J; Liu, Q; Ji, XH; Yan, HG			Unusual conformational changes in 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase as revealed by X-ray crystallography and NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 RESONANCE ASSIGNMENTS; ESCHERICHIA-COLI; PROTEIN; BINDING; REFINEMENT; PROGRAM; COMPLEX; H-1	The crystal structure of Escherichia coli 6-hydroxy-methyl-7,8-dihydropterin pyrophosphokinase (HPPK) in complex with MgADP has been determined at 1.5-Angstrom resolution with a crystallographic R factor of 0.191. The solution structure of HPPK in complex with Mg2+ and beta,gamma -methyleneadenosine 5'-triphosphate (MgAMPPCP) has been determined using a simulated annealing pro. tocol with 3,523 experimental NMR restraints. The root mean square deviation of the ensemble of 20 refined conformers that represent the solution structure from the mean coordinate set derived from them is 0.74 +/- 0.26 A for all backbone atoms and 0.49 +/- 0.22 Angstrom when residues Pro(14), Pro(44)-Gln(50), and Arg(84)-Pro(91) are excluded. Binding of MgADP causes significant changes in the conformation and dynamical property of three loops of HPPK that are involved in catalysis. A dramatic, unusual conformational change is that loop 3 moves away from the active center significantly with some residues moving by > 17 Angstrom. The binding of MgADP also stabilizes loop 1 and loop 3 but makes loop 2 more mobile. Very similar conformational and dynamical changes are observed in the NAM solution structure of HPPK(.)MgAMPPCP. The conformational and dynamical changes may play important roles in both substrate binding and product release in the catalytic cycle.	NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Michigan State University	Ji, XH (corresponding author), NCI, Macromol Crystallog Lab, NIH, Frederick, MD 21702 USA.		Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51901] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bermingham A, 2000, J BIOL CHEM, V275, P17962, DOI 10.1074/jbc.M000331200; Blaszczyk J, 2000, STRUCTURE, V8, P1049, DOI 10.1016/S0969-2126(00)00502-5; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hennig M, 1999, J MOL BIOL, V287, P211, DOI 10.1006/jmbi.1999.2623; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shi GB, 2000, BBA-PROTEIN STRUCT M, V1478, P289, DOI 10.1016/S0167-4838(00)00043-1; Shi GB, 1999, J BIOMOL NMR, V14, P189, DOI 10.1023/A:1008309801414; Stammers DK, 1999, FEBS LETT, V456, P49, DOI 10.1016/S0014-5793(99)00860-1; SWITZER RL, 1974, ENZYMES, V10, P607; Wang LC, 1998, BIOCHEMISTRY-US, V37, P12727, DOI 10.1021/bi9808924; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Xiao B, 1999, STRUCTURE, V7, P489, DOI 10.1016/S0969-2126(99)80065-3; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	24	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40274	40281		10.1074/jbc.M103837200	http://dx.doi.org/10.1074/jbc.M103837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546767	hybrid			2022-12-25	WOS:000171789200102
J	Zhang, CWH; Chishti, Y; Hussey, RE; Reinherz, EL				Zhang, CWH; Chishti, Y; Hussey, RE; Reinherz, EL			Expression, purification, and characterization of recombinant HIV gp140 - The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE CD4 BINDING; RECEPTOR-BINDING; CONFORMATIONAL-CHANGES; GP120-CD4 BINDING; ATOMIC-STRUCTURE; CLEAVAGE SITE; HTLV-III; SIV GP41; TYPE-1; PROTEIN	Efforts to understand the molecular basis of human immunodeficiency virus (HM envelope glycoprotein function have been hampered by the inability to generate sufficient quantities of homogeneous material. We now report on the high level expression, purification, and characterization of soluble HIV gp140 ectodomain proteins in Chinese hamster ovary-Lec3.2.8.1 cells. Gel filtration and analytical ultracentrifugation show that the uncleaved ADA strain-derived gp140 proteins are trimeric without further modification required to maintain oligomers. These spike proteins are native as judged by soluble CD4 (sCD4) (K-D = 1-2 nm) and monoclonal antibody binding studies using surface plasmon resonance. CD4 ligation induces conformational change in the trimer, exposing the chemokine receptor binding site as assessed by 17b monoclonal antibody reactivity. Lack of anti-cooperativity in sCD4-ADA trimer interaction distinct from that observed with sCD4-SrV mac32H implies quaternary structural differences in ground states of their respective spike proteins.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI143649, P01AI043649] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRODER CC, 1994, P NATL ACAD SCI USA, V91, P11699, DOI 10.1073/pnas.91.24.11699; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Center RJ, 2000, J VIROL, V74, P4448, DOI 10.1128/JVI.74.10.4448-4455.2000; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chen B, 2000, J BIOL CHEM, V275, P34946, DOI 10.1074/jbc.M004905200; CHOC H, 1998, SEMIN IMMUNOL, V10, P249; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EARL PL, 1992, J VIROL, V66, P5610, DOI 10.1128/JVI.66.9.5610-5614.1992; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Einfeld D, 1996, CURR TOP MICROBIOL, V214, P133; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FENOUILLET E, 1989, J EXP MED, V169, P807, DOI 10.1084/jem.169.3.807; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1993, VIROLOGY, V193, P510, DOI 10.1006/viro.1993.1156; Hansen JE, 1996, PROTEINS, V25, P1, DOI 10.1002/(SICI)1097-0134(199605)25:1<1::AID-PROT1>3.0.CO;2-N; KIM M, 2001, IN PRESS J BIOL CHEM; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lai JP, 2001, P NATL ACAD SCI USA, V98, P3970, DOI 10.1073/pnas.071052298; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MOULARD M, 1994, FEBS LETT, V338, P281, DOI 10.1016/0014-5793(94)80284-X; Moulard M, 1998, BIOCHEMISTRY-US, V37, P4510, DOI 10.1021/bi972662f; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o; Zhang WT, 2001, BIOCHEMISTRY-US, V40, P1662, DOI 10.1021/bi001397m	63	69	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39577	39585		10.1074/jbc.M107147200	http://dx.doi.org/10.1074/jbc.M107147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514580	hybrid			2022-12-25	WOS:000171789200012
J	Zhukova, E; Sinnett-Smith, J; Rozengurt, E				Zhukova, E; Sinnett-Smith, J; Rozengurt, E			Protein kinase D potentiates DNA synthesis and cell proliferation induced by bombesin, vasopressin, or phorbol esters in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH MOTIFS; D ACTIVATION; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; INTACT-CELLS; IN-VIVO; D PKD	We examined whether protein kinase D (PKD) overexpression in Swiss 3T3 cells potentiates the proliferative response to either the G protein-coupled receptor agonists bombesin and vasopressin or the biologically active phorbol ester phorbol 12,13-dibutyrate (PDBu). In order to generate Swiss 3T3 cells stably overexpressing PKD, cultures of these cells were infected with retrovirus encoding murine PKD and green fluorescent protein (GFP) expressed as two separate proteins translated from the same mRNA. GFP was used as a marker for selection of PKD-positive cells. PKD overexpressed in Swiss 3T3 cells was dramatically activated by cell treatment with bombesin or PDBu as judged by in vitro kinase autophosphorylation assays and exogenous substrate phosphorylation. Concomitantly, these stimuli induced PKD phosphorylation at Ser(744), Ser(748), and Ser(916). PKD activation and phosphorylation were prevented by exposure of the cells to protein kinase C-specific inhibitors. Addition of bombesin, vasopressin, or PDBu to cultures of Swiss 3T3 cells overexpressing PKD induced a striking increase in DNA synthesis and cell number compared with cultures of Swiss 3T3-GFP cells. In contrast, stimulation of DNA synthesis in response to epidermal growth factor, which acts via protein kinase C/PKD-independent pathways, was not enhanced. Our results demonstrate that overexpression of PKD selectively potentiates mitogenesis induced by bombesin, vasopressin, or PDBu in Swiss 3T3 cells.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [P50 CA90388-01] Funding Source: Medline; NIDDK NIH HHS [DK 17294, DK 55003, DK 56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017294, R01DK056930, R37DK017294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Grammer TC, 1996, CANCER SURV, V27, P271; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Hurley JH, 1997, PROTEIN SCI, V6, P477; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OKADA T, 1994, J BIOL CHEM, V269, P3563; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, FREE RADICAL BIO MED, V27, pS67; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Withers DJ, 1997, J BIOL CHEM, V272, P2509; YANO H, 1993, J BIOL CHEM, V268, P25846; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	79	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40298	40305		10.1074/jbc.M106512200	http://dx.doi.org/10.1074/jbc.M106512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514571	hybrid			2022-12-25	WOS:000171789200106
J	Communi, D; Gevaert, K; Demol, H; Vandekerckhove, J; Erneux, C				Communi, D; Gevaert, K; Demol, H; Vandekerckhove, J; Erneux, C			A novel receptor-mediated regulation mechanism of type I inositol polyphosphate 5-phosphatase by calcium/calmodulindependent protein kinase II phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; 1,4,5-TRISPHOSPHATE 3-KINASE; DENDRITIC SPINES; INOSITOL-1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; ESCHERICHIA-COLI; CAM KINASE; RAT-BRAIN; CALCIUM; ACTIVATION	D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) and D-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) are both substrates of the 43-kDa type I inositol polyphosphate 5-phosphatase. Transient and okadaic acid-sensitive inhibition by 70-85% of Ins(1,4,5)P-3 and Ins(1,3,4,5)P4 5-phosphatase activities was observed in homogenates from rat cortical astrocytes, human astrocytoma 1321N1 cells, and rat basophilic leukemia RBL-2H3 cells after incubation with carbachol. The effect was reproduced in response to UTP in rat astrocytic cells and Chinese hamster ovary cells overexpressing human type I 5-phosphatase. Immunodetection as well as mass spectrometric peptide mass fingerprinting and post-source decay (PSD) sequence data analysis after immunoprecipitation permitted unambiguous identification of the major native 5-phosphatase isoform hydrolyzing Ins(1,4,5)P-3 and Ins(1,3,4,5)P4 as type I inositol polyphosphate 5-phosphatase. In ortho P-32-preincubated cells, the phosphorylated 43 kDa-enzyme could be identified after receptor activation by immunoprecipitation followed by electrophoretic separation. Phosphorylation of type I 5-phosphatase was blocked after cell preincubation in the presence of Ca2+/calmodulin kinase II inhibitors (i.e. KN-93 and KN-62). In vitro phosphorylation of recombinant type I enzyme by Ca2+/calmodulin kinase II resulted in an inhibition (i.e. 60-80%) of 5-phosphatase activity. In this study, we demonstrated for the first time a novel regulation mechanism of type I 5-phosphatase by phosphorylation in intact cells.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Ghent Univ VIB, Dept Med Prot Res, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Ghent University	Communi, D (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, Campus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.	dcommuni@ulb.ac.be	Gevaert, Kris/H-3637-2013; Gevaert, Kris/D-6489-2017; Gevaert, Kris/AAE-4212-2019	Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Demol, Hans/0000-0001-7595-0148				ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Auethavekiat V, 1997, J BIOL CHEM, V272, P1786, DOI 10.1074/jbc.272.3.1786; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; Communi D, 1996, BIOCHEM J, V320, P181, DOI 10.1042/bj3200181; Communi D, 1999, J BIOL CHEM, V274, P14734, DOI 10.1074/jbc.274.21.14734; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14245; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; Diviani D, 2001, J CELL SCI, V114, P1431; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; ERNEUX C, 1995, EUR J BIOCHEM, V234, P598, DOI 10.1111/j.1432-1033.1995.598_b.x; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Gevaert K, 1997, ELECTROPHORESIS, V18, P2950, DOI 10.1002/elps.1150181537; GO M, 1993, NEUROSCI LETT, V158, P135, DOI 10.1016/0304-3940(93)90247-I; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HODGKIN M, 1994, BIOCHEM J, V297, P637, DOI 10.1042/bj2970637; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Irvine RF, 1999, CHEM PHYS LIPIDS, V98, P49, DOI 10.1016/S0009-3084(99)00017-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; MAILLEUX P, 1991, BRAIN RES, V539, P203, DOI 10.1016/0006-8993(91)91622-8; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; Oliva AM, 1997, BIOCHEM PHARMACOL, V54, P1243, DOI 10.1016/S0006-2952(97)00329-8; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; Szinyei C, 1999, J PHYSIOL-LONDON, V516, P855, DOI 10.1111/j.1469-7793.1999.0855u.x; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; YAMADA M, 1993, BRAIN RES, V606, P335, DOI 10.1016/0006-8993(93)91004-C; YAMAMOTO H, 1989, J NEUROCHEM, V53, P917, DOI 10.1111/j.1471-4159.1989.tb11792.x	67	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38738	38747		10.1074/jbc.M105640200	http://dx.doi.org/10.1074/jbc.M105640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11517225	hybrid			2022-12-25	WOS:000171673200056
J	Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT				Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT			Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2	ONCOGENE			English	Article						skin tumors; renal tumors; Birt-Hogg-Dube syndrome; linkage analysis	MULTIPLE; ACROCHORDONS; FIBROFOLLICULOMAS; TRICHODISCOMAS; KINASE	Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant neoplasia syndrome characterized mainly by benign skin tumors, and to a lesser extent, renal tumors and spontaneous pneumothorax. To map the BHD locus, we performed a genome-wide linkage analysis using polymorphic microsatellite markers on a large Swedish BHD family. Evidence of linkage was identified on chromosome 17p12-q11.2, with a maximum LOD score of 3.58 for marker D17S1852. Further haplotype analysis defined a similar to 35 cm candidate interval between the two flanking markers, D17S1791 and D17S798. This information will facilitate the identification of the BHD gene, leading to the understanding of its underlying molecular etiology.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Karolinska Inst, Karolinska Hosp, Dept Dermatol & Venereol, S-10401 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Clin Genet, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Nordenskjold, M (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden.			Khoo, Sok Kean/0000-0003-3836-5497; Teh, Bin Tean/0000-0003-1514-1124; Bradley, Maria/0000-0001-7192-5041; Nordenskjold, Magnus/0000-0002-4974-425X				BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Chung JY, 1996, INT J DERMATOL, V35, P365, DOI 10.1111/j.1365-4362.1996.tb03642.x; De la Torre C, 1999, AM J DERMATOPATH, V21, P369, DOI 10.1097/00000372-199908000-00011; FOUCAR K, 1981, CUTIS, V28, P429; Haimowitz JE, 1997, ARCH DERMATOL, V133, P1163, DOI 10.1001/archderm.133.9.1163; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MORENO A, 1985, DERMATOLOGICA, V171, P338, DOI 10.1159/000249448; RONGIOLETTI F, 1989, CLIN EXP DERMATOL, V14, P72, DOI 10.1111/j.1365-2230.1989.tb00890.x; ROTH JS, 1993, J AM ACAD DERMATOL, V29, P1055, DOI 10.1016/S0190-9622(08)82049-X; Schulz T, 1999, J CUTAN PATHOL, V26, P55, DOI 10.1111/j.1600-0560.1999.tb01792.x; STARINK TM, 1985, ARCH DERMATOL, V121, P888, DOI 10.1001/archderm.121.7.888; STARINK TM, 1987, J AM ACAD DERMATOL, V17, P493, DOI 10.1016/S0190-9622(87)70235-7; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; WEINTRAUB R, 1977, J CUTAN PATHOL, V4, P289, DOI 10.1111/j.1600-0560.1977.tb00920.x	17	120	121	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5239	5242		10.1038/sj.onc.1204703	http://dx.doi.org/10.1038/sj.onc.1204703			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526515				2022-12-25	WOS:000170464000020
J	Talavera, K; Staes, M; Janssens, A; Klugbauer, N; Droogmans, G; Hofmann, F; Nilius, B				Talavera, K; Staes, M; Janssens, A; Klugbauer, N; Droogmans, G; Hofmann, F; Nilius, B			Aspartate residues of the Glu-Glu-Asp-Asp (EEDD) pore locus control selectivity and permeation of the T-type Ca2+ channel alpha(1G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM CHANNELS; ION PERMEATION; MOLECULAR-BASIS; VOLTAGE; NEURONS; BLOCK; CONDUCTANCE; CURRENTS; CLONING; SUBUNIT	The structural determinant of the permeation and selectivity properties of high voltage-activated (HVA) Ca2+ channels is a locus formed by four glutamate residues (EEEE), one in each P-region of the domains I-IV of the a, subunit. We tested whether the divergent aspartate residues of the EEDD locus of low voltage-activated (LVA or T-type) Ca2+ channels account for the distinctive permeation and selectivity features of these channels. Using the whole-cell patch-clamp technique in the HEK293 expression system, we studied the properties of the alpha (1G) T-type, the alpha (1C) L-type Ca2+ channel subunits, and alpha (1G) pore mutants, containing aspartate-to-glutamate conversions in domain III, domain IV, or both. Three characteristic features of HVA Ca2+ channel permeation, (a) Ba2+ over Ca2+ permeability, (b) Ca2+/ Ba2+ anomalous mole fraction effect (AMFE), and (c) high Cd2+ sensitivity, were conferred on the domain III mutant (EEED) of alpha (1G). In contrast, the relative Ca2+/ Ba2+ permeability and the lack of AMFE of the alpha (1G) wild type channel were retained in the domain IV mutant (EEDE). The double mutant (EEEE) displayed AMFE and a Cd2+ sensitivity similar to that of alpha (1C), but currents were larger in Ca2+ than in Ba2+-containing solutions. The mutation in domain III, but not that in domain IV, consistently displayed outward fluxes of monovalent cations. H+ blocked Ca2+ currents in all mutants more efficiently than in alpha (1G). In addition, activation curves of all mutants were displaced to more positive voltages and had a larger slope factor than in a,c, wild type. We conclude that the aspartate residues of the EEDD locus of the alpha (1G) Ca2+ channel subunit not only control its permeation properties, but also affect its activation curve. The mutation of both divergent aspartates only partially confers HVA channel permeation properties to the alpha (1G) Ca2+ channel subunit.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Tech Univ Munich, Inst Pharmacol & Toxicol, D-80802 Munich, Germany	KU Leuven; Technical University of Munich	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg Herestr 49, B-3000 Louvain, Belgium.		Talavera, Karel/K-7990-2014	Talavera, Karel/0000-0002-3124-138X; Janssens, Annelies/0000-0002-6735-8248				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BYERLY L, 1985, J GEN PHYSIOL, V85, P491, DOI 10.1085/jgp.85.4.491; CAMPBELL DL, 1988, BIOPHYS J, V54, P945, DOI 10.1016/S0006-3495(88)83030-3; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P571, DOI 10.1113/jphysiol.1987.sp016552; Chen XH, 1997, J BIOL CHEM, V272, P30002, DOI 10.1074/jbc.272.48.30002; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; Cibulsky SM, 2000, J GEN PHYSIOL, V116, P349, DOI 10.1085/jgp.116.3.349; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Delisle BP, 2000, BIOPHYS J, V78, P1895, DOI 10.1016/S0006-3495(00)76738-5; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; FRIEL DD, 1989, P NATL ACAD SCI USA, V86, P5207, DOI 10.1073/pnas.86.13.5207; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Klockner U, 1996, J BIOL CHEM, V271, P22293; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Lee JH, 1999, J NEUROSCI, V19, P1912; Mangoni ME, 1997, RECEPTOR CHANNEL, V5, P1; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Monteil A, 2000, J BIOL CHEM, V275, P16530, DOI 10.1074/jbc.C000090200; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Serrano JR, 2000, BIOPHYS J, V79, P3052, DOI 10.1016/S0006-3495(00)76540-4; Talavera K, 1998, BIOPHYS J, V74, pA108; Varadi G, 1999, CRIT REV BIOCHEM MOL, V34, P181, DOI 10.1080/10409239991209264; VASSORT G, 1994, J CARDIOVASC ELECTR, V5, P376, DOI 10.1111/j.1540-8167.1994.tb01175.x; Wakamori M, 1998, J NEUROPHYSIOL, V79, P622, DOI 10.1152/jn.1998.79.2.622; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yang N, 1999, BIOPHYS J, V76, pA259; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911	37	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45628	45635		10.1074/jbc.M103047200	http://dx.doi.org/10.1074/jbc.M103047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11526105	hybrid			2022-12-25	WOS:000172573100020
J	Caran, N; Johnson, LD; Jenkins, KJ; Tombes, RM				Caran, N; Johnson, LD; Jenkins, KJ; Tombes, RM			Cytosolic targeting domains of gamma and delta calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; PROMOTES NEURITE OUTGROWTH; CAM KINASE; RECEPTOR STIMULATION; AXON GUIDANCE; IN-VIVO; EXPRESSION; ISOFORMS; CELLS; PHOSPHORYLATION	Ca2+/calmodulin-dependent protein kinase II (CaMK-II) isozyme variability is the result of alternative usage of variable domain sequences. Isozyme expression is cell type-specific to transduce the appropriate Ca2+ signals. We have determined the subcellular targeting domain of delta (E) CaMK-II, an isozyme that induces neurite outgrowth, and of a structurally similar isozyme, gamma (C) CaMK-II, which does not induce neurite outgrowth. BE CaMK-II co-localizes with filamentous actin in the perinuclear region and in cellular extensions. In contrast, gamma (C) CaMK-II is uniformly cytosolic. Constitutively active BE CaMK-II induces F-actin-rich extensions, thereby supporting a functional role for its localization. C-terminal constructs, which lack central variable domain sequences, can oligomerize and localize like full-length delta (E) and gamma (C) CaMK-II. Central variable domains themselves are monomeric and have no targeting capability. The C-terminal 95 residues of delta CaMK-II also has no targeting capability but can efficiently oligomerize. These findings define a targeting domain for gamma and delta CaMK-IIs that is in between the central variable and association domains. This domain is responsible for the subcellular targeting differences between gamma and delta CaMK-IIs.	Virginia Commonwealth Univ, Dept Biol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University	Tombes, RM (corresponding author), Virginia Commonwealth Univ, Dept Biol, POB 842012, Richmond, VA 23284 USA.	rtombes@hsc.vcu.edu	Tombes, Robert M/B-5224-2011; Tombes, Robert M/A-7780-2008					Bayer KU, 1999, MOL BRAIN RES, V70, P147, DOI 10.1016/S0169-328X(99)00131-X; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; Donai H, 2000, MOL BRAIN RES, V85, P189, DOI 10.1016/S0169-328X(00)00221-7; Dosemeci A, 1999, BIOCHEM BIOPH RES CO, V263, P657, DOI 10.1006/bbrc.1999.1433; Dosemeci A, 2000, J NEUROSCI, V20, P3076, DOI 10.1523/JNEUROSCI.20-09-03076.2000; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hoch B, 2000, J CELL BIOCHEM, V79, P293, DOI 10.1002/1097-4644(20001101)79:2<293::AID-JCB120>3.3.CO;2-H; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Johnson LD, 2000, J NEUROCHEM, V75, P2380, DOI 10.1046/j.1471-4159.2000.0752380.x; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; Lau PM, 1999, J CELL BIOL, V145, P1265, DOI 10.1083/jcb.145.6.1265; Masse T, 1997, J NEUROSCI, V17, P924; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; Nomura T, 1997, BRAIN RES, V766, P129, DOI 10.1016/S0006-8993(97)00535-0; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; SCOPES RK, 1987, PROTEIN PURIFICATION, P188; Shen K, 1998, J NEUROCHEM, V70, P96; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Singer HA, 1997, J BIOL CHEM, V272, P9393; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; SOLEM M, 1995, J NEUROSCI, V15, P5966; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Takeuchi Y, 2000, J NEUROCHEM, V74, P2557, DOI 10.1046/j.1471-4159.2000.0742557.x; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; URQUIDI V, 1995, FEBS LETT, V358, P23, DOI 10.1016/0014-5793(94)01381-A; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; Wang HY, 1997, J BIOL CHEM, V272, P1817, DOI 10.1074/jbc.272.3.1817; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222	41	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42514	42519		10.1074/jbc.M103013200	http://dx.doi.org/10.1074/jbc.M103013200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535587	hybrid			2022-12-25	WOS:000172450400125
J	Ghosh, SS; Sappal, BS; Kalpana, GV; Lee, SW; Chowdhury, JR; Chowdhury, NR				Ghosh, SS; Sappal, BS; Kalpana, GV; Lee, SW; Chowdhury, JR; Chowdhury, NR			Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INACTIVATION ANALYSIS; PROTEIN-PROTEIN INTERACTIONS; UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR; ISOZYMES; REGION; PHENOL; SITE	Genetic lesions of bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) completely or partially abolish hepatic bilirubin glucuronidation, causing Crigler-Najjar syndrome type I or 2, respectively. Clinical observations indicate that some mutant forms of human UGT1A1 (hUGT1A1) may be dominant-negative, suggesting their interaction with the wildtype enzyme. To evaluate intermolecular interaction of hUGT1A1, Gunn rat fibroblasts were stably transduced with hUGT1A1 cDNA. Gel permeation chromatography of solubilized microsomes suggested dimerization of hUGT1A1 in solution. Nearest-neighbor cross-linking analysis indicated that, within microsomal membranes, hUGT1A1 dimerized more efficiently at pH 7.4 than at pH 9. Two-hybrid analysis in yeast and mammalian systems demonstrated positive interaction of hUGT1A1 with itself, but not with another UGT isoform, human UGT1A6, which differs only in the N-terminal domain. Dimerization was abolished by deletion of the membrane-embedded helix from the N-terminal domain of hUGT1A1, but not by substitution of several individual amino acid residues or partial deletion of the C-terminal domain. A C127Y substitution abolished UGT1A1 activity, but not its dimerization. Coexpression of mutagenized and wild-type hUGT1A1 in COS-7 cells showed that the mutant form markedly suppressed the catalytic activity of wild-type hUGT1A1. Homodimerization of hUGT1A1 may explain the dominant-negative effect of some mutant forms of the enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Chowdhury, NR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	chowdhur@aecom.yu.edu		Kalpana, Ganjam/0000-0003-4111-0604	NIDDK NIH HHS [P30-DK 41296, DK 46057, DK 39137] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046057, P30DK041296, R01DK039137] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BRIGGS MM, 1977, BIOCHEMISTRY-US, V16, P73, DOI 10.1021/bi00620a012; Chowdhury J, 2001, METABOLIC MOL BASES, V2, P3063; CHOWDHURY J R, 1981, Hepatology, V1, P622; CHOWDHURY JR, 1985, P NATL ACAD SCI USA, V82, P2990, DOI 10.1073/pnas.82.9.2990; Ciotti M, 1998, BIOCHEMISTRY-US, V37, P11018, DOI 10.1021/bi980747q; CRIGLER JF, 1952, PEDIATRICS, V10, P169; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gantla S, 1998, AM J HUM GENET, V62, P585, DOI 10.1086/301756; GANTLA S, 1995, EP FOR, V2, P3; GSCHAIDMEIER H, 1994, BIOCHEM PHARMACOL, V48, P1545, DOI 10.1016/0006-2952(94)90198-8; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Kadakol A, 2000, HUM MUTAT, V16, P297, DOI 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z; Kadakol A, 2001, J MED GENET, V38, P244, DOI 10.1136/jmg.38.4.244; Koiwai O, 1996, HUM MOL GENET, V5, P645, DOI 10.1093/hmg/5.5.645; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MATERN H, 1982, J BIOL CHEM, V257, P7422; MATSUI M, 1980, ANAL BIOCHEM, V105, P141, DOI 10.1016/0003-2697(80)90435-2; Meech R, 1997, J BIOL CHEM, V272, P26913, DOI 10.1074/jbc.272.43.26913; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; RITTER JK, 1992, J BIOL CHEM, V267, P3257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seppen J, 1996, BIOCHEM J, V314, P477, DOI 10.1042/bj3140477; SEPPEN J, 1995, PROTEIN EXPRES PURIF, V6, P149, DOI 10.1006/prep.1995.1018; VANES HHG, 1993, CYTOGENET CELL GENET, V63, P114, DOI 10.1159/000133513	28	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42108	42115		10.1074/jbc.M106742200	http://dx.doi.org/10.1074/jbc.M106742200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546782	hybrid			2022-12-25	WOS:000172450400077
J	Junqueira de Azevedo, ILM; Farsky, SHP; Oliveira, MLS; Ho, PL				Junqueira de Azevedo, ILM; Farsky, SHP; Oliveira, MLS; Ho, PL			Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper - A new member of the VEGF family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; NATRIURETIC PEPTIDE; TUMOR-CELLS; RECEPTOR; BINDING; PURIFICATION; DIMERIZATION; NEUROPILIN; BIOLOGY; ENZYME	During the generation of abundant expressed sequence tags from the Viperidae snake Bothrops insularis venom glands, we identified for the first time a cDNA coding for a putative vascular endothelial growth factor-like (VEGF-like) protein. The deduced primary sequence, after complete sequencing of the longest snake venom VEGF (svVEGF) cDNA, displayed similarity with vertebrate VEGFs and with the hypotensive factor from Vipera aspis venom. Its cDNA was subcloned, expressed in Escherichia coli with a His(6) tag as an insoluble monomer, and purified by Ni2+-affinity chromatography after 8 m urea extraction. Antiserum against svVEGF was generated and tested in Western blot against proteins from snake venoms and cellular extracts. The mature svVEGF appears to be ubiquitously distributed throughout snake venoms and was also confirmed by Northern blot studies of other related Viperidae species and by cDNA cloning of svVEGF from Bothrops jararaca pit viper. The produced recombinant protein dimerizes after refolding processes and was biologically characterized, showing ability to increase vascular permeability. These results established that svVEGF is a novel and important active toxin during the early stages of bothropic snake bite envenoming and represents a new member of the VEGF family of proteins.	Inst Butantan, Ctr Biotecnol, BR-05503900 Sao Paulo, Brazil; Inst Butantan, Lab Imunoquim, BR-05503900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Biociencias, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, BR-05508900 Sao Paulo, Brazil	Instituto Butantan; Instituto Butantan; Universidade de Sao Paulo; Universidade de Sao Paulo	Ho, PL (corresponding author), Inst Butantan, Ctr Biotecnol, Av Vital Brazil 1500, BR-05503900 Sao Paulo, Brazil.	plechoib@quim.iq.usp.br	Farsky, Sandra HP/C-4044-2012; Ho, Paulo/P-8267-2015; Oliveira, Maria Leonor S/F-4988-2012; Junqueira-de-Azevedo, Inacio/H-5239-2011	Ho, Paulo/0000-0003-3652-241X; Oliveira, Maria Leonor/0000-0003-4849-3062; Junqueira-de-Azevedo, Inacio/0000-0003-4491-0180				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CEM BPC, 1994, GENE, V139, P73; Desai A, 2000, INFLAMMATION, V24, P1, DOI 10.1023/A:1006995023982; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUARTE MR, 1995, STUD NEOTROP FAUNA E, V30, P1, DOI 10.1080/01650529509360936; DVORAK HF, 1979, J IMMUNOL, V122, P166; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferreira LAF, 1996, TOXICON, V34, P599, DOI 10.1016/0041-0101(96)00010-4; FERREIRA LAF, 1993, TOXICON, V31, P941, DOI 10.1016/0041-0101(93)90253-F; FERREIRA SH, 1965, BRIT J PHARMACOL, V25, P277; Gasmi A, 2000, BIOCHEM BIOPH RES CO, V268, P69, DOI 10.1006/bbrc.2000.2078; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HO PL, 1995, J TOXICOL-TOXIN REV, V14, P327, DOI 10.3109/15569549509019467; Ho PL, 1997, EUR J BIOCHEM, V250, P144, DOI 10.1111/j.1432-1033.1997.00144.x; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Junqueira de Azevedo ILM, 2001, ARCH VIROL, V146, P51, DOI 10.1007/s007050170190; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOMORI Y, 1990, TOXICON, V28, P359, DOI 10.1016/0041-0101(90)90073-G; Komori Y, 1999, BIOCHEMISTRY-US, V38, P11796, DOI 10.1021/bi990562z; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; Markland FS, 1998, TOXICON, V36, P1749, DOI 10.1016/S0041-0101(98)00126-3; MARKLAND FS, 1982, P NATL ACAD SCI-BIOL, V79, P1688, DOI 10.1073/pnas.79.6.1688; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILES AA, 1955, BRIT J EXP PATHOL, V36, P71; Murayama N, 1997, P NATL ACAD SCI USA, V94, P1189, DOI 10.1073/pnas.94.4.1189; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PLATER GM, 1998, TOXICON, V36, P847; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Ribeiro L A, 1997, Rev Soc Bras Med Trop, V30, P475, DOI 10.1590/S0037-86821997000600006; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWEITZ H, 1992, J BIOL CHEM, V267, P13928; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Siemeister G, 1998, J BIOL CHEM, V273, P11115, DOI 10.1074/jbc.273.18.11115; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058	50	69	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39836	39842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517227				2022-12-25	WOS:000171789200045
J	Rosenfeld, SS; Jefferson, GM; King, PH				Rosenfeld, SS; Jefferson, GM; King, PH			ATP reorients the neck linker of kinesin in two sequential steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; KINETIC MECHANISM; DIMERIC KINESIN; LIGHT-CHAIN; ADP RELEASE; SUBFRAGMENT-1; CONTRACTION; NUCLEOTIDES; COMPLEXES	Recent models of the kinesin mechanochemical cycle provide some conflicting information on how the neck linker contributes to movement. Some spectroscopic approaches suggest a nucleotide-induced order-to-disorder transition in the neck linker. However, cryoelectron microscopic imaging suggests instead that nucleotide alters the orientation of the neck linker when docked on the microtubule surface. Furthermore, since these studies utilized transition state or non-hydrolyzable nucleotide analogs, it is not clear at what point in the ATPase cycle this reorientation of the neck linker occurs. We have addressed this issue by developing a strategy to examine the effect of nucleotide on the orientation of the neck linker based on the technique of fluorescence resonance energy transfer. Transient kinetic studies utilizing this approach support a model in which ATP binding leads to two sequential isomerizations, the second of which reorients the neck linker in relation to the microtubule surface.	Univ Alabama, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.			King, Peter/0000-0001-9391-7464	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34856] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; Hoenger A, 2000, J MOL BIOL, V297, P1087, DOI 10.1006/jmbi.2000.3627; HUANG TG, 1994, J BIOL CHEM, V269, P16493; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; Saraswat LD, 1998, J BIOL CHEM, V273, P17671, DOI 10.1074/jbc.273.28.17671; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; TANFORD C, 1961, PHYSICAL CHEM MACROM, P276; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200	26	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40167	40174		10.1074/jbc.M103899200	http://dx.doi.org/10.1074/jbc.M103899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509561	hybrid			2022-12-25	WOS:000171789200088
J	Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M				Sayan, AE; Sayan, BS; Findikli, N; Ozturk, M			Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells	ONCOGENE			English	Article						liver cancer; p73; retinoblastoma; P16(INK4a); p14(ARF); cyclin E	P53 HOMOLOG P73; KINASE C-ABL; APOPTOTIC RESPONSE; DNA-DAMAGE; FAMILY; GENE; RETINOBLASTOMA; LINES; PROTEINS; MUTATION	p53 and p73 proteins activate similar target genes and induce apoptosis and cell cycle arrest. However, p53, but not p73 is considered a tumour-suppressor gene. Unlike p53, p73 deficiency in mice does not lead to a cancer-prone phenotype, and p73 gene is not mutated in human cancers, including hepatocellular carcinoma. Here we report that normal liver cells express only DeltaN-p73 transcript forms giving rise to the synthesis of N-terminally truncated, transcriptionally inactive and dominant negative p73 proteins. In contrast, most hepatocellular carcinoma cells express TA-p73 transcript forms encoding full-length and transcriptionally active p73 proteins, in addition to DeltaN-p73. We also show that together with the acquired expression of TA-p73, the 'retinoblastoma pathway' is inactivated, and E2F1-target genes including cyclin E and p14(ARF) are activated in hepatocellular carcinoma. However, there was no full correlation between 'retinoblastoma pathway' inactivation and TA-p73 expression. Most TA-p73-expressing hepatocellular carcinoma cells have also lost p53 function either by lack of expression or missense mutations. The p73 gene, encoding only DeltaN-p73 protein, may function as a tumour promoter rather than a tumour suppressor in liver tissue. This may be one reason why p73 is not a mutation target in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey	Ihsan Dogramaci Bilkent University	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		OZTURK, MEHMET/AAS-7241-2021; SAYAN, A. EMRE/H-7330-2012; Findikli, Necati/I-4924-2018; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; SAYAN, A. EMRE/0000-0002-5291-1485; Findikli, Necati/0000-0001-9362-5912; 				Agami R, 1999, NATURE, V399, P809; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; BOUZAHZAH B, 1995, J CELL PHYSIOL, V165, P459, DOI 10.1002/jcp.1041650303; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; Morel AP, 2000, J HEPATOL, V33, P254, DOI 10.1016/S0168-8278(00)80366-9; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Tannapfel A, 1999, BRIT J CANCER, V80, P1069, DOI 10.1038/sj.bjc.6690465; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yolcu E, 2001, ONCOGENE, V20, P1398, DOI 10.1038/sj.onc.1204240; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257	33	59	60	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5111	5117		10.1038/sj.onc.1204669	http://dx.doi.org/10.1038/sj.onc.1204669			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526499	Green Submitted, Green Published			2022-12-25	WOS:000170464000004
J	Lomax, M; Fried, M				Lomax, M; Fried, M			Polyoma virus disrupts ARF signaling to p53	ONCOGENE			English	Article						ARF; MDM2; oncogene co-operation; p53; polyoma virus; polyoma virus T-antigens	T-ANTIGEN; MDM2; PROTEIN; P19(ARF); PRODUCT; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; DEGRADATION; INHIBITION	Polyoma virus (Py) differs from other small DNA tumor viruses in not encoding a protein that inactivates p53. The complete Py early region encoding the large T-antigen (PyLT), middle T-antigen (PyMT) and small T-antigen (PyST) will transform primary rodent cells and REF52 cells, but PyMT, the main Py oncogene, by itself will only transform these cells when p53 or ARF is inactivated. We have related Py oncogene cooperation with the effects of the Py T-antigens on the ARF-p53 signaling pathway. PyMT activates an ARF-induced p53-mediated block to cell division explaining the inability of PyMT alone to generate dividing transformed cells. In contrast, in REF52 cells transformed by the whole Py early region (PyREF52), ARF is upregulated but p53 is not activated. Thus PyLT and/or PyST negates the PyMT-induced ARF-mediated block to cell division by disrupting the signaling pathway from ARF to p53. Although there is no detectable interaction or co-localization of endogenous ARF (nucleoli) and MDM2 (nucleoplasm) in PyREF52 cells, expression of transfected ectopic ARF results in an MDM2/ARF interaction and sequestration of MDM2 into the nucleoli. Sequestration of MDM2 by ARF in the nucleoli is not essential for a p53 response in REF52 cells as activation of Raf in REF52Raf-ER cells results in an ARF-induced p53-mediated cell cycle block in the absence of a detectable ARF-MDM2 interaction. Py may provide new insights into the cellular ARF-p53 signaling pathway.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	Cancer Research UK; University of California System; University of California San Francisco	Fried, M (corresponding author), Imperial Canc Res Fund, Lincolns Inn Fields,POB 123, London WC2A 3PX, England.							CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DURO D, 1995, ONCOGENE, V11, P21; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kannan K, 2000, INT J ONCOL, V16, P585; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MANSUR CP, 1995, ONCOGENE, V10, P457; MAO L, 1995, CANCER RES, V55, P2995; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	38	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4951	4960		10.1038/sj.onc.1204717	http://dx.doi.org/10.1038/sj.onc.1204717			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526480				2022-12-25	WOS:000170439800005
J	Bentrop, D; Beyermann, M; Wissmann, R; Fakler, B				Bentrop, D; Beyermann, M; Wissmann, R; Fakler, B			NMR structure of the "ball-and-chain" domain of KCNMB2, the beta(2)-subunit of large conductance Ca2+ and voltage-activated potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; BETA-SUBUNIT; RAPID INACTIVATION; MOLECULAR-BASIS; SMOOTH-MUSCLE; BK CHANNELS; PROGRAM; SPECTROSCOPY; MSLO; RECTIFICATION	The auxiliary beta -subunit KCNMB2 (beta (2)) endows the noninactivating large conductance Ca2+ and voltage-dependent potassium (BK) channel with fast inactivation. This process is mediated by the N terminus of KCNMB2 and closely resembles the "ball-and-chain"-type inactivation observed in voltage-gated potassium channels. Here we investigated the solution structure and function of the KCNMB2 N terminus (amino acids 1-45, BK beta N-2) using NMR spectroscopy and patch clamp recordings. BK beta N-2 completely inactivated BK channels when applied to the cytoplasmic side; its interaction with the BK alpha -subunit is characterized by a particularly slow dissociation rate and an affinity in the upper nanomolar range. The BK beta N-2 structure comprises two domains connected by a flexible linker: the pore-blocking "ball domain" (formed by residues 1-17) and the "chain domain" (between residues 20-45) linking it to the membrane segment of KCNMB2. The ball domain is made up of a flexible N terminus anchored at a well ordered loop-helix motif. The chain domain consists of a 4-turn helix with an unfolded linker at its C terminus. These structural properties explain the functional characteristics of BK2N-mediated inactivation.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Eberhard Karls University of Tubingen	Bentrop, D (corresponding author), Ob Himmelreich 7, D-72074 Tubingen, Germany.	detlef.bentrop@uni-tuebingen.de						Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cox DH, 1997, J GEN PHYSIOL, V110, P257, DOI 10.1085/jgp.110.3.257; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hicks GA, 1998, J PHYSIOL-LONDON, V508, P721, DOI 10.1111/j.1469-7793.1998.721bp.x; Hille B., 1992, IONIC CHANNELS EXCIT; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Schott MK, 1998, EUR BIOPHYS J BIOPHY, V27, P99, DOI 10.1007/s002490050115; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SOLARO CR, 1992, SCIENCE, V257, P1694, DOI 10.1126/science.1529355; TORO L, 1994, BIOCHEMISTRY-US, V33, P7220, DOI 10.1021/bi00189a026; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xia XM, 2000, J NEUROSCI, V20, P4890; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	36	54	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42116	42121		10.1074/jbc.M107118200	http://dx.doi.org/10.1074/jbc.M107118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11517232	hybrid			2022-12-25	WOS:000172450400078
J	Korkaya, H; Jameel, S; Gupta, D; Tyagi, S; Kumar, R; Zafrullah, M; Mazumdar, M; Lal, SK; Li, XF; Sehgal, D; Das, SR; Sahal, D				Korkaya, H; Jameel, S; Gupta, D; Tyagi, S; Kumar, R; Zafrullah, M; Mazumdar, M; Lal, SK; Li, XF; Sehgal, D; Das, SR; Sahal, D			The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE HCK; SH3 DOMAINS; C VIRUS; FULMINANT-HEPATITIS; VIRAL-HEPATITIS; SIGNAL; EXPRESSION; SPECIFICITY; ORIENTATION	The hepatitis E virus (HEV) is the causative agent of hepatitis E, an acute form of viral hepatitis. The biology and pathogenesis of HEV remain poorly understood. We have used in vitro binding assays to show that the HEV ORF3 protein (pORF3) binds to a number of cellular signal transduction pathway proteins. This includes the protein tyrosine kinases Sre, Hck, and Fyn, the p85 alpha regulatory subunit of phosphatidylinositol 3-kinase, phospholipase C gamma and the adaptor protein Grb2. A yeast two-hybrid assay was used to further confirm the pORF3-Grb2 interaction. The binding involves a proline-rich region in pORF3 and the src homology 3 (SH3) domains in the cellular proteins. Competition assays and computer-assisted modeling was used to evaluate the binding surfaces and interaction energies of the pORF3-SH3 complex. In pORF3-expressing cells, pp60(src) was found to associate with an 80-kDa protein, but no activation of the Src kinase was observed in these cells. However, there was increased activity and nuclear localization of ERK in the pORF3-expressing cells. These studies suggest that pORF3 is a viral regulatory protein involved in the modulation of cell signaling. The ORF3 protein of HEV appears to be the first example of a SH3 domain-binding protein encoded by a virus that causes an acute and primarily self-limited infection.	ICGEB, New Delhi 110067, India; Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore		shahid@icgeb.res.in	Das, Suman/ABB-7273-2020; Korkaya, Hasan/GRY-1016-2022; Korkaya, Hasan/C-2201-2009; Korkaya, Hasan/ABD-6282-2020; Das, Suman R/C-8760-2009; Gupta, Dinesh/C-1079-2009; Gupta, Dinesh/AAW-4243-2020	Das, Suman/0000-0003-2496-9724; Korkaya, Hasan/0000-0002-0719-5862; Gupta, Dinesh/0000-0002-7548-8835; Gupta, Dinesh/0000-0002-7548-8835				Ahmad KM, 1998, AIDS RES HUM RETROV, V14, P1491, DOI 10.1089/aid.1998.14.1491; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bliska J, 1996, CHEM BIOL, V3, P7, DOI 10.1016/S1074-5521(96)90076-9; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Collette Y, 1997, IMMUNOL TODAY, V18, P393, DOI 10.1016/S0167-5699(97)01104-3; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Krajcsi P, 1998, J GEN VIROL, V79, P1323, DOI 10.1099/0022-1317-79-6-1323; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; LAU JYN, 1995, J HEPATOL, V22, P605, DOI 10.1016/0168-8278(95)80215-0; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MAYER BJ, 1999, SIGNALING NETWORKS C, P439; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NANDA SK, 1994, J MED VIROL, V42, P133, DOI 10.1002/jmv.1890420207; NAYAK NC, 1989, J GASTROEN HEPATOL, V4, P345, DOI 10.1111/j.1440-1746.1989.tb00846.x; PANDA SK, 1995, J CLIN MICROBIOL, V33, P2653, DOI 10.1128/JCM.33.10.2653-2659.1995; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rose MD., 1990, METHODS YEAST GENETI; ROSENBERG IM, 1996, PROTEIN ANAL PURIFIC, P343; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997; Zafrullah M, 1999, J VIROL, V73, P4074, DOI 10.1128/JVI.73.5.4074-4082.1999; [No title captured]	44	113	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42389	42400		10.1074/jbc.M101546200	http://dx.doi.org/10.1074/jbc.M101546200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11518702	hybrid			2022-12-25	WOS:000172450400111
J	Lowen, M; Scott, G; Zwollo, P				Lowen, M; Scott, G; Zwollo, P			Functional analyses of two alternative isoforms of the transcription factor Pax-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; DNA-BINDING ACTIVITY; NF-KAPPA-B; PAIRED DOMAIN; FACTOR BSAP; NUCLEAR TRANSLOCATION; DIRECT ASSOCIATION; ACTIVATOR PROTEIN; 3'ALPHA ENHANCER; REDOX REGULATION	The Pax-5 gene plays a central role in B cell development, activation, and differentiation. At least four different isoforms have been identified, of which isoform Pax-5a has been extensively studied, while functions for alternative isoforms were previously unknown. Here, using a transient transfection system, we provide evidence that alternative isoform Pax-5d acts as a dominant-negative regulator by suppressing activity of Pax-5a in a dose-dependent manner. In contrast, co-expression in the presence of alternative isoform Pax-5e causes an increase in Pax-5a activity. Protein studies on Pax-5e using Western blot analysis revealed that this 19-kDa isoform migrates as a 27-kDa species on SDS-polyacrylamide electrophoresis gels, while a mutant Pax-5e form in which a C-terminal cysteine residue has been mutated, runs at the expected 19 kDa. Using both Western blot and immunoprecipitation assays, we further provide evidence that this size discrepancy may be caused by a tight association between Pax-5e and a thioredoxin-like factor. Comparison of various B cell lines as well as resting and lipopolysaccharide-activated mature B lymphocytes shows that increased B cell proliferation correlates with increased levels of Pax-5e/thioredoxin, whereas increased Pax-5d amounts correlate with inhibition of cell growth. Together, our results suggest that during activation and differentiation of B lymphocytes, Pax-5a function is modulated by two alternative spliced isoforms: the dominant negative Pax-5d isoform may mediate inhibition of Pax-5a activity in resting B cells, while alternative isoform Pax-5e associated with thioredoxin may increase Pax-5a activity through an unknown (redox) mechanism.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA	William & Mary	Zwollo, P (corresponding author), Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA.							Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; Anspach J, 2001, J IMMUNOL, V166, P2617, DOI 10.4049/jimmunol.166.4.2617; ASANO M, 1992, MECH DEVELOP, V39, P29, DOI 10.1016/0925-4773(92)90023-D; BABERIS A, 1990, GENE DEV, V22, P37; COLIGAN JE, 1998, CURRENT PROTOCOLS IM, V2; Crow MK, 2001, BIOTECHNIQUES, V30, P311, DOI 10.2144/01302st04; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Hagman J, 2000, CURR TOP MICROBIOL, V245, P169; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KAMBE F, 1996, MOL ENDOCRINOL, V10, P810; Khayat M, 2001, J IMMUNOL, V166, P2937, DOI 10.4049/jimmunol.166.5.2937; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Liberg D, 1999, CRIT REV IMMUNOL, V19, P127; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; NEURATH MF, 1994, J IMMUNOL, V153, P730; Nilsson J, 2000, BLOOD, V95, P1420, DOI 10.1182/blood.V95.4.1420.004k12_1420_1426; ORR MD, 1966, BIOCHEM BIOPH RES CO, V25, P109, DOI 10.1016/0006-291X(66)90647-4; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Tavassoli K, 1997, HUM GENET, V101, P371, DOI 10.1007/s004390050644; Tell G, 2000, NUCLEIC ACIDS RES, V28, P1099, DOI 10.1093/nar/28.5.1099; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; Wallin JJ, 1999, J BIOL CHEM, V274, P15959, DOI 10.1074/jbc.274.22.15959; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; Wei SJ, 2000, CANCER RES, V60, P6688; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310; Zwollo P, 1998, J BIOL CHEM, V273, P18647, DOI 10.1074/jbc.273.29.18647; Zwollo P, 1997, J BIOL CHEM, V272, P10160, DOI 10.1074/jbc.272.15.10160	49	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42565	42574		10.1074/jbc.M106536200	http://dx.doi.org/10.1074/jbc.M106536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535600	hybrid			2022-12-25	WOS:000172450400132
J	Fagioli, C; Mezghrani, A; Sitia, R				Fagioli, C; Mezghrani, A; Sitia, R			Reduction of interchain disulfide bonds precedes the dislocation of Ig-mu chains from the endoplasmic reticulum to the cytosol for proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-MEDIATED RETENTION; ER QUALITY-CONTROL; PROTEIN TRANSLOCATION; LIGHT-CHAINS; B-CELLS; RAPID DEGRADATION; SECRETORY PATHWAY; IMMUNOGLOBULIN; MEMBRANE; RETROTRANSLOCATION	Proteins that fail to fold or assemble in the endoplasmic reticulum (ER) are generally dislocated across the membrane to be degraded by cytosolic proteasomes. To investigate how the quality control machinery handles individual subunits that are part of covalent oligomers, we have analyzed the fate of transport-competent Ig light (L) chains that form disulfide bonds with short-lived a heavy chains. When expressed alone, L chains are secreted. In cells producing excess mu, most L chains are retained in the ER as covalent mu .L or mu (2).L-2 complexes. While ft chains present in these complexes are degraded by proteasomes, L chains are stable. Few L chains are secreted; most reassociate with newly synthesized mu chains. Therefore, interchain disulfide bonds are reduced in the ER lumen before the dislocation of fl chains in a site from which freed L chains can be rapidly reinserted in the assembly line. The ER can thus sustain the simultaneous formation and reduction of disulfide bonds.	San Raffaele Sci Inst, Dept Mol Pathol Med, I-21032 Milan, Italy; Univ Vita Salute San Raffaele, I-21032 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Sitia, R (corresponding author), San Raffaele Sci Inst, Dept Mol Pathol Med, I-21032 Milan, Italy.		Fagioli, Claudio/AAN-4147-2020; Sitia, Roberto/AAB-5005-2019	Fagioli, Claudio/0000-0001-9889-4695; Sitia, Roberto/0000-0001-7086-4152				Bader M, 1999, NAT CELL BIOL, V1, pE57, DOI 10.1038/11025; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Brewer JW, 1997, MOL IMMUNOL, V34, P323, DOI 10.1016/S0161-5890(97)00029-1; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Carelli S, 1997, EUR J IMMUNOL, V27, P1283, DOI 10.1002/eji.1830270533; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; Ho SC, 2000, J IMMUNOL, V164, P4713, DOI 10.4049/jimmunol.164.9.4713; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; NEUBERGER MS, 1993, IMMUNOL REV, V132, P147, DOI 10.1111/j.1600-065X.1993.tb00841.x; O'Hare T, 1999, J IMMUNOL, V163, P11; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; Reddy PS, 1999, IMMUNOL TODAY, V20, P582, DOI 10.1016/S0167-5699(99)01542-X; Reth M, 2001, TRENDS IMMUNOL, V22, P356, DOI 10.1016/S1471-4906(01)01964-0; Romisch K, 1999, J CELL SCI, V112, P4185; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; Winitz D, 1996, J BIOL CHEM, V271, P27645, DOI 10.1074/jbc.271.44.27645	45	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40962	40967		10.1074/jbc.M107456200	http://dx.doi.org/10.1074/jbc.M107456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533039	hybrid			2022-12-25	WOS:000171925600079
J	Song, MS; Dallmann, HG; McHenry, CS				Song, MS; Dallmann, HG; McHenry, CS			Carboxyl-terminal domain III of the delta ' subunit of the DNA polymerase III holoenzyme binds delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ESCHERICHIA-COLI; GAMMA-SUBUNIT; CLAMP LOADER; ACCESSORY PROTEINS; EPSILON-SUBUNIT; SLIDING CLAMPS; BETA-SUBUNIT; GENE-PRODUCT; TAU-SUBUNIT	The delta and delta' subunits are essential components of the DNA polymerase III holoenzyme, required for assembly and function of the DnaX-complex clamp loader (tau (2)gamma delta delta'chi psi). The x-ray crystal structure of delta' contains three structural domains (Guenther, B., Onrust, R., Sali, A., O'Donnell, M., and Kuriyan, J. (1997) Cell 91,335-345). In this study, we localize the delta -binding domain of delta' to a carboxyl-terminal domain III by quantifying the interaction of delta with a series of delta' fusion proteins lacking specific domains. Purification and immobilization of the fusion proteins were facilitated by the inclusion of a tag containing hexahistidine and a short biotinylation sequence. Both NH2- and COON-terminal-tagged full-length delta' were soluble and had specific activities comparable with that of native delta'. delta and delta' form a 1:1 heterodimer with a dissociation constant (K-D) of 5 x 10(-7) m determined by equilibrium sedimentation. The KD determined by surface plasmon resonance was comparable. Domain III alone bound delta at an affinity comparable to that of wild type delta', whereas proteins lacking domain III did not bind delta. Using a panel of domain-specific anti-delta' monoclonal antibodies, we found that two of the domain III-specific monoclonal antibodies interfered with delta-delta' interaction and abolished the replication activity of DNA polymerase-III holoenzyme.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Song, MS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CULL MG, 1995, PURIFICATION ESCHERI; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HORIUCHI T, 1978, MOL GEN GENET, V163, P277, DOI 10.1007/BF00271956; HURWITZ J, 1974, P NATL ACAD SCI USA, V71, P6, DOI 10.1073/pnas.71.1.6; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; LEWIS MS, 1986, J BIOL CHEM, V261, P1571; MAKI S, 1988, J BIOL CHEM, V263, P6555; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; PERKINS KK, 1986, P NATL ACAD SCI USA, V83, P887, DOI 10.1073/pnas.83.4.887; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SONG M, 2001, J BIOL CHEM; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TURNER J, 1997, 17 INT C BIOCH MOL B, V11, pA877; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	50	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40668	40679		10.1074/jbc.M106373200	http://dx.doi.org/10.1074/jbc.M106373200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518714	hybrid			2022-12-25	WOS:000171925600040
J	Xu, JG; Paquet, M; Lau, AG; Wood, JD; Ross, CA; Hall, RA				Xu, JG; Paquet, M; Lau, AG; Wood, JD; Ross, CA; Hall, RA			beta(1)-Adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2) - Differential regulation of receptor internalization by MAGI-2 and PSD-95.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; D-ASPARTATE RECEPTORS; LONG-TERM POTENTIATION; HIPPOCAMPAL CA1 REGION; BETA(2)-ADRENERGIC RECEPTOR; PDZ-DOMAIN; POSTSYNAPTIC DENSITY; BETA-2-ADRENERGIC RECEPTORS; BETA-1-ADRENERGIC RECEPTOR; TUMOR-SUPPRESSOR	The beta (1)-adrenergic receptor (beta (1)AR) is known to be localized to synapses and to modulate synaptic plasticity in many brain regions, but the molecular mechanisms determining beta (1)AR subcellular localization are not fully understood. Using overlay and pull-down techniques, we found that the beta (1)AR carboxyl terminus associates with MAGI-2 (membrane-associated guanylate kinase inverted-2), a protein also known as S-SCAM (synaptic scaffolding molecule). MAGI-2 is a multidomain scaffolding protein that contains nine potential protein-protein interaction modules, including 6 PDZ domains, 2 WW domains, and a guanylate kinase-like domain. The beta (1)AR carboxyl terminus binds with high affinity to the first PDZ domain of MAGI-2, with the last few amino acids of the beta (1)AR carboxyl terminus being the key determinants of the interaction. In cells, the association of full-length beta (1)AR with MAGI-2 occurs constitutively and is enhanced by agonist stimulation of the receptor, as assessed by both co-immunoprecipitation experiments and immunofluorescence co-localization studies. Agonist-induced internalization of the beta (1)AR is markedly increased by co-expression with MAGI-2. Strikingly, this result is the opposite of the effect of co-expression with PSD-95, a previously reported binding partner of the beta (1)AR. Further cellular experiments revealed that MAGI-2 has no effect on beta (1)AR oligomerization but does promote association of beta (1)AR with the cytoplasmic signaling protein beta -catenin, a known MAGI-2 binding partner. These data reveal that MAGI-2 is a specific beta (1)AR binding partner that modulates beta (1)AR function and facilitates the physical association of the beta (1)AR with intracellular proteins involved in signal transduction and synaptic regulation.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Neurobiol, Baltimore, MD 21205 USA	Emory University; Johns Hopkins University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Wood, Jonathan D/A-5060-2009	Hall, Randy/0000-0002-8318-8728	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034172] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM60982] Funding Source: Medline; NINDS NIH HHS [R01-NS34172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; AOKI C, 1987, BRAIN RES, V437, P264, DOI 10.1016/0006-8993(87)91642-8; Bramham CR, 1997, NEUROREPORT, V8, P719, DOI 10.1097/00001756-199702100-00028; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CASH R, 1986, BRAIN RES, V370, P127, DOI 10.1016/0006-8993(86)91112-1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen AS, 1999, J NEUROPHYSIOL, V82, P3139, DOI 10.1152/jn.1999.82.6.3139; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; FLEXNER JB, 1985, P NATL ACAD SCI USA, V82, P7458, DOI 10.1073/pnas.82.21.7458; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Furuyashiki T, 1999, J NEUROSCI, V19, P109, DOI 10.1523/JNEUROSCI.19-01-00109.1999; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Ikegaya Y, 1997, NEUROREPORT, V8, P3143, DOI 10.1097/00001756-199709290-00027; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Kawajiri A, 2000, BIOCHEM BIOPH RES CO, V273, P712, DOI 10.1006/bbrc.2000.3002; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; MANTYH PW, 1995, J NEUROSCI, V15, P152; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Moody TD, 1998, BRAIN RES, V794, P75, DOI 10.1016/S0006-8993(98)00217-0; NICHOLAS AP, 1993, NEUROSCIENCE, V56, P1023, DOI 10.1016/0306-4522(93)90148-9; Nicholas AP, 1996, TRENDS PHARMACOL SCI, V17, P245, DOI 10.1016/S0165-6147(96)10022-5; NIELSON KA, 1994, BEHAV NEURAL BIOL, V62, P190, DOI 10.1016/S0163-1047(05)80017-2; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Przybyslawski J, 1999, J NEUROSCI, V19, P6623; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Steinberg SF, 1999, CIRC RES, V85, P1101; Steinberg SF, 2000, CIRC RES, V87, P1079, DOI 10.1161/01.RES.87.12.1079; STRADER CD, 1983, P NATL ACAD SCI-BIOL, V80, P1840, DOI 10.1073/pnas.80.7.1840; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; van Stegeren AH, 1998, PSYCHOPHARMACOLOGY, V138, P305, DOI 10.1007/s002130050675; WAEBER C, 1991, SYNAPSE, V8, P270, DOI 10.1002/syn.890080405; Wang SJ, 1999, J NEUROSCI, V19, P570; Watanabe Y, 1996, NEUROSCIENCE, V71, P1031, DOI 10.1016/0306-4522(95)00498-X; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Xiao RP, 1999, CIRC RES, V85, P1092; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153	77	102	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41310	41317		10.1074/jbc.M107480200	http://dx.doi.org/10.1074/jbc.M107480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526121	hybrid			2022-12-25	WOS:000171925600124
J	Kroslak, T; Koch, T; Kahl, E; Hollt, V				Kroslak, T; Koch, T; Kahl, E; Hollt, V			Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; XENOPUS OOCYTES; MESSENGER-RNA; CYTOSOLIC PROTEIN; CRYSTAL-STRUCTURE; 23-KDA PROTEIN; GAMMA-SUBUNITS; ALPHA-SUBUNITS; CL CURRENTS; RAT	In this study we report that human phosphatidylethanolamine-binding protein (hPBP) facilitates heterotrimeric G protein-coupled signaling. In Xenopus laevis oocytes, coexpression of hPBP with human mu opioid receptor, human delta opioid receptor, or human somatostatin receptor 2 evoked an agonist-induced increase in potassium conductance of G protein-activated inwardly rectifying potassium channels. This activation of heterotrimeric G protein signaling in oocytes could also be elicited by injection of bacterially overexpressed and purified hPBP. Stimulatory effect was pertussis toxin-sensitive and present even in the absence of coexpressed receptors. Additionally, an increase in G protein-mediated inhibition of adenylate cyclase activity, measured by the inhibition of forskolin-mediated cAMP accumulation, could be detected in HEK293 and NIH3T3 cells after expression of hPBP and in Xenopus oocytes after injection of hPBP. As [S-35]guanosine 5'-3-O-(thio) triphosphate (GTP gammaS) binding to membranes prepared from hPBP-expressing cells was significantly elevate and recombinant hPBP dose-dependently stimulated [S-35] GTP gammaS binding to native membranes, the results presented provide strong evidence that hPBP-induced effects are G protein-dependent. These data suggest a novel function of hPBP in regulating G protein and G protein-coupled receptor signaling in vivo.	Univ Magdeburg, Inst Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Hollt, V (corresponding author), Univ Magdeburg, Inst Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Amaya I, 1999, PLANT CELL, V11, P1405, DOI 10.1105/tpc.11.8.1405; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Banfield MJ, 2000, J MOL BIOL, V297, P1159, DOI 10.1006/jmbi.2000.3619; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Erttmann KD, 1996, GENE, V174, P203, DOI 10.1016/0378-1119(96)00040-6; Frayne J, 1998, MOL REPROD DEV, V49, P454, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;454::AID-MRD13&gt;3.0.CO;2-U; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Innocenti M, 1999, FEBS LETT, V460, P357, DOI 10.1016/S0014-5793(99)01374-5; JONES R, 1991, BIOCHIM BIOPHYS ACTA, V1080, P78, DOI 10.1016/0167-4838(91)90114-F; Katada E, 1996, HISTOCHEM CELL BIOL, V105, P43, DOI 10.1007/BF01450877; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 1997, J NEUROCHEM, V69, P1767; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Machaca K, 1999, J BIOL CHEM, V274, P4824, DOI 10.1074/jbc.274.8.4824; Moore C, 1996, MOL BRAIN RES, V37, P74, DOI 10.1016/0169-328X(95)00285-Z; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; OJIKA K, 1994, DEV BRAIN RES, V79, P1, DOI 10.1016/0165-3806(94)90043-4; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PIKIELNY CW, 1994, NEURON, V12, P35, DOI 10.1016/0896-6273(94)90150-3; Pnueli L, 1998, DEVELOPMENT, V125, P1979; QUICK MW, 1994, J BIOL CHEM, V269, P30164; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Seddiqi N, 1996, EXPERIENTIA, V52, P101, DOI 10.1007/BF01923352; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Taiji M, 1996, J NEUROSCI RES, V45, P202, DOI 10.1002/(SICI)1097-4547(19960801)45:3<202::AID-JNR2>3.0.CO;2-H; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; ZHU SZ, 1994, MOL PHARMACOL, V45, P517; Zippel R, 1996, ONCOGENE, V12, P2697	46	80	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39772	39778		10.1074/jbc.M106991200	http://dx.doi.org/10.1074/jbc.M106991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514577	hybrid			2022-12-25	WOS:000171789200036
J	Yang, EJ; Ahn, YS; Chung, KC				Yang, EJ; Ahn, YS; Chung, KC			Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM-MEMORY; SYNDROME CRITICAL REGION; GENE-EXPRESSION; DOWN-SYNDROME; SIGNALING PATHWAYS; HUMAN HOMOLOG; CREB; DROSOPHILA; SPECIFICITY; TRANSCRIPTION	Dyrk is a dual specific protein kinase thought to be involved in normal embryo neurogenesis and brain development. Defects/imperfections in this kinase have been suggested to play an important role in the mental retardation of patients with Down's syndrome. The transcriptional factor cAMP response element-binding protein (CREB) has been implicated in the formation of many types of synaptic plasticity, such as learning and memory. In the present study we show that Dyrk1 activity is markedly induced during the differentiation of immortalized hippocampal progenitor (H19-7) cells. The addition of a neurogenic factor, basic fibroblast growth factor, to the H19-7 cells results in an increased specific binding of Dyrk1 to active CREB. In addition, Dyrk1 directly phosphorylates CREB, leading to the stimulation of subsequent CRE-mediated gene transcription during the neuronal differentiation in H19-7 cells. Blockade of Dyrk1 activation significantly inhibits the neurite outgrowth as well as CREB phosphorylation induced by basic fibroblast growth factor. These findings suggest that Dyrk1 activation and subsequent CREB phosphorylation is important in the neuronal differentiation of central nervous system hippocampal cells.	Yonsei Univ, Coll Med, Dept Pharmacol, Brain Res Inst,Seodaemun Gu, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Chung, KC (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Brain Res Inst,Seodaemun Gu, Shinchon Dong 134, Seoul 120752, South Korea.		Cabrera, Mariel/GMX-2706-2022					ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; BARTSCH D, 2000, SOC NEUR ABSTR, V26, P804; BEAR MF, 1990, J NEUROSCI, V10, P909; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kentrup H, 1996, J BIOL CHEM, V271, P3488; KONRADI C, 1994, J NEUROSCI, V14, P5623; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; MELLO CV, 1992, P NATL ACAD SCI USA, V89, P6818, DOI 10.1073/pnas.89.15.6818; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Okui M, 1999, GENOMICS, V62, P165, DOI 10.1006/geno.1999.5998; Rahmani Z, 1998, BIOCHEM BIOPH RES CO, V253, P514, DOI 10.1006/bbrc.1998.9803; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000	36	135	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39819	39824		10.1074/jbc.M104091200	http://dx.doi.org/10.1074/jbc.M104091200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518709	hybrid			2022-12-25	WOS:000171789200042
J	Berrou, E; Bryckaert, M				Berrou, E; Bryckaert, M			Platelet-derived growth factor inhibits smooth muscle cell adhesion to fibronectin by ERK-dependent and ERK-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; FOCAL ADHESIONS; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; INTEGRIN ACTIVATION; RHO; MIGRATION; KINASE; PAXILLIN	The adhesion of cells to the extracellular matrix plays a major role in cell migration. Pretreatment with platelet-derived growth factor (PDGF) inhibited the adhesion of smooth muscle cells to fibronectin by 80%. This inhibition decreased as concentrations of fibronectin increased. In the presence of 200 muM GRGDS peptide, only 45% of PDGF-treated cells adhered to fibronectin compared with 80% of control cells. This indicates that a decrease in integrin avidity was induced by PDGF. Cell adhesion was partially restored when the activation of the extracellular signal-regulated kinase (ERK) was inhibited with PD98059. The remaining inhibition of adhesion (50%) was independent of the fibronectin concentration, suggesting that the ERK pathway is involved in the decrease in integrin avidity. This was confirmed by depleting ERK protein levels by treatment with ERK antisense oligonucleotide. The adhesion of ERK control oligonucleotide-treated cells decreased by 41% when the concentration of GRGDS peptide was increased from 50 to 200 muM but only decreased by 11% in ERK antisense oligonucleotide-treated cells. Treatment with PDGF also delayed focal complex assembly and inhibited stress fiber formation. Consistent with a delay in tyrosine phosphorylation of paxillin, PDGF treatment caused a lag in focal complex formation, although this was not associated with any change in Src family tyrosine kinase activity. Our results indicate that PDGF inhibits smooth muscle cells adhesion by two pathways. The first involves an ERK-dependent decrease in integrin avidity; the second involves the ERK-independent inhibition of focal complex assembly.	INSERM, U348, IFR Circulat Lariboisiere, F-75475 Paris 10, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Berrou, E (corresponding author), INSERM, U348, IFR Circulat Lariboisiere, 41 Bvd Chapelle, F-75475 Paris 10, France.			Bryckaert, Marijke/0000-0003-3398-0976				Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BERROU E, 1988, J CELL PHYSIOL, V137, P430, DOI 10.1002/jcp.1041370306; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; FERMS GAA, 1991, SCIENCE, V253, P1129; Flinn HM, 1996, J CELL SCI, V109, P1133; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JACKSON CL, 1993, ARTERIOSCLER THROMB, V13, P1218, DOI 10.1161/01.ATV.13.8.1218; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SANDERS M, 1994, PHARMACOL THERAPEUT, V61, P109, DOI 10.1016/0163-7258(94)90060-4; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz SM, 1997, J CLIN INVEST, V99, P2814, DOI 10.1172/JCI119472; Seki J, 1996, CIRC RES, V78, P596, DOI 10.1161/01.RES.78.4.596; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; WILSON L, 1995, J CELL SCI, V108, P2381; Xie H, 1998, J CELL SCI, V111, P615; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	47	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39303	39309		10.1074/jbc.M011751200	http://dx.doi.org/10.1074/jbc.M011751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11517214	hybrid			2022-12-25	WOS:000171673200129
J	Fink, DL; Cope, LD; Hansen, EJ; St Geme, JW				Fink, DL; Cope, LD; Hansen, EJ; St Geme, JW			The Hemophilus influenzae Hap autotransporter is a chymotrypsin clan serine protease and undergoes autoproteolysis via an intermolecular mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROAGGREGATIVE ESCHERICHIA-COLI; HAEMOPHILUS-INFLUENZAE; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; PROTEINS; PATHOGENICITY; PEPTIDASES; SECRETION; FAMILIES; GENES	The Hemophilus influenzae Hap adhesin is an auto-transporter protein that undergoes an autoproteolytic cleavage event resulting in extracellular release of the adhesin domain (Hap(s)) from the membrane-associated translocator domain (Hap(beta)). Hap autoproteolysis is mediated by Ser(243) and occurs at LN1036-7 and to a lesser extent at more COOH-terminal alternate sites. In the present study, we sought to further define the mechanism of Hap autoproteolysis. Site-directed mutagenesis of residues His(98) and Asp(140) identified a catalytic triad conserved among a subfamily of autotransporters and reminiscent of the SA (chymotrypsin) clan of serine proteases. Amino-terminal amino acid sequencing of histidine-tagged Hap(beta) species and site-directed mutagenesis established that autoproteolysis occurs at LT1046-7, FA1077-8, and FS1067-8, revealing a consensus target sequence for cleavage that consists of ((Q/R)(A/S)X(L/F)) at the P4 through P1 positions. Examination of a recombinant strain co-expressing a Hap derivative lacking all cleavage sites (Hap Delta 1036-99) and a Hap derivative lacking proteolytic activity (HapS243A) demonstrated that autoproteolysis occurs by an intermolecular mechanism. Kinetic analysis of Hap autoproteolysis in bacteria expressing Hap under control of an inducible promoter demonstrated that autoproteolysis increases as the density of Hap precursor in the outer membrane increases, confirming intermolecular cleavage and suggesting a novel mechanism for regulation of bacterial adherence and microcolony formation.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	St Geme, JW (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017621] Funding Source: NIH RePORTER; NIAID NIH HHS [AI17621] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Hasani K, 2000, INFECT IMMUN, V68, P2457, DOI 10.1128/IAI.68.5.2457-2463.2000; ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Benjelloun-Touimi Z, 1998, MICROBIOL-SGM, V144, P1815, DOI 10.1099/00221287-144-7-1815; BENJELLOUNTOUIMI Z, 1995, MOL MICROBIOL, V17, P123, DOI 10.1111/j.1365-2958.1995.mmi_17010123.x; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; CARLONE GM, 1986, J CLIN MICROBIOL, V24, P330, DOI 10.1128/JCM.24.3.330-332.1986; COPE LD, 1990, INFECT IMMUN, V58, P3312, DOI 10.1128/IAI.58.10.3312-3318.1990; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 1999, INFECT IMMUN, V67, P5587, DOI 10.1128/IAI.67.11.5587-5596.1999; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Hendrixson DR, 1998, MOL CELL, V2, P841, DOI 10.1016/S1097-2765(00)80298-1; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; Kasche V, 1999, BBA-PROTEIN STRUCT M, V1433, P76, DOI 10.1016/S0167-4838(99)00155-7; KILIAN M, 1980, J IMMUNOL, V124, P2596; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin L, 1997, MOL MICROBIOL, V24, P1083, DOI 10.1046/j.1365-2958.1997.4191776.x; LO RYC, 1991, INFECT IMMUN, V59, P3398, DOI 10.1128/IAI.59.10.3398-3406.1991; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Ohnishi Y, 1997, J BIOCHEM, V121, P902; PLAUT AG, 1994, METHOD ENZYMOL, V244, P137; POHLNER J, 1995, MOL MICROBIOL, V17, P1073, DOI 10.1111/j.1365-2958.1995.mmi_17061073.x; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; Sambrook J., 2002, MOL CLONING LAB MANU; SETLOW JK, 1968, J BACTERIOL, V95, P546, DOI 10.1128/JB.95.2.546-558.1968; SETLOW JK, 1973, J BACTERIOL, V115, P153, DOI 10.1128/JB.115.1.153-161.1973; Stathopoulos C, 1999, INFECT IMMUN, V67, P772, DOI 10.1128/IAI.67.2.772-781.1999; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; STGEME JW, 1994, MOL MICROBIOL, V14, P217, DOI 10.1111/j.1365-2958.1994.tb01283.x; TOMB JF, 1989, J BACTERIOL, V171, P3796, DOI 10.1128/jb.171.7.3796-3802.1989; TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WILLSON PJ, 1989, ANTIMICROB AGENTS CH, V33, P1627, DOI 10.1128/AAC.33.9.1627; Wittlin S, 1999, EUR J BIOCHEM, V265, P384, DOI 10.1046/j.1432-1327.1999.00747.x	42	51	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39492	39500		10.1074/jbc.M106913200	http://dx.doi.org/10.1074/jbc.M106913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504735	hybrid			2022-12-25	WOS:000171673200151
J	Goel, M; Garcia, R; Estacion, M; Schilling, WP				Goel, M; Garcia, R; Estacion, M; Schilling, WP			Regulation of Drosophila TRPL channels by immunophilin FKBP59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN PROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SF9 INSECT CELLS; TRANSIENT RECEPTOR; RELEASE CHANNELS; CATION CHANNEL; FUNCTIONAL-CHARACTERIZATION; SIGNALING COMPLEXES; MOLECULAR-CLONING; DIRECT ACTIVATION	Transient receptor potential and transient receptor potential-like (TRPL) are Ca2+-permeable cation channels found in Drosophila photoreceptor cells associated with large multimeric signaling complexes held together by the scaffolding protein, INAD. To identify novel proteins involved in channel regulation, Drosophila INAD was used as bait in a yeast two-hybrid screen of a Drosophila head cDNA library. Sequence analysis of one identified clone showed it to be identical to the Drosophila homolog of human FK506-binding protein, FKBP52 (previously known as FKBP59). To determine the function of dFKBP59, TRPL channels and dFKBP59 were co-expressed in Sf9 cells. Expression of dFKBP59 produced an inhibition of Ca2+ influx via TRPL in fura-2 assays. Likewise, purified recombinant dFKBP59 produced a graded inhibition of TRPL single channel activity in excised inside-out patches when added to the cytoplasmic membrane surface. Immunoprecipitations from Sf9 cell lysates using recombinant tagged dFKBP59 and TRPL showed that these proteins directly interact with each other and with INAD. Addition of FK506 prior to immunoprecipitation resulted in a temperature-dependent dissociation of dFKBP59 and TRPL. Immunoprecipitations from Drosophila S2 cells and from fly head lysates demonstrated that dFKBP59, but not dFKBP12, interacts with TRPL in vivo. Likewise, INAD immunoprecipitates with dFKBP59 from S2 cell and head lysates. Immunocytochemical evaluation of thin sections of fly heads revealed specific FKBP immunoreactivity associated with the eye. Site-directed mutagenesis showed that mutations of P702Q or P709Q in the highly conserved TRPL sequence (LPPPFN)-L-701-VLP799 eliminated interaction of the TRPL with dFKBP59. These results provide strong support for the hypothesis that immunophilin dFKBP59 is part of the TRPL-INAD signaling complex and plays an important role in modulation of channel activity via interaction with conserved leucyl-prolyl dipeptides located near the cytoplasmic mouth of the channel.	Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Metrohlth Med Ctr, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	MetroHealth System; Case Western Reserve University	Schilling, WP (corresponding author), Metrohlth Med Ctr, Rammelkamp Ctr Educ & Res, Metrohlth Med Ctr, Rm R322,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	wschilling@metrohealth.org	Garcia, Reynaldo L/L-8979-2019; Estacion, Mark/H-2444-2011	Estacion, Mark/0000-0002-7271-1165; Garcia, Reynaldo/0000-0003-1350-1261	NIGMS NIH HHS [GM52019] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052019] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; Estacion M, 1999, BIOCHEM J, V341, P41, DOI 10.1042/0264-6021:3410041; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; FINLEY RL, 1995, DNA CLONING, V2, P169; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haab JE, 2000, J NEUROSCI, V20, P7193; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Kunze DL, 1997, AM J PHYSIOL-CELL PH, V272, pC27, DOI 10.1152/ajpcell.1997.272.1.C27; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Paulsen R, 2000, PFLUG ARCH EUR J PHY, V439, pR181, DOI 10.1007/s004240000138; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; Tsunoda S, 2001, J NEUROSCI, V21, P150, DOI 10.1523/JNEUROSCI.21-01-00150.2001; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Winer B.J., 1962, STAT PRINCIPLES EXPT; Wisnoskey BJ, 2001, FASEB J, V15, pA177; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zaffran S, 2000, GENE, V246, P103, DOI 10.1016/S0378-1119(00)00058-5; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	56	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38762	38773		10.1074/jbc.M104125200	http://dx.doi.org/10.1074/jbc.M104125200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514552	hybrid			2022-12-25	WOS:000171673200059
J	VanHouten, JN; Asch, HL; Asch, BB				VanHouten, JN; Asch, HL; Asch, BB			Cloning and characterization of ectopically expressed transcripts for the actin-binding protein MIPP in mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; mammary; cancer; endoplasmic reticulum; actin; kelch	ENDOPLASMIC-RETICULUM; DROSOPHILA KELCH; GENE; MICROTUBULE; CYTOSKELETON; OUTGROWTHS; FILAMENTS; COMPLEX; ENCODES; DOMAIN	Mipp is a kelch-related, placental-specific gene that is ectopically expressed in many BALB/c mouse mammary carcinomas of various etiologies. The Kelch family encompasses proteins that are emerging as key links between microfilaments and a variety of cellular structures and functions. Mouse mammary tumors express two mipp transcripts (2.2 and 5.6 kb). We cloned the 2.2 kb mipp mRNA and analysed the product of its 1.7 kb ORE The 584 residue MIPP protein has an N-terminal BTB domain and six C-terminal tandem Kelch repeats. Despite expression of two mipp RNAs, only a single MIPP protein is expressed in mammary tumors. MIPP protein binds to microfilaments in vitro and co-immunoprecipitates with actin. MIPP co-localized with concanavalin A at the endoplasmic reticulum, suggesting that MIPP might mediate interactions between microtubules and actin filaments. Because MIPP expression is widespread in mouse mammary tumors, it might contribute to tumorigenesis. Although MIPP had little effect on the growth rate of human breast cell lines following transfection, it greatly reduced the formation of duct-like structures on reconstituted basement membrane. Our results suggest that MIPP could contribute to malignant progression in the mouse mammary epithelial cells by perverting their response to cues from the extracellular matrix.	Roswell Pk Canc Inst Corp, Div Expt Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	VanHouten, JN (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA062014, P30CA016056, R01CA072768] Funding Source: NIH RePORTER; NCI NIH HHS [CA62014, CA16056, CA72768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P3, DOI 10.1007/BF02096298; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schmucker B, 1997, EUR J CELL BIOL, V72, P46; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Tabb JS, 1998, J CELL SCI, V111, P3221; TERASAKI M, 1990, CELL MOTIL CYTOSKEL, V15, P71, DOI 10.1002/cm.970150203; VanHouten JN, 1996, ONCOGENE, V12, P2241; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; WOOD JG, 1981, J NEUROCYTOL, V10, P149, DOI 10.1007/BF01181750; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	35	5	6	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5366	5372		10.1038/sj.onc.1204701	http://dx.doi.org/10.1038/sj.onc.1204701			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536049				2022-12-25	WOS:000170575500012
J	Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL				Persengiev, SP; Li, JQ; Poulin, ML; Kilpatrick, DL			E2F2 converts reversibly differentiated PC12 cells to an irreversible, neurotrophin-dependent state	ONCOGENE			English	Article						terminal differentiation; neuron; apoptosis; growth arrest	NERVE GROWTH-FACTOR; ACTIVE TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN FAMILY; SUBCELLULAR-LOCALIZATION; PHEOCHROMOCYTOMA CELLS; MICE LACKING; CYCLIN D1; DEATH; NEURONS; PROLIFERATION	E2Fs play a central role in cell proliferation and growth arrest through their ability to regulate genes involved in cell cycle progression, arrest and apoptosis. Recent studies further indicate that this family of transcriptional regulators participate in cell fate/differentiation events. They are thus likely to have a prominent role in controlling the terminal differentiation process and its irreversibility. Here we have specifically examined the role of E2F2 in neuronal differentiation using a gain-of-function approach. Endogenous E2F2 increased in PC12 cells in response to nerve growth factor (NGF) and was also expressed in cerebellar granule neurons undergoing terminal differentiation. While PC12 cells normally undergo reversible dedifferentiation and cell cycle reentry upon NGF removal, forced expression of E2F2 inhibited these events and induced apoptosis. Thus, E2F2 converted PC12-derived neurons from a reversible to a 'terminally' differentiated, NGF-dependent state, analogous to postmitotic sympathetic neurons. This contrasts with the effects of E2F4, which enhances the differentiation state of PC12 cells without affecting cell cycle parameters or survival. These results indicate that E2F2 may have a unique role in maintaining the postmitotic state of terminally differentiated neurons, and may participate in apoptosis in neurons attempting to reenter the cell cycle. It may also be potentially useful in promoting the terminally arrested/differentiated state of tumor cells.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Kilpatrick, DL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL CANCER INSTITUTE [R01CA079999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-79999] Funding Source: Medline; NIDDK NIH HHS [DK36468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui H, 1998, DEV BRAIN RES, V106, P129, DOI 10.1016/S0165-3806(97)00204-6; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frade JM, 2000, J CELL SCI, V113, P1139; Francesconi CM, 2000, INVEST OPHTH VIS SCI, V41, P1054; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Heibein JA, 1999, J IMMUNOL, V163, P4683; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Magae J, 1996, J CELL SCI, V109, P1717; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nagy Z, 1999, J NEURAL TRANSM-SUPP, P233; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; PERSENGIEV SP, 1993, INT J BIOCHEM, V25, P441, DOI 10.1016/0020-711X(93)90637-T; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.3.CO;2-8; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; vanGrunsven LA, 1996, ONCOGENE, V12, P855; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	52	17	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5124	5131		10.1038/sj.onc.1204663	http://dx.doi.org/10.1038/sj.onc.1204663			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526501				2022-12-25	WOS:000170464000006
J	Golozoubova, V; Hohtola, E; Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J				Golozoubova, V; Hohtola, E; Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J			Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold	FASEB JOURNAL			English	Article						cold acclimation; uncoupling proteins; electromyography; longevity; oxygen consumption	BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; UNCOUPLING PROTEIN; ACCLIMATED RATS; ENERGY-BALANCE; MICE; GENE; MITOCHONDRIA; CAPILLARITY; OBESITY	Adaptive nonshivering thermogenesis may have profound effects on energy balance and is therefore therefore is a potential mechanism for counteracting the development of obesity. The molecular basis for adaptive nonshivering thermogenesis has remained a challenge that sparked acute interest with the identification of proteins (UCP2, UCP3, etc.) with high-sequence similarity to the original uncoupling protein-1 (UCP1), which is localized only in brown adipose tissue. Using UCP1-ablated mice, we examined whether any adaptive nonshivering thermogenesis could be recruited by acclimation to cold. Remarkably, by successive acclimation, the UCP1-ablated mice could be made to subsist for several weeks at 4 degreesC during which they had to constantly produce heat at four times their resting levels. Despite these extreme requirements for adaptive nonshivering thermogenesis, however, no substitution of shivering by any adaptive nonshivering thermogenic process occurred. Thus, although the existence of, for example, muscular mechanisms for adaptive nonshivering thermogenesis has recurrently been implied, we did not find any indication of such thermogenesis. Not even during prolonged and enhanced demand for extra heat production was any endogenous hormone or neurotransmitter able to recruit any UCP1-independent adaptive nonshivering thermogenic process in muscle or in any other organ, and no proteins other than UCP1-not even UCP2 or UCP3-therefore have the ability to mediate adaptive nonshivering thermogenesis in the cold.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Univ Oulu, Dept Biol, FI-90014 Oulu, Finland	Stockholm University; University of Oulu	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				Alexander G, 1979, Int Rev Physiol, V20, P43; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BEHRENS WA, 1977, J BIOENERG BIOMEMBR, V9, P41, DOI 10.1007/BF00745042; BIGARD AX, 1991, PFLUG ARCH EUR J PHY, V419, P225, DOI 10.1007/BF00371099; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; BOURHIM M, 1990, AM J PHYSIOL, V258, pR1291, DOI 10.1152/ajpregu.1990.258.5.R1291; Cannon B, 2000, LIFE IN THE COLD, P387; Cannon B., 2000, Comparative Biochemistry and Physiology Part A Molecular and Integrative Physiology, V126A, pS22; Chilibeck PD, 1998, CAN J APPL PHYSIOL, V23, P74, DOI 10.1139/h98-005; Cinti S, 1999, ADIPOSE ORGAN; DICKER A, 1995, AM J PHYSIOL-REG I, V269, pR767, DOI 10.1152/ajpregu.1995.269.4.R767; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Gordon CJ, 1993, TEMPERATURE REGULATI, DOI 10.1017/CBO9780511565595; GREENWAY DC, 1978, AM J PHYSIOL, V234, pC7, DOI 10.1152/ajpcell.1978.234.1.C7; Gute D, 1996, J APPL PHYSIOL, V81, P619, DOI 10.1152/jappl.1996.81.2.619; HOHTOLA E, 1982, COMP BIOCHEM PHYS A, V73, P159, DOI 10.1016/0300-9629(82)90049-4; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Nechad M., 1986, BROWN ADIPOSE TISSUE; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; Oberkofler H, 1997, J LIPID RES, V38, P2125; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Smith R., 1961, PHYSIOLOGIST, V4, P113; SNYDER GK, 1992, EUR J APPL PHYSIOL O, V65, P158, DOI 10.1007/BF00705074; Soni A, 1997, J THERM BIOL, V22, P95, DOI 10.1016/S0306-4565(96)00037-X; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzuki J, 1997, JPN J PHYSIOL, V47, P513, DOI 10.2170/jjphysiol.47.513; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WALTERS TJ, 1993, J APPL PHYSIOL, V75, P264, DOI 10.1152/jappl.1993.75.1.264; WIBOM R, 1992, J APPL PHYSIOL, V73, P2004, DOI 10.1152/jappl.1992.73.5.2004; WICKLER SJ, 1981, AM J PHYSIOL, V240, pR289, DOI 10.1152/ajpregu.1981.240.5.R289	35	346	355	0	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2048	+		10.1096/fj.00-0536fje	http://dx.doi.org/10.1096/fj.00-0536fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511509				2022-12-25	WOS:000170318500026
J	Kuo, HJ; Tran, NT; Clary, SA; Morris, NP; Glanville, RW				Kuo, HJ; Tran, NT; Clary, SA; Morris, NP; Glanville, RW			Characterization of EHD4, an EH domain-containing protein expressed in the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VI COLLAGEN; SECRETORY PATHWAY; GLOBULAR DOMAINS; SIGNAL SEQUENCE; ALPHA-3 CHAIN; BINDING-SITES; EPS15; CARTILAGE; SPECIFICITY; NETWORK	To identify proteins that promote assembly of type VI collagen tetramers or stabilize type VI collagen filaments, a two-hybrid screen of a human placenta library was used and a new extracellular protein discovered. The cDNA sequence of the new protein encodes 541 amino acid residues. This cDNA sequence is identical to EHD4, a recently described member of the EH domain family of proteins. Two mRNAs of 4.4 and 3.0 kilobases were present in human skin fibroblasts and most tissues tested but were most prevalent in the heart. The chromosomal localization of the gene for this new protein was determined to be at 15q14-q15. Three polyclonal peptide antibodies were made against synthetic EHD4 peptides. The affinity-purified antibodies were used in immunofluorescent staining of developing limbs and matrices produced by human skin fibroblasts and mouse NIH3T3 fibroblasts in culture. Embryonic rat limb cartilage was strongly stained throughout development, and cultured fibroblasts deposited an extracellular filamentous network containing EHD4. In non-denaturing extracts of fetal bovine cartilage and in human skin fibroblast culture media, two components of similar to 220 and 158 kDa were observed, which, after reduction, migrated as a 56-kDa component on SDS-polyacrylamide gel electrophoresis. EHD4 is the first extracellular matrix protein described that contains an EH domain.	Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Res Ctr, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Glanville, RW (corresponding author), Oregon Med Laser Ctr, 9205 SW Barnes Rd, Portland, OR 97225 USA.							ARNOUX B, 1995, J MOL BIOL, V246, P609, DOI 10.1006/jmbi.1994.0112; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Enmon JL, 2000, BIOCHEMISTRY-US, V39, P4309, DOI 10.1021/bi9927383; GREGORY KE, 2001, IN PRESS J BONE MIN; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Jowett T., 1997, TISSUE IN SITU HYBRI, P128; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Morris NP, 2000, J HISTOCHEM CYTOCHEM, V48, P725, DOI 10.1177/002215540004800601; Murphy JM, 1999, MATRIX BIOL, V18, P487, DOI 10.1016/S0945-053X(99)00042-6; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Suzuki Y, 1998, J DENT RES, V77, P1799, DOI 10.1177/00220345980770100701; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	35	16	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43103	43110		10.1074/jbc.M106128200	http://dx.doi.org/10.1074/jbc.M106128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11533061	hybrid			2022-12-25	WOS:000172169300063
J	Lin, JL; Liang, ZM; Zhang, Z; Li, GP				Lin, JL; Liang, ZM; Zhang, Z; Li, GP			Membrane topography and topogenesis of prenylated rab acceptor (PRA1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-ANCHOR PROTEINS; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE SEGMENTS; MESSENGER-RNA; STOP-TRANSFER; TRANSLOCATION; ORIENTATION; TRANSLATION; INTEGRATION; SEQUENCE	The mouse prenylated Rab acceptor (mPRA1) is associated with the Golgi membrane at steady state and interacts with Rab proteins. It contains two internal hydrophobic domains (34 residues each) that have enough residues to form four transmembrane (TM) segments. In this study, we have determined the membrane topography of mPRA1 in both intact cells and isolated microsomes. The putative TM segments of mPRA1 were used to substitute for a known TM segment of a model membrane protein to determine whether the mPRA1 segments integrate into the membrane. Furthermore, N-linked glycosylation scanning methods were used to distinguish luminal domains from cytoplasmic domains of mPRA1. The data demonstrate that mPRA1 is a polytopic membrane protein containing four TM segments. These TM segments act cooperatively during the translocation and integration at the endoplasmic reticulum membrane. All hydrophilic domains are in the cytoplasm, including the N-terminal domain, the linker domain between the two hydrophobic domains, and the C-terminal domain. As a result, the bulk of mPRA1 is located in the cytoplasm, supporting its postulated role in regulating Rab membrane targeting and intracellular trafficking.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Lin, JL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 SL Young Blvd,BMSB 853, Oklahoma City, OK 73104 USA.	jialing-lin@ouhsc.edu	Li, Guangpu/GRS-5397-2022		NIGMS NIH HHS [R01 GM062964] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liang ZM, 2000, BIOCHEM BIOPH RES CO, V275, P509, DOI 10.1006/bbrc.2000.3316; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MIHARA K, 1980, P NATL ACAD SCI-BIOL, V77, P4160, DOI 10.1073/pnas.77.7.4160; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; SKACH WR, 1993, J BIOL CHEM, V268, P23552; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	32	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41733	41741		10.1074/jbc.M103475200	http://dx.doi.org/10.1074/jbc.M103475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535589	hybrid, Green Accepted			2022-12-25	WOS:000172450400027
J	Li, YH; Martin, LD; Spizz, G; Adler, KB				Li, YH; Martin, LD; Spizz, G; Adler, KB			MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYRISTOYL-ELECTROSTATIC SWITCH; KINASE-C; SIGNAL-TRANSDUCTION; GOBLET CELLS; CGMP ANALOGS; IN-VITRO; ACTIVATION; RELEASE; ALPHA	Hypersecretion of airway mucin characterizes numerous respiratory diseases. Although diverse pathological stimuli can provoke exocytotic release of mucin from secretory cells of the airway epithelium, mechanisms involved remain obscure. This report describes a new paradigm for the intracellular signaling mechanism regulating airway mucin secretion. Direct evidence is provided that the myristoylated alanine-rich C kinase substrate (MARCKS) is a central regulatory molecule linking secretagogue stimulation at the cell surface to mucin granule release by differentiated normal human bronchial epithelial cells in vitro. Down-regulation of MARCKS expression or disruption of MARCKS function in these cells inhibits the secretory response to subsequent stimulation. The intracellular mechanism controlling this secretory process involves cooperative action of two separate protein kinases, protein kinase C and cGMP-dependent protein kinase. Upon stimulation, activated protein kinase C phosphorylates MARCKS, causing translocation of MARCKS from the plasma membrane to the cytoplasm, where it is then dephosphorylated by a protein phosphatase 2A that is activated by cGMP-dependent protein kinase, and associates with both actin and myosin. Dephosphorylated cytoplasmic MARCKS would also be free to interact with mucin granule membranes and thus could link granules to the contractile cytoskeleton, mediating their movement to the cell periphery and subsequent exocytosis. These findings suggest several novel intracellular targets for pharmacological intervention in disorders involving aberrant secretion of respiratory mucin and may relate to other lesions involving exocytosis of membrane-bound granules in various cells and tissues.	N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Adler, KB (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, 4700 Hillsborough St, Raleigh, NC 27606 USA.				NHLBI NIH HHS [R01 HL39862] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdullah LH, 1997, AM J PHYSIOL-LUNG C, V273, pL201, DOI 10.1152/ajplung.1997.273.1.L201; Abdullah LH, 1996, BIOCHEM J, V316, P943, DOI 10.1042/bj3160943; ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; Adler K. B., 1998, Research in Immunology, V149, P245, DOI 10.1016/S0923-2494(98)80093-X; ADLER KB, 1990, AM J RESP CELL MOL, V2, P145, DOI 10.1165/ajrcmb/2.2.145; COHN LA, 1992, EXP LUNG RES, V18, P299, DOI 10.3109/01902149209031687; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; Harlow E., 1988, ANTIBODIES LAB MANUA, P570; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Huang XC, 1996, ADV EXP MED BIOL, V396, P209; KAARTINEN L, 1993, IN VITRO CELL DEV-AN, V29A, P481, DOI 10.1007/BF02639383; Ko KH, 1997, AM J RESP CELL MOL, V16, P194, DOI 10.1165/ajrcmb.16.2.9032127; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685, DOI 10.1165/ajrcmb.22.6.3925; LARIVEE P, 1994, AM J RESP CELL MOL, V11, P199, DOI 10.1165/ajrcmb.11.2.8049080; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; LIN H, 1989, AM J RESP CELL MOL, V1, P41, DOI 10.1165/ajrcmb/1.1.41; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Wei JY, 1998, J MOL NEUROSCI, V10, P53, DOI 10.1007/BF02737085; Wright DT, 1996, AM J PHYSIOL-LUNG C, V271, pL854, DOI 10.1152/ajplung.1996.271.5.L854; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	28	127	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40982	40990		10.1074/jbc.M105614200	http://dx.doi.org/10.1074/jbc.M105614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533058	hybrid			2022-12-25	WOS:000171925600082
J	Sanz, C; Marquez, M; Peralvarez, A; Elouatik, S; Sepulcre, F; Querol, E; Lazarova, T; Padros, E				Sanz, C; Marquez, M; Peralvarez, A; Elouatik, S; Sepulcre, F; Querol, E; Lazarova, T; Padros, E			Contribution of extracellular Glu residues to the structure and function of bacteriorhodopsin - Presence of specific cation-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-BLUE TRANSITION; ELECTRON-SPIN RESONANCE; PURPLE MEMBRANE; PROTON-RELEASE; ANGSTROM RESOLUTION; THERMAL-DENATURATION; ABSORPTION-SPECTRUM; PHASE-TRANSITIONS; ACID PH; PROTEIN	Single and multiple mutants of extracellular Glu side chains of bacteriorhodopsin were analyzed by acid and calcium titration, differential scanning calorimetry, and thermal difference spectrophotometry. Acid titration spectra show that the second group protonating with Asps' is revealed in E204Q in the absence of Cl- but is not observed in the triple mutant E9Q/E194Q/E204Q or in the quadruple mutant E9Q/E74Q/E194Q/E204Q. The results point to Glue as the second group protonating cooperatively with Asp(85). Comparison of the apparent pK(u) of Asp(85) protonation in water and in the deionized forms and results of calcium titration suggest that cation-binding sites are of low affinity in the multiple Glu mutants. Like for deionized wild type bacteriorhodopsin, differential scanning calorimetry reveals a lack of the pretransition in the multiple mutants, whereas in E9Q it appears at lower temperature and with lower cooperativity. Additionally, at neutral pH the band at 630 nm arising from cation release upon temperature increase is absent for the multiple mutants. Based on these results, we propose the presence of two cation-binding sites in the extracellular region of bacteriorhodopsin having as ligands Glu(9), Glu(194), Glu(204), and water molecules.	Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain; Univ Politecn Catalunya, Escola Univ Engn Tecn Ind, Dept Engn Quim, Barcelona 08036, Spain; Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain	Autonomous University of Barcelona; University of Barcelona; Universitat Politecnica de Catalunya; Autonomous University of Barcelona	Padros, E (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain.		Peralvarez-Marin, Alex/AAH-4305-2020; sanz, carolina/D-7868-2016; Peralvarez-Marin, Alex/A-8958-2017	Peralvarez-Marin, Alex/0000-0002-3457-0875; Sepulcre, Francesc/0000-0002-1425-8323				ARIKI M, 1986, J BIOL CHEM, V261, P8167; Azuaga AI, 1996, BIOCHEMISTRY-US, V35, P16328, DOI 10.1021/bi961845j; Balashov SP, 2000, BBA-BIOENERGETICS, V1460, P75, DOI 10.1016/S0005-2728(00)00131-6; BALASHOV SP, 1995, BIOCHEMISTRY-US, V34, P8820, DOI 10.1021/bi00027a034; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Balashov SP, 1999, BIOCHEMISTRY-US, V38, P2026, DOI 10.1021/bi981926a; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bressler S, 1999, BIOCHEMISTRY-US, V38, P2018, DOI 10.1021/bi981901b; CHANG CH, 1986, BIOPHYS J, V49, P731, DOI 10.1016/S0006-3495(86)83699-2; CHANG CH, 1985, P NATL ACAD SCI USA, V82, P396, DOI 10.1073/pnas.82.2.396; CLADERA J, 1988, BIOCHIM BIOPHYS ACTA, V943, P148, DOI 10.1016/0005-2736(88)90546-9; Dencher NA, 2000, BBA-BIOENERGETICS, V1460, P192, DOI 10.1016/S0005-2728(00)00139-0; DUNACH M, 1988, J BIOL CHEM, V263, P17378; DUNACH M, 1989, BIOCHEMISTRY-US, V28, P8940, DOI 10.1021/bi00448a038; DUNACH M, 1986, BIOSCIENCE REP, V6, P961, DOI 10.1007/BF01114972; DUNACH M, 1987, BIOCHEMISTRY-US, V26, P1179, DOI 10.1021/bi00378a028; DUNACH M, 1988, J BIOL CHEM, V263, P7555; EHRENBERG B, 1983, FEBS LETT, V164, P63, DOI 10.1016/0014-5793(83)80019-2; Eliash T, 2001, BIOPHYS J, V81, P1155, DOI 10.1016/S0006-3495(01)75772-4; ENGELHARD M, 1990, EUR BIOPHYS J, V19, P11; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FISHER U, 1979, BIOPHYS J, V28, P211; Fu X, 1997, FEBS LETT, V416, P167, DOI 10.1016/S0014-5793(97)01194-0; Gat Y, 1997, BIOCHEMISTRY-US, V36, P4135, DOI 10.1021/bi962322e; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HIRAKI K, 1981, BIOCHIM BIOPHYS ACTA, V647, P18, DOI 10.1016/0005-2736(81)90291-1; JACKSON MB, 1978, BIOCHEMISTRY-US, V17, P911, DOI 10.1021/bi00598a026; JEFFREY GA, 1994, HYDROGEN BONDING BIO, P459; JONAS R, 1991, P NATL ACAD SCI USA, V88, P149, DOI 10.1073/pnas.88.1.149; KIMURA Y, 1984, PHOTOCHEM PHOTOBIOL, V40, P641, DOI 10.1111/j.1751-1097.1984.tb05353.x; Kusnetzow A, 1999, BIOPHYS J, V76, P2370, DOI 10.1016/S0006-3495(99)77394-7; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Lazarova T, 2000, BIOPHYS J, V78, P2022, DOI 10.1016/S0006-3495(00)76749-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luecke H, 2000, J MOL BIOL, V300, P1237, DOI 10.1006/jmbi.2000.3884; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; METZ G, 1992, FEBS LETT, V303, P237, DOI 10.1016/0014-5793(92)80528-O; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Pardo L, 1998, BIOPHYS J, V75, P777, DOI 10.1016/S0006-3495(98)77567-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; RIVIERE ME, 1991, ARCH BIOCHEM BIOPHYS, V284, P1, DOI 10.1016/0003-9861(91)90253-F; Sanz C, 1999, FEBS LETT, V456, P191, DOI 10.1016/S0014-5793(99)00950-3; Sepulcre F, 1996, BIOPHYS J, V70, P852, DOI 10.1016/S0006-3495(96)79627-3; STUART JA, 1995, BIOSPECTROSCOPY, V1, P9, DOI 10.1002/bspy.350010104; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SZUNDI I, 1987, P NATL ACAD SCI USA, V84, P3681, DOI 10.1073/pnas.84.11.3681; SZUNDI I, 1989, BIOPHYS J, V56, P369, DOI 10.1016/S0006-3495(89)82683-9; SZUNDI I, 1988, BIOPHYS J, V54, P227, DOI 10.1016/S0006-3495(88)82951-5; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P6185, DOI 10.1021/bi00524a042; TSUJI K, 1990, EUR BIOPHYS J, V18, P63, DOI 10.1007/BF00185421; Tuzi S, 1999, BIOPHYS J, V76, P1523, DOI 10.1016/S0006-3495(99)77311-X; VARO G, 1989, BIOPHYS J, V56, P1143, DOI 10.1016/S0006-3495(89)82761-4; Varo G, 1999, BIOPHYS J, V76, P3219, DOI 10.1016/S0006-3495(99)77473-4; Wang JP, 1999, BIOPHYS J, V76, P2777, DOI 10.1016/S0006-3495(99)77431-X; ZHANG YN, 1992, BIOPHYS J, V61, P1201, DOI 10.1016/S0006-3495(92)81929-X; Zscherp C, 1999, P NATL ACAD SCI USA, V96, P5498, DOI 10.1073/pnas.96.10.5498	60	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40788	40794		10.1074/jbc.M104836200	http://dx.doi.org/10.1074/jbc.M104836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524418	hybrid			2022-12-25	WOS:000171925600056
J	Hamma-Kourbali, Y; Vassy, R; Starzec, A; Le Meuth-Metzinger, V; Oudar, O; Bagheri-Yarmand, R; Perret, G; Crepin, M				Hamma-Kourbali, Y; Vassy, R; Starzec, A; Le Meuth-Metzinger, V; Oudar, O; Bagheri-Yarmand, R; Perret, G; Crepin, M			Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165)center dot KDR complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSES TUMOR-GROWTH; SIGNAL-TRANSDUCTION; BREAST-CARCINOMA; PERMEABILITY FACTOR; DERIVATIVE CMDB7; RECEPTOR-BINDING; TYROSINE KINASE; ANGIOGENESIS; KDR; CELLS	We have previously shown that carboxymethyl dextran benzylamide (CMDB7), a heparin-like molecule, inhibits the growth of tumors xenografted in nude mice, angiogenesis, and metastasis by altering the binding of angiogenic growth factors, including platelet-derived growth factor, transforming growth factor beta, and fibroblast growth factor 2, to their specific receptors. In this study, we explore the effect of CMDB7 on the most specific angiogenic growth factor, vascular endothelial growth factor 165 (VEGF(165)). We demonstrate here that CMDB7 inhibits the mitogenic effect of VEGF(165) on human umbilical vein endothelial cells (HUV-ECs) by preventing the VEGF(165)-induced VEGF receptor-2 (KDR) autophosphorylation and consequently a specific intracellular signaling. In competition experiments, the binding of I-125-VEGF(165) to HUV-ECs is inhibited by CMDB7 with an IC50 of 2 muM. Accordingly, CMDB7 inhibits the cross-linking of I-125-VEGF(165), to the surface of HUV-ECs, causing the disappearance of both labeled complexes, 170-180 and 240-250 kDa. We show that CMDB7 increases the electrophoretic mobility of VEGF165, thus evidencing formation of a stable complex with this factor. Moreover, CMDB7 reduces the I-125-VEGF(165) binding to coated heparin-albumin and prevents a heparin-induced increase in iodinated VEGF(165) binding to soluble I-125-KDR-Fc chimera. Concerning KDR, CMDB7 has no effect on I-125-KDR-Fc electrophoretic migration and does not affect labeled KDR-Fc binding to coated heparin-albumin. In the presence of VEGF(165), I-125-KDR-Fc binding to heparin is enhanced, and under these conditions, CMDB7 interferes with KDR binding. These data indicate that CMDB7 effectively inhibits the VEGF(165) activities by interfering with heparin binding to VEGF(165) and VEG(165).KDR complexes but not by direct interactions with KDR.	Univ Paris 13, Fac Med Bobigny, Lab Ciblage Fonctionnel Tumeurs Solies, UPRES 2360, F-93017 Bobigny, France; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hamma-Kourbali, Y (corresponding author), Univ Paris 13, Fac Med Bobigny, Lab Ciblage Fonctionnel Tumeurs Solies, UPRES 2360, F-93017 Bobigny, France.		Hamma-Kourbali, Yamina/R-3692-2018; PERRET, gerard/A-7379-2008; Meuth, Valérie Metzinger-Le/H-6338-2016	Hamma-Kourbali, Yamina/0000-0002-2754-8928; PERRET, gerard/0000-0003-0645-3337; Meuth, Valérie Metzinger-Le/0000-0003-1718-5083; Bagheri-Yarmand, Rozita/0000-0001-5139-6381; Oudar, Olivier/0000-0001-5855-9075				Bagheri-Yarmand R, 1998, CELL GROWTH DIFFER, V9, P497; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Bagheri-Yarmand R, 1998, BRIT J CANCER, V78, P111, DOI 10.1038/bjc.1998.451; BagheriYarmand R, 1997, BIOCHEM BIOPH RES CO, V239, P424, DOI 10.1006/bbrc.1997.7483; Bittoun P, 1999, BIOCHEM PHARMACOL, V57, P1399, DOI 10.1016/S0006-2952(99)00051-9; Chaubet F, 1995, CARBOHYD POLYM, V28, P145, DOI 10.1016/0144-8617(95)00084-4; CHIANG MK, 1995, GROWTH FACTORS, V12, P1, DOI 10.3109/08977199509003208; CREPON B, 1987, BIOMATERIALS, V8, P248, DOI 10.1016/0142-9612(87)90111-6; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FURMANHARAN E, 1994, CANCER RES, V54, P5511; Gasparini G, 1996, CLIN CANCER RES, V2, P1191; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Li SR, 2001, INT J CANCER, V91, P789, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1126>3.3.CO;2-B; MAUZAC M, 1985, BIOMATERIALS, V6, P61, DOI 10.1016/0142-9612(85)90040-7; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; RISEAU W, 1997, NATURE, V386, P671; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	47	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39748	39754		10.1074/jbc.M101117200	http://dx.doi.org/10.1074/jbc.M101117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514538	hybrid			2022-12-25	WOS:000171789200033
J	Tabares, L; Ales, E; Lindau, M; de Toledo, GA				Tabares, L; Ales, E; Lindau, M; de Toledo, GA			Exocytosis of catecholamine (CA)-containing and CA-free granules in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE CYCLE; TORPEDO ELECTRIC ORGAN; FUSION PORE; CAPACITANCE MEASUREMENTS; NEUROMUSCULAR-JUNCTION; CHOLINERGIC SYNAPSES; TRANSMITTER RELEASE; SECRETORY PRODUCTS; ENDOCRINE-CELLS; MAST-CELLS	Recent evidence suggests that endocytosis in neuroendocrine cells and neurons can be tightly coupled to exocytosis, allowing rapid retrieval from the plasma membrane of fused vesicles for future use. This can be a much faster mechanism for membrane recycling than classical clathrin-mediated endocytosis. During a fast exo-endocytotic cycle, the vesicle membrane does not fully collapse into the plasma membrane; nevertheless, it releases the vesicular contents through the fusion pore. Once the vesicle is depleted of transmitter, its membrane is recovered without renouncing its identity. In this report, we show that chromaffin cells contain catecholamine-free granules that retain their ability to fuse with the plasma membrane. These catecholamine-free granules represent 7% of the total population of fused vesicles, but they contributed to 47% of the fusion events when the cells were treated with reserpine for several hours. We propose that rat chromaffin granules that transiently fuse with the plasma membrane preserve their exocytotic machinery, allowing another round of exocytosis.	Univ Seville, Sch Med, Dept Physiol & Biophys, Seville 41009, Spain; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	University of Sevilla; Cornell University	de Toledo, GA (corresponding author), Univ Seville, Sch Med, Dept Physiol & Biophys, Avenida Sanchez Pizjuan 4, Seville 41009, Spain.		Lindau, Manfred/ABD-3449-2021; Alvarez de Toledo, Guillermo/I-2888-2015; Ales, Eva/E-6315-2010; Tabares, Lucia/K-8768-2015	Lindau, Manfred/0000-0002-5722-9557; Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Ales, Eva/0000-0002-5536-4616; Tabares, Lucia/0000-0002-4027-4044				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; Betz WJ, 1998, ANNU REV PHYSIOL, V60, P347, DOI 10.1146/annurev.physiol.60.1.347; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; Chow Robert H., 1995, P245; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DETOLEDO GA, 1988, J GEN PHYSL S, V43, P333; DIXON WR, 1975, J PHYSIOL-LONDON, V244, P805, DOI 10.1113/jphysiol.1975.sp010827; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; Henkel AW, 2000, EMBO J, V19, P84, DOI 10.1093/emboj/19.1.84; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILLE B, 1992, IONIC CHANNELS EXCIT, P296; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; SEARL T, 1991, J PHYSIOL-LONDON, V444, P99, DOI 10.1113/jphysiol.1991.sp018868; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; VANDERKLOOT W, 1994, PHYSIOL REV, V74, P899, DOI 10.1152/physrev.1994.74.4.899; Williams J, 1997, NEURON, V18, P683, DOI 10.1016/S0896-6273(00)80308-6; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; ZIMMERMANN H, 1977, NEUROSCIENCE, V2, P715, DOI 10.1016/0306-4522(77)90025-2; ZIMMERMANN H, 1977, NEUROSCIENCE, V2, P695, DOI 10.1016/0306-4522(77)90024-0	41	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39974	39979		10.1074/jbc.M106498200	http://dx.doi.org/10.1074/jbc.M106498200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11524425	hybrid, Green Published			2022-12-25	WOS:000171789200064
J	Tuveson, DA; Willis, NA; Jacks, T; Griffin, JD; Singer, S; Fletcher, CDM; Fletcher, JA; Demetri, GD				Tuveson, DA; Willis, NA; Jacks, T; Griffin, JD; Singer, S; Fletcher, CDM; Fletcher, JA; Demetri, GD			STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications	ONCOGENE			English	Article						Gastrointestional Stromal Tumors (GIST); c-KIT; STI571	TYROSINE KINASE INHIBITOR; CELL-LINE; BCR-ABL; B-CELLS; MUTATIONS; GROWTH; PATHOGENESIS; EXPRESSION; PROGNOSIS; STI-571	Mutations in the c-KIT receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors (GIST), and similar mutations have been identified at the germline level in kindreds with multiple GISTs. These mutations activate the tyrosine kinase activity of e-KIT and induce constitutive signaling. To investigate the function of activated c-KIT in GIST, we established a human GIST cell line, GIST882, which expresses an activating KIT mutation (K642E) in the first part of the cytoplasmic split tyrosine kinase domain. Notably, the K642E substitution is encoded by a homozygous exon 13 missense mutation, and, therefore, GIST882 cells do not express native KIT. GIST882 c-KIT protein is constitutively tyrosine phosphorylated, but tyrosine phosphorylation was rapidly and completely abolished after incubating the cells with the selective tyrosine kinase inhibitor STI571. Furthermore, GIST882 cells evidenced decreased proliferation and the onset of apoptotic cell death after prolonged incubation with STI571. Similar results were obtained after administering STI571 to a primary GIST cell culture that expressed a c-KIT exon I I juxtamembrane mutation (K558NP). These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor.	MIT, Ctr Canc, Cambridge, MA 02139 USA; Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Tuveson, DA (corresponding author), MIT, Ctr Canc, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Singer, Samuel/0000-0001-9713-8230				Badache A, 1998, ONCOGENE, V17, P795, DOI 10.1038/sj.onc.1201978; Buchdunger E, 1996, CANCER RES, V56, P100; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chan JKC, 1999, ADV ANAT PATHOL, V6, P19, DOI 10.1097/00125480-199901000-00003; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p368A; EDMONSON J, 1999, P AN M AM SOC CLIN, V18, pA541; Ernst SI, 1998, LAB INVEST, V78, P1633; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lasota J, 2000, AM J PATHOL, V157, P1091, DOI 10.1016/S0002-9440(10)64623-8; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Miettinen M, 1999, HUM PATHOL, V30, P1213, DOI 10.1016/S0046-8177(99)90040-0; Moskaluk CA, 1999, ONCOGENE, V18, P1897, DOI 10.1038/sj.onc.1202496; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Nishida T, 2000, HISTOL HISTOPATHOL, V15, P1293, DOI 10.14670/HH-15.1293; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REYNOLDS JE, 1992, HUM GENET, V90, P450; Rubin BP, 2000, INT J SURG PATHOL, V8, P5, DOI 10.1177/106689690000800105; Sarlomo-Rikala M, 1998, MODERN PATHOL, V11, P728; SOMMERHAUSEN NDA, 1998, SARCOMA, V2, P133; Taniguchi M, 1999, CANCER RES, V59, P4297; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UEYAMA T, 1992, CANCER, V69, P947, DOI 10.1002/1097-0142(19920215)69:4<947::AID-CNCR2820690419>3.0.CO;2-X; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698	30	545	584	0	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5054	5058		10.1038/sj.onc.1204704	http://dx.doi.org/10.1038/sj.onc.1204704			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526490				2022-12-25	WOS:000170439800015
J	Wenzel, S; Taimor, G; Piper, HM; Schlueter, KD				Wenzel, S; Taimor, G; Piper, HM; Schlueter, KD			Redox-sensitve intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes	FASEB JOURNAL			English	Article						angiotensin II type I receptor; NAD(P)H oxidase; phox22	SMOOTH-MUSCLE CELLS; CARDIAC-HYPERTROPHY; RECEPTOR ANTAGONIST; HYPERTENSIVE RATS; GENE-EXPRESSION; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; NAD(P)H OXIDASE; PROTEIN-KINASE; IN-VITRO	Cardiac hypertrophy as an adaptation to increased blood pressure leads to an increase in ventricular expression of tranforming growth factor beta (TGF-beta), probably via the renin-angiotensin system. We studied in vivo to determine whether angiotensin II affects TGF-beta expression independent from mechanical effects caused by the concomitant increase in blood pressure and in vitro intracellular signaling involved in angiotensin II-dependent TGF-beta induction. In vivo, the AT(1) receptor antagonist losartan, but not reduction of blood pressure by hydralazine, inhibited the increase in TGF-beta (1) expression caused by angiotensin II. In vitro, angiotensin II caused an induction of TGF-beta (1) expression in adult ventricular cardiomyocytes and induced AP-1 binding activity. Transfection with "decoys" directed against the binding site of AP-1 binding proteins inhibited the angiotensin II-dependent TGF-beta induction. Angiotensin II induced TGF-beta expression in a p38-MAP kinase-dependent way. p38-MAP kinase activation was diminished in presence of the antioxidants or diphenyleneiodium chloride, or by pretreatment with antisense nucleotides directed against phox22 and nox, components of smooth muscle type NAD( P) H oxidase. Thus, our study identifies a previously unrecognized coupling of cardiac AT receptors to a NAD( P) H oxidase complex similar to that expressed in smooth muscle cells and identifies p38-MAP kinase activation as an important downstream target.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Schlueter, KD (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Klaus-Dieter.Schlueter@physiologie.med.uni-giessen.de						Baines CP, 1999, J CARDIOVASC ELECTR, V10, P741, DOI 10.1111/j.1540-8167.1999.tb00251.x; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND T, 1995, J MOL CELL CARDIOL, V27, P5, DOI 10.1016/S0022-2828(08)80003-X; Ehmke H, 1999, HYPERTENSION, V33, P954, DOI 10.1161/01.HYP.33.4.954; Goldberg Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1207, DOI 10.1152/ajpcell.1998.275.5.C1207; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; IZUKA K, 1994, J MOL CELL CARDIOL, V26, P435; Kim S, 1996, BRIT J PHARMACOL, V118, P549, DOI 10.1111/j.1476-5381.1996.tb15437.x; KIM SK, 1995, J PHARMACOL EXP THER, V273, P509; Kimura M, 1999, EUR J PHARMACOL, V386, P271, DOI 10.1016/S0014-2999(99)00739-6; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; LEE YA, 1993, EUR HEART J, V14, P42; MAZZAB KM, 1997, CIRCULATION, V96, P614; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morishita R, 1998, BIOCHEM BIOPH RES CO, V243, P361, DOI 10.1006/bbrc.1997.8012; Nishikawa K, 1998, J HUM HYPERTENS, V12, P301, DOI 10.1038/sj.jhh.1000634; NOGAMI M, 1994, AM J PHYSIOL, V266, pL187, DOI 10.1152/ajplung.1994.266.2.L187; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; Piper HM, 1990, CELL CULTURE TECHNIQ, P158; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schluter KD, 2000, CARDIOVASC RES, V45, P410, DOI 10.1016/S0008-6363(99)00351-X; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; SCHLUTER KD, 1995, AM J PHYSIOL-CELL PH, V269, pC1311, DOI 10.1152/ajpcell.1995.269.5.C1311; SCHLUTER KD, 1995, BIOCHEM J, V310, P439, DOI 10.1042/bj3100439; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Taimor G, 1999, J MOL CELL CARDIOL, V31, P2127, DOI 10.1006/jmcc.1999.1055; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wada H, 1996, AM J PHYSIOL-HEART C, V271, pH29, DOI 10.1152/ajpheart.1996.271.1.H29; Xi XP, 1999, ARTERIOSCL THROM VAS, V19, P73, DOI 10.1161/01.ATV.19.1.73; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Yamazaki T, 1999, AM J CARDIOL, V83, p53H; Zimmermann R, 1999, J MOL CELL CARDIOL, V31, P1447, DOI 10.1006/jmcc.1999.0976	40	116	124	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2291	+		10.1096/fj.00-0827fje	http://dx.doi.org/10.1096/fj.00-0827fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511516				2022-12-25	WOS:000170809900019
J	Casado, M; Callejas, NA; Rodrigo, J; Zhao, XM; Dey, SK; Bosca, L; Martin-Sanz, P				Casado, M; Callejas, NA; Rodrigo, J; Zhao, XM; Dey, SK; Bosca, L; Martin-Sanz, P			Contribution of cyclooxygenase-2 to liver regeneration after partial hepatectomy	FASEB JOURNAL			English	Article						prostaglandins; hepatocyte; inflammation	CCAAT/ENHANCER-BINDING-PROTEIN; NITRIC-OXIDE SYNTHASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; C/EBP-ALPHA; GENE-EXPRESSION; HEPATOCYTE PROLIFERATION; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; MESSENGER-RNA; KAPPA-B	Partial hepatectomy (PH) triggers a rapid regenerative response in the remaining tissue to reinstate the organ function and the cell numbers. Among the molecules that change in the course of regeneration is an accumulation of prostaglandin E-2 in the sera of rats with PH. Analysis of the cyclooxygenase (COX) isoenzymes in the remnant liver showed the preferential expression of COX-2 in hepatocytes. Cultured regenerating hepatocytes expressed significant levels of COX-2, a process that was not observed in the sham counterparts. Maximal expression of COX-2 was detected 16 h after PH with increased levels present even at 96 h. Pharmacological inhibition of COX-2 activity with NS398 shunted the up-regulation of cell proliferation after PH, which suggests a positive interaction of prostaglandins with the progression of the cell cycle. Similar results were obtained after PH of mice lacking the COX-2 gene. The expression of COX-2 in regenerating liver was concomitant with a decrease in CCAAT-enhancer binding protein (C/EBP-alpha) level and an increase in the expression of C/EBP-beta and C/EBP-delta. These results suggest a contribution of the enhanced synthesis of prostaglandins to liver regeneration observed after PH.	Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto CSIC, E-28040 Madrid, Spain; CSIC, Inst Biomed, E-46010 Valencia, Spain; CSIC, Inst Neurobiol Santiago Ramon & Cajal, Madrid 28071, Spain; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC); University of Kansas; University of Kansas Medical Center	Martin-Sanz, P (corresponding author), Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto CSIC, E-28040 Madrid, Spain.	pmartin@eucmos.sim.ucm.es	Casado, Marta/L-2078-2014; Bosca, Lisardo/A-2059-2008; Martín-Sanz, Paloma/K-1303-2014	Casado, Marta/0000-0001-6457-4650; Bosca, Lisardo/0000-0002-0253-5469; 				An MR, 1996, MOL CELL BIOL, V16, P2295; Callejas NA, 2000, GASTROENTEROLOGY, V119, P493, DOI 10.1053/gast.2000.9374; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DiazGuerra MJM, 1997, BIOCHEM J, V326, P791, DOI 10.1042/bj3260791; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FENG J, 1995, NEURAL PROCESS LETT, V2, P1; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERSCHMAN HR, 1995, ADV PROSTAG THROMB L, V23, P23; HORTELANO S, 1995, HEPATOLOGY, V21, P776; Jun DY, 1997, MOL CELLS, V7, P537; Kinugawa K, 1997, CIRC RES, V81, P911; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kramer A, 1996, J BIOL CHEM, V271, P6579; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; LEE JH, 1995, FEBS LETT, V368, P348, DOI 10.1016/0014-5793(95)00703-C; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Martin-Sanz P, 1998, BRIT J PHARMACOL, V125, P1313, DOI 10.1038/sj.bjp.0702196; MARTINSANZ P, 1989, BIOCHEM J, V257, P795, DOI 10.1042/bj2570795; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nanji AA, 1997, GASTROENTEROLOGY, V112, P943, DOI 10.1053/gast.1997.v112.pm9041257; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RODRIGO J, 1994, PHILOS T R SOC B, V345, P175, DOI 10.1098/rstb.1994.0096; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SIROIS J, 1993, J BIOL CHEM, V268, P12199; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Watkins PJ, 1996, CANCER RES, V56, P1063; Williams CS, 1996, AM J PHYSIOL, V270, P393; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135	50	87	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2016	+		10.1096/fj.01-0158fje	http://dx.doi.org/10.1096/fj.01-0158fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511527				2022-12-25	WOS:000170318500019
J	Guignandon, A; Lafage-Proust, MH; Usson, Y; Laroche, N; Caillot-Augusseau, A; Alexandre, C; Vico, L				Guignandon, A; Lafage-Proust, MH; Usson, Y; Laroche, N; Caillot-Augusseau, A; Alexandre, C; Vico, L			Cell cycling determines integrin-mediated adhesion in osteoblastic ROS 17/2.8 cells exposed to space-related conditions	FASEB JOURNAL			English	Article						microgravity; weightlessness; adhesion; cell cycle; osteoblasts; confocal microscopy; TIRFM; image analysis	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; HUMAN-LEUKOCYTES; MESSENGER-RNA; MICROGRAVITY; CYTOSKELETON; MATRIX; RHO; SPACEFLIGHT; ACTIVATION	Six days of microgravity (Bion10 mission) induced dramatic shape changes in ROS 17/2.8 osteoblasts (7). During the Foton 11 and 12 space flights, we studied the kinetics (0-4 days) of ROS 17/2.8 morphology and adhesion, the relationships between adhesion and cell cycle progression after 4 days in space, and osteoblastic growth and activity after 6 days in space. Quantitative analysis of high-resolution adhesion [focal adhesion area imaged by total interference reflection fluorescent microscopy (TIRFM)] and integrin-dependent adhesion (imaged on confocal microscope by vinculin and phosphotyrosine staining) as well as cell cycle phase classification [Ki-67 staining, S-G2, mitotic cells and G1 (postmitotic cells)] were performed using programs validated in parabolic flight and clinostat. We observed disorganization of the cytoskeleton associated with disassembling of vinculin spots and phosphorylated proteins within focal contacts with no major change in TIRFM adhesion after 2 and 4 days of microgravity. Postmitotic cells, alone, accounted for the differences observed in the whole population. They are characterized by immature peripheral contacts with complete loss of central spots and decreased spreading. Osteocalcin, P1CP and alkaline phosphatase, and proliferation were similar in flight cells and 1 g centrifuge and ground controls after 6 days. In conclusion, microgravity substantially affected osteoblastic integrin-mediated cell adhesion. ROS17/2.8 cells responded differently, whether or not they were cycling by reorganizing adhesion plaque topography or morphology. In ROS 17/2.8, this reorganization did not impair osteoblastic phenotype.	Univ St Etienne, LBBTO, INSERM, Equipe Mixte E9901, F-42023 St Etienne Du Rouvray 2, France; Univ Grenoble 1, Inst Albert Bonniot, Lab TIMC UMR 5512, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Guignandon, A (corresponding author), Univ St Etienne, LBBTO, INSERM, Equipe Mixte E9901, 15 Rue Ambroise Pare, F-42023 St Etienne Du Rouvray 2, France.	guignand@univ-st-etienne.fr	USSON, Yves/B-2002-2014; Vico, Laurence/ABG-7239-2020; Vico, Laurence/O-1927-2018	USSON, Yves/0000-0003-0242-191X; Vico, Laurence/0000-0002-2110-287X; Vico, Laurence/0000-0002-2110-287X; GUIGNANDON, Alain/0000-0002-0745-5417; Lafage-Proust, Marie-Helene/0000-0002-2091-3961				Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; Carmeliet G, 1998, BONE, V22, p139S, DOI 10.1016/S8756-3282(98)00007-6; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CLARK E, 1998, J CELL BIOL, V18, P3936; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; DUMANOIR S, 1991, CYTOMETRY, V12, P455; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Guignandon A, 1997, BONE, V20, P109, DOI 10.1016/S8756-3282(96)00337-7; GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369; Guignandon A, 1997, EXP CELL RES, V236, P66, DOI 10.1006/excr.1997.3703; Guillaud P, 1989, Anal Cell Pathol, V1, P25; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; Harris SA, 2000, BONE, V26, P325, DOI 10.1016/S8756-3282(00)00234-9; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hughes-Fulford M, 1999, FASEB J, V13, pS121; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Ingber D, 1999, FASEB J, V13, pS3; Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168-1656(96)01412-5; Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Lim YB, 2000, BIOCHEM BIOPH RES CO, V273, P609, DOI 10.1006/bbrc.2000.2987; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; LOWRY OH, 1957, METHOD ENZYMOL, V4, P366, DOI 10.1016/0076-6879(57)04065-3; MAHLER P, 2000, EXP CELL RES, V260, P189; MAINLY B, 1986, MULTIVARIATE STAT AN, P86; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOSHKOV DA, 1991, TSITOLOGIYA+, V33, P16; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rijken P J, 1994, Adv Space Biol Med, V4, P159; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Usson Y, 1997, CYTOMETRY, V28, P298, DOI 10.1002/(SICI)1097-0320(19970801)28:4<298::AID-CYTO4>3.0.CO;2-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Whelan RDH, 1999, CELL GROWTH DIFFER, V10, P271; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; XIANGDONG R, 2000, J CELL SCI, V113, P3673; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	47	44	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2036	+		10.1096/fj.00-0837fje	http://dx.doi.org/10.1096/fj.00-0837fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511518				2022-12-25	WOS:000170318500013
J	Forwood, JK; Harley, V; Jans, DA				Forwood, JK; Harley, V; Jans, DA			The C-terminal nuclear localization signal of the sex determining region Y (SRY) high mobility group domain mediates nuclear import through beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; RNA-BINDING-PROTEIN; T-ANTIGEN NLS; DNA-BINDING; HMG-BOX; ENHANCES RECOGNITION; RIBOSOMAL-PROTEINS; TRANSPORT FACTORS; MOLECULAR-BASIS; HIGH-AFFINITY	The sex-determining factor SRY is a DNA-binding protein that diverts primordial gonads from the ovarian pathway toward male differentiation to form testes. It gains access to the nucleus through two distinct nuclear localization signals (NLSs) that flank the high mobility group (HMG) DNA-binding domain, but the mechanisms through which these NLSs operate have not been studied. In this study, we reconstitute the nuclear import of SRY in vitro, demonstrating a lack of requirement for exogenous factors for nuclear accumulation and a significant reduction in nuclear transport in the presence of antibodies to importin beta but not importin alpha. Using a range of quantitative binding assays including enzyme-linked immunosorbent assay, fluorescence polarization, and native gel mobility electrophoresis, we assess the binding of importins to SRY, demonstrating a high affinity recognition (in the low nm range) by Imp beta independent of Imp alpha. In assessing the contribution of each NLS, we found that the N-terminal NLS was recognized poorly by importins, whereas the C-terminal NLS was bound by importin beta with similar affinity to SRY. We also found that RanGTP, but not RanGDP, could dissociate the SRY-importin beta complex in solution using FP. We describe a novel double-fluorescent label DNA binding assay to demonstrate mutual exclusivity between importin beta recognition and DNA binding on the part of SRY, which may represent an alternative release mechanism upon nuclear entry. This study represents the first characterization of the nuclear import pathway for a HMG domain-containing protein. Importantly, it demonstrates for the first time that recognition of SRY by Imp beta is of comparable affinity to that with which Imp alpha/beta recognizes conventional NLS-containing substrates.	Australian Natl Univ, Nucl Signaling Lab, Div Biochem & Mol Biol, John Curtin Sch Med Res, Canberra, ACT 0200, Australia; Prince Henry Hosp, Monash Med Ctr, Clayton, Vic 3168, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3152, Australia	Australian National University; John Curtin School of Medical Research; Monash University; Monash University	Jans, DA (corresponding author), Australian Natl Univ, Nucl Signaling Lab, Div Biochem & Mol Biol, John Curtin Sch Med Res, POB 334, Canberra, ACT 0200, Australia.		Harley, Vincent/B-8092-2018; Forwood, Jade K/K-4123-2014	Harley, Vincent/0000-0002-2405-1262; Forwood, Jade K/0000-0003-3267-9997; Jans, David/0000-0001-5115-4745				Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Dasso M, 1998, AM J HUM GENET, V63, P311, DOI 10.1086/301990; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GUSTAFSON ML, 1994, ANNU REV MED, V45, P505, DOI 10.1146/annurev.med.45.1.505; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Imamoto N, 1998, EUR J HISTOCHEM, V42, P9; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1998, RNA, V4, P351; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lixin R, 2001, BIOCHEM BIOPH RES CO, V284, P185, DOI 10.1006/bbrc.2001.4953; MCELREAVEY K, 1993, EUR J BIOCHEM, V218, P769, DOI 10.1111/j.1432-1033.1993.tb18432.x; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rosenblum JS, 1997, J CELL BIOL, V139, P1655, DOI 10.1083/jcb.139.7.1655; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Truant R, 1999, MOL CELL BIOL, V19, P1210; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WEBER G, 1953, ADV PROTEIN CHEM, V8, P415, DOI 10.1016/S0065-3233(08)60096-0; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WERNER MH, 1995, BIOCHEMISTRY-US, V34, P11998, DOI 10.1021/bi00037a042; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	62	94	102	5	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46575	46582		10.1074/jbc.M101668200	http://dx.doi.org/10.1074/jbc.M101668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11535586	hybrid			2022-12-25	WOS:000172573100144
J	Sung, YH; Hong, HD; Cheong, C; Kim, JH; Cho, JM; Kim, YR; Lee, W				Sung, YH; Hong, HD; Cheong, C; Kim, JH; Cho, JM; Kim, YR; Lee, W			Folding and stability of sweet protein single-chain monellin - An insight to protein engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKBONE DYNAMICS; HETERONUCLEAR NMR; SPIN RELAXATION; N-15 NMR; SPECTROSCOPY; SENSITIVITY; ANISOTROPY; STATE; MODEL	Engineered single-chain monellin (SCM) proteins were constructed by recombinant technology without disrupting the topology and sweet activity of native protein. Data from 8-anilinonaphthalene-1-sulfonic acid fluorescence, size-exclusion chromatography, and heteronuclear NMR strongly suggest the presence of a folding intermediate at 1.5 m GdnHCl for SCM protein. The structural feature of the folding intermediate from NMR data reveals that the secondary structures became mostly unstable, and protein experiences a dynamic equilibrium between native and unfolded state. All backbone amide protons exchange within 10 min, which imply that no stable hydrogen bonds exist in the secondary structural regions in the folding intermediate. From equilibrium unfolding and mutagenesis studies, the unfolding transition midpoints of mutant proteins gradually shifted toward lower denaturant concentration, indicating stability reductions of mutant proteins. Our results suggest that stability and folding pathways of SCM proteins could be regulated by a combined study of spectroscopy and mutagenesis, and these studies will provide useful information for understanding the folding kinetics of novel engineered proteins.	Yonsei Univ, Dept Biochem, Coll Sci, Seodaemoon Gu, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Coll Sci, Dept Chem, Seoul 120749, South Korea; Korea Basic Sci Inst, Magnet Resonance Grp, Taejon 305333, South Korea; LG Chem, Biotech Res Inst, Taejon 305380, South Korea	Yonsei University; Yonsei University; Korea Basic Science Institute (KBSI); LG Chem	Lee, W (corresponding author), Yonsei Univ, Dept Biochem, Coll Sci, Seodaemoon Gu, Seoul 120749, South Korea.		LEE, WEON TAE/AAQ-9088-2021; Hong, Heedeok/E-9231-2018	Hong, Heedeok/0000-0003-0118-5193				AGASHE VR, 1995, BIOCHEMISTRY-US, V34, P3286, DOI 10.1021/bi00010a019; Ali V, 1999, BIOCHEMISTRY-US, V38, P13635, DOI 10.1021/bi9907835; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROUWER JN, 1973, ACTA PHYSIOL SCAND, V89, P550, DOI 10.1111/j.1748-1716.1973.tb05549.x; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; DOBSON CM, 1995, NAT STRUCT BIOL, V2, P523; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HOPP TP, 1982, P NATL ACAD SCI USA, V79, P579; HOUGH CAM, 1978, NATURE, V271, P381, DOI 10.1038/271381a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIM SH, 1989, PROTEIN ENG, V2, P571, DOI 10.1093/protein/2.8.571; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; Lee SY, 1999, BIOCHEMISTRY-US, V38, P2340, DOI 10.1021/bi9822731; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MORRIS JA, 1972, BIOCHIM BIOPHYS ACTA, V261, P114, DOI 10.1016/0304-4165(72)90320-0; MURZIN AG, 1993, J MOL BIOL, V230, P689, DOI 10.1006/jmbi.1993.1186; OGATA C, 1987, NATURE, V328, P739, DOI 10.1038/328739a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PTITSYN OB, 1981, FEBS LETT, V131, P197, DOI 10.1016/0014-5793(81)80367-5; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Shakhnovich E, 1998, CURR OPIN STRUC BIOL, V8, P65, DOI 10.1016/S0959-440X(98)80011-0; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Sung YH, 2001, J BIOL CHEM, V276, P19624, DOI 10.1074/jbc.M100930200; VANDERWEL H, 1976, BIOCH SENSORY FUNCT, V197, P235	34	14	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44229	44238		10.1074/jbc.M104239200	http://dx.doi.org/10.1074/jbc.M104239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11517219	hybrid			2022-12-25	WOS:000172297700095
J	Arora, M; Munoz, E; Tenner, AJ				Arora, M; Munoz, E; Tenner, AJ			Identification of a site on mannan-binding lectin critical for enhancement of phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C1Q RECEPTOR; MOLECULAR CHARACTERIZATION; BACTERICIDAL FACTOR; COMPLEMENT; PROTEIN; ACTIVATION; EXPRESSION; DEFENSE; C1QR(P); CELLS	Mannan-binding lectin (MBL) constitutes an important part of the human innate immune defense system. It has been shown to mediate the activation of complement upon binding to specific microbial carbohydrate motifs, to directly opsonize organisms, and to enhance the phagocytosis of targets suboptimally opsonized with IgG or complement components C3b or C4b. This enhancement of phagocytic activity induced by MBL and other molecules that contain a collagen-like region contiguous with a pattern recognition domain is mediated by a 126,000 M-r surface glycoprotein, designated C1qRp. Although it has been known that the collagen-like domain of these "defense collagens" contains the interaction site(s) that triggers this enhancement of uptake, the specific interaction site has not been identified. To address this issue, wild type and mutant MBL constructs were generated, inserted into baculovirus, expressed in Sf9 cells, and the recombinant MBL (rMBL) proteins purified by mannan affinity chromatography. The effect of wild type and mutant rMBL on the phagocytosis of targets suboptimally opsonized with IgG or with IgM and C4b by human peripheral blood monocytes. was then assessed. Two mutants, one of which has five GXY triplets deleted below the kin region of MBL and the other one having only two of the GXY triplets deleted below the kink, failed to enhance phagocytosis, suggesting the importance of the specific sequence GEKGEP in stimulating phagocytic activity. Similar sequences were detected in other defense collagens, implicating the consensus motif GE(K/Q/R)GEP as critical in mediating the enhancement of phagocytosis through C1qRp. Clarification of specific ligand-C1qRp interactions should facilitate the investigation of the signal transduction processes involved in the cell activation, as well as provide the basis for the design of specific modulators of the functions mediated by this receptor.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tenner, AJ (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Biol Sci II, Irvine, CA 92697 USA.	atenner@uci.edu			NCRR NIH HHS [M01 RR00827] Funding Source: Medline; NIAID NIH HHS [AI41090] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041090] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BOBAK DA, 1988, EUR J IMMUNOL, V18, P2001, DOI 10.1002/eji.1830181220; BOBAK DA, 1986, J IMMUNOL, V136, P4604; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BOHNSACK JF, 1985, J EXP MED, V161, P912, DOI 10.1084/jem.161.5.912; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Dean YD, 2000, J BIOL CHEM, V275, P34382, DOI 10.1074/jbc.M006229200; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FONSECA MI, 2001, IN PRESS J LEUKOCYTE; GUAN E, 1994, J IMMUNOL, V152, P4005; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; JI YH, 1993, J IMMUNOL, V150, P571; JI YH, 1988, J IMMUNOL, V141, P4271; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; Lionetti F. J., 1980, METHODS CELL SEPARAT, P141; Lovik G, 2000, EUR J IMMUNOL, V30, P3355, DOI 10.1002/1521-4141(2000012)30:12<3355::AID-IMMU3355>3.0.CO;2-1; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; MASUSHITA M, 1992, J EXP MED, V176, P1497; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Nepomuceno RR, 1998, J IMMUNOL, V160, P1929; Nepomuceno RR, 1999, J IMMUNOL, V162, P3583; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Ruiz S, 1995, J BIOL CHEM, V270, P30627, DOI 10.1074/jbc.270.51.30627; Ruiz S, 1999, J LEUKOCYTE BIOL, V66, P416, DOI 10.1002/jlb.66.3.416; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; TENNER A, 1989, BEHRING I MITT, V84, P220; TENNER AJ, 1980, J IMMUNOL, V125, P1658; Tenner AJ, 1998, IMMUNOBIOLOGY, V199, P250, DOI 10.1016/S0171-2985(98)80031-4; TENNER AJ, 1981, J IMMUNOL, V127, P648; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; TENNER AJ, 1995, IMMUNITY, V3, P485, DOI 10.1016/1074-7613(95)90177-9; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Webster SD, 2000, J LEUKOCYTE BIOL, V67, P109, DOI 10.1002/jlb.67.1.109; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; YOUNG KR, 1991, J IMMUNOL, V146, P3356; Zhao H, 2000, FASEB J, V14, pA689	42	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43087	43094		10.1074/jbc.M105455200	http://dx.doi.org/10.1074/jbc.M105455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11533031	hybrid			2022-12-25	WOS:000172169300061
J	Shi, JX; Boyd, AE; Radic, Z; Taylor, P				Shi, JX; Boyd, AE; Radic, Z; Taylor, P			Reversibly bound and covalently attached ligands induce conformational changes in the omega loop, Cys(69)-Cys(96), of mouse acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE GORGE; CRYSTAL-STRUCTURE; PERIPHERAL SITE; SNAKE-VENOM; FASCICULIN; BINDING; COMPLEX; SUBSTRATE; SPECIFICITY; MECHANISM	We have used a combination of cysteine substitution mutagenesis and site-specific labeling to characterize the structural dynamics of mouse acetylcholinesterase (mAChE). Six cysteine-substituted sites of mAChE (Leu(76), Glu(81), Glu(84), Tyr(124), Ala(262), and His(287)) were labeled with the environmentally sensitive fluorophore, acrylodan, and the kinetics of substrate hydrolysis and inhibitor association were examined along with spectroscopic characteristics of the acrylodan-conjugated, cysteine-substituted enzymes. Residue 262, being well removed from the active center, appears unaffected by inhibitor binding. Following the binding of ligand, hypsochromic shifts in emission of acrylodan at residues 124 and 287, located near the perimeter of the gorge, reflect the exclusion of solvent and a hydrophobic environment created by the associated ligand. By contrast, the bathochromic shifts upon inhibitor binding seen for acrylodan conjugated to three omega loop (Omega loop) residues 76, 81, and 84 reveal that the acrylodan side chains at these positions are displaced from a hydrophobic environment and become exposed to solvent. The magnitude of fluorescence emission shift is largest at position 84 and smallest at position 76, indicating that a concerted movement of residues on the Omega loop accompanies gorge closure upon ligand binding. Acrylodan modification of substituted cysteine at position 84 reduces ligand binding and steady-state kinetic parameters between 1 and 2 orders of magnitude, but a similar substitution at position 81 only minimally alters the kinetics. Thus, combined kinetic and spectroscopic analyses provide strong evidence that conformational changes of the Omega loop accompany ligand binding.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07752, GM18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERMAN JD, 1971, P NATL ACAD SCI USA, V68, P395, DOI 10.1073/pnas.68.2.395; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; CYGLER M, 1993, PROTEIN SCI, V2, P366; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P185; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; Lew J, 1997, J BIOL CHEM, V272, P1507, DOI 10.1074/jbc.272.3.1507; Marchot P, 1996, PROTEIN SCI, V5, P672; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; Radic Z, 2001, J BIOL CHEM, V276, P4622, DOI 10.1074/jbc.M006855200; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; Tara S, 1998, BIOPOLYMERS, V46, P465; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P93; Velan B, 1996, FEBS LETT, V395, P22, DOI 10.1016/0014-5793(96)00995-7; Wilson I. B., 1960, ENZYMES, V4, P501; Wlodek ST, 2000, BIOPOLYMERS, V53, P265, DOI 10.1002/(SICI)1097-0282(200003)53:3<265::AID-BIP6>3.3.CO;2-E; Wong L, 2000, BIOCHEMISTRY-US, V39, P5750, DOI 10.1021/bi992906r; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	46	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42196	42204		10.1074/jbc.M106896200	http://dx.doi.org/10.1074/jbc.M106896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11517229	hybrid			2022-12-25	WOS:000172450400088
J	Hu, ZZ; Meng, JP; Dufau, ML				Hu, ZZ; Meng, JP; Dufau, ML			Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE; DEGRADATION; EXPRESSION; HORMONE; PROTEIN; LIVER; PATHWAYS; MULTIPLE; BINDING	We have identified a novel exon 11 of the human prolactin receptor (hPRLR) gene that is distinct from its rodent counterparts and have demonstrated the presence of two novel short forms of the hPRLR (S1(a) and S1(b)), which are derived from alternative splicing of exons 10 and 11. S1(a) encodes 376 amino acids (aa) that contain partial exon 10 and a unique 39-aa C-terminal region encoded by exon 11. S1(b) encodes 288 as that lack the entire exon 10 and contains 3 amino acids at the C terminus derived from exon 11 using a shifted reading frame. These short forms, which were found in several normal tissues and in breast cancer cell lines, were expressed as cell surface receptors and possessed binding affinities comparable with the long form. Unlike the long form, neither short form was able to mediate the activation of the beta -casein gene promoter induced by prolactin. Instead they acted as dominant negative forms when co-expressed with the long form in transfected cells. Due to a marked difference in the cellular levels between the two short forms in transfected cells, S1(b) was more effective in inhibiting the prolactin-induced activation of the beta -casein gene promoter mediated by the long form of the receptor. The low cellular level of Sla was due to its more rapid turnover than the S1(b) protein. This is attributable to specific residues within the C-terminal unique 39 amino acids of the S1(a) form and may represent a new mechanism by which the hPRLR is modulated at the post-translational level. Since both short forms contain abbreviated cytoplasmic domains with unique C termini, they may also exhibit distinct signaling pathways in addition to modulating the signaling from the long form of the receptor. These receptors may therefore play important roles in the diversified actions of prolactin in human tissues.	NICHHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.							ALI S, 1991, J BIOL CHEM, V266, P20110; Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; BERGERON JJM, 1978, J BIOL CHEM, V253, P4058; Berlanga JJ, 1997, MOL ENDOCRINOL, V11, P1449, DOI 10.1210/me.11.10.1449; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONIFACINO J, 1984, SERONO S PUBL, V9, P141; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; Cope DL, 2000, FEBS LETT, V481, P261, DOI 10.1016/S0014-5793(00)02021-4; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HU ZZ, 1994, BBA-MOL CELL RES, V1220, P333, DOI 10.1016/0167-4889(94)90158-9; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; Hu ZZ, 1999, J CLIN ENDOCR METAB, V84, P1153, DOI 10.1210/jc.84.3.1153; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; Hu ZZ, 1998, TRENDS ENDOCRIN MET, V9, P94, DOI 10.1016/S1043-2760(98)00027-7; HU ZZ, 1999, END SOC 81 ANN M SAN; Kline JB, 1999, J BIOL CHEM, V274, P35461, DOI 10.1074/jbc.274.50.35461; KOPPELMAN MCS, 1982, ENDOCRINOLOGY, V111, P1350, DOI 10.1210/endo-111-4-1350; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Ormandy CJ, 1998, DNA CELL BIOL, V17, P761, DOI 10.1089/dna.1998.17.761; PerrotApplanat M, 1997, MOL ENDOCRINOL, V11, P1020, DOI 10.1210/me.11.8.1020; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; Supino-Rosin L, 1999, EUR J BIOCHEM, V263, P410, DOI 10.1046/j.1432-1327.1999.00516.x; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; WAHLE E, 1992, BIOESSAYS, V14, P113, DOI 10.1002/bies.950140208; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	34	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41086	41094		10.1074/jbc.M102109200	http://dx.doi.org/10.1074/jbc.M102109200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518703	hybrid			2022-12-25	WOS:000171925600096
J	Le Guienr, C; Lejeune, F; Galiana, D; Kister, L; Breathnach, R; Stevenin, J; Del Gatto-Konczak, F				Le Guienr, C; Lejeune, F; Galiana, D; Kister, L; Breathnach, R; Stevenin, J; Del Gatto-Konczak, F			TIA-1 and TIAR activate splicing of alternative exons with weak 5 ' splice sites followed by a U-rich stretch on their own pre-mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; GROWTH-FACTOR RECEPTOR-2; MAMMALIAN STRESS GRANULES; APOPTOTIC CELL-DEATH; MESSENGER-RNA; POLYPYRIMIDINE TRACT; MYOTONIC-DYSTROPHY; INTRON SEQUENCES; POLYMERASE-II; IDENTIFICATION	TIA-1 has recently been shown to activate splicing of specific pre-mRNAs transcribed from transiently transfected minigenes, and of some 5' splice sites in vitro, but has not been shown to activate splicing of any endogenous pre-mRNA. We show here that overexpression of TIA-1 or the related protein TIAR has little effect on splicing of several endogenous pre-mRNAs containing alternative exons, but markedly activates splicing of some normally rarely used alternative exons on the TIA-1 and TIAR pre-mRNAs. These exons have weak 5' splice sites followed by U-rich stretches. When the U-rich stretch following the 5' splice site of a TIA-1 alternative exon was deleted, TIAR overexpression induced use of a cryptic 5' splice site also followed by a U-rich stretch in place of the original splice site. Using in vitro splicing assays, we have shown that TIA-1 is directly involved in activating the 5' splice sites of the TIAR, alternative exons. Activation requires a downstream U-rich stretch of at least 10 residues. Our results confirm that TIA-1 activates 5' splice sites followed by U-rich sequences and show that TIAR exerts a similar activity. They suggest that both proteins may autoregulate their expression at the level of splicing.	CHR Nantes, Inst Biol, INSERM U463, F-44093 Nantes 1, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Del Gatto-Konczak, F (corresponding author), CHR Nantes, Inst Biol, INSERM U463, 9 Quai Moncousu, F-44093 Nantes 1, France.		Del Gatto-Konczak, Fabienne/L-1506-2015; Lejeune, Fabrice/N-3886-2017; Lejeune, Fabrice/P-9843-2019; Breathnach, Richard/K-7599-2015	Lejeune, Fabrice/0000-0002-5132-3585; 				Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; Gottschalk A, 1998, RNA, V4, P374; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hirose Y, 2000, GENE DEV, V14, P1415; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; KAWAKAMI A, 1994, J IMMUNOL, V152, P4937; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Srinivasula SM, 1999, CANCER RES, V59, P999; Sureau A, 2001, EMBO J, V20, P1785, DOI 10.1093/emboj/20.7.1785; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; ZACHAR Z, 1994, GENETICS, V137, P139; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zeng CQ, 2000, MOL CELL BIOL, V20, P8290, DOI 10.1128/MCB.20.21.8290-8301.2000; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	52	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40638	40646		10.1074/jbc.M105642200	http://dx.doi.org/10.1074/jbc.M105642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514562	hybrid			2022-12-25	WOS:000171925600036
J	Huang, CS; Li, JX; Ding, M; Leonard, SS; Wang, LY; Castranova, V; Vallyathan, V; Shi, XL				Huang, CS; Li, JX; Ding, M; Leonard, SS; Wang, LY; Castranova, V; Vallyathan, V; Shi, XL			UV induces phosphorylation of protein kinase B (Akt) at Ser-473 and Thr-308 in mouse epidermal Cl 41 cells through hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; INDUCED AP-1 ACTIVATION; GROWTH-FACTOR RECEPTOR; C-AKT; GENE; TRANSFORMATION; INHIBITION; EXPRESSION; ONCOGENE; DOMAIN	The exposure of mammalian cells to UV irradiation leads to the activation of transcription factors and protein kinases, which are believed to be responsible for the carcinogenic effects of excessive sun exposure. The present study investigated the effect of UV exposure on reactive oxygen species (ROS) generation and protein kinase B (Akt) phosphorylation in epidermal cells and determined if a relationship exists between these UV responses. Exposure of mouse epidermal JB6 Cl 41 cells to UV radiation led to specific phosphorylation of Akt at Ser-473 and Thr-308 in a time-dependent manner. This phosphorylation was confirmed by the observation that overexpression of Akt mutant, Akt-T308/S473A, attenuated phosphorylation of Akt at Ser-473 and Thr-308. UV radiation also generated ROS as measured by electron spin resonance (ESR) in JB6 Cl 41 cells. The generation of ROS by UV radiation was measured further by H2O2 and O . (-)(2) fluorescence staining assays. The mechanism of ROS generation involved reduction of molecular oxygen to O . (-)(2) which generated H2O2 through dismutation. H2O2 produced . OH via a metal-independent pathway. The scavenging of UV-generated H2O2 by N-acety-L-cyteine (NAC, a general antioxidant) or catalase (a specific H2O2 inhibitor) inhibited Akt phosphorylation at Ser-473 and Thr-308, whereas the pretreatment of cells with sodium formate (an (OH)-O-. radical scavenger) or superoxide dismutase (an O . (-)(2) radical scavenger) did not show any inhibitory effects. Furthermore, treatment of cells with H2O2 increased UV-induced phosphorylation of Akt at Ser-473 and Thr-308. These results demonstrate that UV radiation generates a whole spectrum of ROS including O . (-)(2), (OH)-O-., and H2O2 and induces phosphorylation of Akt at Ser-473. Among the various ROS, H2O2 seems most potent in mediating UV-induced phosphorylation of Akt at Ser-473 and Thr-308. It is possible that Akt may play a role in the carcinogenesis effects by UV radiation.	NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NIOSH, Hlth Effects Lab Div, NIH, Morgantown, WV 26505 USA	New York University; New York University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 550 1St Ave, New York, NY 10016 USA.	chuanshu@env.med.nyu.edu; xas0@cdc.gov	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 2000, J BIOL CHEM, V275, P9143, DOI 10.1074/jbc.275.13.9143; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PARRISH JA, 1993, BIOCH PHYSL SKIN, V2, P713; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SHI XL, 1992, FREE RADICAL RES COM, V17, P369, DOI 10.3109/10715769209083141; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIDL M, 1990, CARCINOGENESIS, V11, P229; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974	51	83	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40234	40240		10.1074/jbc.M103684200	http://dx.doi.org/10.1074/jbc.M103684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11507090	hybrid			2022-12-25	WOS:000171789200096
J	Jia, YF; Ransom, RF; Shibanuma, M; Liu, CH; Welsh, MJ; Smoyer, WE				Jia, YF; Ransom, RF; Shibanuma, M; Liu, CH; Welsh, MJ; Smoyer, WE			Identification and characterization of hic-5/ARA55 as an hsp27 binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; FOCAL ADHESION PROTEIN; TUMOR-NECROSIS-FACTOR; EMBRYONIC STEM-CELLS; SMALL STRESS PROTEIN; ACTIN POLYMERIZATION; MOLECULAR-WEIGHT; OXIDATIVE STRESS; RECEPTOR COACTIVATOR	hsp27 has been reported to participate in a wide variety of activities, including resistance to thermal and metabolic stress, regulation of growth and differentiation, and acting as a molecular chaperone or a regulator of actin polymerization. We hypothesized that these diverse functions are regulated in a cell- or tissue-specific manner via interaction with various binding proteins. To investigate this hypothesis, we used hsp27 as a "bait" to screen a yeast two-hybrid cDNA library from rat kidney glomeruli and identified a novel hsp27 binding protein, hic-5 (also known as ARA55), a focal adhesion protein and steroid receptor co-activator. Biochemical interaction between hsp27 and hic-5 was confirmed by co-immunoprecipitation, and critical protein-protein interaction regions were mapped to the hic-5 LIM domains and the hsp27 C-terminal domain. Initial analysis of the functional role of hsp27(.)hic-5 interaction revealed that hic-5 significantly inhibited the protection against heat-induced cell death conferred by hsp27 overexpression in co-transfected 293T cells. In contrast, when a non-hsp27-interacting hic-5 truncation mutant (hic-5/Delta LIM4) was co-expressed with hsp27, the hic-5 inhibition of hsp27 protection was absent. We conclude that hic-5 is a true hsp27 binding protein and inhibits the ability of hsp27 to provide protection against heat shock in an interaction-dependent manner.	Univ Michigan, Med Ctr, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Tokyo 142, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Showa University	Welsh, MJ (corresponding author), Univ Michigan, Med Ctr, Dept Cell & Dev Biol, 4728 MSII,Box 0616, Ann Arbor, MI 48109 USA.	welsh@umich.edu	Welsh, Michael/B-1968-2008		NIDDK NIH HHS [K08 DK02455-01] Funding Source: Medline; NIEHS NIH HHS [ES06265] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006265] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; CIOCCA DR, 1983, CANCER RES, V43, P1204; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; FUQUA SAW, 1994, BREAST CANCER RES TR, V32, P177, DOI 10.1007/BF00665768; Hagmann J, 1998, J CELL SCI, V111, P2181; Hoch B, 1996, MOL CELL BIOCHEM, V161, P231, DOI 10.1007/BF00240054; Horman S, 1997, CELL PROLIFERAT, V30, P21, DOI 10.1111/j.1365-2184.1997.tb00913.x; Hu YH, 1999, P NATL ACAD SCI USA, V96, P10218, DOI 10.1073/pnas.96.18.10218; Huot J, 1996, CANCER RES, V56, P273; Ishino K, 2000, J CELL BIOCHEM, V76, P411, DOI 10.1002/(SICI)1097-4644(20000301)76:3<411::AID-JCB9>3.0.CO;2-J; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KATO K, 1994, J BIOL CHEM, V269, P11274; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; KREISBERG JI, 1978, KIDNEY INT, V14, P21, DOI 10.1038/ki.1978.86; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Landry J, 1999, BIOCHEM SOC SYMP, P79; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Liu CH, 2000, J BIOL CHEM, V275, P18724, DOI 10.1074/jbc.M001981200; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; Lutsch G, 1997, CIRCULATION, V96, P3466; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; ROBERTS KP, 1995, BIOL REPROD, V53, P1446, DOI 10.1095/biolreprod53.6.1446; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Thomas SA, 1996, BRIT J UROL, V77, P367, DOI 10.1046/j.1464-410X.1996.09058.x; Thomas SM, 1999, J CELL SCI, V112, P181; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Welsh MJ, 1996, BIOL REPROD, V55, P141, DOI 10.1095/biolreprod55.1.141; Wu W, 1996, TOXICOL APPL PHARM, V141, P330; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; ZHU Y, 1994, J BIOL CHEM, V269, P22379	56	49	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39911	39918		10.1074/jbc.M103510200	http://dx.doi.org/10.1074/jbc.M103510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546764	hybrid			2022-12-25	WOS:000171789200056
J	Fearnley, IM; Carroll, J; Shannon, RJ; Runswick, MJ; Walker, JE; Hirst, J				Fearnley, IM; Carroll, J; Shannon, RJ; Runswick, MJ; Walker, JE; Hirst, J			GRIM-19, a cell death regulatory gene product, is a subunit of bovine mitochondrial NADH : Ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART-MITOCHONDRIA; RETINOIC ACID; POLYACRYLAMIDE GELS; PROTEIN IMPORT; BETA; SEQUENCES; IDENTIFICATION; SUBCOMPLEXES; COMBINATION; INTERFERON	The sequences of 42 subunits of NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria have been described previously. Seven are encoded by mitochondrial DNA, whereas the remaining 35 are nuclear gene products imported into the organelle from the cytoplasm. An additional protein, which does not correspond to any previously known subunit of the complex I assembly, has now been detected. Denaturing gels of subcomplex Id, the hydrophilic arm of complex I, clearly show a hitherto unidentified band, which was digested with trypsin and subjected to mass-spectrometric analysis to provide several peptide sequences, used in cDNA cloning and sequencing. Measurement of the intact protein mass indicated that the N terminus is acetylated. The new complex I subunit (B16.6) is the bovine homolog of GRIM-19, the product of a cell death regulatory gene induced by interferon-beta and retinoic acid, thus providing a new link between the mitochondrion and its electron-transport chain and apoptotic cell death.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Hirst, J (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Hirst, Judy/F-4803-2011	Hirst, Judy/0000-0001-8667-6797; Walker, John/0000-0001-7929-2162				Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; ARIZMENDI JM, 1992, FEBS LETT, V313, P80, DOI 10.1016/0014-5793(92)81189-S; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; FINEL M, 1994, EUR J BIOCHEM, V226, P237, DOI 10.1111/j.1432-1033.1994.tb20046.x; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	30	200	213	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38345	38348		10.1074/jbc.C100444200	http://dx.doi.org/10.1074/jbc.C100444200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11522775	hybrid			2022-12-25	WOS:000171673200004
J	Claing, A; Chen, W; Miller, WE; Vitale, N; Moss, J; Premont, RT; Lefkowitz, RJ				Claing, A; Chen, W; Miller, WE; Vitale, N; Moss, J; Premont, RT; Lefkowitz, RJ			beta-arrestin-mediated ADP-ribosylation factor 6 activation and beta(2)-adrenergic receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-COUPLED RECEPTORS; PLASMA-MEMBRANE; CLATHRIN ADAPTER; GOLGI-COMPLEX; ARF6; GTPASE; CELLS; DOMAINS; BINDING	beta -Arrestins are multifunctional adaptor proteins known to regulate internalization of agonist-stimulated G protein-coupled receptors by linking them to endocytic proteins such as clathrin and AP-2. Here we describe a previously unappreciated mechanism by which beta -arrestin orchestrates the process of receptor endocytosis through the activation of ADP-ribosylation factor 6 (ARF6), a small GTP-binding protein. Involvement of ARF6 in the endocytic process is demonstrated by the ability of GTP-binding defective and GTP hydrolysis-deficient mutants to inhibit internalization of the beta (2)-adrenergic receptor. The importance of regulation of ARF6 function is shown by the ability of the ARF GTPase-activating protein GIT1 to inhibit and of the ARF nucleotide exchange factor, ARNO, to enhance receptor endocytosis. Endogenous beta -arrestin is found in complex with ARNO. Upon agonist stimulation of the receptor, beta -arrestin also interacts with the GDP-liganded form of ARF6, thereby facilitating ARNO-promoted GTP loading and activation of the G protein. Thus, the agonist-driven formation of a complex including beta -arrestin, ARNO, and ARF6 provides a molecular mechanism that explains how the agonist-stimulated receptor recruits a small G protein necessary for the endocytic process and controls its activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; CNRS, Ctr Neurochim, UPR2356, F-67084 Strasbourg, France; NHLBI, Pulm Crit Care Med Branch, Nihon Univ, Bethesda, MD 20892 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Premont, Richard/0000-0002-8053-5026; Miller, William/0000-0001-6900-4884; Chen, Wei/0000-0002-9934-4000	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Liang JO, 1997, J BIOL CHEM, V272, P33001, DOI 10.1074/jbc.272.52.33001; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Rothman JE, 1996, PROTEIN SCI, V5, P185; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Song J, 1998, J CELL SCI, V111, P2257; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; VON ZM, 1992, J BIOL CHEM, V267, P3530; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	44	172	185	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42509	42513		10.1074/jbc.M108399200	http://dx.doi.org/10.1074/jbc.M108399200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533043	hybrid			2022-12-25	WOS:000172450400124
J	Dick, RA; Kwak, MK; Sutter, TR; Kensler, TW				Dick, RA; Kwak, MK; Sutter, TR; Kensler, TW			Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase - A new role for leukotriene B-4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDO-KETO REDUCTASE; LIPID-PEROXIDATION; RAT-LIVER; ALDEHYDE DEHYDROGENASES; ALCOHOL-DEHYDROGENASE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; SOS CHROMOTEST; CDNA CLONING; PRODUCTS	There are several known routes for the metabolic detoxication of alpha,beta -unsaturated aldehydes and ketones, including conjugation to glutathione and reduction and oxidation of the aldehyde to an alcohol and a carboxylic acid, respectively. In this study, we describe a fourth class of detoxication that involves the reduction of the alpha,beta -carbon = carbon double bond to a single bond. This reaction is catalyzed by NAD(P)H-dependent alkenal/one oxidoreductase (AO), an enzyme heretofore known as leukotriene B-4 12-hydroxydehydrogenase, 15-oxoprostagiandin 13-reductase, and dithiolethione-inducible gene-1. AO is shown to effectively reduce cytotoxic lipid peroxidation products such as 4-hydroxy-2-nonenal (HNE) (k(cat) = 4.0 x 10(3) min(-1); k(cat)/K-m = 3.3 x 10(7) min(-1) M-1) and acrolein (k(cat) = 2.2 x 10(2) min(-1); k(cat)/K-m = 1.5 x 10(6) min(-1) m(-1)) and common industrial compounds such as ethyl vinyl ketone (k(cat) = 9.6 x 10(3) min(-1); k(cat)/K-m = 8.8 x 10(7) min(-1) M-1) and 15-oxoprostaglandin E-1 (k(cat) = 2.4 x 10(3) min(-1); k(cat)/K-m = 2.4 x 10(9) min(-1) M-1). Furthermore, transfection of human embryonic kidney cells with a rat liver AO expression vector protected these cells from challenge with HNE. The concentration of HNE at which 50% of the cells were killed after 24 h increased from similar to 15 mum in control cells to similar to 70 muM in AO-transfected cells. Overexpression of AO also completely abolished protein alkylation by HNE at all concentrations tested (up to 30 muM). Thus, we describe a novel antioxidative activity of a previously characterized bioactive lipid-metabolizing enzyme that could prove to be therapeutically or prophylactically useful due to its high catalytic rate and inducibility.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA; Univ Memphis, W Harry Feinstone Ctr Genom Res, Memphis, TN 38152 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Memphis	Kensler, TW (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Rm 7032,615 N Wolfe, Baltimore, MD 21205 USA.	tkensler@jhsph.edu	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X	NCI NIH HHS [CA39416, T32CA09243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039416, T32CA009243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Aviram M, 2000, FREE RADICAL RES, V33, pS85; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; CARMICHAEL J, 1987, CANCER RES, V47, P936; Carvalho VM, 2000, CHEM RES TOXICOL, V13, P397, DOI 10.1021/tx9901682; Chen HJC, 1996, CHEM RES TOXICOL, V9, P306, DOI 10.1021/tx9501389; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Clapper ML, 1998, PHARMACOL THERAPEUT, V78, P17, DOI 10.1016/S0163-7258(97)00164-2; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; DIANZANI MU, 1993, CRIT REV ONCOL HEMAT, V15, P125, DOI 10.1016/1040-8428(93)90052-6; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Eder E, 2000, MUTAT RES-GEN TOX EN, V470, P29, DOI 10.1016/S1383-5718(00)00078-4; EDER E, 1991, CHEM RES TOXICOL, V4, P50, DOI 10.1021/tx00019a007; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; ESTERBAUER H, 1990, MEMBRANE LIPID OXIDA, V1, P239; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Hayes JD, 1998, CHEM-BIOL INTERACT, V112, P51, DOI 10.1016/S0009-2797(97)00151-8; Haynes RL, 2000, MOL PHARMACOL, V58, P788, DOI 10.1124/mol.58.4.788; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; Kensler T W, 2000, Drug Metabol Drug Interact, V17, P3; Kensler TW, 1999, CHEM RES TOXICOL, V12, P113, DOI 10.1021/tx980185b; KITAMURA S, 1993, BIOCHEM MOL BIOL INT, V30, P839; Kitson TM, 2001, CHEM-BIOL INTERACT, V130, P57, DOI 10.1016/S0009-2797(00)00222-2; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P340; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; Koster J F, 1986, Free Radic Res Commun, V1, P273, DOI 10.3109/10715768609051637; Laurent A, 2000, TOXICOL LETT, V114, P203, DOI 10.1016/S0378-4274(99)00301-X; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; Loureiro APM, 2000, CHEM RES TOXICOL, V13, P601, DOI 10.1021/tx000004h; Luckey SW, 1999, ADV EXP MED BIOL, V463, P71; Mano J, 2000, EUR J BIOCHEM, V267, P3661, DOI 10.1046/j.1432-1327.2000.01398.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; MITCHELL DY, 1987, TOXICOL APPL PHARM, V87, P403, DOI 10.1016/0041-008X(87)90245-6; MITCHELL DY, 1991, HEPATOLOGY, V13, P728, DOI 10.1016/0270-9139(91)92572-P; MITCHELL DY, 1989, ARCH BIOCHEM BIOPHYS, V269, P11, DOI 10.1016/0003-9861(89)90081-7; Montine KS, 1997, AM J PATHOL, V150, P437; Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; Primiano T, 1996, CARCINOGENESIS, V17, P2297, DOI 10.1093/carcin/17.11.2297; *QIAGEN INC, 2001, QIAEXPR; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; SELLIN S, 1991, BIOCHEMISTRY-US, V30, P2514, DOI 10.1021/bi00223a031; Srivastava S, 1998, BIOCHEMISTRY-US, V37, P12909, DOI 10.1021/bi9804333; Srivastava S, 2000, FREE RADICAL BIO MED, V29, P642, DOI 10.1016/S0891-5849(00)00351-8; Srivastava S, 2001, CHEM-BIOL INTERACT, V130, P563, DOI 10.1016/S0009-2797(00)00299-4; TAKEHIKO Y, 1993, J BIOL CHEM, V268, P18128; TAKEHIKO Y, 1996, J BIOL CHEM, V271, P2844; Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102; Vermeiren GLJ, 2000, RESUSCITATION, V45, P35, DOI 10.1016/S0300-9572(00)00168-4	57	111	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40803	40810		10.1074/jbc.M105487200	http://dx.doi.org/10.1074/jbc.M105487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524419	hybrid			2022-12-25	WOS:000171925600058
J	Rojnuckarin, P; Miyakawa, Y; Fox, NE; Deou, J; Daum, G; Kaushansky, K				Rojnuckarin, P; Miyakawa, Y; Fox, NE; Deou, J; Daum, G; Kaushansky, K			The roles of phosphatidylinositol 3-kinase and protein kinase C zeta for thrombopoietin-induced mitogen-activated protein kinase activation in primary murine megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PI 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE-PHOSPHATASE; GLUCOSE-TRANSPORT; RECEPTOR; RAS; PATHWAY; SHP2; GAB1	Thrombopoietin (TPO) stimulates a network of intracellular signaling pathways that displays extensive cross-talk. We have demonstrated previously that the ERK/mitogen-activated protein kinase pathway is important for TPO-induced endomitosis in primary megakaryocytes (MKs). One known pathway by which TPO induces ERR activation is through the association of Shc with the penultimate phosphotyrosine within the TPO receptor, Mpl. However, several investigators found that the membrane-proximal half of the cytoplasmic domain of Mpl is sufficient to activate ERK in vitro and support base-line megakaryopoiesis an vivo. Using BaF3 cells expressing a truncated Mpl (T69Mp1) as a tool to identify non-Shc/Ras-dependent signaling pathways, we describe here novel mechanisms of TPO-induced ERK activation mediated, in part, by phosphoinositide 3-kinase PI3K). Similar to cells expressing full-length receptor, PI3K was activated by its incorporation into a complex with IRS2 or Gab2. Furthermore, the MEK-phosphorylating activity of protein kinase C zeta (PKC zeta) was also enhanced after TPO stimulation of T69Mp1, contributing to ERK activity. PKC zeta and PI3K also contribute to TPO-induced ERK activation in MKs, confirming their physiological relevance. Like in BaF3 cells, a TPO-induced signaling complex containing p85PI3K is detectable in MKs expressing T61Mpl and is probably responsible for PI3K activation. These data demonstrate a novel role of PI3K and PKC zeta in steady-state megakaryopoiesis.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, Box 357710,1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu						BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; King TS, 1997, ALIMENT PHARM THER, V11, P17, DOI 10.1046/j.1365-2036.1997.90262000.x; Kirito K, 2000, BLOOD, V96, p538A; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kunitama M, 1997, BIOCHEM BIOPH RES CO, V231, P290, DOI 10.1006/bbrc.1996.5969; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200	45	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41014	41022		10.1074/jbc.M106508200	http://dx.doi.org/10.1074/jbc.M106508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11535599	hybrid			2022-12-25	WOS:000171925600086
J	Woolhead, CA; Thompson, SJ; Moore, M; Tissier, C; Mant, A; Rodger, A; Henry, R; Robinson, C				Woolhead, CA; Thompson, SJ; Moore, M; Tissier, C; Mant, A; Rodger, A; Henry, R; Robinson, C			Distinct albino3-dependent and -independent pathways for thylakoid membrane protein insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SEC-INDEPENDENT INSERTION; ESCHERICHIA-COLI; POSTTRANSLATIONAL INTEGRATION; INNER MEMBRANE; MITOCHONDRIAL; BACTERIAL; HOMOLOG; BINDING; OXA1P	The homologous proteins Oxa1, YidC, and Alb3 mediate the insertion of membrane proteins in mitochondria, bacteria, and chloroplast thylakoids, respectively. Depletion of YidC in Escherichia coli affects the integration of every membrane protein studied, and Alb3 has been shown previously to be required for the insertion of a signal recognition particle (SRP)-dependent protein, Lhcb1, in thylakoids. In this study we have analyzed the "global" role of Alb3 in the insertion of thylakoid membrane proteins. We show that insertion of two chlorophyll-binding proteins, Lhcb4.1 and Lhcb5, is almost totally blocked by preincubation of thylakoids with anti-Alb3 antibodies, indicating a requirement for Alb3 in the insertion pathway. Insertion of the related PsbS protein, on the other hand, is unaffected by Alb3 antibodies, and insertion of a group of SRP-independent, signal peptide-bearing proteins, PsbX, PsbW, and PsbY, is likewise completely unaffected. Proteinase K is furthermore able to completely degrade Alb3, but this treatment does not affect the insertion of these proteins. Among the thylakoid proteins studied here, Alb3 requirement correlates strictly with a requirement for stromal factors and nucleoside triphosphates. However, the majority of proteins tested do not require Alb3 or any other known form of translocation apparatus.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA	University of Warwick; University of Warwick; University of Arkansas System; University of Arkansas Fayetteville	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk	Rodger, Alison/A-1063-2009	Rodger, Alison/0000-0002-7111-3024; Thompson, Simon/0000-0003-0769-8555; Mant, Alexandra/0000-0001-7169-209X				BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BREYTON C, 1994, J BIOL CHEM, V269, P7597; Bruce BD, 1998, PLANT MOL BIOL, V38, P223, DOI 10.1023/A:1006094308805; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; DOUCE R, 1996, ADV PHOTOSYNTH, V4, P69; Gau AE, 1998, MOL GEN GENET, V260, P56, DOI 10.1007/s004380050870; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 1998, FEBS LETT, V423, P183, DOI 10.1016/S0014-5793(98)00089-1; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Thompson SJ, 1998, J BIOL CHEM, V273, P18979, DOI 10.1074/jbc.273.30.18979; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Zhu YX, 1998, GENE, V208, P1, DOI 10.1016/S0378-1119(97)00613-6	38	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40841	40846		10.1074/jbc.M106523200	http://dx.doi.org/10.1074/jbc.M106523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524428	hybrid, Green Submitted			2022-12-25	WOS:000171925600063
J	Kang, YK; Koo, DB; Park, JS; Choi, YH; Kim, HN; Chang, WK; Lee, KK; Han, YM				Kang, YK; Koo, DB; Park, JS; Choi, YH; Kim, HN; Chang, WK; Lee, KK; Han, YM			Typical demethylation events in cloned pig embryos - Clues on species-specific differences in epigenetic reprogramming of a cloned donor genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSFER; IN-VITRO; PREIMPLANTATION DEVELOPMENT; PATERNAL GENOME; SOMATIC-CELLS; CLONING; MOUSE; FETAL	We investigated whether a genomic demethylation process occurs in pig preimplantation embryos produced by either normal fertilization or somatic cell nuclear transfer. The methylation status of the centromeric satellite and the PRE-1 short interspersed element (SINE) sequences was characterized using bisulfite-sequencing technology. Typical demethylation processes were identified in these repetitive sequences of the cloned donor genome during cleavage, the patterns of which were similar to the ones detected in fertilized counterparts. These findings are different from previous observations with cloned bovine embryos where various repeated regions of the donor genome exhibited aberrant methylation patterns. Our results indicate that species-specific differences exist in modifying the epigenetic status of cloned donor genomes.	KRIBB, Anim Dev Biotechnol Lab, Taejon 305600, South Korea; Natl Livestock Res Inst, Suwon 441350, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Han, YM (corresponding author), KRIBB, Anim Dev Biotechnol Lab, POB 115, Taejon 305600, South Korea.		Han, Yong-Mahn/C-1652-2011					Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Han YM, 1999, BIOL REPROD, V60, P1110, DOI 10.1095/biolreprod60.5.1110; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Kang YK, 2001, NAT GENET, V28, P173, DOI 10.1038/88903; Koo DB, 2000, BIOL REPROD, V63, P986, DOI 10.1095/biolreprod63.4.986; Koo DB, 2001, MOL REPROD DEV, V58, P15, DOI 10.1002/1098-2795(200101)58:1&lt;15::AID-MRD3&gt;3.0.CO;2-Y; Latham KE, 1999, INT REV CYTOL, V193, P71; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; MONK M, 1991, DEVELOPMENT, V112, P189; Onishi A, 2000, SCIENCE, V289, P1188, DOI 10.1126/science.289.5482.1188; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Prather RS, 1998, THERIOGENOLOGY, V49, P23, DOI 10.1016/S0093-691X(97)00399-3; Prather RS, 2000, SCIENCE, V289, P1886, DOI 10.1126/science.289.5486.1886; REIK W, 1997, GENOMIC IMPRINTING F, P1; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2823, DOI 10.1093/nar/12.6.2823; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	23	137	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39980	39984		10.1074/jbc.M106516200	http://dx.doi.org/10.1074/jbc.M106516200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11524426	hybrid			2022-12-25	WOS:000171789200065
J	Saxena, MT; Schroeter, EH; Mumm, JS; Kopan, R				Saxena, MT; Schroeter, EH; Mumm, JS; Kopan, R			Murine Notch homologs (N1-4) undergo presenilin-dependent proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; CLEAVAGE; GENE; SUSCEPTIBILITY; TRANSDUCTION; MUTAGENESIS; EXPRESSION; MUTATION; DOMAIN	Oncogenic forms of Notch1, Notch2, and Notch4 appear to mimic signaling intermediates of Notch1 and suggest that the role of proteolysis in Notch signaling has been conserved. Here we demonstrate that extracellularly truncated Notch homologs are substrates for a presenilin-dependent gamma -secretase activity. Despite minimal conservation within the transmembrane domain, the requirement for a specific amino acid (P1' valine) and its position at the cleavage site relative to the cytosolic border of the transmembrane domain are preserved. Cleaved, untethered Notch intracellular domains from each receptor translocate to the nucleus and interact with the transcriptional regulatory protein CSL. All four Notch proteins display presenilin-dependent transactivating potential on a minimal promoter reporter. Thus, this study increases the number of biochemically characterized gamma -secretase substrates from two to five. Despite a high degree of structural homology and the presenilin-dependent activity of truncated Notch proteins, the extent that this reflects functional redundancy is unknown.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kopan, R (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave,Box 8103, St Louis, MO 63110 USA.	kopan@pcg.wustl.edu	Mumm, Jeff S/F-3125-2013; Kopan, Raphael/AAF-1357-2022; Kopan, Raphael/AFG-3275-2022	Kopan, Raphael/0000-0002-0350-2730; Mumm, Jeff/0000-0002-2575-287X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Ujike H, 2001, NEUROSCI LETT, V301, P41, DOI 10.1016/S0304-3940(01)01602-0; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wei J, 2000, NAT GENET, V25, P376, DOI 10.1038/78044; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	36	149	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40268	40273		10.1074/jbc.M107234200	http://dx.doi.org/10.1074/jbc.M107234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518718	hybrid			2022-12-25	WOS:000171789200101
J	Venkatesan, S; Petrovic, A; Locati, M; Kim, YO; Weissman, D; Murphy, PM				Venkatesan, S; Petrovic, A; Locati, M; Kim, YO; Weissman, D; Murphy, PM			A membrane-proximal basic domain and cysteine cluster in the C-terminal tail of CCR5 constitute a bipartite motif critical for cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLOPHILIN HOMOLOG NINAA; HIV-1 CORECEPTOR ACTIVITY; MACROPHAGE-TROPIC HIV-1; ACETYL-D-GALACTOSAMINE; CHEMOKINE RECEPTOR; ENDOPLASMIC-RETICULUM; O-GLYCOSYLATION; GOLGI-COMPLEX	We examined the structural requirements for cell surface expression, signaling, and human immunodeficiency virus co-receptor activity for the chemokine receptor, CCR5. Serial C-terminal truncation of CCR5 resulted in progressive loss of cell surface expression; mutants truncated at the 317th position and shorter were not detected at the cell surface. Alanine substitution of basic residues in the membrane-proximal domain (residues 314-322) in the context of a full-length C-tail resulted in severe reduction in surface expression. C-terminal truncation that excised the three cysteines in this domain reduced surface expression, but further truncation of upstream basic residue(s) abolished surface expression. Substituting the carboxyl-terminal domain of CXCR4 for that of CCR5 failed to rectify the trafficking defect of the tailless CCR5. In contrast, tailless CXCR4 or a CXCR4 chimera that exchanged the native cytoplasmic domain for that of wild type CCR5 was expressed at the cell surface. Deletion mutants that expressed at the cell surface responded to chemokine stimulation and mediated human immunodeficiency virus entry. Substitution of all serine and threonine residues in the C-terminal tail of CCR5 abolished chemokine-mediated receptor phosphorylation but preserved downstream signaling (Ca2+ flux), while substitutions of tyrosine residues in the C-tail affected neither phenotype. CCR5 mutants that failed to traffic to the plasma membrane did not exhibit obvious changes in metabolic turnover and were retained in the Golgi or pre-Golgi compartments(s). Thus, the basic domain (-KHIAKRF-) and the cysteine cluster (-CKCC-) in the C-terminal tail of CCR5 function cooperatively for optimal surface expression.	NIAID, LMM, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania	Venkatesan, S (corresponding author), NIAID, LMM, NIH, Bldg 10,Rm 6A05, Bethesda, MD 20892 USA.		Locati, Massimo/ABF-6807-2021; Locati, Massimo/H-8404-2015	Locati, Massimo/0000-0003-3077-590X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615, Z01AI000528, ZIAAI000528, ZIAAI000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEIJON C, 1987, J BIOL CHEM, V262, P4153; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOSSHART H, 1991, J CELL PHYSIOL, V147, P149, DOI 10.1002/jcp.1041470119; Boulay F, 1997, ANN NY ACAD SCI, V832, P69, DOI 10.1111/j.1749-6632.1997.tb46238.x; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Bultmann A, 2001, J VIROL, V75, P5263, DOI 10.1128/JVI.75.11.5263-5276.2001; Chen ZW, 1998, J EXP MED, V188, P2057, DOI 10.1084/jem.188.11.2057; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; HANOVER JA, 1982, J BIOL CHEM, V257, P172; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hermida-Matsumoto L, 1999, J VIROL, V73, P1902, DOI 10.1128/JVI.73.3.1902-1908.1999; Hu H, 1998, ARCH VIROL, V143, P851, DOI 10.1007/s007050050337; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Plemper RK, 1999, MOL BIOL REP, V26, P125, DOI 10.1023/A:1006913215484; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; SUNG CH, 1994, J NEUROSCI, V14, P5818; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Welker R, 1998, J VIROL, V72, P8833, DOI 10.1128/JVI.72.11.8833-8840.1998; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Yang W, 1997, BIOCHEMISTRY-US, V36, P15193, DOI 10.1021/bi971594u	84	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40133	40145		10.1074/jbc.M105722200	http://dx.doi.org/10.1074/jbc.M105722200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514564	hybrid			2022-12-25	WOS:000171789200085
J	Cockerill, GW; McDonald, MC; Mota-Filipe, H; Cuzzocrea, S; Miller, NE; Thiemermann, C				Cockerill, GW; McDonald, MC; Mota-Filipe, H; Cuzzocrea, S; Miller, NE; Thiemermann, C			High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock	FASEB JOURNAL			English	Article						cytokines; chemokines; intercellular adhesion molecule 1; interleukin 8; multiple organ failure	MACROPHAGE INFLAMMATORY PROTEIN-2; APOLIPOPROTEIN-A-I; ISCHEMIA-REPERFUSION INJURY; CYTOKINE-INDUCED EXPRESSION; TUMOR-NECROSIS-FACTOR; ADHESION MOLECULES; LUNG INJURY; ALVEOLAR MACROPHAGES; SELECTIN EXPRESSION; ENDOTHELIAL-CELLS	High density lipoproteins (HDLs) inhibit the cytokine-induced expression of endothelial cell adhesion molecules both in vitro and in vivo. We examined the ability of HDLs to mediate a functional anti-inflammatory effect by measuring their ability to prevent neutrophil adhesion and transmigration in vitro. Treatment of human endothelial cell cultures with physiologic concentrations of HDLs inhibited neutrophil binding by 68 +/-5.9% (mean and SE, n=6, P<0.05) and neutrophil transmigration by 48.7<plus/minus>6.7% (n=8, P<0.05). We then examined the effect of HDLs on inflammatory infiltration and subsequent multiple organ dysfunction syndrome (MODS), associated with trauma in a rat model of hemorrhagic shock. Rats given human HDLs (80 mg apo A-I/kg, i.v.) 90 min after hemorrhage (which reduced mean arterial pressure to 50 mmHg) and 1 min before resuscitation showed attenuation of the increases in the serum levels of markers of MODS normally observed in this model. Severe disruption of the architecture of tissues and the extensive cellular infiltration into those tissues were also largely inhibited in animals that received HDLs. Human HDLs attenuate the MODS associated with ischemia and reperfusion injury after hemorrhagic shock in rats.	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London SMD, London EC1M 6BQ, England; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy	University of London; Queen Mary University London; University of Messina	Cockerill, GW (corresponding author), Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London SMD, London EC1M 6BQ, England.	g.w.cockerill@mds.qmw.ac.uk	Miller, Norman E/P-6032-2017; Mota-Filipe, Helder/GSE-1539-2022; Mota-Filipe, Helder/M-6298-2013; Mota-Filipe, Helder/M-6199-2019	Miller, Norman E/0000-0001-7087-3390; Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Thiemermann, Christoph/0000-0003-4228-9722				Akgur FM, 1999, J SURG RES, V87, P232, DOI 10.1006/jsre.1999.5758; ANDERSON BO, 1991, SURGERY, V109, P51; Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BRAITHWAITE CEM, 1993, J TRAUMA, V34, P586; CALEBRESI L, 1997, BIOCHEM BIOPH RES CO, V238, P61; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Cockerill GW, 1999, ARTERIOSCL THROM VAS, V19, P910, DOI 10.1161/01.ATV.19.4.910; COCKERILL GW, 1995, BLOOD, V86, P2689; Cockerill GW, 2001, CIRCULATION, V103, P108; Cryer HG, 1997, SHOCK, V8, P26, DOI 10.1097/00024382-199707000-00005; Demetriades D, 1999, J TRAUMA, V46, P667, DOI 10.1097/00005373-199904000-00018; DiPiro JT, 1996, CRIT CARE MED, V24, P440, DOI 10.1097/00003246-199603000-00013; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Eppihimer MJ, 1997, SHOCK, V8, P16, DOI 10.1097/00024382-199707000-00004; FENGE H, 1995, INT J LEGAL PROF, V2, P95; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; Kalff JC, 1999, ARCH ORTHOP TRAUM SU, V119, P89, DOI 10.1007/s004020050363; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; KOIKE K, 1994, CRIT CARE MED, V22, P1438, DOI 10.1097/00003246-199409000-00014; Lemay S, 2000, TRANSPLANTATION, V69, P959; Lerch PG, 1996, VOX SANG, V71, P155, DOI 10.1046/j.1423-0410.1996.7130155.x; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; Marubayashi S, 1997, SURGERY, V122, P45, DOI 10.1016/S0039-6060(97)90263-4; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILLER GJ, 1975, LANCET, V1, P16; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; Morgan WM, 1998, NEW HORIZ-SCI PRACT, V6, P150; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Nanjee MN, 1999, ARTERIOSCL THROM VAS, V19, P979, DOI 10.1161/01.ATV.19.4.979; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Ramamoorthy C, 1996, AM J PHYSIOL-HEART C, V271, pH1871, DOI 10.1152/ajpheart.1996.271.5.H1871; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; SEEKAMP A, 1993, AM J PATHOL, V143, P464; Shanley TP, 1997, J IMMUNOL, V158, P3439; SHAPPELL SB, 1994, HDB IMMUNOPHARMACOLO, P29; Shi MM, 1999, IMMUNOLOGY, V97, P309; Simons RK, 1996, J TRAUMA, V41, P653, DOI 10.1097/00005373-199610000-00010; Smith WB, 1996, J IMMUNOL, V157, P360; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Thiagarajan RR, 1997, THROMB HAEMOSTASIS, V78, P310; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; VEDDER NB, 1989, SURGERY, V106, P509; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; WU X, 1995, AM J PHYSIOL, V269, P248; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; YAARI S, 1981, LANCET, V1, P1011	61	78	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1941	1952		10.1096/fj.01-0075com	http://dx.doi.org/10.1096/fj.01-0075com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532974				2022-12-25	WOS:000171372700009
J	Lee, JE; Bokoch, G; Liang, BT				Lee, JE; Bokoch, G; Liang, BT			A novel cardioprotective role of RhoA: new signaling mechanism for adenosine	FASEB JOURNAL			English	Article						myocytes; ischemia; cytoprotection; phospholipase D; monomeric G-protein	SENSITIVE POTASSIUM CHANNELS; CHICK VENTRICULAR MYOCYTES; PHOSPHOLIPASE-D; BINDING PROTEINS; A(3) RECEPTORS; KINASE; ISCHEMIA; GTPASES; STIMULATION; ACTIVATION	Adenosine exerts a potent cardioprotective effect that is mediated by adenosine A(1) and A(3) receptors. The signaling pathways activated by the A(1) and A(3) receptors are distinct and involve selective coupling to phospholipases C and D, respectively. The objective of our study was to elucidate the signaling mechanism that mediates the coupling of each receptor to its respective phospholipase and to test the role of RhoA as a novel mediator leading from adenosine receptors to cardioprotection. C3 transferase and dominant negative RhoA (RhoAT19N) blocked the A(3) receptor-mediated phospholipase D activation and cardioprotection but had no effect on A(1) receptor-mediated phospholipase C activation or cardioprotection. In contrast, pertussis toxin treatment caused a greater inhibition of the diacylglycerol accumulation induced by the A(1) agonist than by the A(3) agonist, and it completely abrogated the A(1) agonist-mediated cardioprotection. Thus, adenosine A(1) and A(3) receptors are linked to different G-proteins. The A(3) receptor is coupled via RhoA to activate phospholipase D in exerting its cardioprotective effect, whereas the A(1) receptor is linked via G(i) to phospholipase C to produce cardioprotective responses. The present study identifies a novel role for RhoA and further suggests its importance in regulating cardiac cellular function.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Immunol & Cell Biol, La Jolla, CA 92037 USA	University of Pennsylvania; University of Pennsylvania; Scripps Research Institute	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Room 956,BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	liang@mail.med.upenn.edu			NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Auchampach JA, 1997, CIRC RES, V80, P800; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; LIANG BT, 1988, BIOCHEM PHARMACOL, V37, P4549, DOI 10.1016/0006-2952(88)90671-5; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; XU D, 1992, CIRC RES, V70, P56, DOI 10.1161/01.RES.70.1.56; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	37	48	49	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1886	1894		10.1096/fj.01-0212com	http://dx.doi.org/10.1096/fj.01-0212com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532968				2022-12-25	WOS:000171372700003
J	Aoudjit, F; Vuori, K				Aoudjit, F; Vuori, K			Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; chemotherapeutic agent; extracellular matrix; integrin; paclitaxel	FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; REGULATES BCL-2 EXPRESSION; RESISTANCE CAM-DR; EXTRACELLULAR-MATRIX; CYTOCHROME-C; CARCINOMA CELLS; PROTEIN-KINASE; MICROTUBULE DAMAGE; CELLULAR-SURVIVAL	Inherent or acquired drug resistance is one of the major problems in chemotherapy. The mechanisms by which cancer cells survive and escape the cytotoxic effects of chemotherapeutic agents are essentially unknown. In the present study, we demonstrate that in the MDA-MB-231 and MDA-MB-435 breast cancer cells, ligation of beta1 integrins by their extracellular matrix ligands inhibits significantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed chemotherapeutic agents that are widely used in the therapy of breast cancer. We show that beta1 integrin signaling inhibits drug-induced apoptosis by inhibiting the release of cytochrome c from the mitochondria in response to drug treatment. Further, integrin-mediated protection from drug-induced apoptosis and inhibition of cytochrome c release are dependent on the activation of the PI 3-kinase/Akt pathway. Our results identify beta1 integrin signaling as an important survival pathway in drug-induced apoptosis in breast cancer cells and suggest that activation of this pathway may contribute to the generation of drug resistance.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2000, BLOOD, V95, P2044, DOI 10.1182/blood.V95.6.2044; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Blagosklonny MV, 1997, CANCER RES, V57, P130; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chadebech P, 1999, BIOCHEM BIOPH RES CO, V262, P823, DOI 10.1006/bbrc.1999.1291; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; FISHER B, 1997, CANC MED; Fornier M, 1999, ONCOLOGY-NY, V13, P647; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1997, CANCER RES, V57, P229; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; KUMAR N, 1981, J BIOL CHEM, V256, P435; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lebwohl DE, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008318725670; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Lundstrom A, 1998, BIOCHEM BIOPH RES CO, V250, P735, DOI 10.1006/bbrc.1998.9389; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Page C, 2000, ANTICANCER RES, V20, P407; Petitclerc E, 1999, CANCER RES, V59, P2724; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Pusztai L, 1998, ACTA ONCOL, V37, P629, DOI 10.1080/028418698429964; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seftor REB, 1998, CANCER RES, V58, P5681; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shaw LM, 1996, CANCER RES, V56, P959; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; van der Pluijm G, 1997, LAB INVEST, V77, P665; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Wewer UM, 1997, AM J PATHOL, V151, P1191; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	63	259	277	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4995	5004		10.1038/sj.onc.1204554	http://dx.doi.org/10.1038/sj.onc.1204554			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526484				2022-12-25	WOS:000170439800009
J	Luciano, F; Ricci, JE; Auberger, P				Luciano, F; Ricci, JE; Auberger, P			Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation	ONCOGENE			English	Article						apoptosis; Src kinases; caspases; T and B lymphocytes	PROTEIN-TYROSINE KINASES; FAS-MEDIATED APOPTOSIS; CELL-DEATH; HEMATOPOIETIC-CELLS; DOWN-REGULATION; DEFICIENT MICE; T-LYMPHOCYTES; B-CELLS; RECEPTOR; ACTIVATION	The members of the Src kinase family are expressed in a wide variety of tissues, but some of them such as Blk, Hck, Fgr, Lck and Lyn are found primarily in hematopoietic cells. In the present study, we have undertaken experiments to test whether Src kinase cleavage and relocation is a general mechanism during induction of apoptosis. Our results indicate that Fyn and Lyn are efficiently cleaved in their unique region in hernatopoietic cells undergoing apoptosis. Fyn cleavage occurred in Fas-stimulated Jurkat T cells but Fyn and Lyn were also processed in the SKW6.4 B cell line. Inhibition of caspases by Z-VAD-fmk or Ac-DEVD-CHO totally prevented Fyn and Lyn cleavage in both intact cells and in vitro. Fyn and Lyn but not Lek, Src and Hck were processed in vitro by human recombinant caspase 3 and by cellular extracts prepared from Fas-stimulated cells. Single mutation of Asp 19 or Asp 18 in the unique N-terminal domains of Fyn and Lyn respectively abolished their cleavage and relocation into the cytoplasm of apoptotic cells. When immunoprecipitated from COS cells N-terminal deleted Src kinases exhibited increased enzymatic kinase activity toward enolase. Thus, cleavage of Fyn and Lyn during induction of apoptosis represents a new mechanism for the regulation of Src kinases that may have important functional and physiological consequences.	Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Fac Med, Equipe Labellisee Ligue Natl Canc, INSERM U526, IFR50,Ave Valombrose, F-06107 Nice 2, France.		luciano, frederic/P-6264-2016; Ricci, Jean Ehrland/I-7117-2016; RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013	luciano, frederic/0000-0001-9253-4998; Ricci, Jean Ehrland/0000-0003-1585-8117; RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; Katsuta H, 1998, J IMMUNOL, V160, P1547; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KRUEGER J, 1991, ONCOGENE, V6, P933; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Maruo A, 1999, INT IMMUNOL, V11, P1371, DOI 10.1093/intimm/11.9.1371; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; RICCI JE, 2001, IN PRESS FASEB J; RUDD CE, 1991, ADV EXP MED BIOL, V292, P85; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SUDOL M, 1993, ONCOGENE, V8, P823; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLMAN CL, 1991, BLOOD, V77, P726; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; ZHAO YH, 1991, ONCOGENE, V6, P1725	46	51	51	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4935	4941		10.1038/sj.onc.1204661	http://dx.doi.org/10.1038/sj.onc.1204661			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526478				2022-12-25	WOS:000170439800003
J	Bertini, I; Bryant, DA; Ciurli, S; Dikiy, A; Fernandez, CO; Luchinat, C; Safarov, N; Vila, AJ; Zhao, JD				Bertini, I; Bryant, DA; Ciurli, S; Dikiy, A; Fernandez, CO; Luchinat, C; Safarov, N; Vila, AJ; Zhao, JD			Backbone dynamics of plastocyanin in both oxidation states - Solution structure of the reduced form and comparison with the oxidized state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BLUE-COPPER PROTEINS; HEART CYTOCHROME-C; RESOLUTION SOLUTION STRUCTURE; NMR RELAXATION MEASUREMENTS; MODEL-FREE APPROACH; CRYSTAL-STRUCTURE; HYDROGEN-EXCHANGE; POPLAR PLASTOCYANIN; ANABAENA-VARIABILIS	A model-free analysis based on N-15 R-1, N-15 R-2, and N-15-H-1 nuclear Overhauser effects was performed on reduced (diamagnetic) and oxidized (paramagnetic) forms of plastocyanin from Synechocystis sp. PCC6803. The protein backbone is rigid, displaying a small degree of mobility in the sub-nanosecond time scale. The loops surrounding the copper ion, involved in physiological electron transfer, feature a higher extent of flexibility in the longer time scale in both redox states, as measured from D2O exchange of amide protons and from NH-H2O saturation transfer experiments. In contrast to the situation for other electron transfer proteins, no significant difference in the dynamic properties is found between the two redox forms. A solution structure was also determined for the reduced plastocyanin and compared with the solution structure of the oxidized form in order to assess possible structural changes related to the copper ion redox state. Within the attained resolution, the structure of the reduced plastocyanin is indistinguishable from that of the oxidized form, even though small chemical shift differences are observed. The present characterization provides information on both the structural and dynamic behavior of blue copper proteins in solution that is useful to understand further the role(s) of protein dynamics in electron transfer processes.	Univ Bologna, Dept Agroenvironm Sci & Technol, I-40127 Bologna, Italy; Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; UBA, CONICET, LANAIS RMN 300, RA-1113 Buenos Aires, DF, Argentina; Univ Florida, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florida, Dept Agr Biotechnol, I-50019 Sesto Fiorentino, Italy; Univ Nacl Rosario, Dept Biol Chem, Biophys Sect, RA-2000 Rosario, Argentina	University of Bologna; University of Florence; University of Florence; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; National University of Rosario	Ciurli, S (corresponding author), Univ Bologna, Dept Agroenvironm Sci & Technol, Viale Beryi Pichat 10, I-40127 Bologna, Italy.	sciurli@agrsci.unibo.it	Safarov, Niyaz/AAN-3206-2020; SAFAROV, NIYAZ/S-1375-2016; Ciurli, Stefano/K-4355-2014; Safarov, Niyaz/AAS-5884-2020	Safarov, Niyaz/0000-0002-9293-4921; SAFAROV, NIYAZ/0000-0002-9293-4921; Ciurli, Stefano/0000-0001-9557-926X; Safarov, Niyaz/0000-0002-9293-4921; Fernandez, Claudio Oscar/0000-0003-0454-7735; Vila, Alejandro/0000-0002-7978-3233; Luchinat, Claudio/0000-0003-2271-8921				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Arnesano F, 2000, BIOCHEMISTRY-US, V39, P7117, DOI 10.1021/bi992756k; Arnesano F, 1998, BIOCHEMISTRY-US, V37, P173, DOI 10.1021/bi971896w; ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; Babu CR, 1999, BIOCHEMISTRY-US, V38, P4988, DOI 10.1021/bi983024f; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P6611, DOI 10.1021/bi00187a031; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Baistrocchi P, 1996, BIOCHEMISTRY-US, V35, P13788, DOI 10.1021/bi961110e; Banci L, 1998, BIOCHEMISTRY-US, V37, P12320, DOI 10.1021/bi980885f; Banci L, 1999, J BIOL INORG CHEM, V4, P21, DOI 10.1007/s007750050285; Banci L, 1997, BIOCHEMISTRY-US, V36, P9867, DOI 10.1021/bi970724w; Banci L, 1997, BIOCHEMISTRY-US, V36, P8992, DOI 10.1021/bi963025c; BANCI L, 1995, BIOCHEMISTRY-US, V34, P11385, DOI 10.1021/bi00036a011; Barker PD, 2001, EUR J BIOCHEM, V268, P4468, DOI 10.1046/j.1432-1327.2001.02369.x; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Baxter SM, 1999, BIOCHEMISTRY-US, V38, P4493, DOI 10.1021/bi982742z; Bertini I, 2000, J MAGN RESON, V147, P1, DOI 10.1006/jmre.2000.2131; Bertini I, 1995, CHEM-EUR J, V1, P598, DOI 10.1002/chem.19950010906; Bertini I, 2001, J AM CHEM SOC, V123, P2405, DOI 10.1021/ja0033685; Bertini I, 2000, J BIOL INORG CHEM, V5, P761, DOI 10.1007/s007750000166; Bertini I, 2000, J AM CHEM SOC, V122, P3701, DOI 10.1021/ja992674j; Bertini I, 2000, PROTEINS, V41, P75, DOI 10.1002/1097-0134(20001001)41:1<75::AID-PROT100>3.0.CO;2-2; Bertini I., 1996, NMR PARAMAGNETIC SUB, V150; Bond CS, 1999, ACTA CRYSTALLOGR D, V55, P414, DOI 10.1107/S0907444998012074; Boyd J, 1999, J AM CHEM SOC, V121, P9247, DOI 10.1021/ja9920361; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant D.A., 1994, MOL BIOL CYANOBACTER; Buning C, 2000, J AM CHEM SOC, V122, P204, DOI 10.1021/ja992796b; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; Dangi B, 1998, BIOCHEMISTRY-US, V37, P8289, DOI 10.1021/bi9801964; Donaire A, 1998, INORG CHIM ACTA, V276, P73; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Fetrow JS, 1999, BIOCHEMISTRY-US, V38, P4480, DOI 10.1021/bi9827417; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Gray HB, 2000, J BIOL INORG CHEM, V5, P551, DOI 10.1007/s007750000146; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GUILES RD, 1993, BIOCHEMISTRY-US, V32, P8329, DOI 10.1021/bi00083a037; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Inoue T, 1999, BIOCHEMISTRY-US, V38, P13853, DOI 10.1021/bi990502t; Inoue T, 1999, BIOCHEMISTRY-US, V38, P6063, DOI 10.1021/bi9824442; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; Jeuken LJC, 2000, J MOL BIOL, V299, P737, DOI 10.1006/jmbi.2000.3754; Kalverda AP, 1999, BIOCHEMISTRY-US, V38, P12690, DOI 10.1021/bi990624l; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lyons TA, 1996, PROTEIN SCI, V5, P627; Ma LX, 2000, J AM CHEM SOC, V122, P7823, DOI 10.1021/ja000746x; Ma LX, 2000, J AM CHEM SOC, V122, P9473, DOI 10.1021/ja001368z; MALMSTROM BG, 1994, EUR J BIOCHEM, V223, P711, DOI 10.1111/j.1432-1033.1994.tb19044.x; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Milne JS, 1998, PROTEIN SCI, V7, P739, DOI 10.1002/pro.5560070323; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Pearlman DA, 1997, AMBER 5 0; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; REDINBO MR, 1993, BIOCHEMISTRY-US, V32, P10560, DOI 10.1021/bi00091a005; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; Romero A, 1998, J MOL BIOL, V275, P327, DOI 10.1006/jmbi.1997.1455; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; Sari N, 1999, BIOCHEMISTRY-US, V38, P9862, DOI 10.1021/bi9906423; Shibata N, 1999, J BIOL CHEM, V274, P4225, DOI 10.1074/jbc.274.7.4225; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugawara H, 1999, J BIOCHEM-TOKYO, V125, P899, DOI 10.1093/oxfordjournals.jbchem.a022366; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; SYKES AG, 1991, STRUCT BOND, V75, P175; Thompson GS, 2000, PROTEIN SCI, V9, P846, DOI 10.1110/ps.9.5.846; Tsan P, 1999, J AM CHEM SOC, V121, P1795, DOI 10.1021/ja9820745; Ubbink M, 1996, EUR J BIOCHEM, V242, P132, DOI 10.1111/j.1432-1033.1996.0132r.x; Vetterling W.T., 1988, NUMERICAL RECIPES C; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xue YF, 1998, PROTEIN SCI, V7, P2099, DOI 10.1002/pro.5560071006; Zinn-Justin S, 1997, J BIOMOL NMR, V10, P363, DOI 10.1023/A:1018365815186	94	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47217	47226		10.1074/jbc.M100304200	http://dx.doi.org/10.1074/jbc.M100304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11509552	hybrid			2022-12-25	WOS:000172768500074
J	Baltrusch, S; Lenzen, S; Okar, DA; Lange, AJ; Tiedge, M				Baltrusch, S; Lenzen, S; Okar, DA; Lange, AJ; Tiedge, M			Characterization of glucokinase-binding protein epitopes by a phage-displayed peptide library - Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; TISSUE-SPECIFIC EXPRESSION; GLUCOSE SENSOR PARADIGM; INSULIN-SECRETING CELLS; REGULATORY PROTEIN; FRUCTOSE 6-PHOSPHATE; RAT-BRAIN; B-CELLS; SUBCELLULAR-LOCALIZATION; INTRACELLULAR BINDING	The low affinity glucose-phosphorylating enzyme glucokinase shows the phenomenon of intracellular translocation in beta cells of the pancreas and the liver. To identify potential binding partners of glucokinase by a systematic strategy, human beta cell glucokinase was screened by a 12-mer random peptide library displayed by the M13 phage. This panning procedure revealed two consensus motifs with a high binding affinity for glucokinase. The first consensus motif, LSAXXVAG, corresponded to the glucokinase regulatory protein of the liver. The second consensus motif, SLKVWT, showed a complete homology to the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), which acts as a key regulator of glucose metabolism. Through yeast two-hybrid analysis it became evident that the binding of glucokinase to PFK-2/FBPase-2 is conferred by the bisphosphatase domain, whereas the kinase domain is responsible for dimerization. 5'-Rapid amplification of cDNA ends analysis and Northern blot analysis revealed that rat pancreatic islets express the brain isoform of PFK-2/FBPase-2. A minor portion of the islet PFK-2/FBPase-2 cDNA clones comprised a novel splice variant with 8 additional amino acids in the kinase domain. The binding of the islet/brain PFK-2/ FBPase-2 isoform. to glucokinase was comparable with that of the liver isoform. The interaction between glucokinase and PFK-2/FBPase-2 may provide the rationale for recent observations of a fructose-2,6-bisphosphate level-dependent partial channeling of glycolytic intermediates between glucokinase and glycolytic enzymes. In pancreatic beta cells this interaction may have a regulatory function for the metabolic stimulus-secretion coupling. Changes in fructose-2,6-bisphosphate levels and modulation of PFK-2/FBPase-2 activities may participate in the physiological regulation of glucokinase-mediated glucose-induced insulin secretion.	Hannover Med Sch, Inst Clin Biochem, D-30623 Hannover, Germany; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	Hannover Medical School; University of Minnesota System; University of Minnesota Twin Cities	Tiedge, M (corresponding author), Hannover Med Sch, Inst Clin Biochem, D-30623 Hannover, Germany.				NIDDK NIH HHS [DK-38354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038354, R01DK038354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agius L, 1997, BIOCHEM SOC T, V25, P145, DOI 10.1042/bst0250145; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Batra RS, 1996, FEBS LETT, V393, P167, DOI 10.1016/0014-5793(96)00878-2; BURCH PT, 1981, DIABETES, V30, P923, DOI 10.2337/diabetes.30.11.923; BURCH PT, 1985, DIABETES, V34, P1014, DOI 10.2337/diabetes.34.10.1014; Cascante M, 2000, BIOCHEM J, V352, P899, DOI 10.1042/0264-6021:3520899; CHEN C, 1994, DIABETES, V43, P684, DOI 10.2337/diabetes.43.5.684; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHIKRI M, 1995, BIOCHEMISTRY-US, V34, P8876, DOI 10.1021/bi00027a040; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRIACY M, 1979, J BACTERIOL, V139, P152, DOI 10.1128/JB.139.1.152-160.1979; DACUNHA MV, 1996, J BIOL CHEM, V271, P6292; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; DETHEUX M, 1993, FEBS LETT, V321, P111, DOI 10.1016/0014-5793(93)80089-D; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Jorns A, 1999, VIRCHOWS ARCH, V434, P75, DOI 10.1007/s004280050308; Lenzen S, 2000, BBA-GEN SUBJECTS, V1523, P65, DOI 10.1016/S0304-4165(00)00100-8; LENZEN S, 1988, BIOCHEM PHARMACOL, V37, P371, DOI 10.1016/0006-2952(88)90201-8; LENZEN S, 1987, ACTA ENDOCRINOL-COP, V115, P21, DOI 10.1530/acta.0.1150021; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; Magnuson Mark A., 1994, P155; MALAISSE WJ, 1982, DIABETES, V31, P90, DOI 10.2337/diabetes.31.1.90; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MATSCHINSKY FM, 1993, DIABETOLOGIA, V36, P1215, DOI 10.1007/BF00401072; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NIEMEYER H, 1988, ARCH BIOCHEM BIOPHYS, V265, P91, DOI 10.1016/0003-9861(88)90374-8; Noma Y, 1996, ENDOCRINOLOGY, V137, P1485, DOI 10.1210/en.137.4.1485; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; PERMUTT MA, 1992, DIABETES, V41, P1367, DOI 10.2337/diabetes.41.11.1367; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; Sakurai T, 1996, BIOCHEM BIOPH RES CO, V218, P159, DOI 10.1006/bbrc.1996.0028; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENER A, 1984, BIOCHEM J, V221, P759, DOI 10.1042/bj2210759; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Stubbs M, 2000, DIABETES, V49, P2048, DOI 10.2337/diabetes.49.12.2048; TAULER A, 1989, P NATL ACAD SCI USA, V86, P7316, DOI 10.1073/pnas.86.19.7316; Tiedge M, 1999, DIABETES, V48, P514, DOI 10.2337/diabetes.48.3.514; Tiedge M, 1997, BBA-PROTEIN STRUCT M, V1337, P175, DOI 10.1016/S0167-4838(96)00162-8; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VANSCHAFTINGEN E, 1994, DIABETOLOGIA, V37, pS43, DOI 10.1007/BF00400825; Velho G, 1997, DIABETOLOGIA, V40, P217, DOI 10.1007/s001250050666; WARNER JP, 1995, MAMM GENOME, V6, P532, DOI 10.1007/BF00356171; Watanabe F, 1999, FEBS LETT, V458, P304, DOI 10.1016/S0014-5793(99)01174-6; WATANABE F, 1994, BIOCHEM BIOPH RES CO, V198, P335, DOI 10.1006/bbrc.1994.1047; Watanabe F, 1997, J NEUROCHEM, V69, P1; Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103	62	69	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43915	43923		10.1074/jbc.M105470200	http://dx.doi.org/10.1074/jbc.M105470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11522786	hybrid			2022-12-25	WOS:000172297700058
J	Choy, JS; Tobe, BTD; Huh, JH; Kron, SJ				Choy, JS; Tobe, BTD; Huh, JH; Kron, SJ			Yng2p-dependent NuA4 histone H4 acetylation activity is required for mitotic and meiotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR P33(ING1); B-TYPE CYCLINS; CELL-CYCLE; ACETYLTRANSFERASE COMPLEXES; GENE ACTIVATION; IN-VIVO; TRANSCRIPTION; GROWTH; CHROMATIN	In all eukaryotes, multisubunit histone acetyltransferase (HAT) complexes acetylate the highly conserved lysine residues in the amino-terminal tails of core histones to regulate chromatin structure and gene expression. One such complex in yeast, NuA4, specifically acetylates nucleosome-associated histone H4. Recent studies have revealed that NuA4 comprises at least 11 subunits, including Yng2p, a yeast homolog of the candidate human tumor suppressor gene, ING1. Consistent with prior data, we find that cells lacking Yng2p are deficient for NnA4 activity and are temperature-sensitive. Furthermore, we show that the NuA4 complex is present in the absence of Yng2p, suggesting that Yng2p functions to maintain or activate NuA4 HAT activity. Sporulation of diploid yng2 mutant cells reveals a defect in meiotic progression, whereas synchronized yng2 mutant cells display a mitotic delay. Surprisingly, genome-wide expression analysis revealed little change from wild type. Nocodazole arrest and release relieves the mitotic defects, suggesting that Yng2p may have a critical function prior to or during metaphase. Rather than a uniform decrease in acetylated forms of histone H4, we find striking cell-to-cell heterogeneity in the loss of acetylated histone H4 in yng2 mutant cells. Treating yng2 mutants with the histone deacetylase inhibitor trichostatin A suppressed the mitotic delay and restored global histone H4 acetylation, arguing that reduced H4 acetylation may underlie the cell cycle delay.	Univ Chicago, Ctr Mol Oncol, Donnelley Biol Sci Learning Ctr, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Kron, SJ (corresponding author), Univ Chicago, Ctr Mol Oncol, Donnelley Biol Sci Learning Ctr, 924 E 57th St,Rm R320, Chicago, IL 60637 USA.			Choy, John/0000-0001-9196-3280; Kron, Stephen/0000-0003-1518-2436	NIGMS NIH HHS [R01 GM60443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 1999, MOL BIOL CELL, V10, P3301, DOI 10.1091/mbc.10.10.3301; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DAHMANN C, 1995, GENETICS, V140, P957; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; Haseloff J, 1999, METHOD CELL BIOL, V58, P139; Ikeda K, 1999, MOL CELL BIOL, V19, P855; John S, 2000, GENE DEV, V14, P1196; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	46	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43653	43662		10.1074/jbc.M102531200	http://dx.doi.org/10.1074/jbc.M102531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11544250	hybrid			2022-12-25	WOS:000172297700024
J	Oh, SM; Hahm, DH; Kim, IH; Choi, SY				Oh, SM; Hahm, DH; Kim, IH; Choi, SY			Human neutrophil lactoferrin trans-activates the matrix metalloproteinase 1 gene through stress-activated MAPK signaling modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE KINASE; TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; IN-VIVO; BINDING; EXPRESSION; INHIBITOR; DNA; IDENTIFICATION; COLLAGENASE	It has been proposed that human neutrophil lactoferrin (Lf) could be involved in gene expression as a DNA-binding protein after its translocation. into the nucleus. However, the molecular basis of Lf action has not been defined, and Lf-regulated target genes have not been identified. We report here that overexpressed Lf functions as a specific trans-activator of matrix metalloproteinase 1 (MMP1) gene, and that induction of this AP-1-responsive gene is mediated via the stress-activated MAPK signaling modules. Transactivation of the MMP1 promoter by overexpressed Lf requires the presence of an AP-1 binding site. In gel shift experiments, Lf did not interact directly with AP-1-containing fragments of the MMP1 promoter. However, nuclear extracts from Lf-expressing cells contained increased levels of proteins that bound to AP-1 elements. This Lf-induced AP-1 DNA binding activity was reduced by a p38 MAPK inhibitor. Inhibitors of the MEK kinases had little effect on Lf-induced AP-1. However, expression of dominant-negative MKK4 or JNK1 inhibited Lf-induced gene expression. The JNK activity stimulated by Lf correlates with the enhanced AP-I binding ability. These findings demonstrate that the Lf-induced activation of AP-1 is mediated via JNK and p38 NLAPK pathways.	Korea Univ, Grad Sch Biotechnol, Div Life Sci, SUngbuk Gu, Seoul 136701, South Korea	Korea University	Choi, SY (corresponding author), Korea Univ, Grad Sch Biotechnol, Div Life Sci, SUngbuk Gu, 5-1 Anamdong, Seoul 136701, South Korea.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Baveye S, 2000, FEBS LETT, V469, P5, DOI 10.1016/S0014-5793(00)01243-6; BAYNES RD, 1986, SCAND J HAEMATOL, V36, P79; BEZAULT J, 1994, CANCER RES, V54, P2310; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Damiens E, 1999, J CELL BIOCHEM, V74, P486, DOI 10.1002/(SICI)1097-4644(19990901)74:3<486::AID-JCB16>3.3.CO;2-Y; Damiens E, 1998, BBA-MOL CELL RES, V1402, P277, DOI 10.1016/S0167-4889(98)00013-5; DAVIDSON LA, 1989, AM J PHYSIOL, V257, pG930, DOI 10.1152/ajpgi.1989.257.6.G930; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; FAUCHEUX BA, 1995, P NATL ACAD SCI USA, V92, P9603, DOI 10.1073/pnas.92.21.9603; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACHNICKI M, 1993, INT J EXP PATHOL, V74, P433; NOVAK TJ, 1990, NUCLEIC ACIDS RES, V18, P4523, DOI 10.1093/nar/18.15.4523; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; WATANABE H, 1993, J CELL SCI, V104, P991; WENG HQ, 1995, J BIOL CHEM, V270, P13637, DOI 10.1074/jbc.270.23.13637; WILSON LD, 1987, MOL CELL BIOL, V7, P2406, DOI 10.1128/MCB.7.7.2406	31	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42575	42579		10.1074/jbc.M107724200	http://dx.doi.org/10.1074/jbc.M107724200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535608	hybrid			2022-12-25	WOS:000172450400133
J	Stasiv, Y; Regulski, M; Kuzin, B; Tully, T; Enikolopov, G				Stasiv, Y; Regulski, M; Kuzin, B; Tully, T; Enikolopov, G			The Drosophila nitric-oxide synthase gene (dNOS) encodes a family of proteins that can modulate NOS activity by acting as dominant negative regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXPRESSION; DIVERSITY; PATHWAY; HEME	Nitric oxide (NO) is involved in organ development, synaptogenesis, and response to hypoxia in Drosophila. We cloned and analyzed the only gene in the fly genome that encodes Drosophila nitric-oxide synthase (dNOS). It consists of 19 exons and is dispersed over 34 kilobases of genomic DNA. Alternative transcription start sites and alternative splice sites are used to generate a remarkable variety of mRNAs from the dNOS gene. We identified eight new transcripts that are widely expressed throughout Drosophila development and encode a family of DNOS-related proteins. Alternative splicing affects both the 5'-untranslated region and the coding region of the dNOS primary transcript. Most of the splicing alterations in the coding region of the gene lead to premature termination of the open reading frame. As a result, none of the alternative transcripts encode an enzymatically active protein. However, some of these shorter DNOS protein products can effectively inhibit enzymatic activity of the full-length DNOS1 protein when co-expressed in mammalian cells, thus acting as dominant negative regulators of NO synthesis. Using immunoprecipitation, we demonstrate that these short DNOS protein isoforms can form heterodimers with DNOS1, pointing to a physical basis for the dominant negative effect. Our results suggest a novel regulatory function for the family of proteins encoded by the Drosophila NOS gene.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori N/B-7771-2009; Enikolopov, Grigori/P-5731-2019	Enikolopov, Grigori N/0000-0001-8178-8917; Enikolopov, Grigori/0000-0001-8178-8917; Kuzin, Boris/0000-0001-9951-1553	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036413] Funding Source: NIH RePORTER; NICHD NIH HHS [HD36413] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DiGregorio PJ, 2001, J BIOL CHEM, V276, P1930, DOI 10.1074/jbc.M003911200; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Forstermann U, 1998, FASEB J, V12, P773; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; HALL AV, 1994, J BIOL CHEM, V269, P33082; HARLOW E, 1988, ANTIBODIES LABORATOR, P488; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Kuzin B, 2000, CURR BIOL, V10, P459, DOI 10.1016/S0960-9822(00)00443-7; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Larsson B, 1998, BIOCHEM BIOPH RES CO, V251, P898, DOI 10.1006/bbrc.1998.9578; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Luckhart S, 1999, GENE, V232, P25, DOI 10.1016/S0378-1119(99)00121-3; Luckhart S, 2001, INSECT BIOCHEM MOLEC, V31, P249, DOI 10.1016/S0965-1748(00)00144-2; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Nappi AJ, 2000, NITRIC OXIDE-BIOL CH, V4, P423, DOI 10.1006/niox.2000.0294; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sambrook J., 2002, MOL CLONING LAB MANU; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Truman JW, 1996, DEVELOPMENT, V122, P3949; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Wildemann B, 1999, J NEUROBIOL, V38, P1, DOI 10.1002/(SICI)1097-4695(199901)38:1<1::AID-NEU1>3.0.CO;2-L; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	38	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42241	42251		10.1074/jbc.M105066200	http://dx.doi.org/10.1074/jbc.M105066200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11526108	hybrid			2022-12-25	WOS:000172450400094
J	van Vugt, MATM; Smits, VAJ; Klompmaker, R; Medema, RH				van Vugt, MATM; Smits, VAJ; Klompmaker, R; Medema, RH			Inhibition of polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; ATAXIA-TELANGIECTASIA; CHECKPOINT KINASE; RADIOSENSITIZING AGENT; PROTEIN-KINASE; IN-VITRO; PHOSPHORYLATION; CDC25; CHK1; CAFFEINE	Polo-like kinases play multiple roles in different phases of mitosis. We have recently shown that the mammalian polo-like kinase, Plk1, is inhibited in response to DNA damage and that this inhibition may lead to cell cycle arrests at multiple points in mitosis. Here we have investigated the role of the checkpoint kinases ATM ((a) under bar taxia (t) under bar elangiectasia (m) under bar utated) and ATR (ATM- and Rad3-related) in DNA damage-induced inhibition of Plk1. We show that inhibition of Plk1 kinase activity is efficiently blocked by the radio-sensitizing agent caffeine. Using ATM(-/-) cells we show that under certain circumstances, inhibition of Plk1 by DNA-damaging agents critically depends on ATM. In addition, we show that LN radiation also causes inhibition of Plk1, and we present evidence that this inhibition is mediated by ATR. Taken together, our data demonstrate that ATM and ATR can regulate Plk1 kinase activity in response to a variety of DNA-damaging agents.	Netherlands Canc Inst, Dept Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Medema, RH (corresponding author), Netherlands Canc Inst, Dept Mol Biol, Plesmanlaan 121,H-8, NL-1066 CX Amsterdam, Netherlands.		Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Smits, Veronique A.J./R-2302-2019	Smits, Veronique A.J./0000-0002-9160-4525; Medema, Rene/0000-0002-6754-0381				Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	37	130	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41656	41660		10.1074/jbc.M101831200	http://dx.doi.org/10.1074/jbc.M101831200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11514540	hybrid			2022-12-25	WOS:000172450400017
J	Guittet, O; Hakansson, P; Voevodskaya, N; Fridd, S; Graslund, A; Arakawa, H; Nakamura, Y; Thelander, L				Guittet, O; Hakansson, P; Voevodskaya, N; Fridd, S; Graslund, A; Arakawa, H; Nakamura, Y; Thelander, L			Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT MOUSE; SUBUNIT; CYCLE; R2; PURIFICATION; LOCALIZATION; REPLICATION; CHECKPOINT; TARGET; GENE	Recently, a homologue of the small subunit of mammalian ribonucleotide reductase (RNR) was discovered, called p53R2. Unlike the well characterized S phase-specific RNR R2 protein, the new form was induced in response to DNA damage by the p53 protein. Because the R2 protein is specifically degraded in late mitosis and absent in G(0)/G(1) cells, the induction of the p53R2 protein may explain how resting cells can obtain deoxyribonucleotides for DNA repair. However, no direct demonstration of RNR activity of the p53R2 protein was presented and furthermore, no corresponding RNR large subunit was identified. In this study we show that recombinant, highly purified human and mouse p53R2 proteins contain an iron-tyrosyl free radical center, and both proteins form an active RNR complex with the human and mouse R1 proteins. UV irradiation of serum-starved, G(0)/G(1)-enriched mouse fibroblasts, stably transformed with an RI promoter-luciferase reporter gene construct, caused a 3-fold increase in luciferase activity 24 h after irradiation, paralleled by an increase in the levels of RI protein. Taken together, our data indicate that the RI protein can function as the normal partner of the p53R2 protein and that an R1-p53R2 complex can supply resting cells with deoxyribonucleotides for DNA repair.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; Stockholm Univ, Dept Biophys, SE-10691 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Umea University; Stockholm University; University of Tokyo	Thelander, L (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	lars.thelander@medchem.umu.se	Guittet, Olivier/J-8642-2013; Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638; Hakansson, Pelle/0000-0003-0421-2433				BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; MANN GJ, 1988, CANCER RES, V48, P5151; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARKER NJ, 1991, NUCLEIC ACIDS RES, V19, P3741, DOI 10.1093/nar/19.13.3741; REDDY GPV, 1986, BIOCHEM BIOPH RES CO, V135, P340, DOI 10.1016/0006-291X(86)90983-6; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; SPYROU G, 1983, BIOCHEM BIOPH RES CO, V115, P1022, DOI 10.1016/S0006-291X(83)80037-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544	28	163	171	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40647	40651		10.1074/jbc.M106088200	http://dx.doi.org/10.1074/jbc.M106088200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11517226	hybrid			2022-12-25	WOS:000171925600037
J	Panda, DK; Miao, DS; Lefebvre, V; Hendy, GN; Goltzman, D				Panda, DK; Miao, DS; Lefebvre, V; Hendy, GN; Goltzman, D			The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRY-RELATED GENE; NUCLEAR-LOCALIZATION SIGNAL; P19(ARF) TUMOR-SUPPRESSOR; AUTOSOMAL SEX REVERSAL; N-CADHERIN EXPRESSION; II COLLAGEN GENE; CAMPOMELIC DYSPLASIA; DNA-BINDING; IN-VITRO; PROTEIN	SOX9 is a transcription factor that is essential for chondrocyte differentiation and cartilage formation. We stably overexpressed SOX9 cDNA in the rat chondrocytic cell line CFK2. Compared with the vector control, a greater proportion of SOX9-transfected cells accumulated in the G(0)/G(1) phase. This was associated with an increase in mRNA and protein expression of p21(cip1), an inhibitor of cyclin-dependent kinase activity. SOX9 enhanced p21(cip1) promoter activity in a luciferase reporter assay. CFK2 cells overexpressing SOX9 became more elongated and adhesive and demonstrated a shift in cytoplasmic F-actin distribution. N-cadherin mRNA levels were elevated in the SOX9-transfected cells, and SOX9 enhanced N-cadherin promoter activity. By electrophoretic mobility shift assay, nuclear extracts of SOX9-transfected CFK2 cells specifically bound an oligonucleotide comprising an N-cadherin promoter region containing a consensus SOX9-binding motif. The transcriptional activity of SOX9 depended upon nuclear localization signals required for SOX9 nuclear entry. Differentiation of transfected CFK2 cells was accelerated as evidenced by more rapid accumulation of alkaline phosphatase activity, increased production of proteoglycans, and increased calcium accumulation, and this was associated with decreased ERK1 expression. These studies demonstrate that SOX9 alters the rate of cell cycle progression of chondrocytes and their differentiation by enhancing or inhibiting the expression of selected genes, including p21(cip1) and ERK1, and that N-cadherin is an additional direct target of this transcriptional regulator.	Royal Victoria Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Univ Texas, Dept Mol Genet, Houston, TX 77030 USA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; University of Texas System	Goltzman, D (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	david.goltzman@mcgill.ca		Miao, Dengshun/0000-0002-2682-3502	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046249] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR46249] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BERNIER SM, 1993, J BONE MINER RES, V8, P475; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boumediene K, 1998, EXP CELL RES, V243, P173, DOI 10.1006/excr.1998.4129; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FINNEGAN MCM, 1995, LEUKEMIA LYMPHOMA, V18, P511, DOI 10.3109/10428199509059653; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; KARAPLIS AC, 1999, DYNAMICS BONE CARTIL, P203; LeClair EE, 1999, DEV DYNAM, V214, P101, DOI 10.1002/(SICI)1097-0177(199902)214:2<101::AID-AJA1>3.0.CO;2-4; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li B, 1997, GENE, V191, P7, DOI 10.1016/S0378-1119(97)00006-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; Tavella S, 1997, J CELL SCI, V110, P2261; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; ten Berge D, 1998, DEVELOPMENT, V125, P3831; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Woodward WA, 1999, DEV GENET, V24, P178, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<178::AID-DVG16>3.0.CO;2-M; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	51	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41229	41236		10.1074/jbc.M104231200	http://dx.doi.org/10.1074/jbc.M104231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514554	hybrid			2022-12-25	WOS:000171925600114
J	Tsukada, Y; Miyazawa, K; Kitamura, N				Tsukada, Y; Miyazawa, K; Kitamura, N			High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; TUMOR CYTOTOXIC FACTOR; C-MET RECEPTOR; TRANSCRIPTION FACTOR E2F; PROTEIN-KINASE KINASE; EPITHELIAL-CELLS; RETINOBLASTOMA PROTEIN; CYCLIN-E; MOLECULAR-CLONING; HUMAN FIBROBLASTS	Hepatocyte growth factor (HGF) induces growth stimulation of a variety of cell types, but it also induces growth inhibition of several types of tumor cell lines. The molecular mechanism of the HGF-induced growth inhibition of tumor cells remains obscure. We have investigated the intracellular signaling pathway involved in the antiproliferative effect of HGF on the human hepatocellular carcinoma cell line HepG2. HGF induced strong activation of ERK in HepG2 cells. Although the serum-dependent proliferation of HepG2 cells was inhibited by the MEK inhibitor PD98059 in a dose-dependent manner, 10 muM PD98059 reduced the HGF-induced strong activation of ERK to a weak activation; and as a result, the proliferation inhibited by HGF was completely restored. Above or below this specific concentration, the restoration was incomplete. Expression of constitutively activated Ha-Ras, which induces strong activation of ERK, led to the proliferation inhibition of HepG2 cells, as was observed in HGF-treated HepG2 cells. This inhibition was suppressed by the MEK inhibitor. Furthermore, HGF treatment and expression of constitutively activated Ha-Ras changed the hyperphosphorylated form of the retinoblastoma tumor suppressor gene product pRb to the hypophosphorylated form. This change was inhibited by the same concentration of MEK inhibitor needed to suppress the proliferation inhibition. These results suggest that ERK activity is required for both the stimulation and inhibition of proliferation of HepG2 cells; that the level of ERK activity determines the opposing proliferation responses; and that HGF-induced proliferation inhibition is caused by cell cycle arrest, which results from pRb being maintained in its active hypophosphorylated form via a high-intensity ERK signal in HepG2 cells.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomed Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomed Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		MIYAZAWA, KEIJI/I-9713-2014					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAGNASS AU, 1994, BIOCHEM BIOPH RES CO, V202, P701; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DOWDY SF, 1997, HUMAN GENOME METHODS, P121; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Gius DR, 1999, CANCER RES, V59, P2577; Gohda E, 1998, BIOCHEM BIOPH RES CO, V245, P278, DOI 10.1006/bbrc.1998.8416; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HALABAN R, 1992, ONCOGENE, V7, P2195; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1994, J BIOL CHEM, V269, P16131; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORITA M, 1994, HEPATOLOGY, V19, P426; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHIBAMOTO S, 1992, CELL STRUCT FUNCT, V17, P185, DOI 10.1247/csf.17.185; Shima N, 1998, J CELL PHYSIOL, V177, P130, DOI 10.1002/(SICI)1097-4652(199810)177:1<130::AID-JCP14>3.3.CO;2-O; SHIMA N, 1991, CELL BIOL INT REP, V15, P397, DOI 10.1016/0309-1651(91)90128-6; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yanagawa K, 1998, ONCOL REP, V5, P185; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHU H, 1994, J BIOL CHEM, V269, P29943	85	79	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40968	40976		10.1074/jbc.M010890200	http://dx.doi.org/10.1074/jbc.M010890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533045	hybrid			2022-12-25	WOS:000171925600080
J	Zhai, JB; Lin, H; Shamim, M; Schlaepfer, WW; Canete-Soler, R				Zhai, JB; Lin, H; Shamim, M; Schlaepfer, WW; Canete-Soler, R			Identification of a novel interaction of 14-3-3 with p190RhoGEF.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MOLECULAR-CLONING; EXCHANGE FACTOR; NEURONAL EXPRESSION; MESSENGER-RNAS; NERVOUS-SYSTEM; P115 RHOGEF; RAT CDNAS; KINASE; FAMILY	Activation of Rho GTPases by guanine nucleotide exchange factors (GEFs) mediates a broad range of cytoskeletal alterations that determine cell shape. In the nervous system, Rho GTPases are essential for establishing highly asymmetrical neuronal forms and may fine-tune the shape of dendrites in differentiated neurons. p190RhoGEF is a brain-enriched, RhoA-specific GEF whose highly interactive C-terminal domain provides potential linkage to multiple pathways in the cell. In the present study, a yeast two-hybrid screen was used to identify 14-3-3 eta and 14-3-3 epsilon as additional binding partners of p190RhoGEF. Interactions between p190RhoGEF and 14-3-3 eta were confirmed biochemically and by colocalization of the respective proteins when fused to fluorescent markers and transfected in neuronal cells. We also mapped a unique phosphorylation-independent binding site (I(1370)QAIQNL) in p190RhoGEF. Deletion of the binding site abolished interactions in vitro as well as the ability of 14-3-3 eta to alter the cytoplasmic aggregation of p190RhoGEF in cotransfected cells. The findings suggest a potential role for 14-3-3 in modulating p190RhoGEF activity or in linking p190RhoGEF to the activities of other pathways in the neuron.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Schlaepfer, WW (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 609 Stellar Chance Labs, Philadelphia, PA 19104 USA.							Cacace AM, 1999, MOL CELL BIOL, V19, P229; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WATANABE M, 1993, DEV BRAIN RES, V73, P225, DOI 10.1016/0165-3806(93)90142-W; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WATANABE M, 1993, MOL BRAIN RES, V17, P135, DOI 10.1016/0169-328X(93)90082-Z; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7	29	83	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41318	41324		10.1074/jbc.M107709200	http://dx.doi.org/10.1074/jbc.M107709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533041	hybrid			2022-12-25	WOS:000171925600125
J	Ando, K; Iijima, K; Elliott, JI; Kirino, Y; Suzuki, T				Ando, K; Iijima, K; Elliott, JI; Kirino, Y; Suzuki, T			Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; INTRACELLULAR DOMAIN; SECRETION; BINDING; HOMOLOG; FAMILY; CDNA; X11; APP; IDENTIFICATION	Neuronal Fe65 is an adapter protein that interacts with the cytoplasmic domain of the beta -amyloid precursor protein (APP). Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown. We report here that M a single amino acid mutation at the Thr-668 residue of APP695, located 14 amino acids toward the amino-terminal end from the (682) YENPTY687 motif, reduced the interaction between members of the Fe65 family of proteins and APP, whereas interaction of APP with the phosphotyrosine interaction domain of other APP binders such as X11-like and mammalian disabled-1 was not influenced by this mutation; (ii) the phosphorylation of APP at Thr-668 diminished the interaction of APP with Fe65 by causing a conformational change in the cytoplasmic domain that contains the Fe65-binding motif, YENPTY; and (iii) the expression of Fe65 slightly suppressed maturation of APP and decreased production of beta -amyloid (A beta). Mutation at Thr-668 of APP abolished the effect of Fc65 on APP maturation. This mutation blocked the Fe65-dependent suppression of A beta production and resulted in the release of increased levels of A beta in the presence of Fe65. We previously reported that during maturation of APP in neurons, the protein is specifically phosphorylated at Thr-668 and undergoes O-glycosylation. The present results suggest that the phosphorylation of O-glycosylated mature A-PP at Thr-668 causes a conformational change in its cytoplasmic domain that prevents binding of Fe65 in neurons and may lead to an alteration in the production of A beta.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Hokkaido University; University of Tokyo; Yale University	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.		Suzuki, Toshiharu/B-5342-2013					Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; HAASS C, 1993, J BIOL CHEM, V268, P3021; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Petukhov M, 1996, BIOCHEMISTRY-US, V35, P387, DOI 10.1021/bi9513766; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Ramelot TA, 2000, BIOCHEMISTRY-US, V39, P2714, DOI 10.1021/bi992580m; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P4643, DOI 10.1021/bi962618k; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Watanabe T, 1999, J NEUROCHEM, V72, P549, DOI 10.1046/j.1471-4159.1999.0720549.x; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	41	221	226	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40353	40361		10.1074/jbc.M104059200	http://dx.doi.org/10.1074/jbc.M104059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517218	hybrid			2022-12-25	WOS:000171789200113
J	Yoshimura, M; Homma, K; Saito, J; Inoue, A; Ikebe, R; Ikebe, M				Yoshimura, M; Homma, K; Saito, J; Inoue, A; Ikebe, R; Ikebe, M			Dual regulation of mammalian myosin VI motor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTIN-BASED MOTOR; UNCONVENTIONAL MYOSIN; LIGHT-CHAIN; ACANTHAMOEBA-CASTELLANII; I-BETA; CALMODULIN; PHOSPHORYLATION; KINASE; TRANSPORT	Myosin VI is expressed in a variety of cell types and is thought to play a role in membrane trafficking and endocytosis, yet its motor function and regulation are not understood. The present study clarified mammalian myosin VI motor function and regulation at a molecular level. Myosin VI ATPase activity was highly activated by actin with K-actin of 9 mum. A predominant amount of myosin VI bound to actin in the presence of ATP unlike conventional myosins. K-ATP was much higher than those of other known myosins, suggesting that myosin VI has a weak affinity or slow binding for ATP. On the other hand, ADP markedly inhibited the actin-activated ATPase activity, suggesting a high affinity for ADP. These results suggested that myosin VI is predominantly in a strong actin binding state during the ATPase cycle. p21-activated kinase 3 phosphorylated myosin VI, and the site was identified as Thr(406). The phosphorylation of myosin VI significantly facilitated the actin-translocating activity of myosin VI. On the other hand, Ca2+ diminished the actin-translocating activity of myosin VI although the actin-activated ATPase activity was not affected by Ca2+. Calmodulin was not dissociated from the heavy chain at high Ca2+, suggesting that a conformational change of calmodulin upon Ca2+ binding, but not its physical dissociation, determines the inhibition of the motility activity. The present results revealed the dual regulation of myosin VI by phosphorylation and Ca2+ binding to calmodulin light chain.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60381] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESI JP, 1983, J BIOL CHEM, V258, P176; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Bohrmann J, 1997, CELL MOL LIFE SCI, V53, P652, DOI 10.1007/s000180050084; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Higashihara M, 1989, J BIOL CHEM, V264, P5218; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; MERMALL V, 1995, J CELL BIOL, V129, P1575, DOI 10.1083/jcb.129.6.1575; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers J. R., 1999, MYOSINS; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tang DC, 1996, J BIOL CHEM, V271, P8605, DOI 10.1074/jbc.271.15.8605; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	45	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39600	39607		10.1074/jbc.M105080200	http://dx.doi.org/10.1074/jbc.M105080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517222	hybrid			2022-12-25	WOS:000171789200015
J	Harton, JA; Zika, E; Ting, JPY				Harton, JA; Zika, E; Ting, JPY			The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX CLASS-II; BARE LYMPHOCYTE SYNDROME; IN-VIVO; NF-Y; GTP-BINDING; CIITA; EXPRESSION; GENES; TRANSCRIPTION; INTERACTS	The class II transactivator (CIITA) is a transcriptional co-activator regulating the constitutive and interferon-gamma -inducible expression of class II major histocompatibility complex (MHC) and related genes. Promoter remodeling occurs following CIITA induction, suggesting the involvement of chromatin remodeling factors. Transcription of numerous genes requires the histone acetyltransferase (HAT) activities of CREB-binding protein (CBP), p300, and/or p300/CBP-associated factor (pCAF). These co-activators cooperate with CIITA and are hypothesized to promote class II major histocompatibility complex transcription through their HAT activity. To directly test this, we used HAT-defective CBP and pCAF. We demonstrate that cooperation between CIITA and CBP is independent of CBP HAT activity. Further, although pCAF enhances CIITA-mediated transcription, pCAF HAT domain dependence appears contingent upon the concentration of available CIITA. When HAT-defective CBP and pCAF are both present, cooperativity with CIITA is maintained. Consistent with a recent report, we show that nuclear localization of CIITA is enhanced by lysine 144, an in vitro target of pCAF-mediated HAT. Yet we find that neither mutation of lysine 144 nor deletion of residues 132-209 affects transcriptional cooperation with CBP or pCAF. Thus, acetylation of this residue may not be the primary mechanism for pCAF/CBP cooperation with CIITA. In conclusion, the HAT activities of the co-activators are not necessary for cooperation with CIITA.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.		Harton, Jonathan A/AAW-5283-2021; Harton, Jonathan/F-2848-2010	Harton, Jonathan A/0000-0002-0350-1877; Harton, Jonathan/0000-0002-0350-1877	NIAID NIH HHS [AI29564, AI45580, AI41751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045580, R01AI041751, R01AI029564, R56AI029564, R37AI029564] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kretsovali A, 2001, J BIOL CHEM, V276, P32191, DOI 10.1074/jbc.M103164200; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7; Masternak K, 2000, GENE DEV, V14, P1156; McDevitt HO, 1998, CURR OPIN IMMUNOL, V10, P677, DOI 10.1016/S0952-7915(98)80088-5; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Westerheide SD, 1997, J IMMUNOL, V158, P4812; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	45	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38715	38720		10.1074/jbc.M106652200	http://dx.doi.org/10.1074/jbc.M106652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514574	hybrid, Green Published			2022-12-25	WOS:000171673200053
J	Goukassian, D; Diez-Juan, A; Asahara, T; Schratzberger, P; Silver, M; Murayama, T; Isner, JM; Andres, V				Goukassian, D; Diez-Juan, A; Asahara, T; Schratzberger, P; Silver, M; Murayama, T; Isner, JM; Andres, V			Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis	FASEB JOURNAL			English	Article						p27; adenovirus; gene therapy	DEPENDENT KINASE INHIBITORS; GROWTH-FACTOR EXPRESSION; CYCLIN-E; BREAST-CANCER; METALLOPROTEINASE ACTIVITY; RECOMBINANT ADENOVIRUS; GENE-TRANSFER; P27; DEGRADATION; E2F	Formation of new blood vessels in the adult animal (i.e., angiogenesis) is an important event for tissue repair and for tumor growth and metastasis. Angiogenesis involves the migration and proliferation of endothelial cells. We have investigated the role of the growth suppressor p27(Kip1) (p27) on endothelial cell function in vitro and angiogenesis in vivo. We have generated Ad-TetON, a replication-deficient adenovirus that constitutively expresses the reverse tet-responsive transcriptional activator, and Ad-TRE-p27, which drives expression of p27 under the control of the tet response element. Western blot analysis demonstrated doxycycline-dependent overexpression of p27 in human umbilical vein endothelial cells (HUVECs) coinfected with Ad-TetON and Ad-TRE-p27, which resulted in a marked inhibition of DNA replication and cell migration in vitro. Inducible overexpression of p27 in cultured HUVECs inhibited the formation of tubelike structures and, when applied in a murine model of hind limb ischemia, reduced hind limb blood flow recovery and capillary density. These findings thus underscore a novel role of p27 in regulating endothelial cell migration in vitro and angiogenesis in vivo, suggesting a novel anti-angiogenic therapy based on inducible p27 overexpression.	CSIC, Inst Biomed Valencia, Lab Vasc Biol, Spanish Council Sci Res, Valencia 46010, Spain; Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med Cardiol, Boston, MA 02135 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Boston University; St. Elizabeth's Medical Center; Tufts University	Andres, V (corresponding author), CSIC, Inst Biomed Valencia, Lab Vasc Biol, Spanish Council Sci Res, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869; Goukassian, David/0000-0001-5270-5270				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bouvet M, 1998, CANCER RES, V58, P2288; Boyle JR, 1998, J VASC SURG, V27, P354, DOI 10.1016/S0741-5214(98)70367-2; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen DH, 2000, ARTERIOSCL THROM VAS, V20, P629, DOI 10.1161/01.ATV.20.3.629; Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Diez-Juan A, 2001, FASEB J, V15, P1989, DOI 10.1096/fj.01-0130com; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Feldman AL, 2000, CANCER-AM CANCER SOC, V89, P1181; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fife RS, 2000, CANCER LETT, V153, P75, DOI 10.1016/S0304-3835(00)00348-7; Fiorentino M, 2000, CLIN CANCER RES, V6, P3966; Folkman J, 1999, Forum (Genova), V9, P59; Fukui R, 1997, ATHEROSCLEROSIS, V132, P53, DOI 10.1016/S0021-9150(97)00086-5; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harada H, 1999, CANCER RES, V59, P3783; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Ihling C, 1999, ATHEROSCLEROSIS, V144, P7, DOI 10.1016/S0021-9150(99)00032-5; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Lavia P, 1999, BIOESSAYS, V21, P221; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Ryan ME, 2001, CURR MED CHEM, V8, P305, DOI 10.2174/0929867013373598; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; So JBY, 2000, J SURG RES, V94, P56, DOI 10.1006/jsre.2000.5998; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Vieillard-Baron A, 2000, CIRC RES, V87, P418; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	56	83	88	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1877	1885		10.1096/fj.01-0065com	http://dx.doi.org/10.1096/fj.01-0065com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532967	Green Submitted			2022-12-25	WOS:000171372700002
J	Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T				Miyaki, M; Iijima, T; Shiba, K; Aki, T; Kita, Y; Yasuno, M; Mori, T; Kuroki, T; Iwama, T			Alterations of repeated sequences in 5 ' upstream and coding regions in colorectal tumors from patients with hereditary nonpolyposis colorectal cancer and Turcot syndrome	ONCOGENE			English	Article						mutation; repeated sequence; 5 ' upstream region; HNPCC; Turcot; Dukes stage	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; MICROSATELLITE MUTATOR PHENOTYPE; COLON-CANCER; FRAMESHIFT MUTATIONS; BAX GENE; INSTABILITY; CASPASE-5; RECEPTOR; HOMOLOG	One of the characteristics of tumors from patients with germline mutations of DNA mismatch repair genes is instability at microsatellite regions (MSI). We analysed alterations at repeated sequences of coding regions, as well as those of 5' upstream regions, in 29 MSI-High colorectal tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC) and Turcot syndrome. We found that repeated sequences in 5' upstream regions were altered in these tumors, at considerable frequencies. The (A)(10) repeat in the promoter region (position - 178 similar to - 169) of the GAPDH gene was altered in 17% of the tumors. The (A)(10)(TA)(9) in the 5' upstream region (position -318 similar to -291) of the mitochondrial isoleucyl tRNA synthetase gene (IIeRS-A), coded in nuclear DNA, was altered in 59% of the tumors, whereas (A)(9) in the 5' upstream region (position -859 similar to -851) of cytoplasmic isoleucyl tRNA synthetase gene (IIeRS-B) was not altered. Alteration at repeated sequences in the coding regions were 72% at TGF beta RII(A)(10), 24% at IGFIIR(G)(8), 45% at BAX(G)(8), 55% at E2F4(CAG)(13), 66% at caspase-5 (A)(10), 31% at MBD4(A)(10), 55% at hMSH3(A)(8) and 34% at hMSH6(C)(8). The number of altered genes increased with the advancement of carcinoma according to Dukes categories: mean numbers of altered genes within these 10 genes were 2.6 for Dukes A, 4.7 for Dukes B and 7.8 for Dukes C. The mean number for adenomas was 2.0. These results suggest that the MSI phenotype also causes alteration of 5' upstream regions which may affect apoptosis and some mitochondrial functions in HNPCC and Turcot tumors, and that accumulation of altered genes with repeated sequences is associated with the progression of HNPCC and Turcot colorectal tumors.	Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Inst Med Sci, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan; Inst Canc Res, Tokyo 1708455, Japan; Yamaguchi Univ, Ube, Yamaguchi 7550805, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan; Kyoundo Hosp, Sasaki Inst, Tokyo 1010062, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Japanese Foundation for Cancer Research; Yamaguchi University; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Komagome Hosp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011; Shiba, Kiyotaka/I-9588-2014	Kuroki, Toshio/0000-0001-6369-4351; Shiba, Kiyotaka/0000-0001-6459-0204				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aki T, 1997, J BIOCHEM, V122, P271; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MIYASHITA T, 1995, CELL, V80, P293; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	23	18	22	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5215	5218		10.1038/sj.onc.1204578	http://dx.doi.org/10.1038/sj.onc.1204578			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526511				2022-12-25	WOS:000170464000016
J	Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M				Kanzler, S; Meyer, E; Lohse, AW; Schirmacher, P; Henninger, J; Galle, PR; Blessing, M			Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis	ONCOGENE			English	Article						transforming growth factor-beta; hepatocarcinogenesis; transgenic mice; TGF-beta receptor; tumor suppressor	GROWTH-FACTOR-BETA; C-REACTIVE PROTEIN; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY; FACTOR (TGF)-ALPHA; MESSENGER-RNA; CANCER CELLS; RAT-LIVER; GENE	The potent growth-inhibitory activity of cytokines of the transforming growth factor-beta (TGF-beta) superfamily and their widespread expression in epithelia suggest that they may play an important role in the maintenance of epithetial homeostasis. To analyse TGF-beta mediated tumor suppressor activity in the liver, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in hepatocytes under control of the regulatory elements of the human C-reactive protein gene promoter. Transgenic animals exhibited constitutive and liver-specific transgene expression. The functional inactivation of the TGF-beta signaling pathway in transgenic hepatocytes was shown by reduced TGF-beta induced inhibition of DNA synthesis in primary hepatocyte cultures. Liver morphology and spontaneous tumorigenesis were unchanged in transgenic mice suggesting that interruption of the signaling of all three isoforms of TGF-beta in hepatocytes does not disturb tissue homeostasis in the liver under physiological conditions. However, following initiation with the carcinogen diethylnitrosamine and tumor-promotion with phenobarbital transgenic mice exhibited a moderate albeit significant increase in the incidence, size and multiplicity of both preneoplastic tissue lesions in the liver and of hepatocellular carcinomas. These results give in vivo evidence for a tumor suppressor activity of the endogeneous TGF-beta system in the liver during chemical hepatocarcinogenesis.	Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany; Univ Cologne, Dept Pathol, D-50931 Cologne, Germany	Johannes Gutenberg University of Mainz; University of Cologne	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, D-55131 Mainz, Germany.	Blessing@mail.uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992				Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; ALEXANDROW MG, 1995, CANCER RES, V55, P3928; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Bottinger EP, 1997, CANCER RES, V57, P5564; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRAND T, 1993, J BIOL CHEM, V268, P11500; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1; Chang J, 1997, CANCER RES, V57, P2856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; Cook T, 1998, J BIOL CHEM, V273, P25929, DOI 10.1074/jbc.273.40.25929; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Factor VM, 1997, CANCER RES, V57, P2089; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Gitelman SE, 1997, MAMM GENOME, V8, P212, DOI 10.1007/s003359900391; Glick AB, 1997, CANCER RES, V57, P2079; Gobbi H, 2000, HISTOPATHOLOGY, V36, P168; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; HADDOW S, 1991, ONCOGENE, V6, P1465; HADDOW S, 1991, ONCOGENE, V6, P2377; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOGAN B, 1986, MANIPULATING MOUSE E; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ITO N, 1991, CANCER RES, V51, P4080; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kanzler S, 1999, AM J PHYSIOL-GASTR L, V276, pG1059, DOI 10.1152/ajpgi.1999.276.4.G1059; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim IY, 1996, CANCER RES, V56, P44; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lim IK, 1999, MOL CARCINOGEN, V26, P83, DOI 10.1002/(SICI)1098-2744(199910)26:2<83::AID-MC3>3.3.CO;2-W; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MURPHY C, 1995, J BIOL CHEM, V270, P704, DOI 10.1074/jbc.270.2.704; MYEROFF LL, 1995, CANCER RES, V55, P5545; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PITOT HC, 1987, NONGENOTOXIC MECH CA, P41; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Ruether Ulrich, 1993, Oncogene, V8, P87; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Santoni-Rugiu E, 1999, AM J PATHOL, V154, P1693, DOI 10.1016/S0002-9440(10)65425-9; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shin KH, 2000, CLIN CANCER RES, V6, P536; Sugiyama A, 1997, BIOCHEM BIOPH RES CO, V238, P539, DOI 10.1006/bbrc.1997.7338; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; THORGEIRSSON SS, 1997, ARCH TOXICOL, V19, P3359; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WHITEHEAD AS, 1983, SCIENCE, V221, P69, DOI 10.1126/science.6857266; WU SP, 1993, CELL GROWTH DIFFER, V4, P115	71	68	72	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5015	5024		10.1038/sj.onc.1204544	http://dx.doi.org/10.1038/sj.onc.1204544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526486				2022-12-25	WOS:000170439800011
J	Plemper, RK; Hammond, AL; Cattaneo, R				Plemper, RK; Hammond, AL; Cattaneo, R			Measles virus envelope glycoproteins hetero-oligomerize in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION PROTEIN; HEMAGGLUTININ-NEURAMINIDASE; CELL-FUSION; SURFACE EXPRESSION; EDMONSTON STRAIN; MESSENGER-RNA; F-PROTEIN; RETENTION; IDENTIFICATION; RECEPTOR	The endoplasmic reticulum (ER) was investigated as the initial oligomerization site for the envelope glycoproteins H and F of measles virus (MV), a clinically relevant member of the Paramyxoviridae family, and consequences of this interaction for viral replication were studied. Both proteins were tagged at their cytosolic tails with RRR and KKXX motifs, respectively, resulting in their efficient retention in the ER. Cotransfection of the retained constructs with transport competent ATV glycoproteins revealed a dominant negative effect on their biological activity indicating intracellular complex formation and thus retention. Pulse-chase analysis and co-immunoprecipitation experiments demonstrated that this effect is based on both homo- and hetero-oligomerization in the ER. Recombinant viruses additionally expressing ER-retained F showed an altered cytopathic phenotype accompanied by greatly reduced particle release. Similar mutant viruses additionally expressing ER-retained H could not be rescued indicating an even greater negative effect of this protein on virus viability. Our study suggests that both homo- and hetero-oligomerization of AIV glycoproteins occur in the ER and that these events are of significance for early steps of particle assembly.	Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA	Mayo Clinic	Plemper, RK (corresponding author), Mayo Fdn, Program Mol Med, 200 1st St SW, Rochester, MN 55905 USA.							Bolt G, 1998, VIROLOGY, V252, P387, DOI 10.1006/viro.1998.9464; Browne H, 1996, J VIROL, V70, P4311, DOI 10.1128/JVI.70.7.4311-4316.1996; CALAIN P, 1993, J VIROL, V67, P4822, DOI 10.1128/JVI.67.8.4822-4830.1993; Cathomen T, 1995, VIROLOGY, V214, P628, DOI 10.1006/viro.1995.0075; Cathomen T, 1998, J VIROL, V72, P1224, DOI 10.1128/JVI.72.2.1224-1234.1998; CATTANEO R, 1987, EMBO J, V6, P681, DOI 10.1002/j.1460-2075.1987.tb04808.x; DENG RT, 1995, VIROLOGY, V209, P457, DOI 10.1006/viro.1995.1278; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Duprex WP, 1999, J VIROL, V73, P9568, DOI 10.1128/JVI.73.11.9568-9575.1999; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; HORVATH CM, 1992, J VIROL, V66, P4564, DOI 10.1128/JVI.66.7.4564-4569.1992; Hsu EC, 2001, VIROLOGY, V279, P9, DOI 10.1006/viro.2000.0711; HU AZ, 1995, J GEN VIROL, V76, P705, DOI 10.1099/0022-1317-76-3-705; HU XL, 1992, J VIROL, V66, P1528, DOI 10.1128/JVI.66.3.1528-1534.1992; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Kado G, 1976, Dev Biol Stand, V37, P261; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MALVOISIN E, 1993, J GEN VIROL, V74, P2365, DOI 10.1099/0022-1317-74-11-2365; MARKWELL MAK, 1980, P NATL ACAD SCI-BIOL, V77, P5693, DOI 10.1073/pnas.77.10.5693; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OGURA H, 1991, J GEN VIROL, V72, P2679, DOI 10.1099/0022-1317-72-11-2679; Paterson RG, 1997, VIROLOGY, V237, P1, DOI 10.1006/viro.1997.8759; Plemper RK, 2000, J VIROL, V74, P6485, DOI 10.1128/JVI.74.14.6485-6493.2000; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; RICHARDSON C, 1986, VIROLOGY, V155, P508, DOI 10.1016/0042-6822(86)90212-6; Salzwedel K, 1998, J VIROL, V72, P7523, DOI 10.1128/JVI.72.9.7523-7531.1998; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Suzuki T, 2001, J VIROL, V75, P4604, DOI 10.1128/JVI.75.10.4604-4613.2001; Tanabayashi K, 1996, J VIROL, V70, P6112, DOI 10.1128/JVI.70.9.6112-6118.1996; Tanaka Y, 1996, J VIROL, V70, P5005, DOI 10.1128/JVI.70.8.5005-5015.1996; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Tong SX, 1999, J GEN VIROL, V80, P107, DOI 10.1099/0022-1317-80-1-107; TSURUDOME M, 1995, VIROLOGY, V213, P190, DOI 10.1006/viro.1995.1559; Wang Z, 2001, VACCINE, V19, P2329, DOI 10.1016/S0264-410X(00)00523-5; Yao QZ, 1997, J VIROL, V71, P650, DOI 10.1128/JVI.71.1.650-656.1997	38	88	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44239	44246		10.1074/jbc.M105967200	http://dx.doi.org/10.1074/jbc.M105967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11535597	hybrid			2022-12-25	WOS:000172297700096
J	Bibby, TS; Nield, J; Barber, J				Bibby, TS; Nield, J; Barber, J			Three-dimensional model and characterization of the iron stress-induced CP43 '-photosystem I supercomplex isolated from the cyanobacterium Synechocystis PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; EQUATORIAL PACIFIC-OCEAN; ANACYSTIS-NIDULANS R2; PHOTOSYSTEM-II; SYNECHOCOCCUS SP; ANGULAR RECONSTITUTION; CHLOROPHYLL-PROTEIN; ISIA GENE; RESOLUTION; COMPLEX	The cyanobacterium Synechocystis PCC 6803 has been subjected to growth under iron-deficient conditions. As a consequence, the isiA gene is expressed, and its product, the chlorophyll a-binding protein CP43', accumulates in the cell. Recently, we have shown for the first time that 18 copies of this photosystem II (PSII)-like chlorophyll a-binding protein forms a ring around the trimeric photosystem I (PSI) reaction center (Bibby, T. S., Nield, J., and Barber, J. (2001) Nature, 412, 743-745). Here we further characterize the biochemical and structural properties of this novel CP43'-PSI supercomplex confirming that it is a functional unit of approximately 1900 kDa where the antenna size of PSI is increased by 70% or more. Using electron microscopy and single particle analysis, we have constructed a preliminary three-dimensional model of the CP43'-PSI supercomplex and used it as a framework to incorporate higher resolution structures of PSI and CP43 recently derived from x-ray crystallography. Not only does this work emphasize the flexibility of cyanobacterial light-harvesting systems in response to the lowering of phycobilisome and PSI levels under iron-deficient conditions, but it also has implications for understanding the organization of the related chlorophyll a/b-binding Pcb proteins of oxychlorobacteria, formerly known as prochlorophytes.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England.	j.barber@ic.ac.uk	Nield, Jon/C-5892-2013; Bibby, Thomas/C-9159-2014	Nield, Jon/0000-0001-9983-0239; Bibby, Thomas/0000-0003-1743-473X				Behrenfeld MJ, 1996, NATURE, V383, P508, DOI 10.1038/383508a0; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; BIBBY TS, 2001, IN PRESS NATURE; BRAUN V, 1990, MOL BASIS BACTERIAL, P35; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; FALK S, 1995, PHOTOSYNTH RES, V45, P51, DOI 10.1007/BF00032235; Garczarek L, 1998, PHOTOSYNTH RES, V56, P131, DOI 10.1023/A:1006049832657; Garczarek L, 2000, P NATL ACAD SCI USA, V97, P4098, DOI 10.1073/pnas.070040897; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUIKEMA JA, 1984, PLANT PHYSIOL, V74, P90, DOI 10.1104/pp.74.1.90; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; HANKAMER B, 2001, IN PRESS J STRUCT IO; HUTBER GN, 1977, FEMS MICROBIOL LETT, V1, P193, DOI 10.1111/j.1574-6968.1977.tb00612.x; Ivanov AG, 2000, FEBS LETT, V485, P173, DOI 10.1016/S0014-5793(00)02211-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LAUDENBACH DE, 1988, J BACTERIOL, V170, P258, DOI 10.1128/jb.170.1.258-265.1988; LAUDENBACH DE, 1988, J BACTERIOL, V170, P5018, DOI 10.1128/jb.170.11.5018-5026.1988; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; PAKRASI HB, 1985, P NATL ACAD SCI USA, V82, P6903, DOI 10.1073/pnas.82.20.6903; Park YI, 1999, MOL MICROBIOL, V32, P123, DOI 10.1046/j.1365-2958.1999.01332.x; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RIETHMAN HC, 1988, BIOCHIM BIOPHYS ACTA, V935, P141, DOI 10.1016/0005-2728(88)90211-3; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Tetenkin VL, 1998, BIOCHEMISTRY-MOSCOW+, V63, P584; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANDERSTAAY GWM, 1993, BIOCHIM BIOPHYS ACTA, V1142, P189, DOI 10.1016/0005-2728(93)90101-K; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; XU Q, 1994, J BIOL CHEM, V269, P21512; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	40	65	70	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43246	43252		10.1074/jbc.M106541200	http://dx.doi.org/10.1074/jbc.M106541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11518716	hybrid			2022-12-25	WOS:000172169300080
J	Lockwich, T; Singh, BB; Liu, XB; Ambudkar, IS				Lockwich, T; Singh, BB; Liu, XB; Ambudkar, IS			Stabilization of cortical actin induces internalization of transient receptor potential 3 (Trp3)-associated caveolar Ca2+ signaling complex and loss of Ca2+ influx without disruption of Trp3-inositol trisphosphate receptor association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PROTEIN PHOSPHATASE; POTENTIAL CHANNELS; STORE DEPLETION; ACTIVATION; ORGANIZATION; MEMBRANE; ENTRY; CYTOSKELETAL; DOMAIN	Ca2+ influx via plasma membrane Trp3 channels is proposed to be regulated by a reversible interaction with inositol trisphosphate receptor (IP,R) in the endoplasmic reticulum. Condensation of the cortical actin layer has been suggested to physically disrupt this interaction and inhibit Trp3-mediated Ca2+ influx. This study examines the effect of cytoskeletal reorganization on the localization and function of Trp3 and key Ca2+ signaling proteins. Calyculin-A treatment resulted in formation of condensed actin layer at the plasma membrane; internalization of Trp3, G alpha (q/11), phospholipase C beta, and caveolin-1; and attenuation of 1-oleoyl-2-acetyl-sn-glycerol- and ATP-stimulated Sr2+ influx. Importantly, Trp3 and IP3R-3 remained co-localized inside the cell and were co-immunoprecipitated. Jasplakinolide also induced internalization of Trp3 and caveolin-1. Pretreatment of cells with cytochalasin D or staurosporine did not affect Trp3 but prevented calyculin-A-induced effects. Based on these data, we suggest that Trp3 is assembled in a caveolar Ca2+ signaling complex with IP3R, SERCA, G alpha (q/11), phospholipase C beta, caveolin-1, and ezrin. Furthermore, our data demonstrate that conditions which stabilize cortical actin induce loss of Trp3 activity due to internalization of the Trp3-signaling complex, not disruption of IP3R-Trp3 interaction. This suggests that localization of the Trp3-associated signaling complex, rather than Trp3-IP3R coupling, depends on the status of the actin cytoskeleton.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambukar@nih.gov		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KREIENBUHL P, 1992, BLOOD, V80, P2911; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 1995, J MEMBRANE BIOL, V148, P277; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Sakai T, 1997, PFLUG ARCH EUR J PHY, V433, P464, DOI 10.1007/s004240050301; Sakai T, 1996, AM J PHYSIOL-CELL PH, V271, pC284, DOI 10.1152/ajpcell.1996.271.1.C284; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; SHINOKI N, 1995, J CELL BIOCHEM, V59, P368, DOI 10.1002/jcb.240590308; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Toivola DM, 1997, J CELL SCI, V110, P23; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	42	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42401	42408		10.1074/jbc.M106956200	http://dx.doi.org/10.1074/jbc.M106956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11524429	hybrid			2022-12-25	WOS:000172450400112
J	Song, CS; Echchgadda, I; Baek, BS; Ahn, SC; Oh, T; Roy, AK; Chatterjee, B				Song, CS; Echchgadda, I; Baek, BS; Ahn, SC; Oh, T; Roy, AK; Chatterjee, B			Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MOLECULAR-CLONING; STRUCTURAL CHARACTERIZATION; NUCLEAR RECEPTORS; ANDROGEN; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; PROMOTER	Dehydroepiandrosterone sulfotransferase (STD) is a hydroxysteroid sulfo-conjugating enzyme with preferential substrate specificity for C-19 androgenic steroids and C-24 bile acids. STD is primarily expressed in the liver, intestine and adrenal cortex. Earlier studies have shown that androgens inhibit the rat Std promoter function through a negative androgen response region located between -235 and -310 base pair positions (Song, C. S., Jung, M. H., Kim, S. C., Hassan, T., Roy, A. K., and Chatterjee, B. (1998) J. Biol Chem. 273, 21856-21866). Here we report that the primary bile acid chenodeoxycholic acid (CDCA) also acts as an important regulator of the Std gene promoter. CDCA is a potent inducer of the Std gene, and its inducing effect is mediated through the bile acid-activated farnesoid X receptor (FXR), a recently characterized member of the nuclear receptor superfamily. The ligand-activated FXR acts as a heterodimer with the 9-cis-retinoic acid receptor (RXR) and regulates the Std gene by binding to an upstream region at base pair positions -169 to -193. This specific binding region was initially identified by bile acid responsiveness of the progressively deleted forms of the Std promoter in transfected HepG2 hepatoma and enterocyte-like Caco-2 cells. Subsequently, the precise RXR/FXR binding position was established by protein-DNA interaction using in vitro footprinting and electrophoretic mobility shift analyses. Unlike all other previously characterized FXR target genes, which contain an inverted repeat (IR) of the consensus hexanucleotide half-site (A/G)G(G/T)TCA with a single nucleotide spacer (IR-1), the bile acid response element of the Std promoter does not contain any spacer between the two hexanucleotide repeats (IR-0). A promoter-reporter construct carrying three tandem copies of the IR-0 containing -169/-193 element, linked to a minimal thymidine kinase promoter, can be stimulated more than 70-fold in transfected Caco-2 cells upon CDCA treatment. Autoregulation of the STD gene by its bile acid substrate may provide an important contributing role in the enterohepatic bile acid metabolism and cholesterol homeostasis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Chatterjee, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIA NIH HHS [AG-10486] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010486, R37AG010486] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; BARNES S, 1989, J LIPID RES, V30, P529; Bouly M, 2001, J BIOL CHEM, V276, P25841, DOI 10.1074/jbc.M101160200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILLOOLIVARE.A, 2000, J BIOL CHEM, V275, P17793; Chan J, 1998, CHEM-BIOL INTERACT, V109, P267, DOI 10.1016/S0009-2797(97)00138-5; CHATTERJEE B, 1994, CHEM-BIOL INTERACT, V92, P273, DOI 10.1016/0009-2797(94)90069-8; Chatterjee B, 1996, P NATL ACAD SCI USA, V93, P728, DOI 10.1073/pnas.93.2.728; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; DAVITT NB, 2001, ENDOCRINOLOGY, V142, P2978; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Freimuth RR, 2000, GENOMICS, V65, P157, DOI 10.1006/geno.2000.6150; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; Her C, 1996, DRUG METAB DISPOS, V24, P1328; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Liu MC, 1999, BIOCHEM BIOPH RES CO, V254, P65, DOI 10.1006/bbrc.1998.9872; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; LUUTHE V, 1995, DNA CELL BIOL, V14, P511, DOI 10.1089/dna.1995.14.511; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mulder G.J., 1990, CONJUGATION REACTION, P107; OGURA K, 1994, CHEM-BIOL INTERACT, V92, P129, DOI 10.1016/0009-2797(94)90059-0; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; OTTERNESS DM, 1995, DNA CELL BIOL, V14, P331, DOI 10.1089/dna.1995.14.331; Parker CR, 2000, ENDOCR RES, V26, P517; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160	44	166	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42549	42556		10.1074/jbc.M107557200	http://dx.doi.org/10.1074/jbc.M107557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533040	hybrid			2022-12-25	WOS:000172450400130
J	Devarajan, P; De Leon, M; Talasazan, F; Schoenfeld, AR; Davidowitz, EJ; Burk, RD				Devarajan, P; De Leon, M; Talasazan, F; Schoenfeld, AR; Davidowitz, EJ; Burk, RD			The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; BCL-2 FAMILY MEMBERS; ATP DEPLETION; CYTOCHROME-C; MEDIATED APOPTOSIS; UBIQUITIN LIGASE; CARCINOMA-CELLS; PROTEIN; INJURY; DEATH	Previous studies have reported a protective role for the von Hippel-Lindau (VHL) gene products against proapoptotic cellular stresses, but the mechanisms remain unclear. In this study, we examined the role of VHL in renal cells subjected to chemical hypoxia, using four VHL-negative and two VHL-positive cell lines. VHL-negative renal carcinoma cells underwent apoptosis following chemical hypoxia (short-term glucose deprivation and antimycin treatment), as evidenced by morphologic changes and internucleosomal DNA cleavage. Reintroduction of VHL expression prevented this apoptosis. VHL-negative cells displayed a significant (greater than 5-fold) activation of caspase 9 and release of cytochrome c into the cytosol following chemical hypoxia. In contrast, VHL-positive cells showed minimal caspase 9 activation, and absence of cytochrome c release under the same conditions. Caspase 8 was only minimally activated in both VHL-negative and -positive cells. In addition, VHL-positive cells displayed a striking up-regulation of Bcl-2 expression (5-fold) following chemical hypoxia. Antisense oligonucleotides to Bcl-2 significantly down-regulated Bcl-2 protein expression in VHL-positive cells and rendered them sensitive to apoptosis. Overexpression of Bcl-2 in VHL-negative cells conferred resistance to apoptosis. Our results suggest that VHL protects renal cells from apoptosis via Bcl-2-dependent pathways.	Albert Einstein Coll Med, Dept Pediat, Div Pediat Nephrol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Devarajan, P (corresponding author), Ctr Childrens Kidney, 3326 Bainbridge Ave, Bronx, NY 10467 USA.			Schoenfeld, Alan R./0000-0002-6778-1548	NIDDK NIH HHS [DK 07110, R01 DK 53289, DK 07218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218, R01DK053289, T32DK007110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ananth S, 1999, CANCER RES, V59, P2210; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BACALLAO R, 1994, J CELL SCI, V107, P3301; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; ERKAN E, 2001, AM J PHYSL, V280; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Gobe G, 2000, J AM SOC NEPHROL, V11, P454, DOI 10.1681/ASN.V113454; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagar H, 1997, KIDNEY INT, V51, P1747, DOI 10.1038/ki.1997.240; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Haupt Y, 1996, Behring Inst Mitt, P32; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Katoh S, 1999, BIOCHEM J, V338, P465, DOI 10.1042/0264-6021:3380465; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; Lee S, 1999, MOL CELL BIOL, V19, P1486; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; Van Why SK, 1999, AM J PHYSIOL-RENAL, V277, pF227, DOI 10.1152/ajprenal.1999.277.2.F227; VENKATACHALAM MA, 1988, J CLIN INVEST, V81, P745, DOI 10.1172/JCI113380; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104	51	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40599	40605		10.1074/jbc.M103424200	http://dx.doi.org/10.1074/jbc.M103424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514546	hybrid			2022-12-25	WOS:000171925600031
J	Donovan, JCH; Milic, A; Slingerland, JM				Donovan, JCH; Milic, A; Slingerland, JM			Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27; CYCLIN E-CDK2 ACTIVATION; DEPENDENT KINASE; ESTROGEN-RECEPTOR; PROTEIN-KINASE; TAMOXIFEN RESISTANCE; RESTRICTION POINT; ENDOCRINE THERAPY; EPITHELIAL-CELLS; DOWN-REGULATION	Antiestrogens, such as the drug tamoxifen, inhibit breast cancer growth by inducing cell cycle arrest. Antiestrogens require action of the cell cycle inhibitor p27(Kip1) to mediate G(1) arrest in estrogen receptor-positive breast cancer cells. We report that constitutive activation of the mitogen-activated protein kinase (MAPK) pathway alters p27 phosphorylation, reduces p27 protein levels, reduces the cdk2 inhibitory activity of the remaining p27, and contributes to antiestrogen resistance. In two antiestrogen-resistant cell lines that showed increased MAPK activation, inhibition of the MAPK kinase (MEK) by addition of U0126 changed p27 phosphorylation and restored p27 inhibitory function and sensitivity to antiestrogens. Using antisense p27 oligonucleotides, we demonstrated that this restoration of antiestrogen-mediated cell cycle arrest required p27 function. These data suggest that oncogene-mediated MAPK activation, frequently observed in human breast cancers, contributes to antiestrogen resistance through p27 deregulation.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, JM (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; BRUNNER N, 1993, CANCER RES, V53, P3229; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coutts AS, 1998, CANCER RES, V58, P4071; ELASHRY D, 1997, ONCOGENE, V15, P435; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Florenes VA, 1996, ONCOGENE, V13, P2447; FOSTER J, 1996, MOL ENDOCRINOL, P488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hori M, 2000, PATHOL RES PRACT, V196, P817, DOI 10.1016/S0344-0338(00)80081-3; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kurokawa H, 2000, CANCER RES, V60, P5887; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maemura M, 1999, ONCOLOGY-BASEL, V57, P37, DOI 10.1159/000055273; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Naumann U, 1999, BIOCHEM BIOPH RES CO, V261, P890, DOI 10.1006/bbrc.1999.1126; NICHOLSON S, 1989, LANCET, V1, P182; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; Novotny L, 2000, NEOPLASMA, V47, P3; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; PRESS MF, 1993, CANCER RES, V53, P4960; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Robertson JFR, 1996, BRIT J CANCER, V73, P5, DOI 10.1038/bjc.1996.2; Salh B, 1999, ANTICANCER RES, V19, P731; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Takimoto GS, 1999, J STEROID BIOCHEM, V69, P45, DOI 10.1016/S0960-0760(98)00148-4; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tan P, 1997, CANCER RES, V57, P1259; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WRIGHT C, 1989, CANCER RES, V49, P2087; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200	62	118	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40888	40895		10.1074/jbc.M106448200	http://dx.doi.org/10.1074/jbc.M106448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527971	hybrid			2022-12-25	WOS:000171925600069
J	Johnson, AA; Ray, AS; Hanes, J; Suo, ZC; Colacino, JM; Anderson, KS; Johnson, KA				Johnson, AA; Ray, AS; Hanes, J; Suo, ZC; Colacino, JM; Anderson, KS; Johnson, KA			Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; KINETIC CHARACTERIZATION; NUCLEOTIDE INCORPORATION; FIALURIDINE FIAU; DIDANOSINE DDI; SIV INFECTION; WILD-TYPE; INHIBITION; MECHANISM	To examine the role of the mitochondrial polymerase (Pol gamma) in clinically observed toxicity of nucleoside analogs used to treat AIDS, we examined the kinetics of incorporation catalyzed by Pol gamma for each Food and Drug Administration-approved analog plus 1-(2-deoxy2-fluoro-beta -D-arabinofuranosyl)-5-iodouracil (FIAU), beta -L-(-)-2',3'-dideoxy-3'-thiacytidine (-)3TC, and (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA). We used recombinant exonuclease-deficient (E200A), reconstituted human Poly holoenzyme in single turnover kinetic studies to measure K-d (K-m) and k(pol) (k(cat)) to estimate the specificity constant (k(cat)/K-m) for each nucleoside analog triphosphate. The specificity constants vary more than 500,000-fold for the series ddC > ddA (ddI) much greater than 2',3'-didehydro-2',3'-dideoxythymidine (d4T) much greater than (+)3TC (-)3TC > PMPA > azidothymidine (AZT) Carbovir (CBV). Abacavir (prodrug of CBV) and PMPA are two new drugs that are expected to be least toxic. Notably, the higher toxicities of d4T, ddC, and ddA arose from their 13-36-fold tighter binding relative to the normal dNTP even though their rates of incorporation were comparable with PMPA and AZT. We also examined the rate of exonuclease removal of each analog after incorporation. The rates varied from 0.06 to 0.0004 s(-1) for the series FIAU > (+)3TC (-)3TC > CBV > AZT > PMPA similar to d4T much greater than ddA (ddI) much greater than ddC. Removal of ddC was too slow to measure (<0.00002 s(-1)). The high toxicity of dideoxy compounds, ddC and ddI (metabolized to ddA), may be a combination of high rates of incorporation and ineffective exonuclease removal. Conversely, the more effective excision of (-)3TC, CBV, and AZT may contribute to lower toxicity. FIAU is readily extended by the next correct base pair (0.13 s(-1)) faster than it is removed (0.06 s(-1)) and, therefore, is stably incorporated and highly mutagenic. We define a toxicity index for chain terminators to account for relative rates of incorporation versus removal. These results provide a method to rapidly screen new analogs for potential toxicity.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Eli Lilly & Co, Lilly Res Labs, Infect Dis Res, Indianapolis, IN 46285 USA	University of Texas System; University of Texas Austin; Yale University; Eli Lilly	Johnson, KA (corresponding author), Univ Texas, Inst Mol & Cellular Biol, MBB 3-122,A4800, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu		Ray, Adrian/0000-0002-3508-3008	NIGMS NIH HHS [GM49551, GM44613] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; BALZARINI J, 1994, PHARM WORLD SCI, V16, P113, DOI 10.1007/BF01880662; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8; Brinkman K, 2000, CURR OPIN INFECT DIS, V13, P5, DOI 10.1097/00001432-200002000-00002; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1991, MOL PHARMACOL, V39, P625; Colacino JM, 1996, TOXICOL IN VITRO, V10, P297, DOI 10.1016/0887-2333(96)00016-1; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Deeks SG, 1998, ANTIMICROB AGENTS CH, V42, P2380, DOI 10.1128/AAC.42.9.2380; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Honkoop P, 1997, DRUG SAFETY, V17, P1, DOI 10.2165/00002018-199717010-00001; Horn DM, 1997, ANTIVIR RES, V34, P71, DOI 10.1016/S0166-3542(96)01027-3; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Kewn S, 1999, AIDS RES HUM RETROV, V15, P793, DOI 10.1089/088922299310692; Krayevsky AA, 1998, NUCLEOS NUCLEOT, V17, P1153, DOI 10.1080/07328319808004228; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Kumar A, 2001, VIROLOGY, V279, P97, DOI 10.1006/viro.2000.0710; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; Nusbaum NJ, 1996, DNA CELL BIOL, V15, P363, DOI 10.1089/dna.1996.15.363; Parker WB, 1997, ANTIVIR RES, V34, P131, DOI 10.1016/S0166-3542(97)01033-4; PARKER WB, 1994, J NIH RES, V6, P57; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Periclou AP, 2000, IN VIVO, V14, P377; Ray AS, 2001, NUCLEOS NUCLEOT NUCL, V20, P1247, DOI 10.1081/NCN-100002528; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SEMIZAROV DG, 1994, FEBS LETT, V354, P187, DOI 10.1016/0014-5793(94)01123-0; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; SKOWRON G, 1990, AM J MED, V88, pS20, DOI 10.1016/0002-9343(90)90417-C; Smith MS, 2000, VIROLOGY, V277, P306, DOI 10.1006/viro.2000.0609; STASCHKE KA, 1994, J VIROL, V68, P8265, DOI 10.1128/JVI.68.12.8265-8269.1994; Suo ZC, 1998, J BIOL CHEM, V273, P27250, DOI 10.1074/jbc.273.42.27250; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Tsai CC, 1997, AIDS RES HUM RETROV, V13, P707, DOI 10.1089/aid.1997.13.707; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Wang HY, 1996, BBA-MOL BASIS DIS, V1316, P51, DOI 10.1016/0925-4439(96)00015-4; Zhu CY, 2000, J BIOL CHEM, V275, P26727	58	279	297	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40847	40857		10.1074/jbc.M106743200	http://dx.doi.org/10.1074/jbc.M106743200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526116	hybrid			2022-12-25	WOS:000171925600064
J	Mao, C; Zhou, M; Uckun, FM				Mao, C; Zhou, M; Uckun, FM			Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SRC FAMILY; C-SRC; INSULIN-RECEPTOR; SUBSTRATE RECOGNITION; CONSERVED FEATURES; PEPTIDE SUBSTRATE; CATALYTIC SUBUNIT; SIGNALING COMPLEX; BTK	Bruton's tyrosine kinase is intimately involved in signal transduction pathways regulating survival, activation, proliferation, and differentiation of B lineage lymphoid cells. Mutations in the human btk gene are the cause of X-linked agammaglobulinemia, a male immune deficiency disorder characterized by a lack of mature, immunoglobulin-producing B lymphocytes. We have determined the x-ray crystal structure of the Bruton's tyrosine kinase kinase domain in its unphosphorylated state to a 2.1 Angstrom resolution. A comparison with the structures of other tyrosine kinases and a possible mechanism of activation unique to Bruton's tyrosine kinase are provided.	Parker Hughes Canc Ctr, Dept Biol Struct, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, Dept Immunol, St Paul, MN 55113 USA		Mao, C (corresponding author), Parker Hughes Canc Ctr, 2657 Patton Rd, Roseville, MN 55113 USA.	cmao@ih.org; fatih_uckun@ih.org		Uckun, Fatih M./0000-0001-9334-183X				ACCILI D, 1992, J ENDOCRINOL INVEST, V15, P857, DOI 10.1007/BF03348820; Afar DEH, 1996, MOL CELL BIOL, V16, P3465; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; COPLEY RR, 1994, J MOL BIOL, V242, P321; FERRACINI R, 1990, ONCOGENE RES, V5, P205; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; JONES TA, 1989, CRYSTALLOGRAPHIC COM, P120; JONES TA, 1992, MOL REPLACEMENT, P91; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1994, FIRST MAP FINAL MODE, P59; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; *MOL SIM INC, 1997, INS VERS 2; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597; Nisitani S, 1999, P NATL ACAD SCI USA, V96, P2221, DOI 10.1073/pnas.96.5.2221; Oda A, 2000, BLOOD, V95, P1663; Orlandi P, 2000, Hum Mutat, V15, P117, DOI 10.1002/(SICI)1098-1004(200001)15:1<117::AID-HUMU26>3.0.CO;2-H; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; TSUKADA S, 1994, ADV EXP MED BIOL, V365, P233; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	57	89	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41435	41443		10.1074/jbc.M104828200	http://dx.doi.org/10.1074/jbc.M104828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527964	hybrid			2022-12-25	WOS:000171925600140
J	Geibel, JP; Wagner, CA; Caroppo, R; Qureshi, I; Gloeckner, J; Manuelidis, L; Kirchhoff, P; Radebold, K				Geibel, JP; Wagner, CA; Caroppo, R; Qureshi, I; Gloeckner, J; Manuelidis, L; Kirchhoff, P; Radebold, K			The stomach divalent ion-sensing receptor SCAR is a modulator of gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARIETAL; PH; EXPRESSION	Divalent cation receptors have recently been identified in a wide variety of tissues and organs, yet their exact function remains controversial. We have previously identified a member of this receptor family in the stomach and have demonstrated that it is localized to the parietal cell, the acid secretory cell of the gastric gland. The activation of acid secretion has been classically defined as being regulated by two pathways: a neuronal pathway (mediated by acetylcholine) and an endocrine pathway (mediated by gastrin and histamine). Here, we identified a novel pathway modulating gastric acid secretion through the stomach calcium-sensing receptor (SCAR) located on the basolateral membrane of gastric parietal cells. Activation of SCAR in the intact rat gastric gland by divalent cations (Ca2+ or Mg2+) or by the potent stimulator gadolinium (Gd3+) led to an increase in the rate of acid secretion through the apical H+,K+-ATPase. Gd3+ was able to activate acid secretion through the omeprazole-sensitive H+,K+-ATPase even in the absence of the classical stimulator histamine. In contrast, inhibition of SCAR by reduction of extracellular cations abolished the stimulatory effect of histamine on gastric acid secretion, providing evidence for the regulation of the proton secretory transport protein by the receptor. These studies present the first example of a member of the divalent cation receptors modulating a plasma membrane transport protein and may lead to new insights into the regulation of gastric acid secretion.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06511 USA; Univ Bari, Dept Gen & Environm Physiol, I-70125 Bari, Italy	Yale University; Yale University; Universita degli Studi di Bari Aldo Moro	Geibel, JP (corresponding author), Yale Univ, Sch Med, Dept Surg, BML 265,310 Cedar St, New Haven, CT 06510 USA.	John.Geibel@yale.edu		CAROPPO, Rosa/0000-0002-8773-8985	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014669, R01DK050230, P01DK017433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS012674, R01NS012674, P01NS034569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 14669, DK 50230, DK 17433] Funding Source: Medline; NINDS NIH HHS [NS 12674, NS 34569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baron JH, 2000, MT SINAI J MED, V67, P37; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; Caroppo R, 1998, GASTROENTEROLOGY, V114, pA1132, DOI 10.1016/S0016-5085(98)84605-2; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; FAVUS MJ, 1986, AM J PHYSIOL, V251, pG695, DOI 10.1152/ajpgi.1986.251.5.G695; GEIBEL J, 1995, GASTROENTEROLOGY, V109, P1060, DOI 10.1016/0016-5085(95)90563-4; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; LINDBERG P, 1990, MED RES REV, V10, P1, DOI 10.1002/med.2610100102; NEGULESCU PA, 1995, AM J PHYSIOL-GASTR L, V269, pG770, DOI 10.1152/ajpgi.1995.269.5.G770; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PARADISO AM, 1989, AM J PHYSIOL, V257, pC554, DOI 10.1152/ajpcell.1989.257.3.C554; Rossmann H, 1999, GASTROENTEROLOGY, V116, P1389, DOI 10.1016/S0016-5085(99)70503-2; Sachs G, 1997, PHARMACOTHERAPY, V17, P22; SINGH SK, 1995, P NATL ACAD SCI USA, V92, P11573, DOI 10.1073/pnas.92.25.11573; Swarts HPG, 1997, ANN NY ACAD SCI, V834, P472, DOI 10.1111/j.1749-6632.1997.tb52304.x; WAISBREN SJ, 1994, AM J PHYSIOL, V266, pC1013, DOI 10.1152/ajpcell.1994.266.4.C1013; WISE SR, 1990, SURGERY, V108, P1058; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	22	68	71	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39549	39552		10.1074/jbc.M107315200	http://dx.doi.org/10.1074/jbc.M107315200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11507103	hybrid			2022-12-25	WOS:000171789200008
J	Hermann, S; Berndt, KD; Wright, AP				Hermann, S; Berndt, KD; Wright, AP			How transcriptional activators bind target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; HUMAN GLUCOCORTICOID RECEPTOR; UBIQUITIN-MEDIATED PROTEOLYSIS; HYDROPHOBIC AMINO-ACIDS; C-MYC PROTEIN; TRANSACTIVATION DOMAIN; GENE ACTIVATION; CELL-CYCLE; IN-VIVO; SACCHAROMYCES-CEREVISIAE	The product of the proto-oncogene c-myc influences many cellular processes through the regulation of specific target genes. Through its transactivation domain (TAD), c-Myc protein interacts with several transcription factors, including TATA-binding protein (TBP). We present data that suggest that in contrast to some other transcriptional activators, an extended length of the c-Myc TAD is required for its binding to TBP. Our data also show that this interaction is a multistep process, in which a rapidly forming low affinity complex slowly converts to a more stable form. The initial complex formation results from ionic or polar interactions, whereas the slow conversion to a more stable form is hydrophobic in nature. Based on our results, we suggest two alternative models for activation domain/target protein interactions, which together provide a single universal paradigm for understanding activator-target factor interactions.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, Ctr Struct Biochem, S-14157 Huddinge, Sweden; Sodertorns Hogskola, Dept Nat Sci, S-14104 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Sodertorn University	Hermann, S (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.		Berndt, Kurt/J-8574-2015; Wright, Anthony/J-8187-2015	Berndt, Kurt/0000-0002-3049-967X; Wright, Anthony/0000-0003-1029-9969				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; Berk AJ, 1998, COLD SPRING HARB SYM, V63, P243, DOI 10.1101/sqb.1998.63.243; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2708, DOI 10.1021/bi9923555; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gaudreau L, 1998, MOL CELL, V1, P913, DOI 10.1016/S1097-2765(00)80090-8; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; GAUTHIER JM, 1991, NUCLEIC ACIDS RES, V19, P7073, DOI 10.1093/nar/19.25.7073; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Massari ME, 1996, MOL CELL BIOL, V16, P121; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; Nevado J, 1999, P NATL ACAD SCI USA, V96, P2674, DOI 10.1073/pnas.96.6.2674; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Ober RJ, 1999, ANAL BIOCHEM, V273, P49, DOI 10.1006/abio.1999.4185; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4819; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Sune C, 1999, MOL CELL BIOL, V19, P4719; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Tsai CJ, 1997, PROTEIN SCI, V6, P1793, DOI 10.1002/pro.5560060901; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Warnmark A, 2000, J BIOL CHEM, V275, P15014, DOI 10.1074/jbc.M001007200; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; Zaman Z, 1998, COLD SPRING HARB SYM, V63, P167, DOI 10.1101/sqb.1998.63.167	68	37	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40127	40132		10.1074/jbc.M103793200	http://dx.doi.org/10.1074/jbc.M103793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514548	hybrid			2022-12-25	WOS:000171789200084
J	Hong, YL; Rogers, R; Matunis, MJ; Mayhew, CN; Goodson, M; Park-Sarge, OK; Sarge, KD				Hong, YL; Rogers, R; Matunis, MJ; Mayhew, CN; Goodson, M; Park-Sarge, OK; Sarge, KD			Regulation of heat shock transcription factor 1 by stress-induced SUMO-1 modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; COVALENT MODIFICATION; NUCLEAR-LOCALIZATION; HSF1; PML; ACTIVATION; P53; CONJUGATION; PROTECTION; EXPRESSION	Heat shock transcription factor 1 (HSF1) mediates the induction of heat shock protein gene expression in cells exposed to elevated temperature and other stress conditions. In response to stress HSF1 acquires DNA binding ability and localizes to nuclear stress granules, but the molecular mechanisms that mediate these events are not understood. We report that HSF1 undergoes stress-induced modification at lysine 298 by the small ubiquitin-related protein called SUMO-1. Antibodies against SUMO-1 supershift the HSF1 DNA-binding complex, and modification of HSF1 in a reconstituted SUMO-1 reaction system causes conversion of HSF1 to the DNA-binding form. HSF1 colocalizes with SUMO-1 in nuclear stress granules, which is prevented by mutation of lysine 298. Mutation of lysine 298 also results in a significant decrease in stress-induced transcriptional activity of HSF1 in vivo. This work implicates SUMO-1 modification as an important modulator of HSF1 function in response to stress.	Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	University of Kentucky; University of Kentucky; Johns Hopkins University	Sarge, KD (corresponding author), Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu	Mayhew, Christopher N/AGB-4929-2022; Goodson, Michael L/G-4175-2010	Matunis, Michael/0000-0002-9350-6611; Goodson, Michael/0000-0002-3464-490X	NICHD NIH HHS [HD 32008] Funding Source: Medline; NIEHS NIH HHS [ES 07266] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD032008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007266] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cotto JJ, 1997, J CELL SCI, V110, P2925; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; Duprez E, 1999, J CELL SCI, V112, P381; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Morano KA, 1999, GENE EXPRESSION, V7, P271; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rabergh CMI, 2000, J EXP BIOL, V203, P1817; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SHI YH, 1995, MOL CELL BIOL, V15, P4309; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUMP DG, 1995, GENE, V160, P207, DOI 10.1016/0378-1119(95)00176-7; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	36	188	193	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40263	40267		10.1074/jbc.M104714200	http://dx.doi.org/10.1074/jbc.M104714200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514557	hybrid			2022-12-25	WOS:000171789200100
J	Mauro, L; Bartucci, M; Morelli, C; Ando, S; Surmacz, E				Mauro, L; Bartucci, M; Morelli, C; Ando, S; Surmacz, E			IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; E-CADHERIN; TIGHT JUNCTIONS; COMPLEX; VITRO; PHOSPHORYLATION; METASTASIS; INVASION; OCCLUDIN; CATENIN	Hyperactivation of the insulin-like growth factor I receptor (IGF-IR) contributes to primary breast cancer development, but the role of the IGF-IR in tumor metastasis is unclear. Here we studied the effects of the IGF-IR on intercellular connections mediated by the major epithelial adhesion protein, E-cadherin (E-ead). We found that IGF-IR overexpression markedly stimulated aggregation in E-cad-positive MCF-7 breast cancer cells, but not in E-ead-negative MDA-MB-231 cells. However, when the IGF-IR and E-ead were co-expressed in MDA-MB-231 cells, cell-cell adhesion was substantially increased. The IGF-IR-dependent cell-cell adhesion of MCF-7 cells was not related to altered expression of E-cad or alpha-, beta-, or gamma -catenins but coincided with the up-regulation of another element of the E-cad complex, zonula occludens-1 (ZO-1). ZO-1 expression (mRNA and protein) was induced by IGF-l and was blocked in MCF-7 cells with a tyrosine kinase-defective IGF-IR mutant. By co-immunoprecipitation, we found that ZO-1 associates with the E-cad complex and the IGF-IR. High levels of ZO-1 coincided with an increased IGF-IR/alpha -catenin/ZO-1-binding and improved ZO-1/actin association, whereas down-regulation of ZO-1 by the expression of an anti-ZO-1 RNA inhibited IGF-IR-dependent cell-cell adhesion. The results suggested that one of the mechanisms by which the activated IGF-IR regulates E-cad-mediated cell-cell adhesion is overexpression of ZO-1 and the resulting stronger connections between the E-cad complex and the actin cytoskeleton. We hypothesize that in E-cad-positive cells, the IGF-IR may produce antimetastatic effects.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Dept Cellular Biol, I-87030 Arcavacata Di Rende, Italy; Univ Calabria, Fac Pharm, I-87030 Arcavacata Di Rende, Italy	Jefferson University; University of Calabria; University of Calabria	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@mail.tju.edu	Morelli, Catia/AAE-1886-2019	Morelli, Catia/0000-0002-9407-0805				Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Ericson LE, 1996, EUR J ENDOCRINOL, V135, P118, DOI 10.1530/eje.0.1350118; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mbalaviele G, 1996, CANCER RES, V56, P4063; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PEYRAT JP, 1989, B CANCER, V76, P311; Pezzino V, 1996, ANN NY ACAD SCI, V784, P189, DOI 10.1111/j.1749-6632.1996.tb16236.x; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Resnik JL, 1998, CANCER RES, V58, P1159; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Tsukita S, 1997, SOC GEN PHY, V52, P69; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	31	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39892	39897		10.1074/jbc.M106673200	http://dx.doi.org/10.1074/jbc.M106673200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518717	hybrid			2022-12-25	WOS:000171789200053
J	Qian, YM; Qiu, W; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG				Qian, YM; Qiu, W; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG			Characterization of binding of leukotriene C-4 by human multidrug resistance protein - Evidence of differential interactions with NH2- and COOH-proximal halves of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; VINCRISTINE TRANSPORT; MEMBRANE-VESICLES; ATPASE ACTIVITY; MRP; SITES; DRUG; CELLS; GLUTATHIONE; GENE	Multidrug resistance protein 1 (MRP1) is capable of actively transporting a wide range of conjugated and unconjugated organic anions. The protein can also transport additional conjugated and unconjugated compounds in a GSH- or S-methyl GSH-stimulated manner. How MRP1 binds and transports such structurally diverse substrates is not known. We have used [H-3]leukotriene C-4 (LTC4), a high affinity glutathione-conjugated physiological substrate, to photolabel intact MRP1, as well as fragments of the protein expressed in insect cells. These studies revealed that: (i) LTC4 labels sites in the NH2- and COOH-proximal halves of MRP1, (ii) labeling of the NH2-half of MRP1 is localized to a region encompassing membrane-spanning domain (MSD) 2 and nucleotide binding domain (NBD) 1, (iii) labeling of this region is dependent on the presence of all or part of the cytoplasmic loop (CL3) linking MSD1 and MSD2, but not on the presence of MSD1, (iv) labeling of the NH2-proximal site is preferentially inhibited by S-methyl GSH, (v) labeling of the COON-proximal half of the protein occurs in a region encompassing transmembrane helices 14-17 and appears not to require NBD2 or the cytoplasmic COOH-terminal region of the protein, (vi) labeling of intact MRP1 by LTC4 is strongly attenuated in the presence of ATP and vanadate, and this decrease in labeling is attributable to a marked reduction in LTC4 binding to the NH2-proximal site, and (vii) the attenuation of LTC4 binding to the NH2-proximal site is a consequence of ATP hydrolysis and trapping of Vi-ADP exclusively at NBD2. These data suggest that MRP1-mediated transport involves a conformational change, driven by ATP hydrolysis at NBD2, that alters the affinity with which LTC4 binds to one of two sites composed, at least in part, of elements in the NH2-proximal half of the protein.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Westlake, Christopher/AAG-1150-2019; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Westlake, Christopher/0000-0001-7476-2014; Qian, Yueming/0000-0001-7340-6421				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Ding GY, 1999, ANTICANCER RES, V19, P3243; FALK E, 1989, EUR J BIOCHEM, V186, P741, DOI 10.1111/j.1432-1033.1989.tb15268.x; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; NARE B, 1994, MOL PHARMACOL, V45, P1145; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200	49	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38636	38644		10.1074/jbc.M107025200	http://dx.doi.org/10.1074/jbc.M107025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507101	hybrid			2022-12-25	WOS:000171673200042
J	Sampson, MJ; Decker, WK; Beaudet, AL; Ruitenbeek, W; Armstrong, D; Hicks, MJ; Craigen, WJ				Sampson, MJ; Decker, WK; Beaudet, AL; Ruitenbeek, W; Armstrong, D; Hicks, MJ; Craigen, WJ			Immotile sperm and infertility in mice lacking mitochondrial voltage-dependent anion channel type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CYTOCHROME-C; GENE; PROTEIN; PORIN; YEAST; PERMEABILITY; RESPIRATION; ISOFORM; FAMILY	Voltage-dependent anion channels (VDACs), also known as mitochondrial porins, are small channel proteins involved in the translocation of metabolites across the mitochondrial outer membrane. A single channel-forming protein is found in yeast, whereas higher eukaryotes express multiple VDACs, with humans and mice each harboring three distinct channels (VDAC1-3) encoded by separate genes. To begin to assess the functions of each of the three isoforms, the VDAC3 gene was inactivated by targeted disruption in embryonic stem cells. Here we show that mice lacking VDAC3 are healthy, but males are infertile. Although there are normal sperm numbers, the sperm exhibit markedly reduced motility. Structural defects were found in two-thirds of epididymal axonemes, with the most common abnormality being loss of a single microtubule doublet at a conserved position within the axoneme. In testicular sperm, the defect was only rarely observed, suggesting that instability of a normally formed axoneme occurs with sperm maturation. In contrast, tracheal epithelial cilia showed no structural abnormalities. In addition, skeletal muscle mitochondria were abnormally shaped, and activities of the respiratory chain complexes were reduced. These results demonstrate that axonemal defects may be caused by associated non-axonemal components such as mitochondrial channels and illustrate that normal mitochondrial function is required for stability of the axoneme.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Univ Nijmegen Hosp, Dept Pediat, NL-6500 HB Nijmegen, Netherlands	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Radboud University Nijmegen	Craigen, WJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.				NIGMS NIH HHS [R01 GM055713-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055713] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anflous K, 1998, BBA-GENE STRUCT EXPR, V1399, P47, DOI 10.1016/S0167-4781(98)00088-8; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; Cesar MD, 1998, ARCH BIOCHEM BIOPHYS, V350, P109; Decker WK, 1999, MAMM GENOME, V10, P1041, DOI 10.1007/s003359901158; Decker WK, 2000, MOL GENET METAB, V70, P69, DOI 10.1006/mgme.2000.2987; Dessars B, 1999, Rev Med Brux, V20, pA457; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; ESCUDIER E, 1990, AM REV RESPIR DIS, V142, P674, DOI 10.1164/ajrccm/142.3.674; FRASER LR, 1992, ARCH PATHOL LAB MED, V116, P345; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hinsch KD, 2001, BBA-GENE STRUCT EXPR, V1518, P329, DOI 10.1016/S0167-4781(01)00199-3; Jonas EA, 1999, SCIENCE, V286, P1347, DOI 10.1126/science.286.5443.1347; Linck R. W., 1979, The spermatozoon. Maturation, motility, surface properties and comparative aspects. Proceedings of the Third International Symposium on the Spermatozoon, held at the American Academy of Arts and Sciences, Boston, and the Swope Conference Center, Marine Biological Laboratories, Woods Hole, Massachusetts, May 2-5, 1978., P99; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; LINDEN M, 1989, J BIOENERG BIOMEMBR, V21, P507, DOI 10.1007/BF00762522; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MERLINO GT, 1991, GENE DEV, V5, P1395, DOI 10.1101/gad.5.8.1395; Mierau GW, 1998, HUM PATHOL, V29, P1347, DOI 10.1016/S0046-8177(98)90002-8; PAN RCM, 1997, ARCH ANDROLOGY, V39, P197; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Sampson MJ, 1996, GENOMICS, V36, P192, DOI 10.1006/geno.1996.0445; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1998, J BIOL CHEM, V273, P30482, DOI 10.1074/jbc.273.46.30482; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; TRIJBELS JMF, 1988, EUR J PEDIATR, V148, P92, DOI 10.1007/BF00445910; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540	36	180	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39206	39212		10.1074/jbc.M104724200	http://dx.doi.org/10.1074/jbc.M104724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507092	hybrid, Green Published			2022-12-25	WOS:000171673200115
J	Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R				Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R			The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells	ONCOGENE			English	Article						IGF-IR, insulin-like growth factor-1 receptor; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IRS-1, insulin receptor substrate-1; PI3K, phosphatidylinositol-3 kinase	GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; PHOSPHOTYROSINE-DEPENDENT INTERACTION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; NPEY MOTIF; APOPTOSIS	H19-7/IGF-IR cells are rat hippocampal cells expressing a human IGF-I receptor, which differentiate to a neuronal phenotype when stimulated by IGF-I at 39 degreesC. H19-7/IGF-IR cells have low levels of expression of insulin receptor substrate-1 (IRS-1), a major substrate of the IGF-IR. IGF-I induces serine-phosphorylation and down-regulation of the endogenous IRS-1 upon differentiation of H19-7/IGF-IR cells. The profound influence of IRS-1 on differentiation of H19-7/IGF-IR cells was confirmed by transfecting these cells with a plasmid expressing mouse IRS-1. Over-expression of wild type IRS-1 in H19-7/IGF-IR cells abolishes IGF-I-induced differentiation at 39 degrees C. A mutant of IRS-1 lacking the PTB domain loses the ability to inhibit the differentiation program. H19-7/IGF-IR/IRS-1 cells at 39 degrees C show a stronger and prolonged activation of Akt, when compared to H19-7/IGF-IR cells. The role of Akt in the inhibition of the differentiation program was confirmed by using the inhibitor of Class I PI3 kinases LY29400, which restores IGF-I-induced differentiation of H19-7/IGF-IR/IRS-1 cells. H19-7/IGF-IR/IRS-1 cells show a strong reduction in MAP kinases signaling, which is related to the superactivation of Akt. This was confirmed by expressing in H19-7/IGF-IR cells a constitutively active Akt, which inhibited MAP kinases activation in these cells. These experiments confirm the importance of MAPK in the mechanism of IGF-I-mediated differentiation of H19-7/IGF-IR cells.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Belletti, Barbara/J-2028-2018	Belletti, Barbara/0000-0003-2249-0285	NCI NIH HHS [CA 78890] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NIDDK NIH HHS [KO1 DK 02896-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anlar B, 1999, HORM METAB RES, V31, P120, DOI 10.1055/s-2007-978708; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baserga R, 1999, J CELL BIOCHEM, P68; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; Eves EM, 1996, J NEUROCHEM, V67, P1908; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Guan KL, 2000, J BIOL CHEM, V275, P27354; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LEROITH D, 1993, NEUROTROPHIC FACTORS, P391; Leventhal PS, 1999, CONT ENDOCRINOL, V17, P425; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 2000, CANCER RES, V60, P2263; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	63	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4842	4852		10.1038/sj.onc.1204649	http://dx.doi.org/10.1038/sj.onc.1204649			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521195				2022-12-25	WOS:000170271800008
J	Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V				Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V			The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis	ONCOGENE			English	Article						mutant p53; gain of function; apoptosis; growth arrest; G(2)	WILD-TYPE P53; DNA-BINDING FUNCTION; GAIN-OF-FUNCTION; P53-REGULATED GENE-EXPRESSION; ALTERNATIVELY SPLICED FORM; CELL-CYCLE CONTROL; FUNCTION MUTATIONS; TYROSINE KINASE; MYELOID CELLS; PROTEIN	The ability to suppress wild type p53-independent apoptosis may play an important role in the oncogenicity of p53 mutant proteins. However, structural elements necessary for this activity are unknown. Furthermore, it is unclear whether this mutant p53 mediated inhibition is specific to the apoptotic pathway or a more general suppression of the cellular response to stress. We observed that an unmodified C-terminus was required for the suppression of apoptosis by the p53 135(Ala to Val) oncogenic p53 mutant. It was also required for the novel activity of G(2) arrest suppression, the predominant response at low levels of genotoxic stress. These observations are consistent with a model whereby mutant p53 suppressive activity is not specific to the apoptotic pathway, but rather increases the threshold of genotoxic stress needed for a DNA damage response to occur. Furthermore, these observations indicate that it may be possible to selectively kill mutant p53 expressing cells based on the lower sensitivity of their growth arrest response.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Sigal, Alex/GWC-7488-2022	Sigal, Alex/0000-0001-8571-2004				Agami R, 1999, NATURE, V399, P809; Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2000, CANCER RES, V60, P3425; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P427; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Goi K, 1997, CANCER RES, V57, P1895; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1998, CANCER RES, V58, P4023; Iwamoto KS, 1996, CANCER RES, V56, P3862; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lassus P, 1999, ONCOGENE, V18, P4699, DOI 10.1038/sj.onc.1202841; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Peled A, 1996, CANCER RES, V56, P2148; POWELL SN, 1995, CANCER RES, V55, P1643; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sigal A, 2000, CANCER RES, V60, P6788; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	61	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4891	4898		10.1038/sj.onc.1204724	http://dx.doi.org/10.1038/sj.onc.1204724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521201				2022-12-25	WOS:000170271800014
J	Chu, Y; Hughes, S; Chan-Ling, TL				Chu, Y; Hughes, S; Chan-Ling, TL			Differentiation and migration of astrocyte precursor cells (APCs) and astrocytes in human fetal retina: relevance to optic nerve coloboma	FASEB JOURNAL			English	Article						Pax2; astrocyte; retina; glial fibrillary acidic protein; differentiation	SUBVENTRICULAR ZONE; GLIAL PRECURSORS; VEGF EXPRESSION; BLOOD-VESSELS; CAT RETINA; PAX2 GENE; MOUSE; RAT; VASCULATURE; VIMENTIN	The presence of astrocyte precursor cells (APCs) and time course and topography of astrocyte differentiation during development were investigated by triple-label immunohistochemistry with intact fetal and adult human retinas. Throughout retinal development and adulthood, expression of Pax2 was restricted to cells of the astrocytic lineage. Three distinct stages of astrocytic differentiation were identified during development: i) Pax2(+)/vimentin(+)/GFAP(-) APCs; ii) Pax2(+)/vimentin(+)/GFAP(+) immature perinatal astrocytes; and iii) Pax2(+)/vimentin(-)/GFAP(+) mature perinatal astrocytes. In adult, cells with the antigenic phenotype of mature perinatal astrocytes were restricted to a region surrounding the optic nerve head (ONH), whereas cells at a fourth stage of differentiation, adult astrocytes (Pax2(-)/vimentin(-)/GFAP(+)), were apparent throughout the vascularized retina. APC appearance was centered around the ONH and preceded the appearance of perinatal astrocytes. A cluster of Pax2(+) somas was also present in a small region surrounding the ONH at the ventricular surface of the developing retina, which suggests the existence of two distinct sites of astrocytic differentiation. The coincidence in the location of APCs and perinatal astrocytes at the ventricular zone with that of optic nerve colobomas, together with the association of Pax2 gene mutations with this condition, suggests that coloboma formation may result from impaired astrocyte differentiation during development.	Univ Sydney, Inst Biomed Res, Dept Anat & Histol, Sydney, NSW 2006, Australia	University of Sydney	Chan-Ling, TL (corresponding author), Univ Sydney, Dept Anat & Histol F13, Sydney, NSW 2006, Australia.	tailoi@anatomy.usyd.edu.au	Chan-Ling, Tailoi/A-2177-2008; Chan-Ling, Tailoi/X-2718-2019	Chan-Ling, Tailoi/0000-0002-8225-3671; 				BARISHAK YR, 1992, DEV OPHTHAMOL, V24, P42; CHANLING T, 1991, J COMP NEUROL, V303, P387, DOI 10.1002/cne.903030305; CHANLING T, 1991, J COMP NEUROL, V303, P375, DOI 10.1002/cne.903030304; CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612; ChanLing T, 1997, MICROSC RES TECHNIQ, V36, P1; CHANLING T, 1996, P AUST NEUR SOC, V7, P48; CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201; DAHL D, 1981, EUR J CELL BIOL, V24, P191; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; FEDOROFF S, 1983, DEV BRAIN RES, V7, P303, DOI 10.1016/0165-3806(83)90187-6; FOKSEANG J, 1992, J NEUROSCI, V12, P2751; Gariano RF, 1996, INVEST OPHTH VIS SCI, V37, P2367; Hogan MJ, 1971, HISTOLOGY HUMAN EYE; HOLLANDER H, 1991, J COMP NEUROL, V313, P587, DOI 10.1002/cne.903130405; Hu P, 2000, AM J PATHOL, V156, P1139, DOI 10.1016/S0002-9440(10)64982-6; Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217; HUXLIN KR, 1992, J NEUROCYTOL, V21, P530, DOI 10.1007/BF01186955; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.0.CO;2-8; LEVISON SW, 1993, DEVELOPMENT, V119, P611; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; LING TL, 1988, DEV BRAIN RES, V44, P73, DOI 10.1016/0165-3806(88)90119-8; Maricich SM, 1999, J NEUROBIOL, V41, P281, DOI 10.1002/(SICI)1097-4695(19991105)41:2<281::AID-NEU10>3.0.CO;2-5; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Mi HY, 1999, J NEUROSCI, V19, P1049; NORNES HO, 1990, DEVELOPMENT, V109, P797; OGDEN TE, 1978, INVEST OPHTH VIS SCI, V17, P499; Orentas DM, 1996, GLIA, V16, P27, DOI 10.1002/(SICI)1098-1136(199601)16:1<27::AID-GLIA4>3.0.CO;2-8; Otteson DC, 1998, DEV BIOL, V193, P209, DOI 10.1006/dbio.1997.8794; PERRY VH, 1990, J NEUROCYTOL, V19, P265, DOI 10.1007/BF01217304; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; RAFF MC, 1984, DEV BIOL, V106, P53, DOI 10.1016/0012-1606(84)90060-5; RAMIREZ JM, 1994, VISION RES, V34, P1935, DOI 10.1016/0042-6989(94)90024-8; Sandercoe TM, 1999, EXP EYE RES, V69, P511, DOI 10.1006/exer.1999.0730; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SAVELL J, 1976, ARCH OPHTHALMOL-CHIC, V94, P395; SCHNITZER J, 1986, CELL TISSUE RES, V246, P91; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SMITH GM, 1991, BRAIN RES, V543, P111, DOI 10.1016/0006-8993(91)91054-5; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Terzic J, 1998, INT J DEV BIOL, V42, P701; Torres MA, 1996, DEVELOPMENT, V122, P3381; Trivino A, 1996, VISION RES, V36, P2015, DOI 10.1016/0042-6989(95)00317-7; Trivino A, 1997, VISION RES, V37, P1707, DOI 10.1016/S0042-6989(97)00021-7; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WOLTER JR, 1955, AM J OPHTHALMOL, V40, P88, DOI 10.1016/0002-9394(55)91841-9; [No title captured]	50	80	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2013	+		10.1096/fj.00-0868fje	http://dx.doi.org/10.1096/fj.00-0868fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511521				2022-12-25	WOS:000170318500023
J	Maenaka, K; van der Merwe, PA; Stuart, DI; Jones, EY; Sondermann, P				Maenaka, K; van der Merwe, PA; Stuart, DI; Jones, EY; Sondermann, P			The human low affinity Fc gamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-PROTEIN INTERACTIONS; T-CELL RECEPTORS; CRYSTAL-STRUCTURE; INHIBITORY RECEPTOR; NATURAL-KILLER; CLASS-I; IMMUNOGLOBULIN SUPERFAMILY; LIGAND-BINDING; SOLUBLE FORM	Fc gamma receptors (Fc gamma Rs) are expressed on all immunologically active cells. They bind the Fe portion of IgG, thereby triggering a range of immunological functions. We have used surface plasmon resonance to analyze the kinetic and thermodynamic properties of the interactions between the ectodomains of human low affinity Fc gamma Rs (Fc gamma RIIa, Fc gamma RIIb, and Fc gamma gamma RIIb-NA2) and IgG1 or the Fc fragment of IgG1. All three receptors bind Fc or IgG with similarly low affinities (K-D similar to0.6-2.5 muM) and fast kinetics, suggesting that Fc gammaR-mediated recognition of aggregated IgG and IgG-coated particles or cells is mechanistically similar to cell-cell recognition. Interestingly, the Fe receptors exhibit distinct thermodynamic properties. Whereas the binding of the Fc gamma RIIa and Fc gamma RIIb to Fe is driven by favorable entropic and enthalpic changes, the binding of Fc gamma RIII is characterized by highly unfavorable entropic changes. Although the structural bases for these differences remain to be determined, they suggest that the molecular events coupled to the binding differ among the low affinity Fc gamma Rs.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Natl Inst Genet, Struct Biol Ctr, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Sch Adv Sci, Kanagawa 2400193, Japan; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Oxford Ctr Mol Sci, Oxford OX1 3QT, England	Max Planck Society; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Sondermann, P (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.		Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019; van der Merwe, P. Anton/F-8539-2011	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Dennis G, 2000, P NATL ACAD SCI USA, V97, P13245, DOI 10.1073/pnas.230442897; Edberg JC, 1997, J IMMUNOL, V159, P3849; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; FLEIT HB, 1992, BLOOD, V79, P2721; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HUTIN P, 1994, INT ARCH ALLERGY IMM, V103, P23, DOI 10.1159/000236601; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; KHAYAT D, 1990, J INFECT DIS, V161, P430, DOI 10.1093/infdis/161.3.430; LITTAUA R, 1990, J IMMUNOL, V144, P3183; Maenaka K, 1999, J BIOL CHEM, V274, P28329, DOI 10.1074/jbc.274.40.28329; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; MATHIOT C, 1993, J CLIN IMMUNOL, V13, P41, DOI 10.1007/BF00920634; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Nishimiya Y, 2000, J BIOL CHEM, V275, P12813, DOI 10.1074/jbc.275.17.12813; Powell MS, 1999, IMMUNOL LETT, V68, P17, DOI 10.1016/S0165-2478(99)00025-5; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; Sondermann P, 1999, BIOL CHEM, V380, P717, DOI 10.1515/BC.1999.090; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Sondermann P, 1999, BIOCHEMISTRY-US, V38, P8469, DOI 10.1021/bi982889q; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Tominaga Y, 1998, J IMMUNOL, V161, P4016; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Vales-Gomez M, 2000, HUM IMMUNOL, V61, P28, DOI 10.1016/S0198-8859(99)00159-7; Vales-Gomez M, 1998, IMMUNITY, V9, P337, DOI 10.1016/S1074-7613(00)80616-0; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	50	110	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44898	44904		10.1074/jbc.M106819200	http://dx.doi.org/10.1074/jbc.M106819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11544262	hybrid			2022-12-25	WOS:000172406700076
J	Selvapandiyan, A; Duncan, R; Debrabant, A; Bertholet, S; Sreenivas, G; Negi, NS; Salotra, P; Nakhasi, HL				Selvapandiyan, A; Duncan, R; Debrabant, A; Bertholet, S; Sreenivas, G; Negi, NS; Salotra, P; Nakhasi, HL			Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTIONS; SPINDLE POLE BODY; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; CDC31 GENE; PROTEIN; BINDING; IDENTIFICATION; CELLS; YEAST	Leishmania donovani, a protozoan parasite, causes visceral disease in humans. To identify genes that control growth, we have isolated for the first time in the order Kinetoplastida a gene encoding for centrin from L. donovani. Centrin is a calcium-binding cytoskeletal protein essential for centrosome duplication or segregation. Protein sequence similarity and immunoreactivity confirmed that Leishmania centrin is a homolog of human centrin 2. Immunofluorescence analysis localized the protein in the basal body. Calcium binding analysis revealed that its C-terminal Ca2+ binding domain binds 16-fold more calcium than the N-terminal domain. Electrophoretic mobility shift of centrin treated with EGTA and abrogation of the shift in its mutants lacking a Ca2+ binding site suggest that Ca2+ binding to these regions may have a role in the protein conformation. The levels of centrin mRNA and protein were high during the exponential growth of the parasite in culture and declined to a low level in the stationary phase. Expression of N-terminal-deleted centrin in the parasite significantly reduces its growth rate, and it was found that significantly more cells are arrested in the G(2)/M stage than in control cells. These studies indicate that centrin may have a functional role in Leishmania growth.	US FDA, Lab Bacterial Parasit & Unconvent Agents, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; US FDA, Lab Parasit Biol & Biochem, Div Bacterial Parasit & Allergen Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Safdarjang Hosp, New Delhi 110029, India; Indian Council Med Res, Inst Pathol, New Delhi 110029, India	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Vardhman Mahavir Medical College & Safdarjung Hospital; Indian Council of Medical Research (ICMR); ICMR - National Institute of Pathology (IOP)	Nakhasi, HL (corresponding author), US FDA, Lab Bacterial Parasit & Unconvent Agents, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.		Selvapandiyan, Angamuthu/AAA-8602-2021; Duncan, Robert/I-8168-2015; Selvapandiyan, Angamuthu/AAY-2556-2021	Duncan, Robert/0000-0001-8409-2501; Selvapandiyan, Angamuthu/0000-0002-2194-1534; Gannavaram, Sreenivas/0000-0002-6557-8220; Salotra, Poonam/0000-0002-4057-4872	NIAID NIH HHS [Y3-AI-9319-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad S, 2000, INT J SYST EVOL MICR, V50, P1761, DOI 10.1099/00207713-50-5-1761; BARON AT, 1991, CELL MOTIL CYTOSKEL, V18, P1, DOI 10.1002/cm.970180102; Bastin P, 2000, MICROBES INFECT, V2, P1865, DOI 10.1016/S1286-4579(00)01344-7; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; Brugerolle G, 2000, J EUKARYOT MICROBIOL, V47, P129, DOI 10.1111/j.1550-7408.2000.tb00022.x; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; Hart PE, 1999, GENOMICS, V60, P111, DOI 10.1006/geno.1999.5880; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; Ivanovska I, 2001, GENETICS, V157, P503; Joshi M, 1996, MOL BIOCHEM PARASIT, V81, P53, DOI 10.1016/0166-6851(96)02676-X; JOSHI M, 1995, J EUKARYOT MICROBIOL, V42, P628, DOI 10.1111/j.1550-7408.1995.tb05918.x; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; Khalfan W, 2000, GENETICS, V155, P1543; Klink VP, 2001, MOL BIOL CELL, V12, P761, DOI 10.1091/mbc.12.3.761; Laoukili J, 2000, J CELL SCI, V113, P1355; LeDizet M, 1998, AM J PHYSIOL-LUNG C, V275, pL1145, DOI 10.1152/ajplung.1998.275.6.L1145; Levy YY, 1996, CELL MOTIL CYTOSKEL, V33, P298; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; Middendorp S, 2000, J CELL BIOL, V148, P405, DOI 10.1083/jcb.148.3.405; Nakhasi HL, 1998, PARASITOL TODAY, V14, P157, DOI 10.1016/S0169-4758(97)01180-0; Paoletti A, 1996, J CELL SCI, V109, P3089; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Pogue GP, 1996, MOL BIOCHEM PARASIT, V81, P27, DOI 10.1016/0166-6851(96)02697-7; POGUE GP, 1995, GENE, V165, P31, DOI 10.1016/0378-1119(95)00461-E; POGUE GP, 1995, PARASITOL RES, V81, P282, DOI 10.1007/BF00931531; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SELVAPANDIYAN A, 1995, FEBS LETT, V374, P253, DOI 10.1016/0014-5793(95)01124-W; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEN EA, 1994, GENETICS, V137, P407; WEBER C, 1994, J BIOL CHEM, V269, P15795; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6	46	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43253	43261		10.1074/jbc.M106806200	http://dx.doi.org/10.1074/jbc.M106806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544261	hybrid			2022-12-25	WOS:000172169300081
J	Adlakha, CL; Hart, JP; Pizzo, SV				Adlakha, CL; Hart, JP; Pizzo, SV			Kinetics of nonproteolytic incorporation of a protein ligand into thermally activated alpha(2)-macroglobulin - Evidence for a novel nascent state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; ANTIGEN DELIVERY; THIOL-ESTER; MECHANISM; BINDING; COMPLEMENT	We have previously shown that antigens complexed to the receptor-recognized form of alpha (2)-macroglobulin (alpha M-2*) demonstrate enhanced immune responsiveness mediated by the low density lipoprotein receptor-related protein LRP/CD91. Recently, we developed a proteinase-independent method to covalently bind antigens to alpha M-2*. Given the potential applications of this chemistry, we analyzed the kinetics, thermodynamics, and pH dependence of this reaction. The incorporation of lysozyme into alpha M-2* was a mixed bimolecular second-order reaction with a specific rate constant of 91.0 +/- 6.9 M-1 s(-1), 50.0 degreesC, pH 7.4. The activation energy, activation entropy, and Gibbs' free energy at 50.0 degreesC were 156 kJ mol(-1), 266 J mol(-1) K-1, and 70 kJ mol(-1), respectively. The rate of incorporation increased as a function of pH from pH 5.0 to 7.0 and was unchanged thereafter. Furthermore, the reaction between alpha M-2* and lysozyme was irreversible. The data are consistent with a two-step mechanism. In the first step, alpha M-2* reforms its thiol ester bond, entering a reactive state that mimics the proteolytically induced "nascent state." In the rate-limiting second step, the reformed bond quickly undergoes nucleophilic attack by lysozyme. The kinetic equations derived in this study are the basis for optimizing the formation of stable alpha M-2*-antigen complexes.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-24066] Funding Source: Medline; NIGMS NIH HHS [GM-07171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2001, J IMMUNOL, V166, P4968, DOI 10.4049/jimmunol.166.8.4968; CANFIELD RE, 1963, J BIOL CHEM, V238, P2691; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CHU CT, 1994, LAB INVEST, V71, P792; CHU CT, 1994, J IMMUNOL, V152, P1538; CIANCIOLO GJ, 2001, IN PRESS VACCINE; Gron H, 1998, BIOCHEMISTRY-US, V37, P6009, DOI 10.1021/bi973027c; Gron H, 1996, BIOCHEM J, V318, P539, DOI 10.1042/bj3180539; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; KHAN SA, 1982, J BIOL CHEM, V257, P1864; LARSSON LJ, 1984, BIOCHEMISTRY-US, V23, P2802, DOI 10.1021/bi00307a041; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1982, BIOCHEM BIOPH RES CO, V107, P93, DOI 10.1016/0006-291X(82)91674-6; SOTTRUPJENSEN L, 1981, FEBS LETT, V127, P167, DOI 10.1016/0014-5793(81)80197-4; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; VIRCA GD, 1978, ANAL BIOCHEM, V89, P274, DOI 10.1016/0003-2697(78)90750-9	22	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41547	41552		10.1074/jbc.M106357200	http://dx.doi.org/10.1074/jbc.M106357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11514568	hybrid			2022-12-25	WOS:000172450400003
J	Blaukat, A; Pizard, A; Breit, A; Wernstedt, C; Alhenc-Gelas, F; Muller-Esterl, W; Dikic, I				Blaukat, A; Pizard, A; Breit, A; Wernstedt, C; Alhenc-Gelas, F; Muller-Esterl, W; Dikic, I			Determination of bradykinin B-2 receptor in vivo phosphorylation sites and their role in receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED PHOSPHORYLATION; REQUIRES PHOSPHORYLATION; KINASE SPECIFICITY; THREONINE RESIDUES; B2 RECEPTOR; DESENSITIZATION; PROTEIN; CELLS	Reversible phosphorylation plays important roles in G protein-coupled receptor signaling, desensitization, and endocytosis, yet the precise location and role of in vivo phosphorylation sites is unknown for most receptors. Using metabolic P-32 labeling and phosphopeptide sequencing we provide a complete phosphorylation map of the human bradykinin B-2 receptor in its native cellular environment. We identified three serine residues, Ser(339), Ser(346), and Ser(348), at the C-terminal tail as principal phosphorylation sites. Constitutive phosphorylation occurs at Ser(348), while ligand-induced phosphorylation is found at Ser(339) and Ser(346)/Ser(348) that could be executed by several G protein-coupled receptor kinases. In addition, we found a protein kinase C-dependent phosphorylation of Ser(346) that was mutually exclusive with the basal phosphorylation at Ser(348) and therefore may be implicated in differential regulation of B-2 receptor activation. Functional analysis of receptor mutants revealed that a low phosphorylation stoichiometry is sufficient to initiate receptor sequestration while a clustered phosphorylation around Ser(346) is necessary for desensitization of the B-2 receptor-induced phospholipase C activation. This was further supported by the specifically reduced Ser(346)/Ser(348) phosphorylation observed upon stimulation with a nondesensitizing B-2 receptor agonist. The differential usage of clustered phosphoacceptor sites points to distinct roles of multiple kinases in controlling G protein-coupled receptor function.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; INSERM, U367, F-75005 Paris, France; Univ Frankfurt Hosp, Inst Biochem 2, D-60590 Frankfurt, Germany	Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); Goethe University Frankfurt; Goethe University Frankfurt Hospital	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Pizard, Anne/P-4754-2016; Dikic, Ivan/O-4650-2015	Pizard, Anne/0000-0003-2705-6365; Dikic, Ivan/0000-0001-8156-9511				Aramori I, 1997, MOL PHARMACOL, V52, P16, DOI 10.1124/mol.52.1.16; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; Blaukat A, 1999, BIOCHEMISTRY-US, V38, P1300, DOI 10.1021/bi981727r; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Blaukat A, 1997, IMMUNOPHARMACOLOGY, V36, P115, DOI 10.1016/S0162-3109(97)00009-X; BOHM SK, 1996, BIOCHEM J, V322, P1; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cramer H, 1997, BIOCHEMISTRY-US, V36, P13325, DOI 10.1021/bi9708848; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Fathy DB, 1999, J BIOL CHEM, V274, P29603, DOI 10.1074/jbc.274.42.29603; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PAPAC DL, 1993, BIOCHEMISTRY-US, V32, P5718; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Roush ED, 1999, MOL PHARMACOL, V55, P855; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Ueno A, 1999, IMMUNOPHARMACOLOGY, V45, P89, DOI 10.1016/S0162-3109(99)00148-4; Widmann C, 1996, J BIOL CHEM, V271, P19957, DOI 10.1074/jbc.271.33.19957; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621; YU SS, 1993, J BIOL CHEM, V268, P337	45	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40431	40440		10.1074/jbc.M107024200	http://dx.doi.org/10.1074/jbc.M107024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11517230	hybrid			2022-12-25	WOS:000171925600012
J	Kaiya, H; Kojima, M; Hosoda, H; Koda, A; Yamamoto, K; Kitajima, Y; Matsumoto, M; Minamitake, Y; Kikuyama, S; Kangawa, K				Kaiya, H; Kojima, M; Hosoda, H; Koda, A; Yamamoto, K; Kitajima, Y; Matsumoto, M; Minamitake, Y; Kikuyama, S; Kangawa, K			Bullfrog ghrelin is modified by n-octanoic acid at its third threonine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RELEASE; CYCLASE-ACTIVATING POLYPEPTIDE; SECRETAGOGUE RECEPTOR; PITUITARY-CELLS; ACYLATED PEPTIDE; GLYCOPROTEIN HORMONES; RANA-CATESBEIANA; RAT PITUITARY; PROLACTIN; SITES	We have identified the amphibian ghrelin from the stomach of the bullfrog. We also examined growth hormone (GH)-releasing activity of this novel peptide in both the rat and bullfrog. The three forms of ghrelin identified, each comprised of 27 or 28 amino acids, possessed 29% sequence identity to the mammalian ghrelins. A unique threonine at amino acid position 3 (Thr(3)) in bullfrog ghrelin differs from the serine present in the mammalian ghrelins; this Thr(3) is acylated by either n-octanoic or n-decanoic acid. The frog ghrelin-28 has a complete structure of GLT (O-n-octanoyl)FLSPADMQKLAERQSQNKLRHGNM; the structure of frog ghrelin-27 was determined to be GLT(O-n-octanoyl)FLSPADMQKLAERQSQNKLRHGN; frog ghelin-27-C10 possessed a structure of GLT(O-n-decanoyl)FLSPADMQKLAERQSQNKLRHGN. Northern blot analysis demonstrated that ghrelin mRNA is predominantly expressed in the stomach. Low levels of gene expression were observed in the heart, lung, small intestine, gall bladder, pancreas, and testes, as revealed by reverse transcription polymerase chain reaction analysis. Bullfrog ghrelin stimulated the secretion of both GH and prolactin in dispersed bullfrog pituitary cells with potency 2-3 orders of magnitude greater than that of rat ghrelin. Bullfrog ghrelin, however, was only minimally effective in elevating plasma GH levels following intravenous injection into rats. These results indicate that although the regulatory mechanism of ghrelin to induce GH secretion is evolutionary conserved, the structural changes in the different ghrelins result in species-specific receptor binding.	Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan; Waseda Univ, Sch Educ, Dept Biol, Shinjuku Ku, Tokyo 1698050, Japan; Suntory Inst Med Res & Dev, Gunma 3700503, Japan	National Cerebral & Cardiovascular Center - Japan; Waseda University	Kaiya, H (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Biochem, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.		Kaiya, Hiroyuki/I-9221-2019	Yamamoto, Kazutoshi/0000-0002-7935-7015				Aida T, 1999, GEN COMP ENDOCR, V115, P101, DOI 10.1006/gcen.1999.7289; Alexandre D, 2000, J COMP NEUROL, V421, P234, DOI 10.1002/(SICI)1096-9861(20000529)421:2<234::AID-CNE8>3.0.CO;2-S; Bednarek MA, 2000, J MED CHEM, V43, P4370, DOI 10.1021/jm0001727; BERTHERAT J, 1995, EUR J ENDOCRINOL, V132, P12, DOI 10.1530/eje.0.1320012; BLAKE AD, 1991, J ENDOCRINOL, V129, P11, DOI 10.1677/joe.0.1290011; Bodart V, 1999, CIRC RES, V85, P796, DOI 10.1161/01.RES.85.9.796; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; Bowers CY., 1977, MOL ENDOCRINOL, P287; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; Date Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/en.141.11.4255; Date Y, 2001, BIOCHEM BIOPH RES CO, V280, P904, DOI 10.1006/bbrc.2000.4212; Feighner SD, 1998, MOL ENDOCRINOL, V12, P137, DOI 10.1210/mend.12.1.0051; Geris KL, 1998, GEN COMP ENDOCR, V111, P186, DOI 10.1006/gcen.1998.7102; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Hu ZT, 2000, ENDOCRINOLOGY, V141, P3366, DOI 10.1210/en.141.9.3366; Jeandel L, 1998, J NEUROENDOCRINOL, V10, P187; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KOBAYASHI T, 1991, GEN COMP ENDOCR, V82, P14, DOI 10.1016/0016-6480(91)90291-D; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; Montero M, 2000, J MOL ENDOCRINOL, V25, P157, DOI 10.1677/jme.0.0250157; Muccioli G, 2001, J ENDOCRINOL INVEST, V24, pRC7, DOI 10.1007/BF03343831; Muccioli G, 2000, ANN ENDOCRINOL-PARIS, V61, P27; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oguchi A, 1997, GEN COMP ENDOCR, V107, P128, DOI 10.1006/gcen.1997.6904; Oguchi A, 1996, GEN COMP ENDOCR, V102, P141, DOI 10.1006/gcen.1996.0055; Palyha OC, 2000, MOL ENDOCRINOL, V14, P160, DOI 10.1210/me.14.1.160; Shepherd BS, 2000, J ENDOCRINOL, V167, pR7, DOI 10.1677/joe.0.167R007; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUZUKI H, 1997, ADV COMP ENDOCRINOLO, V2, P1033; TANAKA S, 1991, GEN COMP ENDOCR, V84, P318, DOI 10.1016/0016-6480(91)90055-B; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; YAMAMOTO K, 1982, ENDOCRINOL JAPON, V29, P159	39	130	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40441	40448		10.1074/jbc.M105212200	http://dx.doi.org/10.1074/jbc.M105212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546772	hybrid			2022-12-25	WOS:000171925600013
J	Roelofs, J; Loovers, HM; Van Haastert, PJM				Roelofs, J; Loovers, HM; Van Haastert, PJM			GTP gamma S regulation of a 12-transmembrane guanylyl cyclase is retained after mutation to an adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; AMINO-ACID SUBSTITUTIONS; DICTYOSTELIUM-DISCOIDEUM; MULTICELLULAR DEVELOPMENT; CATALYTIC DOMAINS; BINDING PROTEINS; PHOSPHOLIPASE-C; ALPHA-SUBUNIT	DdGCA is a Dictyostelium guanylyl cyclase with a topology typical for mammalian adenylyl cyclases containing 12 transmembrane-spanning regions and two cyclase domain. In Dictyostelium cells heterotrimeric G-proteins are essential for guanylyl cyclase activation by extracellular cAMP. In lysates, guanylyl cyclase activity is strongly stimulated by guanosine 5'-3-O-(thio) triphosphate (GTP gammaS), which is also a substrate of the enzyme. DdGCA was converted to an adenylyl cyclase by introducing three point mutations. Expression of the obtained DdGCA(kqd) in adenylyl cyclase-defective cells restored the phenotype of the mutant. GTP gammaS stimulated the adenylyl cyclase activity of DdGCAkqd with properties similar to those of the wild-type enzyme (decrease of K-m and increase of V-max), demonstrating that GTP gammaS stimulation is independent of substrate specificity. Furthermore, GTP gammaS activation of DdGCAkqd is retained in several null mutants of Ga and G beta proteins, indicating that GTP gammaS activation is not mediated by a heterotrimerie G-protein but possibly by a monomeric G-protein.	Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Van Haastert, PJM (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Roelofs, Jeroen/AAC-5119-2021	Roelofs, Jeroen/0000-0003-0944-2465				Aubry L, 1998, GENE DEV, V12, P1525, DOI 10.1101/gad.12.10.1525; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; BRANDWEIN HJ, 1982, J BIOL CHEM, V257, P1309; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Carucci DJ, 2000, J BIOL CHEM, V275, P22147, DOI 10.1074/jbc.M001021200; Chubb JR, 2001, BBA-GEN SUBJECTS, V1525, P262, DOI 10.1016/S0304-4165(01)00111-8; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DICOU E, 1980, EUR J BIOCHEM, V109, P507, DOI 10.1111/j.1432-1033.1980.tb04822.x; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Emala CW, 1999, AM J PHYSIOL-LUNG C, V276, pL564, DOI 10.1152/ajplung.1999.276.4.L564; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HALL AL, 1993, DEV BIOL, V157, P73, DOI 10.1006/dbio.1993.1113; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heikoop JC, 1998, EUR J BIOCHEM, V256, P359, DOI 10.1046/j.1432-1327.1998.2560359.x; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; JANSSENS PMW, 1988, BIOCHEM BIOPH RES CO, V150, P405, DOI 10.1016/0006-291X(88)90535-9; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Linder JU, 2000, J BIOL CHEM, V275, P11235, DOI 10.1074/jbc.275.15.11235; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Martelli AM, 1996, BIOCHEM BIOPH RES CO, V218, P182, DOI 10.1006/bbrc.1996.0032; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; OYAMA M, 1991, BIOCHEM BIOPH RES CO, V176, P1245, DOI 10.1016/0006-291X(91)90419-8; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Roelofs J, 2001, BIOCHEM J, V354, P697, DOI 10.1042/0264-6021:3540697; Root PA, 1999, J CELL BIOCHEM, V74, P301, DOI 10.1002/(SICI)1097-4644(19990801)74:2<301::AID-JCB14>3.0.CO;2-9; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; SCHOEN CD, 1992, THESIS U AMSTERDAM; SCHULKES CCGM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P73, DOI 10.1016/0167-4889(92)90168-B; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; SNAARJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; Srinivasan J, 1999, DEV BIOL, V215, P443, DOI 10.1006/dbio.1999.9474; Sucgang R, 1997, DEV BIOL, V192, P181, DOI 10.1006/dbio.1997.8720; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; VALKEMA R, 1992, BIOCHEM BIOPH RES CO, V186, P263, DOI 10.1016/S0006-291X(05)80802-2; VANHAASTERT PJM, 1984, J CELL BIOL, V98, P709, DOI 10.1083/jcb.98.2.709; VANHAASTERT PJM, 1982, FEBS LETT, V147, P149, DOI 10.1016/0014-5793(82)81029-6; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; Wilkins A, 2001, TRENDS GENET, V17, P41, DOI 10.1016/S0168-9525(00)02181-8; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	62	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40740	40745		10.1074/jbc.M105154200	http://dx.doi.org/10.1074/jbc.M105154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522784	Green Published, hybrid			2022-12-25	WOS:000171925600050
J	Yang, T; Davis, RJ; Chow, CW				Yang, T; Davis, RJ; Chow, CW			Requirement of two NFATc4 transactivation domains for CBP potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; ACTIVATED T-CELLS; TRANSCRIPTION FACTOR GATA-1; NUCLEAR-PROTEIN CBP; NF-ATC; CYCLOSPORINE-A; REGULATORY ELEMENTS; SIGNALING PATHWAYS; P300 PROTEIN; CALCINEURIN	Recruitment of the coactivator CREB-binding protein (CBP) to transcription factors is important for gene expression. Various regions of CBP such as the KIX and CH3 domains have been shown to interact with numerous transcription factors. The NFAT group of transcription factors is involved in multiple biological processes. NFATc4/NFAT3 has been proposed to play an important role in heart hypertrophy, adipocyte differentiation, and learning and memory. We demonstrate here that two transactivation domains, located at the NH, and COOH termini of NFATc4, are critical for interacting with CBP. Each transactivation domain interacts with a distinct region of the CBP protein (the KIX and CH3 domains). Binding of CBP potentiates NFATc4-mediated transcription activity. Both transactivation domains of NFATc4 are required for CBP function. Removal of either NFATc4 transactivation domain abolishes CBP potentiation. Conversely, mutation of the KIX or CH3 domain prevents CBP-mediated potentiation of NFATc4 transcription activation. These data demonstrate that formation of a functional NFATc4-CBP transcription complex requires interactions at two distinct sites.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst,Program Mol Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Chow, CW (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R01CA065861, P01CA072009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65861, CA72009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; Falvo JV, 2000, P NATL ACAD SCI USA, V97, P3925, DOI 10.1073/pnas.97.8.3925; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Goodman RH, 2000, GENE DEV, V14, P1553; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lara-Pezzi E, 1998, HEPATOLOGY, V28, P1013, DOI 10.1002/hep.510280416; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	59	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39569	39576		10.1074/jbc.M102961200	http://dx.doi.org/10.1074/jbc.M102961200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514544	hybrid			2022-12-25	WOS:000171789200011
J	Ikeda, N; Eguchi, H; Nishihara, S; Narimatsu, H; Kannagi, R; Irimura, T; Ohta, M; Matsuda, H; Taniguchi, N; Honke, K				Ikeda, N; Eguchi, H; Nishihara, S; Narimatsu, H; Kannagi, R; Irimura, T; Ohta, M; Matsuda, H; Taniguchi, N; Honke, K			A remodeling system of the 3 '-sulfo-Lewis a and 3 '-sulfo-Lewis x epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SIALYL-LEWIS-X; LINKED OLIGOSACCHARIDES; L-SELECTIN; SULFATED OLIGOSACCHARIDES; CARBOHYDRATE CHAINS; MAST-CELLS; FUC-TIX; EXPRESSION; CANCER	It has been reported that the chemically synthesized 3'-sulfo-Le(a) and 3'-sulfo-Le(x) epitopes have a high potential as a ligand for selectins. To elucidate the physiological functions of 3'-sulfated Lewis epitopes, a remodeling system was developed using a combination of a beta Ga1-3-O-sulfotransferase GP3ST, hitherto known alpha1,3/1,4-fucosyltransferases (FucT-III, IV, V, VI, VII, and IX) and arylsulfatase A. The pyridylaminated (PA) lacto-N-tetraose (Gal beta1-3GlcNAc beta1-3Gal beta1-4Glc) was first converted to 3'-sulfolacto-N-fucopentaose II (sulfo-3Gal beta1-3(Fuc alpha1-4)GlcNAc beta1-3Gal beta1-4Glc)-PA by sequential reactions with GP3ST and FucT-III. The 3'-sulfolacto-N-fucopentaose III (sulfo-3Gal beta1-4(Fuc alpha1-3)GlcNAc beta1-3Gal beta1-4Glc)-PA was then synthesized from lacto-N-neotetraose (Gal beta1-4GlcNAc beta1-3Gal beta1-4Glc)-PA by GP3ST and FucT-III, -IV, -V, -VI, -VII, or -IX in a similar manner. The substrate specificity for the 3'-sulfated acceptor of the alpha1,3-fucosyltransferases was considerably different from that for the non-substituted and 3'-sialylated varieties. When the GP3ST gene was introduced into A549 and Chinese hamster ovary cells expressing FucT-III, they began to express 3'-sulfo-Lea and 3'-sulfo-Le(x) epitopes, respectively, suggesting that GP3ST is responsible for their biosynthesis in vivo. The expression of the 3'-sialyl-Le(x) epitope on Chinese hamster ovary cells was attenuated by the introduction of GP3ST gene, indicating that GP3ST and alpha2,3-sialyltransferase compete for the common Gal beta1-4GlcNAc-R oligosaccharides. Last, arylsulfatase A, which is a lysosomal hydrolase that catalyzes the desulfation of 3-O-sulfogalactosyl residues in glycolipids, was found to hydrolyze the sulfate ester bond on the 3'-sulfo-Le(x) (type 2 chain) but not that on the 3'-sulfo-Le(a) (type 1 chain). The present remodeling system might be of potential use as a tool for the study of the physiological roles of 3'-sulfated Lewis epitopes, including interaction with selectins.	Osaka Univ, Sch Med, Dept Biochem, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg, Osaka 5650871, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Tokyo 1928577, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Tsukuba, Ibaraki 3058568, Japan; Aichi Canc Ctr, Program Expt Pathol, Nagoya, Aichi 4648681, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan	Osaka University; Osaka University; Soka University; National Institute of Advanced Industrial Science & Technology (AIST); Aichi Cancer Center; University of Tokyo	Honke, K (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Room B1,2-2 Yamadaoka, Osaka 5650871, Japan.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014; Kannagi, Reiji/Q-6459-2018; Narimatsu, Hisashi/M-4757-2018; Eguchi, Hiromi/GWC-5633-2022	Taniguchi, Naoyuki/0000-0001-5889-5968; Kannagi, Reiji/0000-0003-4202-2921; Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Aubert M, 2000, CANCER RES, V60, P1449; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P23806; Degroote S, 1999, GLYCOBIOLOGY, V9, P1199, DOI 10.1093/glycob/9.11.1199; DEWAARD P, 1991, J BIOL CHEM, V319, P209; El-Fasakhany FM, 2001, J BIOL CHEM, V276, P26988, DOI 10.1074/jbc.M100348200; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; FUJII T, 1992, BIOCHIM BIOPHYS ACTA, V1122, P93, DOI 10.1016/0167-4838(92)90132-W; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HIYAMA J, 1992, GLYCOBIOLOGY, V2, P401, DOI 10.1093/glycob/2.5.401; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Izawa M, 2000, CANCER RES, V60, P1410; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; KATO Y, 1989, J BIOL CHEM, V264, P3364; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; Loveless RW, 1998, GLYCOBIOLOGY, V8, P1237, DOI 10.1093/glycob/8.12.1237; MAWHINNEY TP, 1987, J BIOL CHEM, V262, P2994; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; STRECKER G, 1987, GLYCOCONJUGATE J, V4, P329, DOI 10.1007/BF01048366; Suzuki A, 2001, J BIOL CHEM, V276, P24388, DOI 10.1074/jbc.M103135200; Tanemura M, 1998, J BIOL CHEM, V273, P16421, DOI 10.1074/jbc.273.26.16421; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tsuiji H, 1998, BIOCHEM BIOPH RES CO, V253, P374, DOI 10.1006/bbrc.1998.9726; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; VONFIGURA K, 2001, METABOLIC MOL BASES, P3695; Yamachika T, 1997, VIRCHOWS ARCH, V431, P25, DOI 10.1007/s004280050065; YUEN CT, 1994, J BIOL CHEM, V269, P1595; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	45	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38588	38594		10.1074/jbc.M107390200	http://dx.doi.org/10.1074/jbc.M107390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504739	hybrid			2022-12-25	WOS:000171673200036
J	Rockwell, NC; Fuller, RS				Rockwell, NC; Fuller, RS			Differential utilization of enzyme-substrate interactions for acylation but not deacylation during the catalytic cycle of Kex2 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SERINE PROTEASES; PROCESSING PROTEASES; CRYSTAL-STRUCTURE; SPECIFICITY; SUBTILISIN; CHYMOTRYPSIN; FAMILY; FURIN; LOCALIZATION	Kex2 protease from Saccharomyces cerevisiae is the prototype for a family of eukaryotic proprotein processing proteases belonging to the subtilase superfamily of serine proteases. Kex2 can be distinguished from degradative subtilisins on the basis of stringent substrate specificity and distinct pre-steady-state behavior. To better understand these mechanistic differences, we have examined the effects of substrate residues at P-1 and P-4 on individual steps in the Kex2 catalytic cycle with a systematic series of isosteric peptidyl amide and ester substrates. The results demonstrate that substrates based on known, physiological cleavage sites exhibit high acylation rates (greater than or equal to 550 s(-1)) with Kex2. Substitution of Lys for the physiologically correct Arg at P-1 resulted in a greater than or equal to 200-fold drop in acylation rate with almost no apparent effect on binding or deacylation. In contrast, substitution of the physiologically incorrect Ala for Nle at P-4 resulted in a much smaller defect in acylation and a modest but significant effect on binding with Lys at P-1. This substitution also had no effect on deacylation. These results demonstrate that Kex2 utilizes enzyme-substrate interactions in different ways at different steps in the catalytic cycle, with the S-1-P-1 contact providing a key specificity determinant at the acylation step.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Fuller, RS (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039697, R01GM039697] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P2025, DOI 10.1021/bi00735a001; Fersht A., 1985, ENZYME STRUCTURE MEC; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; HARTLEY BS, 1954, BIOCHEM J, V56, P288, DOI 10.1042/bj0560288; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 2000, ANAL BIOCHEM, V280, P201, DOI 10.1006/abio.2000.4541; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Rockwell NC, 2001, BIOCHEMISTRY-US, V40, P3657, DOI 10.1021/bi0020877; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; YENNAWAR NH, 1994, BIOCHEMISTRY-US, V33, P7326, DOI 10.1021/bi00189a038	32	12	12	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38394	38399		10.1074/jbc.M105782200	http://dx.doi.org/10.1074/jbc.M105782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514565	hybrid			2022-12-25	WOS:000171673200011
J	Safa, P; Boulter, J; Hales, TG				Safa, P; Boulter, J; Hales, TG			Functional properties of Ca(v)1.3 (alpha(1D)) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; HETEROTRIMERIC G-PROTEINS; PANCREATIC BETA-CELLS; N-TYPE; HIPPOCAMPAL-NEURONS; OPIOID RECEPTORS; P/Q-TYPE; T-TYPE; MOLECULAR DIVERSITY; BINDING PROTEIN	Ca2+ enters pituitary and pancreatic neuroendocrine cells through dihydropyridine-sensitive channels triggering hormone release. Inhibitory metabotropic receptors reduce Ca2+ entry through activation of pertussis toxin-sensitive G proteins leading to activation of K+ channels and voltage-sensitive inhibition of L-type channel activity. Despite the cloning and functional expression of several Ca2+ channels, those involved in regulating hormone release remain unknown. Using reverse transcription-polymerase chain reaction we identified mRNAs encoding three alpha (1) (alpha (1A), alpha (1C), and alpha (1D)), four beta, and one alpha (2)-delta subunit in rat pituitary GH(3) cells; alpha (1B) and alpha (1S) transcripts were absent. GH(3) cells express multiple alternatively spliced alpha (1D) mRNAs. Many of the alpha (1D) transcript variants encode "short" alpha (1D) (alpha (1D-S)) subunits, which have a QXXER amino acid sequence at their C termini, a motif found in all other al subunits that couple to opioid receptors. The other splice variants identified terminate with a longer C terminus that lacks the QXXER motif (alpha (1D-L)). We cloned and expressed the predominant alpha (1D-S) transcript variants in rat brain and GH(3) cells and their alpha (1D-L) counterpart in GH(3) cells. Unlike alpha (1A) channels, alpha (1D) channels exhibited current-voltage relationships similar to those of native GH(3) cell Ca2+ channels, but lacked voltage-dependent G protein coupling. Our data demonstrate that alternatively spliced alpha (1D) transcripts form functional Ca2+ channels that exhibit voltage-dependent, G protein-independent facilitation. Furthermore, the QXXER motif, located on the C terminus of alpha (1D-S) subunit, is not sufficient to confer sensitivity to inhibitory G proteins.	George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA; Univ Calif Los Angeles, Neurosci Interdept Program, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Inst Neuropsychiat, Los Angeles, CA 90095 USA	George Washington University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hales, TG (corresponding author), George Washington Univ, Med Ctr, Dept Pharmacol, 2300 Eye St NW, Washington, DC 20037 USA.		Tuluc, Petronel/C-2527-2011		NIDA NIH HHS [P50 DA005010] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abdulla FA, 1997, J NEUROSCI, V17, P8721; Angelotti T, 1996, FEBS LETT, V397, P331, DOI 10.1016/S0014-5793(96)01205-7; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bell DC, 2001, J NEUROPHYSIOL, V85, P816, DOI 10.1152/jn.2001.85.2.816; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Blumenstein Y, 1999, FEBS LETT, V444, P78, DOI 10.1016/S0014-5793(99)00035-6; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Brody DL, 1997, J PHYSIOL-LONDON, V499, P637, DOI 10.1113/jphysiol.1997.sp021956; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; CHIN H, 1992, FEBS LETT, V299, P69, DOI 10.1016/0014-5793(92)80103-N; CHRISTIE BR, 1994, NEUROSCI LETT, V167, P41, DOI 10.1016/0304-3940(94)91023-5; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1999, ADV SEC MESS PHOSPH, V33, P153; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HESCHELER J, 1994, ANN NY ACAD SCI, V733, P306, DOI 10.1111/j.1749-6632.1994.tb17280.x; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; IHARA Y, 1995, MOL ENDOCRINOL, V9, P121, DOI 10.1210/me.9.1.121; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kollmar R, 1997, P NATL ACAD SCI USA, V94, P14889, DOI 10.1073/pnas.94.26.14889; Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; LIEVANO A, 1994, AM J PHYSIOL, V267, pC411, DOI 10.1152/ajpcell.1994.267.2.C411; Lin ZX, 1999, J NEUROSCI, V19, P5322; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; Norris CM, 1998, J NEUROSCI, V18, P3171; Page KM, 1998, J NEUROSCI, V18, P4815; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Piros ET, 1996, MOL PHARMACOL, V50, P947; Piros ET, 1996, NEUROCHEM RES, V21, P1277, DOI 10.1007/BF02532368; PIROS ET, 1995, MOL PHARMACOL, V47, P1041; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Safa P., 1998, Society for Neuroscience Abstracts, V24, P83; Scholze A, 2001, MOL ENDOCRINOL, V15, P1211, DOI 10.1210/me.15.7.1211; Simen AA, 2000, MOL PHARMACOL, V57, P1064; Sun QQ, 1999, J NEUROSCI, V19, P890; Triggle DJ, 1999, EUR J PHARMACOL, V375, P311, DOI 10.1016/S0014-2999(99)00329-5; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	60	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38727	38737		10.1074/jbc.M103724200	http://dx.doi.org/10.1074/jbc.M103724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514547	hybrid			2022-12-25	WOS:000171673200055
J	Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM			The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer	ONCOGENE			English	Article						BNP1350; bax; cyclin B; cdc2; chk1; cdc25C	DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; OVARIAN-CANCER; FISSION YEAST; HUMAN HEAD; THYMOCYTE APOPTOSIS; ANTITUMOR-ACTIVITY; CYCLE ARREST; DEATH; EXPRESSION	Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of cancer treatment. The transfection of the proapoptotic bax gene, which results in the overexpression of bax protein, augments the growth inhibition of A253 cells by BNP1350. Increased drug response was associated with the induction of DNA fragmentation in the size of 30-200 Kb, generating a cleaved fragment of 18 kDa from full-length 21 kDa bax and the cleavage of PARP. A253/vec cells treated with 0.07 muM(IC50) of BNP1350 accumulated in G(2) phase at 24 h after drug removal. In contrast, A253/Bax cells treated with an equimolar concentration of BNP1350 primarily displayed a G(1) phase accumulation with a concurrent decrease in G(2) phase. Certain cell cycle regulatory protein expression and activities were altered following drug exposure in both cell lines under similar conditions. Cdk2- and cdc2-associated HI kinase activities were markedly increased in the A253/Bax cell line with marginal increased activity in the A253/vec cell line. A chk1 activity assay was performed with GST-cdc25C (200 - 256) or GST-cdc25C(S216A) (200-256) fusion proteins as the substrate. Increased chk1 activity was observed in the A253/vec cell line, with little change in the A253/Bax cell line, when exposed to equimolar concentrations of BNP1350 (0.07 MM). A Western blot of immunoprecipitated chk1 indicated that increased chk1 phosphorylation following DNA damage induced by BNP1350 was accompanied by the observed G(2) accumulation in the A253/vec cell line, while only a slight increase in chk1 phosphorylation was seen in the A253/Bax cell line. A decreased expression of cdc25C was observed in the BNP1350-treated A253/Bax cells, but not in the A253/vec cell line. Following exposure to BNP1350, increased binding of 14-3-3 proteins to chk1 occurred in both cell lines, with more being observed in the A253/vec cell line. The data have shown that inhibition of the chk1 pathway accompanied by the abrogation of G(2) arrest is involved in sensitizing A253 cells to BNP1350 by bax gene transfer. These findings suggest that bax gene transfer sensitizes A253 cells to BNP1350 through apoptosis promoting and G(2)/M DNA damage checkpoint regulatory pathways.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA065761, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 65761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Arafat WO, 2000, MOL THER, V1, P545, DOI 10.1006/mthe.2000.0071; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chan TA, 2000, GENE DEV, V14, P1584; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo B, 1999, ONCOL RES, V11, P91; Guo B, 2000, CLIN CANCER RES, V6, P718; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jackson JR, 2000, CANCER RES, V60, P566; Jacotot E, 2000, PATHOL BIOL, V48, P271; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; McPake CR, 1998, ONCOL RES, V10, P235; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PANADERO A, 1995, ONCOL RES, V7, P73; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; ROSHAK A, 1999, P AM ASSOC CANC RES, V40, P413; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Shinoura N, 2000, CANCER GENE THER, V7, P739, DOI 10.1038/sj.cgt.7700158; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Strobel T, 1998, CANCER RES, V58, P4776; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yin MB, 2000, MOL PHARMACOL, V57, P453, DOI 10.1124/mol.57.3.453; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Yin MB, 1999, EXP CELL RES, V247, P189, DOI 10.1006/excr.1998.4346	52	8	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5249	5257		10.1038/sj.onc.1204686	http://dx.doi.org/10.1038/sj.onc.1204686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536038				2022-12-25	WOS:000170575500001
J	Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney	ONCOGENE			English	Article						AXIN1; chromosome 3p22; colon cancer; lung cancer	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN MUTATIONS; WNT SIGNALING PATHWAY; NEGATIVE REGULATOR; HEPATOCELLULAR CARCINOMAS; COLORECTAL CARCINOMAS; CYCLIN D1; CANCER; ACTIVATION; APC	Axin, an important regulator of beta -catenin, is frequently mutated in human hepatocellular carcinomas (HCCs), and transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC cells as well as in colon cancer cells. To investigate the detailed biological function of Axin, we searched on a cDNA microarray for genes whose expression was altered by transfer of wild-type AXIN1 into colon-cancer cell line LoVo. Among the genes showing altered expression, we focused on one, termed AXUD1 (AXIN1 up-regulated(1)), that revealed enhanced expression in response to exogeneously expressed AXIN1 but not to LacZ, a control gene. The AXUD1 gene consists of five exons and encodes a transcript with an open reading frame of 1767 bp. A 3.2-kb transcript of AXUD1 was expressed in all human tissues examined, most abundantly in lung, placenta, skeletal muscle, pancreas and leukocyte. By radiation-hybrid mapping we assigned its chromosomal location at 3p22, a region where frequent loss of heterozygosity has been reported in lung, renal, prostate, breast and cervical cancers. AXUD1 was frequently down-regulated in lung, kidney, liver and colon cancers compared with their corresponding normal tissues, suggesting that AXUD1 may have a tumor-suppressor function in those organs.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	University of Tokyo; RIKEN; Nagoya City University	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Fujita M, 2000, CANCER RES, V60, P6683; Fukuchi T, 1998, CANCER RES, V58, P3526; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Iwao K, 1998, CANCER RES, V58, P1021; Kawasoe T, 2000, CANCER RES, V60, P3354; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miano JM, 1997, GENE, V197, P215, DOI 10.1016/S0378-1119(97)00265-5; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura Y, 1997, NAT MED, V3, P499, DOI 10.1038/nm0597-499; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Ono K, 2000, CANCER RES, V60, P5007; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Voeller HJ, 1998, CANCER RES, V58, P2520; Wistuba II, 1997, CANCER RES, V57, P3154; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yokota J, 1989, Princess Takamatsu Symp, V20, P43; Zurawel RH, 1998, CANCER RES, V58, P896	35	52	57	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5062	5066		10.1038/sj.onc.1204603	http://dx.doi.org/10.1038/sj.onc.1204603			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526492				2022-12-25	WOS:000170439800017
J	Tan, DX; Manchester, LC; Burkhardt, S; Sainz, RM; Mayo, JC; Kohen, R; Shohami, E; Huo, YS; Hardeland, R; Reiter, RJ				Tan, DX; Manchester, LC; Burkhardt, S; Sainz, RM; Mayo, JC; Kohen, R; Shohami, E; Huo, YS; Hardeland, R; Reiter, RJ			N-1-acetyl-N-2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant	FASEB JOURNAL			English	Article						cyclic voltammetry; glutamate; amyloid beta-peptide; hydrogen peroxide; 8-hydroxydeoxyguanosine; lipid peroxidation; free radical; neuron	CYCLIC VOLTAMMETRY; OXIDATIVE DAMAGE; IN-VITRO; PROTECTION; CAPACITY; DEATH; CELLS; RATS; SYSTEM; SERUM	The biogenic amine N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK) was investigated for its potential antioxidative capacity. AFMK is a metabolite generated through either an enzymatic or a chemical reaction pathway from melatonin. The physiological function of AFMK remains unknown. To our knowledge, this report is the first to document the potent antioxidant action of this biogenic amine. Cyclic voltammetry (CV) shows that AFMK donates two electrons at potentials of 456 mV and 668 mV, and therefore it functions as a reductive force. This function contrasts with all other physiological antioxidants that donate a single electron only when they neutralize free radicals. AFMK reduced 8-hydroxydeoxyguanosine formation induced by the incubation of DNA with oxidants significantly. Lipid peroxidation resulting from free radical damage to rat liver homogenates was also prevented by the addition of AFMK. The inhibitory effects of AFMK on both DNA and lipid damage appear to be dose-response related. In cell culture, AFMK efficiently reduced hippocampal neuronal death induced by either hydrogen peroxide, glutamate, or amyloid beta (25-35) peptide. AFMK is a naturally occurring molecule with potent free radical scavenging capacity (donating two electrons/molecule) and thus may be a valuable new antioxidant for preventing and treating free radical-related disorders.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Gottingen, D-37073 Gottingen, Germany; Antropol Inst Zool, D-37073 Gottingen, Germany; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel	University of Texas System; University of Texas Health San Antonio; University of Gottingen; Hebrew University of Jerusalem	Reiter, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	reiter@uthscsa.edu	Sainz, Rosa M./N-5885-2014; Mayo, Juan Carlos/H-3435-2011; tan, dun-xian/E-3610-2010	Sainz, Rosa M./0000-0003-3048-5582; Mayo, Juan Carlos/0000-0002-0882-2047; Kohn, Ron/0000-0001-7268-9845				Andrisano V, 2000, J PHARMACEUT BIOMED, V23, P15, DOI 10.1016/S0731-7085(00)00259-4; Avrova N F, 2000, Neurosci Behav Physiol, V30, P535, DOI 10.1007/BF02462611; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Benot S, 1999, J PINEAL RES, V27, P59, DOI 10.1111/j.1600-079X.1999.tb00597.x; BRADFORD M, 1976, ANN BIOCH, V71, P171; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; Chevion S, 2000, FREE RADICAL BIO MED, V28, P860, DOI 10.1016/S0891-5849(00)00178-7; Ebelt H, 2000, J PINEAL RES, V28, P65, DOI 10.1034/j.1600-079X.2001.280201.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hara M, 2001, J PINEAL RES, V30, P129, DOI 10.1034/j.1600-079X.2001.300301.x; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HERBERT V, 1994, STEM CELLS, V12, P289, DOI 10.1002/stem.5530120305; HIRATA F, 1974, J BIOL CHEM, V249, P1311; Hoyos M, 2000, J PINEAL RES, V28, P150; KELLY RW, 1984, BIOCHEM BIOPH RES CO, V121, P372, DOI 10.1016/0006-291X(84)90732-0; KENNAWAY DJ, 1988, AUST J BIOL SCI, V41, P393, DOI 10.1071/BI9880393; Kohen R, 1999, METHOD ENZYMOL, V300, P285; LIU DX, 1994, J NEUROCHEM, V62, P37; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P572; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; Pappolla MA, 1999, J PINEAL RES, V27, P226, DOI 10.1111/j.1600-079X.1999.tb00619.x; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pourahmad J, 2000, TOXICOLOGY, V143, P263, DOI 10.1016/S0300-483X(99)00178-X; Price JM, 1997, NEUROL RES, V19, P534, DOI 10.1080/01616412.1997.11740853; Qi WB, 2000, J PINEAL RES, V29, P54, DOI 10.1034/j.1600-079X.2000.290108.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ., 2000, CURR TOP BIOPHYS, V24, P171; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Silva SO, 2000, BIOCHEM BIOPH RES CO, V279, P657, DOI 10.1006/bbrc.2000.3993; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tan DX, 1993, ENDOCR J, V1, P57; Zhou LJ, 2000, ACTA PHARMACOL SIN, V21, P75	35	224	233	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2294	+		10.1096/fj.01-0309fje	http://dx.doi.org/10.1096/fj.01-0309fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511530				2022-12-25	WOS:000170809900017
J	Mograbi, B; Bocciardi, R; Bourget, I; Busca, R; Rochet, N; Farahi-Far, D; Juhel, T; Rossi, B				Mograbi, B; Bocciardi, R; Bourget, I; Busca, R; Rochet, N; Farahi-Far, D; Juhel, T; Rossi, B			Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway - Importance for the rescue of neuroectodermic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MICE LACKING GDNF; RECEPTOR TYROSINE KINASE; ENTERIC NERVOUS-SYSTEM; C-RET PROTOONCOGENE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; INDEPENDENT MECHANISMS; RAF-1 KINASE	Glial cell line-derived neurotrophic factor (GDNF) plays a crucial role in rescuing neural crest cells from apoptosis during their migration in the foregut. This survival factor binds to the heterodimer GDNF family receptor alpha1/Ret, inducing the Ret tyrosine kinase activity. ret loss-of-function mutations result in Hirschsprung's disease, a frequent developmental defect of the enteric nervous system. Although critical to enteric nervous system development, the intracellular signaling cascades activated by GDNF and their importance in neuroectodermic cell survival still remain elusive. Using the neuroectodermic SK-N-MC cell line, we found that the Ret tyrosine kinase activity is essential for GDNF to induce phosphatidylinositol 3-kinase (PI3K)/Akt and ERK pathways as well as cell rescue. We demonstrate that activation of PI3K is mandatory for GDNF-induced cell survival. In addition, evidence is provided for a critical up-regulation of the ERK pathway by PI3K at the level of Raf-1. Conversely, Akt inhibits the ERK pathway. Thus, both PI3K and Akt act in concert to finely regulate the level of ERK. We found that Akt activation is indispensable for counteracting the apoptotic signal on mitochondria, whereas ERK is partially involved in precluding procaspase-3 cleavage. Altogether, these findings underscore the importance of the Ret/PI3K/Akt pathway in GDNF-induced neuroectodermic cell survival.	Fac Med Pasteur, INSERM, U364, IFR50, F-06107 Nice 02, France; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; Fac Med Pasteur, INSERM, U385, IFR50, F-06107 Nice 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Genoa; IRCCS Istituto Giannina Gaslini; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Mograbi, B (corresponding author), Fac Med Pasteur, INSERM, U364, IFR50, F-06107 Nice 02, France.		Mograbi, Baharia/Q-7953-2019; Mograbi, Baharia/N-5531-2018; ROCHET, Nathalie/N-1819-2018; Bocciardi, Renata/J-8577-2016; ROCHET, Nathalie/S-3027-2019	ROCHET, Nathalie/0000-0002-9995-6699; Bocciardi, Renata/0000-0001-8415-3802; ROCHET, Nathalie/0000-0002-9995-6699; Mograbi, Baharia/0000-0002-1025-3429; BOURGET, Isabelle/0000-0001-6369-8176; Juhel, Thierry/0000-0002-2271-2952				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; De Vita G, 2000, CANCER RES, V60, P3727; delPeso L, 1997, SCIENCE, V278, P687; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7886; Durbec PL, 1996, DEVELOPMENT, V122, P349; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Golden JP, 1999, EXP NEUROL, V158, P504, DOI 10.1006/exnr.1999.7127; Guan KL, 2000, J BIOL CHEM, V275, P27354; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Kokaia Z, 1999, EUR J NEUROSCI, V11, P1202, DOI 10.1046/j.1460-9568.1999.00513.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pong K, 1998, J NEUROCHEM, V71, P1912; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sawada H, 2000, J NEUROCHEM, V74, P1175; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Soler RM, 1999, J NEUROSCI, V19, P9160; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1997, J NEUROSCI, V17, P3554; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Yu T, 1998, J NEUROSCI, V18, P4684; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	80	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45307	45319		10.1074/jbc.M101220200	http://dx.doi.org/10.1074/jbc.M101220200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11535584	hybrid			2022-12-25	WOS:000172406700126
J	Hallgren, J; Spillmann, D; Pejler, G				Hallgren, J; Spillmann, D; Pejler, G			Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6 - Formation of active tryptase monomers in the presence of low molecular weight heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG TRYPTASE; SPONTANEOUS INACTIVATION; TETRAMER; ENZYME; PROTEOGLYCAN; INFLAMMATION; LACTOFERRIN; FIBRONECTIN; BASOPHILS; HISTAMINE	Mast cell tryptase is stored as an active tetramer in complex with heparin in mast cell secretory granules. Previously, we demonstrated the dependence on heparin for the activation/tetramer formation of a recombinant tryptase. Here we have investigated the structural requirements for this activation process. The ability of heparin-related saccharides to activate a recombinant murine tryptase, mouse mast cell protease-6 (mMCP-6), was strongly dependent on anionic charge density and size. The dose-response curve for heparin-induced mMCP-6 activation displayed a bell-shaped appearance, indicating that heparin acts by binding to more than one tryptase monomer simultaneously. The minimal heparin oligosaccharide required for binding to mMCP-6 was 8-10 saccharide units. Gel filtration analyses showed that such short oligosaccharides were unable to generate tryptase tetramers, but instead gave rise to active mMCP-6 monomers. The active monomers were inhibited by bovine pancreatic trypsin inhibitor, whereas the tetramers were resistant. Furthermore, monomeric (but not tetrameric) mMCP-6 degraded fibronectin. Our results suggest a model for tryptase tetramer formation that involves bridging of tryptase monomers by heparin or other highly sulfated polysaccharides of sufficient chain length. Moreover, our results raise the possibility that some of the reported activities of tryptase may be related to active tryptase monomers that may be formed according to the mechanism described here.	Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University	Pejler, G (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, POB 575, S-75123 Uppsala, Sweden.		Hallgren Martinsson, Jenny/AAZ-6356-2021; Hallgren Martinsson, Jenny/AAZ-5937-2021	Hallgren Martinsson, Jenny/0000-0002-3685-5364				Addington AK, 1996, BIOCHEMISTRY-US, V35, P13511, DOI 10.1021/bi960042t; ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; ALTER SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P26, DOI 10.1016/0003-9861(90)90005-J; Elrod KC, 1997, AM J RESP CRIT CARE, V156, P375, DOI 10.1164/ajrccm.156.2.9607012; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Hallgren J, 2001, BIOCHEMISTRY-US, V40, P7342, DOI 10.1021/bi001988c; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JORDAN RE, 1980, J BIOL CHEM, V255, P81; Kaminska R, 1999, J INVEST DERMATOL, V113, P567, DOI 10.1046/j.1523-1747.1999.00738.x; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; Kozik A, 1998, BBA-PROTEIN STRUCT M, V1385, P139, DOI 10.1016/S0167-4838(98)00053-3; Lindqvist C, 1999, SKANDINAVISTIK, V29, P1; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; Pejler G, 1996, BIOCHEM J, V320, P897, DOI 10.1042/bj3200897; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Sommerhoff CP, 1999, P NATL ACAD SCI USA, V96, P10984, DOI 10.1073/pnas.96.20.10984; Sommerhoff CP, 2000, BBA-PROTEIN STRUCT M, V1477, P75, DOI 10.1016/S0167-4838(99)00265-4; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0	37	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42774	42781		10.1074/jbc.M105531200	http://dx.doi.org/10.1074/jbc.M105531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11533057	hybrid			2022-12-25	WOS:000172169300020
J	Wiltfang, J; Esselmann, H; Cupers, P; Neumann, M; Kretzschmar, H; Beyermann, M; Schleuder, D; Jahn, H; Ruther, E; Kornhuber, J; Annaert, W; De Strooper, B; Saftig, P				Wiltfang, J; Esselmann, H; Cupers, P; Neumann, M; Kretzschmar, H; Beyermann, M; Schleuder, D; Jahn, H; Ruther, E; Kornhuber, J; Annaert, W; De Strooper, B; Saftig, P			Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; NECROSIS-FACTOR-ALPHA; PRECURSOR PROTEIN; A-BETA; CEREBROSPINAL-FLUID; ELECTROPHORETIC SEPARATION; AMINOPEPTIDASE ACTIVITY; BRAIN PARENCHYMA; CLEAVAGE; PRESENILIN-1	Urea-based beta -amyloid (A beta) SDS-polyacrylamide gel electrophoresis and immunoblots were used to analyze the generation of A beta peptides in conditioned medium from primary mouse neurons and a neuroglioma cell line, as well as in human cerebrospinal fluid. A comparable and highly conserved pattern of A beta peptides, namely, 1-40/42 and carboxyl-terminal-truncated 1-37, 1-38, and 1-39, was found. Besides A beta1-42, we also observed a consistent elevation of amino-terminal-truncated A beta2-42 in a detergent-soluble pool in brains of subjects with Alzheimer's disease. A beta2-42 was also specifically elevated in cerebrospinal fluid samples of Alzheimer's disease patients. To decipher the contribution of potential different gamma -secretases (presenilins (PSs)) in generating the amino-terminal- and carboxyl-terminal-truncated A beta peptides, we overexpressed. beta -amyloid precursor protein (APP)-trafficking mutants in PS1+/+ and PS1-/- neurons. As compared with APP-WT (primary neurons from control or PS1-deficient mice infected with Semliki Forest virus), PS1-/- neurons and PS1+/+ neurons overexpressing APP-Delta ct (a slow-internalizing mutant) show a decrease of all secreted A beta peptide species, as expected, because this mutant is processed mainly by alpha -secretase. This drop is even more pronounced for the APP-KK construct (APP mutant carrying an endoplasmic reticulum retention motif). Surprisingly, A beta2-42 is significantly less affected in PS1-/- neurons and in neurons transfected with the endocytosis-deficient APP-Delta ct construct. Our data confirm that PS1 is closely involved in the production of A beta1-40/42 and the carboxyl-terminal-truncated A beta1-37, A beta1-38, and A beta1-39, but the amino-terminal-truncated and carboxyl-terminal-elongated A beta2-42 seems to be less affected by PS1 deficiency. Moreover, our results indicate that the latter A beta peptide species could be generated by a beta (Asp/Ala)-secretase activity.	Univ Gottingen, Dept Psychiat Mol Neurobiol, D-37073 Gottingen, Germany; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Catholic Univ Louvain, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Neuronal Cell Biol Grp, Ctr Human Genet, B-3000 Louvain, Belgium; Univ Munich, Inst Neuropathol, D-81377 Munich, Germany; Res Inst Mol Pharmacol, D-13125 Berlin, Germany; Univ Munster, Inst Med Phys & Biophys, D-48129 Munster, Germany; Univ Hamburg, Dept Psychiat, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Dept Psychiat, D-91054 Erlangen, Germany	University of Gottingen; University of Gottingen; Universite Catholique Louvain; University of Munich; University of Munster; University of Hamburg; University of Erlangen Nuremberg	Wiltfang, J (corresponding author), Univ Gottingen, Dept Psychiat Mol Neurobiol, D-37073 Gottingen, Germany.	jwiltfa@gwdg.de	Kornhuber, Johannes/B-9613-2014; Jahn, Holger/A-9255-2008; Saftig, Paul/A-7966-2010; de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Neumann, Manuela/F-6558-2011; Cruz e Silva, Odete/AAH-5595-2020; , eruether@msn.com/K-2369-2019	Kornhuber, Johannes/0000-0002-8096-3987; Jahn, Holger/0000-0003-3607-7651; De Strooper, Bart/0000-0001-5455-5819; Neumann, Manuela/0000-0002-6232-4057; Wiltfang, Jens/0000-0003-1492-5330				Alliot F, 1999, J NEUROSCI RES, V58, P367; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Association, 1994, DIAGN STAT MAN MENT, P139; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cescato R, 2000, J NEUROCHEM, V74, P1131; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COOPER PN, 1995, ARCH NEUROL-CHICAGO, V52, P1011, DOI 10.1001/archneur.1995.00540340103019; Crawford F, 1997, Ann N Y Acad Sci, V826, P461, DOI 10.1111/j.1749-6632.1997.tb48504.x; Crawford F, 1997, ANN NY ACAD SCI, V826, P35, DOI 10.1111/j.1749-6632.1997.tb48459.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Fujiwara H, 1999, ENDOCR J, V46, P11, DOI 10.1507/endocrj.46.11; Geddes JW, 1999, NEUROBIOL AGING, V20, P75; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hosoda R, 1998, J NEUROPATH EXP NEUR, V57, P1089, DOI 10.1097/00005072-199811000-00012; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Iribar MC, 1998, DEMENT GERIATR COGN, V9, P44, DOI 10.1159/000017021; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janek K, 2001, BIOCHEMISTRY-US, V40, P5457, DOI 10.1021/bi002005e; Jellinger KA, 1998, BRAIN PATHOL, V8, P367; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kouchi Z, 1998, EUR J BIOCHEM, V258, P291, DOI 10.1046/j.1432-1327.1998.2580291.x; Kuda T, 1997, BIOCHEM BIOPH RES CO, V231, P526, DOI 10.1006/bbrc.1996.5920; Kumar-Singh S, 2000, HUM MOL GENET, V9, P2589, DOI 10.1093/hmg/9.18.2589; Kuo YM, 1997, BIOCHEM BIOPH RES CO, V237, P188, DOI 10.1006/bbrc.1997.7083; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Larner AJ, 1999, NEUROBIOL AGING, V20, P65; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Paik SR, 1998, FEBS LETT, V421, P73, DOI 10.1016/S0014-5793(97)01537-8; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Schleuder D, 1999, ANAL CHEM, V71, P3238, DOI 10.1021/ac9810720; SchraderFischer G, 1997, J NEUROCHEM, V68, P1571; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Szendrei GI, 1996, INT J PEPT PROT RES, V47, P289; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; URMONEIT B, 1995, J MOL NEUROSCI, V6, P23, DOI 10.1007/BF02736756; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; WILTFANG J, 1991, ELECTROPHORESIS, V12, P352, DOI 10.1002/elps.1150120507; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	88	110	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42645	42657		10.1074/jbc.M102790200	http://dx.doi.org/10.1074/jbc.M102790200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11526104	hybrid			2022-12-25	WOS:000172169300004
J	de Vet, ECJM; Aguado, B; Campbell, RD				de Vet, ECJM; Aguado, B; Campbell, RD			G6b, a novel immunoglobulin superfamily member encoded in the human major histocompatibility complex, interacts with SHP-1 and SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; CLASS-III REGION; PROTEIN-TYROSINE PHOSPHATASE; INHIBITORY RECEPTOR; MOLECULAR-CLONING; NK CELLS; IDENTIFICATION; SUBSTRATE; DOMAINS; RECOGNITION	The G6b gene, located in the class III region of the human major histocompatibility complex, has been suggested to encode a putative receptor of the immunoglobulin superfamily. Genomic sequence information was used as a starting point to clone the corresponding cDNA. Reverse transcriptase polymerase chain reaction showed that expression of the gene is restricted to certain hematopoietic cell lines including K562, Molt 4, and Jurkat. Several splice variants were detected, varying only in their C-terminal parts. One of the potential membrane-bound isoforms contained two immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic tail. Four of the isoforms were expressed as epitope-tagged proteins in the cell lines K562 and COS-7. The two splice isoforms lacking the hydrophobic transmembrane segment were secreted from the cell. Glycosidase treatment of the four recombinant proteins provided evidence for N- and O-glycosylation. Immunofluorescence studies indicated that the spliced isoforms having a transmembrane segment were directed to the cell membrane. The G6b isoform containing two immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic tail was found to be phosphorylated on tyrosine residues after pervanadate treatment of cells and, subsequently, interacts with the SH2-containing protein-tyrosine phosphatases SHP-1 and SHP-2. Mutagenesis studies showed that phosphorylation of tyrosine 211 is critical for the interaction of G6b with SHP-1 and SHP-2.	MRC UK HGMP Resource Ctr, Cambridge CB10 1SB, England		Campbell, RD (corresponding author), MRC UK HGMP Resource Ctr, Hinxton, Cambridge CB10 1SB, England.	rcampbel@hgmp.mrc.ac.uk	Aguado, Begoña/R-4496-2019	Aguado, Begona/0000-0003-4043-6944				Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; Aguado B, 1999, BIOCHEM J, V341, P679, DOI 10.1042/0264-6021:3410679; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Brown MA, 1998, ARTHRITIS RHEUM, V41, P588, DOI 10.1002/1529-0131(199804)41:4<588::AID-ART5>3.0.CO;2-0; Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L; Chothia C, 1998, J MOL BIOL, V278, P457, DOI 10.1006/jmbi.1998.1653; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fournier N, 2000, J IMMUNOL, V165, P1197, DOI 10.4049/jimmunol.165.3.1197; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Ribas G, 1999, J IMMUNOL, V163, P278; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; Schatzle JD, 1999, P NATL ACAD SCI USA, V96, P3870, DOI 10.1073/pnas.96.7.3870; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIMMONS D, 1988, J IMMUNOL, V141, P2797; Stepp SE, 1999, EUR J IMMUNOL, V29, P2392, DOI 10.1002/(SICI)1521-4141(199908)29:08<2392::AID-IMMU2392>3.3.CO;2-I; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; Taylor L S, 2000, Rev Immunogenet, V2, P204; Todd JA, 1997, PATHOL BIOL, V45, P219; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Xu MJ, 2000, J BIOL CHEM, V275, P17440, DOI 10.1074/jbc.M001313200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453	36	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42070	42076		10.1074/jbc.M103214200	http://dx.doi.org/10.1074/jbc.M103214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11544253	hybrid			2022-12-25	WOS:000172450400072
J	Lamberti, C; Lin, KM; Yamamoto, Y; Verma, U; Verma, IM; Byers, S; Gaynor, RB				Lamberti, C; Lin, KM; Yamamoto, Y; Verma, U; Verma, IM; Byers, S; Gaynor, RB			Regulation of beta-catenin function by the I kappa B kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR LEF-1; IKK-BETA; XENOPUS EMBRYOS; NEGATIVE REGULATION; LIVER DEGENERATION; COLON-CARCINOMA; MICE LACKING; CYCLIN D1; ACTIVATION	Both the beta -catenin and the nuclear factor kappaB (NF-kappaB) proteins are important regulators of gene expression and cellular proliferation. Two kinases, IKK alpha and IKK beta, are critical activators of the NF-kappaB pathway. Here we present evidence that these kinases are also important in the regulation of beta -catenin function. IKK alpha- and IKK beta -eficient mouse embryo fibroblasts exhibited different patterns of beta -catenin cellular localization. IKK beta decreases beta -catenin-dependent transcriptional activation, while IKK alpha increases beta -catenin-dependent transcriptional activity. IKK alpha and IKK beta interact with and phosphorylate beta -catenin using both in vitro and in vivo assays. Our results suggest that differential interactions of beta -catenin with IKK alpha and IKK beta may in part be responsible for regulating beta -catenin protein levels and cellular localization and integrating signaling events between the NF-kappaB and Wingless pathways.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75390 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Salk Institute; Georgetown University; Georgetown University	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NCI NIH HHS [CA 74128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 2000, GENE DEV, V14, P1837; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	61	110	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42276	42286		10.1074/jbc.M104227200	http://dx.doi.org/10.1074/jbc.M104227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527961	hybrid			2022-12-25	WOS:000172450400098
J	Nahoum, V; Gangloff, A; Legrand, P; Zhu, DW; Cantin, L; Zhorov, BS; Luu-The, V; Labrie, F; Breton, R; Lin, SX				Nahoum, V; Gangloff, A; Legrand, P; Zhu, DW; Cantin, L; Zhorov, BS; Luu-The, V; Labrie, F; Breton, R; Lin, SX			Structure of the human 3 alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETO REDUCTASE SUPERFAMILY; HUMAN-PROSTATE; DIHYDRODIOL DEHYDROGENASE; 17-BETA-HYDROXYSTEROID DEHYDROGENASE; STEROID RECOGNITION; CRYSTAL-STRUCTURE; ALDOSE REDUCTASE; PROTEIN MODELS; BINDING; RECEPTOR	The first crystallographic structure of human type 3 3 alpha -hydroxysteroid dehydrogenase (3 alpha -HSD3, AKR1C2), an enzyme playing a critical role in steroid hormone metabolism, has been determined in complex with testosterone and NADP at 1.25-Angstrom resolution. The enzyme's 17 beta -HSD activity was studied in comparison with its 3 alpha -HSD activity. The enzyme catalyzes the inactivation of dihydrotestosterone into 5 alpha -androstane-3 alpha ,17 beta -diol (3 alpha -diol) as well as the transformation of androstenedione into testosterone. Using our homogeneous and highly active enzyme preparation, we have obtained 150-fold higher 3 alpha -HSD specificity as compared with the former reports in the literature. Although the rat and the human 3 alpha -HSDs share 81% sequence homology, our structure reveals significantly different geometries of the active sites. Substitution of the Ser(222) by a histidine in the human enzyme may compel the steroid to adopt a different binding to that previously described for the rat (Bennett, M. J., Albert, R. H., Jez, J. M., Ma, H., Penning, T. M., and Lewis, M. (1997) Structure 5, 799-812). Furthermore, we showed that the affinity for the cofactor is higher in the human 3a-HSD3 than the rat enzyme due to the presence of additional hydrogen bonds on the adenine moiety and that the cofactor is present under its reduced form in the active site in our preparation.	Univ Laval, Ctr Med, CHUL, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Lin, SX (corresponding author), Univ Laval, Ctr Med, CHUL, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.		LEGRAND, Pierre/G-7709-2011; Zhorov, Boris S./V-8072-2019; Zhorov, Boris/T-9892-2019	LEGRAND, Pierre/0000-0003-2431-2255; Zhorov, Boris/0000-0002-3630-7114; Lin, Sheng-Xiang/0000-0001-9149-375X				AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEYASHIKI Y, 1992, BIOCHEM J, V282, P741, DOI 10.1042/bj2820741; Dufort I, 1996, BIOCHEM BIOPH RES CO, V228, P474, DOI 10.1006/bbrc.1996.1684; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; FANG S, 1969, J BIOL CHEM, V244, P6584; GELLER J, 1978, J CLIN ENDOCR METAB, V46, P440; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; HAMMOND GL, 1978, J ENDOCRINOL, V78, P7, DOI 10.1677/joe.0.0780007; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; Jez JM, 1996, J BIOL CHEM, V271, P30190, DOI 10.1074/jbc.271.47.30190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIEG M, 1979, J STEROID BIOCHEM, V11, P615, DOI 10.1016/0022-4731(79)90090-6; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI R, 1993, J APPL CRYSTALLOGR, V26, P91; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; LIAO S, 1973, J BIOL CHEM, V248, P6154; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; LIU SQ, 1993, J BIOL CHEM, V268, P25494; MAINWARING WI, 1969, J ENDOCRINOL, V45, P531, DOI 10.1677/joe.0.0450531; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; SIITERI PK, 1970, J CLIN INVEST, V49, P1737, DOI 10.1172/JCI106391; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; Wilson J D, 1970, Recent Prog Horm Res, V26, P309; Zhorov BS, 2000, PROTEINS, V38, P414, DOI 10.1002/(SICI)1097-0134(20000301)38:4<414::AID-PROT7>3.0.CO;2-X; Zhu DW, 2001, ACTA CRYSTALLOGR D, V57, P589, DOI 10.1107/S0907444901001160	44	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42091	42098		10.1074/jbc.M105610200	http://dx.doi.org/10.1074/jbc.M105610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11514561	hybrid			2022-12-25	WOS:000172450400075
J	Cremo, CR; Wang, F; Facemyer, K; Sellers, JR				Cremo, CR; Wang, F; Facemyer, K; Sellers, JR			Phosphorylation-dependent regulation is absent in a nonmuscle heavy meromyosin construct with one complete head and one head lacking the motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; LIGHT-CHAIN; 2-HEADED STRUCTURE; IN-VITRO; 2 HEADS; ACTIN; SUBFRAGMENT-1; MECHANISM; BINDING	To understand the domain requirements of phosphorylation-dependent regulation, we prepared three recombinant constructs of nonmuscle heavy meromyosin IIB containing 1) two complete heads, 2) one complete head and one head lacking the motor domain, and 3) one complete head and one head lacking both motor and regulatory domains. Steady-state ATPase measurements showed that phosphorylation did not alter the affinity for actin by more than a factor of 2 for any construct. Phosphorylation increased V-max by a factor of 10 for construct 1 and 1.5-3 for construct 2 but had no effect for construct 3. Single turnover measurements, a better measure of slow rates inherent to unphosphorylated regulated myosins, showed that the single-headed construct 2, like construct 3 retains less than 1% of the regulatory properties of the double-headed construct 1 (300-fold activation). Therefore, a complete head cannot be down-regulated by a regulatory domain (without the motor domain) on the partner head. Two motor domains are required for regulation. This result is predicted by a structural model (Wendt, T., Taylor, D., Messier, T., Trybus, K. M., and Taylor, K. A. (1999) J. Cell Biol. 147, 1385-1390) showing interaction between the motor domains for unphosphorylated smooth muscle myosin, if motor-motor interaction is the basis for down-regulation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; Univ Nevada, Dept Biochem, Reno, NV 89557 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Nevada System of Higher Education (NSHE); University of Nevada Reno	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786, Z01HL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Konishi K, 1998, J BIOCHEM-TOKYO, V124, P163, DOI 10.1093/oxfordjournals.jbchem.a022075; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; SELLERS JR, 1982, J BIOL CHEM, V257, P12880; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 2000, J BIOL CHEM, V275, P41273, DOI 10.1074/jbc.M008310200; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098	34	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41465	41472		10.1074/jbc.M107103200	http://dx.doi.org/10.1074/jbc.M107103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11517231	hybrid			2022-12-25	WOS:000171925600143
J	Jacquenet, S; Mereau, A; Bilodeau, PS; Damier, L; Stoltzfus, CM; Branlan, C				Jacquenet, S; Mereau, A; Bilodeau, PS; Damier, L; Stoltzfus, CM; Branlan, C			A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BRANCH SITE SELECTION; U2 SNRNP; IN-VIVO; POLYPYRIMIDINE TRACT; REGULATORY ELEMENTS; KAPOSIS-SARCOMA; TRANSGENIC MICE; FACTOR U2AF(35); GROWTH-FACTOR	An equilibrium between spliced and unspliced primary transcripts is essential for retrovirus multiplication. This equilibrium is maintained by the presence of inefficient splice sites. The A3 3'-splice site of human immunodeficiency virus type I (HIV-1) is required for Tat mRNA production. The infrequent utilization of this splice site has been attributed to the presence of a suboptimal polypyrimidine tract and an exonic splicing silencer (ESS2) in tat exon 2 similar to 60 nucleotides downstream of 3'-splice site A3. Here, using site-directed mutagenesis followed by analysis of splicing in vitro and in HeLa cells, we show that the 5' extremity of tat exon 2 contains a second exonic splicing silencer (ESS2p), which acts to repress splice site A3. The inhibitory property of this exonic silencer was active when inserted downstream of another HIV-1 3'-splice site (A2). Protein hnRNP H binds to this inhibitory element, and two U-to-C substitutions within the ESS2p element cause a decreased hnRNP H affinity with a concomitant increase in splicing efficiency at 3'-splice site A3. This suggests that hnRNP H is directly involved in splicing inhibition. We propose that hnRNP H binds to the HIV-1 ESS2p element and competes with U2AF(35) for binding to the exon sequence flanking 3'-splice site A3. This binding results in the inhibition of splicing at 3'-splice site A3.	Univ Nancy 1, CNRS, Unite Mixte Rech 7567, Lab Maturat Acide Ribo Nucleotid & Enzymol Mol, F-54506 Vandoeuvre Les Nancy, France; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Iowa	Branlan, C (corresponding author), Univ Nancy 1, CNRS, Unite Mixte Rech 7567, Lab Maturat Acide Ribo Nucleotid & Enzymol Mol, Blvd Aiguillettes,BP239, F-54506 Vandoeuvre Les Nancy, France.	christiane.branlant@maem.uhpnancy.fr		MEREAU, AGNES/0000-0002-5603-757X; Branlant, Christiane/0000-0003-4728-5499				AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Bourara K, 2000, SCIENCE, V289, P1564, DOI 10.1126/science.289.5484.1564; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; Guth S, 1999, MOL CELL BIOL, V19, P8263; Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KUIKEN CL, 1999, HUMAN RETROVIRUSES A; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOUR M, 1995, CURR MICROBIOL, V31, P270, DOI 10.1007/BF00314579; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Si ZH, 1998, MOL CELL BIOL, V18, P5404, DOI 10.1128/MCB.18.9.5404; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Swanson AK, 1998, J BIOL CHEM, V273, P34551, DOI 10.1074/jbc.273.51.34551; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOGEL J, 1991, CANCER RES, V51, P6686; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zheng ZM, 1998, P NATL ACAD SCI USA, V95, P14088, DOI 10.1073/pnas.95.24.14088	66	102	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40464	40475		10.1074/jbc.M104070200	http://dx.doi.org/10.1074/jbc.M104070200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526107	hybrid			2022-12-25	WOS:000171925600016
J	Zhang, C; Baudino, TA; Dowd, DR; Tokumaru, H; Wang, W; MacDonald, PN				Zhang, C; Baudino, TA; Dowd, DR; Tokumaru, H; Wang, W; MacDonald, PN			Ternary complexes and cooperative interplay between NCoA-62/Ski-interacting protein and steroid receptor coactivators in vitamin D receptor-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTOR; HISTONE ACETYLTRANSFERASE; TRANSACTIVATION DOMAIN; SKI ONCOPROTEIN; DNA-BINDING; ACTIVATION; GRIP1; AF-2; SPECIFICITY; INHIBITION	The vitamin D receptor (VDR) is a ligand-dependent transcriptional factor that binds to vitamin D-responsive elements as a heterodimer with retinoid X receptor (RXR) to regulate target gene transcription. The steroid receptor coactivator (SRC) proteins are coactivators that interact with the AF-2 domain of VDR to augment 1,25-dihydroxyvitamin D3-dependent transcription. In contrast, NCoA-62/Ski-interacting protein (SKIP) is a distinct, activation function-2-independent coactivator for VDR. The current study examined whether these two distinct classes of coactivators impact functionally on VDR-mediated transcription. Using a ternary complex binding assay, we observed a marked preference for the direct interaction of NCoA-62/SKIP with the VDR-RXR heterodimer as compared with the VDR-VDR homodimer or VDR monomer. The liganded VDR also formed a ternary complex with NCoA-62/SKIP and SRC proteins an vitro. Competition experiments using LXXLL peptides showed that NCoA-62/SKIP and SRC coactivators contact different domains of the VDR-RXR heterodimer. Synergistic interplays were observed between NCoA-62/SKIP and SRC coactivators in VDR-mediated transcriptional assays, and protein interference assays indicated a requirement for both NCoA-62/SKIP and SRCs in VDR-mediated transcription. These studies suggest that the ligand-dependent and simultaneous interaction of NCoA-62/SKIP and SRC coactivators with distinct interaction domains within the VDR-RXR heterodimer results in Cooperative interplays between coactivators in VDR-mediated transcription.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	MacDonald, PN (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Zhang, Chi/K-4467-2012		NIDDK NIH HHS [DK53980] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053980] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SC, 2000, J BIOL CHEM, V275, P15039, DOI 10.1074/jbc.275.20.15039; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; ORGRYZKO VV, 1996, CELL, V87, P953; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WIELAND C, 1992, CHROMOSOMA, V101, P517, DOI 10.1007/BF00352475; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	39	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40614	40620		10.1074/jbc.M106263200	http://dx.doi.org/10.1074/jbc.M106263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514567	hybrid			2022-12-25	WOS:000171925600033
J	Bockers, TM; Mameza, MG; Kreutz, MR; Bockmann, J; Weise, C; Buck, F; Richter, D; Gundelfinger, ED; Kreienkamp, HJ				Bockers, TM; Mameza, MG; Kreutz, MR; Bockmann, J; Weise, C; Buck, F; Richter, D; Gundelfinger, ED; Kreienkamp, HJ			Synaptic scaffolding proteins in rat brain - Ankyrin repeats of the multidomain Shank protein family interact with the cytoskeletal protein alpha-fodrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEINS; HUMAN ERYTHROCYTE ANKYRIN; BINDING-PROTEIN; RECEPTOR; IDENTIFICATION; CORTACTIN; CALMODULIN; PLASTICITY; SPECTRIN; COMPLEX	The postsynaptic density is the ultrastructural entity containing the neurotransmitter reception apparatus of excitatory synapses in the brain. A recently identified family of multidomain proteins termed Src homology 3 domain and ankyrin repeat-containing (Shank), also known as proline-rich synapse-associated protein/somatostatin receptor-interacting protein, plays a central role in organizing the subsynaptic scaffold by interacting with several synaptic proteins including the glutamate receptors. We used the N-terminal ankyrin repeats of Shank1 and -3 to search for interacting proteins by yeast two-hybrid screening and by affinity chromatography. By cDNA sequencing and mass spectrometry the cytoskeletal protein a-fodrin was identified as an interacting molecule. The interaction was verified by pull-down assays and by coimmunoprecipitation experiments from transfected cells and brain extracts. Mapping of the interacting domains of a-fodrin revealed that the highly conserved spectrin repeat 21 is sufficient to bind to the ankyrin repeats. Both interacting partners are coexpressed widely in the rat brain and are colocalized in synapses of hippocampal cultures. Our data indicate that the Shank1 and -3 family members provide multiple independent connections between synaptic glutamate receptor complexes and the cytoskeleton.	Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; Univ Munster, Inst Anat, Arbeitsgrp Mol Neurobiol, D-48149 Munster, Germany; Leibniz Inst Neurobiol, D-39008 Magdeburg, Germany; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	University of Hamburg; University of Munster; Leibniz Institut fur Neurobiologie (LIN); Free University of Berlin	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GLENNEY JR, 1983, J MOL BIOL, V167, P275, DOI 10.1016/S0022-2836(83)80336-2; Goslin K., 1991, CULTURING NERVE CELL, P251; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sheng M, 2000, J CELL SCI, V113, P1851; SIMAN R, 1985, NATURE, V313, P225, DOI 10.1038/313225a0; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	32	106	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40104	40112		10.1074/jbc.M102454200	http://dx.doi.org/10.1074/jbc.M102454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509555	hybrid			2022-12-25	WOS:000171789200081
J	Fukuda, M; Kanno, E; Ogata, Y; Mikoshiba, K				Fukuda, M; Kanno, E; Ogata, Y; Mikoshiba, K			Mechanism of the SDS-resistant synaptotagmin clustering mediated by the cysteine cluster at the interface between the transmembrane and spacer domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; CALCIUM-DEPENDENT OLIGOMERIZATION; C2B DOMAIN; SYNAPTIC VESICLES; ANTIBODY INJECTION; PROTEIN; RELEASE; FAMILY; IV; VI	Synaptotagmin I (Syt I), a proposed major Ca2+ sensor in the central nervous system, has been hypothesized as functioning in an oligomerized state during neurotransmitter release. We previously showed that Syts I, II, VII, and VIII form a stable SDS-resistant, beta -mercaptoethanol-insensitive, and Ca2+-independent oligomer surrounding the transmembrane domain (Fukuda, M., and Mikoshiba, K. (2000) J. BioL Chem. 275, 28180-28185), but little is known about the molecular mechanism of the Ca2+-independent oligomerization by the synaptotagmin family. In this study, we analyzed the Ca2+-independent oligomerization properties of Syt I and found that it shows two distinct forms of self-oligomerization activity: stable SDS-resistant self-oligomerization activity and relatively unstable SDS-sensitive self-oligomerization activity. The former was found to be mediated by a post-translationally modified (i.e. fatty-acylated) cysteine (Cys) cluster (Cys-74, Cys-75, Cys-77, Cys-79, and Cys-82) at the interface between the transmembrane and spacer domains of Syt I. We also show that the number of Cys residues at the interface between the transmembrane and spacer domains determines the SDS-resistant oligomerizing capacity of each synaptotagmin isoform: Syt II, which contains seven Cys residues, showed the strongest SDS-resistant oligomerizing activity in the synaptotagmin family, whereas Syt XII, which has no Cys residues, did not form any SDS-resistant oligomers. The latter SDS-sensitive self-oligomerization of Syt I is mediated by the spacer domain, because deletion of the whole spacer domain, including the Cys cluster, abolished it, whereas a Syt I(CA) mutant carrying Cys to Ala substitutions still exhibited self-oligomerization. Based on these results, we propose that the oligomerization of the synaptotagmin family is regulated by two distinct mechanisms: the stable SDS-resistant oligomerization is mediated by the modified Cys cluster, whereas the relatively unstable (SDS-sensitive) oligomerization is mediated by the environment of the spacer domain.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; Berton F, 2000, EUR J NEUROSCI, V12, P1294, DOI 10.1046/j.1460-9568.2000.00013.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Damer CK, 1996, J NEUROCHEM, V67, P1661; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mochida S, 1997, NEUROSCIENCE, V77, P937; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; Phillips AM, 2000, J NEUROSCI, V20, P8254, DOI 10.1523/JNEUROSCI.20-22-08254.2000; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Thompson CC, 1996, J NEUROSCI, V16, P7832; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; von Poser C, 2001, EUR J CELL BIOL, V80, P41; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	45	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40319	40325		10.1074/jbc.M105356200	http://dx.doi.org/10.1074/jbc.M105356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514560	hybrid			2022-12-25	WOS:000171789200109
J	Zhang, XM; Chai, JY; Azhar, G; Sheridan, P; Borras, AM; Furr, MC; Khrapko, K; Lawitts, J; Misra, RP; Wei, JY				Zhang, XM; Chai, JY; Azhar, G; Sheridan, P; Borras, AM; Furr, MC; Khrapko, K; Lawitts, J; Misra, RP; Wei, JY			Early postnatal cardiac changes and premature death in transgenic mice overexpressing a mutant form of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; MYOCARDIAL HYPERTROPHY; TRANSCRIPTION FACTORS; VENTRICULAR VOLUME; DNA-BINDING; GROWTH; CELL; SRF; ELEMENT; DIFFERENTIATION	Serum response factor (SRF) is a key regulator of a number of extracellular signal-regulated genes important for cell growth and differentiation. A form of the SRF gene with a double mutation (dmSRF) was generated. This mutation reduced the binding activity of SRF protein to the serum response element and reduced the capability of SRF to activate the atrial natriuretic factor promoter that contains the serum response element. Cardiac-specific overexpression of dmSRF attenuated the total SRF binding activity and resulted in remarkable morphologic changes in the heart of the transgenic mice. These mice had dilated atrial and ventricular chambers, and their ventricular wall thicknesses were only (1)/(2) to (1)/(3) the thickness of that of nontransgenic mice. Also these mice had smaller cardiac myocytes and had less myofibrils in their myocytes relative to nontransgenic mice. Altered gene expression and slight interstitial fibrosis were observed in the myocardium. of the transgenic mice. All the transgenic mice died within the first 12 days after birth, because of the early onset of severe, dilated cardiomyopathy. These results indicate that dmSRF overexpression in the heart apparently alters cardiac gene expression and blocks normal postnatal cardiac growth and development.	Beth Israel Deaconess Med Ctr, Dept Med, Gerontol Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02215 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Medical College of Wisconsin	Wei, JY (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Gerontol Div, 330 Brookline Ave, Boston, MA 02215 USA.		Chai, Jianyuan/AAJ-5892-2020; Chai, Jianyuan/A-8300-2009; Khrapko, Konstantin/A-3244-2009	Chai, Jianyuan/0000-0001-6975-6867	NIA NIH HHS [AG 18388, AG 13314, AG 00294, AG 08812, AG 00251] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013314, R01AG018388, P30AG008812, P60AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; BISHOP SP, 1990, TOXICOL PATHOL, V18, P438, DOI 10.1177/0192623390004Part_102; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Ding W, 1999, CANCER RES, V59, P3795; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KAYAR SR, 1992, J MOL CELL CARDIOL, V24, P1155, DOI 10.1016/0022-2828(92)93179-N; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kimpara T, 1997, HEART VESSELS, V12, P143, DOI 10.1007/BF02767132; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OPARIL S, 1985, J AM COLL CARDIOL, V5, pB57, DOI 10.1016/S0735-1097(85)80528-3; Panitz F, 1998, EMBO J, V17, P4414, DOI 10.1093/emboj/17.15.4414; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Robbins J, 1997, TRENDS CARDIOVAS MED, V7, P185, DOI 10.1016/S1050-1738(97)00048-0; Rudolph AM, 2000, ACTA PAEDIATR, V89, P129, DOI 10.1080/080352500750028681; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Takahashi Y, 1996, EARLY HUM DEV, V44, P77, DOI 10.1016/0378-3782(95)01695-3; Tamura M, 1997, EARLY HUM DEV, V48, P1, DOI 10.1016/S0378-3782(96)01801-4; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; Tsou H, 1996, EXP CELL RES, V229, P432, DOI 10.1006/excr.1996.0388; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782	35	32	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40033	40040		10.1074/jbc.M104934200	http://dx.doi.org/10.1074/jbc.M104934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514558	hybrid			2022-12-25	WOS:000171789200072
J	Bodin, K; Bretillon, L; Aden, Y; Bertilsson, L; Broome, U; Einarsson, C; Diczfalusy, U				Bodin, K; Bretillon, L; Aden, Y; Bertilsson, L; Broome, U; Einarsson, C; Diczfalusy, U			Antiepileptic drugs increase plasma levels of 4 beta-hydroxycholesterol in humans - Evidence for involvement of cytochrome P450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID METABOLISM; SMOOTH-MUSCLE CELLS; RECEPTOR LXR-ALPHA; IN-VITRO; CHOLESTEROL; OXIDATION; OXYSTEROLS; IDENTIFICATION; APOPTOSIS; CLONING	The major cholesterol oxidation products in the human circulation are 27-hydroxycholesterol, 24-hydroxy-cholesterol, and 7 alpha -hydroxycholesterol. These oxysterols are formed from cholesterol by specific cytochrome P450 enzymes, CYP27, CYP46, and CYP7A, respectively. An additional oxysterol present in concentrations comparable with 7 alpha- and 24-hydroxycholesterol is 4 beta -hydroxycholesterol. We now report that patients treated with the antiepileptic drugs phenobarbital, carbamazepine, or phenytoin have highly elevated levels of plasma 4 beta -hydroxycholesterol. When patients with uncomplicated cholesterol gallstone disease were treated with ursodeoxycholic acid, plasma 4 beta -hydroxycholesterol increased by 45%. Ursodeoxycholic acid, as well as the antiepileptic drugs, are known to induce cytochrome P450 3A. Recombinant CYP3A4 was shown to convert cholesterol to 4 beta -hydroxycholesterol, whereas no conversion was observed with CYP1A2, CYP2C9, or CYP2B6. The concentration of 4 alpha -hydroxycholesterol in plasma was lower than the concentration of 4 beta -hydroxycholesterol and not affected by treatment with the antiepileptic drugs or ursodeoxycholic acid. Together, these data suggest that 4 beta -hydroxycholesterol in human circulation is formed by a cytochrome P450 enzyme.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Gastroenterol Hepatol, SE-14186 Huddinge, Sweden; INRA, Unite Nutr Lipid, F-21034 Dijon, France	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; INRAE	Diczfalusy, U (corresponding author), Huddinge Univ Hosp C1 74, Karolinska Inst, Div Clin Chem, Dept Med Lab Sci & Technol, SE-14186 Huddinge, Sweden.	ulf.diczfalusy@chemlab.hs.sll.sc	Diczfalusy, Ulf/A-5336-2008	Bretillon, Lionel/0000-0002-6957-100X; Diczfalusy, Ulf/0000-0001-6643-3763				Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; BERTILSSON L, 1995, CLIN PHARMACOKINET, V29, P192, DOI 10.2165/00003088-199529030-00005; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BREUER O, 1995, J LIPID RES, V36, P2275; Breuer O, 1996, BBA-LIPID LIPID MET, V1302, P145, DOI 10.1016/0005-2760(96)00052-5; CALI JJ, 1991, J BIOL CHEM, V266, P7774; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; DUMASWALA R, 1989, J LIPID RES, V30, P847; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; MARTIN KO, 1993, J LIPID RES, V34, P581; Michalets EL, 1998, PHARMACOTHERAPY, V18, P84; Nishio E, 1996, BIOCHEM BIOPH RES CO, V226, P928, DOI 10.1006/bbrc.1996.1452; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pozzetti L, 1999, HEPATOLOGY, V30, P730, DOI 10.1002/hep.510300332; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SETCHELL KDR, 1988, J BIOL CHEM, V263, P16637; Tanaka E, 1999, J CLIN PHARM THER, V24, P87, DOI 10.1046/j.1365-2710.1999.00201.x; Yin JL, 2000, ATHEROSCLEROSIS, V148, P365, DOI 10.1016/S0021-9150(99)00286-5	24	201	205	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38685	38689		10.1074/jbc.M105127200	http://dx.doi.org/10.1074/jbc.M105127200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514559	Green Published, hybrid			2022-12-25	WOS:000171673200049
J	Riddle, TM; Kuhel, DG; Woollett, LA; Fichtenbaum, CJ; Hui, DY				Riddle, TM; Kuhel, DG; Woollett, LA; Fichtenbaum, CJ; Hui, DY			HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; INSULIN-RESISTANCE; PREADIPOCYTE DIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; PERIPHERAL LIPODYSTROPHY; CHOLESTEROL-SYNTHESIS; DIABETES-MELLITUS; GENE-EXPRESSION; HYPERLIPIDEMIA; TRANSCRIPTION	The mechanism by which human immunodeficiency virus (HIV) protease inhibitor therapy adversely induces lipodystrophy and hyperlipidemia has not been defined. This study explored the mechanism associated with the adverse effects of the prototype protease inhibitor ritonavir in mice. Ritonavir treatment increased plasma triglyceride and cholesterol levels through increased fatty acid and cholesterol biosynthesis in adipose and liver. Ritonavir treatment also resulted in hepatic steatosis and hepatomegaly. These abnormalities, which were especially pronounced after feeding a Western type high fat diet, were due to ritonavir-induced accumulation of the activated forms of sterol regulatory binding protein (SREBP)-1 and -2 in the nucleus of liver and adipose, resulting in elevated expression of lipid metabolism genes. Interestingly, protease inhibitor treatment did not alter SREBP mRNA levels in these tissues. Thus, the adverse lipid abnormalities associated with protease inhibitor therapy are caused by the constitutive induction of lipid biosynthesis in liver and adipose tissues due to the accumulation of activated SREBP in the nucleus.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	huidy@Email.uc.edu		Fichtenbaum, Carl/0000-0002-6778-7253	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065915] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65915] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Echevarria KL, 1999, ANN PHARMACOTHER, V33, P859, DOI 10.1345/aph.18174; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Fatkenheuer G, 1999, AIDS, V13, P1485, DOI 10.1097/00002030-199908200-00007; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; GOULD RG, 1953, J BIOL CHEM, V201, P519; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUANG Y, 1994, BBA-LIPID LIPID MET, V1214, P317; Jackson SM, 1998, J LIPID RES, V39, P767; Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Nguyen AT, 2000, AIDS, V14, P2467, DOI 10.1097/00002030-200011100-00007; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SoRelle R, 1998, CIRCULATION, V98, P829, DOI 10.1161/01.CIR.98.9.829; Sullivan AK, 1997, AIDS, V11, P938; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANSTEENBERGEN W, 1995, INT J OBESITY, V19, pS27; Vittecoq D, 1998, LANCET, V351, P1959, DOI 10.1016/S0140-6736(05)78644-X; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	52	156	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37514	37519		10.1074/jbc.M104557200	http://dx.doi.org/10.1074/jbc.M104557200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11546771	hybrid			2022-12-25	WOS:000171375700086
J	Kim, H; You, S; Linda, KF; Farris, J; Foster, DN				Kim, H; You, S; Linda, KF; Farris, J; Foster, DN			The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells	ONCOGENE			English	Article						CEF; cycloheximide; immortalization; mRNA destablization; p53 mRNA; chicken	MESSENGER-RNA DEGRADATION; TUMOR-SUPPRESSOR P53; UNTRANSLATED REGIONS; ELEMENTS; MDM2; GENE; APOPTOSIS; STABILITY; MEDIATOR; PROMOTES	The steady-state levels of p53 mRNA were dramatically lower in immortal chicken embryo fibroblast (CEF) cell lines compared to primary CEF cells. In the presence of cycloheximide (CHX), the steady-state levels of p53 mRNA markedly increased in immortal CEF cell lines, similar to levels found in primary cells. The de novo synthetic rates of p53 mRNA were relatively similar in primary and immortal cells grown in the presence or absence of CHX. Destabilization of p53 mRNA was observed in the nuclei of immortal, but not primary, CEF cells. The half-life of p53 mRNA in primary cells was found to be a relatively long 23 h compared to only 3 It in immortal cells. The expression of transfected p53 cDNA was inhibited in immortal cells, but restored upon CHX treatment. The 5'-region of the p53 mRNA was shown to be involved in the rapid p53 mRNA destabilization in immortal cells by expression analysis of 5'- and 3-deleted p53 cDNAs as well as fusion mRNA constructs of N-terminal p53 and N-terminal deleted LacZ genes. Together, it is suggestive that the downregulation of p53 mRNA in immortal CEF cells occurs through a post-transcriptional destabilizing mechanism.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed,1988 Fitch Ave, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015; Kang, Phil Jun/F-4716-2013	Kim, Hyunggee/0000-0002-4738-0990; 				Attardi LD, 2000, GENE DEV, V14, P704; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; D'Erchia AM, 1999, GENOMICS, V58, P50, DOI 10.1006/geno.1999.5794; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, EXP CELL RES, V265, P339, DOI 10.1006/excr.2001.5207; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	26	24	25	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5118	5123		10.1038/sj.onc.1204664	http://dx.doi.org/10.1038/sj.onc.1204664			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526500				2022-12-25	WOS:000170464000005
J	Lu, Y; Jamieson, L; Brasier, AR; Fields, AP				Lu, Y; Jamieson, L; Brasier, AR; Fields, AP			NF-kappa B/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival	ONCOGENE			English	Article						protein kinase C iota; apoptosis; taxol; nuclear factor-kappa B	TUMOR-NECROSIS-FACTOR; MYELOGENOUS LEUKEMIA-CELLS; DRUG-INDUCED APOPTOSIS; ABL TYROSINE KINASE; FACTOR-ALPHA; TRANSCRIPTION FACTOR; B ACTIVATION; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INTERLEUKIN-8 GENE	In chronic myelogenous leukemia (CML), the oncogene bcr-abl encodes a dysregulated tyrosine kinase that inhibits apoptosis. We showed previously that human erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through the atypical protein kinase C iota isozyme (PKC iota), a kinase downstream of Bcr-Abl. The mechanism(s) by which PKC iota mediates cell survival to taxol is unknown. Here we demonstrate that PKC iota requires the transcription factor nuclear factor-kappaB (NF-kappaB) to confer cell survival. At apoptosis-inducing concentrations, taxol weakly induces I kappaB alpha proteolysis and NF-kappaB translocation in K562 cells, but potently induces its transcriptional activity. Inhibition of NF-kappaB activity (by blocking l kappaB alpha degradation) significantly sensitizes cells to taxol-induced apoptosis. Likewise, K562 cells expressing antisense PKC iota mRNA or kinase dead PKC iota (PKC iota -KD) are sensitized to taxol; these cells are rescued from apoptosis by NF-kappaB overexpression. Expression of constitutively active PKC iota (PKC iota -CA) upregulates NF-kappaB transactivation and rescues cells from apoptosis in the absence of Bcr-Abl tyrosine kinase activity. Using a chimeric GAL4-RelA transactivator, we find that taxol potently activates GAL4-RelA-dependent transcription. This activation was further upregulated by expression of PKC iota -CA and inhibited by expression of PKC iota -KD. Our results indicate that RelA transactivation is an important downstream target of the PKC iota -mediated Bcr-Abl signaling pathway and is required for resistance to taxol-induced apoptosis.	Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.			Brasier, Allan/0000-0002-5012-4090	NCI NIH HHS [CA56869] Funding Source: Medline; NIAID NIH HHS [AI40218] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ANAFI M, 1993, BLOOD, V82, P3524; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blobe GC, 1996, CANCER SURV, V27, P213; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Granville DJ, 1998, LAB INVEST, V78, P893; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kaur G, 1996, ANTI-CANCER DRUG, V7, P815, DOI 10.1097/00001813-199611000-00001; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Samali A, 1997, Adv Pharmacol, V41, P533, DOI 10.1016/S1054-3589(08)61071-6; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WANG D, 2000, J BIOL CHEM; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	61	59	66	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4777	4792		10.1038/sj.onc.1204607	http://dx.doi.org/10.1038/sj.onc.1204607			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521190				2022-12-25	WOS:000170271800003
J	Docagne, F; Colloc'h, N; Bougueret, V; Page, M; Paput, J; Tripier, M; Dutartre, P; MacKenzie, ET; Buisson, A; Komesli, S; Vivien, D				Docagne, F; Colloc'h, N; Bougueret, V; Page, M; Paput, J; Tripier, M; Dutartre, P; MacKenzie, ET; Buisson, A; Komesli, S; Vivien, D			A soluble transforming growth factor-beta (TGF-beta) type I receptor mimics TGF-beta responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSGENIC MICE; INFLAMMATORY RESPONSE; EXTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; HALF-LIFE; GENE; BINDING; FACTOR-BETA-1; EXPRESSION	Transforming growth factor-beta (TGF-beta) signaling requires a ligand-dependent interaction of TGF-beta receptors T betaR-I and T betaR-II. It has been previously demonstrated that a soluble TGF-beta type II receptor could be used as a TGF-beta antagonist. Here we have generated and investigated the biochemical and signaling properties of a soluble TGF-beta type I receptor (T beta RIs-Fc). As reported for the wild-type receptor, the soluble T betaR-I does not bind TGF-beta1 on its own. Surprisingly, in the absence of TGF-beta1, the T beta RIs-Fc mimicked TGF-beta1-induced transcriptional and growth responses in mink lung epithelial cells (Mv1Lu). Signaling induced by the soluble TGF-beta type I receptor is mediated via the obligatory presence of both TGF-beta type I and type II receptors at the cell surface since no signal was observed in Mv1Lu-derivated mutants for TGF-beta receptors R-1B and DR-26. The comparison between the structures of TGF-betas and a three-dimensional model of the extracellular domain of T beta RI has shown that five residues of the supposed binding site of TGF-beta1 (Lys(31), His(34), Glu(5), Tyr(91), and Lys(94)) were found with equivalent biochemical properties and similar spatial positions.	Univ Caen, CNRS, UMR 6551, Ctr CYCERON, F-14074 Caen, France; Lab Fournier SA, F-21121 Daix, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Vivien, D (corresponding author), Univ Caen, CNRS, UMR 6551, Ctr CYCERON, IFR 47,Bd H Becquerel,BP 5229, F-14074 Caen, France.		Colloc'h, Nathalie/L-1570-2015; Docagne, Fabian/S-8308-2018; buisson, alain/AAI-8218-2020; Mackenzie, Eric Thomson/L-1938-2015	buisson, alain/0000-0002-4281-7911; MacKenzie, Eric T/0000-0003-1057-7033; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; Clark JG, 2000, TRANSPLANTATION, V70, P39; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EVERAERDT B, 1994, J IMMUNOL, V152, P5041; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOKIRANTA TS, 1995, FEBS LETT, V376, P31, DOI 10.1016/0014-5793(95)01239-7; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Krieglstein K, 2000, NAT NEUROSCI, V3, P1085, DOI 10.1038/80598; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Letterio JJ, 1996, J CLIN INVEST, V98, P2109, DOI 10.1172/JCI119017; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; LIN F, 1996, NATURE, V381, P620; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SHIHAB FS, 1995, J AM SOC NEPHROL, V6, P286; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIGOUNAS G, 1994, J CLIN IMMUNOL, V14, P134, DOI 10.1007/BF01541346; Sime PJ, 1997, CHEST, V111, pS137, DOI 10.1378/chest.111.6_Supplement.137S; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; Vivien D, 1998, J NEUROCHEM, V70, P2296; Wang D, 2000, CANCER RES, V60, P4507; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535	52	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46243	46250		10.1074/jbc.M010915200	http://dx.doi.org/10.1074/jbc.M010915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11544249	hybrid			2022-12-25	WOS:000172573100103
J	Maeda, S; Akanuma, M; Mitsuno, Y; Hirata, Y; Ogura, K; Yoshida, H; Shiratori, Y; Omata, M				Maeda, S; Akanuma, M; Mitsuno, Y; Hirata, Y; Ogura, K; Yoshida, H; Shiratori, Y; Omata, M			Distinct mechanism of helicobacter pylori-mediated NF-kappa B activation between gastric cancer cells and monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAG PATHOGENICITY ISLAND; EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; INTERLEUKIN-8 EXPRESSION; VIRULENCE FACTORS; KINASE CASCADES; IV SECRETION; C-JUN; INFECTION	NF-kappaB is a critical regulator of genes involved in inflammation. Gastric epithelial cells and macrophages are considered the main sources of pro-inflammatory cytokines. We investigated NF-kappaB activation by Helicobacter pylori in MKN45 gastric epithelial cells and THP-1 monocytic cells. Although, cag pathogenicity island (PAI)-positive H. pylori (wild type) activated NF-kappaB in both cells, isogenic mutant of cagE (Delta cagE) activated it only in THP-1 cells. Supernatant from the wild type culture could activate NF-kappaB in THP-1 cells but not in MKN45 cells. High density cDNA array analysis revealed that mRNA expression of NF-kappaB-regulated genes such as interleukin (IL)-8, tumor necrosis factor-alpha (TNF alpha), and IL-1 beta was significantly up-regulated by the wild type in both cells, whereas it was up-regulated by Delta cagE only in THP-1 cells. Experiments using CD14-neutralizing antibody and IL-1 receptor-associated kinase (IRAK) assay showed that both wild type and Delta cagE H. pylori activated NF-kappaB through CD14 and IRAK in THP-1 cells but not in MKN45 cells. Macrophages from C3H/HeJ mice carrying point mutation in the Toll-like receptor 4 (TLR4) gene showed decreased NF-kappaB activation and TNFa secretion compared with C3H/HeN mouse macrophage when treated with H. pylori. In conclusion, H. pylori-induced NF-kappaB activation in epithelial cells is dependent on cag PAI and contact but does not involve CD14 and IRAK, whereas in macrophage/monocytic cells it is independent of cag PAI or contact but involves CD14 and TLR4.	Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Maeda, S (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEAUERLE PA, 1996, CELL, V87, P13; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; COVACCI A, 1993, MOL MICROBIOL, V8, P429, DOI 10.1111/j.1365-2958.1993.tb01587.x; CRABTREE JE, 1995, J CLIN PATHOL, V48, P41, DOI 10.1136/jcp.48.1.41; CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61; Crabtree JE, 1996, ALIMENT PHARM THER, V10, P29, DOI 10.1046/j.1365-2036.1996.22164003.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Goto T, 2000, J BIOL CHEM, V275, P37311, DOI 10.1074/jbc.M002947200; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ikenoue T, 2001, CLIN DIAGN LAB IMMUN, V8, P181, DOI 10.1128/CDLI.8.1.181-186.2001; Jenks PJ, 1998, GUT, V43, P752, DOI 10.1136/gut.43.6.752; Karin M, 1998, CANCER J SCI AM, V4, pS92; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Maeda S, 1999, GUT, V44, P336, DOI 10.1136/gut.44.3.336; Maeda S, 2001, BIOCHEM BIOPH RES CO, V284, P443, DOI 10.1006/bbrc.2001.5006; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ogura K, 1998, DIGEST DIS SCI, V43, P2738, DOI 10.1023/A:1026671815512; Ogura K, 2000, J EXP MED, V192, P1601, DOI 10.1084/jem.192.11.1601; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 1995, LAB INVEST, V73, P760; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sharma SA, 1998, J IMMUNOL, V160, P2401; SHARMA SA, 1995, INFECT IMMUN, V63, P1681, DOI 10.1128/IAI.63.5.1681-1687.1995; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Yamaoka Y, 1996, GASTROENTEROLOGY, V110, P1744, DOI 10.1053/gast.1996.v110.pm8964399; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZUPAN JR, 1995, PLANT PHYSIOL, V107, P1041, DOI 10.1104/pp.107.4.1041	52	167	175	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44856	44864		10.1074/jbc.M105381200	http://dx.doi.org/10.1074/jbc.M105381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11546774	hybrid			2022-12-25	WOS:000172406700071
J	Chew, LJ; Yuan, XQ; Scherer, SE; Qie, L; Huang, F; Hayes, WP; Gallo, V				Chew, LJ; Yuan, XQ; Scherer, SE; Qie, L; Huang, F; Hayes, WP; Gallo, V			Characterization of the rat GRIK5 kainate receptor subunit gene promoter and its intragenic regions involved in neural cell specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; SODIUM-CHANNEL GENE; GLUTAMATE-RECEPTOR; SYNAPTIC TRANSMISSION; REGULATORY ELEMENTS; MAMMALIAN-CELLS; AMPA RECEPTORS; GROWTH-FACTOR; ION CHANNELS; EXPRESSION	The GRIK5 (glutamate receptor ionotropic kainate-5) gene encodes the kainate-preferring glutamate receptor subunit KA2. The GRIK5 promoter is TATA-less and GC-rich, with multiple consensus initiator sequences. Transgenic mouse lines carrying 4 kilobases of the GRIK5 5'-flanking sequence showed lacZ reporter expression predominantly in the nervous system. Reporter assays in central glial (CG-4) and non-neural cells indicated that a 1200-base pair (bp) 5'-flanking region could sustain neural cell-specific promoter activity. Transcriptional activity was associated with the formation of a transcription factor IID-containing complex on an initiator sequence located 1100 bp upstream of the first intron. In transfection studies, deletion of exonic sequences downstream of the promoter resulted in reporter gene activity that was no longer neural cell-specific. When placed downstream of the GRIK5 promoter, a 77-bp sequence from the deleted fragment completely silenced reporter expression in NIH3T3 fibroblasts while attenuating activity in CG-4 cells. Analysis of the 77-bp sequence revealed a functional SP1-binding site and a sequence resembling a neuron-restrictive silencer element. The latter sequence, however, did not display cell-specific binding of REST-like proteins. Our studies thus provide evidence for intragenic control of GRIK5 promoter activity and suggest that elements contributing to tissue-specific expression are contained within the first exon.	NICHHD, Sect Mol & Cellular Neurobiol, Lab Cellular & Synapt Neurophysiol, NIH, Bethesda, MD 20892 USA; Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Catholic University of America	Gallo, V (corresponding author), NICHHD, Sect Mol & Cellular Neurobiol, Lab Cellular & Synapt Neurophysiol, NIH, Bldg 49,Rm 5A-78,49 Convent Dr, Bethesda, MD 20892 USA.							Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAHN S, 1994, J NEUROSCI, V14, P5525; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BETTLER B, 1990, NEURON, V5, P584; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Bischoff S, 1997, J COMP NEUROL, V379, P541, DOI 10.1002/(SICI)1096-9861(19970324)379:4<541::AID-CNE6>3.0.CO;2-2; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P471; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chew LJ, 1999, J BIOL CHEM, V274, P29366, DOI 10.1074/jbc.274.41.29366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; DeVries SH, 1999, NATURE, V397, P157, DOI 10.1038/16462; Dingledine R, 1999, PHARMACOL REV, V51, P7; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; Emami KH, 1998, NUCLEIC ACIDS RES, V26, P839, DOI 10.1093/nar/26.3.839; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; GALLO V, 1992, J NEUROSCI, V12, P1010; GALLO V, 1995, NEUROCHEM RES, V20, P549, DOI 10.1007/BF01694536; GALLO V, 1995, J NEUROSCI, V15, P394; HAYES WP, 1990, DEVELOPMENT, V110, P747; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huang F, 1997, J BIOL CHEM, V272, P8618, DOI 10.1074/jbc.272.13.8618; Hyder SM, 2000, CANCER RES, V60, P3183; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kamiya H, 2000, J PHYSIOL-LONDON, V523, P653, DOI 10.1111/j.1469-7793.2000.t01-1-00653.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kidd FL, 1999, NATURE, V400, P569, DOI 10.1038/23040; Kim HS, 1998, J NEUROCHEM, V71, P41; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li P, 1999, NATURE, V397, P161, DOI 10.1038/16469; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PATNEAU DK, 1994, NEURON, V12, P357, DOI 10.1016/0896-6273(94)90277-1; PUCHALSKI RB, 1994, NEURON, V13, P131, DOI 10.1016/0896-6273(94)90464-2; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Sahara Y, 1997, J NEUROSCI, V17, P6611; SASNER M, 1998, SOC NEUR ABSTR, V24, P10863; Scherer SE, 1998, J NEUROSCI RES, V52, P356, DOI 10.1002/(SICI)1097-4547(19980501)52:3<356::AID-JNR12>3.0.CO;2-4; Schiffer HH, 1997, NEURON, V19, P1141, DOI 10.1016/S0896-6273(00)80404-3; Schmitz D, 2000, NEURON, V27, P327, DOI 10.1016/S0896-6273(00)00040-4; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1; SZPIRER C, 1994, P NATL ACAD SCI USA, V91, P11849, DOI 10.1073/pnas.91.25.11849; Vignes M, 1998, NEUROPHARMACOLOGY, V37, P1269, DOI 10.1016/S0028-3908(98)00148-8; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WERNER P, 1991, NATURE, V351, P741; WISDEN W, 1993, J NEUROSCI, V13, P3582	66	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42162	42171		10.1074/jbc.M101895200	http://dx.doi.org/10.1074/jbc.M101895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533047	hybrid			2022-12-25	WOS:000172450400084
J	Giedroc, DP; Chen, XH; Pennella, MA; LiWang, AC				Giedroc, DP; Chen, XH; Pennella, MA; LiWang, AC			Conformational heterogeneity in the C-terminal zinc fingers of human MTF-1 - An NMR and zinc-binding study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; METAL-RESPONSE ELEMENT; METALLOTHIONEIN GENE-EXPRESSION; SEQUENTIAL BACKBONE ASSIGNMENT; DNA-BINDING; METALLOREGULATORY PROTEIN; CHEMICAL-SHIFT; FUNCTIONAL-HETEROGENEITY; DEPENDENT STRUCTURE; ESCHERICHIA-COLI	The human metalloregulatory transcription factor, metal-response element (MRE)-binding transcription factor-1 (MTF-1), contains six TFIIIA-type Cys(2)-His(2) motifs, each of which was projected to form well-structured beta beta alpha domains upon Zn(II) binding. In this report, the structure and backbone dynamics of a fragment containing the unusual C-terminal fingers F4-F6 has been investigated. N-15 heteronuclear single quantum coherence (HSQC) spectra of uniformly N-15-labeled hMTF-zf46 show that Zn(ll) induces the folding of hMTF-zf46. Analysis of the secondary structure of Zn-3 hMTF-zf46 determined by C-13 alpha chemical shift indexing and the magnitude of (3)J(H alpha -HN) clearly reveal that zinc fingers F4 and F6 adopt typical beta beta alpha structures. An analysis of the heteronuclear backbone N-15 relaxation dynamics behavior is consistent with this picture and further reveals independent tumbling of the finger domains in solution. Titration of apo-MTF-zf46 with Zn(H) reveals that the F4 domain binds Zn(II) significantly more tightly than do the other two finger domains. In contrast to fingers F4 and F6, the beta beta alpha fold of finger F5 is unstable and only partially populated at substoichiometric Zn(II); a slight molar excess of zinc results in severe conformational exchange broadening of all F5 NH cross-peaks. Finally, although Cd(II) binds to apo-hMTF-zf46 as revealed by intense S---> Cd(II) absorption, a non-native structure results; addition of stoichiometric Zn(II) to the Cd(Il) complex results in quantitative refolding of the beta beta alpha structure in F4 and F6. The functional implications of these results are discussed.	Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Giedroc, DP (corresponding author), Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.	giedroc@tamu.edu	LiWang, Andy/AAE-5205-2020; Giedroc, David/A-8608-2018	LiWang, Andy/0000-0003-4741-6946; Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [T32 GM08523, GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042569, R29GM042569, T32GM008523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; APUY JL, 2001, IN PRESS BIOCHEMISTR, V40; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; Chen XH, 2000, J BIOL INORG CHEM, V5, P93, DOI 10.1007/s007750050012; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; Chu WA, 1999, J BIOL CHEM, V274, P5279, DOI 10.1074/jbc.274.9.5279; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; der Maur Adrian Auf, 1999, Biological Chemistry, V380, P175; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; Foster MP, 1998, J BIOMOL NMR, V12, P51, DOI 10.1023/A:1008290631575; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Gao Y, 1998, PROTEIN SCI, V7, P2265, DOI 10.1002/pro.5560071104; GLEDROC DP, 2001, ANTIAXID REDOX SIGNA, V3, P577; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Guo JQ, 1997, BIOCHEMISTRY-US, V36, P730, DOI 10.1021/bi9617769; HENEHAN CJ, 1993, PROTEIN SCI, V2, P1756, DOI 10.1002/pro.5560021019; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hyre DE, 1998, J MOL BIOL, V279, P929, DOI 10.1006/jmbi.1998.1811; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Koizumi S, 2000, J CELL PHYSIOL, V185, P464, DOI 10.1002/1097-4652(200012)185:3<464::AID-JCP18>3.0.CO;2-4; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; LaRochelle O, 2001, BIOCHEM J, V353, P591, DOI 10.1042/0264-6021:3530591; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; MAKOTO K, 1999, MICROBIOL IMMUNOL, V43, P115; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Murphy BJ, 1999, CANCER RES, V59, P1315; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Parkin G, 2000, CHEM COMMUN, P1971, DOI 10.1039/b004816j; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Razmiafshari M, 2001, TOXICOL APPL PHARM, V172, P1, DOI 10.1006/taap.2001.9132; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WANG AC, 1994, J MAGN RESON SER B, V105, P196, DOI 10.1006/jmrb.1994.1123; Wang AC, 1996, J AM CHEM SOC, V118, P2483, DOI 10.1021/ja9535524; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8	64	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42322	42332		10.1074/jbc.M106517200	http://dx.doi.org/10.1074/jbc.M106517200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11524427	hybrid			2022-12-25	WOS:000172450400103
J	Kumar, PG; Laloraya, M; Wang, CY; Ruan, QG; Davoodi-Semiromi, A; Kao, KJ; She, JX				Kumar, PG; Laloraya, M; Wang, CY; Ruan, QG; Davoodi-Semiromi, A; Kao, KJ; She, JX			The autoimmune regulator (AIRE) is a DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; MUTATIONS; GENE; SPECIFICITY; DISEASE; DOMAIN; RULES	The autoimmune regulator (AIRE) protein is a putative transcription regulator with two plant homeodomain-type zinc fingers, a putative DNA-binding domain (SAND), and four nuclear receptor binding LXXLL motifs. We have shown here that in vitro, recombinant AIRE can form homodimers and homotetramers that were also detected in thymic protein extracts. Recombinant AIRE also oligomerizes spontaneously upon phosphorylation by CAMP dependent protein kinase A or protein kinase C. Similarly, thymic AIRE protein is phosphorylated at the tyrosine and serine/threonine residues. AIRE dimers and tetramers, but not the monomers, can bind to G-doublets with the ATTGGTTA motif and the TTATTA-box. Competition assays revealed that sequences with one TTATTA motif and two tandem repeats of ATTGGTTA had the highest binding affinity. These findings demonstrate that AIRE is an important DNA binding molecule involved in immune regulation.	Univ Florida, Dept Pathol Immunol & Lab Med, Coll Med, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Diabet Ctr Excellence, Coll Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	She, JX (corresponding author), Univ Florida, Dept Pathol Immunol & Lab Med, Coll Med, Ctr Mammalian Genet, Box 100275, Gainesville, FL 32610 USA.	she@ufl.edu	Kumar, Pradeep/GQA-7930-2022; Kumar, Pradeep/Y-4242-2019	Kumar, Pradeep/0000-0001-7603-3579; Wang, Cong-Yi/0000-0001-7914-168X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI042288] Funding Source: NIH RePORTER; NIAID NIH HHS [1P01AI-42288] Funding Source: Medline; NICHD NIH HHS [1RO1HD37800] Funding Source: Medline; NIDDK NIH HHS [1R24DK58778] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Bjorses P, 1996, AM J HUM GENET, V59, P879; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Heino M, 1999, HUM MUTAT, V13, P69, DOI 10.1002/(SICI)1098-1004(1999)13:1<69::AID-HUMU8>3.0.CO;2-6; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; Ishii T, 2000, J CLIN ENDOCR METAB, V85, P2922, DOI 10.1210/jc.85.8.2922; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Wang CY, 1998, HUM GENET, V103, P681, DOI 10.1007/s004390050891	23	119	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41357	41364		10.1074/jbc.M104898200	http://dx.doi.org/10.1074/jbc.M104898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533054	hybrid			2022-12-25	WOS:000171925600130
J	Li, YK; Chin, LS; Weigel, C; Li, L				Li, YK; Chin, LS; Weigel, C; Li, L			Spring, a novel RING finger protein that regulates synaptic vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; MEMBRANE-FUSION; SNARE COMPLEX; NERVE-TERMINALS; KINASE-C; SYNTAXIN; DOCKING; DOMAINS; SNAP-25; PHOSPHORYLATION	The synaptosome-associated protein of 25 kDa (SNAP-25) interacts with syntaxin 1 and vesicle-associated membrane protein 2 (VAMP2) to form a ternary soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) complex that is essential for synaptic vesicle exocytosis. We report a novel RING finger protein, Spring, that specifically interacts with SNAP-25. Spring is exclusively expressed in brain and is concentrated at synapses. The association of Spring with SNAP-25 abolishes the ability of SNAP-25 to interact with syntaxin 1 and VAMP2 and prevents the assembly of the SNARE complex. Overexpression of Spring or its SNAP-25-interacting domain reduces Ca2+-dependent exocytosis from PC12 cells. These results indicate that Spring may act as a regulator of synaptic vesicle exocytosis by controlling the availability of SNAP-25 for the SNARE complex formation.	Univ N Carolina, Sch Med, Dept Pharmacol & Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5109 Rollins Res Ctr, Atlanta, GA 30322 USA.			Chin, Lih-Shen/0000-0002-0817-0368; Li, Lian/0000-0003-4700-1134	NINDS NIH HHS [NS37939] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037939] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Betz A, 1997, J BIOL CHEM, V272, P2520; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Klenchin VA, 2000, BIOCHIMIE, V82, P399, DOI 10.1016/S0300-9084(00)00208-X; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; Seto MH, 1999, PROTEINS, V35, P235, DOI 10.1002/(SICI)1097-0134(19990501)35:2<235::AID-PROT9>3.3.CO;2-O; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tsujimoto S, 2000, J BIOL CHEM, V275, P2938, DOI 10.1074/jbc.275.4.2938; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551	61	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40824	40833		10.1074/jbc.M106141200	http://dx.doi.org/10.1074/jbc.M106141200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524423	Green Published, hybrid			2022-12-25	WOS:000171925600061
J	Lopez-Boado, YS; Wilson, CL; Parks, WC				Lopez-Boado, YS; Wilson, CL; Parks, WC			Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE EXPRESSION; DEFENSINS; PATHOGENESIS; ACTIVATION; ALPHA; GENE; LIPOPOLYSACCHARIDE; IDENTIFICATION; INFECTION; PILI	Matrilysin (matrix metalloproteinase-7) is expressed by mucosal epithelia throughout the body and functions in host defense by activating murine intestinal a-defensins. In normal adult human lung, matrilysin is expressed at low levels in the airway epithelium, but is markedly up-regulated in cystic fibrosis (CF). Because CF lungs support a heavy bacterial load, we assessed if relevant CF pathogens regulate matrilysin expression in human lung epithelial cells. Indeed, acute infection with Pseudomonas aeruginosa (but not Staphylococcus aureus, Haemophilus influenzae, or Klebsiella pneumoniae) induced the expression of matrilysin in Calu-3 lung epithelial cells. Increased matrilysin mRNA levels were detectable at 3 h post-infection and peaked at a 25-fold induction between 6 and 8 h. Both P. aeruginosa CF isolates and laboratory strains induced matrilysin expression to similar levels. Flagellin, the monomeric precursor of bacterial flagella, was identified as the inductive factor released by P. aeruginosa that regulated matrilysin expression. In addition, flagellin-null mutants failed to stimulate matrilysin expression in cultured cells or in lungs infected in vivo. These data show that P. aeruginosa (and specifically flagellin) potently stimulates matrilysin expression in lung epithelial cells and may mediate the overexpression of this proteinase in CF lungs.	Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Parks, WC (corresponding author), Washington Univ, Dept Pediat, Sch Med, Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	parks_w@kids.wustl.edu	Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL29594, HL54619] Funding Source: Medline; NIDCR NIH HHS [DE14040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE014040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bals R, 1999, J CLIN INVEST, V103, P303, DOI 10.1172/JCI6277; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; Brimer CD, 1998, J BACTERIOL, V180, P3209, DOI 10.1128/JB.180.12.3209-3217.1998; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; Comolli JC, 1999, INFECT IMMUN, V67, P3207, DOI 10.1128/IAI.67.7.3207-3214.1999; de Bentzmann S, 2000, LAB INVEST, V80, P209, DOI 10.1038/labinvest.3780024; deBentzmann S, 1996, AM J RESP CRIT CARE, V154, pS155, DOI 10.1164/ajrccm/154.4_Pt_2.S155; DIMANGO E, 1995, J CLIN INVEST, V96, P2204, DOI 10.1172/JCI118275; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Firth JD, 1997, INFECT IMMUN, V65, P4931, DOI 10.1128/IAI.65.12.4931-4936.1997; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Pier GB, 1996, AM J RESP CRIT CARE, V154, pS175, DOI 10.1164/ajrccm/154.4_Pt_2.S175; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190, DOI 10.1111/1523-1747.ep12317104; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Soong LB, 1997, INFLAMM RES, V46, P98, DOI 10.1007/s000110050114; Spangenberg C, 1996, FEBS LETT, V396, P213, DOI 10.1016/0014-5793(96)01099-X; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; TOTTEN PA, 1990, J BACTERIOL, V172, P7188, DOI 10.1128/jb.172.12.7188-7199.1990; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WILSON MJ, 1992, BIOL REPROD, V47, P683, DOI 10.1095/biolreprod47.5.683; Zhang H, 2001, AM J PHYSIOL-LUNG C, V280, pL947, DOI 10.1152/ajplung.2001.280.5.L947	39	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41417	41423		10.1074/jbc.M107121200	http://dx.doi.org/10.1074/jbc.M107121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527977	hybrid			2022-12-25	WOS:000171925600138
J	Morton, NM; Holmes, MC; Fievet, C; Staels, B; Tailleux, A; Mullins, JJ; Seckl, JR				Morton, NM; Holmes, MC; Fievet, C; Staels, B; Tailleux, A; Mullins, JJ; Seckl, JR			Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 beta-hydroxysteroid dehydrogenase type 1 null mice.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; LIPOGENIC ENZYME GENES; FATTY-ACID OXIDATION; MESSENGER-RNA LEVELS; TRANSGENIC MICE; PPAR-ALPHA; GLUCOCORTICOID RECEPTOR; TISSUE-DISTRIBUTION; METABOLIC SYNDROME; PRIMARY CULTURES	Excess tissue glucocorticoid action may underlie the dyslipidemia, insulin resistance, and impaired glucose tolerance of the metabolic syndrome. 11 beta -Hydroxy-steroid dehydrogenase type 1 (11 beta -HSD-1) catalyzes conversion of circulating inert 11-dehydrocorticosterone into active corticosterone, thus amplifying local intracellular glucocorticoid action, particularly in liver. The importance of 11 beta -HSD-1 in glucose homeostasis is suggested by the resistance of 11 beta -HSD-1(-/-) mice to hyperglycemia upon stress or obesity, due to attenuated gluconeogenic responses. The present study further investigates the metabolic consequences of 11 beta -HSD-1 deficiency, focusing on the lipid and lipoprotein profile. Ad lib fed 11 beta -HSD-1(-/-) mice have markedly lower plasma triglyceride levels. This appears to be driven by increased hepatic expression of enzymes of fat catabolism (carnitine palmitoyltransferase-I, acyl-CoA oxidase, and uncoupling protein-2) and their coordinating transcription factor, peroxisome proliferator-activated receptor-a (PPAR alpha). 11 beta -HSD-1(-/-) mice also have increased HDL cholesterol, with elevated liver mRNA and serum levels of apolipoprotein Al. Conversely, liver A alpha -fibrinogen mRNA levels are decreased. Upon fasting, the normal elevation of peroxisome proliferator-activated receptor-a mRNA is lost in 11 beta -HSD-1(-/-) mice, consistent with attenuated glucocorticoid induction. Despite this, crucial oxidative responses to fasting are maintained; carnitine palmitoyltransferase-I induction and glucose levels are similar to wild type. Refeeding shows exaggerated induction of genes encoding lipogenic enzymes and a more marked suppression of genes for fat catabolism in 11 beta -HSD-1(-/-) mice, implying increased liver insulin sensitivity. Concordant with this, 24-h refed 11 beta -HSD-1(-/-) mice have higher triglyceride but lower glucose levels. Further, 11 beta -HSD-1(-/-) mice have improved glucose tolerance. These data suggest that 11 beta -HSD-1 deficiency produces an improved lipid profile, hepatic insulin sensitization, and a potentially atheroprotective phenotype.	Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Inst Pasteur, Dept Atherosclerose, U545, INSERM, F-59019 Lille, France; Univ Lille 2, F-59019 Lille, France	University of Edinburgh; University of Edinburgh; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Morton, NM (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Mol Med Ctr, Crewe Rd S, Edinburgh EH4 2XU, Midlothian, Scotland.	nik.morton@ed.ac.uk	TAILLEUX, Anne/R-5530-2018; Seckl, Jonathan R/C-3555-2013; Staels, Bart/N-9497-2016; Morton, NICHOLAS/ABF-3774-2020	TAILLEUX, Anne/0000-0003-1430-2627; Staels, Bart/0000-0002-3784-1503; 				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; Ambrosi B, 2000, EXP CLIN ENDOCR DIAB, V108, P294, DOI 10.1055/s-2000-8000; Andrew R, 1998, J CLIN ENDOCR METAB, V83, P1806, DOI 10.1210/jc.83.5.1806; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BHATTACHARYA A, 1991, MOL ENDOCRINOL, V5, P587, DOI 10.1210/mend-5-4-587; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Cole TJ, 1999, MOL CELL ENDOCRINOL, V154, P29, DOI 10.1016/S0303-7207(99)00105-7; Collett GP, 2000, CLIN CANCER RES, V6, P3241; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ETTINGER WH, 1987, ATHEROSCLEROSIS, V63, P167, DOI 10.1016/0021-9150(87)90117-1; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FREEDMAN MR, 1986, AM J PHYSIOL, V250, pR595, DOI 10.1152/ajpregu.1986.250.4.R595; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Hargrove GM, 1999, J MOL ENDOCRINOL, V22, P103, DOI 10.1677/jme.0.0220103; Harris HJ, 2001, ENDOCRINOLOGY, V142, P114, DOI 10.1210/en.142.1.114; Hermanowski-Vosatka A, 2000, BIOCHEM BIOPH RES CO, V279, P330, DOI 10.1006/bbrc.2000.3966; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jamieson PM, 2000, J ENDOCRINOL, V165, P685, DOI 10.1677/joe.0.1650685; JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754; Kannel WB, 1997, DRUGS, V54, P32, DOI 10.2165/00003495-199700543-00006; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kockx M, 1999, BLOOD, V93, P2991; KOELEVTSEV Y, P NATL ACAD SCI US, V94, P14924; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Livingstone DEW, 2000, ENDOCRINOLOGY, V141, P560, DOI 10.1210/en.141.2.560; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Murao K, 1998, J BIOL CHEM, V273, P18959, DOI 10.1074/jbc.273.30.18959; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Qi C, 2000, CELL BIOCHEM BIOPHYS, V32, P187, DOI 10.1385/CBB:32:1-3:187; RAJAN V, 1995, J STEROID BIOCHEM, V52, P141, DOI 10.1016/0960-0760(94)00159-J; Rajan V, 1996, J NEUROSCI, V16, P65; Schultz R, 1999, ENDOCRINOLOGY, V140, P2968, DOI 10.1210/en.140.7.2968; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; STAELS B, 1991, ARTERIOSCLER THROMB, V11, P760, DOI 10.1161/01.ATV.11.3.760; Stewart PM, 1999, J CLIN ENDOCR METAB, V84, P1022, DOI 10.1210/jc.84.3.1022; Tailleux A, 2000, ARTERIOSCL THROM VAS, V20, P2453, DOI 10.1161/01.ATV.20.11.2453; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Yau JLW, 2001, P NATL ACAD SCI USA, V98, P4716, DOI 10.1073/pnas.071562698; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901; Zammit VA, 2000, BIOCHEM SOC T, V28, P103, DOI 10.1042/bst0280103	63	366	424	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41293	41300		10.1074/jbc.M103676200	http://dx.doi.org/10.1074/jbc.M103676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546766	hybrid			2022-12-25	WOS:000171925600122
J	Shin, ME; Ogburn, KD; Varban, OA; Gilbert, PM; Burd, CG				Shin, ME; Ogburn, KD; Varban, OA; Gilbert, PM; Burd, CG			FYVE domain targets Pib1p ubiquitin ligase to endosome and vacuolar membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; YEAST; RING; TRANSPORT; COMPLEX; LOCALIZATION; REGULATOR; FINGER	Signaling by phosphatidylinositol 3-kinases (PI3Ks) is often mediated by proteins which bind PI3K products directly and are localized to intracellular membranes rich in PI3K products. The FYVE finger domain binds with high specificity to PtdIns(3)P and proteins containing this domain have been shown to be important components of diverse PI3K signaling pathways. The genome of the yeast Saccharomyces cerevisiae encodes five proteins containing FIVE domains, including Pib1p, whose function is unknown. In addition to a FYVE finger motif, the primary structure of Pib1p contains a region rich in cysteine and histidine residues that we demonstrate binds 2 mol eq of zinc, consistent with this region containing a RING structural domain. The Pib1p RING domain exhibited E2-dependent ubiquitin ligase activity in vitro, indicating that Pib1p is an E3 RING-type ubiquitin ligase. Fluorescence microscopy was used to demonstrate that a GFP-Pib1p fusion protein localized to endosomal and vacuolar membranes and deletional analysis of Pib1p domains indicated that localization of GFP-Pib1p is mediated solely by the FYVE domain. These results suggest that Pib1p mediates ubiquitination of a subset of cellular proteins localized to endosome and vacuolar membranes, and they expand the repertoire of PI3K-regulated pathways identified in eukaryotic cells.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Burd, CG (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.			Gilbert, Penney/0000-0001-5509-9616; Burd, Christopher/0000-0003-1831-8706	NIGMS NIH HHS [GM61221] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061221] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Maniatis T., 1982, MOL CLONING LAB MANU; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sherman F, 1979, METHODS YEAST GENETI; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	32	37	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41388	41393		10.1074/jbc.M105665200	http://dx.doi.org/10.1074/jbc.M105665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526110	hybrid			2022-12-25	WOS:000171925600134
J	Jeon, WB; Cheng, JJ; Ludden, PW				Jeon, WB; Cheng, JJ; Ludden, PW			Purification and characterization of membrane-associated CooC protein and its functional role in the insertion of nickel into carbon monoxide dehydrogenase from Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; COMPLETE GENOME SEQUENCE; BINDING PROTEIN; ESCHERICHIA-COLI; PHYSIOLOGICAL CHARACTERIZATION; BRADYRHIZOBIUM-JAPONICUM; AZOTOBACTER-VINELANDII; SULFUR PROTEIN; NITROGENASE; ACTIVATION	The accessory protein CooC, which contains a nucleotide-binding domain (P-loop) near the N terminus, participates in the maturation of the nickel center of carbon monoxide dehydrogenase (CODH). In this study, CooC was purified from the chromatophore membranes of Rhodospirillum rubrum with a 3,464-fold purification and a 0.8% recovery, and its biochemical properties were characterized. CooC is a homodimer with a molecular mass of 61-63 kDa, contains less than 0.1 atom of Ni2+ or Fe2+ per dimer, and has a lambda (max) at 277.5 nm (epsilon (277.5) 32.1 mM(-1) cm(-1)) with no absorption peaks at the visible region. CooC catalyzes the hydrolysis of ATP and GTP with K-m values of 24.4 and 26.0 muM and V-max values of 58.7 and 3.7 nmol/min/mg protein for ATP and GTP hydrolysis, respectively. The P-loop mutated form of K13Q CooC was generated by site-specific replacement of lysine by glutamine and was purified according to the protocol for wild-type CooC purification. The K13Q CooC was inactive both in ATP hydrolysis and in vivo nickel insertion. In vitro nickel activation of apoCODH in the cell extracts from UR2 (wild type) and UR871 (K13Q CooC) showed that activation of nickel-deficient CODH was enhanced by CooC and dependent upon ATP hydrolysis. The overall results suggest that CooC couples ATP hydrolysis with nickel insertion into apoCODH. On the basis of our results and models for analogous systems, the functional roles of CooC in nickel processing into the active site of CODH are presented.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Cheng, Jiongjia/AAM-9464-2020	Cheng, Jiongjia/0000-0002-0908-3880				ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLLAG DM, 1996, PROTEIN METHODS, P195; BONAM D, 1988, P NATL ACAD SCI USA, V85, P31, DOI 10.1073/pnas.85.1.31; BONAM D, 1987, J BIOL CHEM, V262, P2980; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; ENSIGN SA, 1991, J BIOL CHEM, V266, P18395; EVANS DJ, 1991, MICROB PATHOGENESIS, V10, P15, DOI 10.1016/0882-4010(91)90062-F; Fox JD, 1996, J BACTERIOL, V178, P1515, DOI 10.1128/jb.178.6.1515-1524.1996; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLENNON JD, 1982, BIOCHEM J, V203, P15, DOI 10.1042/bj2030015; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Heo J, 1999, J AM CHEM SOC, V121, P11045, DOI 10.1021/ja990397a; Heo JY, 2000, BIOCHEMISTRY-US, V39, P7956, DOI 10.1021/bi992958g; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; Kansau I, 1996, MOL MICROBIOL, V22, P1013, DOI 10.1046/j.1365-2958.1996.01536.x; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDDEN PW, 1978, BIOCHEM J, V175, P251, DOI 10.1042/bj1750251; Magalon A, 2000, J BIOL CHEM, V275, P21114, DOI 10.1074/jbc.M000987200; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rodrigue A, 1996, J BACTERIOL, V178, P4453, DOI 10.1128/jb.178.15.4453-4460.1996; Ryle MJ, 2000, J BIOL CHEM, V275, P6214, DOI 10.1074/jbc.275.9.6214; SAARI LL, 1984, J BIOL CHEM, V259, P5502; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Spangler NJ, 1998, J BIOL CHEM, V273, P4059, DOI 10.1074/jbc.273.7.4059; Staples CR, 1999, J AM CHEM SOC, V121, P11034, DOI 10.1021/ja990396i; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Watt RK, 1999, J BACTERIOL, V181, P4554, DOI 10.1128/JB.181.15.4554-4560.1999; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019	51	66	68	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38602	38609		10.1074/jbc.M104945200	http://dx.doi.org/10.1074/jbc.M104945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507093	hybrid			2022-12-25	WOS:000171673200038
J	Kitagawa, H; Uyama, T; Sugahara, K				Kitagawa, H; Uyama, T; Sugahara, K			Molecular cloning and expression of a human chondroitin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE-REGION; HEPARAN-SULFATE; N-ACETYLGALACTOSAMINYLTRANSFERASE; TUMOR SUPPRESSORS; CAENORHABDITIS-ELEGANS; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; IDENTIFICATION; PURIFICATION; TETRASACCHARIDE	We have identified a human chondroitin synthase from the HUGE (human unidentified gene-encoded large proteins) protein data base by screening with two keywords: "one transmembrane domain" and "galactosyltransferase family." The identified protein consists of 802 amino acids with a type II transmembrane protein topology. The protein showed weak homology to the beta1,3-galactosyltransferase family on the amino-terminal side and to the beta1,4-galactosyltransferase family on the carboxyl-terminal side. The expression of a soluble recombinant form of the protein in COS-1 cells produced an active enzyme, which transferred not only the glucuronic acid (GlcUA) from UDP-[C-14]GlcUA but also N-acetylgalactosamine (GalNAc) from UDP-[H-3]GalNAc to the polymer chondroitin. Identification of the reaction products demonstrated that the enzyme was chondroitin synthase, with both beta1,3-GlcUA transferase and beta1,4-GalNAc transferase activities. The coding region of the chondroitin synthase was divided into three discrete exons and localized to chromosome 15. Northern blot analysis revealed that the chondroitin synthase gene exhibited ubiquitous but markedly differential expression in the human tissues examined. Thus, we demonstrated that analogous to human heparan sulfate polymerases, the single polypeptide chondroitin synthase possesses two glycosyltransferase activities required for chain polymerization.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				AMADO M, 1999, BIOCHIM BIOPHYS ACTA, V1254, P35; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; Tamura J, 1996, LIEBIGS ANN, P1239; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuchida K, 1999, EUR J BIOCHEM, V264, P461, DOI 10.1046/j.1432-1327.1999.00635.x; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	41	174	186	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38721	38726		10.1074/jbc.M106871200	http://dx.doi.org/10.1074/jbc.M106871200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514575	hybrid			2022-12-25	WOS:000171673200054
J	Wei, M; Cohen, SM; Silverman, AP; Lippard, SJ				Wei, M; Cohen, SM; Silverman, AP; Lippard, SJ			Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-DOMAIN; CANCER-PATIENTS; TRANSLESION SYNTHESIS; CISPLATIN; ADDUCTS; OXALIPLATIN; CIS-DIAMMINEDICHLOROPLATINUM(II); COMPLEXES; DUPLEX	The results presented describe the effects of various spectator ligands, attached to a platinum 1,2-intrastand d(GpG) cross-link in duplex DNA, on the binding of high mobility group box (HMGB) domains and the TATA-binding protein (TBP). In addition to cisplatin-modified DNA, 15-base pair DNA probes modified by (Pt(1R,2R-diaminocyclohexane)}(2+), cis-[Pt(NH3)(cyclohexylamine)}(2+), [Pt(ethylenediamine)}(2+), cis-[Pt(NH3)(cyclobutylamine)}(2+), and cis[Pt(NH3)(2-picoline)}(2+) were examined. Electrophoretic mobility shift assays show that both the A and B domains of HMGB1 as well as TBP discriminate between different platinum-DNA adducts. HMGB1 domain A is the most sensitive to the nature of the spectator ligands on platinum. The effect of the spectator ligands on protein binding also depends highly on the base pairs flanking the platinated d(GpG) site. Double-stranded oligonucleotides containing the AG*G*C sequence, where the asterisks denote the sites of platination, with different spectator ligands are only moderately discriminated by the HMGB proteins and TBP, but the recognition of dsTG*G*A is highly dependent on the ligands. The effects of HMGB1 overexpression in a BG-1 ovarian cancer cell line, induced by steroid hormones, on the sensitivity of cells treated with [Pt(1R,2R-diaminocyclohexane)Cl-2] and cis-[Pt(NH,)(cyclohexylamine)Cl-2] were also examined. The results suggest that HMGB1 protein levels influence the cellular processing of cis-[Pt(NH3)(cyclohexylamine)}(2+), but not [Pt((1R,2R)-diaminocyclohexane)}(2+), DNA lesions. This result is consistent with the observed binding of HMGB1a to platinum-modified dsTG*G*A probes but not with the binding amity of HMGB1a and HMGB1 to platinum-damaged dSAG*G*C oligonucleotides. These experiments reinforce the importance of sequence context in platinum-DNA lesion recognition by cellular proteins.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu			NCI NIH HHS [CA34992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034992, R01CA034992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS MJ, 1987, INORG CHIM ACTA, V131, P3, DOI 10.1016/S0020-1693(00)87896-2; Barton SJ, 1998, INORG CHIM ACTA, V273, P8, DOI 10.1016/S0020-1693(97)05912-4; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; CHU G, 1994, J BIOL CHEM, V269, P787; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P8259, DOI 10.1021/bi0004495; Coin F, 1998, MOL CELL BIOL, V18, P3907, DOI 10.1128/MCB.18.7.3907; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; Dhara S. C., 1970, IND J CHEM, P193; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Dunham SU, 1998, J AM CHEM SOC, V120, P5395, DOI 10.1021/ja9742592; Ferrante K, 1999, CANCER CHEMOTH PHARM, V43, pS61, DOI 10.1007/s002800051100; HARTWIG JF, 1992, J AM CHEM SOC, V114, P5646, DOI 10.1021/ja00040a026; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Jamieson ER, 2000, BIOCHEMISTRY-US, V39, P8426, DOI 10.1021/bi000342h; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Judson I, 2000, DRUGS, V59, P29, DOI 10.2165/00003495-200059004-00004; Kelland LR, 1999, J INORG BIOCHEM, V77, P111, DOI 10.1016/S0162-0134(99)00141-5; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P29; Misset JL, 2000, CRIT REV ONCOL HEMAT, V35, P75, DOI 10.1016/S1040-8428(00)00070-6; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; POIRIER MC, 1985, ENVIRON HEALTH PERSP, V62, P89, DOI 10.2307/3430097; Read C., 1995, NUCL ACIDS MOL BIOL, P222; REED E, 1987, P NATL ACAD SCI USA, V84, P5024, DOI 10.1073/pnas.84.14.5024; REED E, 1986, J CLIN INVEST, V77, P545, DOI 10.1172/JCI112335; Saris CP, 1996, CARCINOGENESIS, V17, P2763, DOI 10.1093/carcin/17.12.2763; SPINGLER B, 2001, IN PRESS INORG CHEM, V40; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; Vaisman A, 1999, BIOCHEMISTRY-US, V38, P11026, DOI 10.1021/bi9909187; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	38	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38774	38780		10.1074/jbc.M106374200	http://dx.doi.org/10.1074/jbc.M106374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514569	hybrid			2022-12-25	WOS:000171673200060
J	Panther, E; Idzko, M; Herouy, Y; Rheinen, H; Gebicke-Haerter, PJ; Mrowietz, U; Dichmann, S; Norgauer, J				Panther, E; Idzko, M; Herouy, Y; Rheinen, H; Gebicke-Haerter, PJ; Mrowietz, U; Dichmann, S; Norgauer, J			Expression and function of adenosine receptors in human dendritic cells	FASEB JOURNAL			English	Article						DCs; calcium; chemotaxis; cytokine release	OXYGEN RADICAL PRODUCTION; CD11B UP-REGULATION; ACTIN REORGANIZATION; CHEMOKINE PRODUCTION; HUMAN EOSINOPHILS; G-PROTEIN; MATURATION; INHIBITION; IL-12; ACTIVATION	Dendritic cells (DCs) are specialized antigen-presenting cells characterized by their ability to migrate into target sites, process antigens, and activate naive T cells. In this study, we analyzed the biological activity and intracellular signaling of adenosine by using reverse transcriptase-polymerase chain reaction assays to investigate mRNA expression of A(1),A(2a) and A(3) adenosine receptors in immature and mature human DCs. Functional experiments on adenosine stimulation showed chemotaxis, intracellular calcium transients, and actin polymerization, but no activation of adenylate cyclase in immature DCs. Experiments with receptor isotype-selective agonists and antagonists as well as pertussis toxin revealed that chemotaxis, calcium transients, and actin polymerization were mediated via G(i)- or G(0)-protein-coupled A(1) and A(3) receptors. Maturation of DCs induced by lipopolysaccharide (LPS) resulted in down-regulation of A(1) and A(3) receptor mRNAs, although A(2a) receptor mRNA was still expressed. However, in LPS-differentiated DCs, adenosine and an A(2a) receptor agonist stimulated adenylate cyclase activity, enhanced intracellular cAMP levels, and inhibited interleukin 12 (IL-12) production. These effects could be completely prevented by pretreatment with A(2) receptor antagonist. These findings strongly suggest that adenosine has important but distinct biological effects in DCs activity as a chemotaxin for immature DCs and as a modulator of IL-12 production in mature DCs. These effects can be explained by differential expression of adenosine receptor subtypes.	Univ Freiburg, Dept Expt Dermatol, D-79104 Freiburg, Germany; Univ Freiburg, Dept Psychiat, D-79104 Freiburg, Germany; Univ Kiel, Dept Dermatol, D-24098 Kiel, Germany	University of Freiburg; University of Freiburg; University of Kiel	Norgauer, J (corresponding author), Univ Freiburg, Dept Expt Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	Norgauer@haut.ukl.uni-freiburg.de	Mrowietz, U/B-1645-2010	Mrowietz, U/0000-0002-9539-0712				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; COUTINHO SR, 1999, AM J PHYSIOL, V276, pC1139; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; Dichmann S, 2000, J CELL PHYSIOL, V185, P394, DOI 10.1002/1097-4652(200012)185:3<394::AID-JCP9>3.3.CO;2-Q; DiVirgilio F, 1996, DRUG DEVELOP RES, V39, P319; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; GREEN HN, 1950, BIOL ACTIONS ADENINE; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; ILLES P, 1993, TRENDS PHARMACOL SCI, V14, P50, DOI 10.1016/0165-6147(93)90030-N; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kohno Y, 1996, BLOOD, V88, P3569, DOI 10.1182/blood.V88.9.3569.bloodjournal8893569; Nardelli B, 1999, J LEUKOCYTE BIOL, V65, P822, DOI 10.1002/jlb.65.6.822; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; Tenscher K, 1997, BIOCHEM BIOPH RES CO, V240, P32, DOI 10.1006/bbrc.1997.7601; TRANQUILLO RT, 1988, J CELL BIOL, V106, P303, DOI 10.1083/jcb.106.2.303; Vassort Guy, 1992, News in Physiological Sciences, V7, P212; WOLBERG G, 1975, SCIENCE, V187, P957, DOI 10.1126/science.167434	31	147	152	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1963	1970		10.1096/fj.01-0169com	http://dx.doi.org/10.1096/fj.01-0169com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532976				2022-12-25	WOS:000171372700011
J	Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM				Coffin, WF; Erickson, KD; Hoedt-Miller, M; Martin, JM			The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain	ONCOGENE			English	Article						LMP-1; EBV; transmembrane topology; signaling	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; INTERNAL SIGNAL SEQUENCE; LYMPHOCYTE TRANSFORMATION; CHARGED RESIDUES; C-TERMINUS; 1 ENGAGES; LMP1; EXPRESSION; ACTIVATION	The Latent Membrane Protein 1 (LMP-1) protein of Epstein-Barr virus (EBV) is localized in the plasma membrane of the infected cell. LMP-1 possesses a hydrophobic membrane spanning domain, and charged, intracellular amino- and carboxy-termini. Two models have been proposed for the contribution of the amino-terminus to LMP-l's function: (i) as an effector domain, interacting with cellular proteins, or (ii) as a structural domain dictating the correct orientation of transmembrane domains and thereby positioning LMP-l's critical effector domains (i.e. the carboxy-terminus). However, no studies to date have addressed directly the structural contributions of LMP-1s cytoplasmic amino-terminus to function. This study was designed to determine if LMP-1's cytoplasmic amino-terminus (N-terminus) encodes information required solely for maintenance of proper topological orientation. We have constructed LMP-1 chimeras in which the cytoplasmic N-terminus of LMP-1 is replaced with an unrelated domain of similar size and charge, but of different primary sequence. Retention of the charged amino-terminal (N-terminal) cytoplasmic domain and first predicted transmembrane domain was required for correct transmembrane topology. The absolute primary sequence of the cytoplasmic N-terminus was not critical for LMP-1's cytoskeletal association, turnover, plasma membrane patching, oligomerization, Tumor Necrosis Factor Receptor-associated factor (TRAF) binding, NF-kappaB activation, rodent cell transformation and cytostatic activity. Furthermore, our results point to the hydrophobic transmembrane domain, independent of the cytoplasmic domains, as the primary LMP-1 domain mediating oligomerization, patching and cytoskeletal association. The cytoplasmic amino-terminus provides the structural information whereby proper transmembrane orientation is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Martin, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Box 347, Boulder, CO 80309 USA.	jm@stripe.colorado.edu	Erickson, Kimberly/AAR-8747-2021	Erickson, Kimberly/0000-0002-6260-282X	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001537] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64610] Funding Source: Medline; NIAID NIH HHS [AI-01537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bankier A T, 1983, Mol Biol Med, V1, P425; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GRATAMA JW, 1991, INT J CANCER, V47, P188, DOI 10.1002/ijc.2910470205; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HEDGE R, 1997, CELL, V28, P575; HEDGE RS, 1999, TRENDS CELL BIOL, V9, P132; HUEN DS, 1995, ONCOGENE, V10, P549; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MILELR G, 1985, EPSTEIN BARR VIRUS; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	76	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5313	5330		10.1038/sj.onc.1204689	http://dx.doi.org/10.1038/sj.onc.1204689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536044				2022-12-25	WOS:000170575500007
J	Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM				Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM			Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor	ONCOGENE			English	Article						herstatin; heregulin; EGF; HER-1; HER-2; HER-3; HER-2/HER-3 heterodimers	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; TYROSINE KINASE-ACTIVITY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; BINDING-SITE; CARCINOMA-CELLS; PHASE-II	The four members of the EGF receptor family are capable of homomeric as well as heteromeric interactions. HER-2/neu (erbB-2) dominates as the preferred coreceptor that amplifies mitogenic signaling. An alternative HER-2/neu product, herstatin, consists of a segment of the ectodomain of p185HER-2 and an intronencoded C-terminus. Recombinant herstatin was found to bind with nm affinity and inhibit p185HER-2. To further examine the impact on receptor activity, herstatin was expressed with various receptor tyrosine kinases. In CHO cells that overexpressed HER-2, herstatin caused a sevenfold inhibition of colony formation that corresponded to a reduction in the tyrosine phosphorylation of p185HER-2. Herstatin also prevented HER-2 mediated transactivation of the kinase impaired HER-3 as reflected in transphosphorylation of HER-3 and heteromers between HER-2 and HER-3. In EGF receptor-overexpressing cells, EGF induction of receptor dimerization and tyrosine phosphorylation were reduced more than 90%, and receptor down-regulation as well as colony formation were also suppressed by coexpression with herstatin. Inhibition was selective for the EGF receptor family since herstatin expression did not reduce tyrosine phosphorylation mediated by the FGF receptor-2 or by insulin-like growth factor -1. Herstatin bound to the EGF receptor as well as to p185HER-2 in pull-down assays suggesting that complex formation may be involved in receptor inhibition. Our findings indicate that herstatin has the capability to negatively regulate combinations of interactions between group I receptor tyrosine kinases that confer synergistic growth signals.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of Southern California	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	clinton@ohsu.edu						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1997, J MAMMARY GLAND BIOL, V2, P165, DOI 10.1023/A:1026355831693; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; Klapper LN, 2000, ADV CANCER RES, V77, P25; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LIN YZJ, 1991, ONCOGENE, V6, P639; LONARDO F, 1990, New Biologist, V2, P992; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Moscatello DK, 1996, ONCOGENE, V13, P85; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Ram TG, 2000, CELL GROWTH DIFFER, V11, P173; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sambrook J, 1989, MOL CLONING; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINTRAUB H, 1986, CELL, V46, P115, DOI 10.1016/0092-8674(86)90865-2; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	64	43	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5199	5209		10.1038/sj.onc.1204555	http://dx.doi.org/10.1038/sj.onc.1204555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526509				2022-12-25	WOS:000170464000014
J	Michaelson, JS; Leder, P				Michaelson, JS; Leder, P			beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland	ONCOGENE			English	Article						beta-catenin; breast cancer; mammary gland; Wnt; adenocarcinoma; MMTV	POLYPOSIS-COLI PROTEIN; CYCLIN D1 GENE; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; FEMALE MICE; IN-VIVO; C-MYC; EXPRESSION; APC; TRANSFORMATION	The Wnt signal transduction pathway has been implicated in mammary tumorigenesis in the mouse. beta -catenin, a key downstream effector of this pathway interacts with and thus activates the Tcf/Lef family of transcription factors. Elevated levels of beta -catenin have been found in many human tumors, notably colon carcinomas. Recently, elevated levels of beta -catenin have been associated with poor prognosis in human adenocarcinoma of the breast. In order to assess the possible role of beta -catenin in mammary carcinoma, we have created transgenic mice bearing the MMTV-LTR driving an activated form of beta -catenin. These mice develop mammary gland hyperplasia and mammary adenocarcinoma, a phenotype very similar to that of transgenic mice expressing an MMTV-driven Writ gene. Indeed, the histopathology of the mammary tumors in Wnt-mediated adenocarcinoma is identical to that observed in our beta -catenin-mediated disease model. Furthermore, putative beta -catenin transcriptional targets, cyclin D1 and c-myc, are elevated in beta -catenin-mediated mammary tumors and cell lines. These observations support the notion that the oncogenic Wnt pathway operates via beta -catenin and its targets in the context of mammary hyperplasia and carcinoma.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.							Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu LF, 2000, GENE DEV, V14, P585; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	31	145	169	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5093	5099		10.1038/sj.onc.1204586	http://dx.doi.org/10.1038/sj.onc.1204586			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526497				2022-12-25	WOS:000170464000002
J	Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F				Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F			Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression	ONCOGENE			English	Article						p21; p27; p45(SKP2); E7; apoptosis; therapy	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT-KINASE INHIBITOR; S-PHASE; TRANSCRIPTIONAL REGULATION; REPRESS TRANSCRIPTION; ECTOPIC EXPRESSION; POTENTIAL MEDIATOR; E7 ONCOPROTEIN; PROTEIN; DEGRADATION	Histone deacetylase (HDAC) inhibitors sodium butyrate and trichostatin A arrest human papillomavirus (HPV)positive carcinoma cells in G1 to S transition of the cell cycle, which is paralleled by an up-regulation of the cyclin-dependent kinase inhibitors (CKIs) p21(CIP1) and p27(KIP1) as well as the complete loss of cdk2 activity. Although HPV expression was hitherto thought to be required to maintain a proliferative phenotype of these cells, cdk2 suppression is achieved even in the presence of ongoing viral transcription. While CKIs normally cannot exert their cdk2-inhibitory function in the presence of the viral oncoprotein E7, co-immunoprecipitation experiments revealed that E7 binding is prevented. Increase of p27(KIP1) correlates with down-regulation of p45(SKP2), a component of the ubiquitin-protein ligase SCFSKP2 controlling the half-life of regulatory proteins during the cell cycle. HDAC inhibition also triggered an E7-dependent degradation of pRb, while the levels of E2F remained unaffected. The presence of free intracellular E2F and the concomitant up-regulation of CKIs during G1 arrest results in a 'conflicting growth situation', which finally renders the cells to undergo apoptosis. These data provide novel molecular insights into how the transforming potential of HPV can be bypassed and open new therapeutical perspectives for the treatment of cervical cancer.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSL F, 1999, POSSIBLE ROLE CHEMOK, P207; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; STOEHR M, 1978, STAIN TECHNOL, V55, P205; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TOMMASINO M, 1993, ONCOGENE, V8, P195; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	95	97	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4768	4776		10.1038/sj.onc.1204652	http://dx.doi.org/10.1038/sj.onc.1204652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521189				2022-12-25	WOS:000170271800002
J	Vrtala, S; Hirtenlehner, K; Susani, M; Akdis, M; Kussebi, F; Akdis, CA; Blaser, K; Hufnagl, P; Binder, BR; Politou, A; Pastore, A; Vangelista, L; Sperr, WR; Semper, H; Valent, P; Ebner, C; Kraft, D; Valenta, R				Vrtala, S; Hirtenlehner, K; Susani, M; Akdis, M; Kussebi, F; Akdis, CA; Blaser, K; Hufnagl, P; Binder, BR; Politou, A; Pastore, A; Vangelista, L; Sperr, WR; Semper, H; Valent, P; Ebner, C; Kraft, D; Valenta, R			Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1	FASEB JOURNAL			English	Article						type I allergy; vaccine; genetic engineering	T-CELL-CLONES; PHL P 1; QUANTITATIVE IGE INHIBITION; FC EPSILON RI; RBET V 1; IMMUNOLOGICAL CHANGES; CROSS-REACT; WILD-TYPE; EPITOPES; IMMUNOTHERAPY	An estimated 100 million individuals suffer from birch pollen allergy. Specific immunotherapy, the only curative allergy treatment, can cause life-threatening anaphylactic side effects. Here, we report the genetic engineering of a recombinant trimer consisting of three covalently linked copies of the major birch pollen allergen, Bet v 1. The trimer exhibited profoundly reduced allergenic activity but contained similar secondary structures such as Bet v 1 wild type, Bet v 1-specific B cell and T-cell epitopes, and induced Th1 cytokine release. As immunogen, rBet v 1 trimer induced IgG antibodies, which blocked patients' IgE binding to Bet v 1 and related allergens. Thus, rBet v 1 trimer represents a novel hypoallergenic vaccine prototype for treatment of one of the most frequent allergy forms.	Univ Vienna, Vienna Gen Hosp, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Vienna, Sch Med, Dept Vasc Biol, A-1090 Vienna, Austria; Univ Crete, Sch Med, Iraklion 71100, Greece; Natl Inst Med Res, Mol Struct Div, London NW7 1AA, England; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Vienna, Vienna Gen Hosp, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria	University of Vienna; Austrian Academy of Sciences; Swiss Institute of Allergy & Asthma Research; University of Vienna; University of Crete; MRC National Institute for Medical Research; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Vienna	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, Sch Med, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@akh-wien.ac.at	Akdis, Cezmi/AAV-4844-2020; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Sperr, Mast/V-4767-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Akdis, Cezmi/0000-0001-8020-019X; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243; Vangelista, Luca/0000-0003-0764-5031				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 1999, J IMMUNOL, V163, P466; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; ZWEIMAN B, 2000, INFLAMMATORY MECH AL	35	107	113	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2045	+		10.1096/fj.00-0767fje	http://dx.doi.org/10.1096/fj.00-0767fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511511				2022-12-25	WOS:000170318500016
J	O'Donovan, CN; Tobin, D; Cotter, TG				O'Donovan, CN; Tobin, D; Cotter, TG			Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CALCIUM-CHANNEL ACTIVITY; OXIDATIVE STRESS; INTRACELLULAR CALCIUM; HYDROGEN-PEROXIDE; AMYLOID PROTEIN; IN-VITRO; BCL-2; DEATH; INHIBITION	The synthetic peptide PrP-(106-126) has previously been shown to be neurotoxic. Here, for the first time, we report that it induces apoptosis in the human neuroblastoma cell line SH-SY5Y. The earliest detectable apoptotic event in this system is the rapid depolarization of mitochondrial membranes, occurring immediately upon treatment of cells with PrP-(106-126). Subsequent to this, cytochrome c release and caspase activation were observed. Caspase inhibitors demonstrated that while the peptide activates caspases they are not an absolute requirement for apoptosis. Parallel to caspase activation, PrP-(106-126) was also observed to trigger a rise in intracellular calcium through release of mitochondrial calcium stores. This leads to the activation of calpains, another family of proteases. A calpain inhibitor demonstrated that while calpains are activated by the peptide they also are not an absolute requirement for apoptosis. Interestingly a combination of caspase and calpain inhibitors significantly inhibited apoptosis. This illustrates alternative pathways leading to apoptosis via caspases and calpains and that blocking both pathways is required to inhibit apoptosis. These results implicate the mitochondrion as a primary site of action of PrP-(106-126).	Natl Univ Ireland Univ Coll Cork, Tumor Biol Lab, Dept Biochem, Cork, Ireland	University College Cork	Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Tumor Biol Lab, Dept Biochem, Cork, Ireland.	t.cotter@ucc.ie		Cotter, Thomas/0000-0003-4626-5613				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Baumann MH, 2000, BIOCHEM J, V349, P77, DOI 10.1042/0264-6021:3490077; BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1997, INT J DEV NEUROSCI, V15, P961, DOI 10.1016/S0736-5748(97)00042-7; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARMODY RJ, 1998, SEPSIS, V2, P9; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; FAIRBAIRN DW, 1994, FEMS MICROBIOL LETT, V115, P341, DOI 10.1111/j.1574-6968.1994.tb06661.x; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Gorman AM, 1996, J NEUROL SCI, V139, P45, DOI 10.1016/0022-510X(96)00097-4; Gray F, 1999, J NEUROPATH EXP NEUR, V58, P321, DOI 10.1097/00005072-199904000-00002; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Gupta PD, 1999, CYTOBIOS, V99, P83; Herms JW, 2000, J NEUROCHEM, V75, P1487, DOI 10.1046/j.1471-4159.2000.0751487.x; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Ishihara I, 2000, NEUROSCI LETT, V279, P97, DOI 10.1016/S0304-3940(99)00960-X; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kawahara M, 2000, BRAIN RES BULL, V53, P389, DOI 10.1016/S0361-9230(00)00370-1; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kowaltowski AJ, 2000, BRAZ J MED BIOL RES, V33, P241, DOI 10.1590/S0100-879X2000000200014; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lin MX, 1997, J BIOL CHEM, V272, P44; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; McHattie SJ, 1999, J NEUROCYTOL, V28, P149, DOI 10.1023/A:1007028323666; MCKENNA SL, 1999, CELL ENG; Mikol J, 1999, BIOMED PHARMACOTHER, V53, P19, DOI 10.1016/S0753-3322(99)80056-0; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Paradis E, 1996, J NEUROSCI, V16, P7533; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Perkins CL, 2000, CANCER RES, V60, P1645; Perovic S, 1997, EXP NEUROL, V147, P518, DOI 10.1006/exnr.1997.6559; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Saez-Valero J, 2000, NEUROSCI LETT, V293, P207, DOI 10.1016/S0304-3940(00)01532-9; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Silei V, 1999, BRAIN RES, V818, P168, DOI 10.1016/S0006-8993(98)01272-4; SIMS NR, 1987, BRAIN RES, V436, P30, DOI 10.1016/0006-8993(87)91553-8; SINGER TP, 1987, J NEUROCHEM, V49, P1, DOI 10.1111/j.1471-4159.1987.tb03384.x; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Thellung S, 2000, NEUROBIOL DIS, V7, P299, DOI 10.1006/nbdi.2000.0301; Tombal B, 2000, PROSTATE, V43, P303; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	75	120	123	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43516	43523		10.1074/jbc.M103894200	http://dx.doi.org/10.1074/jbc.M103894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11533027	hybrid			2022-12-25	WOS:000172297700007
J	Ajuh, P; Sleeman, J; Chusainow, J; Lamond, AI				Ajuh, P; Sleeman, J; Chusainow, J; Lamond, AI			A direct interaction between the carboxyl-terminal region of CDC5L, and the WD40 domain of PLRG1 is essential for pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRP19P-ASSOCIATED COMPLEX; PROTEIN; IDENTIFICATION; COMPONENT; REPEAT; DISSOCIATION; SEPARATION; HOMOLOG; PLANT; PRL1	The human proteins CDC5L (hCDC5) and PLRG1 are both highly conserved components of a multiprotein complex that is a subunit of the spliceosome. The respective homologues in yeast of both proteins are also associated with a sub-spliceosomal multiprotein complex that has been shown to be important for pre-mRNA splicing. We show that these two human proteins are associated in vivo and will interact directly in vitro. The regions containing the interacting domains in both proteins have been identified. Our results indicate that the carboxyl-terminal region of CDC5L, and the WD40 domain of PLRG1 are essential for direct interaction between both proteins. By using a bacterially expressed mutant protein, containing the PLRG1 interacting domain in CDC5L, we show that the CDC5L-PLRG1 interaction in HeLa nuclear extract can be disrupted causing pre-mRNA splicing to be inhibited. Thus, a direct interaction between the CDC5L protein and PLRG1 in the CDC5L, complex is essential for pre-mRNA splicing progression.	Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Lamond, AI (corresponding author), Univ Dundee, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	a.i.lamond@dundee.ac.uk	/F-4368-2012	/0000-0003-0351-4579; Lamond, Angus/0000-0001-6204-6045; Sleeman, Judith/0000-0003-0345-6508				Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Bhalerao RP, 1999, P NATL ACAD SCI USA, V96, P5322, DOI 10.1073/pnas.96.9.5322; Burns CG, 1999, P NATL ACAD SCI USA, V96, P13789, DOI 10.1073/pnas.96.24.13789; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Janda L, 1996, J BACTERIOL, V178, P1487, DOI 10.1128/jb.178.5.1487-1489.1996; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAMER A, 1995, PREMRNA PROCESSING, P39; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; Lei XH, 2000, J CELL SCI, V113, P4523; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561; Potashkin J, 1998, CURR GENET, V34, P153, DOI 10.1007/s002940050381; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; Xia G, 1996, PLANT J, V10, P761, DOI 10.1046/j.1365-313X.1996.10040761.x	34	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42370	42381		10.1074/jbc.M105453200	http://dx.doi.org/10.1074/jbc.M105453200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11544257	hybrid			2022-12-25	WOS:000172450400109
J	Ceccarelli, E; Mann, C				Ceccarelli, E; Mann, C			A Cdc28 mutant uncouples G(1) cyclin phosphorylation and ubiquitination from G(1) cyclin proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION LOOP PHOSPHORYLATION; CDK-DEPENDENT PHOSPHORYLATION; MULTIUBIQUITIN-CHAIN-BINDING; XENOPUS SUC1/CKS PROTEIN; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MUTATIONAL ANALYSIS; ENZYME CDC34; CLN3 CYCLIN; KINASE CAK	Proteolysis of the yeast G, cyclins is triggered by their Cdc28-dependent phosphorylation. Phosphorylated Cln1 and Cln2 are ubiquitinated by the SCF-Grr1 complex and then degraded by the 26 S proteasome. In this study, we identified a cak1 allele in a genetic screen for mutants that stabilize the yeast G(1) cyclins. Further characterization showed that Cln2HA was hypophosphorylated, unable to bind Cdc28, and stabilized in cak1 mutants at the restrictive temperature. Hypophosphorylation of Cln2HA could thus explain its stabilization. To test this possibility, we expressed a Cak1-independent mutant of Cdc28 (Cdc28-43244) in cak1 mutants and found that Cln2HA phosphorylation was restored, but surprisingly, the phospho-Cln2HA was stabilized. When bound to Cdc28-43244, Cln2HA was recognized and polyubiquitinated by SCF-Grr1. The Cdc28-43244 mutant thus reveals an unexpected complexity in the degradation of polyubiquitinated Cln2HA by the proteasome.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Mann, C (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France.			Mann, Carl/0000-0001-7212-1512				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Cross FR, 1998, MOL CELL BIOL, V18, P2923, DOI 10.1128/MCB.18.5.2923; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Cross FR, 2000, GENETICS, V154, P1549; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kishi T, 1998, J CELL SCI, V111, P3655; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lim HH, 1996, MOL CELL BIOL, V16, P4573; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Sambrook J., 2002, MOL CLONING LAB MANU; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679	48	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41725	41732		10.1074/jbc.M107087200	http://dx.doi.org/10.1074/jbc.M107087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527976	hybrid			2022-12-25	WOS:000172450400026
J	Gallagher, PG; Sabatino, DE; Basseres, DS; Nilson, DM; Wong, C; Cline, AP; Garrett, LJ; Bodine, DM				Gallagher, PG; Sabatino, DE; Basseres, DS; Nilson, DM; Wong, C; Cline, AP; Garrett, LJ; Bodine, DM			Erythrocyte ankyrin promoter mutations associated with recessive hereditary spherocytosis cause significant abnormalities in ankyrin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BLOCKING ACTIVITY; BETA-SPECTRIN GENE; TRANSGENIC MICE; GLOBIN GENE; DEFICIENCY; CELLS; DOMINANT; CTCF; METHYLATION; PROTEINS	Ankyrin defects are the most common cause of hereditary spherocytosis (HS). In several kindreds with recessive, ankyrin-deficient HS, mutations have been identified in the ankyrin promoter that have been proposed to decrease ankyrin synthesis. We analyzed the effects of two mutations, - 108T to C and - 108T to C in cis with - 153G to A, on ankyrin expression. No difference between wild type and mutant promoters was demonstrated in transfection or gel shift assays in vitro. Transgenic mice with a wild type ankyrin promoter linked to a human (A)gamma -globin gene expressed gamma -globin in 100% of erythrocytes in a copy number-dependent, position-independent manner. Transgenic mice with the mutant -108 promoter demonstrated variegated gamma -globin expression, but showed copy number-dependent and position-independent expression similar to wild type. Severe effects in ankyrin expression were seen in mice with the linked -108/-153 mutations. Three transgenic lines had undetectable levels of (A)gamma -globin mRNA, indicating position-dependent expression, and four lines expressed significantly lower levels of (A)gamma -globin mRNA than wild type. Two of four expressing lines showed variegated gamma -globin expression, and there was no correlation between transgene copy number and RNA level, indicating copy number-independent expression. These data are the first demonstration of functional defects caused by HS-related, ankyrin gene promoter mutations.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; NGHRI, Genet & Mol Biol Branch, Hematopoiesis Sect, NIH, Bethesda, MD 20892 USA; Univ Estadual Campinas, Hemoctr, BR-13083970 Campinas, SP, Brazil	Yale University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Universidade Estadual de Campinas	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.		Bassères, Daniela S/C-6623-2013	Bassères, Daniela S/0000-0001-7745-3567				AGRE P, 1982, NEW ENGL J MED, V306, P1155, DOI 10.1056/NEJM198205133061906; AGRE P, 1986, NEW ENGL J MED, V315, P1579, DOI 10.1056/NEJM198612183152504; AGRE P, 1985, NATURE, V314, P380, DOI 10.1038/314380a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BECKER PS, 1993, J CLIN INVEST, V92, P612, DOI 10.1172/JCI116628; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BENNETT V, 1992, J BIOL CHEM, V267, P8703; del Giudice EM, 2001, BRIT J HAEMATOL, V112, P42; delGiudice EM, 1996, BRIT J HAEMATOL, V93, P828; Dhermy D, 1998, BLOOD CELL MOL DIS, V24, P251, DOI 10.1006/bcmd.1998.0190; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; EBER SW, 1992, ANN HEMATOL, V64, P88, DOI 10.1007/BF01715351; Gallagher PG, 1998, BLOOD CELL MOL DIS, V24, P539, DOI 10.1006/bcmd.1998.0217; Gallagher PG, 2000, BLOOD, V96, P1136, DOI 10.1182/blood.V96.3.1136.015k48_1136_1143; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; Gallagher PG, 1998, BLOOD, V92, p300A; GALLAGHER PG, 1999, HEMATOLOGY BASIC PRI, P576; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GODAL HC, 1981, SCAND J HAEMATOL, V27, P30; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HOGAN B, 1986, MANIPULATING MOUSE E; Iolascon A, 1998, HAEMATOLOGICA, V83, P240; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; Leite R C, 2000, Hum Mutat, V16, P529, DOI 10.1002/1098-1004(200012)16:6<529::AID-HUMU13>3.0.CO;2-N; MASON P, 1993, GENE TRANSCRIPTION P, P243; Morle L, 1997, AM J HEMATOL, V54, P242, DOI 10.1002/(SICI)1096-8652(199703)54:3<242::AID-AJH11>3.0.CO;2-F; Persons DA, 2001, BLOOD, V97, P3275, DOI 10.1182/blood.V97.10.3275; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; Randon J, 1997, BRIT J HAEMATOL, V96, P500, DOI 10.1046/j.1365-2141.1997.d01-2074.x; SAAD STO, 1994, BRIT J HAEMATOL, V88, P295, DOI 10.1111/j.1365-2141.1994.tb05021.x; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sabatino DE, 2000, J BIOL CHEM, V275, P28549, DOI 10.1074/jbc.M004043200; SAVVIDES P, 1993, BLOOD, V82, P2953; THORPE SJ, 1994, BRIT J HAEMATOL, V87, P125, DOI 10.1111/j.1365-2141.1994.tb04881.x; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; WHITFIELD CF, 1991, BLOOD, V78, P3043; Wichterle H, 1996, J CLIN INVEST, V98, P2300, DOI 10.1172/JCI119041; Yawata Y, 2000, INT J HEMATOL, V71, P118	40	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41683	41689		10.1074/jbc.M105844200	http://dx.doi.org/10.1074/jbc.M105844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527968	hybrid			2022-12-25	WOS:000172450400021
J	Ostrom, RS; Gregorian, C; Drenan, RM; Xiang, Y; Regan, JW; Insel, PA				Ostrom, RS; Gregorian, C; Drenan, RM; Xiang, Y; Regan, JW; Insel, PA			Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; NITRIC-OXIDE SYNTHASE; CARDIAC MYOCYTES; BETA(2)-ADRENERGIC RECEPTOR; G-PROTEIN; VENTRICULAR MYOCYTES; TRANSGENIC MICE; PHOSPHORYLATION; CA2+; STIMULATION	Recent evidence suggests that many signaling molecules localize in microdomains of the plasma membrane, particularly caveolae. In this study, overexpression of adenylyl cyclase was used as a functional probe of G protein-coupled receptor (GPCR) compartmentation. We found that three endogenous receptors in neonatal rat cardiomyocytes couple with different levels of efficiency to the activation of adenylyl cyclase type 6 (AC6), which localizes to caveolin-rich membrane fractions. Overexpression of AC6 enhanced the maximal cAMP response to beta (1)-adrenergic receptor (beta (1)AR)-selective activation 3.7-fold, to beta (2)AR-selective activation only 1.6-fold and to prostaglandin E-2 (PGE(2)) not at all. Therefore, the rank order of efficacy in coupling to AC6 is beta (1)AR > beta (2)AR > prostaglandin E-2 receptor (EP2R). beta (2)AR coupling efficiency was greater when we overexpressed the receptor or blocked its desensitization by expressing beta ARKct, an inhibitor of G protein-coupled receptor kinase activation, but was not significantly greater when cells were treated with pertussis toxin. Assessment of receptor and AC expression indicated co-localization of AC5/6,beta (1)AR, and beta (2)AR, but not EP2R, in caveolin-rich membranes and caveolin-3 immunoprecipitates, likely explaining the observed activation of AC6 by beta AR subtypes but lack thereof by PGE(2). When cardiomyocytes were stimulated with a beta AR agonist, beta (2)AR were no longer found in caveolin-3 immunoprecipitates; an effect that was blocked by expression of beta ARKet. Thus, agonist-induced translocation of beta (2)AR out of caveolae causes a sequestration of receptor from effector and likely contributes to the lower efficacy of beta (2)AR coupling to AC6 as compared with beta (1)AR, which do not similarly translocate. Therefore, spatial co-localization is a ey determinant of efficiency of coupling by particular extracellular signals to activation of GPCR-linked effectors.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Stanford University; University of Arizona		pinsel@ucsd.edu	Ostrom, Rennolds/AAG-9694-2019	Ostrom, Rennolds/0000-0002-7204-0357	NHLBI NIH HHS [HL07444, HL63885, HL53773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773, R01HL063885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BROOKER G, 1973, SCIENCE, V182, P933, DOI 10.1126/science.182.4115.933; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Fagan KA, 2000, J BIOL CHEM, V275, P26530, DOI 10.1074/jbc.M001369200; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Lipskaia L, 2000, CIRC RES, V86, P795, DOI 10.1161/01.RES.86.7.795; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Steinberg SF, 1999, CIRC RES, V85, P1101; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Tepe NM, 1999, BIOCHEMISTRY-US, V38, P16706, DOI 10.1021/bi991619k; XIAO RP, 1994, J BIOL CHEM, V269, P19151; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yatani A, 1999, CELL SIGNAL, V11, P337, DOI 10.1016/S0898-6568(98)00050-3	34	206	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42063	42069		10.1074/jbc.M105348200	http://dx.doi.org/10.1074/jbc.M105348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533056	Green Published, hybrid			2022-12-25	WOS:000172450400071
J	Cervoni, N; Szyf, M				Cervoni, N; Szyf, M			Demethylase activity is directed by histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; TRANSCRIPTIONAL REGULATION; DEACETYLASE COMPLEX; GENE; CHROMATIN; PROTEIN; ACTIVATION; REPRESSION; INHIBITION; MECHANISM	Mammalian genomes are compartmentalized into dense inactive chromatin that is hypermethylated and active open chromatin that is hypomethylated. It is generally accepted that this bimodal pattern of methylation is established during development and is then faithfully inherited through subsequent cell divisions by a maintenance DNA methyltransferase (DNMT1). The pattern of methylation is believed to direct local histone acetylation states. In contrast to this well accepted consensus, we show here using a transient transfection model that an active demethylase is involved in shaping patterns of methylation in somatic cells. Demethylase activity is directed by the state of histone acetylation, and therefore, the resulting methylation pattern is determined by local histone acetylation states contrary to the accepted model. Our data support a new model suggesting that the pattern of methylation is maintained by a dynamic balance of methylation and demethylation activities and the local state of histone acetylation. This provides a simple mechanism for explaining why active genes are not methylated.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 1999, J BIOL CHEM, V274, P8363, DOI 10.1074/jbc.274.13.8363; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Crane-Robinson C, 1999, METHOD ENZYMOL, V304, P533; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lin IG, 2000, MOL CELL BIOL, V20, P2343, DOI 10.1128/MCB.20.7.2343-2349.2000; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen TT, 2000, PROSTATE, V43, P233; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; RAMAIN P, 1986, CELL, V45, P545, DOI 10.1016/0092-8674(86)90286-2; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1977, P NATL ACAD SCI USA, V74, P2725, DOI 10.1073/pnas.74.7.2725; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Stunkel W, 2001, J BIOL CHEM, V276, P20743, DOI 10.1074/jbc.M010967200; SUN YL, 1986, EMBO J, V5, P293, DOI 10.1002/j.1460-2075.1986.tb04212.x; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	37	230	247	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40778	40787		10.1074/jbc.M103921200	http://dx.doi.org/10.1074/jbc.M103921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524416	hybrid			2022-12-25	WOS:000171925600055
J	Knipp, M; Charnock, JM; Garner, CD; Vasak, M				Knipp, M; Charnock, JM; Garner, CD; Vasak, M			Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain - Zn(II) release activates DDAH-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAY-ABSORPTION-SPECTROSCOPY; ZINC-BINDING SITES; N-G,N-G-DIMETHYLARGININE DIMETHYLAMINOHYDROLASE; ENDOTHELIAL DYSFUNCTION; MONOCLONAL-ANTIBODY; PROTEIN; METHYLARGININES; INHIBITOR; DISEASE	L-N-omega,N-omega-Dimethylarginine dimethylaminohydrolase-1 (DDAH-1) is a Zn(II)-containing enzyme that, through hydrolysis of side-chain methylated L-arginines, regulates the activity of nitric-oxide synthase. Herein we report the structural and functional properties of the Zn(II)-binding site in DDAH-1 from bovine brain. Activity measurements of the native and metal-free enzyme have revealed that the endogenously bound Zn(II) inhibits the enzyme. Native DDAH-1 could be fully or partially activated using various concentrations of phosphate, imidazole, histidine, and histamine, a process that is paralleled by the release of Zn(II). The slow activation of the enzyme by the bulky complexing agents EDTA and 1,10-phenantroline suggests that the Zn(II)-binding site is partially buried in the protein structure. The apparent Zn(II)-dissociation constant of 4.2 nM, determined by F-19 NMR using the chelator 5F-BAPTA (1,2-bis(2-amino-5-fluorophenoxy)ethane-N,N,N',N'-tetraacetic acid), lies in the range of intracellular free Zn(II) concentrations. These results suggest a regulatory role for the Zn(II)binding site. The coordination environment of the Zn(II) in DDAH-1 has been examined by Zn K-edge x-ray absorption spectroscopy. The extended x-ray absorption fine structure observed is consistent with Zn(II) being coordinated by 2 S and 2 N (or O) atoms. The biological implications of these findings are discussed.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Manchester, Dept Chem, Manchester M13 9PL, Lancs, England; Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England	University of Zurich; University of Manchester; University of Nottingham	Vasak, M (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	mvasak@bioc.unizh.ch						Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; AULD DS, 1988, METHOD ENZYMOL, V158, P13, DOI 10.1016/0076-6879(88)58043-6; BINSTED N, 1998, CLRC DARESBURY LAB E; Birdsey GM, 2000, ACTA PHYSIOL SCAND, V168, P73; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Bogumil R, 1998, BIOCHEMISTRY-US, V37, P4791, DOI 10.1021/bi972312t; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUSH AI, 1993, J BIOL CHEM, V268, P16109; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; Cooke JP, 2000, ARTERIOSCL THROM VAS, V20, P2032, DOI 10.1161/01.ATV.20.9.2032; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Fickling SA, 1993, ENDOTHELIUM, V1, P137; Frausto da Silva J.J.R., 1991, BIOL CHEM ELEMENTS I; Fundel SM, 1996, FEBS LETT, V395, P33, DOI 10.1016/0014-5793(96)00997-0; GARNER CD, 1991, ADV INORG CHEM, V36, P303, DOI 10.1016/S0898-8838(08)60042-2; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Grover R, 1999, CRIT CARE MED, V27, P913, DOI 10.1097/00003246-199905000-00025; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Kielstein JT, 1999, J AM SOC NEPHROL, V10, P594; KIMOTO M, 1993, ARCH BIOCHEM BIOPHYS, V300, P657, DOI 10.1006/abbi.1993.1091; Kimoto M, 1997, BBA-PROTEIN STRUCT M, V1337, P6, DOI 10.1016/S0167-4838(96)00196-3; KIMOTO M, 1995, J BIOCHEM-TOKYO, V117, P237, DOI 10.1093/jb/117.2.237; Kimoto M, 1998, EUR J BIOCHEM, V258, P863, DOI 10.1046/j.1432-1327.1998.2580863.x; Knipp M, 2000, ANAL BIOCHEM, V286, P257, DOI 10.1006/abio.2000.4805; KOTANI K, 1992, J NEUROCHEM, V58, P1127, DOI 10.1111/j.1471-4159.1992.tb09371.x; KROTKIEWSKA B, 1992, INT J BIOCHEM, V24, P1501, DOI 10.1016/0020-711X(92)90078-F; Lassen LH, 1998, CEPHALALGIA, V18, P27, DOI 10.1046/j.1468-2982.1998.1801027.x; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; LONG GJ, 1994, J BIOL CHEM, V269, P834; MacAllister RJ, 1996, BRIT J PHARMACOL, V119, P1533, DOI 10.1111/j.1476-5381.1996.tb16069.x; MCDERMOTT JR, 1976, BIOCHEM J, V154, P179, DOI 10.1042/bj1540179; Miyazaki H, 1999, CIRCULATION, V99, P1141, DOI 10.1161/01.CIR.99.9.1141; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Nakagomi S, 1999, EUR J NEUROSCI, V11, P2160, DOI 10.1046/j.1460-9568.1999.00634.x; OGAWA T, 1989, J BIOL CHEM, V264, P10205; OGAWA T, 1987, BIOCHEM BIOPH RES CO, V148, P671, DOI 10.1016/0006-291X(87)90929-6; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Smith MA, 1998, FREE RADICAL BIO MED, V25, P898, DOI 10.1016/S0891-5849(98)00119-1; Tojo A, 1997, KIDNEY INT, V52, P1593, DOI 10.1038/ki.1997.490; Tran CTL, 2000, GENOMICS, V68, P101, DOI 10.1006/geno.2000.6262; Tsao PS, 1998, J CARDIOVASC PHARM, V32, pS48; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Tsikas D, 2000, FEBS LETT, V478, P1, DOI 10.1016/S0014-5793(00)01686-0; UENO S, 1992, J NEUROCHEM, V59, P2012; VALLANCE P, 1992, LANCET, V339, P572; VANSOMMEREN APG, 1993, J CHROMATOGR, V639, P23, DOI 10.1016/0021-9673(93)83084-6; Wilcox CS, 1998, CURR OPIN NEPHROL HY, V7, P443; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001	64	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40449	40456		10.1074/jbc.M104056200	http://dx.doi.org/10.1074/jbc.M104056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546769	hybrid			2022-12-25	WOS:000171925600014
J	Moudy, R; Manning, TJ; Beckers, CJ				Moudy, R; Manning, TJ; Beckers, CJ			The loss of cytoplasmic potassium upon host cell breakdown triggers egress of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOPHOROUS VACUOLE; MICRONEME PROTEIN; INVASION; MOBILIZATION; PARASITES; SURFACE; BINDS; EXIT	The ability of intracellular parasites to monitor the viability of their host cells is essential for their survival. The protozoan parasite Toxoplasma gondii actively invades nucleated animal cells and replicates in their cytoplasm. Two to 3 days after infection, the parasite-filled host cell breaks down and the parasites leave to initiate infection of a new cell. Parasite egress from the host cell is triggered by rupture of the host plasma membrane and the ensuing reduction in the concentration of cytoplasmic potassium. The many other changes in host cell composition do not appear be used as triggers. The reduction in the host cell [K+] appears to activate a phospholipase C activity in Toxoplasma that, in turn, causes an increase in cytoplasmic [Ca2+] in the parasite. The latter appears to be necessary and sufficient for inducing egress, as buffering of cytoplasmic Ca2+ blocks egress and calcium ionophores circumvent the need for a reduction of host cell [K+] and parasite phospholipase C activation. The increase in [Ca2+]c brings about egress by the activation of at least two signaling pathways: the protein kinase TgCDPK1 and the calmodulin-dependent protein phosphatase calcineurin.	Univ Alabama, Div Geog Med, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckers, CJ (corresponding author), Univ Alabama, Div Geog Med, Dept Med, Birmingham, AL 35294 USA.				NIAID NIH HHS [AI41765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041765, R29AI041765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Black MW, 2000, MOL CELL BIOL, V20, P9399, DOI 10.1128/MCB.20.24.9399-9408.2000; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; ENDO T, 1982, EXP PARASITOL, V53, P179, DOI 10.1016/0014-4894(82)90059-5; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; FRENKEL JK, 1988, PARASITOL TODAY, V4, P273, DOI 10.1016/0169-4758(88)90018-X; Garcia-Reguet N, 2000, CELL MICROBIOL, V2, P353, DOI 10.1046/j.1462-5822.2000.00064.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; Kieschnick H, 2001, J BIOL CHEM, V276, P12369, DOI 10.1074/jbc.M011045200; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Manning TJ, 1997, GLIA, V20, P163, DOI 10.1002/(SICI)1098-1136(199706)20:2<163::AID-GLIA8>3.0.CO;2-A; Mordue DG, 1999, J EXP MED, V190, P1783, DOI 10.1084/jem.190.12.1783; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; Silverman JA, 1998, J BIOL CHEM, V273, P12352, DOI 10.1074/jbc.273.20.12352; Stommel EW, 1997, EXP PARASITOL, V87, P88, DOI 10.1006/expr.1997.4187; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856	21	159	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41492	41501		10.1074/jbc.M106154200	http://dx.doi.org/10.1074/jbc.M106154200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526113	hybrid			2022-12-25	WOS:000171925600147
J	Rizos, H; Darmanian, AP; Holland, EA; Mann, GJ; Kefford, RF				Rizos, H; Darmanian, AP; Holland, EA; Mann, GJ; Kefford, RF			Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14(ARF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P16(INK4A); MULTIPLE PRIMARY MELANOMAS; CELL-CYCLE ARREST; CUTANEOUS MELANOMA; FAMILIAL MELANOMA; GERMLINE MUTATIONS; CDKN2 GENE; NUCLEOLAR LOCALIZATION; MALIGNANT-MELANOMA; LUNG CANCERS	The INK4a/ARF locus encodes two cell cycle regulatory proteins, the cy clin-dependent kinase inhibitor, p16(INK4a), and the p53 activator, p14(ARF). Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Many of these mutations specifically impair p16(INK4a), whereas mutations uniquely targeting p14(ARF) are rare. Nevertheless, the importance of p14(ARF) has not been excluded because more than 40% of INK4a/ARF alterations affect p16(INK4a) and p14(ARF). We now report that p14(ARF) is functionally impaired in melanoma kindreds carrying INK4a/ARF mutations. Of the seven INK4a/ARF mutations tested, three altered the subcellular distribution of p14(ARF) and diminished the ability of p14(ARF) to activate the p53 pathway. This work establishes the importance of p14(ARF) in melanoma predisposition.	Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Rizos, H (corresponding author), Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.		Mann, Graham J/G-4758-2014; Rizos, Helen/AAE-5010-2020	Mann, Graham J/0000-0003-1301-405X; Rizos, Helen/0000-0002-2094-9198; Kefford, Richard/0000-0001-9251-9229				ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Bartkova J, 1996, CANCER RES, V56, P5475; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fargnoli MC, 1998, J INVEST DERMATOL, V111, P1202, DOI 10.1046/j.1523-1747.1998.00412.x; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Holland EA, 1999, GENE CHROMOSOME CANC, V25, P339, DOI 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MONTANO X, 1994, ONCOGENE, V9, P1455; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Piccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Platz A, 1996, BRIT J CANCER, V73, P344, DOI 10.1038/bjc.1996.59; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PUIG S, 2001, 5 INT C MEL, V11, pS69; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Walker GJ, 1999, INT J CANCER, V82, P305, DOI 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO;2-Z; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; YANG R, 1995, CANCER RES, V55, P2503; Yarbrough WG, 1999, J NATL CANCER I, V91, P1569, DOI 10.1093/jnci/91.18.1569; YEAGER T, 1995, CANCER RES, V55, P493; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; ZHAN GY, 1999, MOL CELL, V3, P579; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	64	88	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41424	41434		10.1074/jbc.M105299200	http://dx.doi.org/10.1074/jbc.M105299200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518711	hybrid			2022-12-25	WOS:000171925600139
J	Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Lund-Katz, S; Phillips, MC				Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Lund-Katz, S; Phillips, MC			Lipid binding-induced conformational change in human apolipoprotein E - Evidence for two lipid-bound states on spherical particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; AMPHIPATHIC HELICAL PEPTIDES; HUMAN PLASMA-LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; N-TERMINAL DOMAIN; CHYLOMICRON REMNANTS; UNILAMELLAR VESICLES; A-I; CHOLESTEROL	Apolipoprotein (apo) E contains two structural domains, a 22-kDa (amino acids 1-191) N-terminal domain and a 10-kDa (amino acids 223-299) C-terminal domain. To better understand apoE-lipid interactions on lipoprotein surfaces, we determined the thermodynamic parameters for binding of apoE4 and its 22- and 10-kDa fragments to triolein-egg phosphatidylcholine emulsions using a centrifugation assay and titration calorimetry. In both large (120 nm) and small (35 nm) emulsion particles, the binding affinities decreased in the order 10-kDa fragment approximate to 34-kDa intact apoE4 > 22-kDa fragment, whereas the maximal binding capacity of intact apoE4 was much larger than those of the 22- and 10-kDa fragments. These results suggest that at maximal binding, the binding behavior of intact apoE4 is different from that of each fragment and that the N-terminal domain of intact apoE4 does not contact lipid. Isothermal titration calorimetry measurements showed that apoE binding to emulsions was an exothermic process. Binding to large particles is enthalpically driven, and binding to small particles is entropically driven. At a low surface concentration of protein, the binding enthalpy of intact apoE4 (-69 kcal/mol) was approximately equal to the sum of the enthalpies for the 22- and 10-kDa fragments, indicating that both the 22- and 10-kDa fragments interact with lipids. In a saturated condition, however, the binding enthalpy of intact apoE4 (-39 kcal/mol) was less exothermic and rather similar to that of each fragment, supporting the hypothesis that only the C-terminal domain of intact apoE4 binds to lipid. We conclude that the N-terminal four-helix bundle can adopt either open or closed conformations, depending upon the surface concentration of emulsion-bound apoE.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Abramson Res Bldg,Suite 302,3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083, P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633, HL56083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITO H, 2001, LANGMUIR, V17, P2528; BORENSZTAJN J, 1988, J LIPID RES, V29, P1087; BRASAEMLE DL, 1993, J LIPID RES, V34, P455; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P1093; Derksen A, 1996, BIOPHYS J, V70, P330, DOI 10.1016/S0006-3495(96)79574-7; DERKSEN A, 1989, BIOCHEMISTRY-US, V28, P900, DOI 10.1021/bi00428a074; Dong LM, 1998, J LIPID RES, V39, P1173; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Gazzara JA, 1997, J LIPID RES, V38, P2147; Gazzara JA, 1997, J LIPID RES, V38, P2134; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Kypreos KE, 2001, BIOCHEMISTRY-US, V40, P6027, DOI 10.1021/bi002414a; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; Massey JB, 1998, BIOPHYS J, V74, P869, DOI 10.1016/S0006-3495(98)74010-X; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Nagle JF, 2000, CURR OPIN STRUC BIOL, V10, P474, DOI 10.1016/S0959-440X(00)00117-2; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Saito H, 1996, J BIOL CHEM, V271, P15515, DOI 10.1074/jbc.271.26.15515; Saito H, 1997, J LIPID RES, V38, P287; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; TAJIMA S, 1983, J BIOL CHEM, V258, P73; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; Wieprecht T, 2000, BIOPHYS CHEM, V85, P187, DOI 10.1016/S0301-4622(00)00120-4; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1985, J LIPID RES, V26, P556; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	49	102	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40949	40954		10.1074/jbc.M106337200	http://dx.doi.org/10.1074/jbc.M106337200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533033	hybrid			2022-12-25	WOS:000171925600077
J	Tong, JF; Killeen, M; Steven, R; Binns, KL; Culotti, J; Pawson, T				Tong, JF; Killeen, M; Steven, R; Binns, KL; Culotti, J; Pawson, T			Netrin stimulates tyrosine phosphorylation of the UNC-5 family of netrin receptors and induces Shp2 binding to the RCM cytodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE GUIDANCE; AXON GUIDANCE; C-ELEGANS; CAENORHABDITIS-ELEGANS; COLORECTAL-CANCER; GENETIC-ANALYSIS; EPH RECEPTOR; SIGNAL-TRANSDUCTION; LIGAND ACTIVATION; DROSOPHILA EMBRYO	Caenorhabditis elegans UNC-5 and its mammalian homologues such as RCM are receptors for the secreted axon guidance cue UNC-6/netrin and are required to mediate the repulsive effects of UNC-6/netrin on growth cones. We find that C. elegans UNC-5 and mouse RCM are phosphorylated on tyrosine in vivo. C. elegans UNC-5 tyrosine phosphorylation is reduced in unc-6 null mutants, and RCM tyrosine phosphorylation is induced by netrin-1 in transfected HEK-293 cells, demonstrating that phosphorylation of UNC-5 proteins is enhanced by UNC-6/netrin stimulation in both worms and mammalian cells. An activated Src tyrosine kinase induces phosphorylation of RCM at multiple cytoplasmic tyrosine residues creating potential binding sites for cytoplasmic signaling proteins. Indeed, the NH2-terminal SH2 domain of the Shp2 tyrosine phosphatase bound specifically to a Tyr(568) RCM phosphopeptide. Furthermore, Shp2 associated with RCM in a netrin-dependent manner in transfected cells, and co-immunoprecipitated with RCM from an embryonic mouse brain lysate. A Y568F mutant RCM receptor failed to bind Shp2 and was more highly phosphorylated on tyrosine than the wild type receptor. These results suggest that netrin-stimulated phosphorylation of RCM Tyr(568) recruits Shp2 to the cell membrane where it can potentially modify RCM phosphorylation and function.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	Pawson@mshri.on.ca	Culotti, Joseph/G-6467-2013; Pawson, Tony J/E-4578-2013; Killeen, Marie/C-1131-2012	Killeen, Marie/0000-0001-9404-4845; Culotti, Joseph/0000-0001-6325-4612				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; BRENNER S, 1974, GENETICS, V77, P71; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, SCIENCE, V281, P706, DOI 10.1126/science.281.5377.706; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Galko MJ, 2000, J BIOL CHEM, V275, P7832, DOI 10.1074/jbc.275.11.7832; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Klein R, 1999, CURR BIOL, V9, pR691, DOI 10.1016/S0960-9822(99)80441-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Merz DC, 2000, J NEUROBIOL, V44, P281, DOI 10.1002/1097-4695(200008)44:2&lt;281::AID-NEU16&gt;3.0.CO;2-4; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Pawson T, 2000, GENE DEV, V14, P1027; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Sun Q, 2000, DEVELOPMENT, V127, P801; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40917	40925		10.1074/jbc.M103872200	http://dx.doi.org/10.1074/jbc.M103872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533026	hybrid			2022-12-25	WOS:000171925600073
J	Filipe, SR; Severina, E; Tomasz, A				Filipe, SR; Severina, E; Tomasz, A			Functional analysis of Streptococcus pneumoniae MurM reveals the region responsible for its specificity in the synthesis of branched cell wall peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-TRANSFORMATION; PENICILLIN RESISTANCE; PEPTIDOGLYCAN; EXPRESSION; COMPETENCE; VARIANTS; STRAINS; MUREIN; MUTANT; DNA	The recently identified murMN operon of Streptococcus pneumoniae encodes enzymes involved in the synthesis of branched structured muropeptides of the pneumococcal cell wall peptidoglycan. Its inactivation was shown to cause production of a peptidoglycan composed exclusively of linear muropeptides and a virtually complete loss of resistance in penicillin-resistant strains. The studies described in this communication follow up these observations in several directions. The substrate of the MurM-catalyzed reaction (addition of alanine or serine) was identified as the lipid-linked N-acetylglucosamine-muramyl pentapeptide. Different murM alleles from several penicillin-resistant S. pneumoniae strains, each with a characteristic branched peptide pattern, were cloned into pLS578, a pneumococcal plasmid capable of replicating in S. pneumoniae, and transformed into the penicillin-susceptible laboratory strain R36A All transformants remained penicillin-susceptible; however, their cell wall composition changed in directions corresponding to the muropeptide pattern of the strain from which the murM allele was derived. This suggests that the muropeptide composition of the pneumococcal cell walls is determined by the particular murM allele carried by the cells. A 30-amino acid long sequence within the MurM protein was shown to be the main determinant of the specificity of the reaction (addition of alanine versus serine).	Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Moscow Region, Russia; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Unit, P-2780 Oeiras, Portugal	Rockefeller University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; Universidade Nova de Lisboa	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.		Filipe, Sergio Raposo/B-9167-2008	Filipe, Sergio Raposo/0000-0002-4485-832X; Tomasz, Alexander/0000-0003-1520-1983	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037275] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI37275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherton D., 1989, TECHNIQUES PROTEIN C, P273; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; Corso A, 1998, MICROB DRUG RESIST, V4, P325, DOI 10.1089/mdr.1998.4.325; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; Filipe SR, 2000, J BACTERIOL, V182, P6798, DOI 10.1128/JB.182.23.6798-6805.2000; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GARCIABUSTOS JF, 1988, J BACTERIOL, V170, P2143, DOI 10.1128/jb.170.5.2143-2147.1988; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; HEDGE SS, 2001, J BIOL CHEM, V276, P6998; KOHLRAUSCH U, 1991, J BACTERIOL, V173, P3425, DOI 10.1128/jb.173.11.3425-3431.1991; Lacks SA, 2000, MOL MICROBIOL, V35, P1089, DOI 10.1046/j.1365-2958.2000.01777.x; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; ORNELASSOARES A, 1994, J BIOL CHEM, V269, P27246; PLAPP R, 1970, J BIOL CHEM, V245, P3675; Pozzi G, 1996, J BACTERIOL, V178, P6087, DOI 10.1128/jb.178.20.6087-6090.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Severin A, 1996, J BACTERIOL, V178, P1788, DOI 10.1128/jb.178.7.1788-1792.1996; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; SEVERIN A, 1992, J BACTERIOL, V174, P5152, DOI 10.1128/JB.174.15.5152-5155.1992; ZIGHELBOIM S, 1980, ANTIMICROB AGENTS CH, V17, P434, DOI 10.1128/AAC.17.3.434	26	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39618	39628		10.1074/jbc.M106425200	http://dx.doi.org/10.1074/jbc.M106425200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11522792	hybrid			2022-12-25	WOS:000171789200017
J	Hayashi, Y; Senba, S; Yazawa, M; Brautigan, DL; Eto, M				Hayashi, Y; Senba, S; Yazawa, M; Brautigan, DL; Eto, M			Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SMOOTH-MUSCLE; MOLECULAR-CLONING; RHO-KINASE; PHOSPHORYLATION; PHOSPHOPROTEIN; IDENTIFICATION; DARPP-32; CPI-17; EXPRESSION	Contractility of smooth muscle and non-muscle micro. filaments involves phosphorylation of myosin II light chain. Myosin light chain phosphatase (MLCP) is specifically inhibited by the protein kinase C-potentiated inhibitor protein of 17 kDa, called CPI-17, as part of Ca2+ sensitization of vascular smooth muscle contraction. Phosphorylation of Thr(38) in CPI-17 enhances inhibitory potency toward MLCP over 1000-fold. In this study we mapped regions of CPI-17 required for inhibition and investigated the mechanism using deletion and point mutants. Deletion of either the N-terminal 34 residues or C-terminal 27 residues gave no change in the IC50 of either phospho- or unphospho-CPI-17. However, further deletion to give CPI-17 proteins of 1-102,1-89,1-76, and 1-67, resulted in much higher IC50 values. The results indicate there is a minimal inhibitory domain between residues 35 and 120. A single Ala substitution at Tyr 41 eliminated phosphorylation-dependent inhibition, and phospho-Thr(38) in the Y41A protein was efficiently dephosphorylated by MLCP itself. The wild type CPI-17 expressed in fibroblast-induced bundling and contraction of actomyosin filaments, whereas expression of the Y41A protein had no obvious effects. Thus, a central domain of CPI-17(35-120) including phospho-Thr(38) is necessary for recognition by myosin phosphatase and Tyr(41) arrests dephosphorylation, thereby producing inhibition.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan	University of Virginia; Hokkaido University	Eto, M (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA.		Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NCI NIH HHS [CA 40042] Funding Source: Medline; NIGMS NIH HHS [GM 56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brautigan DL, 1997, ADV SEC MESS PHOSPH, V31, P113; CONNER JH, 2001, FASEB J, V15; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Eto M, 2001, J BIOL CHEM, V276, P29072, DOI 10.1074/jbc.M103206200; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; Helps NR, 1999, FEBS LETT, V463, P72, DOI 10.1016/S0014-5793(99)01573-2; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; PARK IK, 1994, J BIOL CHEM, V269, P944; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g	37	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39858	39863		10.1074/jbc.M107302200	http://dx.doi.org/10.1074/jbc.M107302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517233	hybrid			2022-12-25	WOS:000171789200048
J	Merlin, D; Sitaraman, S; Liu, X; Eastburn, K; Sun, J; Kucharzik, T; Lewis, B; Madara, JL				Merlin, D; Sitaraman, S; Liu, X; Eastburn, K; Sun, J; Kucharzik, T; Lewis, B; Madara, JL			CD98-mediated links between amino acid transport and beta(1) integrin distribution in polarized columnar epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAINS; PROTEIN; CELLS; CD98; ACTIVATION; THROMBOSPONDIN-1; ALPHA(3)BETA(1); SPECIFICITY; ASSOCIATION; EXPRESSION	In non-polarized cells, CD98 has been shown to both influence beta (1) integrins and heterodimerize with LAT-2, which confers amino acid transport capability on the LAT-2/CD98 heterodimer. Since LAT-2 is most heavily expressed in intestine and CD98 associates with the beta (1) integrin splice form selectively found in such epithelia, we investigated the relationship and polarity of these proteins using the intestinal epithelial model Caco2-BBE. CD98 was found to selectively coimmunoprecipitate with both LAT-2 and beta (1) integrin, and, logically, all three proteins were polarized to the same (basolateral) domain. Furthermore, expression of CD98 in polarized epithelia lacking human CD98 (MDCK cells) disrupted beta (1) integrin surface distribution and cytoskeletal architecture, suggesting that CD98 can influence integrin function. Expression of a CD98 mutant lacking the specific residues conferring LAT-2 binding similarly affected cells, confirming that the latter effect was not due to LAT-2 sequestration. Use of CD98 truncation mutants suggest that a 10-amino acid domain located at the putative cytoplasmic tail/transmembrane domain interface was necessary and sufficient to induce the phenotype change. We conclude that the CD98/LAT-2 amino acid transporter is polarized to the same domain on which beta (1) integrin resides. CD98 appears to associate with beta (1) integrin and, in doing so, may influence its function as revealed by disruption of the outside-in signaling that confers cytoskeletal organization. Furthermore, such findings suggest a link between classic transport events and a critical element of barrier function: integrin-mediated influences on cytoskeletal organization.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathol Unit, Atlanta, GA 30322 USA	Emory University	Merlin, D (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathol Unit, 1639 Pierce Dr, Atlanta, GA 30322 USA.		Sun, Jun/S-7440-2019	Sun, Jun/0000-0001-7465-3133	NIDDK NIH HHS [DK-02802, DK-02831, DK-35932, DK-47662] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002831, R37DK035932, R01DK047662, R01DK035932, K08DK002802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Basson MD, 2000, CELL PHYSIOL BIOCHEM, V10, P27, DOI 10.1159/000016332; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Cali G, 1999, J CELL SCI, V112, P957; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Merlin D, 1998, J CLIN INVEST, V102, P2011, DOI 10.1172/JCI4179; Merlin D, 1998, AM J PHYSIOL-CELL PH, V275, pC484, DOI 10.1152/ajpcell.1998.275.2.C484; MERLIN D, 1995, AM J PHYSIOL-CELL PH, V268, pC1503, DOI 10.1152/ajpcell.1995.268.6.C1503; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Warren AP, 2000, IMMUNOLOGY, V99, P62, DOI 10.1046/j.1365-2567.2000.00953.x; Wilson KE, 1999, J IMMUNOL, V163, P3621; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	29	48	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39282	39289		10.1074/jbc.M105077200	http://dx.doi.org/10.1074/jbc.M105077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507094	hybrid			2022-12-25	WOS:000171673200126
J	Metzler, M; Legendre-Guillemin, V; Gan, L; Chopra, V; Kwok, A; McPherson, PS; Hayden, MR				Metzler, M; Legendre-Guillemin, V; Gan, L; Chopra, V; Kwok, A; McPherson, PS; Hayden, MR			HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN; SPLICE VARIANTS; TERMINAL DOMAIN; COATED PITS; HUNTINGTIN; COMPONENTS; FAMILY; AP-2; IDENTIFICATION; LOCALIZATION	Polyglutamine expansion in huntingtin is the underlying mutation leading to neurodegeneration in Huntington disease. This mutation influences the interaction of huntingtin with different proteins, including huntingtin-interacting protein I (HIP(), in which affinity to bind to mutant huntingtin is profoundly reduced. Here we demonstrate that HIP( colocalizes with markers of clathrin-mediated endocytosis in neuronal cells and is highly enriched on clathrin-coated vesicles (CCVs) purified from brain homogenates. HIP( binds to the clathrin adaptor protein 2 (AP2) and the terminal domain of the clathrin heavy chain, predominantly through a small fragment encompassing amino acids 276-335. This region, which contains consensus clathrin- and AP2-binding sites, functions in conjunction with the coiled-coil domain to target HIP( to CCVs. Expression of various HIP1 fragments leads to a potent block of clathrin-mediated endocytosis. Our findings demonstrate that HIP1 is a novel component of the endocytic machinery.	Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	University of British Columbia; McGill University	Hayden, MR (corresponding author), Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Eckhardt, Erik/G-1567-2010; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kay BK, 1999, PROTEIN SCI, V8, P435; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; MOORE RH, 1995, J CELL SCI, V108, P2983; Morgan JR, 2000, J NEUROSCI, V20, P8667; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933	33	145	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39271	39276		10.1074/jbc.C100401200	http://dx.doi.org/10.1074/jbc.C100401200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11517213	hybrid, Green Accepted			2022-12-25	WOS:000171673200124
J	Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K				Ma, X; Yang, K; Lindblad, P; Egevad, L; Hemminki, K			VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium	ONCOGENE			English	Article						VHL gene; mutation; renal cell carcinoma; linkage disequilibrium; SSCP	TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU-DISEASE; SOMATIC MUTATIONS; CANCER; COMPLEX; DNA; IDENTIFICATION; PROTEIN; LINES	Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR-SSCP and sequencing. In 47 patients (46.1%), 70 different mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P = 0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the alpha domain and the alpha-beta domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41 - 45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C --> T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/ 6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Sundsvall Hosp, Dept Urol, S-85186 Sundsvall, Sweden; Karolinska Hosp, Dept Pathol & Cytol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Hemminki, K (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	kari.hemminki@cnt.ki.se		Egevad, Lars/0000-0001-8531-222X				Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Brauch H, 2000, CANCER RES, V60, P1942; Brauch H, 1999, JNCI-J NATL CANCER I, V91, P854, DOI 10.1093/jnci/91.10.854; Bruning T, 1997, ARCH TOXICOL, V71, P332, DOI 10.1007/s002040050394; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DAY RS, 1987, J CELL SCI, P333; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; GREENBLATT MS, 1994, CANCER RES, V54, P4855; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANDEL JS, 1995, INT J CANCER, V61, P601, DOI 10.1002/ijc.2910610503; MCCREDIE M, 1995, INT J CANCER, V60, P345, DOI 10.1002/ijc.2910600312; McLaughlin JK, 2000, SEMIN ONCOL, V27, P115; MCLAUGHLIN JK, 1995, INT J CANCER, V60, P194, DOI 10.1002/ijc.2910600211; Meyer AJ, 2000, INT J CANCER, V87, P650, DOI 10.1002/1097-0215(20000901)87:5<650::AID-IJC5>3.0.CO;2-3; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Prowse AH, 1997, AM J HUM GENET, V60, P765; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schraml P, 1999, Verh Dtsch Ges Pathol, V83, P218; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Shiao YH, 1998, JNCI-J NATL CANCER I, V90, P1720, DOI 10.1093/jnci/90.22.1720; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; THOENES W, 1990, KLIN WOCHENSCHR, V68, P1102, DOI 10.1007/BF01798060; THOENES W, 1990, EUR UROL, V18, P6; Yang K, 1999, CANCER LETT, V141, P1, DOI 10.1016/S0304-3835(99)00031-2; Yoshida M, 2000, JPN J CANCER RES, V91, P204, DOI 10.1111/j.1349-7006.2000.tb00933.x; Zhuang ZP, 1996, MODERN PATHOL, V9, P838	32	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5393	5400		10.1038/sj.onc.1204692	http://dx.doi.org/10.1038/sj.onc.1204692			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536052				2022-12-25	WOS:000170575500015
J	Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W				Schuringa, JJ; Wojtachnio, K; Hagens, W; Vellenga, E; Buys, CHCM; Hofstra, R; Kruijer, W			MEN2A-RET-induced cellular transformation by activation of STAT3	ONCOGENE			English	Article						Ret tyrosine kinase receptor; MEN2A; STAT3; cellular transformation	RECEPTOR TYROSINE KINASE; RET PROTOONCOGENE; DOCKING SITE; SIGNAL-TRANSDUCTION; GENE; MUTATIONS; ASSOCIATION; SRC; IDENTIFICATION; REQUIRES	The MEN2A oncogene encodes for a constitutive active member of the RET receptor tyrosine kinase family. Here, we report that MEN2A-RET activates Signal Transducer and Activator of Transcription 3 (STAT3) via two YxxV/Q STAT3 docking sites, Tyr752 and Tyr928. MEN2A-RET induces both Tyr705 and Ser727 phosphorylation of STAT3, and STAT3 serine phosphorylation is required for its maximal transcriptional activity. Stable NIH3T3 cell lines expressing both MEN2A-RET and STAT3 alpha but not STAT3 beta, are characterized by enhanced proliferation and cyclin-D1 promoter activity, and enhanced growth in soft agar. These data indicate that malignant cell growth induced by MEN2A-RET involves its activation of STAT3.	Univ Groningen, Biol Ctr Haren, Dept Dev Genet, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Hematol, NL-9751 NN Haren, Netherlands; Univ Groningen, Dept Med Genet, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kruijer, W (corresponding author), Univ Groningen, Biol Ctr Haren, Dept Dev Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	W.Kruijer@biol.rug.nl		Hofstra, Robert/0000-0001-7498-3829				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERBER B, 1994, ONCOGENE, V9, P1295; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Ponder BAJ, 1999, CANCER RES, V59, p1736S; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	51	54	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5350	5358		10.1038/sj.onc.1204715	http://dx.doi.org/10.1038/sj.onc.1204715			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536047				2022-12-25	WOS:000170575500010
J	Molik, S; Karnauchov, I; Weidlich, CE; Herrmann, RG; Klosgen, RB				Molik, S; Karnauchov, I; Weidlich, CE; Herrmann, RG; Klosgen, RB			The Rieske Fe/S protein of the cytochrome b(6)/f complex in chloroplasts - Missing link in the evolution of protein transport pathways in chloroplasts?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; DELTA-PH PATHWAY; BLUE NATIVE ELECTROPHORESIS; OXYGEN-EVOLVING COMPLEX; LUMEN-SIDE DOMAIN; THYLAKOID MEMBRANE; SPINACH-CHLOROPLASTS; PRECURSOR PROTEIN; ESCHERICHIA-COLI; PROTON GRADIENT	The Rieske Fe/S protein, a nuclear-encoded subunit of the cytochrome b(6)/f complex in chloroplasts, is retarded in the stromal space after import into the chloroplast and only slowly translocated further into the thylakoid membrane system. As shown by the sensitivity to nigericin and to specific competitor proteins, thylakoid transport takes place by the Delta pH-dependent TAT pathway. The Rieske protein is an untypical TAT substrate, however. It is only the second integral membrane protein shown to utilize this pathway, and it is the first authentic substrate without a cleavable signal peptide. Transport is instead mediated by the NH2-terminal membrane anchor, which lacks, however, the twin-arginine motif indicative of Delta pH/TAT-dependent transport signals. Furthermore, transport is affected by sodium azide as well as by competitor proteins for the See pathway in chloroplasts, demonstrating for the first time some cross-talk of the two pathways. This might take place in the stroma where the Rieske protein accumulates after import in several complexes of high molecular mass, among which the cpn60 complex is the most prominent. These untypical. features suggest that the Rieske protein represents an intermediate or early state in the evolution of the thylakoidal protein transport pathways.	Univ Halle Wittenberg, Inst Pflanzenphysiol, D-06120 Halle Saale, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany	Martin Luther University Halle Wittenberg; University of Munich	Klosgen, RB (corresponding author), Univ Halle Wittenberg, Inst Pflanzenphysiol, Weinbergweg 10, D-06120 Halle Saale, Germany.							BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BERGHOFER J, 1995, J BIOL CHEM, V270, P18341, DOI 10.1074/jbc.270.31.18341; Berghofer J, 1999, FEBS LETT, V460, P328, DOI 10.1016/S0014-5793(99)01365-4; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Blaudeck N, 2001, J BACTERIOL, V183, P604, DOI 10.1128/JB.183.2.604-610.2001; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Halbig D, 1999, FEBS LETT, V447, P95, DOI 10.1016/S0014-5793(99)00269-0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; KARNAUCHOV I, 1994, J BIOL CHEM, V269, P32871; Karnauchov I, 1997, EUR J BIOCHEM, V249, P497, DOI 10.1111/j.1432-1033.1997.t01-1-00497.x; Karnauchov I, 1997, FEBS LETT, V408, P206, DOI 10.1016/S0014-5793(97)00427-4; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; Klosgen RB, 1997, J PHOTOCH PHOTOBIO B, V38, P1, DOI 10.1016/S1011-1344(96)07408-8; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MADUENO F, 1994, J BIOL CHEM, V269, P17458; MADUENO F, 1992, PLANT MOL BIOL, V20, P289, DOI 10.1007/BF00014496; MANT A, 1994, J BIOL CHEM, V269, P27303; MANT A, 1995, J BIOL CHEM, V270, P23275, DOI 10.1074/jbc.270.40.23275; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Mori H, 1998, J BIOL CHEM, V273, P11405, DOI 10.1074/jbc.273.19.11405; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REUTER W, 1990, FEBS LETT, V273, P155, DOI 10.1016/0014-5793(90)81073-W; SALTER AH, 1992, PLANT MOL BIOL, V20, P569, DOI 10.1007/BF00040617; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; VACHEREAU A, 1989, ANAL BIOCHEM, V179, P206, DOI 10.1016/0003-2697(89)90227-3; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; YUAN JG, 1994, J BIOL CHEM, V269, P18463; Zhang JM, 1996, J BIOL CHEM, V271, P31360, DOI 10.1074/jbc.271.49.31360	56	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42761	42766		10.1074/jbc.M106690200	http://dx.doi.org/10.1074/jbc.M106690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11526115	hybrid			2022-12-25	WOS:000172169300018
J	Shankaranarayanan, P; Chaitidis, P; Kuhn, H; Nigam, S				Shankaranarayanan, P; Chaitidis, P; Kuhn, H; Nigam, S			Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; RETICULOCYTE LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; EXPRESSION; INTERLEUKIN-4; PHOSPHORYLATION; OXYGENATION; 12/15-LIPOXYGENASE; DIFFERENTIATION; IDENTIFICATION	Interleukin-4 (IL-4) induces expression of reticulocyte-type 15-lipoxygenase-1 (15-LOX-1) in various mammalian cells via the Janus kinase/signal transducer and activator of transcription 6 (STAT6) signaling system. We studied the mechanism of 15-LOX-1 induction in A549 lung epithelial cells and found that genistein, a potent tyrosine kinase inhibitor, prevented phopsphorylation of STAT6, its binding to the 15-LOX-1 promoter, and the expression of catalytically active enzyme. In contrast, cycloheximide did not prevent 15-LOX-1 induction. Surprisingly, we found that IL-4 up-regulated the histone acetyltransferase activity of CREB-binding protein (CBP)/p300, which is responsible for acetylation of nuclear histones and STAT6. The acetylation of both proteins appears to be essential for the IL-4-induced signal transduction. cascade, because inhibition of CBP/p300 by the viral wild-type E1A oncoprotein abrogated acetylation of both histones and STAT6 and strongly suppressed transcriptional activation of the 15-LOX-1 gene. Moreover, we found that the inhibition by sodium butyrate of histone deacetylases, which apparently suppress 15-LOX-1 gene transcription, synergistically enhanced the IL-4-stimulated 15-LOX-1 expression. These data suggest that both phosphorylation and acetylation. of STAT6 as well as acetylation of nuclear histones are involved in transcriptional activation of the 15-LOX-1 gene, although these reactions follow differential kinetics. STAT6 phosphorylation proceeds within the first hour of IL-4 stimulation. In contrast, CBP/p300-mediated acetylation requires 9-11 h, and similar kinetics were observed for the expression of the active enzyme. Thus, our results suggest that in the absence of IL-4, nuclear histones may be bound to regulatory elements of the 15-LOX-1 gene, preventing its transcription. IL-4 stimulation causes rapid phosphorylation of STAT6, but its binding to the promoter appears to be prevented by nonacetylated histones. After 9-11 h, when histones become acetylated, STAT6 binding sites may be demasked so that the phosphorylated and acetylated transcription factor can bind to activate gene transcription.	Free Univ Berlin, Med Ctr Benjamin Franklin, Eicosanoid Res Div, Dept Gynaecol, D-12200 Berlin, Germany; Humboldt Univ Charite, Inst Biochem, D-10116 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Nigam, S (corresponding author), Free Univ Berlin, Med Ctr Benjamin Franklin, Eicosanoid Res Div, Dept Gynaecol, Hindenburgdamm 30, D-12200 Berlin, Germany.							BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; Chuang LM, 1996, J BIOCHEM-TOKYO, V120, P111; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hirasawa N, 2000, BBA-BIOENERGETICS, V1456, P45, DOI 10.1016/S0005-2728(99)00104-8; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ikawa H, 1999, CANCER RES, V59, P360; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596, DOI 10.1152/ajplung.1999.276.4.L596; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Kao HY, 2000, GENE DEV, V14, P55; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; LEHMANN WD, 1994, FREE RADICAL BIO MED, V16, P241, DOI 10.1016/0891-5849(94)90149-X; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Lu BF, 1997, J IMMUNOL, V159, P1255; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Miller YI, 2001, J BIOL CHEM, V276, P19431, DOI 10.1074/jbc.M011276200; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STERNER R, 1979, J BIOL CHEM, V254, P1577; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	41	110	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42753	42760		10.1074/jbc.M102626200	http://dx.doi.org/10.1074/jbc.M102626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11509556	hybrid			2022-12-25	WOS:000172169300017
J	Boorstein, RJ; Cummings, A; Marenstein, DR; Chan, MK; Ma, YL; Neubert, TA; Brown, SM; Teebor, GW				Boorstein, RJ; Cummings, A; Marenstein, DR; Chan, MK; Ma, YL; Neubert, TA; Brown, SM; Teebor, GW			Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-(HYDROXYMETHYL) URACIL; CELLS; 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE; 5-HYDROXYMETHYL-2'-DEOXYURIDINE; PURIFICATION; MAINTENANCE; EXPRESSION; CLONING	Purification from calf thymus of a DNA N-glycosylase activity (HMUDG) that released 5-hydroxymethyluracil (5hmUra) from the DNA of Bacillus subtilis phage SPO1 was undertaken. Analysis of the most purified fraction by SDS-polyacrylamide gel electrophoresis revealed a multiplicity of protein species making it impossible to identify HMUDG by inspection. Therefore, we renatured the enzyme after SDS-polyacrylamide gel electrophoresis and assayed slices of the gel for DNA N-glycosylase activity directed against 5hmUra. Maximum enzymatic activity was identified between molecular mass markers 30 and 34 kDa. Protein was extracted from gel slices and subjected to tryptic digestion and analysis by mass spectrometry. Analysis revealed the presence of 11 peptides that were homologous or identical to the sequence of the recently characterized human single-stranded monofunctional uracil DNA N-glycosylase (hSMUG1). The cDNA of hSMUG1 was isolated and expressed as a recombinant glutathione S-transferase fusion protein that was shown to release 5hmUra with 20X the specific activity of the most purified bovine fraction. We conclude that hSMUG1 and HMUDG are the same protein.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Teebor, GW (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	george.teebor@med.nyu.edu		Teebor, George/0000-0002-7397-2500	NCI NIH HHS [CA 49869, 5T32 CA-09161, CA 16087, CA 16669] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016669, R37CA016669, R01CA049869, T32CA009161, P30CA016087] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALTZ RH, 1976, P NATL ACAD SCI USA, V73, P1269, DOI 10.1073/pnas.73.4.1269; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; BOORSTEIN RJ, 1987, MUTAT RES, V183, P257, DOI 10.1016/0167-8817(87)90008-3; BOORSTEIN RJ, 1989, NUCLEIC ACIDS RES, V17, P7653, DOI 10.1093/nar/17.19.7653; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; CERUTTI PA, 1976, PHOTOCHEM PHOTOBIOL, P375; DJURIC Z, 1991, J NATL CANCER I, V83, P766, DOI 10.1093/jnci/83.11.766; Faure H, 1998, FREE RADICAL RES, V28, P377, DOI 10.3109/10715769809070806; Frenkel K, 1998, CANCER EPIDEM BIOMAR, V7, P49; FRENKEL K, 1985, BIOCHEMISTRY-US, V24, P4527, DOI 10.1021/bi00338a007; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; HERZOG M, 1982, EUR J CELL BIOL, V27, P151; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; HOLLSTEIN MC, 1984, P NATL ACAD SCI-BIOL, V81, P4003, DOI 10.1073/pnas.81.13.4003; KALLEN RG, 1962, J MOL BIOL, V5, P248, DOI 10.1016/S0022-2836(62)80087-4; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Pourcelot S, 1999, FREE RADICAL RES, V30, P173, DOI 10.1080/10715769900300191; Rusmintratip V, 2000, P NATL ACAD SCI USA, V97, P14183, DOI 10.1073/pnas.97.26.14183; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	24	118	123	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41991	41997		10.1074/jbc.M106953200	http://dx.doi.org/10.1074/jbc.M106953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11526119	hybrid			2022-12-25	WOS:000172450400061
J	Ivanova, L; Barmada, S; Kummer, T; Harris, DA				Ivanova, L; Barmada, S; Kummer, T; Harris, DA			Mutant prion proteins axe partially retained in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; BIOCHEMICAL-PROPERTIES; THERMODYNAMIC STABILITY; CELLS; METABOLISM; MUTATIONS; FORM; DEGRADATION	Familial prion diseases are linked to point and insertional mutations in the prion protein (PrP) gene that are presumed to favor conversion of the cellular isoform of PrP to the infectious isoform. In this report, we have investigated the subcellular localization of PrP molecules carrying pathogenic mutations using immunofluorescence staining, immunogold labeling, and PrP-green fluorescent protein chimeras. To facilitate visualization of the mutant proteins, we have utilized a novel Sindbis viral replicon engineered to produce high protein levels without cytopathology. We demonstrate that several different pathogenic mutations have a common effect on the trafficking of PrP, impairing delivery of the molecules to the cell surface and causing a portion of them to accumulate in the endoplasmic reticulum. These observations suggest that protein quality control in the endoplasmic reticulum. may play an important role in prion diseases, as it does in some other inherited human disorders. Our experiments also show that chimeric PrP molecules with the sequence of green fluorescent protein inserted adjacent to the glycolipidation site are post-translationally modified and localized normally, thus documenting the utility of these constructs in cell biological studies of PrP.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	dharris@cellbio.wustl.edu		Harris, David/0000-0002-6985-5790; Barmada, Sami/0000-0002-9604-968X	NIGMS NIH HHS [GM07200] Funding Source: Medline; NINDS NIH HHS [R01 NS35496] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agapov EV, 1998, P NATL ACAD SCI USA, V95, P12989, DOI 10.1073/pnas.95.22.12989; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; Chiesa R, 2000, J NEUROCHEM, V75, P72, DOI 10.1046/j.1471-4159.2000.0750072.x; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Frolov I, 1999, J VIROL, V73, P3854, DOI 10.1128/JVI.73.5.3854-3865.1999; Gambetti P, 1999, COLD SPRING HARBOR M, V38, P509; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Harris DA, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P631; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lehmann S, 2000, J BIOL CHEM, V275, P1520; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Perlmutter DH, 1999, LAB INVEST, V79, P623; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555; YOIUNG K, 1999, PRIONS MOL CELLULAR, P1039; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	45	95	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42409	42421		10.1074/jbc.M106928200	http://dx.doi.org/10.1074/jbc.M106928200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527974	hybrid			2022-12-25	WOS:000172450400113
J	Padmanabhan, S; Elias-Arnanz, M; Carpio, E; Aparicio, P; Murillo, FJ				Padmanabhan, S; Elias-Arnanz, M; Carpio, E; Aparicio, P; Murillo, FJ			Domain architecture of a high mobility group A-type bacterial transcriptional factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED CAROTENOGENESIS; GROUP CHROMOSOMAL-PROTEINS; NF-KAPPA-B; MYXOCOCCUS-XANTHUS; BINDING-PROPERTIES; ESCHERICHIA-COLI; RNA-POLYMERASE; CARR REGION; AMINO-ACID; DNA	Myxococcus xanthus transcriptional factor CarD participates in carotenogenesis and fruiting body formation. It is the only reported prokaryotic protein having adjacent "AT-hook" DNA-binding and acidic regions characteristic of eukaryotic high mobility group A (HMGA) proteins. The latter are small, unstructured, nonhistone nuclear proteins that function as architectural factors to remodel DNA and chromatin structure and modulate various DNA binding activities. We find CarD to be predominantly dimeric with two stable domains: (a) an N-terminal domain of defined secondary and tertiary structure which is absent in eukaryotic HMGA proteins; (b) a C-terminal domain formed by the acidic and AT-hook segments and lacking defined structure. CarD, like HMGA proteins, binds specifically to the minor-groove of AT-rich DNA present in two appropriately spaced tracts. As in HMGA proteins, casein kinase II can phosphorylate the CarD acidic region, and this dramatically decreases the DNA binding affinity of CarD. The acidic region, in addition to modulating DNA binding, confers structural stability to CarD. We discuss how the structural and functional plasticity arising from domain organization in CarD could be linked to its role as a general transcriptional factor in M. xanthus.	Univ Murcia, Dept Genet & Microbiol, E-30071 Murcia, Spain; Univ Murcia, Area Inmunol, E-30071 Murcia, Spain	University of Murcia; University of Murcia	Murillo, FJ (corresponding author), Univ Murcia, Dept Genet & Microbiol, E-30071 Murcia, Spain.		Elías-Arnanz, Montserrat/H-4707-2015; Padmanabhan, S./E-8943-2017	Elías-Arnanz, Montserrat/0000-0003-1980-3092; Aparicio, Pedro/0000-0001-9162-1563; Padmanabhan, S./0000-0002-8772-0152				Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V13; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carey J, 2000, METHOD ENZYMOL, V328, P499, DOI 10.1016/S0076-6879(00)28415-2; CAYUELA ML, 1999, THESIS U MURCIA SPAI, P86; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Cohen SL, 1997, ANAL BIOCHEM, V247, P257, DOI 10.1006/abio.1997.2072; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hodgson D, 1993, MYXOBACTERIA, VII, P157; HODGSON DA, 1993, MOL MICROBIOL, V7, P471, DOI 10.1111/j.1365-2958.1993.tb01138.x; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jain R, 1998, J BACTERIOL, V180, P6544, DOI 10.1128/JB.180.24.6544-6550.1998; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAISER D, 1984, MICROBIAL DEV, P197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LONETTO MA, 1994, P NATL ACAD SCI USA, V91, P7573, DOI 10.1073/pnas.91.16.7573; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MCGOWAN SJ, 1993, MOL MICROBIOL, V10, P713, DOI 10.1111/j.1365-2958.1993.tb00943.x; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; MESBAH M, 1989, INT J SYST BACTERIOL, V39, P159, DOI 10.1099/00207713-39-2-159; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; NICOLAS FJ, 1994, GENE DEV, V8, P2375, DOI 10.1101/gad.8.19.2375; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; Schwanbeck R, 2001, J BIOL CHEM, V276, P26012, DOI 10.1074/jbc.M011053200; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; Serrano L, 2000, ADV PROTEIN CHEM, V53, P49; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Treuner-Lange A, 2001, MOL MICROBIOL, V40, P126, DOI 10.1046/j.1365-2958.2001.02362.x; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Zhang XM, 1999, J BIOL CHEM, V274, P20235, DOI 10.1074/jbc.274.29.20235	70	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41566	41575		10.1074/jbc.M106352200	http://dx.doi.org/10.1074/jbc.M106352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533063	hybrid			2022-12-25	WOS:000172450400006
J	Yao, PM; Tabas, I				Yao, PM; Tabas, I			Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; CYTOCHROME-C RELEASE; ACYL-COENZYME-A; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; UP-REGULATION; LOCALIZATION; CELLS; BAX; NECROSIS; DEATH	Macrophage death in advanced atherosclerotic lesions leads to lesional necrosis and possibly plaque rupture and acute vascular occlusion. Among the likely causes of lesional macrophage death is intracellular accumulation of excess free cholesterol (FC), which is known to occur in vivo. We recently showed that FC loading of macrophages causes apoptosis, similar to 50% of which is mediated by activation of cell-surface FasL and triggering of the Fas pathway (Yao, P. M., and Tabas, I. (2000) J. Biol. Chem. 275, 23807-23813). To elucidate other pathways of death in FC-loaded macrophages, we investigated mitochondrial transmembrane potential (Delta psi (m)) and the mitochondrial apoptosis pathway in FC-loaded mouse peritoneal macrophages. Starting between 3 and 6 h of FC loading, Delta psi (m) was markedly decreased in the majority of macrophages and was independent of the Fas pathway. The decrease in Delta psi (m) by FC loading was not prevented by GSH, thus distinguishing it from 7-ketocholesterol-induced mitochondrial dysfunction. Cytochrome c release into the cytosol was noted by 4 h of FC loading, and activation of caspase-9 and effector caspases was observed at 6 h. Finally, we found that both cellular and mitochondrial levels of the pro-apoptotic protein Bax were increased severalfold as early as 4 h after FC loading. Thus, FC loading, perhaps via increased levels of Bax and/or cholesterol overloading of mitochondria, triggers cytochrome c release and activation of caspase-9 and the effector caspases, leading to macrophage apoptosis. These findings and our previous data support a model in which FC loading of macrophages promotes a dual program of caspase-mediated death.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu			NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA13696] Funding Source: Medline; NHLBI NIH HHS [HL-54591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; Bauriedel G, 1997, Z KARDIOL, V86, P902, DOI 10.1007/s003920050130; BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; CALANNI RF, 1986, FEBS LETT, V198, P353; COLEMAN PS, 1978, BIOCHEM BIOPH RES CO, V84, P202, DOI 10.1016/0006-291X(78)90282-6; Colles SM, 1996, J LIPID RES, V37, P2018; ECHEGOYEN S, 1993, BIOCHEM J, V289, P703, DOI 10.1042/bj2890703; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Lizard G, 1999, ARTERIOSCL THROM VAS, V19, P1190, DOI 10.1161/01.ATV.19.5.1190; Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mitchinson MJ, 1996, CURR OPIN LIPIDOL, V7, P324, DOI 10.1097/00041433-199610000-00011; MIYASHITA T, 1995, CELL, V80, P293; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROUSLIN W, 1982, AM J PHYSIOL, V242, pH254, DOI 10.1152/ajpheart.1982.242.2.H254; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlesinger M, 2000, BIOCHEM PHARMACOL, V60, P1693, DOI 10.1016/S0006-2952(00)00484-6; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200	46	156	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42468	42476		10.1074/jbc.M101419200	http://dx.doi.org/10.1074/jbc.M101419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533046	hybrid			2022-12-25	WOS:000172450400119
J	Communi, D; Gonzalez, NS; Detheux, M; Brezillon, S; Lannoy, V; Parmentier, M; Boeynaems, JM				Communi, D; Gonzalez, NS; Detheux, M; Brezillon, S; Lannoy, V; Parmentier, M; Boeynaems, JM			Identification of a novel human ADP receptor coupled to G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE NUCLEOTIDE RECEPTOR; INHIBITS ADENYLYL-CYCLASE; FUNCTIONAL EXPRESSION; PHOSPHOLIPASE-C; MOLECULAR-CLONING; P2Y(1) RECEPTOR; ATP RECEPTOR; G-PROTEINS; CELLS; PURINOCEPTOR	We have cloned and expressed a novel human G-protein-coupled receptor closely related to the human P2Y(12) receptor. It corresponds to the orphan receptor called GPR86. GPR86 proved to be a G; coupled receptor displaying a high affinity for ADP, similar to the P2Y12 receptor and can therefore be tentatively called P2Y(13). In 1321N1 cells, the P2Y13 receptor coupled to the phosphoinositide pathway only when coexpressed with Gals. Inositol trisphosphate formation was stimulated equipotently by nanomolar concentrations of ADP and 2MeSADP, whereas 2MeSATP and ATP were inactive. In CHO-K1 cells expressing the P2Y13 receptor, ADP and 2MeSADP had a biphasic effect on the forskolin-stimulated accumulation of cAMP: inhibition at nanomolar concentrations and potentiation at micromolar levels. In the same cells, ADP and 2MeSADP also stimulated the phosphorylation of Erk1 and Erk2, in a pertussis toxin-sensitive way. The tissue distribution of P2Y13 was investigated by reverse transcriptase-polymerise chain reaction, and the predominant signals were obtained in spleen and brain. Although these can be discriminated by tissue distribution and some pharmacological features, the P2Y12 and P2Y13 receptors form a subgroup of related P2Y subtypes that is structurally different from the other P2Y subtypes but share coupling to Gi and a high affinity for ADP.	Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Euroscreen, B-1070 Brussels, Belgium; Free Univ Brussels, Dept Med Chem, Erasme Hosp, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, 808 Route Lennik, B-1070 Brussels, Belgium.		Gonzalez Cordova, Nadia Lorena/GSN-4164-2022	BREZILLON, stephane/0000-0001-7954-8340; Parmentier, Marc/0000-0001-8081-4685				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Boyer JL, 2000, MOL PHARMACOL, V57, P805, DOI 10.1124/mol.57.4.805; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; COMMUNI D, 1995, CIRC RES, V76, P191, DOI 10.1161/01.RES.76.2.191; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; EASON MG, 1992, J BIOL CHEM, V267, P15795; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; Hechler B, 1998, MOL PHARMACOL, V53, P727, DOI 10.1124/mol.53.4.727; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Janssens R, 1997, BIOCHEM BIOPH RES CO, V236, P106, DOI 10.1006/bbrc.1997.6895; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; Li Q, 1997, BIOCHEM BIOPH RES CO, V236, P455, DOI 10.1006/bbrc.1997.6984; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Simon J, 2001, BRIT J PHARMACOL, V132, P173, DOI 10.1038/sj.bjp.0703816; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200	34	262	268	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41479	41485		10.1074/jbc.M105912200	http://dx.doi.org/10.1074/jbc.M105912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546776	hybrid			2022-12-25	WOS:000171925600145
J	Osawa, M; Tong, KI; Lilliehook, C; Wasco, W; Buxbaum, JD; Cheng, HYM; Penninger, JM; Ikura, M; Ames, JB				Osawa, M; Tong, KI; Lilliehook, C; Wasco, W; Buxbaum, JD; Cheng, HYM; Penninger, JM; Ikura, M; Ames, JB			Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/KChIP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOVERIN; CALSENILIN; CYCLASE; SENSOR	Calsenilin/DREAM/KChIP3, a member of the recoverin branch of the EF-hand superfamily, interacts with presenilins, serves as a calcium-regulated transcriptional repressor, and interacts with A-type potassium channels. Here we report physicochemical characterization of calcium binding, oligomerization, and DNA binding of human calsenilin/DREAM/KChIP3. Equilibrium Ca2+ binding measurements indicate that the protein binds 3 Ca2+ with a dissociation constant of 14 muM and a Hill coefficient of 0.7. Dynamic light scattering and size exclusion chromatography show that the Ca2+-bound protein exists as a dimer at protein concentrations lower than 150 muM and forms a tetramer at concentrations above 200 muM. The Ca2+-free protein is a tetramer in the concentration range 20-450 muM. Isothermal titration calorimetry and dynamic light scattering indicate that the Ca2+-free protein tetramer binds endothermically (DeltaH = +25 kcal/mol) to four molecules of DNA derived from the downstream regulatory element (DRE) of either the prodynorphin or c-fos genes. One DRE molecule binds tightly to the protein with a dissociation constant (K-d) of 75 nM, and the other three bind more weakly (K-d = 640 nM). No significant DNA binding was observed for the Ca2+-bound protein. The N-terminal protein fragment (residues 1-70) binds nonspecifically to DRE in a Ca2+-independent manner, whereas a C-terminal fragment containing the four EF-hands (residues 65-256) binds DRE (K-d = 200 nM) in a Ca2+-regulated and sequence-specific fashion. The C-terminal fragment is a tetramer in the Ca2+-free state and dissociates into dimers at saturating Ca2+ levels.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Univ Toronto, Amgen Inst, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Ames, JB (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.		Penninger, Josef M/I-6860-2013; Osawa, Masanori/GRS-5726-2022; Buxbaum, Joseph D/G-6001-2010	Penninger, Josef M/0000-0002-8194-3777; Osawa, Masanori/0000-0002-1285-4316; Buxbaum, Joseph/0000-0001-8898-8313; Ikura, Mitsuhiko/0000-0002-9524-1303	NEI NIH HHS [EY12347] Funding Source: Medline; NIA NIH HHS [AG05138, AG15801] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015801] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Choi EK, 2001, J BIOL CHEM, V276, P19197, DOI 10.1074/jbc.M008597200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; Ledo F, 2000, BBA-MOL CELL RES, V1498, P162, DOI 10.1016/S0167-4889(00)00092-6; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; TAKAMATSU K, 1992, BIOCHEM BIOPH RES CO, V183, P245, DOI 10.1016/0006-291X(92)91635-4; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	29	109	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41005	41013		10.1074/jbc.M105842200	http://dx.doi.org/10.1074/jbc.M105842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11535596	hybrid, Green Published			2022-12-25	WOS:000171925600085
J	Regel, RE; Ivleva, NB; Zer, H; Meurer, J; Shestakov, SV; Herrmann, RG; Pakrasi, HB; Ohad, I				Regel, RE; Ivleva, NB; Zer, H; Meurer, J; Shestakov, SV; Herrmann, RG; Pakrasi, HB; Ohad, I			Deregulation of electron flow within photosystem II in the absence of the PsbJ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; D1 PROTEIN; IN-VIVO; THERMO-LUMINESCENCE; CYTOCHROME B(559); REACTION CENTERS; LOW-LIGHT; MUTANT; DEGRADATION; MECHANISM	The photosystem II (PSII) complex of photosynthetic oxygen evolving membranes comprises a number of small proteins whose functions remain unknown. Here we report that the low molecular weight protein encoded by the psbJ gene is an intrinsic component of the PSII complex. Fluorescence kinetics, oxygen flash yield, and thermoluminescence measurements indicate that inactivation of the psbJ gene in Synechocystis 6803 cells and tobacco chloroplasts lowers PSII-mediated oxygen evolution activity and increases the lifetime of the reduced primary acceptor Q(A)(-) (more than a 100-fold in the tobacco Delta psbJ mutant). The decay of the oxidized S-2,S-3 states of the oxygen-evolving complex is considerably accelerated, and the oscillations of the Q(B)(-)/S-2,S-3 recombination with the number of exciting flashes are damped. Thus, PSII can be assembled in the absence of PsbJ. However, the forward electron flow from Q(A)(-) to plastoquinone and back electron flow to the oxidized Mn cluster of the donor side are deregulated in the absence of PsbJ, thereby affecting the efficiency of PSII electron flow following the charge separation process.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Munich, Inst Bot, D-80638 Munich, Germany; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Moscow MV Lomonosov State Univ, Dept Genet, Moscow 119899, Russia	Hebrew University of Jerusalem; University of Munich; Washington University (WUSTL); Lomonosov Moscow State University	Ohad, I (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.		Meurer, Jörg/F-8479-2010	Meurer, Jörg/0000-0003-2973-9514	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; Barber J, 1998, BBA-BIOENERGETICS, V1365, P269, DOI 10.1016/S0005-2728(98)00079-6; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; CARPENTER SD, 1993, BIOCHIM BIOPHYS ACTA, V1144, P204, DOI 10.1016/0005-2728(93)90174-E; De Santis-Maciossek G, 1999, PLANT J, V18, P477, DOI 10.1046/j.1365-313X.1999.00473.x; Debus RJ, 2000, MET IONS BIOL SYST, V37, P657; DEBUS RJ, 1986, BIOCHEMISTRY-US, V25, P2276, DOI 10.1021/bi00356a064; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KEREN N, 1995, J BIOL CHEM, V270, P806, DOI 10.1074/jbc.270.2.806; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Krieger A, 1997, BBA-BIOENERGETICS, V1319, P91, DOI 10.1016/S0005-2728(96)00117-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LIND LK, 1993, J BIOL CHEM, V268, P1575; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; Meetam M, 1999, PLANT PHYSIOL, V121, P1267, DOI 10.1104/pp.121.4.1267; Minagawa J, 1999, BIOCHEMISTRY-US, V38, P770, DOI 10.1021/bi981217x; Mizusawa N, 1999, BBA-BIOENERGETICS, V1410, P273, DOI 10.1016/S0005-2728(99)00005-5; MOR TS, 1995, MOL GEN GENET, V246, P600, DOI 10.1007/BF00298966; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Schreiber U, 1996, FEBS LETT, V397, P131, DOI 10.1016/S0014-5793(96)01176-3; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Tal S, 1999, J PHOTOCH PHOTOBIO B, V48, P120, DOI 10.1016/S1011-1344(99)00040-8; Trtilek M, 1997, J LUMIN, V72-4, P597, DOI 10.1016/S0022-2313(97)00066-5; VASS I, 1981, BIOCHIM BIOPHYS ACTA, V634, P140, DOI 10.1016/0005-2728(81)90134-1; Vass I, 1996, PHOTOSYNTH RES, V48, P117, DOI 10.1007/BF00041002; Vrettos JS, 1999, J PHYS CHEM B, V103, P6403, DOI 10.1021/jp991464q; Whitmarsh J., 1996, OXYGENIC PHOTOSYNTHE, P249, DOI 10.1007/0-306-48127-8_13; ZER H, 1994, J BIOL CHEM, V269, P17670; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277	37	44	47	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41473	41478		10.1074/jbc.M102007200	http://dx.doi.org/10.1074/jbc.M102007200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546758	hybrid			2022-12-25	WOS:000171925600144
J	Teusink, B; Mensenkamp, AR; van der Boom, H; Kuipers, F; van Dijk, KW; Havekes, LM				Teusink, B; Mensenkamp, AR; van der Boom, H; Kuipers, F; van Dijk, KW; Havekes, LM			Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; APOE-DEFICIENT MICE; TRANSGENIC MICE; LDL RECEPTOR; GENE-TRANSFER; E EXPRESSION; SECRETION; CLEARANCE; VLDL; TRIGLYCERIDES	Apolipoprotein (apo) E stimulates the secretion of very low density lipoproteins (VLDLs) by an as yet unknown mechanism. Recently, a working mechanism for apoE was proposed (Twisk, J., Gillian-Daniel, D. L., Tebon, A., Wang, L., Barrett, P. H., and Attie, A. D. (2000) J. Clan. Invest. 105, 521-532) in which apoE prevents the inhibitory action of the low density lipoprotein receptor (LDLr) by binding to it. We have first tested whether this newly described effect of the LDLr on VLDL secretion, obtained in vitro, is also observed in vavo. In LDLr knockout mice (LDLr-/-), the production of VLDL triglycerides and apoB was 30% higher than that in controls. Also the ratio of apoB100:apoB48 secretion was increased in the LDLr-/- mice. The composition of nascent VLDL was similar in both strains. To test whether the action of apoE depends on the presence of the LDLr, VLDL production was measured in LDLr-/- and apoE-/- LDLr-/- mice. Deletion of apoE on a LDLr-/-background still caused a 50% decrease of VLDL triglycerides and apoB production. The composition of nascent VLDL was again similar for both strains. We conclude that the effect of apoE on hepatic VLDL production is independent of the presence of the LDLr.	TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Univ Groningen Hosp, Pediat Lab, Ctr Liver Digest & Metab Dis, NL-9713 GZ Groningen, Netherlands; Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Internal Med, NL-2300 RA Leiden, Netherlands	Netherlands Organization Applied Science Research; University of Groningen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Teusink, B (corresponding author), TNO Prevent & Hlth, Gaubius Lab, POB 2215, NL-2301 CE Leiden, Netherlands.		van Dijk, Ko Willems/A-1798-2008; Mensenkamp, Arjen/L-4520-2015; van Dijk, Ko Willems/AAT-4681-2021	van Dijk, Ko Willems/0000-0002-2172-7394; Mensenkamp, Arjen/0000-0003-3805-877X; van Dijk, Ko Willems/0000-0002-2172-7394; Teusink, Bas/0000-0003-3929-0423; Kuipers, Folkert/0000-0003-2518-737X				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Arrol S, 2000, ATHEROSCLEROSIS, V150, P255, DOI 10.1016/S0021-9150(99)00374-3; Brown ML, 2000, P NATL ACAD SCI USA, V97, P7488, DOI 10.1073/pnas.120184097; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; de Beer F, 2000, ARTERIOSCL THROM VAS, V20, P1800, DOI 10.1161/01.ATV.20.7.1800; EGUSA G, 1983, J LIPID RES, V24, P1261; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Jong MC, 1997, BIOCHEM J, V328, P745; Jong MC, 1996, ARTERIOSCL THROM VAS, V16, P934, DOI 10.1161/01.ATV.16.8.934; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Kypreos KE, 2001, FASEB J, V15, P1598, DOI 10.1096/fj.00-0882fje; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; Lewis GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maugeais C, 2000, J LIPID RES, V41, P1673; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; MENSENKAMP AR, 2001, IN PRESS ARTERIOSCLE, V21; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Packard CJ, 1999, CURR OPIN LIPIDOL, V10, P237, DOI 10.1097/00041433-199906000-00006; Packard CJ, 2000, J LIPID RES, V41, P305; Packard CJ, 1997, ARTERIOSCL THROM VAS, V17, P3542, DOI 10.1161/01.ATV.17.12.3542; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Tacken PJ, 2000, J LIPID RES, V41, P2055; Tsukamoto K, 2000, J LIPID RES, V41, P253; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; van Dijk KW, 1999, ARTERIOSCL THROM VAS, V19, P2945, DOI 10.1161/01.ATV.19.12.2945; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Voyiaziakis E, 1999, J LIPID RES, V40, P2004	32	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40693	40697		10.1074/jbc.M106396200	http://dx.doi.org/10.1074/jbc.M106396200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546779	Green Published, hybrid			2022-12-25	WOS:000171925600043
J	AbdAlla, S; Lother, H; Abdel-tawab, AM; Quitterer, U				AbdAlla, S; Lother, H; Abdel-tawab, AM; Quitterer, U			The angiotensin II AT(2) receptor is an AT(1) receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; IDENTIFICATION; HETERODIMERS; EXPRESSION; CLONING; COUPLES; DOMAIN	The vasopressor angiotensin II activates AT(1) and AT(2) receptors. Most of the known in vivo effects of angiotensin II are mediated by AT(1) receptors while the biological functions of AT(2) receptors are less clear. We report here that the AT(2) receptor binds directly to the AT(1) receptor and thereby antagonizes the function of the AT(1) receptor. The AT(1)-specific antagonism of the AT(2) receptor was independent of AT(2) receptor activation and signaling, and it was effective on different cells and on human myometrial biopsies with AT(1)/AT(2) receptor expression. Thus, the AT(2) receptor is the first identified example of a G-protein-coupled receptor which acts as a receptor-specific antagonist.	Ain Shams Univ Hosp, Med Res Ctr, Cairo, Egypt; Heinrich Pette Inst, D-20251 Hamburg, Germany; Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany	Egyptian Knowledge Bank (EKB); Ain Shams University; Heinrich Pette Institute; University of Wurzburg	Quitterer, U (corresponding author), Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	toph029@rzbox.uni-wuerzburg.de	Abdel-tawab, Ahmed M./C-1432-2009	Abdel-tawab, Ahmed M./0000-0001-6412-7404				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; COX BE, 1996, J CLIN ENDOCRINOL S, V1, P49; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; JOHNSON MC, 1991, ENDOCRINOLOGY, V129, P1266, DOI 10.1210/endo-129-3-1266; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lehtonen JYA, 1999, MOL ENDOCRINOL, V13, P1051, DOI 10.1210/me.13.7.1051; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885; Matsumoto T, 1996, J CLIN ENDOCR METAB, V81, P4366, DOI 10.1210/jc.81.12.4366; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; Quitterer U, 2001, J BIOL CHEM, V276, P6763, DOI 10.1074/jbc.M007727200; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; Turner CA, 1999, BIOCHEM BIOPH RES CO, V257, P704, DOI 10.1006/bbrc.1999.0207; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	22	344	363	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39721	39726		10.1074/jbc.M105253200	http://dx.doi.org/10.1074/jbc.M105253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11507095	hybrid			2022-12-25	WOS:000171789200029
J	Diamant, S; Eliahu, N; Rosenthal, D; Goloubinoff, P				Diamant, S; Eliahu, N; Rosenthal, D; Goloubinoff, P			Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OSMOTIC-STRESS; OSMOPROTECTIVE PROPERTIES; IN-VITRO; PROTEIN; SHOCK; AGGREGATION; WATER; DNAK; RESPONSES	Salt and heat stresses, which are often combined in nature, induce complementing defense mechanisms. Organisms adapt to high external salinity by accumulating small organic compounds known as osmolytes, which equilibrate cellular osmotic pressure. Osmolytes can also act as "chemical chaperones" by increasing the stability of native proteins and assisting refolding of unfolded polypeptides. Adaptation to heat stress depends on the expression of heat-shock proteins, many of which are molecular chaperones, that prevent protein aggregation, disassemble protein aggregates, and assist protein refolding. We show here that Escherichia coli cells preadapted to high salinity contain increased levels of glycine betaine that prevent protein aggregation under thermal stress. After heat shock, the aggregated proteins, which escaped protection, were disaggregated in salt-adapted cells as efficiently as in low salt. Here we address the effects of four common osmolytes on chaperone activity in vitro. Systematic dose responses of glycine betaine, glycerol, proline, and trehalose revealed a regulatory effect on the folding activities of individual and combinations of chaperones GroEL, DnaK, and ClpB. With the exception of trehalose, low physiological concentrations of proline, glycerol, and especially glycine betaine activated the molecular chaperones, likely by assisting local folding in chaperone-bound polypeptides and stabilizing the native end product of the reaction. High osmolyte concentrations, especially trehalose, strongly inhibited DnaK-dependent chaperone networks, such as DnaK+GroEL and DnaK+ClpB, likely because high viscosity affects dynamic interactions between chaperones and folding substrates and stabilizes protein aggregates. Thus, during combined salt and heat stresses, cells can specifically control protein stability and chaperone-mediated disaggregation and refolding by modulating the intracellular levels of different osmolytes.	Univ Lausanne, Inst Ecol, CH-8015 Lausanne, Switzerland; Hebrew Univ Jerusalem, Inst Life Sci, Dept Plant Sci, IL-919043 Jerusalem, Israel	University of Lausanne; Hebrew University of Jerusalem	Goloubinoff, P (corresponding author), Univ Lausanne, Inst Ecol, CH-8015 Lausanne, Switzerland.			Goloubinoff, Pierre/0000-0002-4802-0807				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Avron M., 1992, DUNALIELLA PHYSL BIO; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Caldas T, 1999, MICROBIOL-SGM, V145, P2543, DOI 10.1099/00221287-145-9-2543; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CAYLEY S, 1992, J BACTERIOL, V174, P1586, DOI 10.1128/jb.174.5.1586-1595.1992; CHAMBERS S, 1985, J INFECT DIS, V152, P1308, DOI 10.1093/infdis/152.6.1308; Chen BL, 1996, J PHARM SCI, V85, P419, DOI 10.1021/js9504393; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; da Costa M. S., 1998, V61, P117; DeSanctis G, 1996, J PROTEIN CHEM, V15, P599, DOI 10.1007/BF01886742; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; Ellis RJ, 2000, TRENDS BIOCHEM SCI, V25, P210, DOI 10.1016/S0968-0004(00)01576-0; ELLIS RJ, 1997, CURR BIOL, V7, P531; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 1999, J BACTERIOL, V181, P1971, DOI 10.1128/JB.181.6.1971-1974.1999; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RICHEY DP, 1972, J BACTERIOL, V112, P784, DOI 10.1128/JB.112.2.784-790.1972; Samuel D, 2000, PROTEIN SCI, V9, P344; SANNO Y, 1968, BIOCHEM BIOPH RES CO, V32, P344, DOI 10.1016/0006-291X(68)90392-6; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Voziyan PA, 2000, PROTEIN SCI, V9, P2405, DOI 10.1110/ps.9.12.2405; WOO KM, 1992, J BIOL CHEM, V267, P20429; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	47	302	320	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39586	39591		10.1074/jbc.M103081200	http://dx.doi.org/10.1074/jbc.M103081200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517217	hybrid			2022-12-25	WOS:000171789200013
J	Olofsson, A; Ippel, HJ; Baranov, V; Horstedt, P; Wijmenga, S; Lundgren, E				Olofsson, A; Ippel, HJ; Baranov, V; Horstedt, P; Wijmenga, S; Lundgren, E			Capture of a dimeric intermediate during transthyretin amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSTHYRETIN; FIBRIL FORMATION; WILD-TYPE; DENATURATION; MUTATION; DISEASE; PROTOFILAMENTS; VARIANTS; INVITRO; PACKING	Point mutations in the human plasma protein transthyretin are associated with the neurological disorder familial amyloidosis with polyneuropathy type 1. The disease is characterized by amyloid fibril deposits causing damage at the site of deposition. Substitution of two amino acids in the hydrophobic core of transthyretin lead to a mutant that was very prone to form amyloid. In addition, this mutant has also been shown to induce a toxic response on a neuroblastoma cell line. Renaturation of the transthyretin mutant at low temperature facilitated the isolation of an amyloid-forming intermediate state having the apparent size of a dimer. Increasing the temperature effectively enhanced the rate of interconversion from a partly denatured protein to mature amyloid. Using circular dichroism the beta -sheet content of the formed mature fibrils was significantly lower than that of the native fold of transthyretin. Morphology studies using electron microscopy also indicated a temperature-dependent transformation from amorphous aggregates toward mature amyloid fibrils. In addition, 1-anilino-S-naphtalenesulfonate fluorescence studies suggested the loss of the thyroxin-binding channel within both the isolated intermediate and the mature fibrils.	Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden; Umea Univ, Dept Immunol, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden; Umea Univ, Dept Med Biophys, S-90187 Umea, Sweden	Umea University; Umea University; Umea University; Umea University	Lundgren, E (corresponding author), Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden.		Ippel, Hans/D-6917-2016					Benson MD, 1996, CIBA F SYMP, V199, P104; Blake CCF, 1978, BIOCHEM SOC T, V6, P1114, DOI 10.1042/bst0061114; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Colon W, 1996, CIBA F SYMP, V199, P228; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Eneqvist T, 2000, MOL CELL, V6, P1207, DOI 10.1016/S1097-2765(00)00117-9; Ferlini A, 2000, CLIN GENET, V57, P284, DOI 10.1034/j.1399-0004.2000.570407.x; Goldsteins G, 1997, BIOCHEMISTRY-US, V36, P5346, DOI 10.1021/bi961649c; GUSTAVSSON A, 1991, BIOCHEM BIOPH RES CO, V175, P1159, DOI 10.1016/0006-291X(91)91687-8; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014-5793(00)01888-3; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Lai ZH, 1997, BIOCHEMISTRY-US, V36, P10230, DOI 10.1021/bi963195p; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Liu K, 2000, NAT STRUCT BIOL, V7, P754; Liu K, 2000, J MOL BIOL, V303, P555, DOI 10.1006/jmbi.2000.4164; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; NILSSON SF, 1975, J BIOL CHEM, V250, P8554; Otzen DE, 2000, P NATL ACAD SCI USA, V97, P9907, DOI 10.1073/pnas.160086297; Quintas A, 1999, J BIOL CHEM, V274, P32943, DOI 10.1074/jbc.274.46.32943; Quintas A, 1997, FEBS LETT, V418, P297, DOI 10.1016/S0014-5793(97)01398-7; Quintas A, 2001, J BIOL CHEM, V276, P27207, DOI 10.1074/jbc.M101024200; SARAIVA MJM, 1983, T ASSOC AM PHYSICIAN, V96, P261; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; Shnyrov VL, 2000, BIOPHYS CHEM, V88, P61, DOI 10.1016/S0301-4622(00)00199-X; THYLEN C, 1993, EMBO J, V12, P743, DOI 10.1002/j.1460-2075.1993.tb05708.x; Vanhove M, 1998, BIOCHEMISTRY-US, V37, P1941, DOI 10.1021/bi972143c; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843	39	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39592	39599		10.1074/jbc.M103599200	http://dx.doi.org/10.1074/jbc.M103599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518707	hybrid			2022-12-25	WOS:000171789200014
J	Cho, H; Thorvaldsen, JL; Chu, QW; Feng, F; Birnbaum, MJ				Cho, H; Thorvaldsen, JL; Chu, QW; Feng, F; Birnbaum, MJ			Akt1/PKB alpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INSULIN-RECEPTOR; CELL-SIZE; S6 KINASE; DROSOPHILA; IGF-1; ACTIVATION; DISRUPTION; GENE; ADIPOCYTES	The serine-threonine kinase Akt, also known as protein kinase B (PKB), is an important effector for phosphatidylinositol 3-kinase signaling initiated by numerous growth factors and hormones. Akt2/PKB beta, one of three known mammalian isoforms of Akt/PKB, has been demonstrated recently to be required for at least some of the metabolic actions of insulin (Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Science 292,1728-1731). Here we show that mice deficient in another closely related isoform of the kinase, Akt1/PKB alpha, display a conspicuous impairment in organismal growth. Akt1(-/-) mice demonstrated defects in both fetal and postnatal growth, and these persisted into adulthood. However, in striking contrast to Akt2/PKB beta null mice, Akt1/PKB alpha -deficient mice are normal with regard to glucose tolerance and insulin-stimulated disposal of blood glucose. Thus, the characterization of the Akt1 knockout mice and its comparison to the previously reported Akt2 deficiency phenotype reveals the non-redundant functions of Akt1 and Akt2 genes with respect to organismal growth and insulin-regulated glucose metabolism.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [R01 DK56886] Funding Source: Medline; NIGMS NIH HHS [GM07229] Funding Source: Medline; PHS HHS [P30 19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Hill MM, 1999, MOL CELL BIOL, V19, P7771; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murthy SS, 2000, CYTOGENET CELL GENET, V88, P38, DOI 10.1159/000015481; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park BC, 1999, BIOCHEMISTRY-US, V38, P7517, DOI 10.1021/bi9830718; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631	26	776	815	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38349	38352		10.1074/jbc.C100462200	http://dx.doi.org/10.1074/jbc.C100462200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11533044	hybrid			2022-12-25	WOS:000171673200005
J	Jones, KW; Gorzynski, K; Hales, CM; Fischer, U; Badbanchi, F; Terns, RM; Terns, MP				Jones, KW; Gorzynski, K; Hales, CM; Fischer, U; Badbanchi, F; Terns, RM; Terns, MP			Direct interaction of the spinal muscular atrophy disease protein SMN with the small nucleolar RNA-associated protein fibrillarin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL MOTOR-NEURON; WERDNIG-HOFFMANN DISEASE; BOX-C/D MOTIF; COILED BODIES; GENE-PRODUCT; BINDING-PROTEIN; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; SNRNP BIOGENESIS; IN-VIVO	Disruption of the survival motor neuron (SMN) gene leads to selective loss of spinal motor neurons, resulting in the fatal human neurodegenerative disorder spinal muscular atrophy (SMA). SMN has been shown to function in spliceosomal small nuclear ribonucleoprotein (snRNP) biogenesis and pre-mRNA splicing. We have demonstrated that SMN also interacts with fibrillarin, a highly conserved nucleolar protein that is associated with all Box C/D small nucleolar RNAs and functions in processing and modification of rRNA. Fibrillarin and SMN co-immunoprecipitate from HeLa cell extracts indicating that the proteins exist as a complex in vivo. Furthermore, in vitro binding studies indicate that the interaction between SMN and fibrillarin is direct and salt-stable. We show that the glycine/arginine-rich domain of fibrillarin is necessary and sufficient for SMN binding and that the region of SMN encoded by exon 3, including the Tudor domain, mediates the binding of fibrillarin. Tudor domain missense mutations, including one found in an SMA patient, impair the interaction between SMN and fibrillarin (as well as the common snRNP protein SmB). Our results suggest a function for SMN in small nucleolar RNP biogenesis (akin to its known role as an snRNP assembly factor) and reveal a potential link between small nucleolar RNP biogenesis and SMA.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Max Planck Society	Terns, MP (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.		Terns, Michael/N-6435-2016; Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591	NIGMS NIH HHS [GM54682] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054682] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachellerie J. P., 1998, MODIFICATION EDITING, P255; Bechade C, 1999, EUR J NEUROSCI, V11, P293, DOI 10.1046/j.1460-9568.1999.00428.x; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Burlet P, 1998, HUM MOL GENET, V7, P1927, DOI 10.1093/hmg/7.12.1927; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Galliot B, 2000, TRENDS GENET, V16, P1, DOI 10.1016/S0168-9525(99)01888-0; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jordan P, 1996, J CELL BIOL, V133, P225, DOI 10.1083/jcb.133.2.225; Kerr DA, 2000, P NATL ACAD SCI USA, V97, P13312, DOI 10.1073/pnas.230364197; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Pagliardini S, 2000, HUM MOL GENET, V9, P47, DOI 10.1093/hmg/9.1.47; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Sato K, 2000, CELL DEATH DIFFER, V7, P374, DOI 10.1038/sj.cdd.4400660; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TERNS MP, 2001, IN PRESS GENE EXPR; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	68	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38645	38651		10.1074/jbc.M106161200	http://dx.doi.org/10.1074/jbc.M106161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509571	hybrid			2022-12-25	WOS:000171673200043
J	Xu, HX; Wu, JP; Cui, NR; Abdulkadir, L; Wang, RP; Mao, JZ; Giwa, LR; Chanchevalap, S; Jiang, C				Xu, HX; Wu, JP; Cui, NR; Abdulkadir, L; Wang, RP; Mao, JZ; Giwa, LR; Chanchevalap, S; Jiang, C			Distinct histidine residues control the acid-induced activation and inhibition of the cloned K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; FROG SKELETAL-MUSCLE; SENSITIVE POTASSIUM CHANNEL; INTRACELLULAR PH; MODULATION; H+; PROTONS; TRYPSIN	The modulation of K-ATP channels during acidosis has an impact on vascular tone, myocardial rhythmicity, insulin secretion, and neuronal excitability. Our previous studies have shown that the cloned Kir6.2 is activated with mild acidification but inhibited with high acidity. The activation relies on His-175, whereas the molecular basis for the inhibition remains unclear. To elucidate whether the His-175 is indeed the protonation site and what other structures are responsible for the pH-induced inhibition, we performed these studies. Our data showed that the His-175 is the only proton sensor whose protonation is required for the channel activation by acidic pH. In contrast, the channel inhibition at extremely low pH depended on several other histidine residues including His-186, His-193, and His-216. Thus, proton has both stimulatory and inhibitory effects on the Kir6.2 channels, which attribute to two sets of histidine residues in the C terminus.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30302 USA.			Wu, Jianping/0000-0002-2684-6122	NHLBI NIH HHS [HL58410, R01 HL058410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARD B, 1992, PFLUG ARCH EUR J PHY, V422, P185, DOI 10.1007/BF00370419; ALLARD B, 1995, J PHYSIOL-LONDON, V485, P283, DOI 10.1113/jphysiol.1995.sp020730; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DAVIES NW, 1992, J PHYSIOL-LONDON, V445, P549, DOI 10.1113/jphysiol.1992.sp018939; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; Dost R, 2000, EPILEPSY RES, V38, P53; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FAN Z, 1994, AM J PHYSIOL-CELL PH, V267, pC1036; FAN Z, 1993, CIRC RES, V72, P715, DOI 10.1161/01.RES.72.3.715; Gramolini A, 1997, AM J PHYSIOL-CELL PH, V272, pC1936, DOI 10.1152/ajpcell.1997.272.6.C1936; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974, DOI 10.1152/ajpheart.1998.274.3.H974; KOYANO T, 1993, J PHYSIOL-LONDON, V463, P747, DOI 10.1113/jphysiol.1993.sp019620; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LEE K, 1994, MOL PHARMACOL, V46, P176; LIGHT PE, 1994, J PHYSIOL-LONDON, V475, P495, DOI 10.1113/jphysiol.1994.sp020088; Piao HL, 2001, J BIOL CHEM, V276, P36673, DOI 10.1074/jbc.M106123200; PROKS P, 1994, J PHYSIOL-LONDON, V475, P33, DOI 10.1113/jphysiol.1994.sp020047; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VIVAUDOU M, 1995, J PHYSIOL-LONDON, V486, P629, DOI 10.1113/jphysiol.1995.sp020840; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38690	38696		10.1074/jbc.M106595200	http://dx.doi.org/10.1074/jbc.M106595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514573	hybrid			2022-12-25	WOS:000171673200050
J	Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER				Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER			The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1 alpha in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; elongin B; elongin C; Rbx1; HIF-1 alpha; VHL; genomic organization; chromosomal localization; mutation	TUMOR-SUPPRESSOR GENE; INDUCIBLE FACTOR 1-ALPHA; HUMAN HOMOLOG; BETA-CATENIN; ALLELE LOSS; VHL; MUTATIONS; PROTEIN; CANCER; ACTIVATION	The VHL gene product (pVHL) forms a multimeric complex with the elongin B and C, Cul2 and Rbx1 proteins (VCBCR complex), which is homologous to the SCF family of ubiquitin ligase complexes. The VCBCR complex binds HIF-1 alpha and HIF-2 alpha, transcription factors critically involved in cellular responses to hypoxia, and targets them for ubiquitin-mediated proteolysis. Germline mutations in the VHL gene cause susceptibility to haemangioblastomas, renal cell carcinoma (RCC), phaeochromocytoma and other tumours. In addition somatic inactivation of the VHL gene occurs in most sporadic clear cell RCC (CC-RCC). However, the absence of somatic VHL inactivation in 30-40% of CC-RCC implies the involvement of other gatekeeper genes in CC-RCC development. We reasoned that in CC-RCC without VHL inactivation, other pVHL-interacting proteins might be defective. To assess the role of elongin B/C, Rbx1 and HIF-1 alpha in RCC tumorigenesis we (a) mapped the genes to chromosomes 8q(cen) (elongin C), 16p13.3 (elongin B) and 22q11.2 (Rbx1) by FISH, monochromosomal somatic cell hybrid panel screening and in silico GenBank homology searching; (b) determined the genomic organisation of elongin C (by direct sequencing of PAC clones), Rbx1 and elongin B (by GenBank homology searching); and (c) performed mutation analysis of exons comprising the coding regions of elongins B, C and Rbx1 and the oxygen-dependent degradation domain of HIF-1 alpha by SSCP screening and direct sequencing in 35 sporadic clear cell RCC samples without VHL gene inactivation and in 13 individuals with familial non-VHL clear cell RCC. No coding region sequence variations were detected for the elongin 13, elongin C or Rbx1 genes. Two amino acid substitutions (Pro582Ser and Ala588Thr) were identified in the oxygen-dependent degradation/pVHL binding domain of HIF-1 alpha, however neither substitution was observed exclusively in tumour samples. Association analysis in panels of CC-RCC and non-neoplastic samples using the RFLPs generated by each variant did not reveal allelic frequency differences between RCC patients and controls (P >0.32 by chi-squared analysis). Nevertheless, the significance of these variations and their potential for modulation of HIF-1 alpha function merits further investigation in both other tumour types and in non-neoplastic disease. Taken together with our previous Cul2 mutation analysis these data suggest that development of sporadic and familial RCC is not commonly contributed to by genetic events altering the destruction domain of HIF-1 alpha, or components of the HIF-alpha destruction complex other than VHL itself. Although (a) activation of HIF could occur through mutation of another region of HIF-a, and (b) epigenetic silencing of elongin B/C, Cul2 or Rbx1 cannot be excluded, these findings suggest that pVHL may represent the sole mutational target through which the VCBR complex is disrupted in CC-RCC. HIF response is activated in CC-RCC tumorigenesis.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Div Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Maxwell, Patrick H/C-5557-2008; MAHER, EAMONN R/A-9507-2008	Maxwell, Patrick H/0000-0002-0338-2679; MAHER, EAMONN R/0000-0002-6226-6918; Astuti, Dewi/0000-0003-4205-6160; Ratcliffe, Peter/0000-0002-2853-806X; Clifford, Steve/0000-0003-4893-2184				Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Duerr EM, 1999, J CLIN ENDOCR METAB, V84, P3207, DOI 10.1210/jc.84.9.3207; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Kadota M, 2000, ONCOL REP, V7, P529; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KELSELL DP, 1995, ANN HUM GENET, V59, P233, DOI 10.1111/j.1469-1809.1995.tb00743.x; KNOWLES MA, 1993, ONCOGENE, V8, P1357; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Perinchery G, 1999, INT J ONCOL, V14, P495; Poli-Frederico RC, 2000, HEAD NECK-J SCI SPEC, V22, P585, DOI 10.1002/1097-0347(200009)22:6<585::AID-HED7>3.0.CO;2-4; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, GENOMICS, V34, P437, DOI 10.1006/geno.1996.0311; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sparks AB, 1998, CANCER RES, V58, P1130; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THE BT, 1997, LANCET, V349, P848; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Wolter M, 1997, CANCER RES, V57, P2581; Woodward ER, 2000, J MED GENET, V37, P348, DOI 10.1136/jmg.37.5.348; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	41	124	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5067	5074		10.1038/sj.onc.1204602	http://dx.doi.org/10.1038/sj.onc.1204602			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526493				2022-12-25	WOS:000170439800018
J	Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B				Yoon, DS; Li, L; Zhang, RD; Kram, A; Ro, JY; Johnston, D; Grossman, HB; Scherer, S; Czerniak, B			Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease	ONCOGENE			English	Article						tumor suppressor gene loci; chromosome 16; bladder cancer	HUMAN-BREAST-CARCINOMA; URINARY-BLADDER; MICROSATELLITE ANALYSIS; PROSTATE-CANCER; ALLELIC LOSS; E-CADHERIN; EXPRESSION; CARCINOGENESIS; HETEROZYGOSITY; ALLELOTYPE	Histologic and genetic mapping with 30 hypervariable markers mapped to chromosome 16 were performed on 234 DNA samples of five cystectomy specimens from patients with invasive bladder cancer. Allelic losses of individual markers were related to microscopically identified precursor conditions in the entire bladder mucosa and invasive cancer. Their significance for the development and progression of neoplasia from in situ preneoplastic conditions to invasive disease was analysed by the nearest neighbor algorithm and binomial maximum likelihood analysis. Using this approach we identified five distinct regions of allelic losses defined by their flanking markers and predicted size as follows. p13.3(D16S418-D16S406, 1.2 cM), p13.1(D16S748-D16S287, 12.9 cM), q12 1(D16S409-D16S514, 24.0 cM), q22.1 (D16S496-D16S515, 5.4 cM), and q24 (D16S507-D16S511, 5.9 cM and D16S402-D16S413, 17.4 cM). The regions mapping to p13.1 and q24 were involved in early intraurothelial phases of bladder neoplasia such as mild to moderate dysplasia. On the other hand the deleted region mapping to p13.3 was involved in progression of severe dysplasia/carcinoma in situ to invasive bladder cancer. Testing of markers that exhibited statistically significant LOH in relation to progression of neoplasia from precursor conditions to invasive cancer on 28 tumors and voided urine samples from 25 patients with bladder cancer revealed that q12.1 showed LOH in 46.4% of tumor and 32.0% of voided urine samples. The LOH of a single marker D16S541 could be detected in approximately 28% of tumors and 20% of voided urine samples of patients with bladder cancer. These data imply that the deleted region centered around marker D16S541 spanning approximately 10 cM and flanked by D16S409 and D16S415 contains a novel putative tumor suppressor gene or genes playing an important role in the development of human bladder cancer. To facilitate more precise positional mapping and identification of pathogenetically relevent genes, we analysed of human genome contig and sequence databases spanning the deleted regions. Multiple known candidate genes and several smaller gene-rich areas mapping to the target regions of chromosome 16 were identified Oncogene (2001) 20, 5005-5014.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Czerniak, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Kram, Andrzej/0000-0003-0621-0204	NCI NIH HHS [R29CA66723, UO-1 CA85078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085078, R29CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, J CLIN PATHOL; Asgeirsson KS, 2000, EUR J CANCER, V36, P1098, DOI 10.1016/S0959-8049(00)00062-9; Brownlee K. A, 1965, STAT THEORY METHODOL; CAIRNS P, 1994, CANCER RES, V54, P1422; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG WYH, 1995, CANCER RES, V55, P3246; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; Czerniak B, 1999, ONCOGENE, V18, P1185, DOI 10.1038/sj.onc.1202385; Czerniak B, 2000, GENE CHROMOSOME CANC, V27, P392, DOI 10.1002/(SICI)1098-2264(200004)27:4<392::AID-GCC9>3.3.CO;2-E; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Czerniak B, 1995, DIAGNOSTIC CYTOLOGY, P345; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hartigan J., 1975, CLUSTERING ALGORITHM; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; KOSS L G, 1977, Urology, V9, P442, DOI 10.1016/0090-4295(77)90227-8; KOSS LG, 1991, NEW ENGL J MED, V324, P125; KOSS LG, 1974, JAMA-J AM MED ASSOC, V227, P281; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; Mostofi F, 1999, HISTOLOGICAL TYPING; Ott J., 1991, ANAL HUMAN GENETICS; Pan Y, 1998, PROSTATE, V36, P31, DOI 10.1002/(SICI)1097-0045(19980615)36:1<31::AID-PROS5>3.0.CO;2-E; RODGERS CS, 1984, CANCER GENET CYTOGEN, V13, P95, DOI 10.1016/0165-4608(84)90052-9; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; SATO T, 1990, CANCER RES, V50, P7184; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316	34	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5005	5014		10.1038/sj.onc.1204612	http://dx.doi.org/10.1038/sj.onc.1204612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526485				2022-12-25	WOS:000170439800010
J	Perez, P; Page, A; Bravo, A; del Rio, M; Gimenez-Conti, I; Budunova, I; Slaga, TJ; Jorcano, JL				Perez, P; Page, A; Bravo, A; del Rio, M; Gimenez-Conti, I; Budunova, I; Slaga, TJ; Jorcano, JL			Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor	FASEB JOURNAL			English	Article						skin; aplasia cutis congenita; ectodermal dysplasia; NF-kappa B	APLASIA-CUTIS-CONGENITA; GROWTH-FACTOR RECEPTOR; FACTOR-KAPPA-B; TRANSCRIPTION FACTORS; HAIR FOLLICLE; DNA-BINDING; MOUSE SKIN; EXPRESSION; P50-NF-KAPPA-B; ACTIVATION	Glucocorticoids (GCs) are potent inhibitors of epidermal proliferation and effective antiinflammatory compounds, which make them the drug of choice for a wide range of inflammatory and hyperproliferative skin disorders. GC action is mediated via the glucocorticoid receptor (GR). To study the role of GR in skin development and the molecular mechanisms underlying its action, we generated transgenic mice overexpressing GR in epidermis and other stratified epithelia, under the control of the keratin K5 promoter. Newborn mice show altered skin development, manifested as variable-sized skin lesions that range from epidermal hypoplasia and underdeveloped dysplastic hair follicles to a complete absence of this tissue. In the most affected individuals, skin was absent at the cranial and umbilical regions, and the vibrissae and eyebrows appear scarce, short, and curly. In addition, as a consequence of transgene expression in other ectodermally derived epithelia, K5-GR mice exhibited further abnormalities that strikingly resemble the clinical findings in patients with ectodermal dysplasia, which includes aplasia cutis congenita. In adult transgenic skin, topical application of the tumor promoter TPA did not elicit hyperplasia or transcriptional induction of several proinflammatory cytokines. This antiinflammatory role of GR was due at least in part to interference with NF-kappaB, leading to a strong reduction in the kappaB-binding activity without altering the transcriptional levels of the inhibitor I kappaB alpha.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Univ Santiago de Compostela, Fac Vet, Dept Anim Pathol, E-27002 Lugo, Spain; Univ Texas, MD Anderson Canc Ctr, Smithville, TX USA; AMC Canc Res Ctr, Denver, CO USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela; University of Texas System; UTMD Anderson Cancer Center; AMC Cancer Research Center	Jorcano, JL (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Av Complutense 22, E-28040 Madrid, Spain.	jl.jorcano@ciemat.es	Moral, Ana María Bravo/AAD-3339-2021; Perez, Paloma/K-8841-2017; DEL RIO, MARCELA/H-2796-2015	Moral, Ana María Bravo/0000-0002-5282-8921; Perez, Paloma/0000-0002-7166-2824; DEL RIO, MARCELA/0000-0003-2910-7189; Page, Angustias/0000-0002-0231-8536				Ahluwalia A, 1998, MEDIAT INFLAMM, V7, P183, DOI 10.1080/09629359891126; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; CHITAYAT D, 1992, AM J MED GENET, V44, P562, DOI 10.1002/ajmg.1320440506; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; FRIEDEN IJ, 1986, J AM ACAD DERMATOL, V14, P646, DOI 10.1016/S0190-9622(86)70082-0; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hansen LA, 1997, AM J PATHOL, V150, P1959; Hogan B, 1994, MANIPULATING MOUSE E; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; LEBOUCQ N, 1994, NEURORADIOLOGY, V36, P480, DOI 10.1007/BF00593689; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOORE KL, 1999, CLIN EMBRYOLOGY; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SLAGA TJ, 1996, J INVEST DERMATOL, V2, P151; STEPHAN MJ, 1982, J PEDIATR-US, V101, P850, DOI 10.1016/S0022-3476(82)80346-6; Tobin D, 1996, ONCOGENE, V12, P785; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365	25	67	69	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2030	+		10.1096/fj.00-0772fje	http://dx.doi.org/10.1096/fj.00-0772fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511512				2022-12-25	WOS:000170318500014
J	Brusca, EM; True, HL; Celander, DW				Brusca, EM; True, HL; Celander, DW			Novel RNA-binding properties of Pop3p support a role for eukaryotic RNase P protein subunits in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; RIBOZYME; MRP; COMPONENT; COMPLEX; ENZYME	Ribonuclease P (RNase P) catalyzes the 5'-end maturation of transfer RNA molecules. Recent evidence suggests that the eukaryotic protein subunits may provide substrate-binding functions (True, H. L., and Celander, D. W. (1998) J. Biol Chem. 273, 7193-7196). We now report that Pop3p, an essential protein subunit of the holoenzyme in Saccharomyces cerevisiae, displays novel RNA-binding properties. A recombinant form of Pop3p (H6Pop3p) displays a 3-fold greater affinity for binding pre-tRNA substrates relative to tRNA products. The recognition sequence for the H6Pop3p-substrate interaction in vitro was mapped to a 39-nucleotide long sequence that extends from position -21 to +18 surrounding the natural processing site in pre-tRNA substrates. H6Pop3p binds a variety of RNA molecules with high affinity (K-d = 16-25 nm) and displays a preference for single-stranded RNAs. Removal or modification of basic C-terminal residues attenuates the RNA-binding properties displayed by the protein specifically for a pre-tRNA substrate. These studies support the model that eukaryotic RNase P proteins bind simultaneously to the RNA subunit and RNA substrate.	Loyola Univ, Dept Chem, Chicago, IL 60626 USA	Loyola University Chicago	Celander, DW (corresponding author), Loyola Univ, Dept Chem, 6525 N Sheridan Rd, Chicago, IL 60626 USA.		True, Heather/D-2979-2012					ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P2627, DOI 10.1073/pnas.92.7.2627; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; Dichtl B, 1997, EMBO J, V16, P417, DOI 10.1093/emboj/16.2.417; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARDT WD, 1993, BIOCHEMISTRY-US, V32, P13046, DOI 10.1021/bi00211a014; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Kurz JC, 1998, BIOCHEMISTRY-US, V37, P2393, DOI 10.1021/bi972530m; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; Mohan A, 2000, J MOL BIOL, V303, P605, DOI 10.1006/jmbi.2000.4162; Niranjanakumari S, 1998, P NATL ACAD SCI USA, V95, P15212, DOI 10.1073/pnas.95.26.15212; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; Pannucci JA, 1999, P NATL ACAD SCI USA, V96, P7803, DOI 10.1073/pnas.96.14.7803; Pluk H, 1999, RNA, V5, P512, DOI 10.1017/S1355838299982079; RYAN PC, 1989, BIOCHEMISTRY-US, V28, P9949, DOI 10.1021/bi00452a012; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; True HL, 1998, J BIOL CHEM, V273, P7193, DOI 10.1074/jbc.273.13.7193; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Ziehler WA, 2000, BIOCHEMISTRY-US, V39, P9909, DOI 10.1021/bi000603n	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42543	42548		10.1074/jbc.M107293200	http://dx.doi.org/10.1074/jbc.M107293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527978	hybrid			2022-12-25	WOS:000172450400129
J	Lo Bello, M; Nuccetelli, M; Caccuri, AM; Stella, L; Parker, MW; Rossjohn, J; McKinstry, WJ; Mozzi, AF; Federici, G; Polizio, F; Pedersen, JZ; Ricci, G				Lo Bello, M; Nuccetelli, M; Caccuri, AM; Stella, L; Parker, MW; Rossjohn, J; McKinstry, WJ; Mozzi, AF; Federici, G; Polizio, F; Pedersen, JZ; Ricci, G			Human glutathione transferase P1-1 and nitric oxide carriers - New role for an old enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; S-NITROSOGLUTATHIONE; CRYSTAL-STRUCTURE; IRON COMPLEXES; POSITIVE COOPERATIVITY; IN-VIVO; RAT; PROTEIN; IDENTIFICATION; NITROSYLATION	S-Nitrosoglutathione and the dinitrosyl-diglutathionyl iron complex are involved in the storage and transport of NO in biological systems. Their interactions with the human glutathione transferase P1-1 may reveal an additional physiological role for this enzyme. In the absence of GSH, S-nitrosoglutathione causes rapid and stable S-nitrosylation of both the CyS47 and Cys(101) residues. Ion spray ionization-mass spectrometry ruled out the possibility of S-glutathionylation and confirms the occurrence of a poly-S-nitrosylation in GST P1-1. S-Nitrosylation of Cys(47) lowers the affinity 10-fold for GSH, but this negative effect is minimized by a half-site reactivity mechanism that protects one Cys(47)/dimer from nitrosylation. Thus, glutathione transferase P1-1, retaining most of its original activity, may act as a NO carrier protein when GSH depletion occurs in the cell. The dinitrosyl-diglutathionyl iron complex, which is formed by S-nitrosoglutathione decomposition in the presence of physiological concentrations of GSH and traces of ferrous ions, binds with extraordinary affinity to one active site of this dimeric enzyme (K-i < 10(-12) M) and triggers negative cooperativity in the vacant subunit (K-i = 10(-9) m). The complex bound to the enzyme is stable for hours, whereas in the free form and at low concentrations, its life time is only a few minutes. ESR and molecular modeling studies provide a reasonable explanation of this strong interaction, suggesting that Tyr(7) and enzyme-bound GSH could be involved in the coordination of the iron atom. All of the observed findings suggest that glutathione transferase P1-1, by means of an intersubunit communication, may act as a NO carrier under different cellular conditions while maintaining its well known detoxificating activity toward dangerous compounds.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Chem, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Childrens Hosp, I-00165 Rome, Italy; Ist Ric & Cura Caratters Sci Bambino Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; St. Vincent's Institute of Medical Research; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy.	riccig@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; McKinstry, William J/D-2612-2013; Rossjohn, Jamie/F-9032-2013; Stella, Lorenzo/A-7996-2010; Parker, Michael W/F-9069-2013	McKinstry, William J/0000-0001-9668-9364; Rossjohn, Jamie/0000-0002-2020-7522; Stella, Lorenzo/0000-0002-5489-7381; Parker, Michael W/0000-0002-3101-1138; Ricci, Giorgio/0000-0002-7108-2846				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOESE M, 1985, J BIOL CHEM, V272, P29244; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; CLARK AG, 1988, BIOCHEM PHARMACOL, V37, P3199, DOI 10.1016/0006-2952(88)90321-8; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Habig W H, 1981, Methods Enzymol, V77, P398; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kauser K, 1999, ENDOTHEL CELL RES S, V5, P195; Keese MA, 1997, BIOCHEM PHARMACOL, V54, P1307, DOI 10.1016/S0006-2952(97)00348-1; Kleschyov AL, 2000, AM J PHYSIOL-HEART C, V279, pH2743, DOI 10.1152/ajpheart.2000.279.6.H2743; Kluge I, 1997, J NEUROCHEM, V69, P2599; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Lo Bello M, 1998, J MOL BIOL, V284, P1717; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; MEY C, 1998, CURR MED RES OPIN, V14, P187; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Mitchell AE, 1998, BIOCHEMISTRY-US, V37, P6752, DOI 10.1021/bi971846r; MONCADA S, 1994, J HYPERTENS, V12, pS35; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; PARK JW, 1988, BIOCHEM BIOPH RES CO, V152, P916, DOI 10.1016/S0006-291X(88)80127-X; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; RICCI G, 1989, J BIOL CHEM, V264, P5462; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stella L, 1999, PROTEINS, V37, P1; TAMIR S, 1996, BIOCHIM BIOPHYS ACTA, V1288, P31; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; Vanin AF, 1996, BBA-PROTEIN STRUCT M, V1295, P5, DOI 10.1016/0167-4838(95)00247-2; VANIN AF, 1975, STUD BIOPHYS, V49, P13; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V211, P313, DOI 10.1016/0014-2999(92)90386-I; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	65	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42138	42145						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533048				2022-12-25	WOS:000172450400081
J	Zhang, M; Chiang, JYL				Zhang, M; Chiang, JYL			Transcriptional regulation of the human sterol 12 alpha-hydroxylase gene (CYP8B1) - Roles of hepatocyte nuclear factor 4 alpha in mediating bile acid repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; LIVER-SPECIFIC EXPRESSION; HEPATITIS-B VIRUS; ALPHA PPAR-ALPHA; ACTIVATED RECEPTOR; CYP7A1 TRANSCRIPTION; RESPONSIVE ELEMENT; P450 CYP8B; RAT-LIVER; IDENTIFICATION	Sterol 12 alpha -hydroxylase catalyzes the synthesis of cholic acid and controls the ratio of cholic acid over chenodeoxycholic acid in the bile. Transcription of CYP8B1 is inhibited by bile acids, cholesterol, and insulin. To study the mechanism of CYP8B1 transcription by bile acids, we have cloned and determined 3389 base pairs of the 5'-upstream nucleotide sequences of the human CYP8B1. Deletion analysis of CYP8B1/luciferase reporter activity in HepG2 cells revealed that the sequences from -57 to +300 were important for basal and liver-specific promoter activities. Hepatocyte nuclear factor 4 alpha (IINF4 alpha) strongly activated human CYP8B1 promoter activities, whereas cholesterol 7 alpha -hydroxylase promoter factor (CPF), an NR5A2 family of nuclear receptors, had much less effect. Electrophoretic mobility shift assay identified an overlapping HNF4 alpha- and CPF-binding site in the +198/+227 region. The human CYP8B1 promoter activities were strongly repressed by bile acids, and the bile acid response element was localized between +137 and +220. Site-directed mutagenesis of the HNF4 alpha -binding site markedly reduced promoter activity and its response to bile acid repression. On the other hand, mutation of the CPF-binding site had little effect on promoter activity and bile acid inhibition. A negative nuclear receptor, small heterodimer partner markedly inhibited transactivation of CYP8B1 by HNF4 alpha. Mammalian two-hybrid assay confirmed that HNF4 alpha interacted with small heterodimer partner. Furthermore, bile acids and farnesoid X receptor reduced the expression of nuclear HNF4 alpha in HepG2 cells and rat livers and its binding to DNA. Bile acids and farnesoid X receptor also inhibited mouse HNF4 alpha gene transcription. In summary, our data revealed the critical roles HNF4 alpha play on CYP8B1 transcription and its repression by bile acids. Bile acids repress human CYP8B1 transcription by reducing the transactivation activity of HNF4 alpha through interaction of HNF4 alpha with SHP and reduction of HNF4 alpha expression in the liver.	NE Ohio Univ, Coll Med, Dept Biochem & Mol Pathol, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Chiang, JYL (corresponding author), NE Ohio Univ, Coll Med, Dept Biochem & Mol Pathol, POB 95, Rootstown, OH 44272 USA.		Chiang, John Y. L./G-2658-2011	Chiang, John Y. L./0000-0001-9360-7650	NIDDK NIH HHS [R01 DK044442, DK44442, R01 DK058379] Funding Source: Medline; NIGMS NIH HHS [GM31584] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK044442, R01DK058379, R01DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Andersson U, 1999, BBA-MOL CELL BIOL L, V1438, P167, DOI 10.1016/S1388-1981(99)00036-0; BJORKHEM I, 1983, J LIPID RES, V24, P1451; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chen WL, 2001, J LIPID RES, V42, P1402; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Gafvels M, 1999, GENOMICS, V56, P184, DOI 10.1006/geno.1998.5606; Galarneau L, 1998, CYTOGENET CELL GENET, V82, P269, DOI 10.1159/000015116; Gilbert S, 2000, J VIROL, V74, P5032, DOI 10.1128/JVI.74.11.5032-5039.2000; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Ishida H, 2000, J BIOCHEM, V127, P57, DOI 10.1093/oxfordjournals.jbchem.a022584; ISHIDA H, 1992, J BIOL CHEM, V267, P21319; Ishida H, 1999, J BIOCHEM-TOKYO, V126, P19, DOI 10.1093/oxfordjournals.jbchem.a022422; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Marrapodi M, 2000, J LIPID RES, V41, P514; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; OBRIEN RM, 1996, DIABETES MELLITUS, P234; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	48	194	200	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41690	41699		10.1074/jbc.M105117200	http://dx.doi.org/10.1074/jbc.M105117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535594	hybrid			2022-12-25	WOS:000172450400022
J	Han, JW; Liu, SC; Rose, DM; Schlaepfer, DD; McDonald, H; Ginsberg, MH				Han, JW; Liu, SC; Rose, DM; Schlaepfer, DD; McDonald, H; Ginsberg, MH			Phosphorylation of the integrin alpha(4) cytoplasmic domain regulates paxillin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL INTERACTIONS; MIGRATING FIBROBLASTS; ADHESION; TYROSINE; ACTIVATION; MODULATION; RECEPTOR; PROTEINS; SUBUNIT; TAIL	alpha4 integrins are essential for embryogenesis, hematopoiesis, inflammation, and immune response possibly because alpha (4) integrins have distinct signaling properties from other integrins. Specifically, the alpha (4) cytoplasmic domain binds tightly to paxillin, a signaling adaptor protein, leading to increased cell migration and an altered cytoskeletal organization that results in reduced cell spreading. The alpha (4) tail contains potential phosphorylation sites clustered in its core paxillin binding region. We now report that the alpha (4) tail is phosphorylated in vitro and in viva. Furthermore, Ser(988) is a major phosphorylation site. Using antibodies specific for Ser(988)- phosphorylated alpha (4), we found the stoichiometry of a4 phosphorylation varied in different cells. However, > 60% of a4 was phosphorylated in Jurkat T cells. Phosphorylation at Ser(988) blocked paxillin binding to the alpha (4) tail. A phosphorylation-mimicking mutant of alpha (4) (alpha (4)S988D) blocked paxillin binding and reversed the inhibitory effect of alpha (4) on cell spreading. Consequently, alpha (4) phosphorylation is a biochemical mechanism to modulate paxillin binding to alpha (4) integrins with consequent regulation of alpha (4) integrin-dependent cellular functions.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu			NCI NIH HHS [CA-75240] Funding Source: Medline; NCRR NIH HHS [RR11823-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075240, R01CA075240] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arroyo AG, 1999, IMMUNITY, V11, P555, DOI 10.1016/S1074-7613(00)80131-4; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUYON JP, 1990, J IMMUNOL, V144, P191; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; Law DA, 1998, BLOOD, V92, p701A; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; LUO K, 1990, ONCOGENE, V5, P921; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; ZENT R, 2001, MOL BASIS BLOOD DIS, P485; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351	33	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40903	40909		10.1074/jbc.M102665200	http://dx.doi.org/10.1074/jbc.M102665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533025	hybrid			2022-12-25	WOS:000171925600071
J	Jain, D; Nair, DT; Swaminathan, GJ; Abraham, EG; Nagaraju, J; Salunke, DM				Jain, D; Nair, DT; Swaminathan, GJ; Abraham, EG; Nagaraju, J; Salunke, DM			Structure of the induced antibacterial protein from tasar silkworm, Antheraea mylitta - Implications to molecular evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT DEFENSIN-A; ANTIFUNGAL PROTEIN; IMMUNE HEMOLYMPH; INNATE IMMUNITY; PURIFICATION; ALIGNMENT; PEPTIDES; GLOVERIN; LARVAE; PUPAE	The crystal structure of an antibacterial protein of immune origin (TSWAB), purified from tasar silkworm (Antheraea mylitta) larvae after induction by Escherichia cola infection, has been determined. This is the first insect lysozyme structure and represents induced lysozymes of innate immunity. The core structure of TSWAB is similar to c-type lysozymes and alpha -lactalbumins. However, TSWAB shows significant differences with respect to the other two proteins in the exposed loop regions. The catalytic residues in TSWAB are conserved with respect to the chicken lysozyme, indicating a common mechanism of action. However, differences in the noncatalytic residues in the substrate binding groove imply subtle differences in the specificity and the level of activity. Thus, conformational differences between TSWAB and chicken lysozyme exist, whereas functional mechanisms appear to be similar. On the other hand, alpha -lactalbumins and c-type lysozymes exhibit drastically different functions with conserved molecular conformation. It is evident that a common molecular scaffold is exploited in the three enzymes for apparently different physiological roles. It can be inferred on the basis of the structure-function comparison of these three proteins having common phylogenetic origin that the conformational changes in a protein are minimal during rapid evolution as compared with those in the normal course of evolution.	Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India; Seribiotech Res Lab, Bangalore 560086, Karnataka, India; Ctr DNA Fingerprinting & Diagnost, Hyderabad 500076, Andhra Pradesh, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Salunke, DM (corresponding author), Natl Inst Immunol, Struct Biol Unit, Aruna Asaf Ali Marg, New Delhi 110067, India.		Nair, Deepak T/AAR-5234-2020	Swaminathan, Jawahar/0000-0002-0215-4084; Jain, Deepti/0000-0002-8631-7230; Nair, Deepak/0000-0002-0677-9444				ABRAHAM EG, 1995, J INVERTEBR PATHOL, V65, P17, DOI 10.1006/jipa.1995.1003; Akuffo H, 1998, INT J MOL MED, V1, P77; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Axen A, 1997, EUR J BIOCHEM, V247, P614, DOI 10.1111/j.1432-1033.1997.00614.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARLSSON A, 1991, INFECT IMMUN, V59, P3040, DOI 10.1128/IAI.59.9.3040-3045.1991; CASTEELS P, 1990, RES IMMUNOL, V141, P940, DOI 10.1016/0923-2494(90)90199-9; CHIPMAN DM, 1969, SCIENCE, V165, P454, DOI 10.1126/science.165.3892.454; Chung KT, 2000, EUR J BIOCHEM, V267, P677, DOI 10.1046/j.1432-1327.2000.01034.x; Copley RR, 2000, J MOL BIOL, V303, P627, DOI 10.1006/jmbi.2000.4152; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; JOLLES J, 1979, J MOL EVOL, V14, P267, DOI 10.1007/BF01732494; JONES TA, 1994, O MANUAL; Katsutoshi N., 1989, EUR J BIOCHEM, V182, P111; Landon C, 1997, PROTEIN SCI, V6, P1878, DOI 10.1002/pro.5560060908; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee KH, 1998, FEBS LETT, V439, P41, DOI 10.1016/S0014-5793(98)01333-7; Lee YT, 1999, BIOCHEM MOL BIOL INT, V47, P369; Mackintosh JA, 1998, DEV COMP IMMUNOL, V22, P387, DOI 10.1016/S0145-305X(98)00025-1; MAGETDANA R, 1995, BIOCHIMIE, V77, P240, DOI 10.1016/0300-9084(96)88130-2; Mandard N, 1998, EUR J BIOCHEM, V256, P404, DOI 10.1046/j.1432-1327.1998.2560404.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAGARAJU J, 1992, WILD SILKMOTH 92, P22; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKADA M, 1985, J BIOL CHEM, V260, P7174; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHIPPS DJ, 1994, DEV COMP IMMUNOL, V18, P13, DOI 10.1016/0145-305X(94)90248-8; POWNING RF, 1976, COMP BIOCHEM PHYS B, V55, P221, DOI 10.1016/0305-0491(76)90234-0; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; [No title captured]	39	24	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41377	41382		10.1074/jbc.M104674200	http://dx.doi.org/10.1074/jbc.M104674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522783	hybrid			2022-12-25	WOS:000171925600132
J	Mitsuzawa, H; Wada, I; Sano, H; Iwaki, D; Murakami, S; Himi, T; Matsushima, N; Kuroki, Y				Mitsuzawa, H; Wada, I; Sano, H; Iwaki, D; Murakami, S; Himi, T; Matsushima, N; Kuroki, Y			Extracellular toll-like receptor 2 region containing Ser(40)-Ile(64) but not Cys(30)-Ser(39) is critical for the recognition of Staphylococcus aureus peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL COMPONENTS; LEUCINE-RICH REPEAT; CUTTING EDGE; LIPOPOLYSACCHARIDE-BINDING; SOLUBLE PEPTIDOGLYCAN; CD14; PROTEINS; GENE; ACTIVATION; MICE	Toll-like receptor 2 (TLR2) and CD14 function as pat tern recognition receptors for bacterial peptidoglycan (PGN). TLRs and CD14 possess repeats of the leucine rich motif. To address the role of the extracellular domain of TLR2 in PGN signaling, we constructed CD14/TLR2 chimeras, in which residues 1-356 or 1-323 of CD14 were substituted for the extracellular domain of TLR2, and five deletion mutants of TLR2, in which the progressively longer regions of extracellular TLR2 regions were deleted. PGN induced NF-kappaB activation in HEK293 cells expressing TLR2 but not in cells expressing CD14/TLR2 chimeras. The cells transfected with a deletion mutant TLR2(Delta Cys30-Ile64) as well as TLR2(Delta Cys30-Asp160) and TLR2 Delta (Cys30-Asp305) failed to respond to PGN, indicating the importance of the TLR2 region Cys(30)-Ile(64). Although TLR2(Delta Cys30-Ser39) conferred cell responsiveness to PGN, the cells expressing TLR2(Delta Ser40-Ile64) failed to induce NF-kappaB activation. In addition, NF-kappaB activity elicited by PGN was significantly attenuated in the presence of synthetic peptide corresponding to the TLR2 region Ser(40)-Ile(64). From these results, we conclude that; 1) CD14 cannot functionally replace the extracellular domain of TLR2 in PGN signaling; 2) the TLR2 region Cys(30)-Ser(39) is not required for PGN recognition; 3) the TLR2 region containing Ser(40)-Ile(64) is critical for PGN recognition.	Sapporo Med Univ, Sch Med, Dept Biochem 1, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Biochem 2, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Otolaryngol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Biochem 1, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Biochem 2, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Dept Otolaryngol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South-1 West-17, Sapporo, Hokkaido 0608556, Japan.			Wada, Ikuo/0000-0001-5668-6994				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; FERRERO E, 1990, J IMMUNOL, V145, P331; GUPTA D, 1995, J IMMUNOL, V155, P2620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoshino K, 1999, J IMMUNOL, V162, P3749; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SIMMONS DL, 1989, BLOOD, V73, P284; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Yoshimura A, 1999, J IMMUNOL, V163, P1	36	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41350	41356		10.1074/jbc.M104177200	http://dx.doi.org/10.1074/jbc.M104177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522781	hybrid			2022-12-25	WOS:000171925600129
J	Monroy, MA; Ruhl, DD; Xu, XQ; Granner, DK; Yaciuk, P; Chrivia, JC				Monroy, MA; Ruhl, DD; Xu, XQ; Granner, DK; Yaciuk, P; Chrivia, JC			Regulation of cAMP-responsive element-binding protein-mediated transcription by the SNF2/SWI-related protein, SRCAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RNA-POLYMERASE-II; COACTIVATORS P300; CONSTITUTIVE ACTIVATION; GLUCOCORTICOID RESPONSE; GENE-TRANSCRIPTION; CREB INTERACTS; FACTOR GATA-1; CBP; DOMAIN	SRCAP (SNF2-related CPB activator protein) belongs to the SNF2 family of proteins whose members participate in various aspects of transcriptional regulation, including chromatin remodeling. It was identified by its ability to bind to cAMP-responsive-binding protein (CREB)-binding protein (CBP), and it increases the transactivation function of CBP. The phosphoenolpyruvate carboxykinase (PEPCK) promoter was used as a model system to explore the role of SRCAP in the regulation of transcription mediated by factors that utilize CBP as a coactivator. We show that transcription of a PEPCK chloramphenicol acetyltransferase (CAT) reporter gene activated by protein kinase A (PKA) is enhanced 7-fold by SRCAP. In the absence of PKA this SRCAP-mediated enhancement does not occur, suggesting that SRCAP functions as a coactivator for PKA-activated factors such as CREB. Replacing the PEPCK promoter binding site for CREB with a binding site for Gal4 (Delta CRE (CAMP-responsive element) Gal4 PEPCK-CAT reporter gene) blocks the ability of SRCAP to activate transcription despite the presence of PKA. Expression of a Gal-CREB chimera restores the ability of PKA to regulate transcription of the Delta CRE Gal4 PEPCK gene and restored the ability of SRCAP to stimulate PKA-activated transcription. In addition, SRCAP in the presence of PKA enhances the ability of the Gal-CREB chimera to activate transcription of a Gal-CAT reporter gene that contains only binding sites for Gal4. SRCAP binds to CBP amino acids 280-460, a region that is important for CBP to function as a coactivator for CREB. Overexpression of a SRCAP peptide corresponding to this CBP binding domain acts as a dominant negative inhibitor of CREB-mediated transcription. Structure-function studies were done to explore the mechanism(s) by which SRCAP regulates transcription. These studies indicate that the N-terminal region of SRCAP, which contains five of the seven regions that comprise the ATPase domain, is not needed for activation of CREB-mediated transcription. SRCAP apparently has several domains that participate in the activation of transcription.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Saint Louis University; Saint Louis University; Vanderbilt University	Chrivia, JC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand, St Louis, MO 63104 USA.	Chrivia@SLU.edu						Alleva DG, 1997, J IMMUNOL, V159, P2941; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chen CJ, 2001, MOL CELL BIOL, V21, P476, DOI 10.1128/MCB.21.2.476-487.2001; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Ugai H, 1999, J MOL MED, V77, P481, DOI 10.1007/s001099900021; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1994, J BIOL CHEM, V269, P28732; Xu XQ, 2001, J VIROL, V75, P10033, DOI 10.1128/JVI.75.21.10033-10040.2001; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000	54	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40721	40726		10.1074/jbc.M103615200	http://dx.doi.org/10.1074/jbc.M103615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522779	hybrid			2022-12-25	WOS:000171925600047
J	Prosch, S; Heine, AK; Volk, HD; Kruger, DH				Prosch, S; Heine, AK; Volk, HD; Kruger, DH			CCAAT/enhancer-binding proteins alpha and beta negatively influence the capacity of tumor necrosis factor alpha to up-regulate the human cytomegalovirus IE1/2 enhancer/promoter by nuclear factor kappa B during monocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY ENHANCER; C/EBP FAMILY MEMBERS; SERUM-ALBUMIN GENE; TRANSPLANT RECIPIENTS; TRANSCRIPTIONAL CONTROL; INTERLEUKIN-8 GENE; DNA-BINDING; TNF-ALPHA; IN-VITRO; NF-M	Recently we demonstrated that the ability of tumor necrosis factor alpha (TNF alpha) to stimulate the human cytomegalovirus (HCMV) IE1/2 enhancer/promoter activity in myeloid progenitor-like cells decreases when these cells differentiate into promonocytic cells. In addition, TNF alpha stimulation in the progenitor-like cell line HL-60 was shown to be mediated by nuclear factor kappaB (NF-kappaB) activation and its binding to the 18-base pair sequence motifs of the IE1/2 enhancer. We demonstrate here that the cell differentiation-dependent reduction of TNFa stimulation is not due to insufficient NF-kappaB activation but correlates with increased synthesis of the monocyte differentiation-associated factors CCAAT/enhancer-binding protein (C/EBP) alpha and beta. Overexpression of C/EBP alpha /3 in HL-60 cells, which normally produce only very small amounts of C/EBP, stimulated the basal activity of the promoter in the absence of NF-kappaB but suppressed the stimulatory effect of TNF alpha. A novel C/EBP-binding site was identified in the IE1/2 enhancer directly downstream of a NF-kappaB site. In order to understand the mechanisms of interaction, we used an IE1/2 promoter mutant that failed to bind C/EBP at this position and several constructs that contained exclusively NF-kappaB- and/or C/EBP-binding sites upstream of the minimal IE1/2 promoter. We could demonstrate that C/EBP alpha/beta interacts with NF-kappaB p65 and displays inhibitory activity even in the absence of direct DNA binding by forming p65-C/EBP-containing protein complexes bound to the NF-kappaB site. Moreover, C/EBP binding to the DNA adjacent to NF-kappaB supports the down-regulatory effect of C/EBPs possibly due to stabilization of a multimeric NF-kappaB-C/EBP complex. Our results show that cell differentiation factors may interfere with TNF alpha -induced human cytomegalovirus gene (re)activation.	Humboldt Univ, Charite, Sch Med, Inst Virol,Dept Virol, D-10098 Berlin, Germany; Humboldt Univ, Charite, Sch Med, Dept Med Immunol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Prosch, S (corresponding author), Humboldt Univ, Charite, Sch Med, Inst Virol,Dept Virol, D-10098 Berlin, Germany.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Asadullah K, 1999, BRIT J DERMATOL, V141, P94; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CRISTY RJ, 1989, GENE DEV, V31, P1323; Dittmer D, 1997, J VIROL, V71, P1629, DOI 10.1128/JVI.71.2.1629-1634.1997; DOCKE WD, 1994, LANCET, V343, P268, DOI 10.1016/S0140-6736(94)91116-9; FICKENSCHER H, 1989, J GEN VIROL, V70, P107, DOI 10.1099/0022-1317-70-1-107; FIETZE E, 1994, TRANSPLANTATION, V58, P675; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Greaves RF, 1998, J VIROL, V72, P366, DOI 10.1128/JVI.72.1.366-379.1998; Grundy JE, 1998, MONOGR VIROL, V21, P67; HAAS JG, 1992, J IMMUNOL, V149, P237; Hahn G, 1998, P NATL ACAD SCI USA, V95, P3937, DOI 10.1073/pnas.95.7.3937; HENRY S, 1999, J CLIN VIROL, V12, P98; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kondo K, 1996, P NATL ACAD SCI USA, V93, P11137, DOI 10.1073/pnas.93.20.11137; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Kutza AST, 1998, CLIN INFECT DIS, V26, P1076, DOI 10.1086/520307; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Meier JL, 1996, INTERVIROLOGY, V39, P331, DOI 10.1159/000150504; Mendelson M, 1996, J GEN VIROL, V77, P3099, DOI 10.1099/0022-1317-77-12-3099; Mikita T, 1998, J IMMUNOL, V161, P1822; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mutimer D, 1997, TRANSPLANTATION, V63, P1411, DOI 10.1097/00007890-199705270-00007; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Prosch S, 1998, MG VIROLOGY, V21, P29; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCOTT LM, 1992, BLOOD, V80, P1725; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Soderberg-Naucler C, 1997, J CLIN INVEST, V100, P3154, DOI 10.1172/JCI119871; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; Staak K, 1997, BLOOD, V89, P3682, DOI 10.1182/blood.V89.10.3682.3682_3682_3690; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; Stenberg RM, 1996, INTERVIROLOGY, V39, P343, DOI 10.1159/000150505; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vietor I, 1996, J BIOL CHEM, V271, P5595, DOI 10.1074/jbc.271.10.5595; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Yamada Y, 1998, AM J PATHOL, V152, P1577; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974; Yonemitsu Y, 1997, BIOCHEM BIOPH RES CO, V231, P447, DOI 10.1006/bbrc.1997.6035	54	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40712	40720		10.1074/jbc.M009815200	http://dx.doi.org/10.1074/jbc.M009815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522776	hybrid			2022-12-25	WOS:000171925600046
J	Reeder, MK; Serebriiskii, IG; Golemis, EA; Chernoff, J				Reeder, MK; Serebriiskii, IG; Golemis, EA; Chernoff, J			Analysis of small GTPase signaling pathways using p21-activated kinase mutants that selectively couple to Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PROTEIN-KINASE; ADAPTER PROTEIN; PAK KINASES; RHO GTPASES; ALPHA-PAK; ACTIN; RAC; EFFECTOR; BINDING	p21-activated kinase 1 (Pak1) is an effector for the small GTPases Cdc42 and Rac. Because Pak1 binds to and is activated by both these GTPases, it has been difficult to precisely delineate the signaling pathways that link extracellular stimuli to Pak1 activation. To separate activation of Pak1 by Cdc42 versus activation by Rae, we devised a genetic screen in yeast that enabled us to create and identify Pak1 mutants that selectively couple to Cdc42 but not Rac1. We recovered several such Pak1 mutants and found that the residues most often affected lie within the p21 binding domain, a region previously known to mediate Pak1 binding to GTPases, but that several mutations also map outside the borders of the p21 binding domain. Pak1 mutants that associate with Cdc42 but not Rac1 were also activated by Cdc42 but not Rac1. In rat 3Y1 cells expressing oncogenic Ha-Ras, the Pak1 mutants defective in Rac1 binding are not activated, suggesting that Ras signals through a GTPase other than Cdc42 to activate Pak1. Similar results were obtained when epidermal growth factor was used to activate Pak1. However, Pak1 mutants that are unable to bind Rae are nonetheless well activated by calf serum, implying that this stimulus may induce Pak activation independent of Rae.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836; Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [R01 GM54168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FROMANT M, 1998, ANAL BIOCHEM, V224, P347; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Joberty G, 1999, MOL CELL BIOL, V19, P6585; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	50	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40606	40613		10.1074/jbc.M103925200	http://dx.doi.org/10.1074/jbc.M103925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514549	hybrid			2022-12-25	WOS:000171925600032
J	Tung, L; Shen, TJ; Abel, MG; Powell, RL; Takimoto, GS; Sartorius, CA; Horwitz, KB				Tung, L; Shen, TJ; Abel, MG; Powell, RL; Takimoto, GS; Sartorius, CA; Horwitz, KB			Mapping the unique activation function 3 in the progesterone B-receptor upstream segment - Two LXXLL motifs and a tryptophan residue are required for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; DNA-BINDING DOMAIN; CARBOXYL-TERMINAL REGIONS; HYDROPHOBIC AMINO-ACIDS; HUMAN-BREAST-CANCER; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; ANDROGEN RECEPTOR; A-FORM	Progesterone receptors (PR) contain three activation functions (AFs) that together define the extent to which they regulate transcription. AF I and AF2 are common to the two isoforms of PR, PR-A and PR-B, whereas AF3 lies within the N-terminal 164 amino acids unique to PR-B, termed the "B-upstream segment" (BUS). To define the BUS regions that contribute to AF3 function, we generated a series of deletion and amino acid substitution mutants and tested them in three backgrounds as follows: BUS alone fused to the PR DNA binding domain (BUS-DBD), the entire PR-B N terminus linked to its DBD (NT-B), and full-length PR-B. Analyses of these mutants identified two regions in BUS whose loss reduces AF3 activity by more than 90%. These are associated with amino acids 54-90 (RI) and 120-154 (R2). RI contains a consensus (LXXLL59)-L-55 motif (LI) identical to ones found in nuclear receptor co-activators. R2 is adjacent to a second nuclear receptor box (L2) at (LXXLL119)-L-115 and contains a conserved tryptophan (Trp-140). Their mutation completely disrupts AF3 activity in a promoter and cell type-independent manner. Critical mutations elicited similar effects on all three B-receptor backgrounds. This underscores the probability that these mutations alter a process linking BUS structure to the function of full-length PR-B in a fundamental way.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sartorius, CA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol, Box B-151,4200 E 9th Ave, Denver, CO 80262 USA.			Horwitz, Kathryn/0000-0001-7402-6455	NCI NIH HHS [CA 26869] Funding Source: Medline; NIDDK NIH HHS [DK 48238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Bain DL, 2001, J BIOL CHEM, V276, P23825, DOI 10.1074/jbc.M102611200; Bamberger AM, 2000, HORM RES, V54, P32; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chang CY, 1999, MOL CELL BIOL, V19, P8226; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FOLKERS GE, 1995, J BIOL CHEM, V270, P23552, DOI 10.1074/jbc.270.40.23552; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GRAHAM JD, 1995, CANCER RES, V55, P5063; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KNOTTES TA, 2000, J BIOL CHEM, V60, P4; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mangal RK, 1997, J STEROID BIOCHEM, V63, P195, DOI 10.1016/S0960-0760(97)00119-2; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MOHAMED MK, 1994, J STEROID BIOCHEM, V51, P241, DOI 10.1016/0960-0760(94)90036-1; Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rowan BG, 2000, STEROIDS, V65, P545, DOI 10.1016/S0039-128X(00)00112-4; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; Schaufele F, 2000, MOL ENDOCRINOL, V14, P2024, DOI 10.1210/me.14.12.2024; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; Solomon C, 2001, J BONE MINER RES, V16, P39, DOI 10.1359/jbmr.2001.16.1.39; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; van Tilborg MAA, 2000, J MOL BIOL, V301, P947, DOI 10.1006/jmbi.2000.4001; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	69	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39843	39851		10.1074/jbc.M106843200	http://dx.doi.org/10.1074/jbc.M106843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546784	hybrid			2022-12-25	WOS:000171789200046
J	Chen, P; Melchior, C; Brons, NHC; Schlegel, N; Caen, J; Kieffer, N				Chen, P; Melchior, C; Brons, NHC; Schlegel, N; Caen, J; Kieffer, N			Probing conformational changes in the I-like domain and the cysteine-rich repeat of human beta(3) integrins following disulfide bond disruption by cysteine mutations - Identification of cysteine 598 involved in alpha(IIb)beta(3) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB; FIBRINOGEN BINDING; LIGAND-BINDING; PLATELET-AGGREGATION; GLANZMANNS-THROMBASTHENIA; IIIA; SUBUNIT; ISOMERASE; VARIANT; ANTIBODIES	We have investigated receptor function and epitope expression of recombinant alpha (IIb)beta (3) mutated at Cys(177) or Cys(273) in the I-like domain as well as Cys(598), located in the fourth repeat of the membrane-proximal cysteine-rich region and mutated in a Glanzmann's thrombasthenia type II patient. The beta (3) mutants beta (3)C177A, beta (3)C273A, and beta (3)C598Y exhibited a decreased electrophoretic mobility in SDS-polyacrylamide gel electrophoresis under nonreducing conditions, confirming the disruption of the respective disulfide loops. Despite reduced surface expression, the alpha (IIb)beta (3)C177A, alpha (IIb)beta (3)C273A, and alpha (IIb)beta (3)C598Y receptors mediated cell adhesion to immobilized fibrinogen and translocated into focal adhesion plaques. The beta (3)C598Y mutation, but not the beta (3)C177A or beta (3)C273A mutations, induced spontaneous binding of the ligand mimetic monoclonal antibody PAC-1, while the beta (3)C177A and beta (3)C273A mutants exhibited reduced complex stability in the absence of Ca2+. Epitope mapping of function-blocking monoclonal antibodies (mAbs) allowed the identification of two distinct subgroups; mAbs A2A9, p12-46, 10E5, and P256 did not interact with alpha (IIb)beta (3)C273A and bound only weakly to alpha (IIb)beta (3)C177A, while mAbs AP2, LM609 and 7E3 bound normally to mutant alpha (IIb)beta (3)C273A, but interacted only weakly with mutant alpha (IIb)beta (3)C177A. Furthermore, a cryptic epitope recognized by mAb 4D10G3 and not exposed on wild type alpha (IIb)beta (3) became accessible only on mutant alpha (IIb)beta (3)C177A and was mapped to the 60-kDa chymotrypsin fragment of beta (3). Finally, the ligand-induced binding site (LIBS) epitopes AP5, D3, LIBS1, and LIBS2 were spontaneously expressed on all three mutants independent of RGDS or dithiothreitol treatment. Our results provide evidence that disruption of a single cysteine disulfide bond in the cysteine-rich repeat domain, but not in the I-like domain, activates integrin alpha (IIb)beta (3). In contrast, disruption of each of the disulfide bonds in the two long insertions of the I-like domain predicted to be in close contact with the alpha subunit beta -propeller domain affect the stability of the alpha (IIb)beta (3) heterodimer and inhibit complex-specific mAb binding without affecting the RGD binding capacity of the metal ion-dependent adhesion site-like domain.	Ctr Univ, CRP Sante, CNRS, Lab Franco Luxembourgeois Rech Biomed, L-1511 Luxembourg, Luxembourg; Hop Robert Debre, Serv Hematol Biol, F-75019 Paris, France; Inst France, Acad Sci, F-7506 Paris, France	Luxembourg Institute of Health; University of Luxembourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Kieffer, N (corresponding author), LFL Univ Ctr, 162A,Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	kieffer@cu.lu						BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; Calvete JJ, 1999, P SOC EXP BIOL MED, V222, P29, DOI 10.1111/j.1525-1373.1999.09993.x; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; DJAFFAR I, 1993, HUM MOL GENET, V2, P2179, DOI 10.1093/hmg/2.12.2179; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 1999, BRIT J HAEMATOL, V104, P448, DOI 10.1046/j.1365-2141.1999.01197.x; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRENCH DL, 1998, BLOOD S, V92, P33; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GoferDadosh N, 1997, BIOCHEM BIOPH RES CO, V232, P724, DOI 10.1006/bbrc.1997.6201; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Jackson DE, 1998, THROMB HAEMOSTASIS, V80, P42, DOI 10.1055/s-0037-1615136; Kieffer N, 1999, BLOOD, V94, p445A; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1994, BLOOD, V84, P1108; KOUNS WC, 1991, BLOOD, V78, P3215; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIU CY, 1997, BLOOD, V90, P573; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; MILET S, 1997, THROMB HAEMOSTASIS, V78, P360; NIEWIAROWSKI S, 1985, J LAB CLIN MED, V106, P651; NURDEN AT, 1987, J CLIN INVEST, V79, P962, DOI 10.1172/JCI112907; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Ruan J, 1999, BRIT J HAEMATOL, V105, P523, DOI 10.1111/j.1365-2141.1999.01376.x; RUIZ C, 2001, THROMB HAEMOSTASIS, V86; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Schlegel N, 1999, BLOOD, V94, p451A; SCHLEGEL N, 2000, BLOOD S, V96, P255; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Takagi J, 1997, J BIOCHEM, V121, P914; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; VALENTIN N, 1995, BLOOD, V85, P3028, DOI 10.1182/blood.V85.11.3028.bloodjournal85113028; Wang RG, 1997, BLOOD, V90, P1718, DOI 10.1182/blood.V90.4.1718.1718_1718_1719; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	54	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38628	38635		10.1074/jbc.M105737200	http://dx.doi.org/10.1074/jbc.M105737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507099	hybrid			2022-12-25	WOS:000171673200041
J	Lubert, EJ; Hong, YL; Sarge, KD				Lubert, EJ; Hong, YL; Sarge, KD			Interaction between protein phosphatase 5 and the A subunit of protein phosphatase 2A - Evidence for a heterotrimeric form of protein phosphatase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; SERINE/THREONINE PHOSPHATASE; REGULATORY SUBUNITS; CATALYTIC SUBUNIT; RECEPTOR; FAMILY; IDENTIFICATION; NUCLEUS; BINDING; DOMAIN	Members of the phosphoprotein phosphatase family of serine/threonine phosphatases are thought to exist in different native oligomeric complexes. Protein phosphatase 2A (PP2A) is composed of a catalytic subunit (PP2Ac) that complexes with an A subunit, which in turn also interacts with one of many B subunits that regulate substrate specificity and/or (sub)cellular localization of the enzyme. Another family member, protein phosphatase 5 (PP5), contains a tetratricopeptide repeat domain at its N terminus, which has been suggested to mediate interactions with other proteins. PP5 was not thought to interact with partners homologous to the A or B subunits that exist within PP2A. However, our results indicate that this may not be the case. A yeast two-hybrid screen revealed an interaction between PP5 and the A subunit of PP2A. This interaction was confirmed for endogenous proteins in vivo using immunoprecipitation analysis and for recombinant proteins by in vitro binding experiments. Our results also indicate that the tetratricopeptide repeat domain of PP5 is required and sufficient for this interaction. In addition, immunoprecipitated PP5 contains associated B subunits. Thus, our results suggest that PP5 can exist in a PP2A-like heterotrimeric form containing both A and B subunits.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	University of Kentucky	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NIGMS NIH HHS [GM61053] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061053] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; James P, 1996, GENETICS, V144, P1425; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kobe B, 1999, STRUCTURE, V7, pR91, DOI 10.1016/S0969-2126(99)80060-4; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	26	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38582	38587		10.1074/jbc.M106906200	http://dx.doi.org/10.1074/jbc.M106906200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504734	hybrid			2022-12-25	WOS:000171673200035
J	Gorin, Y; Kim, NH; Feliers, D; Bhandari, B; Choudhury, GG; Abboud, HE				Gorin, Y; Kim, NH; Feliers, D; Bhandari, B; Choudhury, GG; Abboud, HE			Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase	FASEB JOURNAL			English	Article						kidney; mesangium; hypertrophy; Akt/PKB; Ang II	NF-KAPPA-B; CYTOSOLIC PHOSPHOLIPASE A(2); GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; NADPH OXIDASE; GROWTH-FACTOR; MESANGIAL CELLS; ENDOTHELIAL-CELLS; MESSENGER-RNA; DNA-SYNTHESIS	Angiotensin II (Ang II) exerts contractile and trophic effects in glomerular mesangial cells (MCs). One potential downstream target of Ang II is the protein kinase Akt/protein kinase B (PKB). We investigated the effect of Ang II on Akt/PKB activity in MCs. Ang II causes rapid activation of Akt/PKB (5-10 min) but delayed activation of phosphoinositide 3-kinase (PI3-K) (30 min). Activation of Akt/PKB by Ang II was not abrogated by the PI3-K inhibitors or by the introduction of a dominant negative PI3-K, indicating that in MCs, PI3-K is not an upstream mediator of Akt/PKB activation by Ang II. Incubation of MCs with phospholipase A(2) Inhibitors also blocked Akt/PKB activation by Ang II. AA mimicked the effect of Ang II. Inhibitors of cyclooxygenase-, lipoxyogenase-, and cytochrome P450-dependent metabolism did not influence AA-induced Akt/PKB activation. However, the antioxidants N-acetylcysteine and diphenylene iodonium inhibited both AA- and Ang II-induced Akt/PKB activation. Dominant negative mutant of Akt/PKB or antioxidants, but not the dominant negative form of PI3-K, inhibited Ang II-induced protein synthesis and cell hypertrophy. These data provide the first evidence that Ang II induces protein synthesis and hypertrophy in MCs through AA/redox-dependent pathway and Akt/PKB activation independent of PI3-K.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Abboud, HE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol MC 7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	abboud@uthscsa.edu		Feliers, Denis/0000-0003-1952-1386	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050190, R01DK043988, R29DK050190] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43988, DK 50190] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arar M, 2000, J BIOL CHEM, V275, P9527, DOI 10.1074/jbc.275.13.9527; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS40; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Hack N, 1996, CLIN EXP PHARMACOL P, V23, P71; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Huang SM, 1999, KIDNEY INT, V55, P1740, DOI 10.1046/j.1523-1755.1999.00440.x; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; Jacobs LS, 1996, HYPERTENSION, V28, P663, DOI 10.1161/01.HYP.28.4.663; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Leusen Jeanette H. W., 1996, Frontiers in Bioscience (online), V1, pD72; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Ruiz-Ortega M, 1998, J IMMUNOL, V161, P430; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Torrecillas G, 2001, MOL PHARMACOL, V59, P104, DOI 10.1124/mol.59.1.104; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wilmer WA, 1997, J BIOL CHEM, V272, P10877; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	51	89	89	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1909	1920		10.1096/fj..01-0165com	http://dx.doi.org/10.1096/fj..01-0165com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532971				2022-12-25	WOS:000171372700006
J	Sorby, M; Sandstrom, J; Ostman, A				Sorby, M; Sandstrom, J; Ostman, A			An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1	ONCOGENE			English	Article						DEP-1; Matrigel (TM); protein tyrosine phosphatase	T-CELL ACTIVATION; HOMOPHILIC BINDING; EXPRESSION; CD148; BETA; PHOSPHORYLATION; DIMERIZATION; GROWTH; ALPHA; INHIBITION	Cellular growth, differentiation and migration is regulated by protein tyrosine phosphorylation. Receptor-like protein tyrosine phosphatases are thus likely to be key regulators of vital cellular processes. The regulation of these enzymes is in general poorly understood. Ligands have been identified only for a small subset of the receptor-like protein tyrosine phosphatases and in no case has upregulation of the specific activity by extracellular ligands been demonstrated. Prompted by earlier findings of ligands for receptor-like protein tyrosine phosphatases in extracellular matrix we investigated if Matrigel (TM), a preparation of extracellular matrix proteins, contained modulators of the specific activity of the receptor-like protein tyrosine phosphatase DEP-1. Matrigel (TM) stimulation of cells increased the specific activity of immunoprecipitated DEP-1. Also, incubation of immunoprecipitated DEP-1 with Matrigel (TM) led to an increase in DEP-1 activity, which was blocked by soluble DEP-1 extracellular domain. Finally, immunoprecipitated Delta ECD-DEP-1, a mutant form of DEP-1 lacking most of the extracellular domain, failed to respond to Matrigel (TM) stimulation. These experiments identify Matrigel (TM) as a source of DEP-1 agonist(s) and provide the first evidence for upregulation of the specific activity of receptor-like protein tyrosine phosphatases by extracellular ligands.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.							Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Keane MM, 1996, CANCER RES, V56, P4236; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Leppanen O, 2000, BIOCHEMISTRY-US, V39, P2370, DOI 10.1021/bi9919192; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 1998, EXP CELL RES, V245, P195, DOI 10.1006/excr.1998.4257; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SAP J, 1994, MOL CELL BIOL, V14, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	33	32	34	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5219	5224		10.1038/sj.onc.1204581	http://dx.doi.org/10.1038/sj.onc.1204581			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526512				2022-12-25	WOS:000170464000017
J	Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C				Fruhwald, MC; O'Dorisio, MS; Dai, ZY; Tanner, SM; Balster, DA; Gao, X; Wright, FA; Plass, C			Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - Implications for tumor biology and potential clinical utility	ONCOGENE			English	Article						medulloblastoma; primitive neuroectodermal tumor; DNA methylation; genome scanning	PRIMITIVE NEUROECTODERMAL TUMORS; HUMAN BRAIN-TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; CHROMOSOME ARM 17P; CHILDHOOD MEDULLOBLASTOMA; DNA HYPERMETHYLATION; E-CADHERIN; DELETION; P16	Medulloblastomas exhibit an array of diverse cytogenetic abnormalities. To evaluate the significance of epigenetic rather than genetic lesions in medulloblastomas and other primitive neuroectodermal tumors (PNETs) of the childhood CNS we performed a systematic analysis of gene specific and global methylation. Methylation-specific PCR detected no methylation for p15(INK4B), von Hippel Lindau and TP53 and only limited methylation for E-Cadherin and p16(INK4A) in tumors. The cell lines Daoy and MHH-PNET-5 in which the p16(INK4A) promoter was methylated did not express the gene, but demonstrated abnormalities by SSCP. Immunohistochemistry for p16 was negative in all examined normal cerebella and medulloblastomas. Using the technique of Restriction Landmark Genomic Scanning we detected methylation affecting up to 1% of all CpG islands in primary MB/PNETs and 6% in MB cell lines. Methylation patterns differed between medulloblastomas and PNETs. Examination of several methylated sequences revealed homologies to known genes and expressed sequences. Analysis of survival data identified seven of 30 hypermethylated sequences significantly correlating with poor prognosis. We suggest that DNA hypermethylation has an outstanding potential for the identification of novel tumor suppressors as well as diagnostic and therapeutic targets in MBs and other PNETs of the CNS.	Univ Munster, Klin & Poliklin Kinderheilkunde, D-48149 Munster, Germany; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	University of Munster; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Plass, C (corresponding author), Univ Munster, Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48149 Munster, Germany.	plass-1@medctr.osu.edu	Plass, Christoph/H-7192-2014	O'Dorisio, M Sue/0000-0003-0690-1160	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldosari N, 2000, ACTA NEUROPATHOL, V99, P345, DOI 10.1007/s004010051134; Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; FRUHWALD MC, 1999, NEURO-ONCOLOGY, V1, P311; GRAFF JR, 1995, CANCER RES, V55, P5195; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JEN J, 1994, CANCER RES, V54, P6353; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KLABFLEISCH JD, 1984, STAT ANAL FAILURE TI; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lescop S, 1999, J NEURO-ONCOL, V44, P119, DOI 10.1023/A:1006387518100; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; LITOFSKY NS, 1994, NEUROSURGERY, V34, P967, DOI 10.1227/00006123-199406000-00003; Marino S, 2000, GENE DEV, V14, P994; Mulhern RK, 1999, ANN NEUROL, V46, P834, DOI 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Reardon DA, 1997, CANCER RES, V57, P4042; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J., 2002, MOL CLONING LAB MANU; Sato K, 1996, INT J CANCER, V66, P305, DOI 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.0.CO;2-2; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Schwechheimer K, 1998, VIRCHOWS ARCH, V432, P163, DOI 10.1007/s004280050151; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Tanner SM, 1998, HUM MUTAT, V11, P62, DOI 10.1002/(SICI)1098-1004(1998)11:1<62::AID-HUMU10>3.3.CO;2-C; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	39	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5033	5042		10.1038/sj.onc.1204613	http://dx.doi.org/10.1038/sj.onc.1204613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526488				2022-12-25	WOS:000170439800013
J	Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS				Ndisang, D; Budhram-Mahadeo, V; Pedley, B; Latchman, DS			The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo	ONCOGENE			English	Article						cervical cancer; human papilloma virus; Brn-3a transcription factor; tumour growth	NEURONAL CELLS; POU-DOMAIN; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; GENE-EXPRESSION; DNA; POLYMORPHISM; CARCINOMA; PROMOTER; DISTINCT	The cellular Brn-3a transcription factor is known to activate transcription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-expressed in women with cervical neoplasia. We show that cervical cell hues with reduced Brn-3a expression show a greatly reduced ability to form tumours in nude mice compared to control cells and also show reduced expression of the HPV E6 and cellular Bcl-2 oncogenes. These effects are also observed in cervical cells over-expressing the related Brn-3b factor, which is known to antagonize activation of HPV gene expression by Brn-3a. These results demonstrate, for the first time, that inhibition of Brn-3a expression or enhanced Brn-3b expression can inhibit cervical cell-derived tumour growth in vivo as well as in vitro. Hence they establish Brn-3a as a key factor in cervical tumorigenesis and as a potential therapeutic target in human cervical neoplasia.	Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; UCL Royal Free & Univ Coll Med Sch, Dept Oncol, London NW3, England	University of London; University College London; University of London; University College London; UCL Medical School	Latchman, DS (corresponding author), Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.							BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; COX MF, 1986, LANCET, V2, P157; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MEANWELL CA, 1987, LANCET, V1, P703; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; van Duin M, 2000, J GEN VIROL, V81, P317, DOI 10.1099/0022-1317-81-2-317; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8	18	18	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4899	4903		10.1038/sj.onc.1204634	http://dx.doi.org/10.1038/sj.onc.1204634			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521202				2022-12-25	WOS:000170271800015
J	Hirsch, E; Bosco, O; Tropel, P; Laffargue, M; Calvez, R; Altruda, F; Wymann, MP; Montrucchio, G				Hirsch, E; Bosco, O; Tropel, P; Laffargue, M; Calvez, R; Altruda, F; Wymann, MP; Montrucchio, G			Resistance to thromboembolism in PI3K gamma-deficient mice	FASEB JOURNAL			English	Article						platelet aggregation; thrombosis; G protein-coupled receptors	PHOSPHOINOSITIDE 3-KINASE; HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; ADENOSINE-DIPHOSPHATE; ADP RECEPTORS; ACTIVATION; THROMBIN; PHOSPHORYLATION; AGGREGATION; INTEGRIN	Platelet aggregation and subsequent thrombosis are the major cause of ischemic diseases such as heart attack and stroke. ADP, acting via G protein-coupled receptors (GPCRs), is an important signal in thrombus formation and involves activation of phosphoinositide 3-kinases (PI3K). When platelets from mice lacking the G protein-activated PI3K gamma isoform were stimulated with ADP, aggregation was impaired. Collagen or thrombin, however, evoked a normal response. ADP stimulation of PI3K gamma -deficient platelets resulted in decreased PKB/Akt phosphorylation and alpha (IIb)beta (3) fibrinogen receptor activation. These effects did not influence bleeding time but protected PI3K gamma -null mice from death caused by ADP-induced platelet-dependent thromboembolic vascular occlusion. This result demonstrates an unsuspected, well-defined role for PI3K gamma downstream of ADP and suggests that pharmacological targeting of PI3K gamma has a potential use as antithrombotic therapy.	Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; Univ Turin, Dipartimento Fisiopatol Clin, I-10126 Turin, Italy; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Turin; University of Turin; University of Fribourg	Hirsch, E (corresponding author), Univ Turin, Dipartimento Genet Biol & Biochim, Via Santena 5 Bis, I-10126 Turin, Italy.	emilio.hirsch@unito.it	Laffargue, Muriel/AAE-7849-2021; Hirsch, Emilio/F-4848-2013; Wymann, Matthias P/C-3227-2008; Bosco, Ornella/AAB-2105-2019	Hirsch, Emilio/0000-0002-9073-6024; Wymann, Matthias P/0000-0003-3349-4281; Calvez, Ronan/0000-0001-5762-1244; Laffargue, Muriel/0000-0003-1833-639X				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; CATTANEO M, 1990, BLOOD, V75, P1081; Cattaneo M, 1999, ARTERIOSCL THROM VAS, V19, P2281, DOI 10.1161/01.ATV.19.10.2281; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Gachet C, 1997, J BIOL CHEM, V272, P4850, DOI 10.1074/jbc.272.8.4850; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; Kirk RI, 2000, J BIOL CHEM, V275, P30901, DOI 10.1074/jbc.M001908200; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; NORDOY A., 1964, SCAND J HAEMATOL, V1, P16; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Selheim F, 1999, BIOCHEM BIOPH RES CO, V263, P780, DOI 10.1006/bbrc.1999.1450; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177, DOI 10.1055/s-0037-1614439; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	37	176	189	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2019	+		10.1096/fj.00-0810fje	http://dx.doi.org/10.1096/fj.00-0810fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511514				2022-12-25	WOS:000170318500025
J	Shofuda, K; Hasenstab, D; Kenagy, RD; Shofuda, T; Li, ZY; Lieber, A; Clowes, AW				Shofuda, K; Hasenstab, D; Kenagy, RD; Shofuda, T; Li, ZY; Lieber, A; Clowes, AW			Membrane-type matrix metalloproteinase-1 and-3 activity in primate smooth muscle cells	FASEB JOURNAL			English	Article						membrane-type matrix metalloporteinases (MT-MMPs); smooth muscle cells (SMCs); adenovirus; migration	TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; IV COLLAGENASE; PRO-GELATINASE; ACTIVATION; EXPRESSION; MIGRATION; INVASION; CLEAVAGE; ASSOCIATION	Membrane-type matrix metalloproteinases-1 and -3 (MT1- and MT3-MMPs) are expressed by activated smooth muscle cells (SMCs) both in vitro and in vivo (19). To define their functions in SMCs, we transduced MT1- and MT3-MMP cDNAs into baboon SMCs by using adenoviral vectors. Overexpression of MT1-MMP increased the conversion of proMMP-2 to the intermediate and active forms. In contrast, in MT3-MMP-overexpressing cells, MMP-2 was activated partially. Immunoblot analyses revealed that MT1-MMP protein was present in the SMCs and accumulated in the presence of the synthetic MMP inhibitor, BB94, or tissue inhibitor of metalloproteinase-2 (TIMP-2). However, MT3-MMP protein was detectable only when BB94, but not TIMP-2, was present. Zymographic analyses showed that MT3-MMP had much stronger casein- and gelatin-degrading activities than did MT1- MMP. Furthermore, when MT3-MMP and MT1- MMP were coexpressed, MT1- MMP degradation was enhanced; this result supports the possibility that MT3-MMP can degrade MT1- MMP. SMCs overexpressing either MT1- or MT3-MMP exhibited altered morphology, without changing their proliferation. This alteration was prevented by BB94 addition. The cells, which underwent this change, showed reduced adhesion to both collagen and fibronectin and increased migration in a Boyden chamber. The present study demonstrates that MT1- and MT3-MMPs have different enzymatic activities but may nevertheless affect SMC function in the same way.	Univ Washington, Sch Med, Dept Surg, Div Vasc Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Clowes, AW (corresponding author), Univ Washington, Sch Med, Dept Surg, Div Vasc Surg, HSB BB442,Box 356410,1959 NE Pacific St, Seattle, WA 98195 USA.	clowes@u.washington.edu		Kenagy, Richard/0000-0002-2021-5565				AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Fabunmi RP, 1996, BIOCHEM J, V315, P335, DOI 10.1042/bj3150335; FUKAI F, 1991, J BIOL CHEM, V266, P8807; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; KENAGY RD, 1994, J CLIN INVEST, V93, P1987, DOI 10.1172/JCI117191; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Koyama N, 1996, AM J PATHOL, V148, P749; Koyama N, 1998, CIRC RES, V83, P305, DOI 10.1161/01.RES.83.3.305; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; LIEBER A, 1995, P NATL ACAD SCI USA, V92, P6210, DOI 10.1073/pnas.92.13.6210; LIOTTA LA, 1986, CANCER RES, V46, P1; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Nagase H, 1998, Cell Res, V8, P179; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1998, LAB INVEST, V78, P915; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; THOMPSON RW, 1996, ANN NY ACAD SCI, V18, P157; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	38	23	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2010	+		10.1096/fj.00-0871fje	http://dx.doi.org/10.1096/fj.00-0871fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511522				2022-12-25	WOS:000170318500022
J	Maynes, JT; Bateman, KS; Cherney, MM; Das, AK; Luu, HA; Holmes, CFB; James, MNG				Maynes, JT; Bateman, KS; Cherney, MM; Das, AK; Luu, HA; Holmes, CFB; James, MNG			Crystal structure of the tumor-promoter okadaic acid bound to protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-PRODUCT INHIBITORS; SER-THR PHOSPHATASES; CATALYTIC SUBUNIT; BETA-12-BETA-13 LOOP; BINDING; PP1; CALCINEURIN; MOTUPORIN; MOLSCRIPT; PROGRAM	Protein phosphatase-1 (PP1) plays a key role in dephosphorylation in numerous biological processes such as glycogen metabolism, cell cycle regulation, smooth muscle contract-ion, and protein synthesis. Microorganisms produce a variety of inhibitors of PP1, which include the microcystin class of inhibitors and okadaic acid, the latter being the major cause of diarrhetic shellfish poisoning and a powerful tumor promoter. We have determined the crystal structure of the molecular complex of okadaic acid bound to PPI to a resolution of 1.9 Angstrom. This structure reveals that the acid binds in a hydrophobic groove adjacent to the active site of the protein and interacts with basic residues within the active site. Okadaic acid exhibits a cyclic structure, which is maintained via an intramolecular hydrogen bond. This is reminiscent of other macrocyclic protein phosphatase inhibitors. The inhibitor-bound enzyme shows very little conformational change when compared with two other PPI structures, except in the inhibitor-sensitive beta 12-beta 13 loop region. The selectivity of okadaic acid for protein phosphatases-1 and -2A but not PP-2B (calcineurin) may be reassessed in light of this study.	Univ Alberta, Fac Med, Dept Biochem, Grp Prot Struct & Funct,Canadian Inst Hlth Res, Edmonton, AB T6G 2H7, Canada; Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India	Institute for Work & Health; University of Alberta; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur	James, MNG (corresponding author), Univ Alberta, Fac Med, Dept Biochem, Grp Prot Struct & Funct,Canadian Inst Hlth Res, Edmonton, AB T6G 2H7, Canada.	Michael.James@ualberta.ca	Maynes, Jason/AAE-4344-2020					Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; DAWSON JF, 1998, THESIS U ALBERTA EDM; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evans DRH, 2001, FEBS LETT, V498, P110, DOI 10.1016/S0014-5793(01)02448-6; Gauss CM, 1997, BIOORGAN MED CHEM, V5, P1751, DOI 10.1016/S0968-0896(97)00145-4; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE EY, 1999, FRONT BIOSCI, V15, pD270; Lindvall MK, 1997, J BIOL CHEM, V272, P23312, DOI 10.1074/jbc.272.37.23312; MCREE DE, 1993, PRACTICAL PROTEIN CR, P303; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QUINN RJ, 1993, BIOORG MED CHEM LETT, V3, P1029, DOI 10.1016/S0960-894X(00)80281-4; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1992, BIOCHEM J, V284, P539, DOI 10.1042/bj2840539; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	36	135	144	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44078	44082		10.1074/jbc.M107656200	http://dx.doi.org/10.1074/jbc.M107656200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11535607	hybrid			2022-12-25	WOS:000172297700077
J	Jankova, L; Harrop, SJ; Saunders, DN; Andrews, JL; Bertram, KC; Gould, AR; Baker, MS; Curmi, PMG				Jankova, L; Harrop, SJ; Saunders, DN; Andrews, JL; Bertram, KC; Gould, AR; Baker, MS; Curmi, PMG			Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM STRUCTURE; SERPIN; PROTEIN; MODEL; ALPHA(1)-ANTITRYPSIN; OVALBUMIN; MECHANISM; INSERTION; SIGNAL; ACID	The structure of the serpin, plasminogen activator inhibitor type-2 (PAI-2), in a complex with a peptide mimicking its reactive center loop (RCL) has been determined at 1.6-Angstrom resolution. The structure shows the relaxed state serpin structure with a prominent six-stranded beta -sheet. Clear electron density is seen for all residues in the peptide. The P1 residue of the peptide binds to a well defined pocket at the base of PAI-2 that may be important in determining the specificity of protease inhibition. The stressed-to-relaxed state (S --> R) transition in PAI-2 can be modeled as the relative motion between a quasirigid core domain and a smaller segment comprising helix hF and beta -strands s1A, s2A, and s3A. A comparison of the Ramachandran plots of the stressed and relaxed state PAI-2 structures reveals the location of several hinge regions connecting these two domains. The hinge regions cluster in three locations on the structure, ensuring a cooperative S --> R transition. We hypothesize that the hinge formed by the conserved Gly(206) on P-strand s3A in the breach region of PAI-2 effects the S --> R transition by altering its backbone torsion angles. This torsional change is due to the binding of the P14 threonine of the RCL to the open breach region of PAI-2.	Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia; Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Biotech Australia, Roseville, NSW 2069, Australia; Univ Melbourne, Royal Womens Hosp, Dept Obstet & Gynaecol, Gynaecol Canc Res Ctr, Melbourne, Vic 3153, Australia	University of New South Wales Sydney; University of Wollongong; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Melbourne	Curmi, PMG (corresponding author), Univ New S Wales, Sch Phys, Initiat Biomol Struct, Sydney, NSW 2052, Australia.	p.curmi@unsw.edu.au	Curmi, Paul/G-7185-2011; Saunders, Darren/B-7677-2008	Curmi, Paul/0000-0001-5762-7638; Baker, Mark/0000-0001-5858-4035; Saunders, Darren/0000-0003-0924-0513				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dougherty KM, 1999, P NATL ACAD SCI USA, V96, P686, DOI 10.1073/pnas.96.2.686; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LECANDER I, 1986, BRIT J HAEMATOL, V62, P221, DOI 10.1111/j.1365-2141.1986.tb02925.x; LESLIE A, 1993, CRYSTALLOGRAPHIC COM, V5; Li JP, 1999, STRUCTURE, V7, P103, DOI 10.1016/S0969-2126(99)80013-6; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Risse BC, 1998, HISTOCHEM CELL BIOL, V110, P559, DOI 10.1007/s004180050318; Risse BC, 2000, J CELL PHYSIOL, V182, P281, DOI 10.1002/(SICI)1097-4652(200002)182:2<281::AID-JCP17>3.0.CO;2-D; Saunders DN, 1998, J BIOL CHEM, V273, P10965, DOI 10.1074/jbc.273.18.10965; Saunders DN, 2001, J BIOL CHEM, V276, P43383, DOI 10.1074/jbc.M103123200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	50	25	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43374	43382		10.1074/jbc.M103021200	http://dx.doi.org/10.1074/jbc.M103021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11546761	hybrid			2022-12-25	WOS:000172169300096
J	Howes, BD; Feis, A; Raimondi, L; Indiani, C; Smulevich, G				Howes, BD; Feis, A; Raimondi, L; Indiani, C; Smulevich, G			The critical role of the proximal calcium ion in the structural properties of horseradish peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; C-TYPE CYTOCHROMES; MANGANESE PEROXIDASE; CRYSTAL-STRUCTURE; SPECTROSCOPIC EVIDENCE; ANGSTROM RESOLUTION; CIRCULAR-DICHROISM; PEANUT PEROXIDASE; LIGNIN PEROXIDASE; HEME CAVITY	The extent to which the structural Ca2+ ions of horseradish peroxidase (HRPC) are a determinant in defining the heme pocket architecture is investigated by electronic absorption and resonance Raman spectroscopy upon removal of one Ca2+ ion. The Fe(III) heme states are modified upon Ca2+ depletion, with an uncommon quantum mechanically mixed spin state becoming the dominant species. Ca2+-depleted HRPC forms complexes with benzohydroxamic acid and CO which display spectra very similar to those of native HRPC, indicating that any changes to the distal cavity structural properties upon Ca2+ depletion are easily reversed. Contrary to the native protein, the Ca2+-depleted ferrous form displays a low-spin bis-histidyl heme state and a small proportion of high-spin heme. Furthermore, the v(Fe-Im) stretching mode downshifts 27 cm(-1) upon Ca2+ depletion revealing a significant structural perturbation of the proximal cavity near the histidine ligand. The specific activity of the Ca2+-depleted enzyme is 50% that of the native form. The effects on enzyme activity and spectral features observed upon Ca2+ depletion are reversible upon reconstitution. Evaluation of the present and previous data firmly favors the proximal Ca2+ ion as that which is lost upon Ca2+ depletion and which likely plays the more critical role in regulating the heme pocket structural and catalytic properties.	Univ Florence, Dipartimento Chim, I-50121 Florence, Italy; Dipartimento Farmacol Preclin & Clin, I-50134 Florence, Italy	University of Florence	Smulevich, G (corresponding author), Univ Florence, Dipartimento Chim, Via G Capponi 9, I-50121 Florence, Italy.	smulev@chim.unifi.it	Feis, Alessandro/J-1724-2014; smulevich, giulietta/A-6510-2008; Raimondi, laura/A-9280-2013	Feis, Alessandro/0000-0003-3469-0647; Raimondi, Laura/0000-0002-8423-0860; Smulevich, Giulietta/0000-0003-3021-8919				BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BARBER KR, 1995, EUR J BIOCHEM, V232, P825, DOI 10.1111/j.1432-1033.1995.tb20879.x; Chattopadhyay K, 2000, BIOCHEMISTRY-US, V39, P263, DOI 10.1021/bi990729o; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; deRopp JS, 1997, J AM CHEM SOC, V119, P4732, DOI 10.1021/ja9642018; Feis A, 1998, J RAMAN SPECTROSC, V29, P933, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<933::AID-JRS319>3.0.CO;2-P; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Fuhrhop J.H., 1975, LAB METHODS PORPHYRI, P757; FUJII S, 1995, BBA-PROTEIN STRUCT M, V1251, P161, DOI 10.1016/0167-4838(95)00092-9; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; George SJ, 1999, BIOCHEM J, V344, P237, DOI 10.1042/0264-6021:3440237; Gilfoyle DJ, 1996, EUR J BIOCHEM, V236, P714, DOI 10.1111/j.1432-1033.1996.00714.x; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Howes BD, 1999, BIOPHYS J, V77, P478, DOI 10.1016/S0006-3495(99)76905-5; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; Howes BD, 2001, BIOCHEM J, V353, P181, DOI 10.1042/0264-6021:3530181; Indiani C, 2000, J AM CHEM SOC, V122, P7368, DOI 10.1021/ja000587h; Kishi K, 1997, BIOCHEMISTRY-US, V36, P4268, DOI 10.1021/bi962627t; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; MARANON MJR, 1993, BIOCHEM BIOPH RES CO, V194, P326, DOI 10.1006/bbrc.1993.1823; MARKLUND S, 1974, BIOCHIM BIOPHYS ACTA, V350, P304, DOI 10.1016/0005-2744(74)90504-X; Nie GJ, 1997, BIOCHEMISTRY-US, V36, P5113, DOI 10.1021/bi962583o; Nissum M, 1998, BIOSPECTROSCOPY, V4, P355, DOI 10.1002/(SICI)1520-6343(1998)4:6<355::AID-BSPY1>3.0.CO;2-I; OGAWA S, 1979, BIOCHEM BIOPH RES CO, V90, P674, DOI 10.1016/0006-291X(79)91288-9; OTHMAN S, 1994, BIOCHEMISTRY-US, V33, P15437, DOI 10.1021/bi00255a026; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; OTHMAN S, 1993, BIOCHEMISTRY-US, V32, P9781, DOI 10.1021/bi00088a033; PAPPA HS, 1993, EUR J BIOCHEM, V212, P227, DOI 10.1111/j.1432-1033.1993.tb17654.x; Reading NS, 2001, BIOCHEMISTRY-US, V40, P8161, DOI 10.1021/bi010440i; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SMITH AT, 1990, J BIOL CHEM, V265, P13335; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Smulevich G, 1999, J BIOL INORG CHEM, V4, P39, DOI 10.1007/s007750050287; SMULEVICH G, 1994, BIOCHEMISTRY-US, V33, P7398, DOI 10.1021/bi00189a046; SMULEVICH G, 1994, BIOCHEMISTRY-US, V33, P15425, DOI 10.1021/bi00255a024; Spiro, 1988, BIOL APPL RAMAN SPEC, P1; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P8567, DOI 10.1021/bi970484k; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Tanaka M, 1998, BIOCHEMISTRY-US, V37, P2629, DOI 10.1021/bi9725273; TERAOKA J, 1981, J BIOL CHEM, V256, P3969; Tsaprailis G, 1998, BIOCHEMISTRY-US, V37, P2004, DOI 10.1021/bi971032a; Veitch NC, 2001, ADV INORG CHEM, V51, P107; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	52	65	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40704	40711		10.1074/jbc.M107489200	http://dx.doi.org/10.1074/jbc.M107489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546788	hybrid			2022-12-25	WOS:000171925600045
J	Misura, KMS; Gonzalez, LC; May, AP; Scheller, RH; Weis, WI				Misura, KMS; Gonzalez, LC; May, AP; Scheller, RH; Weis, WI			Crystal structure and biophysical properties of a complex between the N-terminal SNARE region of SNAP25 and syntaxin 1a.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; SENSITIVE FUSION PROTEIN; MEMBRANE-FUSION; DOMAIN; IDENTIFICATION; EXOCYTOSIS; MECHANISM; TRANSPORT; DOCKING; SNAP-25	SNARE proteins are required for intracellular membrane fusion. In the neuron, the plasma membrane SNARES syntaxin 1a and SNAP25 bind to VAMP2 found on neurotransmitter-containing vesicles. These three proteins contain "SNARE regions" that mediate their association into stable tetrameric coiled-coil structures. Syntaxin la contributes one such region, designated H3, and SNAP25 contributes two SNARE regions to the fusogenic complex with VAMP2. Syntaxin la H3 (synlaH3) and SNAP25 can form a stable assembly, which can then be bound by VAMP2 to form the full SNARE complex. Here we show that syn1aH3 can also form a stable but kinetically trapped complex with the N-terminal SNARE region of SNAP25 (S25N). The crystal structure of this complex reveals an extended parallel four-helix bundle similar to that of the core SNARE and the syn1aH3(.)SNAP25 complexes. The inherent ability of synlaH3 and S25N to associate stably in vitro implies that the intracellular fusion machinery must prevent formation of, or remove, any nonproductive complexes. Comparison with the syn1aH3(.)SNAP25 complex suggests that the linkage of the N- and C-terminal SNAP25 SNARE regions is kinetically advantageous in preventing formation of the non-productive syn1aH3(.)S25N complex. We also demonstrate that the syn1aH3(.)S25N complex can be disassembled by a-SNAP and N-ethylmaleimide-sensitive factor.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011; Gonzalez, Lino/E-4102-2012	Weis, William I/0000-0002-5583-6150; Gonzalez, Lino/0000-0003-3817-6450	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038710, R01MH058570, R37MH038710] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08294] Funding Source: Medline; NIMH NIH HHS [MH38710, MH58570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Grosse-Kunstleve RW, 1999, ACTA CRYSTALLOGR D, V55, P1568, DOI 10.1107/S0907444999007763; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HESS DT, 1992, J NEUROSCI, V12, P4634; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Wade N, 2001, J BIOL CHEM, V276, P19820, DOI 10.1074/jbc.M010838200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	51	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41301	41309		10.1074/jbc.M106853200	http://dx.doi.org/10.1074/jbc.M106853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533035	hybrid			2022-12-25	WOS:000171925600123
J	Wang, HZ; Yang, BF; Zhang, YQ; Han, H; Wang, JX; Shi, H; Wang, ZG				Wang, HZ; Yang, BF; Zhang, YQ; Han, H; Wang, JX; Shi, H; Wang, ZG			Different subtypes of alpha(1)-adrenoceptor modulate different K+ currents via different signaling pathways in canine ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; HUMAN ATRIAL MYOCYTES; PROTEIN-KINASE; PURKINJE-FIBERS; CHANNEL; STIMULATION; MECHANISMS; MYOCARDIUM; AGONISTS; ANTAGONISTS	Multiple subtypes (alpha (1A), alpha (1B), and alpha (1D)) of alpha (1)-adrenoreceptors (alpha (1)ARs) co-exist in the heart and mediate a variety of cellular functions. We studied alpha (1)AR modulation of inward rectifier (I-K1) and transient outward (I-to) K+ currents in canine ventricular myocytes. Phenylephrine at 10 mum depressed only It. without affecting I-K1 and at 100 muM inhibited both I-to and I-K1. The effect of phenylephrine on I-to. was abolished by (+)niguldipine (10 nm) to inhibit alpha (1A)ARs but not by chloroethyclonidine (10 mum) to inactivate alpha (1B)ARs nor by BMY-7378 to antagonize alpha (1D)ARs. In contrast, phenylephrine inhibition of I-K1 was reversed only by BMY-7378 (1 nM). PDD (100 nM, phorbol ester activator of protein kinase C (PKC)) simulates and bisindolylmaleimide (50 nM, PKC inhibitor) weakens phenylephrine modulation of I-to. but not I-K1. Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93 and inhibitor peptides abolished the effects of phenylephrine on I-K1. Enhancement of PKC or CaMKII activities was seen in alpha (1a)AR- or alpha (1d)dAR-transfected HEK293 cells and in myocytes pretreated with 10 or 100 muM phenylephrine, respectively. Our data suggest that different subtypes of alpha 1ARs selectively modulate different cardiac K+ currents via different signal transduction mechanisms; alpha (1A)ARs mediate It. regulation via PKC, and alpha (1D)ARs mediate I-K1 regulation via CaMKII.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Coll, Dept Pharmacol, Harbin 150086, Heilongjiang, Peoples R China	Universite de Montreal; Universite de Montreal; Harbin Medical University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 500 Belanger E, Montreal, PQ H1T 1C8, Canada.		Wang, Zhiguo/GRS-4339-2022; wang, zhiguo/AAN-4182-2021; Zhang, Yiqiang/D-9613-2012; Han, Ho Jae/M-1476-2016	Wang, Zhiguo/0000-0002-0811-2045; Zhang, Yiqiang/0000-0003-0691-6645; Han, Ho Jae/0000-0002-0657-1766				ANYUKHOVSKY EP, 1991, CIRCULATION, V83, P2076, DOI 10.1161/01.CIR.83.6.2076; APKON M, 1988, P NATL ACAD SCI USA, V85, P8756, DOI 10.1073/pnas.85.22.8756; BEAUMONT J, 1995, AM J PHYSIOL-HEART C, V268, pH1181, DOI 10.1152/ajpheart.1995.268.3.H1181; BILLMAN GE, 1994, J CARDIOVASC PHARM, V24, P394, DOI 10.1097/00005344-199409000-00007; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; BRAUN AP, 1990, J PHYSIOL-LONDON, V431, P689, DOI 10.1113/jphysiol.1990.sp018355; Butta N, 1996, BRIT J PHARMACOL, V118, P1797, DOI 10.1111/j.1476-5381.1996.tb15606.x; Chevalier P, 1998, J PHARMACOL EXP THER, V284, P832; Deng XF, 1996, BRIT J PHARMACOL, V119, P269, DOI 10.1111/j.1476-5381.1996.tb15981.x; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Drouin E, 1996, J CARDIOVASC PHARM, V27, P320, DOI 10.1097/00005344-199603000-00003; Endoh M, 1996, NEUROCHEM RES, V21, P217, DOI 10.1007/BF02529138; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; FEDIDA D, 1991, J PHYSIOL-LONDON, V441, P673, DOI 10.1113/jphysiol.1991.sp018772; GOETZ AS, 1995, EUR J PHARMACOL, V272, pR5, DOI 10.1016/0014-2999(94)00751-R; Guo WN, 1998, PFLUG ARCH EUR J PHY, V436, P26, DOI 10.1007/s004240050600; HAN C, 1991, MOL PHARMACOL, V40, P531; HAN C, 1987, MOL PHARMACOL, V32, P505; Han C, 1995, EUR J PHARMACOL, V294, P593, DOI 10.1016/0014-2999(95)00607-9; Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hieble J P, 1996, Prog Drug Res, V47, P81; Koh SD, 1999, J PHYSIOL-LONDON, V517, P75, DOI 10.1111/j.1469-7793.1999.0075z.x; Li GR, 1996, CIRC RES, V78, P903, DOI 10.1161/01.RES.78.5.903; MINNEMAN KP, 1994, MOL PHARMACOL, V46, P929; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; Ohmi K, 1999, BRIT J PHARMACOL, V127, P756, DOI 10.1038/sj.bjp.0702588; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Roeper J, 1997, J NEUROSCI, V17, P3379; SATO R, 1995, J MEMBRANE BIOL, V148, P185; Shi H, 2000, AM J PHYSIOL-HEART C, V278, pH295, DOI 10.1152/ajpheart.2000.278.1.H295; Taguchi K, 1998, N-S ARCH PHARMACOL, V357, P100, DOI 10.1007/PL00005143; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; VanWagoner DR, 1996, AM J PHYSIOL-HEART C, V271, pH937, DOI 10.1152/ajpheart.1996.271.3.H937; Varma DR, 2000, CAN J PHYSIOL PHARM, V78, P267, DOI 10.1139/cjpp-78-4-267; Wang HZ, 2001, MOL PHARMACOL, V59, P1029, DOI 10.1124/mol.59.5.1029; Wang HZ, 2000, CIRCULATION, V102, P1165, DOI 10.1161/01.CIR.102.10.1165; WANG XL, 1991, J PHARMACOL EXP THER, V259, P783; Wang ZG, 1999, CIRC RES, V84, P551, DOI 10.1161/01.RES.84.5.551; Wang ZG, 1998, CIRCULATION, V98, P2422, DOI 10.1161/01.CIR.98.22.2422; WILLIAMSON AP, 1994, CAN J PHYSIOL PHARM, V72, P1574, DOI 10.1139/y94-226; Yang HT, 1997, BRIT J PHARMACOL, V122, P1541, DOI 10.1038/sj.bjp.0701506; Yue LX, 1999, J PHYSIOL-LONDON, V516, P385, DOI 10.1111/j.1469-7793.1999.0385v.x; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	45	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40811	40816		10.1074/jbc.M105572200	http://dx.doi.org/10.1074/jbc.M105572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11524420	hybrid			2022-12-25	WOS:000171925600059
J	Wiens, GD; O'Hare, T; Rittenberg, MB				Wiens, GD; O'Hare, T; Rittenberg, MB			Recovering antibody secretion using a hapten ligand as a chemical chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; COMPLEMENTARITY-DETERMINING REGION-2; NEPHROGENIC DIABETES-INSIPIDUS; AFFINITY CHOLINE TRANSPORTER; KEYHOLE LIMPET HEMOCYANIN; IG LIGHT-CHAINS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; ANTIGEN-BINDING; IMMUNOLOGICAL MEMORY	Engineered antibodies have come to the forefront as research reagents and clinical therapeutics. However, reduced stability or expression levels pose a major problem with many engineered antibodies. As a model for understanding functional consequences of variable region mutation, we have studied the assembly and trafficking of anti-phenylphosphocholine antibodies. Previously, we identified severe secretion defects because of mutations in the heavy chain second complementarity determining region, which is involved in antigen binding. Here we demonstrate that immunoglobulin secretion is increased up to 27-fold by incubating stably transfected PCG1-1 cells with cognate hapten p-nitro-phenylphosphocholine. Secretion was unaffected by nonbinding analogs. Radiotracer and metabolic labeling experiments demonstrated specific cellular uptake of p-nitrophenylphosphocholine and increased intracellular heavy and light chain assembly. Brefeldin A inhibited hapten-mediated immunoglobulin secretion but not assembly, indicating that assembly occurs early within the biosynthetic pathway. Recovery of secretion correlated with antigen binding capacity, suggesting that the rescue mechanism involves stabilization of heavy and light chain variable domains. This model system provides the first demonstration that cognate ligands can increase intracellular assembly of functional anti-hapten antibody within mammalian cells and suggests that small molecules of appropriate specificity and affinity acting as chemical chaperones may find application for increasing or regulating immunoglobulin expression.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Wiens, GD (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, L220,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Wiens, Gregory/0000-0002-5478-7780	NIAID NIH HHS [AI-26827, AI-14985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026827, R01AI014985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTHONY J, 1992, MOL IMMUNOL, V29, P1237, DOI 10.1016/0161-5890(92)90060-B; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; BROWN M, 1992, J IMMUNOL, V148, P339; Brown M, 2000, J EXP MED, V191, P2101, DOI 10.1084/jem.191.12.2101; BRUDERER U, 1989, MOL IMMUNOL, V26, P63, DOI 10.1016/0161-5890(89)90021-7; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; CHEN C, 1994, J EXP MED, V180, P577, DOI 10.1084/jem.180.2.577; CHESEBRO B, 1972, BIOCHEMISTRY-US, V11, P766, DOI 10.1021/bi00755a014; Day PM, 1997, P NATL ACAD SCI USA, V94, P8064, DOI 10.1073/pnas.94.15.8064; Dul JL, 1996, J IMMUNOL, V157, P2969; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P3121, DOI 10.1002/eji.1830221214; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Gavilondo JV, 2000, BIOTECHNIQUES, V29, P128, DOI 10.2144/00291ov01; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HORWITZ AH, 1994, MOL IMMUNOL, V31, P683, DOI 10.1016/0161-5890(94)90178-3; Jager M, 1999, J MOL BIOL, V285, P2005, DOI 10.1006/jmbi.1998.2425; JOST CR, 1994, J BIOL CHEM, V269, P26267; Klein U, 1998, IMMUNOL REV, V162, P261; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; Leitzgen K, 1997, J BIOL CHEM, V272, P3117, DOI 10.1074/jbc.272.5.3117; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Martin TM, 1998, J IMMUNOL, V160, P5963; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; MORRISON SL, 1978, EUR J IMMUNOL, V8, P194, DOI 10.1002/eji.1830080311; MOULTON HM, 1996, THESIS PORTLAND STAT; O'Hare T, 1999, J IMMUNOL, V163, P11; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Okuda T, 2000, NAT NEUROSCI, V3, P120, DOI 10.1038/72059; Pellequer JL, 1999, J MOL RECOGNIT, V12, P267, DOI 10.1002/(SICI)1099-1352(199907/08)12:4<267::AID-JMR465>3.0.CO;2-9; PILLAI S, 1991, INT REV CYTOL, V130, P1, DOI 10.1016/S0074-7696(08)61500-4; Rajan DP, 2000, J BIOL CHEM, V275, P14331, DOI 10.1074/jbc.275.19.14331; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SAUERS LJ, 1986, J IMMUNOPHARMACOL, V8, P611; SCHARFF MD, 1975, HARVEY LECT, V69, P125; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; Sompuram SR, 1996, J IMMUNOL, V156, P1071; STENZELPOORE MP, 1987, J IMMUNOL, V139, P1698; Stevens FJ, 1999, IMMUNOL TODAY, V20, P451, DOI 10.1016/S0167-5699(99)01502-9; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; Ueda H, 1996, NAT BIOTECHNOL, V14, P1714, DOI 10.1038/nbt1296-1714; Verma R, 1998, J IMMUNOL METHODS, V216, P165, DOI 10.1016/S0022-1759(98)00077-5; Wang J, 1999, J BIOL CHEM, V274, P12883, DOI 10.1074/jbc.274.18.12883; Wiens GD, 2001, J IMMUNOL, V167, P2179, DOI 10.4049/jimmunol.167.4.2179; Wiens GD, 1997, J IMMUNOL, V159, P1293; WILSON A, 1993, CURR OPIN STRUC BIOL, V3, P113; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	55	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40933	40939		10.1074/jbc.M104979200	http://dx.doi.org/10.1074/jbc.M104979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533029	hybrid			2022-12-25	WOS:000171925600075
J	Aschenbach, WG; Suzuki, Y; Breeden, K; Prats, C; Hirshman, MF; Dufresne, SD; Sakamoto, K; Vilardo, PG; Steele, M; Kim, JH; Jing, SL; Goodyear, LJ; DePaoli-Roach, AA				Aschenbach, WG; Suzuki, Y; Breeden, K; Prats, C; Hirshman, MF; Dufresne, SD; Sakamoto, K; Vilardo, PG; Steele, M; Kim, JH; Jing, SL; Goodyear, LJ; DePaoli-Roach, AA			The muscle-specific protein phosphatase PP1G/R-GL(G(M)) is essential for activation of glycogen synthase by exercise	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; TARGETING SUBUNITS; CONTRACTILE ACTIVITY; MOLECULAR-MECHANISM; PRO-GLYCOGENOLYSIS; INSULIN; KINASE; PHOSPHORYLATION; GLUCOSE-6-PHOSPHATE	In skeletal muscle both insulin and contractile activity are physiological stimuli for glycogen synthesis, which is thought to result in part from the dephosphorylation and activation of glycogen synthase (GS). PP1G/R-GL(G(M)) is a glycogen/sarcoplasmic reticulum-associated type I phosphatase that was originally postulated to mediate insulin control of glycogen metabolism. However, we recently showed (Suzuki, Y., Lanner, C., Kim, J.-H., Vilardo, P. G., Zhang, H., Jie Yang, J., Cooper, L. D., Steele, M., Kennedy, A., Bock, C., Scrimgeour, A., Lawrence, J. C. Jr., L., and DePaoli-Roach, A. A. (2001) Mol. Cell. Biol. 21, 2683-2694) that insulin activates GS in muscle of R-GL(G(M)) knockout (KO) mice similarly to the wild type (WT). To determine whether PP1G is involved in glycogen metabolism during muscle contractions, RGL KO and overexpressors (OE) were subjected to two models of contraction, in vivo treadmill running and in situ electrical stimulation. Both procedures resulted in a 2-fold increase in the GS -/+ glucose-6-P activity ratio in WT mice, but this response was completely absent in the KO mice. The KO mice, which also have a reduced GS activity associated with significantly reduced basal glycogen levels, exhibited impaired maximal exercise capacity, but contraction-induced activation of glucose transport was unaffected. The R-GL OE mice are characterized by enhanced GS activity ratio and an similar to3-4-fold increase in glycogen content in skeletal muscle. These animals were able to tolerate exercise normally. Stimulation of GS and glucose uptake following muscle contraction was not significantly different as compared with WT littermates. These results indicate that although PP1G/R-GL is not necessary for activation of GS by insulin, it is essential for regulation of glycogen metabolism under basal conditions and in response to contractile activity, and may explain the reduced muscle glycogen content in the R-GL KO mice, despite the normal insulin activation of GS.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.	DePaoli-Roach, AA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	adepaoli@iupui.edu	sakamoto, kei/C-8806-2019; Prats, Clara/F-5993-2014	sakamoto, kei/0000-0001-8839-5980; Prats, Clara/0000-0001-6465-3068	NIAMS NIH HHS [AR 45670, AR 42238] Funding Source: Medline; NIDDK NIH HHS [DK 59769, DK 36569] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045670, R01AR042238, R29AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569, F32DK059769] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLQUIST LE, 1992, EUR J APPL PHYSIOL O, V65, P360, DOI 10.1007/BF00868141; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; Bergmeyer H. V., 1974, METHOD ENZYMAT AN, V2, P1196; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; BLOCH G, 1994, AM J PHYSIOL, V266, pE85, DOI 10.1152/ajpendo.1994.266.1.E85; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; COHEN P, 1987, BIOCHEM SOC T, V15, P999, DOI 10.1042/bst0150999; Cohen P., 1986, ENZYMES, VXVII, P461; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cushman SW, 1998, ADV EXP MED BIOL, V441, P63; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Derave W, 1999, AM J PHYSIOL-ENDOC M, V277, pE1103, DOI 10.1152/ajpendo.1999.277.6.E1103; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Franch J, 1999, BIOCHEM J, V344, P231, DOI 10.1042/0264-6021:3440231; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; Goodyear L J, 2000, Exerc Sport Sci Rev, V28, P113; Graham TE, 2001, J APPL PHYSIOL, V90, P873, DOI 10.1152/jappl.2001.90.3.873; Hayashi T, 1999, AM J PHYSIOL-CELL PH, V277, pC701, DOI 10.1152/ajpcell.1999.277.4.C701; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hogan B, 1994, MANIPULATING MOUSE E; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; Ivy JL, 1998, ACTA PHYSIOL SCAND, V162, P295, DOI 10.1046/j.1365-201X.1998.0302e.x; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; Katz A, 1995, PFLUG ARCH EUR J PHY, V431, P259, DOI 10.1007/BF00410199; Kawanaka K, 2000, AM J PHYSIOL-ENDOC M, V279, pE1311, DOI 10.1152/ajpendo.2000.279.6.E1311; Laurent D, 2000, AM J PHYSIOL-ENDOC M, V278, pE663, DOI 10.1152/ajpendo.2000.278.4.E663; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; Lerin C, 2000, J BIOL CHEM, V275, P39991, DOI 10.1074/jbc.M006251200; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; O'Gorman DJ, 2000, J APPL PHYSIOL, V89, P1412, DOI 10.1152/jappl.2000.89.4.1412; Price TB, 1999, P NUTR SOC, V58, P851, DOI 10.1017/S0029665199001159; Price TB, 2000, J APPL PHYSIOL, V88, P698, DOI 10.1152/jappl.2000.88.2.698; PRICE TB, 1994, MED SCI SPORT EXER, V26, P983; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Ragolia L, 2000, J BIOL CHEM, V275, P26102, DOI 10.1074/jbc.M001955200; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Roach PJ, 2001, HDB PHYSL 7, VII, P609, DOI DOI 10.1002/CPHY.CP070219; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Shearer J, 2001, J APPL PHYSIOL, V90, P880, DOI 10.1152/jappl.2001.90.3.880; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHERMAN WM, 1995, AM J CLIN NUTR, V62, p228S, DOI 10.1093/ajcn/62.1.228S; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; WAGENMAKERS AJM, 1991, AM J PHYSIOL, V260, pE883, DOI 10.1152/ajpendo.1991.260.6.E883; Walker KS, 2000, FEBS LETT, V466, P121, DOI 10.1016/S0014-5793(99)01771-8; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	69	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39959	39967		10.1074/jbc.M105518200	http://dx.doi.org/10.1074/jbc.M105518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11522787	hybrid			2022-12-25	WOS:000171789200062
J	Nikolakaki, E; Kohen, R; Hartmann, AM; Stamm, S; Georgatsou, E; Giannakouros, T				Nikolakaki, E; Kohen, R; Hartmann, AM; Stamm, S; Georgatsou, E; Giannakouros, T			Cloning and characterization of an alternatively spliced form of SR protein kinase 1 that interacts specifically with scaffold attachment factor-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IN-VIVO; CELL-CYCLE; SAF-B; SACCHAROMYCES-CEREVISIAE; NUCLEAR-RECEPTOR; PREMESSENGER RNA; SERINE-RICH; FAMILY; LOCALIZATION	Serine/arginine protein kinases have been conserved throughout evolution and are thought to play important roles in the regulation of mRNA processing, nuclear import, germline development, polyamine transport, and ion homeostasis. Human SRPK1, which was first identified as a kinase specific for the SR family of splicing factors, is located on chromosome 6p21.2-p21.3. We report here the cloning and characterization of SRPK1a, which is encoded by an alternatively processed transcript derived from the SRPK1 gene. SRPK1a contains an insertion of 171 amino acids at its NH2-terminal domain and is similar to SRPK1 in substrate specificity and subcellular localization. Moreover, both isoforms can induce alternative splicing of human tau exon 10 in transfected cells. Using the yeast two-hybrid assay, we found that the extended NH2-terminal domain of SRPK1a interacts with Scaffold Attachment Factor-B, a nuclear scaffold-associated protein. Confirmation of this interaction was provided by in, vitro binding assays, as well as by co-immunoprecipitation from 293T cells doubly transfected with SRPK1a and SAF-B. Our studies suggest that different SRPK family members are uniquely regulated and targeted and thus the multiple SRPK kinases present in higher eukaryotes may perform specialized and differentiable functions.	Aristotelian Univ Thessaloniki, Sch Chem, Biochem Lab, Thessaloniki 54006, Greece; Univ Thessaly, Sch Med, Biochem Lab, Larisa 41222, Greece; Univ Munich, D-80336 Munich, Germany; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	Aristotle University of Thessaloniki; University of Thessaly; University of Munich; University of Erlangen Nuremberg	Nikolakaki, E (corresponding author), Aristotelian Univ Thessaloniki, Sch Chem, Biochem Lab, Thessaloniki 54006, Greece.		Hartmann, Annette/AAS-6331-2021; GIANNAKOUROS, THOMAS/R-3204-2019					Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Blencowe BJ, 2000, RNA, V6, P111, DOI 10.1017/S1355838200991982; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; Erez O, 2001, MOL CELL BIOL, V21, P175, DOI 10.1128/MCB.21.1.175-184.2001; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; Harlow E., 1988, ANTIBODIES LAB MANUA; Hartmann AM, 2001, MOL CELL NEUROSCI, V18, P80, DOI 10.1006/mcne.2001.1000; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; James P, 1996, GENETICS, V144, P1425; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kuroyanagi H, 2000, MECH DEVELOP, V99, P51, DOI 10.1016/S0925-4773(00)00477-9; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Maniatis T., 1982, MOL CLONING LAB MANU; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Papoutsopoulou S, 1999, NUCLEIC ACIDS RES, V27, P2972, DOI 10.1093/nar/27.14.2972; Papoutsopoulou S, 1999, BIOCHEM BIOPH RES CO, V255, P602, DOI 10.1006/bbrc.1999.0249; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Rose MD., 1990, METHODS YEAST GENETI; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; Stoss O, 1999, BRAIN RES PROTOC, V4, P383, DOI 10.1016/S1385-299X(99)00043-4; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wang HY, 1999, GENOMICS, V57, P310, DOI 10.1006/geno.1999.5770; WANG J, 1995, RNA, V1, P335; Weighardt F, 1999, J CELL SCI, V112, P1465; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	57	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40175	40182		10.1074/jbc.M104755200	http://dx.doi.org/10.1074/jbc.M104755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509566	hybrid			2022-12-25	WOS:000171789200089
J	Sheluho, D; Ackerman, SH				Sheluho, D; Ackerman, SH			An accessible hydrophobic surface is a key element of the molecular chaperone action of Atp11p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL F-1-ATPASE; F1-ATPASE; YEAST; SUBSTRATE; IDENTIFICATION; MECHANISM; BINDING	Atp11p is a soluble protein of mitochondria that binds unassembled beta subunits of the F-1-ATPase and prevents them from aggregating in the matrix. In this report, we show that Atp11p protects the insulin B chain from aggregating in vitro and therefore acts as a molecular chaperone. The chaperone action of Atp11p is mediated by hydrophobic interactions. An accessible hydrophobic surface in Atp11p was identified with the environment-sensitive fluorescent probe 1,1'-bis(4-anilino-5-napth-thalenesulfonic acid (bis-ANS). The spectral changes of bis-ANS in the presence of Atp11p indicate that the probe binds to a nonpolar region of the protein. Furthermore, the dye quenches the fluorescence of Atp11p tryptophan residues in a concentration-dependent manner. Although up to three molecules of bis-ANS can bind cooperatively to Atp11p, the binding of only one dye molecule is sufficient to virtually eliminate the chaperone activity of the protein.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, 1225 Ellman Bldg,421 E Canfield Ave, Detroit, MI 48201 USA.				NIGMS NIH HHS [GM48157] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HONG S, 1995, J BIOCHEM MOL BIOL, V29, P230; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Lakowicz J. R, 1999, PRINCIPLES FLUORESCE, P446; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Panse VG, 2000, J BIOL CHEM, V275, P18698, DOI 10.1074/jbc.275.25.18698; SANGER F, 1949, BIOCHEM J, V44, P126, DOI 10.1042/bj0440126; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; Smoot AL, 2001, BIOCHEMISTRY-US, V40, P4484, DOI 10.1021/bi001822b; TUITE MF, 1990, ANTON LEEUW INT J G, V58, P147, DOI 10.1007/BF00548925; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 1999, FEBS LETT, V452, P305, DOI 10.1016/S0014-5793(99)00676-6; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296	28	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39945	39949		10.1074/jbc.M107252200	http://dx.doi.org/10.1074/jbc.M107252200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11522798	hybrid			2022-12-25	WOS:000171789200060
J	Han, ZY; Pantazis, P; Wyche, JH; Kouttab, N; Kidd, VJ; Hendrickson, EA				Han, ZY; Pantazis, P; Wyche, JH; Kouttab, N; Kidd, VJ; Hendrickson, EA			A Fas-associated Death Domain Protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; HUMAN COLORECTAL-CANCER; CASPASE 9; IN-VIVO; FADD; CYCLOOXYGENASE; ACTIVATION; ASPIRIN; MICE; PROLIFERATION	Non-steroidal anti-inflammatory drugs (NSAIDs) are inhibitors of cyclooxygenase-1 and -2 and are useful for prevention and cure of cancers, especially colon and rectal cancers. The NSAIDs indomethacin and sulindac sulfide have been shown to induce apoptosis of colon epithelial cancer cells by a Bax-dependent mechanism that involves mitochondria-mediated activation of a caspase-9-dependent pathway. In this report, we demonstrate that indomethacin and sulindac sulfide induce apoptosis of human leukemic Jurkat cells by a mechanism that requires the Fas-associated Death Domain Protein-mediated activation of a caspase-8-dependent pathway. Therefore, NSAIDs induce apoptosis by different mechanisms depending on the cell type.	Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Boston Univ, Dept Pathol, Roger Williams Med Ctr, Providence, RI 02906 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Brown University; Boston University; Roger Williams Medical Center; St Jude Children's Research Hospital; University of Minnesota System; University of Minnesota Twin Cities	Hendrickson, EA (corresponding author), Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church S SE, Minneapolis, MN 55455 USA.	hendr064@tc.umn.edu			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NCI NIH HHS [CA679389, CA21765] Funding Source: Medline; NIAID NIH HHS [AI35763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barnes CJ, 1996, CELL PROLIFERAT, V29, P467, DOI 10.1111/j.1365-2184.1996.tb00989.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Petak I, 2000, CANCER RES, V60, P2643; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; Reddy BS, 1996, CANCER RES, V56, P4566; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841	47	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38748	38754		10.1074/jbc.M106214200	http://dx.doi.org/10.1074/jbc.M106214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514566	hybrid			2022-12-25	WOS:000171673200057
J	Okado-Matsumoto, A; Fridovich, I				Okado-Matsumoto, A; Fridovich, I			Subcellular distribution of superoxide dismutases (SOD) in rat liver - Cu,Zn-SOD in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-ZINC; LOCALIZATION; MECHANISM; RADICALS; REACTIVITY; ACIDS; SITE; DNA	Rat liver was homogenized in isotonic buffer, fractionated by differential centrifugation, and then subfractionated by equilibrium sedimentation in Nycodenz gradients. Fractions were assayed for both Cu,Zn-superoxide dismutase (SOD) and Mn-SOD by exploiting the cyanide sensitivity of the former activity and by the use of specific antibodies. As expected, the cytosol and lysosomal fractions contained Cu,Zn-SOD; while the mitochondrial matrix contained Mn-SOD. In mitochondria, Cu,Zn-SOD was found in the intermembrane space and Mn-SOD in the matrix and also on the inner membrane. The Mn-SOD associated with the inner membrane was solubilized by 0.5 M NaCl. Surprisingly the intracellular membrane fraction (microsomes) contained bound Cu,Zn-SOD that could be solubilized with a detergent, and to lesser degree with 0.5 M NaCl. Both the cytosolic and mitochondrial Cu,Zn-SODs were isolated and compared. They have identical molecular mass, cyanide sensitivity, SDS sensitivity, heat stability, and chloroform + ethanol stability. Tissue from Cu,Zn-SOD knockout mice was entirely devoid of Cu,Zn-SOD; indicating that the cytosolic and the intermembrane space Cu,Zn-SODS are coded for by the same gene. The significance of this distribution of the SODS is discussed.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							ALBERTS B, 1994, MOL BIOL CELL, P657; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V340, P305, DOI 10.1006/abbi.1997.9940; BENSON SW, 1980, J AM CHEM SOC, V102, P2843, DOI 10.1021/ja00528a057; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG GG, 1991, ARCH BIOCHEM BIOPHYS, V284, P285, DOI 10.1016/0003-9861(91)90297-V; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; COHEN HJ, 1971, J BIOL CHEM, V246, P359; CRANE D, 1982, BIOCHIM BIOPHYS ACTA, V712, P57, DOI 10.1016/0005-2760(82)90084-4; Dix TA, 1996, BIOCHEMISTRY-US, V35, P4578, DOI 10.1021/bi952010w; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; GELLER BL, 1983, ANAL BIOCHEM, V128, P86, DOI 10.1016/0003-2697(83)90348-2; GELLER BL, 1982, J BIOL CHEM, V257, P8945; Greenawalt J W, 1979, Methods Enzymol, V55, P88; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; KEELE BB, 1971, J BIOL CHEM, V246, P2875; LAMM G, 1990, P NATL ACAD SCI USA, V87, P9033, DOI 10.1073/pnas.87.22.9033; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; Lombard M, 2001, BIOCHEMISTRY-US, V40, P5032, DOI 10.1021/bi0023908; LuchterWasylewska E, 1996, ANAL BIOCHEM, V241, P167, DOI 10.1006/abio.1996.0394; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Nishiyama J, 1996, ACTA HISTOCHEM CYTOC, V29, P215, DOI 10.1267/ahc.29.215; SAGRISTA ML, 1987, BIOCHIMIE, V69, P1207, DOI 10.1016/0300-9084(87)90148-9; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SLOT JW, 1986, LAB INVEST, V55, P363; STEINMAN HM, 1994, J BIOL CHEM, V269, P28629; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Wharton DC., 1967, METHOD ENZYMOL, P245	31	731	748	5	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38388	38393		10.1074/jbc.M105395200	http://dx.doi.org/10.1074/jbc.M105395200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11507097	hybrid			2022-12-25	WOS:000171673200010
J	Schlax, PJ; Xavier, KA; Gluick, TC; Draper, DE				Schlax, PJ; Xavier, KA; Gluick, TC; Draper, DE			Translational repression of the Escherichia coli alpha operon mRNA - Importance of an mRNA conformational switch and a ternary entrapment complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; INITIATION; RIBOSOME; RECOGNITION; POLYMERASE; EXPRESSION	Ribosomal protein S4 represses synthesis of the four ribosomal proteins (including itself) in the Escherichia coli a operon by binding to a nested pseudoknot structure that spans the ribosome binding site. A model for the repression mechanism previously proposed two unusual features: (i) the mRNA switches between conformations that are "active" or "inactive" in translation, with S4 as an allosteric effector of the inactive form, and (ii) S4 holds the 30 S subunit in an unproductive complex on the mRNA ("entrapment"), in contrast to direct competition between repressor and ribosome binding ("displacement"). These two key points have been experimentally tested. First, it is found that the mRNA pseudoknot exists in an equilibrium between two conformers with different electrophoretic mobilities. S4 selectively binds to one form of the RNA, as predicted for an allosteric effector; binding of ribosomal 30 S subunits is nearly equal in the two forms. Second, we have used S4 labeled at a unique cysteine with either of two fluorophores to characterize its interactions with mRNA and 30 S subunits. Equilibrium experiments detect the formation of a specific ternary complex of S4, mRNA pseudoknot, and 30 S subunits. The existence of this ternary complex is unambiguous evidence for translational repression of the alpha operon by an entrapment mechanism.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Johns Hopkins University	Draper, DE (corresponding author), Johns Hopkins Univ, Dept Chem, 3400 N Charles St, Baltimore, MD 21218 USA.	draper@jhunix.hcf.jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056968] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56968] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER AM, 1995, J BIOL CHEM, V270, P22939, DOI 10.1074/jbc.270.39.22939; BEDWELL D, 1985, NUCLEIC ACIDS RES, V13, P3891, DOI 10.1093/nar/13.11.3891; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHANGCHIEN LM, 1976, J MOL BIOL, V108, P381, DOI 10.1016/S0022-2836(76)80126-X; DECKMAN IC, 1987, J MOL BIOL, V196, P313, DOI 10.1016/0022-2836(87)90692-9; Draper D.E., 1987, TRANSLATIONAL REGULA, P1; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; Draper DE, 1998, COLD SPRING HARBOR M, P415; DRAPER DE, 1996, ESCHERICHIA COLI SAL, P902; Gluick TC, 1997, J MOL BIOL, V270, P451, DOI 10.1006/jmbi.1997.1119; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; Kohrer C, 1996, EUR J BIOCHEM, V236, P234, DOI 10.1111/j.1432-1033.1996.00234.x; NEWBERRY V, 1977, EUR J BIOCHEM, V76, P51, DOI 10.1111/j.1432-1033.1977.tb11569.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; Sayers EW, 2000, BIOCHEMISTRY-US, V39, P13602, DOI 10.1021/bi0013391; SPEDDING G, 1993, P NATL ACAD SCI USA, V90, P4399, DOI 10.1073/pnas.90.10.4399; SPEDDING G, 1993, J MOL BIOL, V229, P609, DOI 10.1006/jmbi.1993.1067; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TANG CK, 1990, BIOCHEMISTRY-US, V29, P4434, DOI 10.1021/bi00470a025; THOMAS MS, 1987, J MOL BIOL, V196, P333, DOI 10.1016/0022-2836(87)90694-2; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	24	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38494	38501		10.1074/jbc.M106934200	http://dx.doi.org/10.1074/jbc.M106934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504736	hybrid			2022-12-25	WOS:000171673200024
J	Diez-Juan, A; Andres, V				Diez-Juan, A; Andres, V			The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis	FASEB JOURNAL			English	Article						cell cycle; p27; hypercholesterolemia	DEPENDENT KINASE INHIBITOR; MUSCLE CELL-PROLIFERATION; NUCLEAR ANTIGEN; CYCLIN-E; IN-VIVO; BALLOON ANGIOPLASTY; PARAFFIN SECTIONS; APOLIPOPROTEIN-E; BREAST-CANCER; MICE LACKING	The molecular basis of atherosclerosis is associated with excessive proliferation of vascular cells. Previous studies have suggested an inverse correlation between the expression of the growth suppressor p27(Kip1) (p27) and cellular proliferation within human atherosclerotic tissue. However, no causal link between diminished p27 expression and atherogenesis has been established. We investigated the effect of p27 inactivation on diet-induced atherogenesis. We find that p27-deficient mice challenged with a high-fat diet for 1 month remain normocholesterolemic and have essentially no visible atheromas. However, when generated in an apolipoprotein E-null genetic background that leads to severe hypercholesterolemia in response to the atherogenic diet, deletion of p27 enhances arterial cell proliferation (similar to fourfold) and accelerates atherogenesis (similar to sixfold) compared with apolipoprotein E-deficient mice with an intact p27 gene. Analysis of apolipoprotein E-null mice bearing only one p27 allele inactivated reveals that a moderate decrease in p27 protein expression in the setting of hypercholesterolemia is sufficient to predispose to atherogenesis. Thus, our study establishes a molecular link between decreased p27 protein expression and atherogenesis in hypercholesterolemic animals.	CSIC, IBV, Spanish Council Sci Res, Valencia 46010, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Andres, V (corresponding author), CSIC, IBV, Spanish Council Sci Res, C Jaime Roig 11, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869				Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen HM, 2000, SUPERLATTICE MICROST, V27, P1, DOI 10.1006/spmi.1999.0794; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; Ihling C, 1999, ATHEROSCLEROSIS, V144, P7, DOI 10.1016/S0021-9150(99)00032-5; KAWAKITA N, 1992, AM J PATHOL, V140, P513; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lavia P, 1999, BIOESSAYS, V21, P221; Libby P, 1997, PROG CARDIOVASC DIS, V40, P97, DOI 10.1016/S0033-0620(97)80002-3; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Ueno H, 1997, ANN NY ACAD SCI, V811, P401, DOI 10.1111/j.1749-6632.1997.tb52020.x; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1998, CIRC RES, V82, P147; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	41	73	73	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1989	1995		10.1096/fj.01-0130com	http://dx.doi.org/10.1096/fj.01-0130com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532979	Green Submitted			2022-12-25	WOS:000171372700014
J	Tseng, YT; Kopel, R; Stabila, JP; McGonnigal, BG; Nguyen, TT; Gruppuso, PA; Padbury, JF				Tseng, YT; Kopel, R; Stabila, JP; McGonnigal, BG; Nguyen, TT; Gruppuso, PA; Padbury, JF			beta-Adrenergic receptors (bAR) regulate cardiomyocyte proliferation during early postnatal life	FASEB JOURNAL			English	Article						MAPK; p70 S6K; propranolol	PROTEIN-KINASE PATHWAY; NEONATAL RAT; TARGETED DISRUPTION; CARDIAC GROWTH; HEART; ADRENOCEPTOR; STIMULATION; ACTIVATION; AGONISTS; CASCADE	Cardiomyocyte development switches from hyperplasmic to hypertrophic growth between postnatal days 3 and 4 in rats. The mechanisms responsible for this transition have been controversial. beta -Adrenergic receptor (beta AR) activation of mitogenic responses in vitro has been reported. We hypothesized that tonic activation of the beta AR signaling regulates cell division in neonatal cardiomyocytes via effects on signaling kinases known to be important in cell cycle regulation. The purpose of the current study was to elucidate the roles of beta AR in rat cardiomyocyte growth in vivo. We demonstrated that beta AR blockade induced a significant reduction in cardiomyocyte proliferation as measured by the BrdU labeling index. Blockade of beta AR did not affect p38 or p44/42 MAPK activities. We further demonstrated that beta AR blockade induced a prompt deactivation of the p70 ribosomal protein S6 kinase (p70 S6K). To confirm these results, we measured p70 S6K activity directly. Basal activity of p70 S6K in neonatal cardiomyocytes was fourfold higher than that of insulin-treated adult rat liver. The activity of p70 S6K was reduced by 60% within 1 min after beta AR blockade. We conclude that the beta AR are involved in regulation of neonatal cardiomyocyte proliferation and that this mitogenic control may be mediated via the p70 S6K pathway.	Women & Infants Hosp Rhode Isl, Rhode Isl Hosp, Brown Med Sch, Dept Pediat, Providence, RI 02905 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Women & Infants Hospital Rhode Island	Tseng, YT (corresponding author), Women & Infants Hosp Rhode Isl, Rhode Isl Hosp, Brown Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	Yi-Tang_Tseng@brown.edu			NICHD NIH HHS [2P01 HD11343] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011343] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agarwal D, 1999, CELL PROLIFERAT, V32, P215, DOI 10.1046/j.1365-2184.1999.3240215.x; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Boney CM, 1998, ENDOCRINOLOGY, V139, P1638, DOI 10.1210/en.139.4.1638; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; De Paepe ME, 1998, AM J PATHOL, V152, P179; Dzimiri N, 1999, PHARMACOL REV, V51, P465; Ghatpande S, 1999, MOL CELL BIOCHEM, V196, P93, DOI 10.1023/A:1006974330613; Kim D, 1999, IEEE COMMUN LETT, V3, P9, DOI 10.1109/4234.740114; KUDLACZ EM, 1990, J DEV PHYSIOL, V14, P307; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Li FQ, 1996, J MOL CELL CARDIOL, V28, P1737, DOI 10.1006/jmcc.1996.0163; Liggett SB, 2000, CIRCULATION, V101, P1707; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MCGILL CJ, 1995, CARDIOVASC RES, V30, P557, DOI 10.1016/S0008-6363(95)00113-1; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Renick SE, 1997, PEDIATR RES, V41, P359, DOI 10.1203/00006450-199703000-00009; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Simm A, 1998, J MOL CELL CARDIOL, V30, P2059, DOI 10.1006/jmcc.1998.0768; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	32	25	25	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2001	15	11					1921	1926		10.1096/fj.01-0151com	http://dx.doi.org/10.1096/fj.01-0151com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532972				2022-12-25	WOS:000171372700007
J	Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE				Roopchand, DE; Lee, JM; Shahinian, S; Paquette, D; Bussey, H; Branton, PE			Toxicity of human adenovirus E4orf4 protein in Saccharomyces cerevisiae results from interactions with the Cdc55 regulatory B subunit of PP2A	ONCOGENE			English	Article						protein phosphatase 2A; CDC55; adenovirus; E4orf4	PHOSPHATASE 2A; P53-INDEPENDENT APOPTOSIS; TUMOR-ANTIGENS; EARLY REGION-4; A-SUBUNIT; ACTIN CYTOSKELETON; TRANSFORMED-CELLS; DNA-REPLICATION; E1A PROTEINS; YEAST	The E4orf4 protein of human adenovirus induces p53-independent apoptosis, a process that may promote cell death and viral spread. When expressed alone, E4orf4 kills transformed cells but not normal human cells. The only clear target of E4orf4 in mammalian cells is the Ba (B55) subunit of protein phosphatase 2A (PP2A), a member of one of three classes of regulatory B subunits. Here we report the effects of E4orf4 in Saccharomyces cerevisiae, which encodes two PP2A regulatory B subunits, CDC55 and RTS1, that share homology with mammalian B and B' subunits, respectively. E4orf4 expression was found to be toxic in yeast, resulting in the accumulation of cells in G2/M phase that failed to grow upon removal of E4orf4. E4orf4-expressing yeast also displayed an elongated cell morphology similar to cdc55 deletion strains. E4orf4 required CDC55 to elicit its effect, whereas RTS1 was dispensable. The recruitment of the PP2A holoenzyme by E4orf4 was entirely dependent on Cdc55. These studies indicate that E4orf4-induced apoptosis in mammalian cells and cell death in yeast require functional interactions with B-type subunits of PP2A. However, some inhibition of growth by E4orf4 was observed in the cdc55 strain and with an E4orf4 mutant that fails to interact with Cdc55, indicating that E4orf4 may possess a second Cdc55-independent function affecting cell growth.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; GeminX Biotechnol Inc, Montreal, PQ H2W 2M9, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	branton@med.mcgill.ca						CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DIEN BS, 1994, METHOD CELL BIOL, V42, P457; Evans DRH, 1997, GENETICS, V145, P227; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lechward K, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1373; LIN FC, 1995, EMBO J, V14, P2745, DOI 10.1002/j.1460-2075.1995.tb07275.x; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; TEODORO JG, 1995, ONCOGENE, V11, P467; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	59	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5279	5290		10.1038/sj.onc.1204693	http://dx.doi.org/10.1038/sj.onc.1204693			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536041				2022-12-25	WOS:000170575500004
J	Dennis, JH; Budhram-Mahadeo, V; Latchman, DS				Dennis, JH; Budhram-Mahadeo, V; Latchman, DS			The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells	ONCOGENE			English	Article						Brn-3; MCF7; stable cell line; breast cancer; transcription factor	MAMMARY-CARCINOMA CELLS; CENTRAL-NERVOUS-SYSTEM; ESTROGEN-RECEPTOR; AUTOREGULATORY ELEMENT; RESPONSE ELEMENT; FACTOR SECRETION; NEURONAL CELLS; RETINOIC ACID; EXPRESSION; ACTIVATION	The Brn-3b POU domain containing transcription factor is expressed in the developing sensory nervous system as well as in epithelial cells of the breast, cervix, and testes. Brn-3b functionally interacts with the estrogen receptor (ER) and in association with the ER, regulates transcription from estrogen responsive genes. In addition, Brn-3b expression is elevated in breast tumours compared to levels in normal mammary cells. To explore the role of Brn-3b in breast cancer, we established stable cell lines derived from the MCF7 human breast cancer cell line which had been transfected with Brn-3b sense or anti-sense constructs. The Brn-3b over-expressing cell Hues exhibited increased growth rate, reached confluence at a higher saturation density, had higher proliferative activity, and an enhanced ability to form colonies in soft agar when compared to the control empty vector transfected cells. Likewise, the Brn-3b anti-sense cell lines showed reduced cellular growth and proliferation, reached confluence at a lower density, and exhibited a decreased ability to form colonies in soft agar when compared to the vector controls. Five to ten per cent of the Brn-3b over-expressing cells exhibited a severely altered morphology characterized by reduced adherence to tissue culture plastic, increased cell size, and a vacuolar cell shape. These results thus further indicate a role for the Brn-3b transcription factor in regulating mammary cell growth and suggest that its elevation in breast cancer is of functional significance.	Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Latchman, DS (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.							AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; Elledge RM, 1997, BRIT MED J, V314, P1843, DOI 10.1136/bmj.314.7098.1843; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FUQUA SA, 1992, J NATL CANCER I, V84, P554, DOI 10.1093/jnci/84.8.554; FUQUA SAW, 1992, CANCER RES, V52, P483; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LIPPMAN ME, 1987, J LAB CLIN MED, V109, P230; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; LOU L, 1995, NUCLEIC ACIDS RES, V23, P3481, DOI 10.1093/nar/23.17.3481; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MURPHY LC, 1983, J CLIN ENDOCR METAB, V57, P373, DOI 10.1210/jcem-57-2-373; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Packer AI, 1998, DEVELOPMENT, V125, P1991; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; REDDEL RR, 1983, CANCER RES, V43, P4618; REDDEL RR, 1983, EUR J CANCER CLIN ON, V19, P1179, DOI 10.1016/0277-5379(83)90047-0; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	34	25	28	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4961	4971		10.1038/sj.onc.1204491	http://dx.doi.org/10.1038/sj.onc.1204491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526481				2022-12-25	WOS:000170439800006
J	Martins, BM; Grimm, B; Mock, HP; Huber, R; Messerschmidt, A				Martins, BM; Grimm, B; Mock, HP; Huber, R; Messerschmidt, A			Crystal structure and substrate binding modeling of the uroporphyrinogen-III decarboxylase from Nicotiana tabacum - Implications for the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAPYRROLE BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; PURIFICATION; PORPHOBILINOGEN; RECOGNITION; EXPRESSION; SEQUENCE; TOBACCO; GENE	The enzymatic catalysis of many biological processes of life is supported by the presence of cofactors; and prosthetic groups originating from the common tetrapyrrole precursor uroporphyrinogen-III. Uroporphyrinogen-III decarboxylase catalyzes its conversion into coproporphyrinogen-III, leading in plants to chlorophyll and heme biosynthesis. Here we report the first crystal structure of a plant (Nicotiana tabacum) uroporphyrinogen-M decarboxylase, together with the molecular modeling of substrate binding in tobacco and human enzymes. Its structural comparison with the homologous human protein reveals a similar catalytic cleft with six invariant polar residues, Arg(32), Arg(36), Asp(82), Ser(214) (Thr in Escherichia coli), Tyr(159), and His(329) (tobacco numbering). The functional relationships obtained from the structural and modeling analyses of both enzymes allowed the proposal for a refined catalytic mechanism. Asp(82) and Tyr(159) seem to be the catalytic functional groups, whereas the other residues may serve in substrate recognition and binding, with Arg(32) steering its insertion. The crystallographic dimer appears to represent the protein dimer under physiological conditions. The dimeric arrangement offers a plausible mechanism at least for the first two (out of four) decarboxylation steps.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Humboldt Univ, Lehrstuhl Pflanzenphysiol, D-10099 Berlin, Germany; Inst Pflanzengenet & Kulturpflanzenforsch, Abt Mol Zellbiol, D-06466 Gatersleben, Germany	Max Planck Society; Humboldt University of Berlin; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Martins, BM (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18a, D-82152 Martinsried, Germany.	martins@biochem.mpg.de	Mock, Hans-Peter/C-8202-2019; Messerschmidt, Albrecht/A-8337-2008	Mock, Hans-Peter/0000-0002-3983-3099; 				AKHTAR M, 1994, CIBA F SYMP, V180, P131; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNARD GF, 1979, J CHEM SOC PERK T 1, P2354, DOI 10.1039/p19790002354; BARNARD GF, 1975, J CHEM SOC CHEM COMM, P494, DOI 10.1039/c39750000494; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Dasgupta S, 1997, PROTEINS, V28, P494, DOI 10.1002/(SICI)1097-0134(199708)28:4<494::AID-PROT4>3.0.CO;2-A; DEVERNEUIL H, 1983, J BIOL CHEM, V258, P2454; Elder GH, 1998, HEPATOLOGY, V27, P289, DOI 10.1002/hep.510270142; ELDER GH, 1995, J BIOENERG BIOMEMBR, V27, P207, DOI 10.1007/BF02110035; Erskine PT, 1999, BIOCHEMISTRY-US, V38, P4266, DOI 10.1021/bi982137w; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FELIX F, 1990, EUR J BIOCHEM, V188, P393, DOI 10.1111/j.1432-1033.1990.tb15416.x; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; GAREY JR, 1992, EUR J BIOCHEM, V205, P1011, DOI 10.1111/j.1432-1033.1992.tb16868.x; Grimm B, 1998, CURR OPIN PLANT BIOL, V1, P245, DOI 10.1016/S1369-5266(98)80112-X; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Hu GS, 1998, PLANT CELL, V10, P1095, DOI 10.1105/tpc.10.7.1095; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; JACKSON AH, 1976, PHILOS T ROY SOC B, V273, P191, DOI 10.1098/rstb.1976.0009; JACOBS JM, 1993, PLANT PHYSIOL, V101, P1181, DOI 10.1104/pp.101.4.1181; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; KAWANISHI S, 1983, J BIOL CHEM, V258, P4285; LASH TD, 1991, BIOCHEM J, V278, P901, DOI 10.1042/bj2780901; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehmann C, 1997, HELV CHIM ACTA, V80, P1421, DOI 10.1002/hlca.19970800508; LEHNEN LP, 1990, PESTIC BIOCHEM PHYS, V37, P239, DOI 10.1016/0048-3575(90)90130-T; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; LUO J, 1993, BIOCHEM J, V289, P529, DOI 10.1042/bj2890529; Martins BM, 2001, ACTA CRYSTALLOGR D, V57, P1709, DOI 10.1107/S0907444901013361; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mock HP, 1997, PLANT PHYSIOL, V113, P1101, DOI 10.1104/pp.113.4.1101; MOCK HP, 1995, PLANT MOL BIOL, V28, P245, DOI 10.1007/BF00020244; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano N, 1999, PROTEIN SCI, V8, P2072, DOI 10.1110/ps.8.10.2072; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shalygo NV, 1997, PHYSIOL PLANTARUM, V99, P160, DOI 10.1034/j.1399-3054.1997.990122.x; STRAKA JG, 1983, BIOCHEMISTRY-US, V22, P4664, DOI 10.1021/bi00289a009; TURK D, 1992, WEITERENTWICKLUNG PR; Whitby FG, 1998, EMBO J, V17, P2463, DOI 10.1093/emboj/17.9.2463; Wyckoff EE, 1996, BBA-PROTEIN STRUCT M, V1298, P294, DOI 10.1016/S0167-4838(96)00148-3	44	37	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44108	44116		10.1074/jbc.M104759200	http://dx.doi.org/10.1074/jbc.M104759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11524417	hybrid			2022-12-25	WOS:000172297700081
J	Finlin, BS; Gau, CL; Murphy, GA; Shao, HP; Kimel, T; Seitz, RS; Chiu, YF; Botstein, D; Brown, PO; Tamanoi, F; Andres, DA; Perou, CM				Finlin, BS; Gau, CL; Murphy, GA; Shao, HP; Kimel, T; Seitz, RS; Chiu, YF; Botstein, D; Brown, PO; Tamanoi, F; Andres, DA; Perou, CM			RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION PATTERNS; SMALL GTPASES; G-PROTEIN; CELLS; RIT; FAMILY; TRANSFORMATION; SUPERFAMILY; SEQUENCES; MEMBER	Using microarray analysis, we identified a unique ras superfamily gene, termed RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or lost in a significant percentage of primary human breast tumors that show a poor clinical prognosis. Importantly, high RERG expression correlated with expression of a set of genes that define a breast tumor subtype that is estrogen receptor-positive and associated with a slow rate of tumor cell proliferation and a favorable prognosis for these cancer patients. RERG mRNA expression was induced rapidly in MCF-7 cells stimulated by beta -estradiol and repressed by tamoxifen treatment. Like Ras, RERG protein exhibited intrinsic GDP/GTP binding and GTP hydrolysis activity. Unlike Ras proteins, RERG lacks a known recognition signal for COOH-terminal prenylation and was localized primarily in the cytoplasm. Expression of RERG protein in MCF-7 breast carcinoma cells resulted in a significant inhibition of both anchorage-dependent and anchorage-independent growth in vitro and inhibited tumor formation in nude mice. These features of RERG are strikingly different from most Ras superfamily GTP-binding proteins and suggest that the loss of RERG expression may contribute to breast tumorigenesis.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Res Genet Inc, Huntsville, AL 35801 USA; Appl Genom Inc, Huntsville, AL 35801 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; University of California System; University of California Los Angeles; Stanford University; Howard Hughes Medical Institute; Stanford University	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biostat, CB 7295, Chapel Hill, NC 27599 USA.		Chiu, Yen-Feng/E-3847-2010; Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Der, Channing/0000-0002-7751-2747; Repasky, Gretchen/0000-0001-6466-6467	NATIONAL CANCER INSTITUTE [R01CA041996, R01CA069577] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996, CA69577] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bilan PJ, 1998, EXP CELL RES, V242, P391, DOI 10.1006/excr.1998.4092; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNIGHT WA, 1977, CANCER RES, V37, P4669; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PEROU CM, 2000, NEW TECHNOLOGIES LIF, P67; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tavassoli FA, 1992, PATHOLOGY BREAST, P193; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214	38	129	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42259	42267		10.1074/jbc.M105888200	http://dx.doi.org/10.1074/jbc.M105888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533059	hybrid, Green Published			2022-12-25	WOS:000172450400096
J	Brzovic, PS; Meza, JE; King, MC; Klevit, RE				Brzovic, PS; Meza, JE; King, MC; Klevit, RE			BRCA1 RING domain cancer-predisposing mutations - Structural consequences and effects on protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER	Cancer-predisposing missense mutations in the RING domain of BRCA1 primarily target Zn2+-liganding residues. Here we report on the structural consequences of such mutations introduced into the second Zn2+ site (Site II) of the BRCA1 RING domain and their effect on the interaction with the BARD1 RING domain. Each of the BRCA1 Site II mutants still interact and form a stable heterodimer with BARD1. Limited proteolysis of BRCA1/BARD1 complexes, monitored by matrix-assisted laser desorption ionization time-of-flight spectrometry, show that the mutations cause a local structural perturbation that is primarily confined to the second Zn2+ binding loop of the BRCA1 subunit. These findings are consistent with the structure of the BRCA1/BARD1 heterodimer, which shows this region is well removed from the helices required for dimerization with BARD1. Instead, the mutations alter a region of BRCA1 that appears to be required for interaction with ubiquitin-conjugating enzymes.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Klevit, RE (corresponding author), Univ Washington, Dept Biochem, Box 357742, Seattle, WA 98195 USA.	klevit@u.washington.edu	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [R01 CA79953, R01 CA27632-18S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079953, R01CA027632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	19	104	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41399	41406		10.1074/jbc.M106551200	http://dx.doi.org/10.1074/jbc.M106551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526114	hybrid			2022-12-25	WOS:000171925600136
J	Jeon, Y; Lee, YS; Han, JS; Kim, JB; Hwang, DS				Jeon, Y; Lee, YS; Han, JS; Kim, JB; Hwang, DS			Multimerization of phosphorylated and non-phosphorylated ArcA is necessary for the response regulator function of the Arc two-component signal transduction system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEDIATING REPRESSION; 2-COMPONENT SYSTEM; AEROBIC PATHWAYS; DNA-BINDING; IN-VITRO; PROTEIN; ACTIVATION; MODULES; CHEY	To adapt to anaerobic conditions, Escherichia coli operates the Arc two-component signal transduction system, consisting of a sensor kinase, ArcB, and a response regulator, ArcA. ArcA is converted to the active form, phosphorylated ArcA (ArcA-P), by ArcB-mediated phosphorylation. The active ArcA-P binds to the promoter regions of target genes, thereby regulating their transcriptional activities. The phosphoryl group of ArcA-P is unstable with a half-life of 30 min. However, we were able to inhibit the dephosphorylation for more than 12 h by the addition of EDTA; this allowed us to characterize ArcA-P. Gel-filtration and glycerol sedimentation experiments demonstrated that ArcA exists as a homo-dimer. ArcA phosphorylated by either ArcB or carbamyl phosphate multimerizes to form a tetramer of dimers; this multimer binds to the ArcA DNA binding site. Isoelectric focusing gel electrophoresis and nitrocellulose-filter binding analyses indicated that the ArcA multimer is composed of both ArcA-P and ArcA in a ratio, 1:1. The ArcA(D54E) mutant protein was unable to be phosphorylated by ArcB. This defect resulted in the inability of ArcA(D54E) to form a multimer or to bind to the ArcA DNA binding site. These results indicate that phosphorylation of ArcA induces multimerization prior to DNA binding, and the multimerization is a prerequisite for binding. Our results suggest a novel model that phosphorylation of ArcA by ArcB regulates multimerization of ArcA, which in turn functions as a response regulator.	Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea	Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea.							Colloms SD, 1998, MOL MICROBIOL, V28, P521, DOI 10.1046/j.1365-2958.1998.00812.x; DRAPAL N, 1995, MOL MICROBIOL, V16, P597, DOI 10.1111/j.1365-2958.1995.tb02422.x; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; HWANG DS, 1992, J BIOL CHEM, V267, P2209; IUCHI S, 1989, J BACTERIOL, V171, P868, DOI 10.1128/jb.171.2.868-873.1989; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; Lee YS, 2001, J BIOL CHEM, V276, P9917, DOI 10.1074/jbc.M008629200; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; McCleary WR, 1996, MOL MICROBIOL, V20, P1155, DOI 10.1111/j.1365-2958.1996.tb02636.x; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1996, ESCHERICHIA COLI SAL, V1, P1246; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	26	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40873	40879		10.1074/jbc.M104855200	http://dx.doi.org/10.1074/jbc.M104855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527965	hybrid			2022-12-25	WOS:000171925600067
J	Ringstad, N; Nemoto, Y; De Camilli, P				Ringstad, N; Nemoto, Y; De Camilli, P			Differential expression of endophilin 1 and 2 dimers at central nervous system synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; FROG NEUROMUSCULAR JUNCTION; SH3 DOMAIN; TRANSMITTER RELEASE; ACTIN CYTOSKELETON; CONTAINING PROTEIN; BINDING PARTNERS; DYNAMIN; SYNAPTOJANIN; HOMOLOGY	Endophilin 1 is proposed to participate in synaptic vesicle biogenesis through SH3 domain-mediated interactions with the polyphosphoinositide phosphatase synaptojanin and the GTPase dynamin. Endophilin family members have also been identified as binding partners for a number of diverse cellular proteins. We define here the endophilin 1-binding site within synaptojanin 1 and show that this sequence independently and selectively purifies from brain extracts endophilin 1 and a closely related protein, endophilin 2. Endophilin 2, like endophilin 1, is highly expressed in brain, concentrated in nerve terminals, and found in complexes with synaptojanin and dynamin. Although a fraction of endophilins 1 and 2 coexist in the same complex, the distribution of these endophilin isoforms among central synapses only partially overlaps. Endophilins 1 and 2 are found predominantly as stable dimers through a predicted coiled-coil domain in their conserved NH2-terminal moiety. Dimerization may allow endophilins to link a number of different cellular targets to the endocytic machinery.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst,Dept Cell Biol, 295 Congress Ave, New Haven, CT 06520 USA.	pietro.decamilli@yale.edu			NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R42NS036252, R41NS036252] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams A, 2000, J BIOL CHEM, V275, P27414; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Farsad K, 2000, MOL BIOL CELL, V11, p278A; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	37	66	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40424	40430		10.1074/jbc.M106338200	http://dx.doi.org/10.1074/jbc.M106338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518713	hybrid			2022-12-25	WOS:000171925600011
J	Jelich-Ottmann, C; Weiler, EW; Oecking, C				Jelich-Ottmann, C; Weiler, EW; Oecking, C			Binding of regulatory 14-3-3 proteins to the C terminus of the plant plasma membrane H+-ATPase involves part of its autoinhibitory region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSICOCCIN; 14-3-3-PROTEINS; DOMAIN; PHOSPHORYLATION; YEAST; SITE; COMPLEMENTATION; RESIDUES; COMPLEX; SYSTEM	The plant plasma membrane H+-ATPase is activated by the binding of 14-3-3 proteins to its extreme C-terminal amino acids (YTV) and phosphorylation of the penultimate threonine (YpTV) is necessary for this interaction in vivo. However, in the presence of the fungal toxin fusicoccin (FC), binding of 14-3-3 proteins occurs independently of phosphorylation but still involves the YTV motif. Since FC exclusively binds to the complex consisting of both 14-3-3 homologs and the C-terminal domain of the H+-ATPase, the toxin was used as a tool to reveal potential protein-protein interaction sites in the enzyme's C terminus. We performed in vitro interaction studies by applying various C-terminal parts of the H+-ATPase PMA2 from Nicotiana plumbaginifolia expressed as glutathione S-transferase fusion peptides in E. coli. Interestingly, the PMA2 region encompassing residues 905-922 is implicated in FC-dependent binding of 14-3-3 homologs. Recently, part of this region has been shown to contribute to the autoinhibitory action of the PMA2 C terminus. Site-directed mutagenesis of individual amino acids localized within this region resulted in a drastic decrease in FC-dependent binding of 14-3-3 proteins. Furthermore, by expressing the corresponding mutants of PMA2 in yeast, we observed a reduced capability of the mutant enzymes to functionally replace the endogenous H+-ATPase. Notably, the decreased activity of the mutant enzymes was accompanied by a weakened binding of yeast 14-3-3 homologs to the plasma membrane of transformed cells. Taken together, our results suggest that a section of the autoinhibitory C-terminal PMA2 region contributes to binding of activatory 14-3-3 proteins in the absence of FC.	Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44801 Bochum, Germany	Ruhr University Bochum	Oecking, C (corresponding author), Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, Univ Str 150, D-44801 Bochum, Germany.							Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4; Dambly S, 2001, J BIOL CHEM, V276, P7017, DOI 10.1074/jbc.M007740200; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFERMEIJER FC, 1994, PLANT PHYSIOL, V104, P1277, DOI 10.1104/pp.104.4.1277; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oecking C, 1999, PLANTA, V207, P480, DOI 10.1007/s004250050507; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Piotrowski M, 1998, PLANTA, V204, P127, DOI 10.1007/s004250050238; Piotrowski M, 1998, J BIOL CHEM, V273, P30018, DOI 10.1074/jbc.273.45.30018; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	23	40	43	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39852	39857		10.1074/jbc.M106746200	http://dx.doi.org/10.1074/jbc.M106746200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517228	hybrid			2022-12-25	WOS:000171789200047
J	Steveson, TC; Zhao, GC; Keutmann, HT; Mains, RE; Eipper, BA				Steveson, TC; Zhao, GC; Keutmann, HT; Mains, RE; Eipper, BA			Access of a membrane protein to secretory granules is facilitated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; TRANS-GOLGI NETWORK; MANNOSE 6-PHOSPHATE RECEPTOR; PEPTIDE PROCESSING ENZYME; CYTOSOLIC ROUTING DETERMINANTS; PH-DEPENDENT AGGREGATION; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; IN-VITRO; INTRACELLULAR TRAFFICKING	Peptidylglycine a-amidating monooxygenase (PAM), an integral membrane protein essential for the biosynthesis of amidated peptides, was used to assess the role of cytosolic acidic clusters in trafficking to regulated secretory granules. Casein kinase II phosphorylates Ser(949) and Thr(946) of PAM, generating a short, cytosolic acidic cluster. P-CIP2, a protein kinase identified by its ability to interact with several juxtamembrane determinants in the PAM cytosolic domain, also phosphorylates Ser(949). Antibody specific for phospho-Ser(949)-PAM-CD demonstrates that a small fraction of the PAM-1 localized to the perinuclear region bears this modification. Pituitary cell lines expressing PAM-1 mutants that mimic (TS/DD) or prevent (TS/AA) phosphorylation at these sites were studied. PAM-1 TS/AA yields a lumenal monooxygenase domain that enters secretory granules inefficiently and is rapidly degraded. In contrast, PAM-1 TS/DD is routed to regulated secretory granules more efficiently than wild-type PAM-1 and monooxygenase release is more responsive to secretagogue. Furthermore, this acidic cluster affects exit of internalized PAM-antibody complexes from late endosomes; internalized PAM-1 TS/DD accumulates in a late endocytic compartment instead of the trans-Golgi network. The increased ability of solubilized PAM-1 TS/DD to aggregate at neutral pH may play an important role in its altered trafficking.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; Georgetown Univ, Georgetown Med Ctr, Washington, DC 20007 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA	University of Connecticut; Georgetown University; Harvard University; Massachusetts General Hospital	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, MC 3401,263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NIDDK NIH HHS [DK-09520, DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009520, R01DK032949, R37DK032949, R56DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 2001, MOL BIOL CELL, V12, P629, DOI 10.1091/mbc.12.3.629; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Bell-Parikh LC, 2001, J BIOL CHEM, V276, P29854, DOI 10.1074/jbc.M103936200; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047, DOI 10.1091/mbc.12.7.2047; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; FUTTER CE, 1989, J CELL SCI, V94, P685; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HEMER F, 1993, J BIOL CHEM, V268, P17108; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JIN MJ, 1993, J BIOL CHEM, V268, P18390; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; Rohn WM, 2000, J CELL SCI, V113, P2093; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; Simmen T, 1999, MOL CELL BIOL, V19, P3136; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Tooze SA, 2001, SCIENCE, V292, P1663, DOI 10.1126/science.1062239; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YUN HY, 1995, J BIOL CHEM, V270, P30075; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	81	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40326	40337		10.1074/jbc.M011460200	http://dx.doi.org/10.1074/jbc.M011460200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11524414	hybrid			2022-12-25	WOS:000171789200110
J	Kersten, S; Mandard, S; Escher, P; Gonzalez, FJ; Tafuri, S; Desvergne, B; Wahli, W				Kersten, S; Mandard, S; Escher, P; Gonzalez, FJ; Tafuri, S; Desvergne, B; Wahli, W			The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism	FASEB JOURNAL			English	Article						fasting; microarray; PPAR alpha; SABRE	CYCLE ENZYME GENES; CHAIN FATTY-ACIDS; UREA CYCLE; LIPOPROTEIN METABOLISM; ADAPTIVE RESPONSE; PPAR-ALPHA; EXPRESSION; INDUCTION; SUPPRESSION; GLUCONEOGENESIS	The peroxisome proliferator-activated receptor a is alpha ligand-activated transcription factor that plays an important role in the regulation of lipid homeostasis. PPAR alpha mediates the effects of fibrates, which are potent hypolipidemic drugs, on gene expression. To better understand the biological effects of fibrates and PPAR alpha, we searched for genes regulated by PPAR alpha using oligonucleotide microarray and subtractive hybridization. By comparing liver RNA from wild-type and PPAR alpha null mice, it was found that PPAR alpha decreases the mRNA expression of enzymes involved in the metabolism of amino acids. Further analysis by Northern blot revealed that PPAR alpha influences the expression of several genes involved in trans- and deamination of amino acids, and urea synthesis. Direct activation of PPAR alpha using the synthetic PPAR alpha ligand WY14643 decreased mRNA levels of these genes, suggesting that PPAR alpha is directly implicated in the regulation of their expression. Consistent with these data, plasma urea concentrations are modulated by PPAR alpha in vivo. It is concluded that in addition to oxidation of fatty acids, PPAR alpha also regulates metabolism of amino acids in liver, indicating that PPAR alpha is a key controller of intermediary metabolism during fasting.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	University of Lausanne; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kersten, S (corresponding author), Univ Wageningen & Res Ctr, Nutr Metab & Genom Grp, POB 8129, NL-6700 EV Wageningen, Netherlands.	sander.kersten@staff.nutepi.wau.nl	Mandard, Stéphane/J-4800-2019; Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Kersten, Sander/A-1116-2011; Desvergne, Beatrice/C-8892-2016	Mandard, Stéphane/0000-0002-7298-821X; Wahli, Walter/0000-0002-5966-9089; Kersten, Sander/0000-0003-4488-7734; Desvergne, Beatrice/0000-0001-5483-288X				Anderson SP, 1999, MOL CARCINOGEN, V26, P226, DOI 10.1002/(SICI)1098-2744(199912)26:4<226::AID-MC2>3.0.CO;2-Q; Auwerx J, 1999, CELL, V97, P161; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; DERR RF, 1976, J PHARMACOL EXP THER, V197, P675; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Edgar AD, 1998, TOXICOL LETT, V98, P13, DOI 10.1016/S0378-4274(98)00042-3; HAGGERTY DF, 1983, MOL CELL BIOCHEM, V53-4, P57; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kimura T, 1998, J BIOL CHEM, V273, P27505, DOI 10.1074/jbc.273.42.27505; Kockx M, 1999, BLOOD, V93, P2991; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Lavery DJ, 1997, P NATL ACAD SCI USA, V94, P6831, DOI 10.1073/pnas.94.13.6831; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; Pan DA, 2000, J LIPID RES, V41, P742; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Strang BD, 1998, J DAIRY SCI, V81, P728, DOI 10.3168/jds.S0022-0302(98)75629-2; Tomomura M, 1996, FEBS LETT, V399, P310, DOI 10.1016/S0014-5793(96)01344-0; Tomomura M, 1997, J BIOCHEM-TOKYO, V121, P172, DOI 10.1093/oxfordjournals.jbchem.a021562; ULBRIGHT C, 1993, ARCH BIOCHEM BIOPHYS, V301, P237, DOI 10.1006/abbi.1993.1139; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2	32	173	178	2	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1971	1978		10.1096/fj.01-0147com	http://dx.doi.org/10.1096/fj.01-0147com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532977				2022-12-25	WOS:000171372700012
J	Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW				Lu, AP; Gupta, A; Li, C; Ahlborn, TE; Ma, YS; Shi, EY; Liu, JW			Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences	ONCOGENE			English	Article						breast cancer specific gene 1; DNA demethylation; transcriptional repression	ONCOSTATIN-M; SYNUCLEIN-GAMMA; IDENTIFICATION; DISEASE; POLYMORPHISM; PROMOTER; RECEPTOR; CLONING; GROWTH	Breast cancer specific gene I (BCSG1), also referred as synuclein gamma, is the third member of a neuronal protein family synuclein. BCSG1 is not expressed in normal breast tissues but highly expressed in advanced infiltrating breast carcinomas. When over expressed, BCSG1 significantly stimulates breast cancer metastasis. To elucidate the molecular mechanisms underlying the abnormal transcription of BCSG1 in breast cancer cells, in this study, we isolated a 2195 base pair fragment of human BCSG1 gene. This fragment includes I kb 5'-flanking region, exon 1, and intron 1. By analysing the promoter activity and the methylation status of the exon I region, we show that (1) Intron I plays critical roles in the control of BCSG1 gene transcription through cis-regulatory sequences that affect BCSG1 transcription in cell type-specific and cell type-nonspecific manners. (2) The activator protein-1 (AP-1) is functionally involved in BCSG1 transcription in breast cancer cells through its binding to an AP-I motif located in the intron 1. (3) The exon I region of BCSG1 gene contains a CpG island that is unmethylated in BCSG1-positive SKBR-3 and T47D cells but densely methylated in BCSG1-negative MCF-7 cells. (4) Treating MCF-7 cells with a demethylating agent 5-Aza-2'-deoxycytidine specifically activated BCSG1 transcription. Thus, our results suggest that while the cellular content of transcription activators and repressors that interact with the cis-regulatory sequences present in the intron I contribute prominently to the tissue-specific expression of BCSG1, demethylation of exon 1 is an important factor responsible for the aberrant expression of BCSG1 in breast carcinomas.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; VA Med Ctr, Idaho Falls, ID 83702 USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Northwell Health	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NCI NIH HHS [1RO1CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Esteller M, 2000, CANCER RES, V60, P4366; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Griswold MD, 2001, BIOL REPROD, V64, P602, DOI 10.1095/biolreprod64.2.602; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SHARRARD R, 1992, ONCOGENE, V1, P670; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Xia Y, 1996, ANN NEUROL, V40, P207, DOI 10.1002/ana.410400212	20	55	62	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5173	5185		10.1038/sj.onc.1204668	http://dx.doi.org/10.1038/sj.onc.1204668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526506				2022-12-25	WOS:000170464000011
J	Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R				Gayet, J; Zhou, XP; Duval, A; Rolland, S; Hoang, JM; Cottu, P; Hamelin, R			Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines	ONCOGENE			English	Article						colorectal cancer; cell lines; genetic alterations	MICROSATELLITE MUTATOR PHENOTYPE; GRADIENT GEL-ELECTROPHORESIS; NONPOLYPOSIS COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN GENE; II RECEPTOR GENE; FRAMESHIFT MUTATIONS; SOMATIC MUTATIONS; K-RAS; INSTABILITY	A number of genetic alterations have been described in colorectal cancers. They include allelic losses on specific chromosomal arms, mutations of oncogenes, tumor suppressor genes and mismatch repair genes, microsatellite instability in coding repeat sequences of target genes and methylation defects in gene promoters. Since these alterations have been reported by different groups on different tumors and cell lines, the complete repertoire of genetic alterations for any given tumor sample remains unknown. In the present study, we analysed a series of 22 colorectal cancer cell lines for 31 different genetic alterations. We found significant correlations between mutational profiles in these colorectal cell lines associated with differences in mismatch repair status. This panel of colon cancer cell lines is representative of the genetic heterogeneity occurring in sporadic colorectal carcinoma. Our results may prove to be very useful for understanding the different biological pathways involved in the development of colon cancer, and for groups studying cellular biology and pharmacology on the same cell lines.	INSERM, U434, CEPH, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hamelin, R (corresponding author), INSERM, U434, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.		Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Casares S, 1995, ONCOGENE, V11, P2303; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Cottu PH, 1996, ONCOGENE, V13, P2727; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deng GR, 1999, CANCER RES, V59, P2029; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Duval A, 2000, CANCER RES, V60, P3872; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1993, ONCOGENE, V8, P2213; HEINEN CD, 1995, CANCER RES, V55, P4797; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Iwao K, 1998, CANCER RES, V58, P1021; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kane MF, 1997, CANCER RES, V57, P808; Kitaeva MN, 1997, CANCER RES, V57, P4478; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LI YJ, 1995, ONCOGENE, V11, P597; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzeau F, 1997, BRIT J CANCER, V75, P1336, DOI 10.1038/bjc.1997.226; Myohanen SK, 1998, CANCER RES, V58, P591; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PEINADO MA, 1993, INT J ONCOL, V2, P123; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sparks AB, 1998, CANCER RES, V58, P1130; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	63	155	159	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5025	5032		10.1038/sj.onc.1204611	http://dx.doi.org/10.1038/sj.onc.1204611			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526487				2022-12-25	WOS:000170439800012
J	Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH				Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH			Genes for human general transcription initiation factors TFIIIB, TFIIIB-associated proteins, TFIIIC2 and PTF/SNAPC: functional and positional candidates for tumour predisposition or inherited genetic diseases?	ONCOGENE			English	Article						Cancer Genome Anatomy Project; oncogenesis; human general transcription factors; regulation of gene expression; cell proliferation, differentiation and apoptosis	RNA-POLYMERASE-III; TATA-BINDING PROTEIN; OVARIAN-TUMORS; CLONING; SUBUNIT; ACTIVATION; COMPLEX; SIMIAN-VIRUS-40; INVOLVEMENT; INTERACTS	TFIIIB, TFIIIC2, and PTF/SNAPC are heteromultimeric general transcription factors (GTFs) needed for expression of genes encoding small cytoplasmic (scRNAs) and small nuclear RNAs (snRNAs). Their activity is stimulated by viral oncogenes, such as SV40 large T antigen and Adenovirus EIA, and is repressed by specific transcription factors (STFs) acting as antioncogenes, such as p53 and pRb. GTFs role as final targets of critical signal transduction pathways, that control cell proliferation and differentiation, and their involvement in gene expression regulation suggest that the genes encoding them are potential proto-oncogenes or anti-oncogenes or may be otherwise involved in the pathogenesis of inherited genetic diseases. To test our hypothesis through the positional candidate gene approach, we have determined the physical localization in the human genome of the 11 genes, encoding the subunits of these GTFs, and of three genes for proteins associated with TFIIIB (GTF3BAPs). Our data, obtained by chromosomal in situ hybridization, radiation hybrids and somatic cell hybrids analysis, demonstrate that these genes are present in the human genome as single copy sequences and that some cluster to the same cytogenetic band, alone or in combination with class II GTFs. Intriguingly, some of them are localized within chromosomal regions where recurrent, cytogenetically detectable mutations are seen in specific neoplasias, such as neuroblastoma, uterine leyomioma, mucoepidermoid carcinoma of the salivary glands and hemangiopericytoma, or where mutations causing inherited genetic diseases map, such as Peutz-Jeghers syndrome. Their molecular function and genomic position make these GTF genes interesting candidates for causal involvement in oncogenesis or in the pathogenesis of inherited genetic diseases.	Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy; Univ Marburg, Zentrum Humangenet, D-35037 Marburg, Germany; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	University of Catania; Philipps University Marburg; Rockefeller University	Purrello, M (corresponding author), Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy.		Teichmann, Martin/M-7407-2014	Teichmann, Martin/0000-0002-5257-0510; DI PIETRO, Cinzia Santa/0000-0002-6036-4469				Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Bai L, 1996, MOL CELL BIOL, V16, P5419; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pedeutour F, 2000, GENE CHROMOSOME CANC, V27, P209, DOI 10.1002/(SICI)1098-2264(200002)27:2<209::AID-GCC14>3.0.CO;2-U; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; White RJ, 1998, INT J ONCOL, V12, P741; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yoon JB, 1996, MOL CELL BIOL, V16, P1	25	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4877	4883		10.1038/sj.onc.1204604	http://dx.doi.org/10.1038/sj.onc.1204604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521199				2022-12-25	WOS:000170271800012
J	Escargueil, AE; Plisov, SY; Skladanowski, A; Borgne, A; Meijer, L; Gorbsky, GJ; Larsen, AK				Escargueil, AE; Plisov, SY; Skladanowski, A; Borgne, A; Meijer, L; Gorbsky, GJ; Larsen, AK			Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling	FASEB JOURNAL			English	Article						mitosis; condensation; phosphorylation; nuclear targeting; chromosome structure; nuclear docking; scaffolding protein	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; IN-VIVO; CHROMOSOME CONDENSATION; MITOTIC CHROMOSOMES; ALPHA; PROTEIN; PHOSPHORYLATION; INHIBITION; INTERACTS	Although initiation of chromosome condensation during early prophase is linked temporally to the appearance of the mitotic cdc2 kinase in the nucleus, it is not known what targets the kinase to the nucleus and how this is coupled to chromatin remodeling. We now report that cdc2 kinase forms stable molecular complexes with the nuclear enzyme DNA topoisomerase II, which is associated with marked stimulation of both DNA binding and catalytic activity of topoisomerase II, albeit in a phosphorylation-independent manner. The molecular interaction is required for recruitment of cdc2 kinase, as shown by incubation of purified enzymes with chicken erythrocyte nuclei, which have neither endogenous topoisomerase II nor cdc2 kinase. The physical association between the two enzymes alters the DNA/topoisomerase II interaction as shown by pulse-field electrophoresis after incubation of intact nuclei with the specific topoisomerase II inhibitor VM-26. Furthermore, the presence of both enzymes, but not either enzyme alone, is accompanied by extensive chromatin remodeling converting the interphase nuclei into precondensation chromosomes with striking resemblance to early prophase structures. Our results reveal a novel property of cyclin-dependent kinases and demonstrate that the recruitment of cdc2 kinase by topoisomerase II is coupled to chromatin remodeling.	Inst Gustave Roussy PR2, CNRS, UMR 8532, Lab Tumor Biol & Pharmacol, F-94805 Villejuif, France; Gdansk Univ Technol, Dept Pharmaceut Technol & Biochem, PL-80952 Gdansk, Poland; CNRS, Biol Stn, F-29682 Roscoff, France; Univ Oklahoma, Dept Cell Biol, Oklahoma City, OK USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Fahrenheit Universities; Gdansk University of Technology; Centre National de la Recherche Scientifique (CNRS); University of Oklahoma System; University of Oklahoma Health Sciences Center	Larsen, AK (corresponding author), Inst Gustave Roussy PR2, CNRS, UMR 8532, Lab Tumor Biol & Pharmacol, F-94805 Villejuif, France.	aklarsen@igr.fr	Escargueil, Alexandre/K-5192-2019	Escargueil, Alexandre/0000-0002-7419-7518; , laurent/0000-0003-3511-4916; Gorbsky, Gary/0000-0003-3076-4725				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bojanowski K, 1998, J CELL BIOCHEM, V69, P127, DOI 10.1002/(SICI)1097-4644(19980501)69:2<127::AID-JCB4>3.0.CO;2-U; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KROLL DJ, 1993, MOL ENDOCRINOL, V7, P305, DOI 10.1210/me.7.3.305; Kurz EU, 2000, J BIOL CHEM, V275, P13948, DOI 10.1074/jbc.275.18.13948; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; RAZIN SV, 1991, P NATL ACAD SCI USA, V88, P8515, DOI 10.1073/pnas.88.19.8515; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	47	26	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2001	15	10					2288	+		10.1096/fj.00-0726fje	http://dx.doi.org/10.1096/fj.00-0726fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511510	Bronze			2022-12-25	WOS:000170809900018
J	Kono, M; Nagata, H; Umemura, S; Kawana, S; Osamura, RY				Kono, M; Nagata, H; Umemura, S; Kawana, S; Osamura, RY			In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin	FASEB JOURNAL			English	Article						reverse-transcription; central nervous system; hypothalamus	MELANOCYTE-STIMULATING HORMONE; BLOOD MONONUCLEAR-CELLS; HUMAN KERATINOCYTES; ALPHA-MSH; PEPTIDES; STRESS; PROLIFERATION; IMMUNOMODULATION; DIFFERENTIATION; EPIDERMIS	Systemic stresses induce corticotropin-releasing hormone (CRH) expression in hypothalamus. CRH is released to the pituitary gland, where it stimulates proopiomelanocortin (POMC) production acting via the CRH receptor (CRH-R). CRH and POMC peptides are also detected in sites outside of the central nervous system (CNS), such as the skin. However, it has not been elucidated whether these peptides detected in the skin are derived from CNS or are produced locally. Using immunohistochemical and in situ reverse-transcription (RT)-PCR techniques, we demonstrated coexpression of CRH and POMC mRNAs in the epidermis and pilosebaceous units of the human skin. This coexpression was confirmed by the combination of laser-capture microdissection (LCM) with RT-PCR, analyzing mRNA expressions in captured sebaceous cells. Immunoreactivities and expressions of CRH and POMC mRNAs were strong in inflammatory lesions, melanocytic nevus, seborrheic keratosis, and also in the periphery of the benign tumor. These findings suggest that CRH and POMC peptides are produced locally in the skin and are regulated by inflammatory cells as well as by autocrine mechanisms. The skin may have "a local stress response system," whose activity is mediated by CRH and POMC peptides, in an equivalent to hypothalamus-pituitary adrenal axis.	Tokai Univ, Dept Pathol, Sch Med, Boseidai Isehara, Kanagawa 2591193, Japan; Nippon Med Coll, Dept Dermatol, Tokyo 113, Japan	Tokai University; Nippon Medical School	Osamura, RY (corresponding author), Tokai Univ, Dept Pathol, Sch Med, Boseidai Isehara, Kanagawa 2591193, Japan.	osamura@is.icc.u-tokai.ac.jp						ANGIONI S, 1993, LIFE SCI, V53, P1735, DOI 10.1016/0024-3205(93)90160-5; AUDHYA T, 1991, CELL IMMUNOL, V134, P77, DOI 10.1016/0008-8749(91)90332-6; Can G, 1998, J INVEST DERMATOL, V111, P485, DOI 10.1046/j.1523-1747.1998.00315.x; Chakraborty AK, 1999, J INVEST DERMATOL, V112, P853, DOI 10.1046/j.1523-1747.1999.00608.x; Grabbe S, 1996, J IMMUNOL, V156, P473; HILTZ ME, 1990, PEPTIDES, V11, P979, DOI 10.1016/0196-9781(90)90020-6; Jin L, 1999, LAB INVEST, V79, P511; KAVELAARS A, 1989, J IMMUNOL, V142, P2338; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; LIU MY, 1995, J FOOD DRUG ANAL, V3, P203; LLOYD RV, 1995, DIAGN MOL PATHOL, V4, P143, DOI 10.1097/00019606-199506000-00011; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; LUGER TA, 1993, ANN NY ACAD SCI, V680, P567, DOI 10.1111/j.1749-6632.1993.tb19741.x; MAKRIGIANNAKIS A, 1995, J CLIN ENDOCR METAB, V80, P185, DOI 10.1210/jc.80.1.185; MCGILLIS JP, 1989, J NEUROSCI RES, V23, P346, DOI 10.1002/jnr.490230316; Orel L, 1997, J INVEST DERMATOL, V108, P401, DOI 10.1111/1523-1747.ep12289699; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; Rose J, 1998, J INVEST DERMATOL, V110, P456, DOI 10.1046/j.1523-1747.1998.00142.x; Sanno N, 1997, J CLIN ENDOCR METAB, V82, P2731, DOI 10.1210/jc.82.8.2731; Sanno N, 1997, J CLIN ENDOCR METAB, V82, P1974, DOI 10.1210/jc.82.6.1974; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Shibutani M, 2000, LAB INVEST, V80, P199, DOI 10.1038/labinvest.3780023; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; Slominski A, 1999, HUM PATHOL, V30, P208, DOI 10.1016/S0046-8177(99)90278-2; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; SMITH EM, 1992, P NATL ACAD SCI USA, V89, P782, DOI 10.1073/pnas.89.2.782; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496	36	88	90	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2297	+		10.1096/fj.01-0254fje	http://dx.doi.org/10.1096/fj.01-0254fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511529				2022-12-25	WOS:000170809900014
J	Lopez, F; Ferjoux, G; Cordelier, P; Saint-Laurent, N; Esteve, JP; Vaysse, N; Buscail, L; Susini, C				Lopez, F; Ferjoux, G; Cordelier, P; Saint-Laurent, N; Esteve, JP; Vaysse, N; Buscail, L; Susini, C			Neuronal nitric oxide synthase is a SHP-1 substrate involved in sst2 somatostatin receptor growth inhibitory signaling	FASEB JOURNAL			English	Article						CHO; acini; pancreas; motheaten mice; cGMP	SMOOTH-MUSCLE CELLS; PROTEIN-TYROSINE PHOSPHATASES; GASTROINTESTINAL-TRACT; GENE-EXPRESSION; TERMINAL REGION; TUMOR-GROWTH; CYCLE ARREST; PROLIFERATION; KINASE; PHOSPHORYLATION	Somatostatin receptor sst2 is an inhibitory G protein-coupled receptor, which inhibits normal and tumor cell growth by a mechanism involving the tyrosine phosphatase SHP-1. We reported previously that SHP-1 associates transiently with and is activated by sst2 and is a critical component for sst2 growth inhibitory signaling. Here, we demonstrate that in Chinese hamster ovary cells expressing sst2, SHP-1 is associated at the basal level with the neuronal nitric oxide synthase (nNOS). Following sst2 activation by the somatostatin analog RC-160, SHP-1 rapidly recruits nNOS tyrosine dephosphorylates and activates it. The resulting NO activates guanylate cyclase and inhibits cell proliferation. Coexpression of a catalytically inactive SHP-1 mutant with sst2 blocks RC-160-induced nNOS dephosphorylation and activation, as well as guanylate cyclase activation. In mouse pancreatic acini, RC-160 treatment reduces nNOS tyrosine phosphorylation accompanied by an increase of its activity. By opposition, in acini from viable motheaten (me(v)/me(v)) mice, which express a markedly inactive SHP-1, RC-160 has no effect on nNOS activity. Finally, expression of a dominant-negative form of nNOS prevents both RC-160-induced p27 up-regulation and cell proliferation inhibition. We therefore identified nNOS as a novel SHP-1 substrate critical for sst2-induced cell-growth arrest.	CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Susini, C (corresponding author), CHU Rangueil, IFR 31, INSERM, U531, F-31403 Toulouse 4, France.	susinich@rangueil.inserm.fr	Cordelier, Pierre/D-1150-2014; Nathalie, Saint-Laurent/G-5487-2017	Cordelier, Pierre/0000-0003-2096-7967; 				Bandyopadhyay A, 1997, AM J PHYSIOL-CELL PH, V272, pC1790, DOI 10.1152/ajpcell.1997.272.6.C1790; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Buscail L, 1996, CANCER RES, V56, P1823; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Christopoulos A., 1999, Life Sciences, V64, P1; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Feniuk W, 2000, NEUROPHARMACOLOGY, V39, P1443, DOI 10.1016/S0028-3908(00)00035-6; GARBERS DL, 1992, CELL, V71, P1; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Hajri A, 1998, BRIT J CANCER, V78, P841, DOI 10.1038/bjc.1998.591; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ishida A, 1997, J BIOL CHEM, V272, P10050; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Khaled AR, 1998, CELL IMMUNOL, V185, P49, DOI 10.1006/cimm.1998.1272; Kibbe MR, 2000, J VASC SURG, V31, P1214, DOI 10.1016/S0741-5214(00)90112-5; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Komeima K, 2000, J BIOL CHEM, V275, P28139; Kuzin B, 2000, CURR BIOL, V10, P459, DOI 10.1016/S0960-9822(00)00443-7; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LOGSDON CD, 1983, GASTROENTEROLOGY, V85, P339; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Patel HJ, 1999, FASEB J, V13, P1810, DOI 10.1096/fasebj.13.13.1810; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; RODRIGUEZMARTIN E, 1995, PEPTIDES, V16, P1461, DOI 10.1016/0196-9781(95)02023-3; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sarkar R, 1997, J HYPERTENS, V15, P275, DOI 10.1097/00004872-199715030-00009; Sato J, 2000, CARDIOVASC RES, V47, P697, DOI 10.1016/S0008-6363(00)00137-1; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; SCHALLY AV, 1988, CANCER RES, V48, P6977; SCHALLY AV, 1989, CANCER RES, V49, P1618; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Taylor-Gooby P, 1999, SOC POLICY ADMIN, V33, P1, DOI 10.1111/1467-9515.00128; Viollet C, 2000, EUR J NEUROSCI, V12, P3761, DOI 10.1046/j.1460-9568.2000.00249.x; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Weinstock JV, 2000, EUR J ENDOCRINOL, V143, pS15, DOI 10.1530/eje.0.143S015; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YU SM, 1997, BIOCHIM BIOPHYS ACTA, V1334, P123; [No title captured]	58	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2001	15	10					2300	+		10.1096/fj.00-0867fje	http://dx.doi.org/10.1096/fj.00-0867fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	469JC	11511520				2022-12-25	WOS:000170809900013
J	Brignone, C; Munoz, O; Batoz, M; Rouquette-Jazdanian, A; Cousin, JL				Brignone, C; Munoz, O; Batoz, M; Rouquette-Jazdanian, A; Cousin, JL			Proteases produced by activated neutrophils release soluble CD23 fragments endowed with proinflammatory effects	FASEB JOURNAL			English	Article						polymorphonuclear neutrophils; cathepsin G; monocytes	REGULATES MONOCYTE ACTIVATION; COLLAGEN-INDUCED ARTHRITIS; EPSILON RECEPTOR-II; RHEUMATOID-ARTHRITIS; PROTEOLYTIC ACTIVITY; CATHEPSIN-G; CELL-SURFACE; STIMULATED NEUTROPHILS; MONOCLONAL-ANTIBODY; CYTOKINE PRODUCTION	Polymorphonuclear neutrophils (PMNs) are the major source of proteolytic activities involved mainly in tissue injuries observed in chronic inflammatory disorders. High levels of soluble forms of CD23 (the low-affinity receptor for IgE) were found in biological fluids from these patients, and recent reports focused on a CD23-mediated regulation of inflammatory response. In this context, we show here that co-culture of activated PMN with CD23(+) B cells resulted in a drastic release of soluble CD23 fragments from the cell surface. This cleavage was inhibited by serine proteases inhibitors, including alpha1-antitrypsin. We next demonstrated that purified human leukocyte elastase or cathepsin G efficiently cleaved membrane CD23 on B cells with a high specificity. Soluble fragments released by serine proteases-mediated CD23 proteolysis stimulated resting monocytes to produce oxidative burst and proinflammatory cytokine without any co-stimulatory signal. This work strongly supports the idea that the capacity of PMN-derived proteases to release soluble forms of CD23 participates in the inflammatory process mediated by these cells.	Hop Archet, INSERM, U343, F-06202 Nice 3, France; Dana Farber Canc Inst, Boston, MA 02115 USA	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Dana-Farber Cancer Institute	Cousin, JL (corresponding author), Hop Archet, INSERM, U343, BP 79, F-06202 Nice 3, France.	cousin@unice.fr		ROUQUETTE-JAZDANIAN, Alexandre K./0000-0003-2646-0040				ARMANT M, 1995, J IMMUNOL, V155, P4868; ARMANT M, 1994, J EXP MED, V180, P1005, DOI 10.1084/jem.180.3.1005; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Boccafogli A, 1997, ALLERGY, V52, P357, DOI 10.1111/j.1398-9995.1997.tb01009.x; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; BORISH L, 1991, J IMMUNOL, V146, P63; BRISTOW CL, 1991, BIOCHEM BIOPH RES CO, V181, P232, DOI 10.1016/S0006-291X(05)81407-X; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; CARP H, 1980, J CLIN INVEST, V66, P987, DOI 10.1172/JCI109968; Champagne B, 1998, J IMMUNOL, V161, P6398; CHOMARAT P, 1993, ARTHRITIS RHEUM-US, V36, P234, DOI 10.1002/art.1780360215; Christie G, 1997, EUR J IMMUNOL, V27, P3228, DOI 10.1002/eji.1830271221; Dasic G, 1999, EUR J IMMUNOL, V29, P2957, DOI 10.1002/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO;2-4; de Leon D, 1991, J Neurosci Nurs, V23, P191; DIERKS SE, 1993, J IMMUNOL, V150, P2372; DORING G, 1994, AM J RESP CRIT CARE, V150, pS114; DORING G, 1995, J IMMUNOL, V154, P4842; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; FLORESROMO L, 1989, IMMUNOLOGY, V67, P547; Fremeaux-Bacchi V, 1998, EUR J IMMUNOL, V28, P4268, DOI 10.1002/(SICI)1521-4141(199812)28:12<4268::AID-IMMU4268>3.0.CO;2-9; GRENIERBROSSETTE N, 1992, EUR J IMMUNOL, V22, P1573, DOI 10.1002/eji.1830220634; Gu B, 1998, BLOOD, V92, P946; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Hofman P, 1998, INFECT IMMUN, V66, P2494, DOI 10.1128/IAI.66.6.2494-2500.1998; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; JASIN HE, 1991, J CLIN INVEST, V87, P1531, DOI 10.1172/JCI115164; KATIRA A, 1995, ALLERGY, V50, P689, DOI 10.1111/j.1398-9995.1995.tb02587.x; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Kleinau S, 1999, J IMMUNOL, V162, P4266; Kutukculer N, 1998, AUTOIMMUNITY, V27, P155, DOI 10.3109/08916939809003863; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; LecoanetHenchoz S, 1997, EUR J IMMUNOL, V27, P2290, DOI 10.1002/eji.1830270924; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; LEVINE JJ, 1993, PEDIATR RES, V34, P204, DOI 10.1203/00006450-199308000-00021; Munoz O, 1998, J BIOL CHEM, V273, P31795, DOI 10.1074/jbc.273.48.31795; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; PLATERZYBERK C, 1995, NAT MED, V1, P781, DOI 10.1038/nm0895-781; PORTEU F, 1991, J BIOL CHEM, V266, P18846; REDDY VY, 1994, J BIOL CHEM, V269, P4683; REMOLDODONNELL E, 1995, BLOOD, V86, P2395, DOI 10.1182/blood.V86.6.2395.bloodjournal8662395; Ribbens C, 2000, CLIN EXP IMMUNOL, V120, P194, DOI 10.1046/j.1365-2249.2000.01198.x; ROUSSOU E, 1991, BR J RHEUMATOL S2, V30, P110; SARFATI M, 1987, IMMUNOLOGY, V60, P539; TOSI MF, 1992, J CLIN INVEST, V90, P462, DOI 10.1172/JCI115882; vanderPoll T, 1996, BLOOD, V88, P922; Vella A, 1999, INFLAMMATION, V23, P471, DOI 10.1023/A:1021969127489; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; Walzog B, 1999, FASEB J, V13, P1855, DOI 10.1096/fasebj.13.13.1855; WOODMAN RC, 1993, BLOOD, V82, P2188; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YUKAWA K, 1987, J IMMUNOL, V138, P2576	57	15	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2027	+		10.1096/fj.00-0773fje	http://dx.doi.org/10.1096/fj.00-0773fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511513				2022-12-25	WOS:000170318500015
J	El-Husseini, AE; Craven, SE; Brock, SC; Bredt, DS				El-Husseini, AE; Craven, SE; Brock, SC; Bredt, DS			Polarized targeting of peripheral membrane proteins in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; HIPPOCAMPAL-NEURONS; PLASMA-MEMBRANE; COATED PITS; GLUTAMATE RECEPTORS; LIPID COMPLEXES; CELL-MEMBRANES; DOMAINS; PALMITOYLATION; GAP-43	Differential targeting of neuronal proteins to axons and dendrites is essential for directional information flow within the brain, however, little is known about this protein-sorting process. Here, we investigate polarized targeting of lipid-anchored peripheral membrane proteins, postsynaptic density-95 (PSD-95) and growth-associated protein-43 (GAP-43). Whereas the N-terminal palmitoylated motif of PSD-95 is necessary but not sufficient for sorting to dendrites, the palmitoylation motif of GAP-43 is sufficient for axonal targeting and can redirect a PSD-95 chimera to axons. Systematic mutagenesis of the GAP-43 and PSD-95 palmitoylation motifs indicates that the spacing of the palmitoylated cysteines and the presence of nearby basic amino acids determine polarized targeting by these two motifs. Similarly, the axonal protein paralemmin contains a C-terminal palmitoylated domain, which resembles that of GAP-43 and also mediates axonal targeting. These axonally targeted palmitoylation motifs also mediate targeting to detergent-insoluble glycolipid-enriched complexes in heterologous cells, suggesting a possible role for specialized lipid domains in axonal sorting of peripheral membrane proteins.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036017] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS36017] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; Hsueh YP, 1998, PROG BRAIN RES, V116, P123, DOI 10.1016/S0079-6123(08)60434-3; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kaech S, 1996, MOL BRAIN RES, V35, P344, DOI 10.1016/0169-328X(95)00238-N; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kutzleb C, 1998, J CELL BIOL, V143, P795, DOI 10.1083/jcb.143.3.795; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LIU YC, 1994, J NEUROSCI, V14, P5807; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; MATUS AI, 1979, J NEUROCYTOL, V8, P513, DOI 10.1007/BF01214806; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	40	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44984	44992		10.1074/jbc.M103049200	http://dx.doi.org/10.1074/jbc.M103049200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11546762	hybrid			2022-12-25	WOS:000172406700087
J	Tanner, A; Bowater, L; Fairhurst, SA; Bornemann, S				Tanner, A; Bowater, L; Fairhurst, SA; Bornemann, S			Oxalate decarboxylase requires manganese and dioxygen for activity - Overexpression and characterization of Bacillus subtilis YvrK and YoaN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED STORAGE PROTEINS; SUPEROXIDE-DISMUTASE; MICROBIAL RELATIVES; ANGSTROM RESOLUTION; COLLYBIA-VELUTIPES; CRYSTAL-STRUCTURE; GERMIN-LIKE; PURIFICATION; LIPOXYGENASE; SUPERFAMILY	The Bacillus subtilis oxalate decarboxylase (EC 4.1.1.2), YvrK, converts oxalate to formate and CO2. YvrK and the related hypothetical proteins YoaN and YxaG from B. subtilis have been successfully overexpressed in Escherichia coli. Recombinant YvrK and YoaN were found to be soluble enzymes with oxalate decarboxylase activity only when expressed in the presence of manganese salts. No enzyme activity has yet been detected for YxaG, which was expressed as a soluble protein without the requirement for manganese salts. YvrK and YoaN were found to catalyze minor side reactions: oxalate oxidation to produce H2O2; and oxalate-dependent, H2O2-independent dye oxidations. The oxalate decarboxylase activity of purified YvrK was O-2-dependent. YvrK was found to contain between 0.86 and 1.14 atoms of manganese/subunit. EPR spectroscopy showed that the metal ion was predominantly but not exclusively in the Mn(H) oxidation state. The hyperfine coupling constant (A = 9.5 millitesla) of the main g = 2 signal was consistent with oxygen and nitrogen ligands with hexacoordinate geometry. The structure of YvrK was modeled on the basis of homology with oxalate oxidase, canavalin, and phaseolin, and its hexameric oligomerization was predicted by analogy with proglycinin and homogentisate 1,2-dioxygenase. Although YvrK possesses two potential active sites, only one could be fully occupied by manganese. The possibility that the C-terminal domain active site has no manganese bound and is buried in an intersubunit interface within the hexameric enzyme is discussed. A mechanism for oxalate decarboxylation is proposed, in which both Mn(II) and O-2 are cofactors that act together as a two-electron sink during catalysis.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Bornemann, S (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.		Bornemann, Stephen/K-2938-2012	Bornemann, Stephen/0000-0001-5930-9473; Bowater, Laura/0000-0003-3232-8062				Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BENSON D, 1976, MONOGRAPH, V10, P204; Carter C, 2000, J BIOL CHEM, V275, P36726, DOI 10.1074/jbc.M006461200; Cessna SG, 2000, PLANT CELL, V12, P2191, DOI 10.1105/tpc.12.11.2191; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Dunwell JM, 1998, BIOTECHNOL GENET ENG, V15, P1; Dunwell JM, 1998, J MOL EVOL, V46, P147, DOI 10.1007/PL00006289; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; EMILIANI E, 1968, BIOCHIM BIOPHYS ACTA, V167, P414, DOI 10.1016/0005-2744(68)90221-0; EMILIANI E, 1964, ARCH BIOCHEM BIOPHYS, V105, P488, DOI 10.1016/0003-9861(64)90040-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARA MP, 1977, ARCH BIOCHEM BIOPHYS, V183, P511; HARPEL MR, 1990, J BIOL CHEM, V265, P22187; Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d; Iwabuchi T, 1998, J BIOL CHEM, V273, P8332, DOI 10.1074/jbc.273.14.8332; Kathiara M, 2000, MYCOL RES, V104, P345, DOI 10.1017/S095375629900129X; Kesarwani M, 2000, J BIOL CHEM, V275, P7230, DOI 10.1074/jbc.275.10.7230; Khuri S, 2001, MOL BIOL EVOL, V18, P593, DOI 10.1093/oxfordjournals.molbev.a003840; KO TP, 1993, PLANT PHYSIOL, V101, P729, DOI 10.1104/pp.101.3.729; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; LILLEHOJ EB, 1965, ARCH BIOCHEM BIOPHYS, V109, P216, DOI 10.1016/0003-9861(65)90355-3; Mabbs F. E., 1992, STUDIES INORGANIC CH, V16; MAGRO P, 1988, FEMS MICROBIOL LETT, V49, P49, DOI 10.1016/0378-1097(88)90100-0; MEHTA A, 1991, J BIOL CHEM, V266, P23548; MEIROVITCH E, 1978, J PHYS CHEM-US, V82, P1920, DOI 10.1021/j100506a013; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURTHY MSR, 1981, IRCS MED SCI-BIOCHEM, V9, P683; NOGAMI T, 1975, B CHEM SOC JPN, V48, P3709, DOI 10.1246/bcsj.48.3709; OGASAWARA N, 1966, J BIOL CHEM, V241, P613; Papoutsopoulou SV, 1997, MOL CELL BIOCHEM, V177, P183, DOI 10.1023/A:1006825825681; Que L, 2000, MET IONS BIOL SYST, V37, P505; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Rodriguez-Lopez M, 2001, FEBS LETT, V490, P44, DOI 10.1016/S0014-5793(01)02135-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMAZONO H, 1955, J BIOCHEM-TOKYO, V42, P321, DOI 10.1093/oxfordjournals.jbchem.a126533; Su C, 2000, J BIOL CHEM, V275, P18830, DOI 10.1074/jbc.M001408200; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tanner A, 2000, J BACTERIOL, V182, P5271, DOI 10.1128/JB.182.18.5271-5273.2000; Titus GP, 2000, NAT STRUCT BIOL, V7, P542; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036; YAMAGUCHI K, 1978, J BIOCHEM-TOKYO, V83, P479, DOI 10.1093/oxfordjournals.jbchem.a131935; Yamahara T, 1999, J BIOL CHEM, V274, P33274, DOI 10.1074/jbc.274.47.33274	48	111	120	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43627	43634		10.1074/jbc.M107202200	http://dx.doi.org/10.1074/jbc.M107202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546787	hybrid			2022-12-25	WOS:000172297700021
J	Yang, WN; Lin, Q; Zhao, JH; Guan, JL; Cerione, RA				Yang, WN; Lin, Q; Zhao, JH; Guan, JL; Cerione, RA			The nonreceptor tyrosine kinase ACK2, a specific target for Cdc42 and a negative regulator of cell growth and focal adhesion complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACTIN; RHO; GTPASES; PHOSPHORYLATION; FILOPODIA; PATHWAYS; BINDING; BRAIN; CYCLE	ACK2 (activated Cdc42-associated tyrosine kinase-2) is a nonreceptor tyrosine kinase that is a specific target/ effector for the GTP-binding protein Cdc42. Thus far the biological function of this tyrosine kinase has not been determined. Using an inducible eukaryotic expression system in fibroblasts, we demonstrate that ACK2 can strongly influence cell shape and growth as well as focal complex formation. ACK2 was found to associate with the focal adhesion complex components talin and vinculin, but not with the focal adhesion kinase (FAK), in a kinase-independent manner. The tyrosine kinase activity of FAK was also inhibited in cells overexpressing both wild-type and kinase-defective ACK2. This may be due to a competition between ACK2 and FAK for Src, which is an essential cofactor for FAK activation, as we have found that ACK2 specifically binds Src in cells. The ACK2-Src interaction appears to be mediated by the SH3 domain of Src, and the phosphorylation of ACK2 is enhanced in cells overexpressing the hyperactivated Src(Y527F) mutant. Overexpression of both wild-type and kinase-defective ACK2 also results in a severe inhibition of cell growth. In addition, ACK2 dissolves actin stress fibers and disassembles focal complexes but in a kinase-dependent manner. These results, taken together with previous studies demonstrating an association of ACK2 with integrin beta1 (Yang, W., Lin, Q., Guan, J.-L., Cerione, R. A (1999) J. Biol. Chem. 274,8524-8530) and clathrin (Yang, W., Lo, C. G., Dispenza, T., and Cerione, R. A. (2001) J. Biol. Chem. 276,17468-17473), suggest that the binding and protein tyrosine kinase activities of ACK2 coordinate changes in cell morphology and growth with the disassembly of focal adhesion sites, perhaps to organize new integrin complexes that are required for endocytosis and/or for cellular differentiation.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458, R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	22	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43987	43993		10.1074/jbc.M104819200	http://dx.doi.org/10.1074/jbc.M104819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11535592	hybrid			2022-12-25	WOS:000172297700066
J	El-Tanani, M; Fernig, DG; Barraclough, R; Green, C; Rudland, P				El-Tanani, M; Fernig, DG; Barraclough, R; Green, C; Rudland, P			Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS-INDUCING DNA; OSTEOPONTIN EXPRESSION; ER-ALPHA; GENE; BINDING; IDENTIFICATION; ACTIVATION; MECHANISMS; CLONING; PREGNANCY	Two major signaling pathways, those triggered by estrogen (E-2) and by the Wnt family, interact in the breast to cause growth and differentiation. The estrogen receptors ERalpha and ERbeta are activated by binding E-2 and act as ligand-dependent transcription factors. The effector for the Wnt family is the Tcf family of transcription factors. Both sets of transcription factors recognize discrete but different nucleotide sequences in the promoters of their target genes. By using transient transfections of reporter constructs for the osteopontin and thymidine kinase promoters in rat mammary cells, we show that Tcf-4 antagonizes and Tcf-1 stimulates the effects of activated ER/E-2. For mutants of the former promoter, the stimulatory effects of ERalpha/E-2 can be made to be dependent on Tcf-1, and for the latter promoter the effects of the T cell factors (TCFs) are dependent on ER/E-2. Direct interaction between ERs and Tcfs either at the Tcf/ERalpha-binding site on the DNA or in the absence of DNA is established by gel retardation assays or by coimmuno-precipitation/biosensor methods, respectively. These results show that the two sets of transcription factors can interact directly, the interaction between ERs and Tcf-4 being antagonistic and that between ERs and Tcf-1 being synergistic on the activity of the promoters employed. Since Tcf-4 is the major Tcf family member in the breast, it is suggested that the antagonistic interaction is normally dominant in vivo in this tissue.	Univ Liverpool, Sch Biol Sci, Mol Med Grp, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Rudland, P (corresponding author), Univ Liverpool, Sch Biol Sci, Mol Med Grp, Canc & Polio Res Fund Labs, POB 147, Liverpool L69 7ZB, Merseyside, England.		Barraclough, Roger/AAH-6516-2020; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; El-Tanani, Mohamed/0000-0002-4735-5445; Barraclough, Roger/0000-0002-7203-1194				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2000, ADV CANCER RES, V77, P1; BARKER PE, 1984, P NATL ACAD SCI-BIOL, V81, P5826, DOI 10.1073/pnas.81.18.5826; Bellahcene A, 1996, LAB INVEST, V75, P203; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Curtis SH, 2000, ADV PHARMACOL, V47, P357; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Edwards PAW, 1998, BIOCHEM SOC SYMP, P21; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2001, ONCOGENE, V20, P1793, DOI 10.1038/sj.onc.1204358; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; INCE BA, 1993, J BIOL CHEM, V268, P14026; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Oates AJ, 1996, ONCOGENE, V13, P97; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Van den Bemd GJCM, 1999, BIOCHEM BIOPH RES CO, V261, P1, DOI 10.1006/bbrc.1999.0864; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	49	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41675	41682		10.1074/jbc.M103966200	http://dx.doi.org/10.1074/jbc.M103966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11522780	hybrid			2022-12-25	WOS:000172450400020
J	Mari, M; Macia, E; Le Marchand-Brustel, Y; Cormont, M				Mari, M; Macia, E; Le Marchand-Brustel, Y; Cormont, M			Role of the FYVE finger and the RUN domain for the subcellular localization of Rabip4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; AUTOANTIGEN EEA1; RAB5 EFFECTOR; PROTEIN; BINDING; MEMBRANE; ENDOSOMES; IDENTIFICATION; INVOLVEMENT; YEAST	Rabip4 is a Rab4 effector, which possesses a RUN domain, two coiled-coil domains, and a FYVE finger. It is associated with the early endosomes and leads, in concert with Rab4, to the enlargement of endosomes, resulting in the fusion of sorting and recycling endosomes. Our goal was to characterize the role of these various domains in Rabip4 subcellular localization and their function in Chinese hamster ovary cells. Although the FYVE finger domain specifically bound phosphatidylinositol 3-phosphate and was necessary for the function of Rabip4, it was not sufficient for the protein association with membranes. Indeed a protein containing the FYVE finger and the Rab4-binding site was cytosolic, whereas the total protein was mostly associated to the membrane fraction, whether or not cells were pretreated with wortmannin. By contrast, a construct corresponding to the N-terminal end, Rabip4-(1-212), and containing the RUN domain was membrane-associated. The complete protein partitioned between the Triton X-100-insoluble and -soluble fractions and a wortmannin treatment increased the amount of the protein in the Triton X-100 fraction. Rabip4-(1-212) was totally Triton X-100-insoluble, and confocal microscopic examination showed that it labeled not only the endosomes, positive for Rabip4, but also a filamentous network with a honeycomb appearance. The Triton X-100-insoluble fraction that contains Rabip4 did not correspond to the caveolin or glycosylphosphatidylinositol-enriched lipid rafts. Rabip4 did not appear directly linked to actin but seemed associated to the actin network. We propose that the subcellular localization of the protein is primarily driven by the RUN domain to endosomal microdomains characterized by Triton X-100 insolubility and that the FYVE domain and the Rab4-binding domain then allow for the recruitment of the protein to lipophilic microdomains enriched in phosphatidylinositol 3-phosphate.	Fac Med, INSERM, EPI9911, F-06107 Nice 02, France; Fac Med, INSERM, IFR50, F-06107 Nice 02, France; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cormont, M (corresponding author), Fac Med, INSERM E9911, Ave Vallombrose, F-06107 Nice 02, France.	cormont@unice.fr	Macia, Eric/AAW-2964-2021	macia, eric/0000-0003-3686-2000; Mari, Muriel/0000-0002-2677-6945; CORMONT, Mireille/0000-0001-6918-2410				Bortoluzzi MN, 1996, DIABETOLOGIA, V39, P899, DOI 10.1007/BF00403908; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callebaut I, 2001, TRENDS BIOCHEM SCI, V26, P79, DOI 10.1016/S0968-0004(00)01730-8; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	33	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42501	42508		10.1074/jbc.M104885200	http://dx.doi.org/10.1074/jbc.M104885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11509568	hybrid			2022-12-25	WOS:000172450400123
J	Fukuda, M; Yamamoto, A; Mikoshiba, K				Fukuda, M; Yamamoto, A; Mikoshiba, K			Formation of crystalloid endoplasmic reticulum induced by expression of synaptotagmin lacking the conserved WHXL motif in the C terminus - Structural importance of the WHXL motif in the C2B domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT SYNAPSE; HIGH-POLYPHOSPHATE BINDING; PC12 CELLS; NEUROTRANSMITTER RELEASE; FUNCTIONAL DIVERSITY; TRANSMITTER RELEASE; MUTATIONAL ANALYSIS; ANTIBODY INJECTION; NEURITE OUTGROWTH; COS CELLS	Synaptotagmin (Syt) is a family of type I membrane proteins that consists of a single transmembrane domain, a spacer domain, two Ca2+-binding C2 domains, and a short C terminus. We recently showed that deletion of the short C terminus (17 amino acids) of Syt IV prevented the Golgi localization of Syt IV proteins in PC12 cells and induced granular structures of various sizes in the cell body by an unknown mechanism (Fukuda, M., Ibata, K., and Mikoshiba, K. (2001) J. New rochem. 77, 730-740). In this study we showed by electron microscopy that these structures are crystalloid endoplasmic reticulum (ER), analyzed the mechanism of its induction, and demonstrated that: (a) mutation or deletion of the evolutionarily conserved WHXL motif in the C terminus of the synaptotagmin family (Syt DeltaC) destabilizes the C2B domain structure (i.e. causes misfolding of the protein), probably by disrupting the formation of stable anti-parallel beta -sheets between the beta -1 and beta -8 strands of the C2B domain; (b) the resulting malfolded proteins accumulate in the ER rather than being transported to other membrane structures (e.g. the Golgi apparatus), with the malfolded proteins also inducing the expression of BiP (immunoglobulin binding protein), one of the ER stress proteins; and (c) the ERs in which the Syt AC proteins have accumulated associate with each other as a result of oligomerization capacity of the synaptotagmin family, because the Syt IAC mutant, which lacks oligomerization activity, cannot induce crystalloid ER. Our findings indicate that the conserved WHXL motif is important not only for protein interaction site but for proper folding of the C2B domain.	RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Kansai Med Univ, Dept Physiol, Moriguchi, Osaka 5708506, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; Kansai Medical University; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Detrait ER, 2000, J NEUROSCI RES, V62, P566, DOI 10.1002/1097-4547(20001115)62:4<566::AID-JNR11>3.3.CO;2-W; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2000, NEUROSCI LETT, V295, P33, DOI 10.1016/S0304-3940(00)01585-8; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Ibata K, 2000, J NEUROCHEM, V74, P518, DOI 10.1046/j.1471-4159.2000.740518.x; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; ISHIHARA N, 1995, J BIOCHEM-TOKYO, V118, P397, DOI 10.1093/oxfordjournals.jbchem.a124920; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kabayama H, 1999, NEUROSCIENCE, V88, P999, DOI 10.1016/S0306-4522(98)00547-8; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Krasnov PA, 2000, J CELL SCI, V113, P1389; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LENNY N, 1991, J BIOL CHEM, V266, P20532; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mochida S, 1997, NEUROSCIENCE, V77, P937; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; PATHAK RK, 1986, J CELL BIOL, V102, P2158, DOI 10.1083/jcb.102.6.2158; Perin MS, 1996, BIOCHEMISTRY-US, V35, P13808, DOI 10.1021/bi960853x; PERIN MS, 1991, J BIOL CHEM, V266, P623; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; Reist NE, 1998, J NEUROSCI, V18, P7662; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugimori M, 1998, NEUROSCIENCE, V86, P39, DOI 10.1016/S0306-4522(97)00689-1; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Thomas DM, 1998, J NEUROSCI, V18, P3511; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Yamamoto A, 1996, J CELL SCI, V109, P1727	69	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41112	41119		10.1074/jbc.M106209200	http://dx.doi.org/10.1074/jbc.M106209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533032	hybrid			2022-12-25	WOS:000171925600099
J	Richard, P; Londesborough, J; Putkonen, M; Kalkkinen, N; Penttila, M				Richard, P; Londesborough, J; Putkonen, M; Kalkkinen, N; Penttila, M			Cloning and expression of a fungal L-arabinitol 4-dehydrogenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PICHIA-STIPITIS; SACCHAROMYCES-CEREVISIAE; XYLOSE REDUCTASE; XYLITOL-DEHYDROGENASE; ASPERGILLUS-NIGER; SEQUENCE; PROTEINS; PURIFICATION	L-Arabinitol 4-dehydrogenase (EC 1.1.1.12) was purified from the filamentous fungus Trichoderma reesei (Hypocrea jecorina). It is an enzyme in the L-arabinose catabolic pathway of fungi catalyzing the reaction from L-arabinitol to L-xylulose. The amino acid sequence of peptide fragments was determined and used to identify the corresponding gene. We named the gene lad1. It is not constitutively expressed. In a Northern analysis we found it only after growth on L-arabinose. The gene was cloned and overexpressed in Saccharomyces cerevisiae, and the enzyme activity was confirmed in a cell extract. The enzyme consists of 377 amino acids and has a calculated molecular mass of 39,822 Da. It belongs to the family of zinc-binding dehydrogenases and has some amino acid sequence similarity to sorbitol dehydrogenases. It shows activity toward L-arabinitol, adonitol (ribitol), and xylitol with K-m values of about 40 mm toward L-arabinitol and adonitol and about 180 mm toward xylitol. No activity was observed with D-sorbitol, D-arabinitol, and D-mannitol. NAD is the required cofactor with a K-m of 180 muM. No activity was observed with NADP.	VTT Biotechnol, FIN-02044 Espoo, Finland; Univ Helsinki, Inst Biotechnol, Prot Chem Lab, FIN-00014 Helsinki, Finland	VTT Technical Research Center Finland; University of Helsinki	Richard, P (corresponding author), VTT Biotechnol, Tietotie 2,POB 1500, FIN-02044 Espoo, Finland.		Richard, Peter/A-4229-2009; Kalkkinen, Nisse EJ/B-3923-2010; Penttilä, Merja E/A-4710-2013	Richard, Peter/0000-0003-0922-6092; Penttila, Merja/0000-0002-6929-1032				AMORE R, 1991, GENE, V109, P89, DOI 10.1016/0378-1119(91)90592-Y; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BILLARD P, 1995, GENE, V162, P93, DOI 10.1016/0378-1119(95)00294-G; Bolen PL, 1996, YEAST, V12, P1367, DOI 10.1002/(SICI)1097-0061(199610)12:13<1367::AID-YEA33>3.3.CO;2-R; BRUINENBERG PM, 1985, ARCH MICROBIOL, V142, P302, DOI 10.1007/BF00693408; CHIANG C, 1961, BIOCHIM BIOPHYS ACTA, V46, P271, DOI 10.1016/0006-3002(61)90750-8; CHIANG C, 1960, BIOCHEM BIOPH RES CO, V3, P554, DOI 10.1016/0006-291X(60)90174-1; CHIRGWIN JM, 1979, BIOCHEM J, V18, P251; Dien BS, 1996, APPL BIOCHEM BIOTECH, V57-8, P233, DOI 10.1007/BF02941704; Hacker B, 1999, BIOL CHEM, V380, P1395, DOI 10.1515/BC.1999.179; HAYN A, 1993, BIOCONVERSION FOREST, P33; HO NWY, 1989, ENZYME MICROB TECH, V11, P417, DOI 10.1016/0141-0229(89)90136-1; KOTTER P, 1990, CURR GENET, V18, P493, DOI 10.1007/BF00327019; KUHN A, 1995, APPL ENVIRON MICROB, V61, P1580, DOI 10.1128/AEM.61.4.1580-1585.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandel M, 1969, ADV CHEM SER, V95, P391, DOI [10.1021/ba-1969-0095.ch023, DOI 10.1021/BA-1969-0095.CH023]; MargollesClark E, 1996, APPL ENVIRON MICROB, V62, P3840, DOI 10.1128/AEM.62.10.3840-3846.1996; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMILLAN JD, 1994, APPL BIOCHEM BIOTECH, V45-6, P569, DOI 10.1007/BF02941831; Nyman TA, 2000, EUR J BIOCHEM, V267, P4011, DOI 10.1046/j.1432-1327.2000.01433.x; Richard P, 1999, FEBS LETT, V457, P135, DOI 10.1016/S0014-5793(99)01016-9; RIZZI M, 1989, J FERMENT BIOENG, V67, P20, DOI 10.1016/0922-338X(89)90080-9; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sedlak M, 2001, ENZYME MICROB TECH, V28, P16, DOI 10.1016/S0141-0229(00)00282-9; Shi NQ, 2000, APPL BIOCHEM BIOTECH, V84-6, P201, DOI 10.1385/ABAB:84-86:1-9:201; STRYER L, 1988, BIOCHEMISTRY-US, P805; SUOMALAINEN I, 1989, J GEN MICROBIOL, V135, P1537; VERDUYN C, 1985, BIOCHEM J, V226, P668; Wang CY, 1998, POSTHARVEST BIOL TEC, V14, P179, DOI 10.1016/S0925-5214(98)00047-7; WITTEVEEN CFB, 1989, J GEN MICROBIOL, V135, P2163; WITTEVEEN CFB, 1994, MICROBIOL-SGM, V140, P1679, DOI 10.1099/13500872-140-7-1679	31	82	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40631	40637		10.1074/jbc.M104022200	http://dx.doi.org/10.1074/jbc.M104022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514550	hybrid			2022-12-25	WOS:000171925600035
J	Schonherr, E; Levkau, B; Schaefer, L; Kresse, H; Walsh, K				Schonherr, E; Levkau, B; Schaefer, L; Kresse, H; Walsh, K			Decorin-mediated signal transduction in endothelial cells - Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR RECEPTOR; SULFATE PROTEOGLYCANS; CARCINOMA-CELLS; GENE-EXPRESSION; TUBE FORMATION; SURVIVAL; AKT; ANGIOGENESIS; SUPPRESSION	Endothelial cells undergoing angiogenesis express decorin, a small multifunctional proteoglycan. We have shown that decorin is causally involved in the formation of capillary-like structures and a decrease in apoptosis in endothelial cells cultured in a collagen lattice. Here we investigate signal transduction pathways mediating the effects of decorin. Reverse transcription-polymerase chain reaction demonstrated that p21 and p27, two inhibitors of cyclin-dependent kinases, were up-regulated by decorin induction. Decorin also increased protein levels of p21 and caused its translocation into the nucleus. p21 synthesis started 6 h after decorin addition and reached a plateau after 18 h, while cyclin A, which was also induced, peaked at 12 h and declined below basal levels within 24 h. These effects were mediated by the Akt/protein kinase B pathway. Akt phosphorylation at Thr-308 increased 4-fold and at Ser-473 1.4-fold within 10 min after decorin addition. Overexpression of dominant negative Akt inhibited the decorin-mediated induction of p21 and cyclin A, but had no effect on p27. These results show that decorin is a signaling molecule in sprouting endothelial cells where it acts via different pathways, one of them involving Akt/protein kinase B.	Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Munster, Inst Internal Med, D-48149 Munster, Germany; Univ Hosp Munster, D-48149 Munster, Germany; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA	University of Munster; University of Munster; University of Munster; University of Munster; St. Elizabeth's Medical Center	Schonherr, E (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.		Levkau, Bodo/N-9144-2017	Schaefer, Liliana/0000-0002-3318-3005				Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen DH, 2000, ARTERIOSCL THROM VAS, V20, P629, DOI 10.1161/01.ATV.20.3.629; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GOTTE M, 1995, EUR J CELL BIOL, V66, P226; GREVE H, 1990, BIOCHEM J, V269, P149, DOI 10.1042/bj2690149; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rots NY, 1999, BLOOD, V93, P2721, DOI 10.1182/blood.V93.8.2721.408k28_2721_2729; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2001, J CELL PHYSIOL, V187, P37, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1048>3.0.CO;2-W; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0	39	98	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40687	40692		10.1074/jbc.M105426200	http://dx.doi.org/10.1074/jbc.M105426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546775	hybrid			2022-12-25	WOS:000171925600042
J	Sumi-Ichinose, C; Urano, F; Kuroda, R; Ohye, T; Kojima, M; Tazawa, M; Shiraishi, H; Hagino, Y; Nagatsu, T; Nomura, T; Ichinose, H				Sumi-Ichinose, C; Urano, F; Kuroda, R; Ohye, T; Kojima, M; Tazawa, M; Shiraishi, H; Hagino, Y; Nagatsu, T; Nomura, T; Ichinose, H			Catecholamines and serotonin are differently regulated by tetrahydrobiopterin - A study from 6-pyruvoyltetrahydropterin synthase knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; TYROSINE-HYDROXYLASE ACTIVITY; DOPA-RESPONSIVE DYSTONIA; MOUSE FETAL DEVELOPMENT; TARGETED DISRUPTION; INTERFERON-GAMMA; GENE; STRIATUM; COFACTOR	(6R)-L-erythro-5,6,7,8-Tetrahydrobiopterin (BH4) is an essential cofactor for tyrosine hydroxylase (TH), tryptophan hydroxylase, phenylalanine hydroxylase, and nitric-oxide synthase. These enzymes synthesize neurotransmitters, e.g. catecholamines, serotonin, and nitric oxide (NO). We established mice unable to synthesize BH4 by disruption of the 6-pyruvoyltetrahydropterin synthase gene, the encoded protein of which catalyzes the second step of BH4 biosynthesis. Homozygous mice were born at the almost expected Mendelian ratio, but died within 48 h after birth. In the brain of homozygous mutant neonates, levels of biopterin, catecholamines, and serotonin were extremely low. The number of TH molecules was highly dependent on the intracellular concentration of BH4 at nerve terminals. Alteration of the TH protein level by modulation of the BH4 content is a novel regulatory mechanism. Our data showing that catecholaminergic, serotonergic, and NO systems were differently affected by BH4 starvation suggest the possible involvement of BH4 synthesis in the etiology of monoamine-based neurological and neuropsychiatric disorders.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, Toyoake, Aichi 4701192, Japan; Fujita Hlth Univ, Sch Med, Dept Pharmacol, Toyoake, Aichi 4701192, Japan	Fujita Health University; Fujita Health University	Ichinose, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, Toyoake, Aichi 4701192, Japan.		Ichinose, Hiroshi/D-8986-2015	Ichinose, Hiroshi/0000-0001-6008-6860; Sumi-Ichinose, Chiho/0000-0001-5261-0853; Kojima, Masayo/0000-0002-8946-1131				ANDERSON GM, 1987, MED BIOL, V65, P67; Betarbet R, 1997, J NEUROSCI, V17, P6761; Blau N, 1996, J INHERIT METAB DIS, V19, P8, DOI 10.1007/BF01799342; BLAU N, 1994, CLIN CHIM ACTA, V226, P159, DOI 10.1016/0009-8981(94)90213-5; BLAU N, 1985, CLIN CHIM ACTA, V148, P47, DOI 10.1016/0009-8981(85)90299-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Cook Edwin H. Jr., 1996, Current Opinion in Pediatrics, V8, P348, DOI 10.1097/00008480-199608000-00008; Flatmark T, 1999, EUR J BIOCHEM, V262, P840, DOI 10.1046/j.1432-1327.1999.00445.x; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Furukawa Y, 1999, NEUROLOGY, V53, P1032, DOI 10.1212/WNL.53.5.1032; Hirschfeld RMA, 2000, J CLIN PSYCHIAT, V61, P4; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; ICHIKAWA S, 1991, BIOCHEM BIOPH RES CO, V176, P1610, DOI 10.1016/0006-291X(91)90472-J; ICHINOSE H, 1985, ANAL BIOCHEM, V150, P408, DOI 10.1016/0003-2697(85)90529-9; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Jaber M, 1999, EUR J NEUROSCI, V11, P3499, DOI 10.1046/j.1460-9568.1999.00764.x; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KETTLER R, 1974, NATURE, V249, P476, DOI 10.1038/249476a0; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; Kumer SC, 1996, J NEUROCHEM, V67, P443; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEVINE RA, 1981, SCIENCE, V214, P919, DOI 10.1126/science.6117945; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MIWA S, 1985, ARCH BIOCHEM BIOPHYS, V239, P234, DOI 10.1016/0003-9861(85)90831-8; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Nagatsu I, 1995, J NEURAL TRANSM-GEN, V102, P175, DOI 10.1007/BF01281153; NAGATSU I, 1993, TEC BEHAV N 1, V11, P151; NAGATSU T, 1979, J CHROMATOGR, V163, P247, DOI 10.1016/S0378-4347(00)81411-5; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NASRIN S, 1994, J BIOCHEM-TOKYO, V116, P393, DOI 10.1093/oxfordjournals.jbchem.a124537; OKUNO S, 1985, J BIOL CHEM, V260, P2633; Pastor CM, 1996, J BIOL CHEM, V271, P24534, DOI 10.1074/jbc.271.40.24534; RAJPUT AH, 1994, ANN NEUROL, V35, P396, DOI 10.1002/ana.410350405; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; Segawa M, 1976, Adv Neurol, V14, P215; Segawa M., 1971, SHINRYO TOKYO, V24, P667; TASHIRO Y, 1989, NEUROSCI LETT, V97, P6, DOI 10.1016/0304-3940(89)90130-4; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	50	113	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41150	41160		10.1074/jbc.M102237200	http://dx.doi.org/10.1074/jbc.M102237200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11517215	hybrid			2022-12-25	WOS:000171925600104
J	Szaszi, K; Kurashima, K; Kaibuchi, K; Grinstein, S; Orlowski, J				Szaszi, K; Kurashima, K; Kaibuchi, K; Grinstein, S; Orlowski, J			Role of the cytoskeleton in mediating cAMP-dependent protein kinase inhibition of the epithelial Na+/H+ exchanger NHE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; RHO-KINASE; BRUSH-BORDER; CYCLIC-AMP; F-ACTIN; PHOSPHATIDYLINOSITOL 3-KINASE; MORPHOLOGICAL-CHANGES; REGULATORY PROTEIN; MAMMALIAN-CELLS; ATP DEPENDENCE	The Na+/H+ exchanger NHE3 isoform mediates the entry of Na+ into epithelial cells of the kidney and gastrointestinal tract. Hormones and pharmacological agents that activate cAMP-dependent protein kinase A (PKA) are potent inhibitors of native and ectopically expressed NHE3 in epithelial and Chinese hamster ovary AP-1 cells, respectively. Previous studies have shown that acute inhibition is coupled to direct phosphorylation of the exchanger, but this only partly accounts for the observed effects. In this report, we show that inhibition of NHE3 activity by forskolin, an activator of adenylate cyclase, occurs without changes in surface expression of the exchanger but is associated with altered cytoskeletal structure. This effect resembles that obtained with cytochalasin D or latrunculin B, actin disrupting agents that also inhibit NHE3. Such similarities prompted us to further investigate the relationship between PKA-induced inhibition of the exchanger and changes in the actin cytoskeleton. Inhibition of NHE3 by cytochalasin D does not require PKA, because the inhibitory effect is preserved in a mutant NHE3 that is not phosphorylated by PKA and in cells pretreated with the PKA inhibitor H89. In contrast, involvement of actin in the effect of cAMP on the exchanger is supported by the following observations: (i) jasplakinolide, an F-actin stabilizer, prevents the inhibition caused by forskolin, and (ii) constitutively active forms of RhoA and Rho kinase interfere with actin disruption by forskolin and also decrease inhibition of the transporter. These results suggest that reorganization of the cytoskeleton by PKA is involved in mediating inhibition of NHE3.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Nara Institute of Science & Technology; McGill University	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422; Orlowski, John/0000-0001-7371-175X				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chow CW, 1999, CLIN INVEST MED, V22, P195; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMPUGNANI MG, 1990, LAB INVEST, V63, P521; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Szaszi K, 2000, CELL PHYSIOL BIOCHEM, V10, P265, DOI 10.1159/000016358; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; WU MS, 1994, J MEMBRANE BIOL, V142, P323; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	57	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40761	40768		10.1074/jbc.M106724200	http://dx.doi.org/10.1074/jbc.M106724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522794	hybrid			2022-12-25	WOS:000171925600053
J	Zamora-Leon, SP; Lee, G; Davies, P; Shafit-Zagardo, B				Zamora-Leon, SP; Lee, G; Davies, P; Shafit-Zagardo, B			Binding of Fyn to MAP-2c through an SH3 binding domain - Regulation of the interaction by ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; PROLINE-RICH; TYROSINE KINASE; RAT-BRAIN; ALZHEIMERS-DISEASE; TERMINAL DOMAIN; TAU-PROTEIN; PHOSPHORYLATION; MAP2; LOCALIZATION	Microtubule-associated protein 2 (MAP-2) isoforms are developmentally expressed in the nervous system and contain a number of functional domains. Adjacent to the first repeat of the microtubule-binding domain is an RTPPKSP motif for binding SH3 domains. To identify SH3-containing proteins that interact with MAP-2, transfections, filter overlay assays, glutathione S-transferase (GST)-mediated binding assays, co-immunoprecipitations and enzyme-linked immunosorbent assays were performed. Transfections of MAP-2a, MAP-2b, and MAP-2c constructs into COS7 cells, followed by incubation of the cell lysates with SH3-GST fusion proteins, determined that the strongest interaction was between MAP-2c and the non-receptor tyrosine kinase Fyn; how. ever, MAP-2b and MAP-2c also bound to Grb2. Co-immunoprecipitation of Fyn and MAP-2c from human fetal homogenates confirmed the interaction in vivo. MAP-2 synthetic peptides spanning the RTPPKSP motif bound to Fyn, and the interaction was regulated by phosphorylation. Co-transfections with MAP-2c and the extracellular signal-regulated kinase 2 (ERK2) demonstrated that MAP-2c is theronine/serine-phosphorylated on its R (T) over bar PPK (S) over barP motif and that threonine phosphorylation abolished the MAP-2c/Fyn binding. Kinase assays and co-transfection of MAP-2c and Fyn confirmed that Fyn tyrosine kinase phosphorylates MAP-2c. Thus, the activation of signaling pathways may regulate cytoskeletal dynamics by altering the state of phosphorylation of MAP-2 by both ERK2 and Fyn kinase.	Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	Yeshiva University; Albert Einstein College of Medicine; University of Iowa	Shafit-Zagardo, B (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zagardo@aecom.yu.edu	Lee, Gloria/F-5965-2011; -León, S. Pilar Zamora/AAL-8512-2020	-León, S. Pilar Zamora/0000-0002-4738-9768; Lee, Gloria/0000-0002-8633-1534	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038623, R37MH038623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032100, R01NS038102] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 38623] Funding Source: Medline; NINDS NIH HHS [NS 32100, NS 38102] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; AKIYAMA T, 1986, J BIOL CHEM, V261, P5648; ALBALA JS, 1995, J NEUROCHEM, V64, P2480; ALBALA JS, 1993, GENE, V136, P377, DOI 10.1016/0378-1119(93)90502-T; BARE DJ, 1993, ONCOGENE, V8, P1429; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Bhat RV, 1998, J NEUROCHEM, V70, P558; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CARDINE AM, 1995, EUR J IMMUNOL, V25, P3290; Chung WJ, 1996, J NEUROCHEM, V66, P1273; DOLL T, 1993, J CELL SCI, V106, P633; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; GARNER CC, 1988, J NEUROCHEM, V50, P609, DOI 10.1111/j.1471-4159.1988.tb02954.x; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GREER K, 1989, CELL MOVEMENT, V2, P47; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; GUILLEMINOT J, 1995, CR ACAD SCI III-VIE, V318, P959; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Jicha GA, 1997, J NEUROCHEM, V69, P2087; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; KALCHEVA N, 1994, J NEUROCHEM, V63, P2336; Kalcheva N, 1998, CELL MOTIL CYTOSKEL, V40, P272, DOI 10.1002/(SICI)1097-0169(1998)40:3<272::AID-CM6>3.0.CO;2-F; KALCHEVA N, 1995, J NEUROCHEM, V65, P1472; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee G, 1998, J CELL SCI, V111, P3167; Lim RWL, 2000, J BIOL CHEM, V275, P20578, DOI 10.1074/jbc.M001887200; Lu PJ, 1999, NATURE, V399, P784; Martin CS, 1998, NEUROSCIENCE, V87, P861, DOI 10.1016/S0306-4522(98)00195-X; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Morgan JC, 2000, J NEUROSCI RES, V59, P226, DOI 10.1002/(SICI)1097-4547(20000115)59:2<226::AID-JNR9>3.0.CO;2-J; Morton CJ, 1996, STRUCTURE, V4, P705, DOI 10.1016/S0969-2126(96)00076-7; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Quinlan EM, 1996, J NEUROSCI, V16, P7627; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Sanchez C, 1996, EUR J BIOCHEM, V241, P765, DOI 10.1111/j.1432-1033.1996.00765.x; Scaife RM, 2000, J CELL SCI, V113, P215; SCHULZE E, 1987, J CELL BIOL, V104, P277, DOI 10.1083/jcb.104.2.277; Shafit-Zagardo B, 2000, GLIA, V29, P233, DOI 10.1002/(SICI)1098-1136(20000201)29:3<233::AID-GLIA5>3.0.CO;2-U; Shafit-Zagardo B, 1998, MOL NEUROBIOL, V16, P149, DOI 10.1007/BF02740642; SILLIMAN CC, 1989, BIOCHEM BIOPH RES CO, V160, P993, DOI 10.1016/S0006-291X(89)80099-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sperber BR, 2001, J NEUROSCI, V21, P2039, DOI 10.1523/JNEUROSCI.21-06-02039.2001; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TUCKER RP, 1988, J NEUROSCI, V8, P4503; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VIERECK C, 1989, J NEUROSCI, V9, P3547; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	61	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39950	39958		10.1074/jbc.M107807200	http://dx.doi.org/10.1074/jbc.M107807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546790	hybrid			2022-12-25	WOS:000171789200061
J	Berdiev, BK; Mapstone, TB; Markert, JM; Gillespie, GY; Lockhart, J; Fuller, CM; Benos, DJ				Berdiev, BK; Mapstone, TB; Markert, JM; Gillespie, GY; Lockhart, J; Fuller, CM; Benos, DJ			pH alterations "reset" Ca2+ sensitivity of brain Na+ channel 2, a degenerin/epithelial Na+ ion channel, in planar lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNELS; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; PSEUDOHYPOALDOSTERONISM TYPE-1; MOLECULAR-CLONING; XENOPUS-OOCYTES; GAMMA-SUBUNIT; BETA-SUBUNIT; EXPRESSION; FAMILY	Members of the degenerin/epithelial Na+ channel superfamily of ion channels subserve many functions, ranging from whole body sodium handling to mechanoelectrical transduction. We studied brain Na+ channel 2 (BNaC-2) in planar lipid bilayers to examine its single channel properties and regulation by Ca2+. Upon incorporation of vesicles made from membranes of oocytes expressing either wild-type (WT) BNaC-2 or BNaC-2 with a gain-of-function (GF) point mutation (G433F), functional channels with different properties were obtained. WT BNaC-2 resided in a closed state with short openings, whereas GF BNaC-2 was constitutively activated; a decrease in the pH in the trans compartment of the bilayer activated WT BNaC-2 and decreased its permeability for Na+ over K+. Moreover, these maneuvers made the WT channel more resistant to amiloride. In contrast, GF BNaC-2 did not respond to a decrease in pH, and its amiloride sensitivity and selectivity for Na+ over K+ were unaffected by this pH change. Buffering the bathing solutions with EGTA to reduce the free [Ca2+] to < 10 nm increased WT single channel open probability 10-fold, but not that of GF BNaC-2. Ca2+ blocked both WT and GF BNaC-2 in a dose- and voltage-dependent fashion; single channel conductances were unchanged. A drop in pH reduced the ability of Ca2+ to inhibit these channels. These results show that BNaC-2 is an amiloride-sensitive sodium channel and suggest that pH activation of these channels could be, in part, a consequence of H+ "interference" with channel regulation by Ca2+.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	Fuller, Cathy/B-4046-2011	Gillespie, George/0000-0001-6436-9542	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206, R01DK056095] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Adams CM, 1999, J BIOL CHEM, V274, P15500, DOI 10.1074/jbc.274.22.15500; Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Adams CM, 1999, BIOPHYS J, V76, P1377, DOI 10.1016/S0006-3495(99)77299-1; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benos DJ, 1996, KIDNEY INT, V49, P1632, DOI 10.1038/ki.1996.237; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Berdiev BK, 1999, CURR TOP MEMBR, V47, P351; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; Grunder S, 2000, NEUROREPORT, V11, P1607; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V245, P589, DOI 10.1006/bbrc.1998.8483; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Ismailov II, 1997, BIOPHYS J, V72, P1182, DOI 10.1016/S0006-3495(97)78766-6; ISMAILOV II, 1995, J GEN PHYSIOL, V106, P445, DOI 10.1085/jgp.106.3.445; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Ji HL, 2000, J BIOL CHEM, V275, P27947; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; OBrodovich HM, 1996, P ASSOC AM PHYSICIAN, V108, P345; PALMER LG, 1987, AM J PHYSIOL, V253, pF333, DOI 10.1152/ajprenal.1987.253.2.F333; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Schaedel C, 1999, J PEDIATR-US, V135, P739, DOI 10.1016/S0022-3476(99)70094-6; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SHREFFLER W, 1995, GENETICS, V139, P1261; Siesjo BK, 1996, ACT NEUR S, V66, P8; SILVER RB, 1993, AM J PHYSIOL, V264, pF557, DOI 10.1152/ajprenal.1993.264.3.F557; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Zhang P, 2001, J GEN PHYSIOL, V117, P563, DOI 10.1085/jgp.117.6.563	78	19	20	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38755	38761		10.1074/jbc.M107266200	http://dx.doi.org/10.1074/jbc.M107266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514582	hybrid			2022-12-25	WOS:000171673200058
J	Satoh, S; Tominaga, T				Satoh, S; Tominaga, T			mDia-interacting protein acts downstream of Rho-mDia and modifies Src activation and stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; TYROSINE KINASE; SMALL GTPASE; CYTOSKELETON; INTEGRINS; PROFILIN; HOMOLOG; BNI1P; GENE	The formin homology protein mDia is a Rho GTPase effector protein that participates in stress fiber formation, cytokinesis, and transcriptional activation of the serum response factor. Although the function of another effector of Rho, Rho-associated kinase, is well established, relatively little is known about the functional mechanism and the downstream targets of mDia. Our recent report of a Rho-mDia-Src-tyrosine kinase pathway suggested an important role for mDia in cell adhesion turnover. We identified a new mDia-interacting protein which is expressed ubiquitously. The new protein mainly binds to the proline-rich region of mDia through its Src homology 3 domain and also binds to Grb2 through its proline-rich domain. The protein is localized at the cell periphery and membrane ruffles and co-localizes with mDia. Co-expression of vSrc and the mDia-interacting protein induces significant morphological changes at focal contacts and activation of vSrc. Furthermore, we found that the mDia-interacting protein plays an important role in stress fiber formation induced by active mDia1. Our results suggest that this new protein regulates actin polymerization and cell adhesion turnover in the downstream portion of the Rho-mDia pathway by interacting with Grb2 and Src.	Dokkyo Univ, Sch Med, Dept Mol & Cell Biol, Mibu, Tochigi 3210293, Japan; Fdn Adv Int Sci, Tsukuba, Ibaraki 3050062, Japan	Dokkyo Medical University	Tominaga, T (corresponding author), Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan.							Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kato M, 1999, J BIOL CHEM, V274, P27225, DOI 10.1074/jbc.274.38.27225; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	26	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39290	39294		10.1074/jbc.M107026200	http://dx.doi.org/10.1074/jbc.M107026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509578	hybrid			2022-12-25	WOS:000171673200127
J	Kim, D; Kim, S; Koh, H; Yoon, SO; Chung, AS; Cho, KS; Chung, J				Kim, D; Kim, S; Koh, H; Yoon, SO; Chung, AS; Cho, KS; Chung, J			Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production	FASEB JOURNAL			English	Article						cell migration; PI3 kinase; NF-kappa B; MMP-9; tumor invasion	NF-KAPPA-B; AKT PROTOONCOGENE; MATRIX METALLOPROTEINASES-2; ACTIN ORGANIZATION; IV COLLAGENASE; KINASE; ACTIVATION; RAC; EXPRESSION; GROWTH	The Akt/protein kinase B (PKB) serine/threonine kinase is well known as an important mediator of many cell survival signaling pathways. Here, we demonstrate for the first time a major role of Akt/PKB in the cell invasion properties of the highly metastatic cell line HT1080. Using confocal microscopic analyses of live samples, we found Akt/PKB to be localized in the leading edge membrane area of migrating HT1080 cells. This localization was dependent on phosphoinositide 3-kinase and required the lipid binding ability of the phosphoinositide binding pleckstrin homology domain of Akt/PKB. We examined the possible function of Akt/PKB in HT1080 invasion. Surprisingly, Akt/PKB potently promoted HT1080 invasion, by increasing cell motility and matrix metalloproteinase-9 (MMP-9) production, in a manner highly dependent on its kinase activity and membrane-translocating ability. The increase in MMP-9 production was mediated by activation of nuclear factor-kappaB transcriptional activity by Akt/PKB. However, Akt/PKB did not affect the cell-cell or cell-matrix adhesion properties of HT1080. Our findings thus establish Akt/PKB as a major factor in the invasive abilities of cancer cells.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Cell Growth Regulat, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				ALBINI A, 1987, CANCER RES, V47, P3239; Allen WE, 1997, J CELL SCI, V110, P707; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bohle AS, 1999, LANGENBECK ARCH SURG, V384, P133, DOI 10.1007/s004230050183; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hua J, 1996, CANCER RES, V56, P5279; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Nishizaka T, 2000, P NATL ACAD SCI USA, V97, P692, DOI 10.1073/pnas.97.2.692; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Ozes ON, 1999, NATURE, V401, P82; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sugiura Y, 1998, CANCER RES, V58, P2209; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tanno S, 2001, CANCER RES, V61, P589; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	45	416	443	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2001	15	11					1953	1962		10.1096/fj.01-0198com	http://dx.doi.org/10.1096/fj.01-0198com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	478XE	11532975				2022-12-25	WOS:000171372700010
J	Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP				Malabarba, MG; Milia, E; Faretta, M; Zamponi, R; Pelicci, PG; Di Fiore, PP			A repertoire library that allows the selection of synthetic SH2s with altered binding specificities	ONCOGENE			English	Article						SH2; phosphotyrosine; scaffold library; scaffold engineering	AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CRYSTAL-STRUCTURES; DOMAIN; PROTEIN; KINASE; BIOSENSORS; COMPLEXES; RESIDUES	Tyrosine phosphorylation is one of the major mechanisms involved in the intracellular propagation of external signals. Strategies aimed at interfering with this process might allow the control of several cellular phenotypes. SH2 domains mediate protein-protein interactions by recognizing phosphotyrosine (pY) residues in the context of specific phosphopeptides. We created an SH2-scaffolded repertoire library by randomly mutagenizing five critical amino acid positions in the specificity-determining region of the PLC gamma C-terminal SH2 domain. Synthetic SH2 domains were selected from the library using biotinylated phosphopeptides; derived from a natural PLC gamma -SH2 ligand as well as unrelated SH2 ligands. The isolated SH2s displayed high binding affinity constants for the selecting peptides and were capable of interacting with the corresponding proteins.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM, FIRC Inst Mol Oncol, I-20090 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Di Fiore, Pier Paolo/K-2130-2012; Faretta, Mario/H-8946-2012; Zamponi, Raffaella/V-5683-2018; Malabarba, Maria Grazia/L-4805-2015	Di Fiore, Pier Paolo/0000-0002-2252-0950; Faretta, Mario/0000-0003-1678-5781; Malabarba, Maria Grazia/0000-0002-9457-2047; Zamponi, Raffaella/0000-0002-3313-1387				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Bradshaw JM, 2000, J MOL BIOL, V299, P521; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Ikeda M, 1996, GENE, V181, P167, DOI 10.1016/S0378-1119(96)00497-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAROSE L, 1993, ONCOGENE, V8, P2493; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NARULA SS, 1995, STRUCTURE, V3, P1061, DOI 10.1016/S0969-2126(01)00242-8; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	28	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5186	5194		10.1038/sj.onc.1204654	http://dx.doi.org/10.1038/sj.onc.1204654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526507				2022-12-25	WOS:000170464000012
J	Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F				Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F			hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors	ONCOGENE			English	Article						hH-Rev107; tumor suppressor gene; spermatogenesis; carcinoma in situ; testicular germ cell tumors	CARCINOMA-IN-SITU; DOWN-REGULATION; HUMAN TESTIS; CANCER; IDENTIFICATION; HYBRIDIZATION; H-REV107; RNA; CHROMOSOME; CLONING	By systematic analysis of a human testis library, we have isolated the hH-Rev107-3 cDNA, identical to hH-Rev107-1 cDNA, which was previously described as a class II tumor suppressor gene. In this study, two transcripts (I and 0.8 kb) were detected by Northern blot in all human tissues, excepted in thymus. The strongest expression was found in testis, skeletal muscle and heart. These two mRNA are probably transcribed from only one gene that we mapped to the q12-q13 region of the chromosome 11. In human testis, hH-Rev107 gene expression was localized, by in situ hybridization, within the round spermatids. To investigate a possible role for hH-Rev107 protein in testicular malignant growth, we examined the expression of this gene in germ cell tumors. A strong hH-Rev107 gene expression was observed in normal testis as well as in samples with preinvasive carcinoma in situ but was completely absent in overt tumors, both seminomas and non-seminomas. By in situ hybridization, CIS was found hH-ReP107 positive and tumor negative. A semi-quantitative assessment of hH-Rev107 mRNA level in testicular germ cell tumors, by RT-PCR, exhibited a ninefold decrease in the gene expression. No gross structural aberrations of hH-Rev107 gene were detected in these human primary tumors. The results suggest that down-regulation of hH-Rev107 may be associated with invasive progression of testicular germ cell tumors.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Fac Med Marseille, INSERM, U491, F-13385 Marseille, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Feral, Chloe C/O-5781-2016; Bulle-Thomas, Frederique/L-2528-2017; FERAL, Chloe/AAB-6111-2020; Rajpert-De Meyts, Ewa/H-6526-2019; Chami, Mounia/S-6471-2019	Feral, Chloe C/0000-0001-9756-2082; FERAL, Chloe/0000-0001-9756-2082; Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Chami, Mounia/0000-0003-1498-7187				Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; BOS JL, 1989, CANCER RES, V49, P4682; Braun RE, 1998, SEMIN CELL DEV BIOL, V9, P483, DOI 10.1006/scdb.1998.0226; Bulle F, 1996, ANN GENET-PARIS, V39, P139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Duvic M, 2000, CLIN CANCER RES, V6, P3249; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; HAJNAL A, 1994, ONCOGENE, V9, P479; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Levy I, 1996, FEBS LETT, V382, P276, DOI 10.1016/0014-5793(96)00183-4; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MULDER MP, 1989, ONCOGENE, V4, P1345; PAWLAK A, 1995, GENOMICS, V26, P151, DOI 10.1016/0888-7543(95)80096-5; PECKHAM M, 1988, ACTA ONCOL, V27, P439, DOI 10.3109/02841868809093570; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RICHIE JP, 1993, CA-CANCER J CLIN, V43, P151, DOI 10.3322/canjclin.43.3.151; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHMIDT B, 1995, J MOL MED, V73, P355; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x	28	25	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5155	5163		10.1038/sj.onc.1204658	http://dx.doi.org/10.1038/sj.onc.1204658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526504	Green Submitted, Green Accepted			2022-12-25	WOS:000170464000009
J	Zhong, J; Troppmair, J; Rapp, UR				Zhong, J; Troppmair, J; Rapp, UR			Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria	ONCOGENE			English	Article						Raf; Bcl-2; apoptosis; mitochondria	NF-KAPPA-B; INDUCED APOPTOSIS; FAMILY PROTEINS; KINASE RAF-1; DEATH; EXPRESSION; MICE; PHOSPHORYLATION; TRANSFORMATION; TRANSLOCATION	Bcl-2 family proteins play a critical role in the regulation of cell survival by controlling the activation of the cell death executing caspase machinery. Recent work demonstrated that they also provide a link between growth factor signaling and cell survival control. Raf-1 has been identified initially as an essential component of the mitogenic Ras-Raf-MEK-ERK cascade. However, expression of oncogenic Raf-1 also efficiently suppresses apoptotic cell death. This process requires mitochondrial translocation of Raf-1 which can be achieved either by co-expression of the anti-apoptotic protein Bcl-2 or by fusion with the transmembrane domain of the yeast outer mitochondrial membrane protein Mas 70p. It is currently unclear how mitochondrial Raf-1 prevents apoptosis. One possible mechanism involves the phosphorylation of the pro-apoptotic protein Bad resulting in the restoration of Bcl-2 function. Alternatively, the role of Bcl-2 could be limited to the mitochondrial translocation of Raf-1 and survival signaling by Raf-1 is Bcl-2 independent. To test for the mutual requirement of Raf-1 and Bcl-2 in apoptosis suppression the individual proteins were singly tested for survival activity in a genetic background which precludes the expression of the other. The results obtained in these studies demonstrate that ablation of Raf-1 or Bcl-2 expression in fibroblast cells significantly increases the sensitivity towards doxorubicin induced cell death. Reversion of the mutant phenotype could be achieved in either case by introducing a functional bcl-2 gene or a mitochondria targeted version of oncogenic Raf-1, demonstrating that each protein by itself is sufficient to confer protection. Our data thus suggest the existence of two separate pathways of survival signaling at the mitochondria controlled either by Bcl-2 or by Raf-1.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lau QC, 1998, ONCOGENE, V16, P1899, DOI 10.1038/sj.onc.1201709; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Naumann U, 1997, Recent Results Cancer Res, V143, P237; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	49	52	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4807	4816		10.1038/sj.onc.1204614	http://dx.doi.org/10.1038/sj.onc.1204614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521192				2022-12-25	WOS:000170271800005
J	Focke, M; Mahler, V; Ball, T; Sperr, WR; Majlesi, Y; Valent, P; Kraft, D; Valenta, R				Focke, M; Mahler, V; Ball, T; Sperr, WR; Majlesi, Y; Valent, P; Kraft, D; Valenta, R			Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination	FASEB JOURNAL			English	Article						Type I allergy; IgE; non-allergenic allergy vaccine	FC-EPSILON-RI; IGG MONOCLONAL-ANTIBODIES; ANTIGEN-PRESENTING CELLS; BET V 1; HAY-FEVER; P-I; RECOMBINANT ALLERGENS; IMMUNOTHERAPY; BINDING; DISEASES	Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens. We have used the major timothy grass pollen allergen Phl p 1, which cross-reacts with most grass-, corn-, and monocot-derived group 1 allergens to develop a generally applicable strategy for the production of hypoallergenic allergy vaccines. On the basis of the experimentally determined B cell epitopes of Phl p 1, we have synthesized five synthetic peptides. These peptides are derived from the major Phl p 1 IgE epitopes and were between 28-32 amino acids long. We demonstrate by nuclear magnetic resonance that the peptides exhibit no secondary and tertiary structure and accordingly failed to bind IgE antibodies from grass pollen allergic patients. The five peptides, as well as an equimolar mixture thereof, lacked allergenic activity as demonstrated by basophil histamine release and skin test experiments in grass pollen allergic patients. When used as immunogens in mice and rabbits, the peptides induced protective IgG antibodies, which recognized the complete Phl p 1 wild-type allergen and group 1 allergens from other grass species. Moreover, peptide-induced antibodies inhibited the binding of grass pollen allergic patients IgE antibodies to the wild-type allergen. We thus demonstrate that synthetic hypoallergenic peptides derived from B cell epitopes of major allergens represent safe vaccine candidates for the treatment of IgE-mediated allergies.	Univ Vienna, Vienna Gen Hosp, AKH, Dept Pathophysiol,Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, AKH, Dept Hematol & Hemostaseol, A-1090 Vienna, Austria; Univ Erlangen Nurnberg, Dept Dermatol, D-8520 Erlangen, Germany	University of Vienna; University of Vienna; University of Erlangen Nuremberg	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, AKH, Dept Pathophysiol,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	valenta@akh-wien.ac.at	Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Sperr, Mast/V-4767-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valenta, Rudolf/0000-0001-5944-3365; Sperr, Wolfgang/0000-0003-3288-8027				Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; ATTALLAH NA, 1969, IMMUNOCHEMISTRY, V6, P609, DOI 10.1016/0019-2791(69)90199-2; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; BALL T, 1994, J BIOL CHEM, V269, P28323; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooke RA, 1937, J EXP MED, V66, P689, DOI 10.1084/jem.66.6.689; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Focke M, 2001, INT ARCH ALLERGY IMM, V124, P398, DOI 10.1159/000053769; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P397, DOI 10.1016/0091-6749(85)90661-X; Harley D, 1937, J PATHOL BACTERIOL, V44, P589, DOI 10.1002/path.1700440307; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Kay A.B., 1997, ALLERGY ALLERGIC DIS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; Loveless MH, 1940, J IMMUNOL, V38, P25; MALLEY O, 1969, J ALLERGY, V43, P59; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1993, ANN ALLERGY, V71, P330; SCHEFFER GL, 1995, NAT MED, V1, P1; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 1998, INT ARCH ALLERGY IMM, V116, P167, DOI 10.1159/000023942; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Visco V, 1996, J IMMUNOL, V157, P956; Vrtala S, 1998, J IMMUNOL, V160, P6137; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wheeler AW, 1997, ALLERGY, V52, P602, DOI 10.1111/j.1398-9995.1997.tb01038.x	39	110	121	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2042	+		10.1096/fj.01-0016fje	http://dx.doi.org/10.1096/fj.01-0016fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511525				2022-12-25	WOS:000170318500017
J	Padmanabhan, U; Dasgupta, S; Biswas, BB; Dasgupta, D				Padmanabhan, U; Dasgupta, S; Biswas, BB; Dasgupta, D			High affinity association of myo-inositol trisphosphates with phytase and its effect upon the catalytic potential of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; DOMAIN-PEPTIDE COMPLEX; PROLINE-RICH MOTIF; INOSITOL PHOSPHATES; EVH1 DOMAIN; MUNG BEANS; METABOLISM; PROTEINS; CALCIUM; RAT	A neutral phytase from germinating mung bean (Vigna radiata) seeds dephosphorylates myo-inositol hexakisphosphate sequentially to myo-inositol. The enzyme also binds with higher affinity to myo-inositol trisphosphates (1,4,5), (2,4,5), and (1,3,4) isomers without catalysis. The high affinity complex elicits Ca2+ mobilization in vitro from microsomes/vacuoles via the formation of a ternary complex with the receptor for Ins(1,4,5)P-3. As a sequel to our previous report, we have carried out a detailed characterization of the two sites and examined the mutual interactions between them. Presaturation of the high affinity site leads to an increase in the affinity of the enzyme for phytic acid and its rate of dephosphorylation as well. From the products of limited tryptic cleavage of phytase, two peptides, each with one activity, have been isolated. The larger ;peptide (similar to 66 kDa) contains the catalytic site, and the smaller peptide (similar to5 kDa) has the high affinity myo-inositol trisphosphate-binding site. The interaction between the dual activities of phytase has been observed also at the level of the two peptides. A sequence homology search using N-terminal 12 amino acid residues of the 5-kDa fragment has revealed significant homology with the Homer class of proteins implicated in signaling pathways involving metabotropic glutamate receptor and myo-inositol 1,4,5-trisphosphate receptor. These results indicate a second role of phytase in Ca2+ mobilization during germination of mung been seed via a salvage pathway that involves allosteric activation by myo-inositol trisphosphate.	Saha Inst Nucl Phys, Div Biophys, Kolkata 700037, W Bengal, India; Univ Calcutta, Biophys & Mol Biol Dept, Kolkata 700009, W Bengal, India	Saha Institute of Nuclear Physics; University of Calcutta	Dasgupta, D (corresponding author), Saha Inst Nucl Phys, Div Biophys, 37 Belgachia Rd, Kolkata 700037, W Bengal, India.	dipak@biop.saha.ernet.in						BANIK U, 1990, BIOCHEM J, V266, P611; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biswas S, 1996, Subcell Biochem, V26, P287; BITAR K, 1972, BIOCHIM BIOPHYS ACTA, V268, P442, DOI 10.1016/0005-2744(72)90340-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELLAN GW, 1989, PHYSICAL CHEM, P277; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Dasgupta S, 1996, BIOCHEMISTRY-US, V35, P4994, DOI 10.1021/bi9525233; Dasgupta S, 1997, BIOCHEM J, V321, P355, DOI 10.1042/bj3210355; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; FISKE CYRUS H., 1929, JOUR BIOL CHEM, V81, P629; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Kammermeier PJ, 2000, J NEUROSCI, V20, P7238; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; Lehrer S S, 1978, Methods Enzymol, V49, P222; Lim D, 2000, NAT STRUCT BIOL, V7, P108; LOWRY OH, J BIOL CHEM, V193, P265; MAITRA R, 1988, INDIAN J BIOCHEM BIO, V25, P655; MANDAL NC, 1970, PLANT PHYSIOL, V45, P4, DOI 10.1104/pp.45.1.4; MANDAL NC, 1972, PHYTOCHEMISTRY, V11, P495, DOI 10.1016/0031-9422(72)80003-7; MAZOROW DL, 1990, ANAL BIOCHEM, V186, P28, DOI 10.1016/0003-2697(90)90567-S; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; SAIO K, 1964, PLANT CELL PHYSIOL, V5, P393; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; Soloviev MM, 2000, J MOL BIOL, V295, P1185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; WANG JL, 1971, J BIOL CHEM, V246, P1185; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; YANG WJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P75	36	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43635	43644		10.1074/jbc.M107531200	http://dx.doi.org/10.1074/jbc.M107531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11527980	hybrid			2022-12-25	WOS:000172297700022
J	Ingley, E; Chappell, D; Poon, SYK; Sarna, MK; Beaumont, JG; Williams, JH; Stillitano, JP; Tsai, S; Leedman, PJ; Tilbrook, PA; Klinken, SP				Ingley, E; Chappell, D; Poon, SYK; Sarna, MK; Beaumont, JG; Williams, JH; Stillitano, JP; Tsai, S; Leedman, PJ; Tilbrook, PA; Klinken, SP			Thyroid hormone receptor-interacting protein 1 modulates cytokine and nuclear hormone signaling in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN-INDUCED DIFFERENTIATION; TRANSCRIPTION FACTOR; RETINOIC ACID; BINDING PROTEIN; IN-VITRO; ACTIVATION; LYN; INACTIVATION; KINASE; TARGET	Erythropoietin (Epo) and thyroid hormone (T-3) are key molecules in the development of red blood cells. We have shown previously that the tyrosine kinase Lyn is involved in differentiation signals emanating from an activated erythropoietin receptor. Here we demonstrate that Lyn interacts with thyroid hormone receptor-interacting protein 1 (Trip-1), a transcriptional regulator associated with the T-3 receptor, providing a link between the Epo and T-3 signaling pathways. Trip-1 co-localized with Lyn and the T-3 receptor alpha in the cytoplasm/plasma membrane of erythroid cells but translocated to discrete nuclear foci shortly after Epo-induced differentiation. Our data reveal that T-3 stimulated the proliferation of immature erythroid cells, and inhibited maturation promoted by erythropoietin. Removal of T-3 reduced cell division and enhanced terminal differentiation. This was accompanied by large increases in the cell cycle inhibitor P27(Kip1) and by increasing expression of erythroid transcription factors GATA-1, EKLF, and NF-E2. Strikingly, a truncated Trip-1 inhibited both erythropoietin-induced maturation and T-3-initiated cell division. This mutant Trip-1 acted in a dominant negative fashion by eliminating endogenous Lyn, elevating p27(Kip1), and blocking T-3 response elements. These data demonstrate that Trip-1 can simultaneously modulate responses involving both cytokine and nuclear receptors.	Univ Western Australia, Dept Biochem, Lab Canc Med, Perth, WA 6000, Australia; Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; CUNY Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10030 USA	University of Western Australia; Royal Perth Hospital; University of Western Australia; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Klinken, SP (corresponding author), Univ Western Australia, Dept Biochem, Lab Canc Med, Level 6,Med Res Fdn Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@cyllene.uwa.edu.au	Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Leedman, Peter J/O-4044-2014	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; BUSFIELD SJ, 1992, BLOOD, V80, P412; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Chin H, 1998, BLOOD, V91, P3734; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DeFranceschi L, 1997, J CLIN INVEST, V99, P220, DOI 10.1172/JCI119150; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FEIN HG, 1975, MED CLIN N AM, V59, P1133, DOI 10.1016/S0025-7125(16)31963-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HAWLEY RG, 1994, GENE THER, V1, P136; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; KRANTZ SB, 1991, BLOOD, V77, P419; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MALGOR LA, 1975, BLOOD, V45, P671; Marcus SL, 1996, J BIOL CHEM, V271, P27197, DOI 10.1074/jbc.271.44.27197; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PERKINS AC, 1995, NATURE, V375, P318; Perrin MC, 1997, HEMATOL CELL THER, V39, P19, DOI 10.1007/s00282-997-0019-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; Singh V, 1998, ENDOCRINOLOGIST, V8, P87, DOI 10.1097/00019616-199803000-00006; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; TRAINOR CD, 1995, MOL ENDOCRINOL, V9, P1135, DOI 10.1210/me.9.9.1135; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	58	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43428	43434		10.1074/jbc.M106645200	http://dx.doi.org/10.1074/jbc.M106645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544260	Green Published, hybrid			2022-12-25	WOS:000172169300103
J	Trent, MS; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH				Trent, MS; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH			An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A - Induction in polymyxin-resistant mutants and role of a novel lipid-linked donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; ACID-DEFICIENT MUTANT; PMRA-MUTANTS; POLYSACCHARIDE SYNTHESIS; PHOSPHATE GROUPS; O-ANTIGEN; TYPHIMURIUM; LIPOPOLYSACCHARIDE; GENE; PHOSPHOETHANOLAMINE	Attachment of the cationic sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N) to lipid A is required for the maintenance of polymyxin resistance in Escherichia coli and Salmonella typhimurium. The enzymes that synthesize L-Ara4N and transfer it to lipid A have not been identified. We now report an inner membrane enzyme, expressed in polymyxin-resistant mutants, that adds one or two L-Ara4N moieties to lipid A or its immediate precursors. No soluble factors are required. A gene located near minute 51 on the S. typhimurium and E. coli chromosomes (previously termed orf5, pmrK, or yfbI) encodes the L-Ara4N transferase. The enzyme, renamed ArnT, consists of 548 amino acid residues in S. typhimurium with 12 possible membrane-spanning regions. ArnT displays distant similarity to yeast protein mannosyltransferases. ArnT adds two L-Ara4N units to lipid A precursors containing a Kdo disaccharide. However, as shown by mass spectrometry and NMR spectroscopy, it transfers only a single L-Ara4N residue to the 1-phosphate moiety of lipid IVA, a precursor lacking Kdo. Proteins with full-length sequence similarity to ArnT are present in genomes of other bacteria thought to synthesize L-Ara4N-modified lipid A, including Pseudomonas aeruginosa and Yersinia pestis. As shown in the following article (Trent, M. S., Ribeiro, A. A., Doerrler, W. T., Lin, S., Cotter, R. J., and Raetz, C. R. H. (2001) J. Biol. Chem. 276, 43132-43144), ArnT utilizes the novel lipid undecaprenyl phosphate-alpha -L-Ara4N as its sugar donor, suggesting that L-Ara4N transfer to lipid A occurs on the periplasmic side of the inner membrane.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Duke University; Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIGMS NIH HHS [GM54882, GM-51310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM054882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P927; BRYN K, 1978, EUR J BIOCHEM, V86, P311, DOI 10.1111/j.1432-1033.1978.tb12312.x; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MUHLRADT PF, 1977, EUR J BIOCHEM, V81, P193, DOI 10.1111/j.1432-1033.1977.tb11941.x; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; STINAVAGE P, 1989, INFECT IMMUN, V57, P3894, DOI 10.1128/IAI.57.12.3894-3900.1989; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	62	238	246	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43122	43131		10.1074/jbc.M106961200	http://dx.doi.org/10.1074/jbc.M106961200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11535604	hybrid			2022-12-25	WOS:000172169300065
J	Mark, BL; Vocadlo, DJ; Zhao, DL; Knapp, S; Withers, SG; James, MNG				Mark, BL; Vocadlo, DJ; Zhao, DL; Knapp, S; Withers, SG; James, MNG			Biochemical and structural assessment of the 1-N-azasugar GalNAc-isofagomine as a potent family 20 beta-N-acetylhexosaminidase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; ALPHA-GLUCOSIDASE INHIBITOR; GLYCOSYL HYDROLASES; SIASTATIN-B; MECHANISM; CATALYSIS; PARTICIPATION; GLYCOSIDASE; CHITOBIASE; ACARBOSE	Azasugar inhibitors of the isofagomine class are potent competitive inhibitors of configuration-retaining beta -glycosidases. This potency results from the formation of a strong electrostatic interaction between a protonated endocyclic nitrogen at the "anomeric" center of the inhibitor and the catalytic nucleophile of the enzyme. Although the majority of retaining beta -glycosidases use a mechanism involving a carboxylate residue as a nucleophile, Streptomyces plicatus beta -N-acetylhexosaminidase (SpHEX) and related family 20 glycosidases lack such a catalytic residue and use instead the carbonyl oxygen of the 2-acetamido group of the substrate as a nucleophile to "attack" the anomeric center. Thus, a strong electrostatic interaction between the inhibitor and enzyme is not expected to occur; nonetheless, the 1-N-azasugar (2R,3R,4S,5R)-2-acetamido-3,4-dihydroxy5-hydroxymethyl-piperidinium hydrochloride (Ga1NAc-isofagomine . HCl), which was synthesized and assayed for its ability to inhibit SpHEX, was found to be a potent competitive inhibitor of the enzyme (K-i = 2.7 mum). A crystallographic complex of Ga1NAc-isofagomine bound to SpHEX was solved and refined to 1.75 Angstrom and revealed that the lack of a strong electrostatic interaction between the "anomeric" center of Ga1NAc-isofagomine and SpHEX is compensated for by a novel 2.8-Angstrom hydrogen bond formed between the equatorial proton of the endocyclic nitrogen of the azasugar ring and the carboxylate of the general acid-base residue Glu-314 of SpHEX. This interaction appears to contribute to the unexpected potency of Ga1NAc-isofagomine toward SpHEX.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Rutgers State Univ, Dept Chem, New Brunswick, NJ 08903 USA	University of Alberta; University of British Columbia; Rutgers State University New Brunswick	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.		Withers, Stephen G/I-7229-2019; Vocadlo, David J/E-5508-2014	Withers, Stephen G/0000-0002-6722-5701; Vocadlo, David J/0000-0001-6897-5558; Mark, Brian/0000-0002-7344-1355				Bols M, 1998, ACCOUNTS CHEM RES, V31, P1, DOI 10.1021/ar970058r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Drouillard S, 1997, BIOCHEM J, V328, P945, DOI 10.1042/bj3280945; GILARDI RD, 1974, ACTA CRYSTALLOGR B, V30, P2931, DOI 10.1107/S0567740874008569; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Ichikawa Y, 1998, J AM CHEM SOC, V120, P5854, DOI 10.1021/ja985509x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Knapp S, 2000, ORG LETT, V2, P4037, DOI 10.1021/ol0066680; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R. J., 1998, GRAFIT VERSION 4 0; Liu HZ, 2001, J AM CHEM SOC, V123, P5116, DOI 10.1021/ja010240u; Mark BL, 1998, J BIOL CHEM, V273, P19618, DOI 10.1074/jbc.273.31.19618; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Martin AE, 1996, AM J HEALTH-SYST PH, V53, P2277, DOI 10.1093/ajhp/53.19.2277; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCCARTER JD, 1992, BIOCHEM J, V286, P721, DOI 10.1042/bj2860721; MO F, 1978, ACTA CRYSTALLOGR B, V34, P1562, DOI 10.1107/S0567740878006081; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; Nishimura Y, 1996, BIOORGAN MED CHEM, V4, P91, DOI 10.1016/0968-0896(95)00166-2; Notenboom V, 2000, BIOCHEMISTRY-US, V39, P11553, DOI 10.1021/bi0010625; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Welborn TA, 1998, MED J AUSTRALIA, V168, P76, DOI 10.5694/j.1326-5377.1998.tb126718.x; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149	38	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42131	42137		10.1074/jbc.M107154200	http://dx.doi.org/10.1074/jbc.M107154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11522797	hybrid			2022-12-25	WOS:000172450400080
J	Vaccaro, P; Brannetti, B; Montecchi-Palazzi, L; Philipp, S; Citterich, MH; Cesareni, G; Dente, L				Vaccaro, P; Brannetti, B; Montecchi-Palazzi, L; Philipp, S; Citterich, MH; Cesareni, G; Dente, L			Distinct binding specificity of the multiple PDZ domains of INADL, a human protein with homology to INAD from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY; BACTERIOPHAGE-LAMBDA; ADAPTER PROTEINS; SODIUM-CHANNELS; MEMBRANE; PEPTIDE; RECOGNITION; RECEPTOR; FAMILY; MUPP1	PDZ domains are protein-protein interaction modules that typically bind to short peptide sequences at the carboxyl terminus of target proteins. Proteins containing multiple PDZ domains often bind to different transmembrane and intracellular proteins, playing a central role as organizers of multimeric complexes. To characterize the rules underlying the binding specificity of different PDZ domains, we have assembled a novel repertoire of random peptides that are displayed at high density at the carboxyl terminus of the capsid D protein of bacteriophage lambda. We have exploited this combinatorial library to determine the peptide binding preference of the seven PDZ domains of human INADL, a multi-PDZ protein that is homologous to the INAD protein of Drosophila melanogaster. This approach has permitted the determination of the consensus ligand for each PDZ domain and the assignment to class I, class II, and to a new specificity class, class IV, characterized by the presence of an acidic residue at the carboxyl-terminal position. Homology modeling and site-directed mutagenesis experiments confirmed the involvement of specific residues at contact positions in determining the domain binding preference. However, these experiments failed to reveal simple rules that would permit the association of the chemical characteristics of any given residue in the peptide binding pocket to the preference for specific amino acid sequences in the ligand peptide. Rather, they suggested that to infer the binding preference of any PDZ domain, it is necessary to simultaneously take into account all contact positions by using computational procedures. For this purpose we extended the SPOT algorithm, originally developed for SH3 domains, to evaluate the probability that any peptide would bind to any given PDZ domain.	Univ Pisa, Dept Physiol & Biochem, I-56010 Pisa, Italy; Univ Roma Tor Vergata, Dept BIol Enrico Calef, I-00133 Rome, Italy; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	University of Pisa; University of Rome Tor Vergata; Saarland University	Dente, L (corresponding author), Univ Pisa, Dept Physiol & Biochem, Via G Carducci 13, I-56010 Pisa, Italy.	dentel@dfb.unipi.it	Philipp, Stephan/AAR-7519-2020	DENTE, LUCIANA/0000-0002-9617-0922; , Barbara/0000-0001-9436-0362; Helmer-Citterich, Manuela/0000-0001-9530-7504; Philipp, Stephan/0000-0003-1959-9167				BANNER DW, 1981, NATURE, V289, P814, DOI 10.1038/289814a0; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brannetti B, 2000, J MOL BIOL, V298, P313, DOI 10.1006/jmbi.2000.3670; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Castagnoli L, 2001, COMB CHEM HIGH T SCR, V4, P121; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Gee SH, 1998, J NEUROSCI, V18, P128; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kay BK, 2000, FEBS LETT, V480, P55, DOI 10.1016/S0014-5793(00)01778-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Santi E, 2000, J MOL BIOL, V296, P497, DOI 10.1006/jmbi.1999.3471; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Stathakis DG, 1997, GENOMICS, V44, P71, DOI 10.1006/geno.1997.4848; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wes PD, 1999, NAT NEUROSCI, V2, P447, DOI 10.1038/8116; Wilson DR, 1998, CAN J MICROBIOL, V44, P313, DOI 10.1139/cjm-44-4-313; Yang F, 2000, NAT STRUCT BIOL, V7, P230; Zucconi A, 2001, J MOL BIOL, V307, P1329, DOI 10.1006/jmbi.2001.4572	48	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42122	42130		10.1074/jbc.M104208200	http://dx.doi.org/10.1074/jbc.M104208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11509564	hybrid, Green Published			2022-12-25	WOS:000172450400079
J	Chauvin, C; De Oliveira, F; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E				Chauvin, C; De Oliveira, F; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E			Rotenone inhibits the mitochondrial permeability transition-induced cell death in U937 and KB cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CYTOCHROME-C; UBIQUINONE ANALOGS; INDUCED APOPTOSIS; PORE; BUTYLHYDROPEROXIDE; ACTIVATION; INDUCTION; RELEASE	The permeability transition pore (PTP) is a mitochondrial inner membrane Ca2+-sensitive channel that plays a key role in different models of cell death. Because functional links between the PTP and the respiratory chain complex I have been reported, we have investigated the effects of rotenone on PTP regulation in U937 and KB cells. We show that rotenone was more potent than cyclosporin A at inhibiting Ca2+-induced PTP opening in digitonin-permeabilized cells energized with succinate. Consistent with PTP regulation by electron flux through complex I, the effect of rotenone persisted after oxidation of pyridine nucleotides by duroquinone. tert-Butyl hydroperoxide induced PTP opening in intact cells (as shown by mitochondrial permeabilization to calcein and cobalt), as well as cytochrome c release and cell death. All these events were prevented by rotenone or cyclosporin A. These data demonstrate that respiratory chain complex I plays a key role in PTP regulation in vivo and confirm the importance of PTP opening in the commitment to cell death.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appliquee, F-38041 Grenoble 09, France; Inst Albert Bonniot, Lab Dynam Cellulaire, F-38706 La Tronche, France; Hop Albert Michalon, Med Oncol Serv, F-38043 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes	Fontaine, E (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appliquee, BP 53X, F-38041 Grenoble 09, France.		Fontaine, Eric/ABA-8853-2020; Mousseau, Mireille/M-5942-2014; RONOT, Xavier/B-8412-2014	Fontaine, Eric/0000-0002-5204-9477; 				Beghetto C, 2000, EUR J BIOCHEM, V267, P5585, DOI 10.1046/j.1432-1327.2000.01625.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gastman BR, 2000, CANCER RES, V60, P6811; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guidarelli A, 1997, EXP CELL RES, V237, P176, DOI 10.1006/excr.1997.3779; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, BIOPHYS J, V77, P1747, DOI 10.1016/S0006-3495(99)77020-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Sestili P, 1999, FEBS LETT, V457, P139, DOI 10.1016/S0014-5793(99)01027-3; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549; Zuurendonk P F, 1979, Methods Enzymol, V56, P207	42	111	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41394	41398		10.1074/jbc.M106417200	http://dx.doi.org/10.1074/jbc.M106417200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527970	hybrid			2022-12-25	WOS:000171925600135
J	MacAulay, N; Bendahan, A; Loland, CJ; Zeuthen, T; Kanner, BI; Gether, U				MacAulay, N; Bendahan, A; Loland, CJ; Zeuthen, T; Kanner, BI; Gether, U			Engineered Zn2+ switches in the gamma-aminobutyric acid (GABA) transporter-1 - Differential effects on GABA uptake and currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+CL COTRANSPORT FUNCTION; HUMAN DOPAMINE TRANSPORTER; OOCYTE MEMBRANE PATCHES; XENOPUS-OOCYTES; NEUROTRANSMITTER TRANSPORTERS; ELECTROGENIC PROPERTIES; GLUTAMATE TRANSPORTER; GLUCOSE COTRANSPORTER; CHLORIDE CHANNEL; RAT-BRAIN	Two high affinity Zn2+ binding sites were engineered in the otherwise Zn2+-insensitive rat gamma -aminobutyric acid (GABA) transporter-1 (rGAT-1) based on structural information derived from Zn2+ binding sites engineered previously in the homologous dopamine transporter. Introduction of a histidine (T349H) at the extracellular end of transmembrane segment (TM) 7 together with a histidine (E370H) or a cysteine (Q374C) at the extracellular end of TM 8 resulted in potent inhibition of [H-3]GABA uptake by Zn2+ (IC50 = 35 and 44 muM, respectively). Upon expression in Xenopus laevis oocytes it was similarly observed that Zn2+ was a potent inhibitor of the GABA-induced current (IC50 = 21 muM for T349H/E370H and 51 muM for T349H/Q374C), albeit maximum inhibition was only similar to 40% in T349H/E370H versus similar to 90% in T349H/Q374C. In the wild type, Zn2+ did not affect the Na+-dependent transient currents elicited by voltage jumps and thought to reflect capacitive charge movements associated with Na+ binding. However, in both mutants Zn2+ caused a reduction of the inward transient currents upon jumping to hyperpolarized potentials as reflected in rightward-shifted Q/V relationships. This suggests that Zn2+ is inhibiting transporter function by stabilizing the outward-facing Na+-bound state. Translocation of lithium by the transporter does not require GAGA binding and analysis of this uncoupled Li+ conductance revealed a potent inhibition by Zn2+ in T349H/E370H, whereas surprisingly the T349H/Q374C leak was unaffected. This differential effect supports that the leak conductance represents a unique operational mode of the transporter involving conformational changes different from those of the substrate translocation process. Altogether our results support both an evolutionary conserved structural organization of the TM 7/8 domain and a key role of this domain in GABA-dependent and -independent conformational changes of the transporter.	Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mel Physiol, DK-2200 Copenhagen N, Denmark; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	University of Copenhagen; Hebrew University of Jerusalem	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mel Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	gether@mfi.ku.dk	Loland, Claus/E-5975-2014; MacAulay, Nanna/AER-7709-2022	Loland, Claus/0000-0002-1773-1446; MacAulay, Nanna/0000-0002-7800-6600; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, R37DA005477] Funding Source: NIH RePORTER; NIDA NIH HHS [R37 DA05477, P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1998, METHOD ENZYMOL, V296, P475; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Galli A, 1997, J NEUROSCI, V17, P3401; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MILLER JW, 1997, NEUROTRANSMITTER TRA, P101; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0	43	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40476	40485		10.1074/jbc.M105578200	http://dx.doi.org/10.1074/jbc.M105578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527967	hybrid			2022-12-25	WOS:000171925600017
J	Masuda, M; Suzuki, T; Friesen, MD; Ravanat, JL; Cadet, J; Pignatelli, B; Nishino, H; Ohshima, H				Masuda, M; Suzuki, T; Friesen, MD; Ravanat, JL; Cadet, J; Pignatelli, B; Nishino, H; Ohshima, H			Chlorination of guanosine and other nucleosides by hypochlorous acid and myeloperoxidase of activated human neutrophils - Catalysis by nicotine and trimethylamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER RISK; CALF THYMUS DNA; NITRIC-OXIDE; HYDROXYL RADICALS; MASS-SPECTROMETRY; CELLULAR DNA; OXIDATION; MECHANISM; CHLORIDE; MARKER	Activated human neutrophils secrete myeloperoxidase, which generates HOCl from H2O2 and Cl-. We have found that various (2'-deoxy)nucleosides react with HOCl to form chlorinated (2'-deoxy)nucleosides, including novel 8-chloro(2'-deoxy)guanosine, 5-chloro(2'-deoxy)cytidine, and 8-chloro(2'-deoxy)adenosine formed in yields of 1.6, 1.6, and 0.2%, respectively, when 0.5 mM nucleoside reacted with 0.5 mM HOCl at pH 7.4. The relative chlorination, oxidation, and nitration activities of HOCl, myeloperoxidase, and activated human neutrophils in the presence and absence of nitrite were studied by analyzing 8-chloro-, 8-oxo-7,8-dihydro-, and 8-nitro-guanosine, respectively, using guanosine as a probe. 8-Chloroguanosine was always more easily formed than 8-oxo-7,8-dihydro- or 8-nitro-guanosine. Using electrospray ionization tandem mass spectrometry, we show that several chlorinated nucleosides including 8-chloro(2'-deoxy)guanosine are formed following exposure of isolated DNA or RNA to HOCl. Micromolar concentrations of tertiary amines such as nicotine and trimethylamine dramatically enhanced chlorination of free (2'-deoxy)nucleosides and nucleosides in RNA by HOCl. As the G-463A polymorphism of the MPO gene, which strongly reduces myeloproxidase mRNA expression, is associated with a reduced risk of lung cancer, chlorination damage of DNA/RNA and nucleosides by myeloperoxidase and its enhancement by nicotine may be important in the pathophysiology of human diseases associated with tobacco habits.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 8, France; Int Agcy Res Canc, Unit Nutr & Canc, Lyon, France; CEA, Dept Rech Fondamentale Mat Condensee, Serv Chim Inorgan & Biol, Lab Les Acides Nucl,UMR 5046, F-38054 Grenoble, France; Kyoto Prefectural Univ Med, Dept Biochem, Kyoto 6028566, Japan	World Health Organization; International Agency for Research on Cancer (IARC); World Health Organization; International Agency for Research on Cancer (IARC); CEA; Kyoto Prefectural University of Medicine	Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 8, France.		Ravanat, Jean-Luc/E-3452-2018; Cadet, Jean/M-2971-2018; Friesen, Marlin D/D-7328-2012; Ohshima, Hiroshi/E-8044-2010	Ravanat, Jean-Luc/0000-0002-7123-6358; Cadet, Jean/0000-0003-2594-9485; 				AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; ARNHOLD J, 1995, CHEM PHYS LIPIDS, V78, P55, DOI 10.1016/0009-3084(95)02484-Z; Brezonik P.L., 1994, CHEM KINETICS PROCES; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; CANDEIAS LP, 1994, FREE RADICAL RES, V20, P241, DOI 10.3109/10715769409147520; Cascorbi I, 2000, CANCER RES, V60, P644; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; ELLIS AJ, 1954, J CHEM SOC, P1750, DOI 10.1039/jr9540001750; Frelon S, 2000, CHEM RES TOXICOL, V13, P1002, DOI 10.1021/tx000085h; GOULD JP, 1984, WATER RES, V18, P991, DOI 10.1016/0043-1354(84)90250-1; Guengerich FP, 1999, CHEM RES TOXICOL, V12, P906, DOI 10.1021/tx990094u; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; HIGUCHI T, 1969, J CHEM SOC B, P626, DOI 10.1039/j29690000626; HUMPHREYS WG, 1992, P NATL ACAD SCI USA, V89, P8278, DOI 10.1073/pnas.89.17.8278; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1986, IARC MON EV CARC RIS, V38; IARC Working group on the Evaluation of Carcinogenic Risks to Humans, 1993, IARC MON EV CARC RIS, V56; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KHAN AU, 1994, P NATL ACAD SCI USA, V91, P12362, DOI 10.1073/pnas.91.26.12362; Koethe SM, 2000, AM J PATHOL, V157, P1735, DOI 10.1016/S0002-9440(10)64810-9; KOPPENOL WH, 1994, FEBS LETT, V347, P5, DOI 10.1016/0014-5793(94)00494-3; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; London SJ, 1997, CANCER RES, V57, P5001; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; Niles JC, 1999, P NATL ACAD SCI USA, V96, P11729, DOI 10.1073/pnas.96.21.11729; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; OHSHIMA H, 2000, FREE RADICALS CHEM B, P92; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V357, P265, DOI 10.1006/abbi.1998.0822; Ravanat JL, 2000, ARCH BIOCHEM BIOPHYS, V374, P118, DOI 10.1006/abbi.1999.1610; RYU EK, 1981, J ORG CHEM, V46, P2819, DOI 10.1021/jo00326a053; Saran M, 1999, FREE RADICAL BIO MED, V26, P482, DOI 10.1016/S0891-5849(98)00187-7; SAYO H, 1990, XENOBIOTICA, V20, P957, DOI 10.3109/00498259009046911; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Tanigawa T, 2000, JPN J CANCER RES, V91, P769, DOI 10.1111/j.1349-7006.2000.tb01011.x; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Vialas C, 1998, J AM CHEM SOC, V120, P11548, DOI 10.1021/ja981597+; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; ZEISEL SH, 1986, CANCER RES, V46, P6136	50	114	115	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40486	40496		10.1074/jbc.M102700200	http://dx.doi.org/10.1074/jbc.M102700200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533049	Green Published, hybrid			2022-12-25	WOS:000171925600018
J	Pioli, PA; Rigby, WFC				Pioli, PA; Rigby, WFC			The von Hhippel-Lindau protein interacts with heteronuclear ribonucleoprotein A2 and regulates its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; ENDOTHELIAL GROWTH-FACTOR; FACTOR MESSENGER-RNA; BIOLOGICALLY-ACTIVE PRODUCT; RENAL-CELL CARCINOMA; GENE-PRODUCT; UBIQUITIN LIGASE; HUMAN TISSUES; LUNG-CANCER; HYPOXIA	The product of the von Hippel-Lindau (VHL) tumor suppressor gene, pVHL, functions as a ubiquitin-protein isopeptide ligase in regulating HIF-1 protein turnover, thus accounting for the increased transcription of hypoxia-inducible genes that accompanies VHL mutations. The increased vascular endothelial growth factor mRNA stability in cells lacking pVHL has been hypothesized to be due to a similar regulation of an RNA-binding protein. We report the expression of the GLUT-1 3'-untranslated region RNA-binding protein, heteronuclear ribonucleoprotein (hnRNP) A2, is specifically increased in pVHL-deficient cell lines. Enhanced hnRNP A2 expression was apparent in all cell fractions, including polysomes, where a similar modest effect on hnRNP L (a GLUT-1 and VEGF 3'-untranslated region-binding protein), was seen. Steady state levels of hnRNP A2 m-RNA were unaffected. Regulation of hnRNP A2 levels correlated with the ability of pVHL to bind elongin C. Proteasome inhibition of cells expressing wild type pVHL selectively increased cytoplasmic hnRNP A2 levels to that seen in pVHL-deficient cells. Finally, an in vivo interaction between pVHL and hnRNP A2 was demonstrated in both the nucleus and the cytoplasm. Collectively, these data indicate that hnRNP A2 expression is regulated by pVHL in a manner that is dependent on elongin C interactions as well as functioning proteasomes.	Dartmouth Coll Sch Med, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Lebanon, NH 03756 USA; Vet Adm Med Ctr, White River Jct, VT 05009 USA	Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rigby, WFC (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA.	william.rigby@dartmouth.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010736, R01AI034928] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34928, T32 AI 10736 3] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; CROSSEY PA, 1994, HUM GENET, V93, P53; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDE DW, 1981, ANN INTERN MED, V95, P71, DOI 10.7326/0003-4819-95-1-71; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hamilton BJ, 1999, BIOCHEM BIOPH RES CO, V261, P646, DOI 10.1006/bbrc.1999.1040; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jackson PK, 1996, CURR BIOL, V6, P1209, DOI 10.1016/S0960-9822(96)00697-5; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McKusick V.A., 1992, MENDELIAN INHERITANC; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; Tsukamoto H, 1998, MOL BRAIN RES, V58, P170, DOI 10.1016/S0169-328X(98)00121-1; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760	67	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40346	40352		10.1074/jbc.M105391200	http://dx.doi.org/10.1074/jbc.M105391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517223	hybrid			2022-12-25	WOS:000171789200112
J	Zhao, XH; Varnai, P; Tuymetova, G; Balla, A; Toth, ZE; Oker-Blom, C; Roder, J; Jeromin, A; Balla, T				Zhao, XH; Varnai, P; Tuymetova, G; Balla, A; Toth, ZE; Oker-Blom, C; Roder, J; Jeromin, A; Balla, T			Interaction of neuronal calcium sensor-1 (NCS-1) with phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and affects membrane trafficking in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE KINASES; FREQUENIN; METABOLISM; PROTEIN; PHOSPHORYLATION; PTDINS(4,5)P-2; SECRETION; HOMOLOG; STT4P; GOLGI	Phosphatidylinositol 4-kinases (PI4K) catalyze the first step in the synthesis of phosphatidylinositol 4,5-bisphosphate, an important lipid regulator of several cellular functions. Here we show that the Ca2+-binding protein, neuronal calcium sensor-1 (NCS-1), can physically associate with the type III P14K beta with functional consequences affecting the kinase. Recombinant P14K beta, but not its glutathione S-transferase-fused form, showed enhanced PI kinase activity when incubated with recombinant NCS-1, but only if the latter was myristoylated. Similarly, in vitro translated NCS-1, but not its myristoylation-defective mutant, was found associated with recombinant- or in vitro translated PI4K beta in PI4K beta -immunoprecipitates. When expressed in COS-7 cells, PI4K beta and NCS-1 formed a complex that could be immunoprecipitated with antibodies against either proteins, and PI 4-kinase activity was present in anti-NCS-1 immunoprecipitates. Expressed NCS-1-YFP showed colocalization with endogenous PI4K beta primarily in the Golgi, but it was also present in the walls of numerous large perinuclear vesicles. Co-expression of a catalytically inactive PI4K beta inhibited the development of this vesicular phenotype. Transfection of PI4K beta and NCS-1 had no effect on basal PIP synthesis in permeabilized COS-7 cells, but it increased the wortmannin-sensitive [P-32]phosphate incorporation into phosphatidylinositol 4-phosphate during Ca2+-induced phospholipase C activation. These results together indicate that NCS-1 is able to interact with PI4K beta also in mammalian cells and may play a role in the regulation of this enzyme in specific cellular compartments affecting vesicular trafficking.	NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Jyvaskyla; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Balla, T (corresponding author), NICHHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.		Toth, Zsuzsanna/U-2579-2019; Roder, John/G-6468-2013	Balla, Andras/0000-0002-6450-2793; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BALLA T, 1988, J BIOL CHEM, V263, P4083; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Burgoyne RD, 2001, BIOCHEM J, V353, P1; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642	32	122	129	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40183	40189		10.1074/jbc.M104048200	http://dx.doi.org/10.1074/jbc.M104048200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11526106	hybrid			2022-12-25	WOS:000171789200090
J	Theiler, RN; Compton, T				Theiler, RN; Compton, T			Characterization of the signal peptide processing and membrane association of human cytomegalovirus glycoprotein O	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; UL115 GENE-PRODUCT; CELL-FUSION; NEUTRALIZING ANTIBODIES; ENDOPLASMIC-RETICULUM; ENVELOPE COMPLEX; PROTEIN; IDENTIFICATION; RECEPTOR; EXPRESSION	Human cytomegalovirus (HCMV) has a structurally complex envelope that contains multiple glycoproteins. These glycoproteins are involved in virus entry, virus maturation, and cell-cell spread of infection. Glycoprotein H (gH), glycoprotein L (gL), and glycoprotein O (gO) associate covalently to form a unique disulfide-bonded tripartite complex. Glycoprotein O was recently discovered, and its basic structure, as well as that of the tripartite complex, remains uncharacterized. Based on hydropathy analysis, we hypothesized that gO could adopt a type II transmembrane orientation. The data presented here, however, reveal that the single hydrophobic domain of gO functions as a cleavable signal peptide that is absent from the mature molecule. Although it lacks a membrane anchor, glycoprotein O is associated with the membranes of HCMV-infected cells. The sophisticated organization of the gH.gL.gO complex reflects the intricate nature of the multicomponent entry and fusion machinery encoded by HCMV.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Compton, T (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	tcompton@facstaff.wisc.edu		Theiler, Regan/0000-0002-3412-3653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM 07215] Funding Source: Medline; PHS HHS [R01 A144203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAGHIAN A, 1993, J VIROL, V67, P2396, DOI 10.1128/JVI.67.4.2396-2401.1993; Baldick CJ, 1996, J VIROL, V70, P6097, DOI 10.1128/JVI.70.9.6097-6105.1996; Baldwin BR, 1996, BIOCHEM BIOPH RES CO, V219, P668, DOI 10.1006/bbrc.1996.0291; Bold S, 1996, J GEN VIROL, V77, P2297, DOI 10.1099/0022-1317-77-9-2297; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; Boyle KA, 1998, J VIROL, V72, P1826, DOI 10.1128/JVI.72.3.1826-1833.1998; Boyle KA, 1999, MOL CELL BIOL, V19, P3607; BRITT WJ, 1984, VIROLOGY, V135, P369, DOI 10.1016/0042-6822(84)90193-4; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; COMPTON T, 1993, J VIROL, V67, P3644, DOI 10.1128/JVI.67.6.3644-3648.1993; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; CRANAGE MP, 1988, J VIROL, V62, P1416, DOI 10.1128/JVI.62.4.1416-1422.1988; CRANAGE MP, 1986, EMBO J, V5, P3057, DOI 10.1002/j.1460-2075.1986.tb04606.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRETCH DR, 1988, J VIROL, V62, P875, DOI 10.1128/JVI.62.3.875-881.1988; GROSE C, 1991, REV INFECT DIS, V13, pS960; HEINEMAN T, 1988, J VIROL, V62, P1101, DOI 10.1128/JVI.62.4.1101-1107.1988; Huber MT, 1999, J VIROL, V73, P3886, DOI 10.1128/JVI.73.5.3886-3892.1999; Huber MT, 1998, J VIROL, V72, P8191, DOI 10.1128/JVI.72.10.8191-8197.1998; Huber MT, 1997, J VIROL, V71, P5391, DOI 10.1128/JVI.71.7.5391-5398.1997; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; JOSEPHS SF, 1991, J VIROL, V65, P5597, DOI 10.1128/JVI.65.10.5597-5604.1991; KAYE JF, 1992, J GEN VIROL, V73, P2693, DOI 10.1099/0022-1317-73-10-2693; KEAY S, 1991, J VIROL, V65, P5124, DOI 10.1128/JVI.65.9.5124-5128.1991; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; LEATHAM MP, 1991, J VIROL, V65, P6144, DOI 10.1128/JVI.65.11.6144-6153.1991; Li L, 1997, J VIROL, V71, P3090, DOI 10.1128/JVI.71.4.3090-3097.1997; Lindquester GJ, 1997, ARCH VIROL, V142, P103, DOI 10.1007/s007050050062; Messerle M, 2000, ADV VIRUS RES, V55, P463, DOI 10.1016/S0065-3527(00)55013-1; Milne RSB, 1998, J GEN VIROL, V79, P855, DOI 10.1099/0022-1317-79-4-855; Mochida S, 2000, NEUROSCI RES, V36, P175, DOI 10.1016/S0168-0102(99)00128-5; Mukai T, 1997, MICROBIOL IMMUNOL, V41, P43, DOI 10.1111/j.1348-0421.1997.tb01171.x; NAVARRO D, 1992, VIROLOGY, V186, P99, DOI 10.1016/0042-6822(92)90064-V; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NOWLIN DM, 1991, J VIROL, V65, P3114, DOI 10.1128/JVI.65.6.3114-3121.1991; PACHL C, 1989, VIROLOGY, V169, P418, DOI 10.1016/0042-6822(89)90167-0; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; ROBERTS SR, 1994, J VIROL, V68, P4538, DOI 10.1128/JVI.68.7.4538-4546.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; Sinzger C, 1996, INTERVIROLOGY, V39, P302, DOI 10.1159/000150502; SPAETE RR, 1993, VIROLOGY, V193, P853, DOI 10.1006/viro.1993.1194; SPAETE RR, 1994, J GEN VIROL, V75, P3287, DOI 10.1099/0022-1317-75-12-3287; Turner A, 1998, J VIROL, V72, P873, DOI 10.1128/JVI.72.1.873-875.1998; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; WILSONRAWLS J, 1993, VIROLOGY, V195, P6, DOI 10.1006/viro.1993.1341; YASWEN LR, 1993, VIROLOGY, V195, P387, DOI 10.1006/viro.1993.1388	49	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39226	39231		10.1074/jbc.M106300200	http://dx.doi.org/10.1074/jbc.M106300200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504733	hybrid			2022-12-25	WOS:000171673200118
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; PREDICTED TRANSMEMBRANE DOMAIN; HIV-1 PROTEASE INHIBITORS; BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; LABELING SITES	The human multidrug resistance P-glycoprotein (P-gp) interacts with a broad range of compounds with diverse structures and sizes. There is considerable evidence indicating that residues in transmembrane segments 4-6 and 10-12 form the drug-binding site. We attempted to measure the size of the drug-binding site by using thiol-specific methanethiosulfonate (MTS) cross-linkers containing spacer arms of 2 to 17 atoms. The majority of these cross-linkers were also substrates of P-gp, because they stimulated ATPase activity (2.5- to 10.1-fold). 36 P-gp mutants with pairs of cysteine residues introduced into transmembrane segments 4-6 and 10-12 were analyzed after reaction with 0.2 mm MTS cross-linker at 4 degreesC. The cross-linked product migrated with lower mobility than native P-gp in SDS gels. 13 P-gp mutants were cross-linked by MTS cross-linkers with spacer arms of 9-25 Angstrom Vinblastine and cyclosporin A inhibited crosslinking. The emerging picture from these results and other studies is that the drug-binding domain is large enough to accommodate compounds of different sizes and that the drug-binding domain is "funnel" shaped, narrow at the cytoplasmic side, at least 9-25 Angstrom in the middle, and wider still at the extracellular surface.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; Institute for Work & Health; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [R01 CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bass RB, 1999, STRUCT FOLD DES, V7, P829, DOI 10.1016/S0969-2126(99)80106-3; Bau R, 2000, J CHEM SOC PERK T 1, P2079, DOI 10.1039/b001855o; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CHAN HS, 1996, EUR J CANCER, V6, P1051; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Jegorov A, 2000, COLLECT CZECH CHEM C, V65, P1317, DOI 10.1135/cccc20001317; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Walmsley AR, 2001, J BIOL CHEM, V276, P6378, DOI 10.1074/jbc.M008105200; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	57	172	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36877	36880		10.1074/jbc.C100467200	http://dx.doi.org/10.1074/jbc.C100467200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11518701	hybrid			2022-12-25	WOS:000171375700005
J	Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM				Jia, L; Patwari, Y; Srinivasula, SM; Newland, AC; Fernandes-Alnemri, T; Alnemri, ES; Kelsey, SM			Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bax expression and translocation; caspases; chemotherapy; etoposide; leukaemia	CYTOCHROME-C; BCR-ABL; DEPENDENT APOPTOSIS; CASPASE ACTIVATION; BCL-2; P53; RELEASE; MITOCHONDRIA; INDUCTION; RESISTANT	Bax translocation from cytosol to mitochondria is believed to be a crucial step for triggering cytochrome c release from mitochondria. However, it is unclear whether Bax translocation is associated with Bax induction by DNA damaging agents. The induction of Bax in response to DNA damaging agents has been considered to be linked with p53. In this study, we used the p53 negative human chronic myeloid leukaemia K562 cell line. Bax up-regulation occurred at the whole cell level after DNA damage induced by etoposide. However, after incubation with etoposide, Bax failed to translocate to mitochondria and as a result, the apoptotic process was blocked. A Bax stable transfectant, the K/Bax cell line, expressed more Bax protein in the cytosol, mitochondria and nuclei. This Bax overexpression induced cytochrome c release, a reduction of cytochrome c oxidase activity and mitochondrial membrane potential (Delta Psim). However, Bax-induced apoptosis was blocked downstream of mitochondria in K562 cells. The increased levels of mitochondrial Bax sensitized cells to etoposide-induced activation of caspases-2, -3 and -9 and apoptosis. However, after transient transfection with the Apaf-1 gene, K/Bax cells were sensitized to etoposide-induced caspase activation and apoptosis to a larger extent compared with Bax or Apaf-1 transfection alone. We therefore conclude that two mechanisms contribute to the resistance of K562 cells to etoposide-induced apoptosis; firstly failure of Bax targeting to mitochondria and, secondly, deficiency of Apaf-1. Uncoupling of Bax translocation from Bax induction can occur in response to etoposide-induced DNA damage.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, London E1 2AD, England; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol, Turner St, London E1 2AD, England.	L.Jia@mds.qmw.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; Jia L, 1997, BRIT J HAEMATOL, V98, P686, DOI 10.1046/j.1365-2141.1997.2683085.x; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; KANTER PM, 1982, MOL PHARMACOL, V22, P145; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MIYASHITA T, 1995, CELL, V80, P293; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PROKOCIMER M, 1986, BLOOD, V68, P113; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	69	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4817	4826		10.1038/sj.onc.1204628	http://dx.doi.org/10.1038/sj.onc.1204628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521193				2022-12-25	WOS:000170271800006
J	Avis, I; Hong, SH; Martinez, A; Moody, T; Choi, YH; Trepel, J; Das, R; Jett, M; Mulshine, JL				Avis, I; Hong, SH; Martinez, A; Moody, T; Choi, YH; Trepel, J; Das, R; Jett, M; Mulshine, JL			Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions	FASEB JOURNAL			English	Article						breast cancer; leukotrienes; 5-lipoxygenase pathway; peroxisome proliferator-activated receptor; apoptosis	PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN-KINASE-C; IN-VITRO GROWTH; ARACHIDONIC-ACID; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; RETINOIC ACID; GAMMA; LIGANDS; FLAP	Many arachidonic acid metabolites function in growth signaling for epithelial cells, and we previously reported the expression of the major arachidonic acid enzymes in human breast cancer cell lines. To evaluate the role of the 5-lipoxygenase (5-LO) pathway on breast cancer growth regulation, we exposed cells to insulinlike growth factor-1 or transferrin, which increased the levels of the 5-LO metabolite, 5(S)-hydrooxyeicosa-6E,8C,11Z,14Z-tetraenoic acid (5-HETE), by radioimmunoassay and high-performance liquid chromatography. Addition of 5-HETE to breast cancer cells resulted in growth stimulation, whereas selective biochemical inhibitors of 5-LO reduced the levels of 5-HETE and related metabolites. Application of 5-LO or 5-LO activating protein-directed inhibitors, but not a cyclooxygenase inhibitor, reduced growth, increased apoptosis, down-regulated bcl-2, up-regulated bax, and increased G1 arrest. Exposure of breast cancer cells to a 5-LO inhibitor up-regulated peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma expression, and these same cells were growth inhibited when exposed to relevant PPAR agonists. These results suggest that disruption of the 5-LO signaling pathway mediates growth arrest and apoptosis in breast cancer cells. Additional experiments suggest that this involves the interplay of several factors, including the loss of growth stimulation by 5-LO products, the induction of PPAR gamma, and the potential activation of PPAR gamma by interactions with shunted endoperoxides.	NCI, Dept Cell & Canc Biol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Pathol, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Mulshine, JL (corresponding author), NCI, Intervent Sect, CCB,MB, DCS,NIH,Clin Ctr, B10,12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.	mulshinj@mail.nih.gov	Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044; Mulshine, James/0000-0002-4648-9177				Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Battu S, 1998, FEBS LETT, V437, P49, DOI 10.1016/S0014-5793(98)01196-X; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; BOYLE T, 1994, ANAL BIOCHEM, V216, P373, DOI 10.1006/abio.1994.1055; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; Chang TH, 2000, CANCER RES, V60, P1129; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; CULLEN KJ, 1990, CANCER RES, V50, P48; Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; EARASHI M, 1995, ONCOLOGY-BASEL, V52, P150; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FORDHUTCHINSON AW, 1994, CANCER METAST REV, V13, P257, DOI 10.1007/BF00666096; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gupta N, 1997, CAN J PHYSIOL PHARM, V75, P1212, DOI 10.1139/cjpp-75-10-11-1212; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong SH, 1999, CANCER RES, V59, P2223; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Hussey HJ, 1996, BRIT J CANCER, V74, P683, DOI 10.1038/bjc.1996.422; Inoue H, 2000, J BIOL CHEM, V275, P28028; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Mancini JA, 1998, J BIOL CHEM, V273, P32842, DOI 10.1074/jbc.273.49.32842; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Menck HR, 1997, CA-CANCER J CLIN, V47, P161, DOI 10.3322/canjclin.47.3.161; Miller AM, 1997, J CELL PHYSIOL, V170, P309, DOI 10.1002/(SICI)1097-4652(199703)170:3<309::AID-JCP12>3.3.CO;2-Y; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nakayama K., 1988, CIRP ANN MANUF TECHN, V37, P89, DOI 10.1016/S0007-8506(07)61592-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; ONDREY F, 1989, CANCER RES, V49, P1138; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; PIAZZA GA, 1995, CANCER RES, V55, P3110; Przylipiak A, 1998, GYNECOL OBSTET INVES, V46, P61, DOI 10.1159/000010000; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SHEARMAN MS, 1989, FEBS LETT, V243, P177, DOI 10.1016/0014-5793(89)80125-5; Smirnov SV, 1998, BRIT J PHARMACOL, V124, P572, DOI 10.1038/sj.bjp.0701855; Smith T., 1893, US DEP AGR BUREAU AN, V1; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Tsujii M, 1998, CELL, V94; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; WANG TTY, 1995, CANCER RES, V55, P2487; WEINSTEIN I, 1991, ORIGINS HUMAN CANC C; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu GD, 1998, GASTROENTEROLOGY, V115, P1283, DOI 10.1016/S0016-5085(98)70102-7; YAMAMOTO S, 1992, CANCER CHEMOPREVENTION, P141; YANO T, 1992, CANCER RES, V52, P4545; Yee D, 1991, Cancer Treat Res, V53, P93; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	74	166	174	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2007	+		10.1096/fj.00-0866fje	http://dx.doi.org/10.1096/fj.00-0866fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511519				2022-12-25	WOS:000170318500024
J	Maehara, K; Oh-Hashi, K; Isobe, K				Maehara, K; Oh-Hashi, K; Isobe, K			Early growth responsive-1-dependent manganese superoxide dismutase gene transcription mediated by platelet-derived growth factor	FASEB JOURNAL			English	Article						Mn-SOD; Egr-1; PDGF; MAPK	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FLUID SHEAR-STRESS; AGE-1 PI3 KINASE; MEK-ERK PATHWAY; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; FACTOR-ALPHA; LIFE-SPAN; ENCODING GENE	Manganese superoxide dismutase (Mn-SOD) plays a major role in protecting mitochondria from oxidative damage. Overexpression of Mn-SOD maintains cell survival under conditions that lead to apoptotic death. In addition to the antioxidative enzyme, platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation by activating survival signaling pathways in various cells. Here we show that PDGF induced the expression of the Mn-SOD gene in NIH3T3 cells, and its induction was associated with early growth response-1 (Egr-1), a transcription factor. An electrophoretic mobility shift assay demonstrated that Egr-1 bound to the proximal promoter of the Mn-SOD gene in response to PDGF. The proximal promoter region of Mn-SOD was shown to be transcriptionally responsive to both basal and PDGF stimulation by transfection studies. Forced expression of Egr-1 in the cells activated Mn-SOD transcription in a dose-dependent manner. The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor. These findings indicate that the induction of Mn-SOD is part of the anti-apoptotic properties mediated by PDGF.	Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan		Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo,Morioka Cho, Aichi 4748522, Japan.	kenisobe@nils.go.jp	isobe, ken-ichi/A-6685-2011	isobe, ken-ichi/0000-0002-8150-2496				Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; JONES S, 1997, WORKING PAPERS LIT, V1, P17; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Li JJ, 1997, CANCER RES, V57, P1991; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARK J, 1996, MED IMAGE ANAL J, V1, P1; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1990, EXP GERONTOL, V25, P499, DOI 10.1016/0531-5565(90)90017-V; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					2025	+		10.1096/fj.00-0909fje	http://dx.doi.org/10.1096/fj.00-0909fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511524				2022-12-25	WOS:000170318500021
J	Klingler-Hoffmann, M; Fodero-Tavoletti, MT; Mishima, K; Narita, Y; Cavenee, WK; Furnari, FB; Huang, HJS; Tiganis, T				Klingler-Hoffmann, M; Fodero-Tavoletti, MT; Mishima, K; Narita, Y; Cavenee, WK; Furnari, FB; Huang, HJS; Tiganis, T			The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS ENHANCED TUMORIGENICITY; PHOSPHOINOSITIDE 3-KINASE; EGF RECEPTOR; GLIOMA-CELLS; ACTIVATION; KINASE; EGFRVIII; VARIANT; COMMON; RAS	Glioblastoma multiforme (GBM) is the most aggressive type of glioma and GBMs frequently contain amplifications or mutations of the EGFR gene. The most common mutation results in a truncated receptor tyrosine kinase known as Delta EGFR that signals constitutively and promotes GBM growth. Here, we report that the 45-kDa variant of the protein tyrosine phosphatase TCPTP (TC45) can recognize Delta EGFR as a cellular substrate. TC45 dephosphorylated Delta EGFR in U87MG glioblastoma cells and inhibited mitogen-activated protein kinase ERK2 and phosphatidylinositol 3-kinase signaling. In contrast, the substrate-trapping TC45-D182A mutant, which is capable of forming stable complexes with TC45 substrates, suppressed the activation of ERK2 but not phosphatidylinositol 3-kinase. TC45 inhibited the proliferation and anchorage-independent growth of Delta EGFR cells but TC45-D182A only inhibited cellular proliferation. Notably, neither TC45 nor TC45-D182A inhibited the proliferation of U87MG cells that did not express Delta EGFR. Delta EGFR activity was necessary for the activation of ERK2, and pharmacological inhibition of ERK2 inhibited the proliferation of Delta EGFR-expressing U87MG cells. Expression of either TC45 or TC45-D182A also suppressed the growth of Delta EGFR-expressing U87MG cells in vivo and prolonged the survival of mice implanted intracerebrally with these tumor cells. These results indicate that TC45 can inhibit the Delta EGFR-mediated activation of ERK2 and suppress the tumorigenicity of Delta EGFR-expressing glioblastoma cells in vivo.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Monash University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Tiganis, T (corresponding author), Monash Univ, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3800, Australia.		Tiganis, Tony/AAV-3495-2020; Klingler-Hoffmann, Manuela/D-1934-2018	Tiganis, Tony/0000-0002-8065-9942; Klingler-Hoffmann, Manuela/0000-0003-2165-7813; Furnari, Frank/0000-0003-1909-4361				Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Han YC, 1996, CANCER RES, V56, P3859; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; Lee SH, 2000, INT J MOL MED, V6, P559; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1997, CANCER RES, V57, P4130	31	58	60	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46313	46318		10.1074/jbc.M106571200	http://dx.doi.org/10.1074/jbc.M106571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11514572	hybrid			2022-12-25	WOS:000172573100112
J	Zhou, ZM; Ribeiro, AA; Lin, SH; Cotter, RJ; Miller, SI; Raetz, CRH				Zhou, ZM; Ribeiro, AA; Lin, SH; Cotter, RJ; Miller, SI; Raetz, CRH			Lipid A modifications in polymyxin-resistant Salmonella typhimurium - PMRA-dependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE RESISTANCE; ACID-DEFICIENT MUTANT; ESCHERICHIA-COLI; PHOSPHATE GROUPS; A PRECURSORS; PHOP-PHOQ; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; ENDOTOXINS; VIRULENCE	Lipid A of Salmonella typhimurium can be resolved into multiple molecular species. Many of these substances are more polar than the predominant hexa-acylated lipid A 1,4'-bisphosphate of Escherichia coli K-12. By using new isolation methods, we have purified six lipid A subtypes (St1 to St6) from wild type S. typhimurium. We demonstrate that these lipid A variants are covalently modified with one or two 4-amino-4-deoxy-L-arabinose (L-Ara4N) moieties. Each lipid A species with a defined set of polar modifications can be further derivatized with a palmitoyl moiety and/or a 2-hydroxymyristoyl residue in place of the secondary myristoyl chain at position 3'. The unexpected finding that St5 and St6 contain two L-Ara4N residues accounts for the anomalous structures of lipid A precursors seen in S. typhimurium mutants defective in 3-deoxy-D-manno-octulosonic, acid biosynthesis in which only the 1-phosphate group is modified with the L-Ara4N moiety (Strain, S. M., Armitage, I. M., Anderson, L., Takayama, K., Quershi, N., and Raetz, C. R. H. (1985) J. Biol. Chem. 260, 16089-16098). Phosphoethanolamine (pEtN)-modified lipid A species are much less abundant than L-Ara4N containing forms in wild type S. typhimurium grown in broth but accumulate to high levels when L-Ara4N synthesis is blocked in pmrA(C)pmrE(-) and pmrA(C)pmrF(-) mutants. Purification and analysis of selected compounds demonstrate that one or two pEtN moieties may be present. Our findings show that S. typhimurium contains versatile enzymes capable of modifying both the 1- and 4'-phosphates of lipid A with L-Ara4N and/or pEtN groups. PmrA null mutants of S. typhimurium produce lipid A species without any pEtN or L-Ara4N substituents. However, PmrA is not needed for the incorporation of 2-hydroxymyristate or palmitate.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Duke University; Duke University; Duke University; Johns Hopkins University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM054882] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30479] Funding Source: Medline; NIGMS NIH HHS [GM54882, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BRYN K, 1978, EUR J BIOCHEM, V86, P311, DOI 10.1111/j.1432-1033.1978.tb12312.x; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Miller J.H., 1972, EXPT MOL GENETICS; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MUHLRADT PF, 1977, EUR J BIOCHEM, V81, P193, DOI 10.1111/j.1432-1033.1977.tb11941.x; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; QURESHI N, 1985, J BIOL CHEM, V260, P5271; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	38	177	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43111	43121		10.1074/jbc.M106960200	http://dx.doi.org/10.1074/jbc.M106960200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11535603	hybrid			2022-12-25	WOS:000172169300064
J	Kimura, T; Tani, S; Matsumoto, Y; Takeda, T				Kimura, T; Tani, S; Matsumoto, Y; Takeda, T			Serum amyloid P component is the shiga toxin 2-neutralizing factor in human blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI O157-H7; HEMOLYTIC-UREMIC SYNDROME; VERO TOXIN; BINDING; PROTEIN; INFECTIONS; VT2; PURIFICATION; ASSOCIATION; ANTIBODIES	It has been suggested that some factor present in human plasma binds to Shiga toxin 2 (Stx2) and neutralizes it in vitro (Bitzan, M., Klemt, M., Steffens, R., and Muller-Wiefel, D. E. (1993) Infection 21, 140-145). This factor does not exist in other species (Caprioli, A., Luzzi, I., Seganti, L., Marchetti, M., Karmali, M., Clarke, I., and Boyd, B. (1994) Recent Ada. VTEC Infect. 353-356). Because analysis of this factor is important to understanding the pathology induced by Shiga toxin-producing Escherichia coli, we purified this factor from human plasma and identified it. Purification was carried out by serially subjecting human plasma to Con A-Sepharose, DEAF-Sepharose, hydroxyapatite, and gel-filtration high performance liquid chromatography (HPLC), using Stx2-neutralizing activity as the indicator. The gel-filtration HPLC fraction yielded a single band on SDS-polyacrylamide gel electrophoresis. Twenty N-terminal amino acid residues of this fraction were analyzed and found to correspond perfectly to human serum amyloid P component (HuSAP). Because commercially available HuSAP also showed Stx2 binding and neutralizing activity, we identified this factor as HuSAP.	Teijin Ltd, Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan; Teijin Ltd, Pharmaceut Dev Dept 1, Chiyoda Ku, Tokyo 1008585, Japan; Natl Childrens Med Res Ctr, Dept Infect Dis Res, Setagaya Ku, Tokyo 1548509, Japan	Teijin Limited; Teijin Limited; National Center for Child Health & Development - Japan	Kimura, T (corresponding author), Teijin Ltd, Teijin Inst Biomed Res, 4-3-2 Asahigaoka, Hino, Tokyo 1918512, Japan.	t.kimura@teijin.co.jp						ASHKENAZI S, 1988, J PEDIATR-US, V113, P1008, DOI 10.1016/S0022-3476(88)80572-9; Bell BP, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e12; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; BITZAN M, 1993, INFECTION, V21, P140, DOI 10.1007/BF01710530; Boerlin P, 1999, J CLIN MICROBIOL, V37, P497, DOI 10.1128/JCM.37.3.497-503.1999; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CAPRIOLI A, 1992, J INFECT DIS, V166, P154, DOI 10.1093/infdis/166.1.154; CAPRIOLI A, 1994, INT CONGR SER, V1072, P353; CORIA F, 1988, LAB INVEST, V58, P454; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; KURAZONO H, 1987, FEMS MICROBIOL LETT, V44, P23, DOI 10.1016/0378-1097(87)90193-5; Kurioka T, 1998, INFECT IMMUN, V66, P1726, DOI 10.1128/IAI.66.4.1726-1734.1998; LI XA, 1994, BBA-GEN SUBJECTS, V1201, P143, DOI 10.1016/0304-4165(94)90034-5; LINDGREN SW, 1993, INFECT IMMUN, V61, P3832, DOI 10.1128/IAI.61.9.3832-3842.1993; Melton-Chelsa A.R., 1998, ESCHERICHIA COLI O15, P121; Morooka T, 1996, ACTA PAEDIATR JAPON, V38, P294; NODA M, 1987, MICROB PATHOGENESIS, V2, P339, DOI 10.1016/0882-4010(87)90076-3; OSTROFF SM, 1989, J INFECT DIS, V160, P994, DOI 10.1093/infdis/160.6.994; PEPYS MB, 1982, ANN NY ACAD SCI, V389, P286, DOI 10.1111/j.1749-6632.1982.tb22144.x; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; Shimizu H, 1998, BIOCHEMISTRY-US, V37, P11078, DOI 10.1021/bi980946+; SKINNER M, 1988, METHOD ENZYMOL, V163, P523; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990; YUTSUDO T, 1987, MICROB PATHOGENESIS, V3, P21, DOI 10.1016/0882-4010(87)90034-9; YUTSUDO T, 1987, FEMS MICROBIOL LETT, V48, P273, DOI 10.1016/0378-1097(87)90175-3; Zahedi K, 1996, J BIOL CHEM, V271, P14897, DOI 10.1074/jbc.271.25.14897; Zahedi K, 1997, J BIOL CHEM, V272, P2143	36	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41576	41579		10.1074/jbc.M107819200	http://dx.doi.org/10.1074/jbc.M107819200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11533067	hybrid			2022-12-25	WOS:000172450400007
J	Andersson, J; Bodevin, S; Westman, M; Sahlin, M; Sjoberg, BM				Andersson, J; Bodevin, S; Westman, M; Sahlin, M; Sjoberg, BM			Two active site asparagines are essential for the reaction mechanism of the class III anaerobic ribonucleotide reductase from bacteriophage T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; THIOREDOXIN-LIKE ACTIVITY; ESCHERICHIA-COLI; PROTEIN R1; DIPHOSPHATE REDUCTASE; ALLOSTERIC REGULATION; PHENOTYPIC SELECTION; RADICAL INTERMEDIATE; CATALYTIC MECHANISM; CYSTEINE RESIDUES	Class III ribonucleotide reductase is an anaerobic enzyme that uses a glycyl radical to catalyze the reduction of ribonucleotides to deoxyribonucleotides and formate as ultimate reductant. The reaction mechanism of class III ribonucleotide reductases requires two cysteines within the active site, Cys-79 and Cys-290 in bacteriophage T4 NrdD numbering. Cys-290 is believed to form a transient thiyl radical that initiates the reaction with substrate and Cys-79 to take part as a transient thiyl radical in later steps of the reductive reaction. The recently solved three-dimensional structure of class III ribonucleotide reductase (RNR) from bacteriophage T4 shows that two highly conserved asparagines, Asn-78 and Asn-311, are positioned close to the essential Cys-79. We have investigated the function of Asn-78 and Asn-311 by site-directed mutagenesis and measured enzyme activity and glycyl radical formation in five single (N78(A/C/D) and N311(A/C)) and one double (N78A/N311A) mutant proteins. Our results suggest that both asparagines are important for the catalytic mechanism of class III RNR and that one asparagine can partially compensate for the lack of the other functional group in the single Asn --> Ala mutant proteins. A plausible role for these two asparagines could be in positioning formate in the active site to orient it toward the proposed thiyl radical of Cys-79. This would also control the highly reactive carbon dioxide radical anion form of formate within the active site before it is released as carbon dioxide. A detailed reaction scheme including the function of the two asparagines and two formate molecules is proposed for class III RNRs.	Univ Stockholm, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Univ Stockholm, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	bitte@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; Andersson J, 2000, J BIOL CHEM, V275, P19443, DOI 10.1074/jbc.M001490200; Andersson J, 2000, J BIOL CHEM, V275, P19449, DOI 10.1074/jbc.M001278200; ANDERSSON J, 2000, THESIS STOCKHOLM U S; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Broderick JB, 2000, BIOCHEM BIOPH RES CO, V269, P451, DOI 10.1006/bbrc.2000.2313; Cho KB, 2001, J PHYS CHEM B, V105, P6445, DOI 10.1021/jp0107614; Eklund H, 1999, STRUCT FOLD DES, V7, pR257, DOI 10.1016/S0969-2126(00)80019-2; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; FinerMoore JS, 1996, BIOCHEMISTRY-US, V35, P5125, DOI 10.1021/bi952751x; FREY M, 1994, J BIOL CHEM, V269, P12432; Gray TE, 1996, BIOCHEMISTRY-US, V35, P15640, DOI 10.1021/bi961942c; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Himo F, 1998, J AM CHEM SOC, V120, P11449, DOI 10.1021/ja9820947; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Hulsmeyer M, 1998, PROTEIN SCI, V7, P1286; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; Leuthner B, 1998, MOL MICROBIOL, V28, P615, DOI 10.1046/j.1365-2958.1998.00826.x; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Sahlin M, 2000, Subcell Biochem, V35, P405; Schiott B, 1998, J AM CHEM SOC, V120, P7192, DOI 10.1021/ja9807338; Selmer T, 2001, EUR J BIOCHEM, V268, P1363, DOI 10.1046/j.1432-1327.2001.02001.x; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Torrents E, 2000, J BIOL CHEM, V275, P2463, DOI 10.1074/jbc.275.4.2463; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uhlin U, 1996, J MOL BIOL, V262, P358, DOI 10.1006/jmbi.1996.0519; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	48	11	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40457	40463		10.1074/jbc.M106863200	http://dx.doi.org/10.1074/jbc.M106863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526118	hybrid			2022-12-25	WOS:000171925600015
J	Hou, ZJ; Narindrasorasak, S; Bhushan, B; Sarkar, B; Mitra, B				Hou, ZJ; Narindrasorasak, S; Bhushan, B; Sarkar, B; Mitra, B			Functional analysis of chimeric proteins of the Wilson Cu(I)-ATPase (ATP7B) and ZntA, a Pb(II)/Zn(II)/Cd(II)-ATPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; COPPER-TRANSPORTING ATPASE; N-TERMINAL DOMAIN; MENKES DISEASE; CANDIDATE GENE; SACCHAROMYCES-CEREVISIAE; ENCODES; EXPRESSION; ASSAY	ATP7B, the Wilson disease-associated Cu(I)-transporter, and ZntA from Escherichia coli are soft metal P1-type ATPases with mutually exclusive metal ion substrates. P1-type ATPases have a distinctive amino-terminal domain containing the conserved metal-binding motif GXXCXXC. ZntA has one copy of this motif while ATP7B has six copies. The effect of interchanging the amino-terminal domains of ATP7B and ZntA was investigated. Chimeric proteins were constructed in which either the entire amino-terminal domain of ATP7B or only its sixth metal-binding motif replaced the aminoterminal domain of ZntA. Both chimeras conferred resistance to lead, zinc, and cadmium salts but not to copper salts. The purified chimeras displayed activity with lead, cadmium, zinc, and mercury, which are substrates of ZntA. There was no activity with copper or silver, which are substrates of ATP7B. The chimeras were 2-3-fold less active than ZntA. Thus, the amino-terminal domain of P1-type ATPases cannot alter the metal specificity determined by the transmembrane segment. Also, these results suggest that this domain interacts with the rest of the transporter in a metal ion-specific manner; the amino-terminal domain of ATP7B cannot replace that of ZntA in restoring full catalytic activity.	Hosp Sick Children, Dept Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Wayne State University	Sarkar, B (corresponding author), Hosp Sick Children, Dept Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-61689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Cogan EB, 1999, ANAL BIOCHEM, V271, P29, DOI 10.1006/abio.1999.4100; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Morrison J F, 1979, Methods Enzymol, V63, P257; ODERMATT A, 1995, J BIOL CHEM, V270, P4349, DOI 10.1074/jbc.270.9.4349; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; SIGEL H, 1987, EUR J BIOCHEM, V165, P65, DOI 10.1111/j.1432-1033.1987.tb11194.x; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7	33	41	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40858	40863		10.1074/jbc.M107455200	http://dx.doi.org/10.1074/jbc.M107455200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527979	hybrid			2022-12-25	WOS:000171925600065
J	de Menezes, SL; Augusto, O				de Menezes, SL; Augusto, O			EPR detection of glutathionyl and protein-tyrosyl radicals during the interaction of peroxynitrite with macrophages (J774)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; CARBON-DIOXIDE; PHOSPHOLIPID-MEMBRANES; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DECOMPOSITION; CELLS; SUPEROXIDE; ACID; NITRATION	Peroxynitrite is one of the biological oxidants whose addition to cells has been shown to either activate signaling pathways or lead to cell injury, depending on cell type and oxidant concentration. The intermediacy of free radicals in these processes has been directly demonstrated only during the interaction of peroxynitrite with erythrocytes, a particular cell type, due to its high hemoglobin content. Here, we demonstrate that the addition of peroxynitrite to a macrophage cell line (J774) led to the production of glutathionyl and protein-tyrosyl radicals. The glutathionyl radical was characterized by EPR spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide. Protein-tyrosyl radical formation was suggested by direct EPR spectroscopy and confirmed by EPR spin-trapping experiments with 3,5-dibromo-4-nitrosobenzenesulfonic acid and Western blot analysis of nitrated proteins in treated macrophages. Time dependence studies of free radical formation indicate that intracellular glutathione and unidentified proteins are the initial peroxynitrite targets in macrophages and that their derived radicals trigger radical chain reactions. The results are likely to be relevant to the understanding of the bioregulatory and biodamaging effects of peroxynitrite.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil	Universidade de Sao Paulo	Augusto, O (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.		Augusto, Ohara/D-3839-2012	Augusto, Ohara/0000-0002-7220-4286				Akerboom T P, 1981, Methods Enzymol, V77, P373; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Castro LA, 1998, ARCH BIOCHEM BIOPHYS, V359, P215, DOI 10.1006/abbi.1998.0898; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; Gerasimov OV, 1999, INORG CHEM, V38, P4317, DOI 10.1021/ic990384y; Giorgio S, 1998, INFECT IMMUN, V66, P807, DOI 10.1128/IAI.66.2.807-814.1998; Goldstein S, 1999, J AM CHEM SOC, V121, P2444, DOI 10.1021/ja9822254; Gow AJ, 2000, AM J PHYSIOL-CELL PH, V278, pC1099, DOI 10.1152/ajpcell.2000.278.6.C1099; HIRAMOTO K, 1994, FREE RADICAL RES, V21, P341, DOI 10.3109/10715769409056586; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; Hurst JK, 1999, ACCOUNTS CHEM RES, V32, P520, DOI 10.1021/ar9703488; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; KALYANARAMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1126, P309, DOI 10.1016/0005-2760(92)90245-Q; Khairutdinov RF, 2000, BIOCHEMISTRY-US, V39, P14238, DOI 10.1021/bi001270x; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOHNO M, 1991, B CHEM SOC JPN, V64, P1447, DOI 10.1246/bcsj.64.1447; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; Lee C, 2000, J BIOL CHEM, V275, P38965, DOI 10.1074/jbc.M006341200; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; LI ASW, 1988, J MAGN RESON, V79, P140, DOI 10.1016/0022-2364(88)90329-0; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; Minetti M, 1999, BIOCHEMISTRY-US, V38, P2078, DOI 10.1021/bi982311g; Nakao LS, 1999, CHEM RES TOXICOL, V12, P1010, DOI 10.1021/tx990055i; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; RADI R, 1991, J BIOL CHEM, V266, P4244; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; Romao PRT, 1999, PARASITOLOGY, V118, P559, DOI 10.1017/S0031182099004278; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Santos CXC, 2000, ARCH BIOCHEM BIOPHYS, V377, P146, DOI 10.1006/abbi.2000.1751; Soszynski M, 1996, BBA-GEN SUBJECTS, V1291, P107, DOI 10.1016/0304-4165(96)00052-9; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; VANDERMEER RA, 1988, FEBS LETT, V235, P194, DOI 10.1016/0014-5793(88)81261-4; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zouki C, 2001, FASEB J, V15, P25; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	54	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39879	39884		10.1074/jbc.M104012200	http://dx.doi.org/10.1074/jbc.M104012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518708	hybrid			2022-12-25	WOS:000171789200051
J	Karasarides, M; Anand-Apte, B; Wolfman, A				Karasarides, M; Anand-Apte, B; Wolfman, A			A direct interaction between oncogenic Ha-Ras and phosphatidylinositol 3-kinase is not required for Ha-Ras-dependent transformation of epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; N-RAS; PHOSPHOINOSITIDE 3-KINASE; INCREASING COMPLEXITY; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; FACTOR RECEPTOR; PATHWAY	Cells expressing oncogenic Ras proteins transmit a complex set of signals that ultimately result in constitutive activation of signaling molecules, culminating in unregulated cellular function. Although the role of oncogenic Ras in a variety of cellular responses including transformation, cell survival, differentiation, and migration is well documented, the direct Ras/effector interactions that contribute to the different Ras biological end points have not been as clearly defined. Observations by other groups in which Ras-dependent transformation can be blocked by expression of either dominant negative forms of Phosphatidylinositol (Pl) 3-kinase or PTEN, a 3-phosphoinositide-specific phosphatase, support an essential role for PI 3-kinase and its lipid products in the transformation process. These observations coupled with the in vitro observations that the catalytic subunits of PI 3-kinase, the p110 isoforms, bind directly to Ras-GTP foster the implication that a direct interaction between an oncogenic Ras protein and PI 3-kinase are causal in the oncogenicity of mutant Ras proteins. Using an activated Ha-Ras protein (Y64G/Y71G/F156L) that fails to interact with PI 3-kinase, we demonstrate that oncogenic Ha-Ras does not require a direct interaction with PI 3-kinase to support anchorage-independent growth of IEC-6 epithelial cells. We do find, however, that IEC-6 cells expressing an oncogenic Ha-Ras protein that no longer binds PI 3-kinase are greatly impaired in their ability to migrate toward fibronectin.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland State University; Cleveland Clinic Foundation	Wolfman, A (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	wolfmaa@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062644] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62644] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CHENG YT, 1995, MOL CARCINOGEN, V13, P173, DOI 10.1002/mc.2940130307; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DIBATTISTE D, 1993, ONCOGENE, V8, P637; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HALL A, 1986, J BIOL CHEM, V261, P963; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mangues R, 1998, CANCER RES, V58, P1253; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Zhang QX, 1996, BBA-MOL CELL RES, V1312, P207, DOI 10.1016/0167-4889(96)00025-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	57	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39755	39764		10.1074/jbc.M102401200	http://dx.doi.org/10.1074/jbc.M102401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11514541	hybrid			2022-12-25	WOS:000171789200034
J	Kimberly, WT; Zheng, JB; Guenette, SY; Selkoe, DJ				Kimberly, WT; Zheng, JB; Guenette, SY; Selkoe, DJ			The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a Notch-like manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SECRETASE CLEAVAGE; C-TERMINAL FRAGMENTS; DISINTEGRIN-METALLOPROTEASE; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; GAMMA-SECRETASE; BINDING; RELEASE; NEURONS; GENE	The beta -amyloid precursor protein (APP) is a ubiquitous receptor-like molecule without a known function. However, the recent recognition that APP and Notch undergo highly similar proteolytic processing has suggested a potential signaling function for APP. After ligand binding, Notch is cleaved by the ADAM-17 metalloprotease followed by an intramembrane cleavage mediated by gamma -secretase. The gamma -secretase cut releases the Notch intracellular domain (NICD), which enters the nucleus and modulates transcription. Because APP is processed similarly by ADAM-17 and gamma -secretase, we reasoned that the APP intracellular domain (AICD) has a role analogous to the NICD. We therefore generated a plasmid encoding the AICD sequence and studied the subcellular localization of the expressed protein (C60). Our results demonstrate that the cytoplasmic domain of APP is a highly labile fragment that is stabilized by forming complexes with Fe65 and can then enter the nucleus in neurons and non-neural cells. These findings strongly support the hypothesis that APP signals in the nucleus in a manner analogous to the function of Notch.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Selkoe, DJ (corresponding author), Harvard Inst Med, Ctr Neurol Dis, 730,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NIA NIH HHS [AG 06173] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Murai S, 2000, ENANTIOMER, V5, P197; Perez RG, 1997, J NEUROSCI, V17, P9407; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	33	373	386	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40288	40292		10.1074/jbc.C100447200	http://dx.doi.org/10.1074/jbc.C100447200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11544248	hybrid			2022-12-25	WOS:000171789200104
J	Zhao, XX; Murata, T; Ohno, S; Day, N; Song, J; Nomura, N; Nakahara, T; Yokoyama, KK				Zhao, XX; Murata, T; Ohno, S; Day, N; Song, J; Nomura, N; Nakahara, T; Yokoyama, KK			Protein kinase C alpha plays a critical role in mannosylerythritol lipid-induced differentiation of melanoma B16 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIC-CELLS; RETINOIC ACID; ERYTHROID DIFFERENTIATION; HEMOGLOBIN SYNTHESIS; CELLULAR-REGULATION; DIMETHYL-SULFOXIDE; GROWTH-INHIBITION; POTENT INDUCER; BUTYRIC-ACID; IN-VITRO	Mannosylerythritol lipid (MEL), a novel extracellular glycolipid from yeast, was found to inhibit the proliferation of mouse melanoma B16 cells in a dose-dependent manner and to induce the apoptosis of B16 cells at concentrations higher than 10 mum (Zhao, X., Wakamatsu, Y., Shibahara, M., Nomura, N., Geltinger, C., Nakahara, T., Murata, T., and Yokoyama, K. K. (1999) Cancer Res. 59, 482-486). We show here that exposure of B16 cells to MEL (5 mum) for 2 days resulted in an increase of the levels of differentiation-associated markers of melanoma cells such as melanogenesis and tyrosinase activity, which were accompanied by morphological changes. The MEL-induced differentiation of B16 cells at this concentration was closely associated with arrest of the cell cycle at G, phase, but no significant population of apoptotic cells was identified. Expression of protein kinase C alpha (PKC alpha) was enhanced after exposure of B16 cells to MEL for 48 h. Antisense oligodeoxynucleotides against the mouse gene for PKC alpha prevented MEL-induced melanogenesis in B16 cells. Conversely, the effects of the expression of a constitutively active form of PKCa mimicked the effects of MEL on B16 cells. These data suggest that MEL, a yeast-derived glycolipid, triggers the differentiation of B16 melanoma cells through a signaling pathway that involves PKC alpha.	RIKEN, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3050006, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	RIKEN; University of Tsukuba; Yokohama City University	Yokoyama, KK (corresponding author), RIKEN, Tsukuba Inst, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	kazu@rtc.riken.go.jp	Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Nomura, Nobuhiko/0000-0003-1103-9157				Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; Dean N, 1996, CANCER RES, V56, P3499; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUBERMAN E, 1979, CANCER RES, V39, P2618; Isoda H, 1997, LIPIDS, V32, P263, DOI 10.1007/s11745-997-0033-0; JOHNSTON D, 1992, EXP CELL RES, V201, P91, DOI 10.1016/0014-4827(92)90351-8; KAWAI S, 1995, ANTICANCER RES, V15, P427; Kim DG, 1998, PIGM CELL RES, V11, P143, DOI 10.1111/j.1600-0749.1998.tb00724.x; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KITAMOTO D, 1990, AGR BIOL CHEM TOKYO, V54, P31, DOI 10.1080/00021369.1990.10869918; KOBAYASHI T, 1993, CANCER RES, V53, P2484; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LOTAN R, 1983, CANCER RES, V43, P2868; Mahalingam H, 1996, J CELL PHYSIOL, V168, P549, DOI 10.1002/(SICI)1097-4652(199609)168:3<549::AID-JCP7>3.0.CO;2-P; MARKS PA, 1984, CANCER, V11, P2766; NILES RM, 1987, IN VITRO CELL DEV B, V23, P803, DOI 10.1007/BF02620957; NILES RM, 1978, J NATL CANCER I, V61, P523; NILES RM, 1989, CANCER RES, V49, P4483; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORDENBERG J, 1986, EXP CELL RES, V162, P77, DOI 10.1016/0014-4827(86)90427-1; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; ROSEN JM, 1992, J REHABIL RES DEV, V29, P1, DOI 10.1682/JRRD.1992.04.0001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHER W, 1973, J CELL PHYSIOL, V81, P63, DOI 10.1002/jcp.1040810108; Shibahara M, 2000, CYTOTECHNOLOGY, V33, P247, DOI 10.1023/A:1008155111024; SPREMULLI EN, 1984, J CLIN ONCOL, V2, P227, DOI 10.1200/JCO.1984.2.3.227; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wakamatsu Y, 2001, EUR J BIOCHEM, V268, P374, DOI 10.1046/j.1432-1033.2001.01887.x; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Zhao XX, 1999, CANCER RES, V59, P482; Zhao XX, 2000, CYTOTECHNOLOGY, V33, P123, DOI 10.1023/A:1008129616127	48	53	55	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39903	39910		10.1074/jbc.M010281200	http://dx.doi.org/10.1074/jbc.M010281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546757	hybrid			2022-12-25	WOS:000171789200055
J	Schuetz, EG; Strom, S; Yasuda, K; Lecureur, V; Assem, M; Brimer, C; Lamba, J; Kim, RB; Ramachandran, V; Komoroski, BJ; Venkataramanan, R; Cai, HB; Sinal, CJ; Gonzalez, FJ; Schuetz, JD				Schuetz, EG; Strom, S; Yasuda, K; Lecureur, V; Assem, M; Brimer, C; Lamba, J; Kim, RB; Ramachandran, V; Komoroski, BJ; Venkataramanan, R; Cai, HB; Sinal, CJ; Gonzalez, FJ; Schuetz, JD			Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome p450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; FAMILIAL INTRAHEPATIC CHOLESTASIS; RESISTANCE-ASSOCIATED PROTEIN-3; P-GLYCOPROTEIN; RAT-LIVER; IN-VIVO; URSODEOXYCHOLIC ACID; UP-REGULATION; GENE; EXPRESSION	Sister of P-glycoprotein (SPGP) is the major hepatic bile salt export pump (BSEP). BSEP/SPGP expression varies dramatically among human livers. The potency and hierarchy of bile acids as ligands for the farnesyl/ bile acid receptor (FXR/BAR) paralleled their ability to induce BSEP in human hepatocyte cultures. FXR:RXR heterodimers bound to IR1 elements and enhanced bile acid transcriptional activation of the mouse and human BSEP/SPGP promoters. In FXR/BAR nullizygous mice, which have dramatically reduced BSEP/SPGP levels, hepatic CYP3A11 and CYP2B10 were strongly but unexpectedly induced. Notably, the rank order of bile acids as CYP3A4 inducers and activators of pregnane X receptor/steroid and xenobiotic receptor (PXR/SXR) closely paralleled each other but was markedly different from their hierarchy and potency as inducers of BSEP in human hepatocytes. Moreover, the hepatoprotective bile acid ursodeoxycholic acid, which reverses hydrophobic bile acid hepatotoxicity, activates PXR and efficaciously induces CYP3A4 (a bile-metabolizing enzyme) in primary human hepatocytes thus providing one mechanism for its hepatoprotection. Because serum and urinary bile acids increased in FXR/BAR -/- mice, we evaluated hepatic transporters for compensatory changes that might circumvent the profound decrease in BSEP/SPGP. We found weak MRP3 up-regulation. In contrast, MRP4 was substantially increased in the FXR/ BAR nullizygous mice and was further elevated by cholic acid. Thus, enhanced hepatocellular concentrations of bile acids, due to the down-regulation of BSEP/SPGP-mediated efflux in FXR nullizygous mice, result in an alternate but apparent compensatory up-regulation of CYP3A, CYP2B, and some ABC transporters that is consistent with activation of PXR/SXR by bile acids.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37203 USA; NIH, Lab Med, Bethesda, MD 20892 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University; National Institutes of Health (NIH) - USA	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	John.schuetz@stjude.org	Kim, Richard/D-6971-2011; Cline, Cynthia D/F-7065-2012; Cai, Huaibin/H-3359-2013; Schuetz, John D/N-2692-2018; Schuetz, Erin/N-8087-2018; Strom, Stephen C/A-6501-2008; LECUREUR, Valérie/J-9095-2015	Kim, Richard/0000-0001-8148-1632; Cai, Huaibin/0000-0002-8596-6108; Sinal, Christopher/0000-0001-8301-3349	NCI NIH HHS [P30 CA21745] Funding Source: Medline; NIDDK NIH HHS [DK92310] Funding Source: Medline; NIEHS NIH HHS [ES05780, ES08648, ES058571] Funding Source: Medline; NIGMS NIH HHS [GM60346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK092310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrese M, 2001, HEPATOLOGY, V33, P1551, DOI 10.1053/jhep.2001.0331551; Cancado ELR, 1998, AM J GASTROENTEROL, V93, P1510, DOI 10.1111/j.1572-0241.1998.00472.x; CHILDS S, 1995, CANCER RES, V55, P2029; Donner MG, 2001, HEPATOLOGY, V34, P351, DOI 10.1053/jhep.2001.26213; Funk C, 2001, MOL PHARMACOL, V59, P627, DOI 10.1124/mol.59.3.627; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Gupta S, 2000, HEPATOLOGY, V32, P341, DOI 10.1053/jhep.2000.9605; HEUMAN DM, 1993, GASTROENTEROLOGY, V104, P1865, DOI 10.1016/0016-5085(93)90672-Y; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; HOFMANN AF, 1992, J LIPID RES, V33, P599; HOSTETLER KA, 1987, BIOCHEM J, V245, P27, DOI 10.1042/bj2450027; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; KHANUJA B, 1995, P NATL ACAD SCI USA, V92, P7729, DOI 10.1073/pnas.92.17.7729; Kostrubsky VE, 1999, DRUG METAB DISPOS, V27, P887; Lan LB, 2000, MOL PHARMACOL, V58, P863, DOI 10.1124/mol.58.4.863; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LEUSCHNER U, 1985, DIGEST DIS SCI, V30, P642, DOI 10.1007/BF01308413; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Paolini M, 2000, J INVEST MED, V48, P49; POUPON R, 1981, DIGEST DIS SCI, V26, P284, DOI 10.1007/BF01391647; Pozzetti L, 1999, HEPATOLOGY, V30, P730, DOI 10.1002/hep.510300332; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Schuetz EG, 2000, MOL PHARMACOL, V57, P188; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ EG, 1995, J PHARMACOL EXP THER, V275, P1011; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Stieger B, 2000, GASTROENTEROLOGY, V118, P422, DOI 10.1016/S0016-5085(00)70224-1; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; STROM SC, 1998, ILOTS LANGERHANS HEP, P195; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; ZHANG J, 2001, IN PRESS PHARMACOGEN	47	322	329	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39411	39418		10.1074/jbc.M106340200	http://dx.doi.org/10.1074/jbc.M106340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509573	hybrid			2022-12-25	WOS:000171673200141
J	Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y				Fukuhara, H; Kuramochi, M; Nobukuni, T; Fukami, T; Saino, M; Maruyama, T; Nomura, S; Sekiya, T; Murakami, Y			Isolation of the TSLL1 and TSLL2 genes, members of the tumor suppressor TSLC1 gene family encoding transmembrane proteins	ONCOGENE			English	Article						tumor suppressor gene; TSLC1; TSLL1; TSLL2; glioma; prostate cancer	BINDING INTERFACE; CHROMOSOME 19Q; GLYCOPHORIN-C; HYBRIDIZATION; NEUREXIN; DOMAIN	We have recently identified the TSLC1 gene as a novel tumor suppressor in human non-small cell lung cancers. TSLC1 encodes a membrane glycoprotein with an extracellular domain homologous to those of immunoglobulin superfamily proteins. Truncation of TSLC1 in the cytoplasmic domain in a primary human tumor suggests that this domain is important for tumor suppressor activity. Here, we report the isolation of two TSLC1-like genes, TSLL1 and TSLL2, based on their structural homology with the sequences corresponding to the cytoplasmic domain of TSLC1. Significant similarity was also observed in the extracellular domain as well as in the overall gene structure, indicating that these three genes form a unique subfamily (the TSLC1-gene family) in the immunoglobulin superfamily genes. In contrast to the ubiquitous expression of TSLC1, TSLL1 is expressed exclusively in adult and fetal human brain, while TSLL2 is expressed in several specific tissues including prostate, brain, kidney and some other organs. Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML Inc, R&D Ctr, Kawagoe, Saitama 3501101, Japan	National Cancer Center - Japan; BML, Inc.	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022	Nomura, Sachio/0000-0001-9214-4041				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; DebiecRychter M, 1995, CANCER GENET CYTOGEN, V85, P61, DOI 10.1016/0165-4608(95)00129-8; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Shimura M, 1999, CANCER RES, V59, P2259; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73	17	61	71	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5401	5407		10.1038/sj.onc.1204696	http://dx.doi.org/10.1038/sj.onc.1204696			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536053				2022-12-25	WOS:000170575500016
J	Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG				Rounbehler, RJ; Schneider-Broussard, R; Conti, CJ; Johnson, DG			Myc lacks E2F1's ability to suppress skin carcinogenesis	ONCOGENE			English	Article						Myc; E2F1; apoptosis; cell cycle; carcinogenesis	SQUAMOUS-CELL CARCINOMA; C-MYC; TRANSGENIC MICE; ORNITHINE DECARBOXYLASE; IN-VIVO; INDUCED APOPTOSIS; EXPRESSION; E2F-1; GENE; P53	Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Park Rd 1C, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA42157, CA16672, CA79648] Funding Source: Medline; NIEHS NIH HHS [ES007784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA042157, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIGIOVANNI J, 1994, CARCINOGENESIS, P265; ELSON A, 1995, ONCOGENE, V11, P181; FIELD JK, 1989, ONCOGENE, V4, P1463; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hunt KK, 1997, CANCER RES, V57, P4722; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PENA A, 1993, J BIOL CHEM, V268, P27277; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	41	33	34	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5341	5349		10.1038/sj.onc.1204691	http://dx.doi.org/10.1038/sj.onc.1204691			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536046				2022-12-25	WOS:000170575500009
J	Maslyar, DJ; Aoki, M; Vogt, PK				Maslyar, DJ; Aoki, M; Vogt, PK			The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3	ONCOGENE			English	Article						anchorage-independent growth; apoptosis; BH3 proteins; 14-3-3	BH3 DOMAIN; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; BCL-2; INACTIVATE; INDUCTION; DISPLACES; AKT2; DNA	Phosphorylation of the Bad protein is a key regulatory event in the prevention of apoptosis by survival factors. Phosphorylated Bad binds to the cytosolic 14-3-3 protein and is sequestered from the apoptotic machinery of the mitochondrial membrane. To examine the role of Bad in cell growth and apoptosis in primary cultures, we produced stable Bad transfectants of chicken embryo fibroblasts (CEF). As expected, serum starvation of Bad transfectants promoted apoptosis. However, Bad-transfected CEF maintained in media with a high serum concentration were capable of anchorage-independent growth and grew to a higher saturation density than control CEF transfected with the empty vector. High dilutions of the infectious retroviral vector RCAS expressing Bad led to the formation of multilayered cell foci. The growth-promoting effects of Bad were dependent on the serine 136 phosphorylation site and correlated directly with binding of Bad to 14-3-3. These results suggest that phosphorylated Bad promotes cell growth and in oncogenic transformation may contribute to the neoplastic phenotype of the cell.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC 239, La Jolla, CA USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NATIONAL CANCER INSTITUTE [R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreeff M, 1999, LEUKEMIA, V13, P1881, DOI 10.1038/sj.leu.2401573; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kitada S, 1998, AM J PATHOL, V152, P51; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5087	5092		10.1038/sj.onc.1204662	http://dx.doi.org/10.1038/sj.onc.1204662			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526496				2022-12-25	WOS:000170464000001
J	Song, Y; Cohler, AN; Weinstein, DC				Song, Y; Cohler, AN; Weinstein, DC			Regulation of Laloo by the Xenopus C-terminal Src kinase (Xcsk) during early vertebrate development	ONCOGENE			English	Article						Laloo; Csk; Fyn; Src; Xenopits; mesoderm	MESODERM INDUCTION; TYROSINE KINASES; MAP KINASE; EMBRYOS; EXPRESSION; LAEVIS; FGF; CSK; INHIBITION; XWNT-8	Mesoderm formation in the frog, Xenopus laevis, is dependent on the activity of one or more members of the Src family kinases; the molecular interactions underlying this requirement are not well understood. The C-terminal Src Kinase (Csk) is a potent inhibitor of Src activity, and is required for normal mammalian development; here we report the characterization of Xenopus Csk (Xcsk). Xcsk is widely expressed during early development, physically interacts with the Src kinase Laloo, and inhibits the generation of mesoderm by the Src kinases. Xcsk activity requires a functional kinase domain; furthermore, a kinase-inactive Xcsk mutant potently synergizes with Laloo during early vertebrate development, suggesting a fundamental role for the Src kinase-Csk regulatory circuit during mesoderm induction, in vivo.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Weinstein, DC (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA.			Weinstein, Daniel/0000-0001-7832-9285				BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; Curran KL, 2000, DEV BIOL, V228, P41, DOI 10.1006/dbio.2000.9917; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; STEELE RE, 1990, ONCOGENE, V5, P369; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Weinstein DC, 2001, DEV DYNAM, V220, P163, DOI 10.1002/1097-0177(2000)9999:9999<1::AID-DVDY1098>3.0.CO;2-5; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0	21	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5210	5214		10.1038/sj.onc.1204672	http://dx.doi.org/10.1038/sj.onc.1204672			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526510				2022-12-25	WOS:000170464000015
J	Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J				Yakicier, MC; Legoix, P; Vaury, C; Gressin, L; Tubacher, E; Capron, F; Bayer, J; Degott, C; Balabaud, C; Zucman-rossi, J			Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; loss of heterozygosity; tumor suppressor gene; chromosome 16; homozygous deletion; WWOX/FOR gene	FRAGILE SITE FRA16D; BETA-CATENIN GENE; P53 GENE; MULTIPLE-MYELOMA; BREAST-CANCER; REGION; HETEROZYGOSITY; MUTATIONS; FREQUENT; CELLS	Loss of heterozygosity (LOH) represents the most frequent genetic alteration observed in hepatocellular carcinoma (HCC). Chromosome 16q is of particular interest as it exhibits LOH in 29% of HCC tumors and is frequently lost in breast, prostate, ovarian and gastric carcinomas. We genotyped 157 HCC tumors for 17 microsatellite markers distributed on chromosome 16q and determined a common region of LOH localized between the markers D16S518 and D16S504. By refining the boundaries of two interstitial LOH and two homozygous deletions, the critical region was delimited to 180 kb between D16S3096 and D16S3029. This region is located in intron 8 of the WWOX/FOR gene, but a search for mutations in all coding exons of this gene in 27 HCC tumors and cell lines did not reveal any tumor somatic alterations. Furthermore, by RT-PCR, no abnormal transcripts of this WWOX/FOR gene was detected in nine HCC cell lines. Finally, analysis of the p53 gene mutations with the clinical parameters of all tumors revealed that the two homozygous deletions have occurred in tumors presenting a R249S mutation. Our data revealed a relationship between chromosome 16q homozygous deletions and R249S p53 mutations in tumors where the patient had been exposed to Aflatoxin B1 (P = 0.002). These results are consistent with a role of Aflatoxin B1 in the instability of chromosome 16q at the fragile site FRA16D. However, the nature of the specific gene that is altered during hepato carcino genesis remains to be elucidated.	INSERM, U434, F-75010 Paris, France; Hop Antoine Beclere, Serv Anat Pathol, F-92140 Clamart, France; Hop Beaujon, F-92110 Clichy, France; Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Zucman-rossi, J (corresponding author), INSERM, U434, CEPH 27 Rue Juliette Dodu, F-75010 Paris, France.		zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021	zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334				Autrup H., 1988, IARC SCI PUBL, V89, P63; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Chen TP, 1996, CANCER RES, V56, P5605; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; ECKL PM, 1987, CARCINOGENESIS, V8, P1077, DOI 10.1093/carcin/8.8.1077; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ELZAWAHRI M, 1977, ANN NUTR ALIMENT, V31, P859; FABRY L, 1981, TOXICOL LETT, V7, P245, DOI 10.1016/0378-4274(81)90076-X; *FAO, 1991, FAO PAHO, P3; Feo F, 2000, CRIT REV ONCOGENESIS, V11, P19; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IWABUCHI H, 1995, CANCER RES, V55, P6172; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Latil A, 1997, CANCER RES, V57, P1058; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Miyoshi Y, 1998, CANCER RES, V58, P2524; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; ODA T, 1992, CANCER RES, V52, P6358; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Paige AJW, 2000, CANCER RES, V60, P1690; Piao Z, 1999, BRIT J CANCER, V80, P850, DOI 10.1038/sj.bjc.6690431; Preisler V, 2000, MUTAGENESIS, V15, P91, DOI 10.1093/mutage/15.1.91; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sengstag C, 1996, CANCER RES, V56, P5457; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Wong N, 2000, CLIN CANCER RES, V6, P4000; Zucman-Rossi J, 1996, GENOMICS, V38, P247, DOI 10.1006/geno.1996.0625	41	47	56	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5232	5238		10.1038/sj.onc.1204674	http://dx.doi.org/10.1038/sj.onc.1204674			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526514				2022-12-25	WOS:000170464000019
J	Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M				Soucek, T; Rosner, M; Miloloza, A; Kubista, M; Cheadle, JP; Sampson, JR; Hengstschlager, M			Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression	ONCOGENE			English	Article						tuberous sclerosis; TSC2; tuberin; proliferation; p27	EKER RAT MODEL; CELL-CYCLE; RENAL-CARCINOMA; HAMARTIN; IDENTIFICATION; SUPPRESSION; GAP	The autosomal dominant disease tuberous sclerosis (TSC) is caused by mutations in either TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16p13.3, encoding tuberin. TSC is characterized by hamartomas that occur in many organs of affected patients and these have been considered to likely result from defects in proliferation control. Although the true biochemical functions of the two TSC proteins have not been clarified, a series of independent investigations demonstrated that modulated hamartin or tuberin expression cause deregulation of proliferation/cell cycle in human, rodent and Drosophila cells. In support of tuberin acting as a tumor suppressor, ectopic overexpression of TSC2 has been shown to decrease proliferation rates of mammalian cells. Furthermore, overexpression of TSC2 has been demonstrated to trigger upregulation of the cyclin-dependent kinase inhibitor p27. We report that three different naturally occurring and TSC causing mutations within the TSC2 gene elliminate neither the anti-proliferative capacity of tuberin nor tuberin's effects on p27 expression. For the first time these data provide strong evidence that deregulation of proliferation and/or upregulation of p27 are not likely to be the primary/only mechanisms of hamartoma development in TSC. These results demand reassessment of previous hypotheses of the pathogenesis of TSC.	Univ Vienna, A-1090 Vienna, Austria; Univ Wales Hosp, Inst Med Genet, Cardiff CF14 4XW, S Glam, Wales	University of Vienna; Cardiff University	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				AICHER LD, 2001, IN PRESS J BIOL CHEM; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Sambrook J., 2002, MOL CLONING LAB MANU; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3	32	42	42	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4904	4909		10.1038/sj.onc.1204627	http://dx.doi.org/10.1038/sj.onc.1204627			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521203				2022-12-25	WOS:000170271800016
J	Hail, N; Lotan, R				Hail, N; Lotan, R			Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CERVICAL-CARCINOMA CELLS; CYTOCHROME-C; OXYGEN; DEATH; INDUCTION; COMPLEX; CHAIN; RETINAMIDE; INCREASE	The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) is being examined in both chemoprevention and therapy clinical trials. Yet, its mechanism(s) of action is still not fully elucidated. In previous studies, an increase in mitochondrial reactive oxygen species has been proposed as one mechanism through which 4HPR could exert its proapoptotic effects. This study explored whether mitochondrial respiration is required for 4HPR action using human cutaneous squamous cell carcinoma cells and respiration-deficient clones. In parental cells, 4HPR rapidly promoted hydroperoxide production followed by mitochondrial permeability transition, caspase activity, and DNA fragmentation. Short term exposure to 4HPR also inhibited oxygen consumption in parental cells. This activity was reversed by the antioxidant vitamin C indicating the prooxidant effect of 4HPR directly impaired mitochondrial function. In respiration-deficient clones, the proapoptotic qualities of 4HPR were conspicuously diminished illustrating a central role for mitochondrial respiration in 4HPR-induced cell death. In parental cells, various mitochondrial inhibitors were examined to determine potential sites associated with the prooxidant activity of 4HPR. Inhibitors of Complex II as well as center i inhibitors of Complex III enhanced 4HPR-induced hydroperoxide production. Complex I inhibitors, center o inhibitors of Complex III, cyanide, oligomycin A, and coenzyme Q analogues decreased 4HPR-induced hydroperoxide production. The coenzyme Q analogues were very effective in this respect, and they also blocked the enhanced by droperoxide production obtained when center i inhibitors were combined with 4HPR. These results suggest the prooxidant property of 4HPR is associated with redox metabolism via an enzymatic process occurring at a quinone-binding site in Complex I and/or center o of Complex III.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org			NCI NIH HHS [P01 CA68233, R25 CA57780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA068233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Buxser SE, 1999, METHOD ENZYMOL, V300, P256; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dallaporta B, 1999, J IMMUNOL, V162, P6534; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; ESPOSTI MD, 1994, BIOCHEM SOC T, V22, P209, DOI 10.1042/bst0220209; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P176; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; Marchetti P, 1999, CANCER RES, V59, P6257; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; MODICANAPOLITANO JS, 1989, CANCER RES, V49, P3369; MOORE GE, 1975, CANCER RES, V35, P2684; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Sun SY, 1999, MOL PHARMACOL, V55, P403; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Waliszewski P, 1999, J PHOTOCH PHOTOBIO B, V52, P137, DOI 10.1016/S1011-1344(99)90000-3; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x; YAGUZHINSKY LS, 1973, J BIOENERG, V5, P163, DOI 10.1007/BF01648987; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	43	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45614	45621		10.1074/jbc.M106559200	http://dx.doi.org/10.1074/jbc.M106559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11546781	hybrid			2022-12-25	WOS:000172573100018
J	Wilkens, S; Forgac, M				Wilkens, S; Forgac, M			Three-dimensional structure of the vacuolar ATPase proton channel by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SUBUNIT VPH1P; SYNTHASE; PROTEIN; TOPOGRAPHY; RESOLUTION; 100-KDA; PUMP	Vacuolar ATPases are ATP hydrolysis-driven proton pumps found in the endomembrane system of eucaryotic cells where they are involved in pH regulation. We have determined the three-dimensional structure of the proton channel domain of the vacuolar ATPase from bovine brain clathrin-coated vesicles by electron microscopy at 21 Angstrom resolution. The model shows an asymmetric protein ring with two small openings on the luminal side and one large opening on the cytoplasmic side. The central hole on the luminal side is covered by a globular protein, while the cytoplasmic opening is covered by two elongated proteins arranged in a collar-like fashion.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California Riverside; Tufts University	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	stephan.wilkens@ucr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058600, R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58600, R01 GM034478, GM34478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Graham LA, 2000, J EXP BIOL, V203, P61; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PALI T, 1995, BIOCHEMISTRY-US, V34, P9211, DOI 10.1021/bi00028a034; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUPEK F, 1994, J BIOL CHEM, V269, P24102; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	32	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44064	44068		10.1074/jbc.M106579200	http://dx.doi.org/10.1074/jbc.M106579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11533034	hybrid			2022-12-25	WOS:000172297700075
J	Li, RX; Liu, YH; Ladisch, S				Li, RX; Liu, YH; Ladisch, S			Enhancement of epidermal growth factor signaling and activation of src kinase by gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; LIPID RAFTS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; MEDIATED MODULATION; CAVEOLAE MEMBRANE; DOMAIN; TRANSDUCTION; MICRODOMAINS; PATHWAY	In a recent study, inhibition of cellular ganglioside synthesis blocked growth factor-induced fibroblast proliferation. Conversely, enrichment of cell membrane gangliosides by ganglioside preincubation enhanced growth factor-elicited cell proliferation. In the absence of serum and growth factors, NeuNAc alpha2-3Gal beta1-3GalNAc beta1-4(NeuNAc alpha2-3)Gal beta1-4Glc beta1-1Cer (G(D1a)) acted like a growth factor when cells were pretreated with the ganglioside, stimulating proliferation of normal human dermal fibroblasts and Swiss 3T3 fibroblasts. In contrast, growth inhibition was observed when high concentrations of gangliosides were continuously present in the culture medium during incubation of fibroblasts with growth factors (Li, R., Manela, J., Kong, Y., and Ladisch, S. (2000) J. Biol. Chem. 275,34213-34223). Here, we investigated the mechanisms whereby gangliosides elicit proliferation-coupled signaling in normal human dermal fibroblasts. Incubation of the fibroblasts with G(D1a) enhanced epidermal growth factor (EGF) receptor autophosphorylation and Ras and MAPK activation in a dose-dependent manner. Exposure of the cells to G(D1a) also enhanced the phosphorylation of Elk-1 by the activated MAPK. Brief pretreatment of the cells with PD98059 blocked the enhancing effect of gangliosides on EGF-induced MAPK activation. In the absence of serum and growth factors, G(D1a) incubation induced phosphorylation of Src kinase, Ras activation, and phosphorylation of MAPK and Elk-1 in a dose-dependent manner. The activation of Src kinase was confirmed by enhanced Src kinase activity. Brief treatment of the cells with PPI blocked the activation of Src kinase and MAPK. Again, PD98059 treatment inhibited ganglioside-elicited MAPK phosphorylation. Among the gangliosides tested, G(D1a), was the most active molecule, whereas lactosylceramide was the least active one, indicating relative structural specificity of the ganglioside action. In conclusion, gangliosides promote fibroblast proliferation through enhancement of growth factor signaling and activation of Src kinase.	Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, Washington, DC 20010 USA; George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; George Washington Univ, Sch Med, Dept Biochem Mol Biol, Washington, DC 20052 USA	George Washington University; George Washington University	Li, RX (corresponding author), Childrens Res Inst, Ctr Canc & Transplantat Biol, Glycobiol Program, 111 Michigan Ave NW, Washington, DC 20010 USA.	ruixiangli@msn.com			NCI NIH HHS [CA61010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chigorno V, 2000, EUR J BIOCHEM, V267, P4187, DOI 10.1046/j.1432-1327.2000.01454.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Ladisch S, 2000, METHOD ENZYMOL, V312, P135; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meuillet EJ, 1999, CANCER RES, V59, P234; Olshefski R, 1996, FEBS LETT, V386, P11, DOI 10.1016/0014-5793(96)00392-4; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; SAQR HE, 1993, J NEUROCHEM, V61, P395; SAQR HE, 1995, J NEUROSCI RES, V41, P491, DOI 10.1002/jnr.490410408; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Sorice M, 1997, J LIPID RES, V38, P969; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006; YATES AJ, 1995, J NEURO-ONCOL, V24, P65, DOI 10.1007/BF01052661; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	43	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42782	42792		10.1074/jbc.M101481200	http://dx.doi.org/10.1074/jbc.M101481200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11535585	hybrid			2022-12-25	WOS:000172169300021
J	Trent, MS; Ribeiro, AA; Doerrler, WT; Lin, SH; Cotter, RJ; Raetz, CRH				Trent, MS; Ribeiro, AA; Doerrler, WT; Lin, SH; Cotter, RJ; Raetz, CRH			Accumulation of a polyisoprene-linked amino sugar in polymyxin-resistant Salmonella typhimurium and Escherichia coli - Structural characterization and transfer to lipid A in the periplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; ENTEROBACTERIAL COMMON ANTIGEN; ACID-DEFICIENT MUTANT; CHEMICAL-STRUCTURE; NMR-SPECTROSCOPY; LIPOTEICHOIC ACIDS; PMRA MUTANTS; 4-AMINO-4-DEOXY-L-ARABINOSE; BIOSYNTHESIS; LIPOPOLYSACCHARIDE	Polymyxin-resistant mutants of Escherichia coli and Salmonella typhimurium accumulate a novel minor lipid that can donate 4-amino-4-deoxy-L-arabinose units (L-Ara4N) to lipid A. We now report the purification of this lipid from a pss(-) pmrA(C) mutant of E. coli and assign its structure as undecaprenyl phosphate-alpha -L-Ara4N. Approximately 0.2 mg of homogeneous material was isolated from an 8-liter culture by solvent extraction, followed by chromatography on DEAE-cellulose, C18 reverse phase resin, and silicic acid. Matrix-assisted laser desorption ionization/time of flight mass spectrometry in the negative mode yielded a single species [M - H]- at m/z 977.5, consistent with undecaprenyl phosphate-alpha -L-Ara4N (M-r = 978.41). P-31 NMR spectroscopy showed a single phosphorus atom at -0.44 ppm characteristic of a phosphodiester linkage. Selective inverse decoupling difference spectroscopy demonstrated that the undecaprenyl phosphate group is attached to the anomeric carbon of the L-Ara4N unit. One- and two-dimensional H-1 NMR studies confirmed the presence of a polyisoprene chain and a sugar moiety with chemical shifts and coupling constants expected for an equatorially substituted arabinopyranoside. Heteronuclear multiple-quantum coherence spectroscopy analysis demonstrated that a nitrogen atom is attached to C-4 of the sugar residue. The purified donor supports in vitro conversion of lipid IVA to lipid IIA, which is substituted with a single L-Ara4N moiety. The identification of undecaprenyl phosphate-alpha -L-Ara4N implies that L-Ara4N transfer to lipid A occurs in the periplasm of polymyxin-resistant strains, and establishes a new enzymatic pathway by which Gram-negative bacteria acquire antibiotic resistance.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Duke University; Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14236] Funding Source: Medline; NIAID NIH HHS [1 F32 AI1056-02] Funding Source: Medline; NIGMS NIH HHS [GM-51310, GM54882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Allison GE, 2000, TRENDS MICROBIOL, V8, P17, DOI 10.1016/S0966-842X(99)01646-7; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; BARR K, 1987, J BIOL CHEM, V262, P7142; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLL M, 1994, FEMS IMMUNOL MED MIC, V8, P329; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; DAME JB, 1979, J BACTERIOL, V137, P1043, DOI 10.1128/JB.137.2.1043-1047.1979; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DOTSON SB, 1995, ARCH BIOCHEM BIOPHYS, V316, P773, DOI 10.1006/abbi.1995.1103; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASE S, 1977, EUR J BIOCHEM, V75, P23, DOI 10.1111/j.1432-1033.1977.tb11500.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; IWASAKI H, 1989, J BACTERIOL, V171, P424, DOI 10.1128/jb.171.1.424-429.1989; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee RE, 1998, BIOORG MED CHEM LETT, V8, P951, DOI 10.1016/S0960-894X(98)00147-4; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; Mavris M, 1997, MOL MICROBIOL, V26, P939, DOI 10.1046/j.1365-2958.1997.6301997.x; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAHMAN A, 1992, 13C NMR NATURAL PROD, V2; Rahman A.U., 1992, 13C NMR NATURAL PROD, V1; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SHIMADA A, 1988, EUR J BIOCHEM, V176, P559, DOI 10.1111/j.1432-1033.1988.tb14314.x; SHIMADA A, 1989, J BACTERIOL, V171, P2835, DOI 10.1128/jb.171.5.2835-2841.1989; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANELONI RJ, 1982, CRC CR REV BIOCH MOL, V12, P289, DOI 10.1080/10409238209104422; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J BIOL CHEM, V270, P20151, DOI 10.1074/jbc.270.34.20151; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; WRIGHT A, 1967, P NATL ACAD SCI USA, V57, P1798, DOI 10.1073/pnas.57.6.1798; YOKOYAMA K, 1988, EUR J BIOCHEM, V173, P453, DOI 10.1111/j.1432-1033.1988.tb14020.x; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	72	103	106	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43132	43144		10.1074/jbc.M106962200	http://dx.doi.org/10.1074/jbc.M106962200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11535605	hybrid			2022-12-25	WOS:000172169300066
J	Igal, RA; Wang, SL; Gonzalez-Baro, M; Coleman, RA				Igal, RA; Wang, SL; Gonzalez-Baro, M; Coleman, RA			Mitochondrial glycerol phosphate acyltransferase directs the incorporation of exogenous fatty acids into triacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ACYL-COA; SELECTIVE CHANGES; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; 3T3-L1 PREADIPOCYTES; MICROSOMAL-ENZYMES; BINDING PROTEIN; OBESE RATS; LIVER; DIFFERENTIATION	The mitochondrial isoform of glycerol-3-phosphate acyltransferase (GPAT), the first step in glycerolipid synthesis, is up-regulated by insulin and by high carbohydrate feeding via SREBP-1c, suggesting that it plays a role in triacylglycerol synthesis. To test this hypothesis, we overexpressed mitochondrial GPAT in Chinese hamster ovary (CHO) cells. When GPAT was overexpressed 3.8-fold, triacylglycerol mass was 2.7-fold higher than in control cells. After incubation with trace [C-14]oleate (similar to3 mum), control cells incorporated 4.7-fold more label into phospholipid than triacylglycerol, but GPAT-overexpressing cells incorporated equal amounts of label into phospholipid and triacylglycerol. In GPAT-overexpressing cells, the incorporation of label into phospholipid, particularly phosphatidylcholine, decreased 30%, despite normal growth rate and phospholipid content, suggesting that exogenous oleate was directed primarily toward triacylglycerol synthesis. Transiently transfected HEK293 cells that expressed a 4.4-fold increase in GPAT activity incorporated 9.7-fold more [C-14]oleate into triacylglycerol compared with control cells, showing that the effect of GPAT overexpression was similar in two different cell types that had been transfected by different methods. When the stable, GPAT-overexpressing CHO cells were incubated with 100 mum oleate to stimulate triacylglycerol synthesis, they incorporated 1.9-fold more fatty acid into triacylglycerol than did the control cells. Confocal microscopy of CHO and HEK293 cells transfected with the GPAT-FLAG construct showed that GPAT was located correctly in mitochondria and was not present elsewhere in the cell. These studies indicate that overexpressed mitochondrial GPAT directs incorporation of exogenous fatty acid into triacylglycerol rather than phospholipid and imply that (a) mitochondrial GPAT and lysophosphatidic acid acyltransferase produce a separate pool of lysophosphatidic acid and phosphatidic acid that must be transported to the endoplasmic reticulum where the terminal enzymes of triacylglycerol synthesis are located, and W this pool remains relatively separate from the pool of lysophosphatidic acid and phosphatidic acid that contributes to the synthesis of the major phospholipid species.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC 27599 USA; Natl Univ La Plata, Fac Ciencias Med, Inst Invest Bioquim, RA-1900 La Plata, Argentina	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National University of La Plata	Coleman, RA (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Ariel, Pablo/AGJ-4118-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER; FIC NIH HHS [TW00891] Funding Source: Medline; NIDDK NIH HHS [DK56598] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIS RJ, 1976, ANAL BIOCHEM, V73, P1, DOI 10.1016/0003-2697(76)90135-4; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; HOMAN R, 1991, J LIPID RES, V32, P231; Igal RA, 2001, J LIPID RES, V42, P88; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; ROSENTHAL MD, 1981, LIPIDS, V16, P173, DOI 10.1007/BF02535435; ROSENTHAL MD, 1980, LIPIDS, V15, P838, DOI 10.1007/BF02534374; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; VANCURA A, 1992, J BIOL CHEM, V267, P14353; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; [No title captured]	33	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42205	42212		10.1074/jbc.M103386200	http://dx.doi.org/10.1074/jbc.M103386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546763	Green Published, hybrid			2022-12-25	WOS:000172450400089
J	Westwood, M; Aplin, JD; Collinge, IA; Gill, A; White, A; Gibson, JM				Westwood, M; Aplin, JD; Collinge, IA; Gill, A; White, A; Gibson, JM			alpha(2)-macroglobulin: a new component in the insulin-like growth factor/insulin-like growth factor binding protein-1 axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-1; HUMAN AMNIOTIC-FLUID; IGF-I; ALPHA-2-MACROGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; NORMAL PLASMA; FACTOR-XIII; FORMS; CELLS; IGFBP-1	Insulin-like growth factors (IGFs) are crucial for many aspects of development, growth, and metabolism yet control of their activity by IGF-binding proteins (IGFBPs) remains controversial. The effect of IGFBP-1 depends on its phosphorylation status; phosphorylated IGFBP-1 inhibits IGF actions whereas the nonphosphorylated isoform is stimulatory. In order to understand this phenomenon, we purified phosphorylated IGFBP-1 from normal human plasma by immunoaffinity chromatography. Unexpectedly, the resulting preparation enhanced IGF-stimulated 3T3-L1 fibroblast proliferation, due to the presence of a co-purified protein of approximate to 700 kDa. Matrix-assisted laser desorption ionization-mass spectrometry and Western immunoblotting analysis identified this copurified protein as alpha (2)-macroglobulin (alpha M-2). Anti-alpha M-2 antibodies co-immunoprecipitated IGFBP-1 from human plasma and from I-125-IGFBP-1(.)alpha M-2 complexes formed in vitro. The I-125-IGFBP-1/alpha M-2 association could be inhibited with excess unlabeled IGFBP-1. Surface plasmon resonance analysis indicated that alpha M-2 preferentially associates with the phosphorylated isoform of IGFBP-1 and that when complexed to alpha M-2, IGFBP-1 can still bind IGF-I. These findings have functional significance since alpha M-2 protects IGFBP-1 from proteolysis and abrogates the inhibitory effect of phosphorylated. IGFBP-1 on IGF-I stimulated 3T3-L1 cell proliferation. We conclude that alpha M-2 is a binding protein of IGFBP-1 which modifies IGF-I/IG-FBP-1 actions resulting in enhanced IGF effects. In line with its role in regulating the clearance and activity of other growth factors, we predict that alpha M-2 has a novel and important role in controlling the transport and biological activity of IGFs.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, St Marys Hosp, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England; Hope Hosp, Dept Endocrinol & Diabet, Salford M6 8HD, Lancs, England	University of Manchester; University of Manchester	Westwood, M (corresponding author), Univ Manchester, Sch Biol Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Westwood, Melissa/G-5954-2015; White, Anne/C-3753-2011; White, Anne/G-7717-2015; Aplin, John/AET-4363-2022	Westwood, Melissa/0000-0001-9725-7010; White, Anne/0000-0002-7686-2884; gibson, martin/0000-0002-1331-1524; Aplin, John/0000-0001-8777-9261				BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BAUMRUCKER CR, 1999, 81 ANN M END SOC JUN, P404; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; CLEMMONS DR, 1990, J CELL PHYSIOL, V145, P129, DOI 10.1002/jcp.1041450118; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; Frost RA, 1999, ENDOCRINOLOGY, V140, P3962, DOI 10.1210/en.140.9.3962; FROST RA, 1993, BIOL REPROD, V49, P104, DOI 10.1095/biolreprod49.1.104; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P7916, DOI 10.1021/bi00082a012; Gibson JM, 2001, MOL HUM REPROD, V7, P79, DOI 10.1093/molehr/7.1.79; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; Irwin JC, 1998, GROWTH HORM IGF RES, V8, P21, DOI 10.1016/S1096-6374(98)80318-3; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LIU B, 1999, 81 ANN M END SOC SAN, P405; LIU L, 1991, BIOCHEM BIOPH RES CO, V174, P673, DOI 10.1016/0006-291X(91)91470-W; Martina NA, 1997, J CLIN ENDOCR METAB, V82, P1894, DOI 10.1210/jc.82.6.1894; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; PHILIP A, 1991, J BIOL CHEM, V266, P22290; Sakai K, 2001, J BIOL CHEM, V276, P8740, DOI 10.1074/jbc.M008359200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SOKER S, 1993, J BIOL CHEM, V268, P7685; SOTTRUPJENSEN L, 1983, ANN NY ACAD SCI, V421, P41, DOI 10.1111/j.1749-6632.1983.tb18091.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; WEINZIMER SA, 1999, 81 ANN M END SOC SAN, P83; WESTWOOD M, 1994, J CLIN ENDOCR METAB, V79, P1735, DOI 10.1210/jc.79.6.1735; Westwood M, 1997, ENDOCRINOLOGY, V138, P1130, DOI 10.1210/en.138.3.1130; WRIGHT JF, 1982, J IMMUNOL METHODS, V48, P311, DOI 10.1016/0022-1759(82)90332-5; Yu J, 1998, GROWTH HORM IGF RES, V8, P65, DOI 10.1016/S1096-6374(98)80323-7	48	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41668	41674		10.1074/jbc.M102793200	http://dx.doi.org/10.1074/jbc.M102793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11546760	hybrid			2022-12-25	WOS:000172450400019
J	Wu, Y; Egerton, G; Underwood, AP; Sakuda, S; Bianco, AE				Wu, Y; Egerton, G; Underwood, AP; Sakuda, S; Bianco, AE			Expression and secretion of a larval-specific chitinase (family 18 glycosyl hydrolase) by the infective stages of the parasitic nematode, Onchocerca volvulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; INHIBITION; SEQUENCE; CLASSIFICATION; MICROFILARIAE; PROTEINS; HEVAMINE; ANTIGENS; CLONING	A recently reported chitinase gene, expressed in the infective, third-stage (L3) larvae of the human filarial parasite Onchocerca volvulus, belongs to the family 18 glycosyl hydrolases and has been designated Ov-chi-1. The gene product of Ov-chi-1 is chitinolytic. Allosamidin ablates activity of the native enzyme in a dose-dependent manner but did not significantly inhibit the moulting of L3 larvae. Mono-specific antibodies were used to characterize Ov-CHI-1 as a 60-kDa protein expressed almost exclusively in L3 stages. Immunoelectron microscopy showed that Ov-CHI-1 expression is initiated in late L2 larvae and increases markedly in infective, L3 larvae. It is synthesized exclusively in the glandular esophagus and stored within discrete secretory granules. Secretion occurs through de-granulation during post-infective development, and the primary route of transport appears to be via the pseudo-coelom. An orthologue of Ov-chi-1 was detected in Caenorhabditis elegans by BLAST analysis. It is constitutively expressed at a low level and is overexpressed in dauer larvae and embryonated eggs. It is chitinolytic. We conclude that Ov-CHI-1 is a highly stage-specific enzyme that may have a role in infectivity of the parasite, aiding escape from the vector or participating in early post-infective migration and/or development. The identification of an orthologue in C. elegans opens the way for further studies into the biological function(s) of this intriguing parasite product.	Univ Liverpool, Liverpool Sch Trop Med, Div Mol Biol & Immunol, Liverpool L3 5QA, Merseyside, England; Univ Tokyo, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan	Liverpool School of Tropical Medicine; University of Liverpool; University of Tokyo	Wu, Y (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Mol Biol & Immunol, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	ywu@liverpool.ac.uk		Sakuda, Shohei/0000-0001-7966-1167; Underwood, Anthony/0000-0002-8547-4277				Adam R, 1996, J BIOL CHEM, V271, P1441, DOI 10.1074/jbc.271.3.1441; Blaxter ML, 1997, PARASITOL TODAY, V13, P416, DOI 10.1016/S0169-4758(97)01140-X; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; BRENNER S, 1974, GENETICS, V77, P71; Burglin TR, 1998, INT J PARASITOL, V28, P395, DOI 10.1016/S0020-7519(97)00208-7; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; CONNOR DH, 1985, REV INFECT DIS, V7, P809; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FRANZ M, 1983, TROPENMED PARASITOL, V34, P155; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; GOODAY GW, 1988, MOL BIOCHEM PARASIT, V29, P223, DOI 10.1016/0166-6851(88)90077-1; Harrison RA, 1999, VACCINE, V18, P647, DOI 10.1016/S0264-410X(99)00274-1; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; IBRAHIM MS, 1992, MOL BIOCHEM PARASIT, V52, P97, DOI 10.1016/0166-6851(92)90039-M; Jenkins RE, 1996, PARASITE IMMUNOL, V18, P29, DOI 10.1046/j.1365-3024.1996.d01-10.x; KING TP, 1987, HISTOCHEM J, V19, P281, DOI 10.1007/BF01675688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDINADELAGARZA CE, 1987, TROP MED PARASITOL, V38, P53; MILEWSKI S, 1992, J GEN MICROBIOL, V138, P2545, DOI 10.1099/00221287-138-12-2545; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; SAKUDA S, 1987, J ANTIBIOT, V40, P296, DOI 10.7164/antibiotics.40.296; Sakuda S, 1998, BIOORG MED CHEM LETT, V8, P2987, DOI 10.1016/S0960-894X(98)00542-3; SCHLEIN Y, 1991, P ROY SOC B-BIOL SCI, V245, P121, DOI 10.1098/rspb.1991.0097; SCHLEIN Y, 1992, PARASITOL TODAY, V8, P367, DOI 10.1016/0169-4758(92)90169-3; Shahabuddin M, 1996, INFECT IMMUN, V64, P739, DOI 10.1128/IAI.64.3.739-743.1996; SHAHABUDDIN M, 1993, PARASITOL TODAY, V9, P252, DOI 10.1016/0169-4758(93)90069-R; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; SOMERS PJB, 1987, J ANTIBIOT, V40, P1751, DOI 10.7164/antibiotics.40.1751; STROTE G, 1991, PARASITOL RES, V77, P526, DOI 10.1007/BF00928422; STROTE G, 1987, TROP MED PARASITOL, V38, P211; THYLEFORS B, 1978, B WORLD HEALTH ORGAN, V56, P63; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2; vanScheltinga ACT, 1996, J MOL BIOL, V262, P243, DOI 10.1006/jmbi.1996.0510; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351; Wang SH, 1997, AM J TROP MED HYG, V56, P474, DOI 10.4269/ajtmh.1997.56.474; WATANABE T, 1993, J BIOL CHEM, V268, P18567; Wood WB, 1988, NEMATODE CAENORHABDI, P587; Wu Y, 1996, MOL BIOCHEM PARASIT, V75, P207, DOI 10.1016/0166-6851(95)02529-4; Yamage M, 1999, MOL BIOL CELL, V10, p183A	45	52	53	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42557	42564		10.1074/jbc.M103479200	http://dx.doi.org/10.1074/jbc.M103479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535590	hybrid			2022-12-25	WOS:000172450400131
J	Fu, XY; Kassim, SY; Parks, WC; Heinecke, JW				Fu, XY; Kassim, SY; Parks, WC; Heinecke, JW			Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HYDROGEN-PEROXIDE; OXIDATION; COLLAGENASE; NITROGEN; INACTIVATION; REACTIVITIES; PATHOGENESIS; CHLORAMINES; THIOCYANATE	Myeloperoxidase uses hydrogen peroxide (H2O2) to generate hypochlorous acid (HOCl), a potent cytotoxic oxidant. We demonstrate that HOCl regulates the activity of matrix metalloproteinase-7 (MMP-7, matrilysin) in vitro, suggesting that this oxidant activates MMPs in the artery wall. Indeed, both MMP-7 and myeloperoxidase were colocalized to lipid-laden macrophages in human atherosclerotic lesions. A highly conserved domain called the cysteine switch has been proposed to regulate MMP activity. When we exposed a synthetic peptide that mimicked the cysteine switch to HOCl, HPLC analysis showed that the thiol residue reacted rapidly, generating a near-quantitative yield of products. Tandem mass spectrometric analysis identified the products as sulfinic acid, sulfonic acid, and a dimer containing a disulfide bridge. In contrast, the peptide reacted slowly with H2O2, and the only product was the disulfide. Moreover, HOCl markedly activated pro-MMP-7, an MMP expressed at high levels in lipid-laden macrophages in vivo. Tandem mass spectrometric analysis of trypsin digests revealed that the thiol residue of the enzyme's cysteine switch domain had been converted to sulfinic acid. Thiol oxidation was associated with autolytic cleavage of pro-MMP-7, strongly suggesting that oxygenation activates the latent enzyme. In contrast, H2O2 failed to oxidize the thiol residue of the protein or activate the enzyme. Thus, HOCl activates pro-MMP-7 by converting the thiol residue of the cysteine switch to sulfinic acid. This activation mechanism is distinct from the well-studied proteolytic cleavage of MMP pro-enzymes. Our observations raise the possibility that HOCl generated by myeloperoxidase contributes to MMP activation, and therefore to plaque rupture, in the artery wall. HOCl and other oxidants might regulate MMP activity by the same mechanism in a variety of inflammatory conditions.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Zhejiang Univ, Dept Chem, Hangzhou 310027, Peoples R China	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Zhejiang University	Heinecke, JW (corresponding author), Div Atherosclerosis Nutr & Lipid Res, Campus Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	heinecke@im.wustl.edu	Parks, William C./AAH-6786-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015013] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [HL29594, HL64344, HL54619] Funding Source: Medline; NIA NIH HHS [AG15013] Funding Source: Medline; NIDDK NIH HHS [DK56341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Arlandson M, 2001, J BIOL CHEM, V276, P215, DOI 10.1074/jbc.M004881200; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Dunford H. B., 1999, HEME PEROXIDASES; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; George SJ, 1998, CURR OPIN LIPIDOL, V9, P413, DOI 10.1097/00041433-199810000-00005; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HOLZ RC, 1992, J AM CHEM SOC, V114, P9611, DOI 10.1021/ja00050a048; Hope HR, 2000, PROTEIN EXPRES PURIF, V18, P269, DOI 10.1006/prep.1999.1197; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTIONA; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Libby P, 2000, AM J CARDIOL, V86, p3J; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Lohi J, 2001, J BIOL CHEM, V276, P10134, DOI 10.1074/jbc.M001599200; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; Owens MW, 1997, AM J PHYSIOL-LUNG C, V273, pL445, DOI 10.1152/ajplung.1997.273.2.L445; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; vanDalen CJ, 1997, BIOCHEM J, V327, P487; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Woessner J.F., 2000, PROTEIN PROFILE SER; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P485; Yates JR, 1998, J MASS SPECTROM, V33, P1	56	376	392	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41279	41287		10.1074/jbc.M106958200	http://dx.doi.org/10.1074/jbc.M106958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533038	hybrid			2022-12-25	WOS:000171925600120
J	Gorgoni, B; Caivano, M; Arizmendi, C; Poli, V				Gorgoni, B; Caivano, M; Arizmendi, C; Poli, V			The transcription factor C/EBP beta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE-2 GENE; ACTIVATED PROTEIN-KINASE; FACTOR KAPPA-B; RESPONSE ELEMENT; NUCLEAR FACTOR; PROSTAGLANDIN SYNTHASE-2; CYCLOOXYGENASE-2 GENE; GRANULOSA-CELLS; PHORBOL ESTER; PROMOTER	Cyclooxygenase-2 (COX-2) is the rate-limiting enzyme for the inducible synthesis of prostaglandins, and its up-regulated activity is thought to play a pathological role in diseases such as inflammatory bowel disease, rheumatoid arthritis, and cancer. Regulation of COX-2 expression is complex and appears to involve diversified mechanisms in different cell types and conditions. Here we make use of immortalized macrophages and fibroblasts that we have generated from C/EBP beta -deficient mice to directly test and compare the specific role played by this factor in inducible COX-2 expression in these two cell types. We could demonstrate that COX-2 mRNA induction and promoter activity were profoundly impaired in C/EBP beta (-/-) macrophages and could be rescued by expression of C/EBP beta. The obligatory role of C/EBP beta in COX-2 expression appeared to be mediated exclusively by the C/EBP element located at positions -138/-130 of the murine cox-2 promoter; and did not involve altered activity at the level of the other promoter elements described previously (the -402/-392 NF-kappaB site, the -59/-48 CRE/E box element, and a potential second C/EBP site located at positions -93/-85). In contrast, COX-2 induction was completely normal in C/EBP beta -deficient fibroblasts, thus highlighting the diversity of cell-specific molecular mechanisms in determining inducible COX-2 expression and prostaglandins production.	Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Salamanca, Sch Med, Dept Biochem & Mol Biol, E-37007 Salamanca, Spain	University of Dundee; University of Dundee; University of Salamanca	Poli, V (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.		Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966				Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; CAREY M, 2000, TRANSCRIPTIONAL REGU, P65; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DOYLE AG, 1996, WEIRS HDB EXPT IMMUN, V4; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Everts B, 2000, CLIN RHEUMATOL, V19, P331, DOI 10.1007/s100670070024; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Nishioka K, 2000, ARTHRITIS RHEUM-US, V43, P1591, DOI 10.1002/1529-0131(200007)43:7<1591::AID-ANR24>3.0.CO;2-9; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Potter S, 2000, MOL HUM REPROD, V6, P771, DOI 10.1093/molehr/6.9.771; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	41	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40769	40777		10.1074/jbc.M106865200	http://dx.doi.org/10.1074/jbc.M106865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522796	hybrid			2022-12-25	WOS:000171925600054
J	Jung, K; Hamann, K; Revermann, A				Jung, K; Hamann, K; Revermann, A			K+ stimulates specifically the autokinase activity of purified and reconstituted EnvZ of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SIGNAL-TRANSDUCTION; PHOSPHATASE-ACTIVITY; PHOSPHORYLATED OMPR; PERIPLASMIC DOMAIN; TURGOR SENSOR; PROTEIN; OSMOREGULATION; KINASE; OSMOSENSOR; MUTATIONS	The histidine kinase/response regulator system EnvZ/ OmpR of Escherichia coli regulates transcription of the genes ompF and ompC, encoding two porins of the outer membrane. Although the total amount of OmpF and OmpC remains constant, the relative levels of the two proteins fluctuate in a reciprocal manner depending on medium osmolality. The membrane-anchored sensor EnvZ somehow monitors changes in environmental osmolality. To characterize the nature of the stimulus perceived by EnvZ, this protein was overproduced, purified, and reconstituted into proteoliposomes. Autokinase activity of purified and reconstituted EnvZ was stimulated by an increase of the K+ concentration. Rb+, Na+, and NH4+ also stimulated the activity but to a smaller extent, whereas an osmotic upshift imposed by various sugars or increasing concentrations of glycine betaine, proline, or Tris/MES were without influence. Neither the transfer of the phosphoryl group from EnvZ similar toP to OmpR nor the EnvZ-mediated OmpR similar toP dephosphorylation were affected by one of the tested solutes. Experiments with the reconstructed signal transduction cascade including DNA fragments demonstrated a substantial increase of the amount of phosphorylated OmpR in the presence of K+ and to a lower extent in the presence of Na+, Rb+, and NH4+. Various K+ salts were tested indicating that the determined effects were K+-specific and not dependent on the anion. In a further in vitro test system, which utilizes right-side-out membrane vesicles, the K+-specific activation of EnvZ autokinase from the luminal side was confirmed. These results clearly indicate a regulation of EnvZ autokinase activity by monovalent ions, specifically K+. Whether K+ accumulation, which is one of the first responses of E. coli after an osmotic upshift, is related to the stimulation of the EnvZ autokinase activity in vivo is discussed.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung_k@biologie.uni-osnabrueck.de						Ames SK, 1999, P NATL ACAD SCI USA, V96, P11792, DOI 10.1073/pnas.96.21.11792; BARRON A, 1986, J BACTERIOL, V167, P433, DOI 10.1128/jb.167.2.433-438.1986; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Head CG, 1998, J MOL BIOL, V281, P857, DOI 10.1006/jmbi.1998.1985; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Hsing WH, 1997, J BACTERIOL, V179, P3729, DOI 10.1128/jb.179.11.3729-3735.1997; HUANG KJ, 1994, J BACTERIOL, V176, P1309, DOI 10.1128/jb.176.5.1309-1315.1994; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BACTERIOL, V183, P3800, DOI 10.1128/JB.183.12.3800-3803.2001; Jung K, 2000, J BIOL CHEM, V275, P40142, DOI 10.1074/jbc.M008917200; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AI, 1999, J BACTERIOL, V181, P5309, DOI 10.1128/JB.181.17.5309-5316.1999; Leonardo MR, 1996, MOL MICROBIOL, V22, P405, DOI 10.1046/j.1365-2958.1996.1271487.x; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; MCLAGGAN D, 1994, J BIOL CHEM, V269, P1911; MILNER JL, 1988, J BIOL CHEM, V263, P14900; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Qin L, 2000, MOL MICROBIOL, V36, P24, DOI 10.1046/j.1365-2958.2000.01837.x; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Roessler M, 2001, FEBS LETT, V489, P125, DOI 10.1016/S0014-5793(01)02099-3; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; TOKISHITA S, 1990, J BIOCHEM-TOKYO, V108, P488, DOI 10.1093/oxfordjournals.jbchem.a123226; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Waukau J, 1999, J BACTERIOL, V181, P5534, DOI 10.1128/JB.181.17.5534-5538.1999; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	50	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40896	40902		10.1074/jbc.M107871200	http://dx.doi.org/10.1074/jbc.M107871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533042	hybrid			2022-12-25	WOS:000171925600070
J	Soutourina, J; Blanquet, S; Plateau, P				Soutourina, J; Blanquet, S; Plateau, P			Role of D-cysteine desulfhydrase in the adaptation of Escherichia coli to D-cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-AMINOCYCLOPROPANE-1-CARBOXYLATE DEAMINASE; INHIBITION; STARVATION; SEQUENCE; PROTEIN; GENES; PEPTIDES; TAURINE; ENZYME; OPERON	D-Cysteine, a powerful inhibitor of Escherichia coli growth, is decomposed in vitro into pyruvate, H2S, and NH3 by D-cysteine desulfhydrase. To assess the role of this reaction in the adaptation of the bacterium to growth on D-cysteine, the gene of the desulfhydrase was cloned. It corresponds to the open reading frame yedO at 43.03 min on the genetic map of E. coli. The amino acid sequence deduced from this gene is homologous to those of several 1-aminocyclopropane-carboxylate deaminases. However, the E. coli desulfhydrase does not use 1-aminocyclopropane-1-carboxylate as substrate. Various mutants in which the yedO gene was inactivated or overexpressed were constructed. They exhibited hypersensitivity or resistance, respectively, to the presence of D-cysteine in the culture medium. Growth protection against D-cysteine in minimal medium was conferred by the simultaneous addition of isoleucine, leucine, and valine. In agreement with this behavior, D-cysteine inhibited the activity of threonine deaminase, a key enzyme of the isoleucine, leucine, and valine pathway. Finally, in the presence of the intact yedO gene, E. coli growth was improved by addition of D-cysteine as the sole sulfur source. In agreement with a role of the desulfhydrase in sulfur metabolism, yedO expression was induced under conditions of sulfate limitation.	CNRS, Ecole Polytech, Unite Mixte Rech 7654, Biochim Lab, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Plateau, P (corresponding author), CNRS, Ecole Polytech, Unite Mixte Rech 7654, Biochim Lab, F-91198 Gif Sur Yvette, France.		Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				Berlyn MKB, 1998, MICROBIOL MOL BIOL R, V62, P814, DOI 10.1128/MMBR.62.3.814-984.1998; BODANSZK.M, 1974, P NATL ACAD SCI USA, V71, P2791, DOI 10.1073/pnas.71.7.2791; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BURNELL JN, 1977, BIOCHIM BIOPHYS ACTA, V481, P246, DOI 10.1016/0005-2744(77)90157-7; BUTLER JD, 1993, LIFE SCI, V52, P1209, DOI 10.1016/0024-3205(93)90103-A; Campbell BG, 1996, FEMS MICROBIOL LETT, V138, P207, DOI 10.1016/0378-1097(96)00108-5; CLAESSON R, 1990, ORAL MICROBIOL IMMUN, V5, P137, DOI 10.1111/j.1399-302X.1990.tb00411.x; CORRIGAN JJ, 1969, SCIENCE, V164, P142, DOI 10.1126/science.164.3876.142; DATTA P, 1971, METHOD ENZYMOL, V17, P566; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; ESAKI N, 1988, J BACTERIOL, V170, P751, DOI 10.1128/jb.170.2.751-756.1988; Friedman M, 1999, J AGR FOOD CHEM, V47, P3457, DOI 10.1021/jf990080u; HAMA H, 1991, J BIOCHEM-TOKYO, V109, P604, DOI 10.1093/oxfordjournals.jbchem.a123427; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HARRIS CL, 1981, J BACTERIOL, V145, P1031, DOI 10.1128/JB.145.2.1031-1035.1981; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; Ikebe T, 1999, MICROBIOL-SGM, V145, P1389, DOI 10.1099/13500872-145-6-1389; Jack RW, 1998, CHIMIA, V52, P48; Jia YJ, 2000, BIOSCI BIOTECH BIOCH, V64, P299, DOI 10.1271/bbb.64.299; KANZAKI H, 1987, EUR J BIOCHEM, V163, P105, DOI 10.1111/j.1432-1033.1987.tb10742.x; LEONCINI R, 1989, BIOCHIM BIOPHYS ACTA, V994, P52, DOI 10.1016/0167-4838(89)90061-7; MCFALL E, 1987, CELL MOL BIOL, P1520; MCIVER CJ, 1993, J CLIN MICROBIOL, V31, P2790, DOI 10.1128/JCM.31.10.2790-2793.1993; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; Mytelka DS, 1996, J BACTERIOL, V178, P24, DOI 10.1128/jb.178.1.24-34.1996; NAGASAWA T, 1982, J BIOL CHEM, V257, P13749; NAGASAWA T, 1985, EUR J BIOCHEM, V153, P541, DOI 10.1111/j.1432-1033.1985.tb09335.x; NAGASAWA T, 1988, ARCH MICROBIOL, V149, P413, DOI 10.1007/BF00425580; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PHILLIPS A. T., 1964, BIOCHEM BIOPHYS RES COMMUN, V15, P530, DOI 10.1016/0006-291X(64)90499-1; Quadroni M, 1996, EUR J BIOCHEM, V239, P773, DOI 10.1111/j.1432-1033.1996.0773u.x; Salgado H, 2000, NUCLEIC ACIDS RES, V28, P65, DOI 10.1093/nar/28.1.65; SCHMIDT A, 1987, METHOD ENZYMOL, V143, P449; SCHMIDT A, 1983, Z NATURFORSCH C, V38, P428; SELIGER HH, 1961, P NATL ACAD SCI USA, V47, P1129, DOI 10.1073/pnas.47.8.1129; Shah S, 1998, CAN J MICROBIOL, V44, P833, DOI 10.1139/cjm-44-9-833; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; SMITH IK, 1971, BIOCHIM BIOPHYS ACTA, V227, P288, DOI 10.1016/0005-2744(71)90061-1; SORENSEN MA, 1991, J BACTERIOL, V173, P5244, DOI 10.1128/jb.173.16.5244-5246.1991; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomii K, 1998, GENOME RES, V8, P1048, DOI 10.1101/gr.8.10.1048; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; YEGGY JP, 1980, CAN J MICROBIOL, V26, P1386, DOI 10.1139/m80-231	48	61	69	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40864	40872		10.1074/jbc.M102375200	http://dx.doi.org/10.1074/jbc.M102375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527960	hybrid			2022-12-25	WOS:000171925600066
J	Umebayashi, K; Fukuda, R; Hirata, A; Horiuchi, H; Nakano, A; Ohta, A; Takagi, M				Umebayashi, K; Fukuda, R; Hirata, A; Horiuchi, H; Nakano, A; Ohta, A; Takagi, M			Activation of the Ras-cAMP signal transduction pathway inhibits the proteasome-independent degradation of misfolded protein aggregates in the endoplasmic reticulum lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIVEUS ASPARTIC PROTEINASE; CYCLIC AMP PATHWAY; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; RHIZOPUS-NIVEUS; STRESS-RESPONSE; ER DEGRADATION; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; TRANSMEMBRANE PROTEIN; MOLECULAR CHAPERONES	Many kinds of misfolded secretory proteins are known to be degraded in the endoplasmic reticulum (ER). Dislocation of misfolded proteins from the ER to the cytosol and subsequent degradation by the proteasome have been demonstrated. Using the yeast Saccharomyces cerevisiae, we have been studying the secretion of a heterologous protein, Rhizopus niveus aspartic proteinase-I (RNAP-I). Previously, we found that the pro sequence of RNAP-I is important for the folding and secretion, and that Delta pro, a mutated derivative of RNAP-I in which the entire region of the pro sequence is deleted, forms gross aggregates in the yeast ER. In this study, we show that the degradation of Delta pro occurs independently of the proteasome. Its degradation was not inhibited either by a potent proteasome inhibitor or in a proteasome mutant. We also show that neither the export from the ER nor the vacuolar proteinase is required for the degradation of Delta pro. These results raise the possibility that the Delta pro aggregates are degraded in the ER lumen. We have isolated a yeast mutant in which the degradation of Delta pro is delayed. We show that the mutated gene is IRA2, which encodes a GTPase-activating protein for Ras. Because Ira2 protein is a negative regulator of the Ras-cAMP pathway, this result suggests that hyperactivation of the Ras-cAMP pathway inhibits the degradation of Delta pro. Consistently, down-regulation of the Ras-CAMP pathway in the ira2 mutant suppressed the defect of the degradation of Delta pro. Thus, the Ras-cAMP signal transduction pathway seems to control the proteasome-independent degradation of the ER misfolded protein aggregates.	RIKEN, Mol Membrane Biol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1138657, Japan	RIKEN; University of Tokyo; University of Tokyo	Umebayashi, K (corresponding author), RIKEN, Mol Membrane Biol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kyohei@postman.riken.go.jp	Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Nakano, Akihiko/C-6185-2009	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; 				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BOLENDER RP, 1973, J CELL BIOL, V56, P746, DOI 10.1083/jcb.56.3.746; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CANNON JF, 1994, GENETICS, V136, P485; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fukuda R, 1996, J BIOL CHEM, V271, P14252, DOI 10.1074/jbc.271.24.14252; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanninen AL, 1999, MOL BIOL CELL, V10, P3623, DOI 10.1091/mbc.10.11.3623; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holkeri H, 1998, FEBS LETT, V429, P162, DOI 10.1016/S0014-5793(98)00586-9; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; HUAN GLJ, 1999, J CELL BIOL, V145, P951; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUE S, 1992, J BIOL CHEM, V267, P9080; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; LUM PY, 1995, J CELL BIOL, V131, P81, DOI 10.1083/jcb.131.1.81; MATSUURA A, 1993, MOL GEN GENET, V238, P6, DOI 10.1007/BF00279524; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MORI K, 1993, CELL, V74, P743; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Ozols J, 1997, MOL BIOL CELL, V8, P2281, DOI 10.1091/mbc.8.11.2281; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Reynolds TB, 1998, J CELL BIOL, V143, P935, DOI 10.1083/jcb.143.4.935; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; Umebayashi K, 1999, EUR J CELL BIOL, V78, P726, DOI 10.1016/S0171-9335(99)80041-7; Umebayashi K, 1997, YEAST, V13, P1009; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; YOUNG J, 1993, J BIOL CHEM, V268, P19810; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	85	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41444	41454		10.1074/jbc.M105829200	http://dx.doi.org/10.1074/jbc.M105829200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526112	hybrid			2022-12-25	WOS:000171925600141
J	Angata, T; Varki, NM; Varki, A				Angata, T; Varki, NM; Varki, A			A second uniquely human mutation affecting sialic acid biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; IMMUNOGLOBULIN SUPERFAMILY; HUMAN GENOME; SIALOADHESIN; PROTEIN; DOMAIN; CD22; PURIFICATION; RECOGNITION; PHYLOGENY	Siglecs are immunoglobulin superfamily member lectins that selectively recognize different types and linkages of sialic acids, which are major components of cell surface and secreted glycoconjugates. We report here a human Siglec-like molecule (Siglec-L1) that lacks a conserved arginine residue known to be essential for optimal sialic acid recognition by previously known Siglecs. Loss of the arginine from an ancestral molecule was caused by a single nucleotide substitution that occurred after the common ancestor of humans with the great apes but before the origin of modern humans. The chimpanzee Siglec-L1 ortholog remains fully functional and preferentially recognizes N-glycolylneuraminic acid, which is a common sialic acid in great apes and other mammals. Reintroducing the ancestral arginine into the human molecule regenerates the same properties. Thus, the single base pair mutation that replaced the arginine on human Siglec-L1 is likely to be evolutionarily related to the previously reported loss of N-glycolylneuraminic acid expression in the human lineage. Siglec-L1 and its chimpanzee Siglec ortholog also have a different expression pattern from previously reported Siglecs because they are found on the lumenal edge of epithelial cell surfaces. Notably, the human genome contains several Siglec-like pseudogenes that have independent mutations that would have replaced the arginine residue required for optimal sialic acid recognition. Thus, additional changes in the biology of sialic acids may have taken place during human evolution.	Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med, Glycobiol Res & Training Ctr, Dept Med, 9500 Gilman Dr,MC0687, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIGMS NIH HHS [R01-GM323373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Cann RL, 2001, SCIENCE, V291, P1742, DOI 10.1126/science.1058948; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Crocker PR, 1998, GLYCOBIOLOGY, V8; Darwin G., 1871, P423; Gagneux P, 1999, P NATL ACAD SCI USA, V96, P5077, DOI 10.1073/pnas.96.9.5077; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAW CL, 1995, J IMMUNOL, V155, P3368; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Ruvolo M, 1997, MOL BIOL EVOL, V14, P248, DOI 10.1093/oxfordjournals.molbev.a025761; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schachner M, 2000, GLIA, V29, P154, DOI 10.1002/(SICI)1098-1136(20000115)29:2<154::AID-GLIA9>3.0.CO;2-3; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Varki A, 2000, GENOME RES, V10, P1065, DOI 10.1101/gr.10.8.1065; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200	39	65	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40282	40287		10.1074/jbc.M105926200	http://dx.doi.org/10.1074/jbc.M105926200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546777	hybrid			2022-12-25	WOS:000171789200103
J	Kobayashi, K; Tagawa, S; Daff, S; Sagami, I; Shimizu, T				Kobayashi, K; Tagawa, S; Daff, S; Sagami, I; Shimizu, T			Rapid calmodulin-dependent interdomain electron transfer in neuronal nitric-oxide synthase measured by pulse radiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILK XANTHINE DEHYDROGENASE; FLAVIN SEMIQUINONE; L-ARGININE; HEME; BINDING; REDUCTASE; BRAIN; SITE; HYDROXYARGININE; OXYGENATION	Electron transfer within rat neuronal nitric-oxide synthase (nNOS) was investigated by pulse radiolysis. Radiolytically generated 1-methyl-3-carbamoyl pyridinium (MCP) radical was found to react predominantly with the heme of the enzyme with a second-order rate constant for heme reduction of 3 x 10(8) m(-1) s(-1). In the calmodulin (CaM)-bound enzyme a subsequent first-order phase was observed which had a rate constant of 1.2 x 10(3) s(-1). In the absence of CaM, this phase was absent. Kinetic difference spectra for nNOS reduction indicated that the second phase consisted of heme reoxidation accompanied by formation of a neutral flavin semiquinone, suggesting that it is heme to flavin electron transfer. Experiments with the heme proximal surface mutant, K423E, had no second phase, confirming that the mutation blocks interdomain electron transfer. With the autoinhibitory loop deletion mutant, Delta 40, the slow phase was observed even in the absence of CaM consistent with the role of the loop in impeding interdomain electron transfer. The rate of heme to FMN electron transfer observed in the wild-type enzyme is similar to 1000 times faster than the FMN to heme electron transfer rate predicted during catalysis from kinetic modeling, suggesting that the catalytic process is slowed by kinetic gating.	Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan	Osaka University; University of Edinburgh; Tohoku University	Kobayashi, K (corresponding author), Osaka Univ, Inst Sci & Ind Res, Mihogaoka 8-1, Ibaraki, Osaka 5670047, Japan.	kobayasi@sanken.osaka-u.ac.jp	Kobayashi, Kazuo/H-9279-2012; Tagawa, Seiichi/B-8078-2010	Kobayashi, Kazuo/0000-0002-5586-9112; Shimizu, Toru/0000-0002-3950-5554				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HILLE R, 1991, J BIOL CHEM, V266, P5608; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; Kobayashi K, 1999, BIOCHEMISTRY-US, V38, P5913, DOI 10.1021/bi982088n; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P15620, DOI 10.1021/bi0014094; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; Ludwig ML, 1999, STRUCTURE, V7, pR73, DOI 10.1016/S0969-2126(99)80047-1; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 2000, NITRIC OXIDE; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Sato H, 1998, FEBS LETT, V430, P377, DOI 10.1016/S0014-5793(98)00699-1; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Witteveen CFB, 1998, BIOCHEM BIOPH RES CO, V250, P36, DOI 10.1006/bbrc.1998.8807	53	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39864	39871		10.1074/jbc.M102537200	http://dx.doi.org/10.1074/jbc.M102537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518705	hybrid			2022-12-25	WOS:000171789200049
J	Wang, XH; Connor, M; Wilson, D; Wilson, HI; Nicholson, GM; Smith, R; Shaw, D; Mackay, JP; Alewood, PF; Christie, MJ; King, GF				Wang, XH; Connor, M; Wilson, D; Wilson, HI; Nicholson, GM; Smith, R; Shaw, D; Mackay, JP; Alewood, PF; Christie, MJ; King, GF			Discovery and structure of a potent and highly specific blocker of insect calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIDER; NEUROTOXINS; ANTAGONIST; PEPTIDES; CURRENTS; PROGRAM; TOXINS	We have isolated a novel family of insect-selective neurotoxins that appear to be the most potent blockers of insect voltage-gated calcium channels reported to date. These toxins display exceptional phylogenetic specificity, with at least a 10,000-fold preference for insect versus vertebrate calcium channels. The structure of one of the toxins reveals a highly structured, disulfide-rich core and a structurally disordered C-terminal extension that is essential for channel blocking activity. Weak structural/functional homology with omega -agatoxin-IVA/B, the prototypic inhibitor of vertebrate P-type calcium channels, suggests that these two toxin families might share a similar mechanism of action despite their vastly different phylogenetic specificities.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Technol Sydney, Dept Hlth Sci, Sydney, NSW 2007, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia	University of Connecticut; University of Sydney; University of Sydney; University of Queensland; University of Queensland; University of Technology Sydney; Australian National University; John Curtin School of Medical Research	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC3305,263 Farmington Ave, Farmington, CT 06032 USA.	glenn@psel.uchc.edu	Wilson, David/Q-9865-2019; Connor, Mark/A-4197-2008; Nicholson, Graham M/E-8136-2010; King, Glenn F/J-5059-2012; Mackay, Joel/D-6834-2011	Wilson, David/0000-0001-5047-0711; Connor, Mark/0000-0003-2538-2001; Nicholson, Graham M/0000-0002-4277-4296; King, Glenn F/0000-0002-2308-2200; Christie, MacDonald/0000-0002-0622-609X; Mackay, Joel/0000-0001-7508-8033				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Benquet P, 1999, J NEUROPHYSIOL, V82, P2284, DOI 10.1152/jn.1999.82.5.2284; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; BRANTON WD, 1993, NATURE, V365, P496, DOI 10.1038/365496a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CORY JS, 1994, NATURE, V370, P138, DOI 10.1038/370138a0; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; DINIZ MRV, 1993, J BIOL CHEM, V268, P15340; Feyereisen R, 1995, TOXICOL LETT, V82-3, P83, DOI 10.1016/0378-4274(95)03470-6; ffrench-Constant RH, 1998, PHILOS T R SOC B, V353, P1685, DOI 10.1098/rstb.1998.0319; Fletcher JI, 1997, STRUCTURE, V5, P1525, DOI 10.1016/S0969-2126(97)00301-8; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; Fletcher JI, 1999, EUR J BIOCHEM, V264, P525, DOI 10.1046/j.1432-1327.1999.00659.x; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leisy DJ, 1996, INSECT BIOCHEM MOLEC, V26, P411, DOI 10.1016/0965-1748(95)00070-4; LENGUYEN D, 1993, PROTEIN SCI, V2, P165; LEUNG HT, 1989, NEURON, V3, P767, DOI 10.1016/0896-6273(89)90245-6; LUDVIGSEN S, 1992, J BIOMOL NMR, V2, P227, DOI 10.1007/BF01875318; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; Szeto TH, 2000, TOXICON, V38, P429, DOI 10.1016/S0041-0101(99)00174-9; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022	36	73	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40306	40312		10.1074/jbc.M105206200	http://dx.doi.org/10.1074/jbc.M105206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11522785	hybrid, Green Submitted			2022-12-25	WOS:000171789200107
J	Weiss, MA; Hua, QX; Jia, WH; Nakagawa, SH; Chu, YC; Hu, SQ; Katsoyannis, PG				Weiss, MA; Hua, QX; Jia, WH; Nakagawa, SH; Chu, YC; Hu, SQ; Katsoyannis, PG			Activities of monomeric insulin analogs at position A8 are uncorrelated with their thermodynamic stabilities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; RECEPTOR-BINDING; BIOLOGICAL-ACTIVITY; STRUCTURAL SWITCH; SIDE-CHAIN; MAIN CHAIN; X-RAY; PROTEIN; HELIX; PEPTIDES	Previous studies have demonstrated that the potency and thermodynamic stability of human insulin are enhanced in concert by substitution of Thr(A8) by arginine or histidine. These surface substitutions stabilize the N-terminal alpha -helix of the A chain, a key element of hormone-receptor recognition. Does enhanced stability necessarily imply enhanced activity? Here, we test by structure-based mutagenesis the relationship between the stability and activity of the hormone. To circumvent confounding effects of insulin self-association, A chain analogs were combined with a variant B chain (Asp(B10), Lys(B28), and Pro(B29) (DKP)) to create a monomeric template. Five analogs were obtained by chain combination; disulfide pairing proceeded in each case with native yield. CD and H-1 NMR spectra of the DKP analogs are essentially identical to those of DKP-insulin, indicating a correspondence of structures. Receptor binding affinities were determined by competitive displacement of I-125-insulin from human placental membranes. Thermodynamic stabilities were measured by CD titration; unfolding was monitored as a function of guanidine concentration. In this broader collection of analogs receptor binding affinities are uncorrelated with stability. We suggest that receptor binding affinities of AS analogs reflect local features of the hormone-receptor interface rather than the stability of the free hormone or the intrinsic C-capping propensity of the AS side chain.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Case Western Reserve University; University of Chicago; Icahn School of Medicine at Mount Sinai; New York University	Weiss, MA (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.							BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; BREMS DN, 1992, PROTEIN ENG, V5, P527, DOI 10.1093/protein/5.6.527; Buse, 2001, CURR OPIN ENDOCRINOL, V8, P95; CARA JF, 1990, J BIOL CHEM, V265, P17820; CHAKRABARTTY A, 1993, P NATL ACAD SCI USA, V90, P11332, DOI 10.1073/pnas.90.23.11332; CHU YC, 1994, BIOCHEMISTRY-US, V33, P11278, DOI 10.1021/bi00203a025; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; HU SQ, 1993, BIOCHEMISTRY-US, V32, P2631, DOI 10.1021/bi00061a022; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; KAARSHOLM NC, 1993, BIOCHEMISTRY-US, V32, P10773, DOI 10.1021/bi00091a031; KITAGAWA K, 1984, BIOCHEMISTRY-US, V23, P1405, DOI 10.1021/bi00302a011; KOBAYASHI M, 1982, BIOCHEM J, V206, P597, DOI 10.1042/bj2060597; KOBAYASHI M, 1982, BIOCHEM BIOPH RES CO, V107, P329, DOI 10.1016/0006-291X(82)91708-9; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LIANG DC, 1985, SCI SIN B-CHEM B A M, V28, P472; Ludvigsen S, 1998, J MOL BIOL, V279, P1, DOI 10.1006/jmbi.1998.1801; MARSHALL RN, 1974, J CLIN ENDOCR METAB, V39, P283, DOI 10.1210/jcem-39-2-283; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; Myers JK, 1997, BIOCHEMISTRY-US, V36, P10923, DOI 10.1021/bi9707180; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; Olsen HB, 1998, J MOL BIOL, V284, P477, DOI 10.1006/jmbi.1998.2175; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; Sauer R T, 1990, Adv Protein Chem, V40, P1, DOI 10.1016/S0065-3233(08)60286-7; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004	41	27	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40018	40024		10.1074/jbc.M104634200	http://dx.doi.org/10.1074/jbc.M104634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517220	hybrid			2022-12-25	WOS:000171789200070
J	Bounhar, Y; Zhang, Y; Goodyer, CG; LeBlanc, A				Bounhar, Y; Zhang, Y; Goodyer, CG; LeBlanc, A			Prion protein protects human neurons against Bax-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SYNAPTIC TRANSMISSION; CELLULAR ISOFORM; MICE DEFICIENT; KNOCKOUT MICE; SCRAPIE; CELLS; BCL-2; GENE; PRP	The function of the cellular prion protein (PrP) is still poorly understood. We present here an unprecedented role for PrP against Bax-mediated neuronal apoptosis and show that PrP potently inhibits Bax-induced cell death in human primary neurons. Deletion of four octapeptide repeats of PrP (PrP Delta OR) and familial D178N and T183A PrP mutations completely or partially eliminate the neuroprotective effect of PrP. PrP remains anti-apoptotic despite truncation of the glycosylphosphatidylinositol (GPI) anchor signal peptide, indicating that the neuroprotective form of PrP does not require the abundant cell surface GPI-anchored PrP. Our results implicate PrP as a potent and novel anti-apoptotic protein against Bax-mediated cell death.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	LeBlanc, A (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; HARLOW E, 1999, USING ANTIBODIES LAB, P223; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEBLANC A, 1998, HDB AGING BRAIN, P202; LEBLANC AC, 1994, BIOCHEM BIOPH RES CO, V204, P1371, DOI 10.1006/bbrc.1994.2615; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Nishida N, 1999, LAB INVEST, V79, P689; Nitrini R, 1997, ANN NEUROL, V42, P138, DOI 10.1002/ana.410420203; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Shindler KS, 1997, J NEUROSCI, V17, P3112; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Whatley SA, 1995, NEUROREPORT, V6, P2333, DOI 10.1097/00001756-199511270-00015; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000	42	293	300	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39145	39149		10.1074/jbc.C100443200	http://dx.doi.org/10.1074/jbc.C100443200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11522774	hybrid			2022-12-25	WOS:000171673200107
J	Chen, F; Ma, L; Al-Ansari, N; Shneider, B				Chen, F; Ma, L; Al-Ansari, N; Shneider, B			The role of AP-1 in the transcriptional regulation of the rat apical sodium-dependent bile acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; BINDING PROTEIN GENE; COTRANSPORTER GENE; SERUM-CHOLESTEROL; MESSENGER-RNA; REPORTER GENE; ILEAL; PROMOTER; DNA	Ileal reclamation of bile salts, a critical determinant of their enterohepatic circulation, is mediated primarily by the apical sodium-dependent bile acid transporter (ASBT=SLC10A2). We have defined mechanisms involved in the transcriptional regulation of ASBT. The ASBT gene extends over 17 kilobases and contains five introns. Primer extension analysis localized two transcription initiation sites 323 and 255 base pairs upstream of the initiator methionine. Strong promoter activity is imparted by both a 2.7- and 0.2-kilobase 5'-flanking region of ASBT. The promoter activity is cell line specific (Caco-2, not Hep-G2, HeLa-S3, or Madin-Darby canine kidney cells). Four distinct specific binding proteins were identified by gel shift and cross-linking studies using Caco-2 or rat ileal nuclear extracts. Two AP-1 consensus sites were identified in the proximal promoter. DNA binding and promoter activity could be abrogated by mutation of the proximal AP-1 site. Supershift analysis revealed binding of c-Jun and c-Fos to this AP-1 element. Co-expression of c-Jun enhanced promoter activity in Caco-2 cells and activated the promoter in Madin-Darby canine kidney cells. Region and developmental stage-specific expression of ASBT in the rat intestine correlated with the presence of one of these DNA-protein complexes and both c-Fos and c-Jun proteins. A specific AP-1 element regulates transcription of the rat ASBT gene.	CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol Nutr & Liver Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Shneider, B (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Div Pediat Gastroenterol Nutr & Liver Dis, Box 1656,1 Gustave L Levy Pl, New York, NY 10029 USA.	Benjamin.Shneider@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002076, R01DK054165] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02076, DK 54165] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpini G, 1997, GASTROENTEROLOGY, V113, P1734, DOI 10.1053/gast.1997.v113.pm9352879; Arrese M, 1998, HEPATOLOGY, V28, P1081, DOI 10.1002/hep.510280424; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Boudreau F, 1999, MOL CELL BIOCHEM, V195, P99, DOI 10.1023/A:1006987313013; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CARRASCO D, 1995, ONCOGENE, V10, P1069; CHANDLER CE, 1993, AM J PHYSIOL, V264, pG1118, DOI 10.1152/ajpgi.1993.264.6.G1118; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; Chen FY, 1997, P NATL ACAD SCI USA, V94, P4348, DOI 10.1073/pnas.94.9.4348; Christie DM, 1996, AM J PHYSIOL-GASTR L, V271, pG377, DOI 10.1152/ajpgi.1996.271.2.G377; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; Coppola CP, 1998, GASTROENTEROLOGY, V115, P1172, DOI 10.1016/S0016-5085(98)70088-5; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; Ding QM, 1998, LIFE SCI, V64, P175, DOI 10.1016/S0024-3205(98)00549-9; Dumaswala R, 1996, HEPATOLOGY, V23, P623; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Ghazi A, 2000, NATURE, V408, P419, DOI 10.1038/35044174; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HEUBI JE, 1982, GASTROENTEROLOGY, V83, P804; Higaki J, 1998, ARTERIOSCL THROM VAS, V18, P1304, DOI 10.1161/01.ATV.18.8.1304; HIGGINS JV, 1993, HEPATOLOGY, V18, pA298; HIGGINS JV, 1994, AM J PHYSIOL-GASTR L, V267, pG501, DOI 10.1152/ajpgi.1994.267.4.G501; Hofmann A.F., 1993, GASTROINTESTINAL DIS, V1, P127; Hollands CM, 1998, J PEDIATR SURG, V33, P220, DOI 10.1016/S0022-3468(98)90435-3; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lazaridis KN, 1997, J CLIN INVEST, V100, P2714, DOI 10.1172/JCI119816; LEWIS MC, 1995, J LIPID RES, V36, P1098; LILLIENAU J, 1993, GASTROENTEROLOGY, V104, P38, DOI 10.1016/0016-5085(93)90833-X; Martin MG, 2000, AM J PHYSIOL-GASTR L, V278, pG591, DOI 10.1152/ajpgi.2000.278.4.G591; Matsumoto K, 1998, ONCOGENE, V16, P1611, DOI 10.1038/sj.onc.1201675; Nowicki MJ, 1997, AM J PHYSIOL-GASTR L, V273, pG197, DOI 10.1152/ajpgi.1997.273.1.G197; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Parsons SJW, 2000, ANAL BIOCHEM, V281, P187, DOI 10.1006/abio.2000.4570; Patel AR, 1999, AM J PHYSIOL-GASTR L, V276, pG441, DOI 10.1152/ajpgi.1999.276.2.G441; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shneider BL, 1997, PEDIATR RES, V42, P189, DOI 10.1203/00006450-199708000-00010; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Srinivas P, 2000, PLASMID, V44, P262, DOI 10.1006/plas.2000.1492; Stelzner M, 2000, GASTROENTEROLOGY, V118, pA77, DOI 10.1016/S0016-5085(00)82384-7; Stelzner M, 2000, PFLUG ARCH EUR J PHY, V440, P157, DOI 10.1007/s004240000281; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Stravitz RT, 1997, GASTROENTEROLOGY, V113, P1599, DOI 10.1053/gast.1997.v113.pm9352862; Sundaram U, 1998, AM J PHYSIOL-GASTR L, V275, pG1259, DOI 10.1152/ajpgi.1998.275.6.G1259; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Walters HC, 2000, AM J PHYSIOL-GASTR L, V279, pG1188, DOI 10.1152/ajpgi.2000.279.6.G1188; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WONG MH, 1994, J BIOL CHEM, V269, P1340; WU GD, 1994, J BIOL CHEM, V269, P17080; Yeh KY, 2000, GASTROENTEROLOGY, V118, P525, DOI 10.1016/S0016-5085(00)70258-7	63	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38703	38714		10.1074/jbc.M104511200	http://dx.doi.org/10.1074/jbc.M104511200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509565	hybrid			2022-12-25	WOS:000171673200052
J	Keller, G; Ray, E; Brown, PO; Winge, DR				Keller, G; Ray, E; Brown, PO; Winge, DR			Haa1, a protein homologous to the copper-regulated transcription factor Ace1, is a novel transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; IDENTIFICATION; GENE; RESISTANCE; METALLOTHIONEIN; BINDING; DOMAIN; EXPRESSION; REPRESSION	The Saccharomyces cerevisiae genome contains a predicted gene, YPR008w, homologous to the gene encoding the copper-activated transcription factor Ace1. The product of the YPR008w gene, designated Haa1, regulates the transcription of a set of yeast genes, many of which encode membrane proteins. Two main target genes of Haa1 are the multidrug resistance gene YGR138c and the YRO2 homolog to the plasma membrane Hsp30. Haa1 is localized to the nucleus. Haa1-induced expression of YGR138c and YRO2 appears to be direct. Induction of HAA1 using a GAL1/HHAA1 fusion gene resulted in rapid galactose-induced expression of both HAA1 and target genes. Although Haa1 has a sequence very similar to the Cu-activated DNA binding domain of Ace1, expression of Haa1 target genes was found to be independent of the copper status of cells. Haa1 does not exhibit metalloregulation in cells incubated with a range of transition metal salts. Haa1 does not exhibit any cross-talk with Ace1. Overexpression of Haa1 does not compensate for cells lacking a functional Ace1. The lack of metalloregulation of Haa1 despite the strong sequence similarity to the copper regulatory domain of Ace1 is discussed.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Biochem, Stanford, CA 94305 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Stanford University	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010		NATIONAL CANCER INSTITUTE [P30CA042014, R01CA061286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61286, 5P30-CA 42014] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOBI A, 1995, J BIOL CHEM, V270, P10171, DOI 10.1074/jbc.270.17.10171; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; FOGEL S, 1988, J BASIC MICROB, V28, P147, DOI 10.1002/jobm.3620280302; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; HU S, 1990, New Biologist, V2, P544; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Jungwirth H, 2000, EUR J BIOCHEM, V267, P4809, DOI 10.1046/j.1432-1327.2000.01537.x; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lee JG, 2000, J BIOCHEM-TOKYO, V128, P1059, DOI 10.1093/oxfordjournals.jbchem.a022834; Nunes PA, 2001, ANTIMICROB AGENTS CH, V45, P1528, DOI 10.1128/AAC.45.5.1528-1534.2001; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; PETTIJEAN A, 1995, MOL CELL BIOL, V15, P5071; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	36	39	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38697	38702		10.1074/jbc.M107131200	http://dx.doi.org/10.1074/jbc.M107131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11504737	hybrid			2022-12-25	WOS:000171673200051
J	Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D				Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D			Functional cooperation between JunD and NF-kappa B in rat hepatocytes	ONCOGENE			English	Article						NF-kappa B; p65; AP-1; JunD; hepatocytes	TUMOR-NECROSIS-FACTOR; GM-CSF PROMOTER; C-JUN; GLUCOCORTICOID RECEPTOR; LIVER-REGENERATION; TRANSCRIPTION FACTORS; AP-1 COMPLEX; DNA-BINDING; ACTIVATES TRANSCRIPTION; HEPATIC REGENERATION	AP-I and NF-kappaB are rapidly activated during liver regeneration. Whether these parallel inductions have potential functional implications is not known. Isolated rat hepatocytes were stimulated with two mitogens, epidermal growth factor or hepatocyte growth factor and with tumor necrosis factor, a cytokine involved in the liver regenerative response in vivo and a strong inducer of NF-kappaB. All three cytokines increased AP-1 and NF-kappaB binding to their cognate cis-element and induced a 2.5-fold activation of NF-kappaB-dependent transcription. Inactivation of AP-I by TAM67, a dominant negative mutant of AP-I drastically inhibited basal and cytokine-induced NF-kappaB transactivation. Overexpression of Jun D, but not of the other Jun or Fos proteins increased by threefold NF-kappaB transactivation. Functional cooperation between JunD and p65 was demonstrated in a simple Gal-hybrid system. Finally, a twofold decrease in NF-kappaB transactivation was found in hepatocytes isolated from JunD (-/-) mice compared with hepatocytes from JunD(+/+) mice. Altogether these data demonstrate a functional cooperation of p65 with JunD, a major constituent of AP-1 in normal hepatocytes.	Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, F-75018 Paris, France; Univ Paris 07, F-75018 Paris, France; Inst Pasteur, Dept Biotechnol, CNRS, Unite Virus Oncogenes,URA 1644, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bernuau, D (corresponding author), Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, 16 Rue Henri Huchard, F-75018 Paris, France.		Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Rahmani, Mohamed/0000-0002-3992-8039; bakiri, latifa/0000-0002-6300-2420; Weitzman, Jonathan/0000-0001-8445-0102				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BALAVOINE S, 1990, EUR J BIOCHEM, V189, P617, DOI 10.1111/j.1432-1033.1990.tb15530.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; FAUSTO N, 1989, LAB INVEST, V60, P4; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIRAI SI, 1990, ONCOGENE, V5, P39; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Kralova J, 1996, ONCOGENE, V12, P2595; Le Cam A, 1995, Methods Mol Biol, V48, P141; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN L, 1998, CELL, V70, P777; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Menegazzi M, 1997, HEPATOLOGY, V25, P585, DOI 10.1002/hep.510250316; METTOUCHI A, 1997, MOL CELL BIOL, V17, P3020; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nadori F, 1997, HEPATOLOGY, V26, P1477; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rahmani M, 1999, J HEPATOL, V30, P916, DOI 10.1016/S0168-8278(99)80148-2; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; Thepot D, 2000, DEVELOPMENT, V127, P143; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	71	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5132	5142		10.1038/sj.onc.1204678	http://dx.doi.org/10.1038/sj.onc.1204678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526502				2022-12-25	WOS:000170464000007
J	Mor, I; Grisaru, D; Titelbaum, L; Evron, T; Richler, C; Wahrman, J; Sternfeld, M; Yogev, L; Meiri, N; Seidman, S; Soreq, H				Mor, I; Grisaru, D; Titelbaum, L; Evron, T; Richler, C; Wahrman, J; Sternfeld, M; Yogev, L; Meiri, N; Seidman, S; Soreq, H			Modified testicular expression of stress-associated "readthrough" acetylcholinesterase predicts male infertility	FASEB JOURNAL			English	Article						psychological stress; sperm motility; spermatogenesis	SEMEN QUALITY; VARIANT; GENE; DIFFERENTIATION; SPERMATOZOA; PESTICIDE; PROTEINS; SYSTEM; GROWTH; CELLS	Male infertility is often attributed to stress. However, the protein or proteins that mediate stress-related infertility are not yet known. Overexpression of the "readthrough" variant of acetylcholinesterase (AChE-R) is involved in the cellular stress response in a variety of mammalian tissues. Here, we report testicular overexpression of AChE-R in heads, but not tails, of postmeiotic spermatozoa from mice subjected to a transient psychological stress compared with age-matched control mice. Transgenic mice overexpressing AChE-R displayed reduced sperm counts, decreased seminal gland weight, and impaired sperm motility compared with age-matched nontransgenic controls. AChE-R was prominent in meiotic phase spermatocytes and in tails, but not heads, of testicular spermatozoa from AChE-R transgenic mice. Head-localized AChE-R was characteristic of human sperm from fertile donors. In contrast, sperm head AChE-R staining was conspicuously reduced in samples from human couples for whom the cause of infertility could not be determined, similar to the pattern found in transgenic mice. These findings indicate AChE-R involvement in impaired sperm quality, which suggests that it is a molecular marker for stress-related infertility.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, Jerusalem, Israel; Surasky Med Ctr, Inst Study Fertil, Tel Aviv, Israel; Sackler Sch Med, Tel Aviv, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, Bet Dagan, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel.	soreq@cc.huji.ac.il	Mor, Inbal/GON-5297-2022	Soreq, Hermona/0000-0002-0955-526X; Mor, Inbal/0000-0003-4564-9690				Bigbee JW, 2000, BRAIN RES, V861, P354, DOI 10.1016/S0006-8993(00)02046-1; Clarke RN, 1999, HUM REPROD, V14, P753, DOI 10.1093/humrep/14.3.753; DWIVEDI C, 1989, BIOCHEM MED METAB B, V42, P66, DOI 10.1016/0885-4505(89)90042-X; EGBUNIKE GN, 1980, INT J ANDROL, V3, P459, DOI 10.1111/j.1365-2605.1980.tb00134.x; Garner DL, 1999, MOL REPROD DEV, V53, P222, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;222::AID-MRD11&gt;3.0.CO;2-L; GIBLIN PT, 1988, FERTIL STERIL, V49, P127; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Jolly C, 1999, GENE EXPRESSION, V7, P261; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; Kronman C, 2000, J BIOL CHEM, V275, P29488, DOI 10.1074/jbc.M004298200; LEONHARDT H, 1993, COLOR ATLAS TXB HUMA, V2, P274; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; LevLehman E, 1997, BLOOD, V89, P3644, DOI 10.1182/blood.V89.10.3644.3644_3644_3653; LIFSON YL, 1992, P NATL ACAD SCI USA, V89, P579; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; NEGROVILAR A, 1993, ENVIRON HEALTH PERSP, V101, P59, DOI 10.2307/3431377; Palmero S, 1999, EUR J HISTOCHEM, V43, P277; PRINCE FP, 1992, CELL TISSUE RES, V269, P383, DOI 10.1007/BF00353893; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sarkar R, 2000, J REPROD FERTIL, V118, P29, DOI 10.1530/reprod/118.1.29; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Taylor P, 1996, GOODMAN GILMANS PHAR, P177; Tielemans E, 1999, LANCET, V354, P484, DOI 10.1016/S0140-6736(99)00599-1; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; YOUNG RJ, 1991, MOL REPROD DEV, V28, P55, DOI 10.1002/mrd.1080280109; Zhang Q, 1999, ENDOCRINOLOGY, V140, P2790, DOI 10.1210/en.140.6.2790; [No title captured]	34	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2039	+		10.1096/fj.00-0814fje	http://dx.doi.org/10.1096/fj.00-0814fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511515				2022-12-25	WOS:000170318500027
J	Cunningham, CC; Vegner, R; Bucki, R; Funaki, M; Korde, N; Hartwig, JH; Stossel, TP; Janmey, PA				Cunningham, CC; Vegner, R; Bucki, R; Funaki, M; Korde, N; Hartwig, JH; Stossel, TP; Janmey, PA			Cell permeant polyphosphoinositide-binding peptides that block cell motility and actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HUMAN PLATELETS; CANALICULAR MEMBRANE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; GELSOLIN; DOMAIN; RECEPTOR; PROTEIN; SITE	Polyphosphoinositides (PPIs) affect the localization and activities of many cellular constituents, including actin-modulating proteins. Several classes of polypeptide sequences, including pleckstrin homology domains, FYVE domains, and short linear sequences containing predominantly hydrophobic and cationic residues account for phosphoinositide binding by most such proteins. We report that a ten-residue peptide derived from the phosphatidylinositol 4,5-bisphosphate (PIP2) binding region in segment 2 of gelsolin, when coupled to rhodamine B has potent PIP2 binding activity in vitro; crosses the cell membrane of fibroblasts, platelets, melanoma cells, and neutrophils by a process not involving endocytosis; and blocks cell motility. This peptide derivative transiently disassembles actin filament structures in GFP-actin-expressing NIH3T3 fibroblasts and prevents thrombin- or chemotactic peptide-stimulated actin assembly in platelets and neutrophils, respectively, but does not block the initial [Ca2+] increase caused by these agonists. The blockage of actin assembly and motility is transient, and cells recover motility within an hour after their immobilization by 5-20 muM peptide. This class of reagents confirms the critical relation between inositol lipids and cytoskeletal structure and may be useful to probe the location and function of polyphosphoinositides in vivo.	Univ Penn, Inst Med & Engn, Dept Physiol, Vagelos Labs 1010, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA; Latvian Organ Synth Inst, LV-1006 Riga, Latvia	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Latvian Institute of Organic Synthesis	Janmey, PA (corresponding author), Univ Penn, Inst Med & Engn, Dept Physiol, Vagelos Labs 1010, 3340 Smith Walk, Philadelphia, PA 19104 USA.			Bucki, Robert/0000-0001-7664-9226	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; FIC NIH HHS [TW00100] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABSOLOM D, 1986, PHAGOCYTOSIS CELL ME, P95; Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; CUNNINGHAM CC, 1998, PEPTIDES 1996, P317; DUCLOHIER H, 1994, TOXICOLOGY, V87, P175, DOI 10.1016/0300-483X(94)90160-0; FLANAGAN L, 1999, BIOL PHOSPHOINOSITID, P166; Foster WJ, 2001, BIOPHYS CHEM, V91, P211, DOI 10.1016/S0301-4622(01)00171-5; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Hubner S, 1998, EUR J BIOCHEM, V258, P846, DOI 10.1046/j.1432-1327.1998.2580846.x; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Isenberg G, 1998, INT REV CYTOL, V178, P73; Isenberg G, 1996, FEBS LETT, V397, P316, DOI 10.1016/S0014-5793(96)01203-3; JAMNEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; KAJI T, 1991, TOXICOLOGY, V68, P11; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Ma L, 1998, J CELL BIOL, V140, P1125; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; Medina OP, 2001, CANCER RES, V61, P3978; Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rogers KL, 2000, EUR J PHARM SCI, V9, P355, DOI 10.1016/S0928-0987(99)00074-3; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sai Y, 1999, J CELL SCI, V112, P4535; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Sechi AS, 2000, J CELL SCI, V113, P3685; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SIMOES AP, 1995, FEBS LETT, V365, P155; SIMOES AP, 1993, FEBS LETT, V331, P248, DOI 10.1016/0014-5793(93)80346-V; Stock A, 1999, EMBO J, V18, P5274, DOI 10.1093/emboj/18.19.5274; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; VonSteyern FV, 1996, J HISTOCHEM CYTOCHEM, V44, P267, DOI 10.1177/44.3.8648087; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YU FX, 1992, J BIOL CHEM, V267, P14616	47	97	104	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43390	43399		10.1074/jbc.M105289200	http://dx.doi.org/10.1074/jbc.M105289200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11533030	hybrid			2022-12-25	WOS:000172169300098
J	Amor, JC; Horton, JR; Zhu, XJ; Wang, Y; Sullards, C; Ringe, D; Cheng, XD; Kahn, RA				Amor, JC; Horton, JR; Zhu, XJ; Wang, Y; Sullards, C; Ringe, D; Cheng, XD; Kahn, RA			Structures of yeast ARF2 and ARL1 - Distinct roles for the N terminus in the structure and function of ARF family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ELECTRON-DENSITY MAPS; GTP-BINDING-PROTEIN; DROSOPHILA; ACTIVATION; COATOMER; COMPLEX; GDP	Structures were determined by x-ray crystallography for two members of the ADP-ribosylation factor (ARF) family of regulatory GTPases, yeast ARF1 and ARL1, and were compared with previously determined structures of human ARF1 and ARF6. These analyses revealed an overall conserved fold but differences in primary sequence and length, particularly in an N-terminal loop, lead to differences in nucleotide and divalent metal binding. Packing of hydrophobic residues is central to the interplay between the N-terminal a-helix, switch I, and the interswitch region, which along with differences in surface electrostatics provide explanations for the different biophysical and biochemical properties of ARF and ARF-like proteins.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Brandeis Univ, Rosenstiel Basic Med Res Ctr, Dept Biochem & Chem, Waltham, MA 02454 USA	Emory University; Brandeis University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Hu, Ruogu/B-2203-2008; Horton, John/F-2375-2010; Kahn, Richard/ABD-2666-2020; Horton, John R/ABB-4770-2020	Kahn, Richard/0000-0002-0259-0601; Horton, John/0000-0001-9749-8068	NIAID NIH HHS [AI43996] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043996] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Beraud-Dufour S, 2001, METHOD ENZYMOL, V329, P245; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Hillig RC, 2000, STRUCTURE, V8, P1239, DOI 10.1016/S0969-2126(00)00531-1; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kahn RA, 1996, J LIPID MEDIAT CELL, V14, P209, DOI 10.1016/0929-7855(96)00527-5; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; Lacal JC, 1993, RAS SUPERFAMILY GTPA; MARTIN ACR, 1998, PROFIT VERSION 1 8 S; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Renault L, 2001, ACTA CRYSTALLOGR D, V57, P1167, DOI 10.1107/S0907444901009556; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465	29	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42477	42484		10.1074/jbc.M106660200	http://dx.doi.org/10.1074/jbc.M106660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11535602	hybrid			2022-12-25	WOS:000172450400120
J	Zheng, ZF; Zou, JT				Zheng, ZF; Zou, JT			The initial step of the glycerolipid pathway - Identification of glycerol 3-phosphate/dihydroxyacetone phosphate dual substrate acyltransferases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID-SYNTHESIS; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; DIHYDROXYACETONE PHOSPHATE; CHOLINE-TRANSPORT; ESCHERICHIA-COLI; LIPID PARTICLES; GENE; BIOSYNTHESIS; ACID	The initial step of phospholipid biosynthesis in yeast is carried out through the acylation of glycerol 3-phosphate (G-3-P) and dihydroxyacetone phosphate by stereospecific sn-1 acyltransferases. Here we report the identification of two key fatty acyltransferases of the glycerolipid biosynthesis pathway in Saccharomyces cerevisiae. Disruption of the open reading frame YBLO11w, corresponding to a gene previously identified as a choline transporter suppressor (SCT1), resulted in a substantial decrease of total cellular G-3-P acyltransferase activity. A yeast strain disrupted at the open reading frame YKR067w, which encodes a protein closely related to Sct1p, also exhibited a dramatic reduction in G-3-P acyltransferase activity. Molecular characterizations of the genes revealed that a missense mutation in YKR067w accounted for a defect in the activities of the G-3-P acyltransferase in the yeast mutant strain TTA1. Heterologous expression of YKR067w in Escherichia coli further confirmed its enzyme activity. These results indicate that YKR067w and YBLO11w, designated herein as GAT1 and GAT2(SCT1), respectively, are yeast G-3-P acyltransferase genes. Furthermore, biochemical results are presented to show that both Gat1p and Gat2p(Sct1p) are G-3-P/dihydroxyacetone phosphate dual substrate-specific sn-1 acyltransferases. The fatty acyl specificity of Gat1p is similar to that of the mammalian microsomal G-3-P acyltransferase, as it can effectively utilize a broad range of fatty acids as acyl donors. In contrast, Gat2p(Sct1p) displayed preference toward 16-carbon fatty acids. The most notable of the altered phospholipid compositions of the gat1 Delta and gat2(sct1)Delta strains are a decreased phosphatidic acid pool and an increased phosphatidylserine/phosphatidyl-inositol ratio. This did not appear to affect the mutants as no growth defect was found. However, null mutations of both GAT1 and GAT2(SCT1) are synthetically lethal to yeast.	Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	National Research Council Canada	Zou, JT (corresponding author), Natl Res Council Canada, Inst Plant Biotechnol, 110 Gymnasium Rd, Saskatoon, SK S7N 0W9, Canada.							Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1974, J BACTERIOL, V117, P1065, DOI 10.1128/JB.117.3.1065-1076.1974; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CHRISTIANSEN K, 1978, BIOCHIM BIOPHYS ACTA, V530, P78, DOI 10.1016/0005-2760(78)90128-5; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; Dircks LK, 1997, BBA-LIPID LIPID MET, V1348, P17, DOI 10.1016/S0005-2760(97)00106-9; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; Heath RJ, 1999, J BACTERIOL, V181, P1944, DOI 10.1128/JB.181.6.1944-1946.1999; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; MATSUSHITA M, 1995, J BIOCHEM-TOKYO, V117, P447, DOI 10.1093/jb/117.2.447; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORASH SC, 1994, J BIOL CHEM, V269, P28769; Murata N, 1997, BBA-LIPID LIPID MET, V1348, P10, DOI 10.1016/S0005-2760(97)00115-X; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; Wilkison WO, 1997, BBA-LIPID LIPID MET, V1348, P3, DOI 10.1016/S0005-2760(97)00099-4; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x	27	113	127	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41710	41716		10.1074/jbc.M104749200	http://dx.doi.org/10.1074/jbc.M104749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11544256	hybrid			2022-12-25	WOS:000172450400024
J	Uchiyama, T; Katouno, F; Nikaidou, N; Nonaka, T; Sugiyama, J; Watanabe, T				Uchiyama, T; Katouno, F; Nikaidou, N; Nonaka, T; Sugiyama, J; Watanabe, T			Roles of the exposed aromatic residues in crystalline chitin hydrolysis by chitinase a from Serratia marcescens 2170	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; VALONIA CELLULOSE MICROCRYSTALS; ACID-SEQUENCE SIMILARITIES; BINDING DOMAIN; GLYCOSYL HYDROLASES; TRICHODERMA-REESEI; RESOLUTION; LYSOZYME; SERRATIA-MARCESCENS-2170; DEGRADATION	Four exposed aromatic residues, two in the N-terminal domain (Trp-69 and Trp-33) and two in the catalytic domain (Trp-245 and Phe-232) of Serratia marcescens chitinase A, are linearly aligned with the deep catalytic cleft. To investigate the importance of these residues in the binding activity and hydrolyzing activity against insoluble chitin, site-directed mutagenesis to alanine was carried out. The substitution of Trp-69, Trp-33, or Trp-245 significantly reduced the binding activity to both highly crystalline beta -chitin and colloidal chitin. The substitution of Phe-232, which is located closest to the catalytic cleft, did not affect the binding activity. On the other hand, the hydrolyzing activity against beta -chitin microfibrils was significantly reduced by the substitution of any one of the four aromatic residues including Phe-232. None of the mutations reduced the hydrolyzing activity against soluble substrates. These results clearly demonstrate that the four exposed aromatic residues are essential determinants for crystalline chitin hydrolysis. Three of them, two in the N-terminal domain and one in the catalytic domain, play vital roles in the chitin binding. Phe-232 appeared to be important for guiding the chitin chain into the catalytic cleft. Based on these observations, a model for processive hydrolysis of crystalline chitin by chitinase A is proposed.	Niigata Univ, Fac Agr, Dept Appl Biol Chem, Niigata 9502181, Japan; Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; Kyoto Univ, Wood Res Inst, Kyoto 6110011, Japan	Niigata University; Nagaoka University of Technology; Kyoto University	Watanabe, T (corresponding author), Niigata Univ, Fac Agr, Dept Appl Biol Chem, 8050 Ikarashi 2, Niigata 9502181, Japan.	wata@agr.niigata-u.ac.jp	Sugiyama, Junji/G-2879-2019; Sugiyama, Junji/ABD-5589-2020	Sugiyama, Junji/0000-0002-5388-4925; Sugiyama, Junji/0000-0002-5388-4925				Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; CHANZY H, 1985, FEBS LETT, V184, P285, DOI 10.1016/0014-5793(85)80623-2; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; HART PJ, 1995, J MOL BIOL, V248, P402, DOI 10.1006/jmbi.1995.0230; Hashimoto M, 2000, J BACTERIOL, V182, P3045, DOI 10.1128/JB.182.11.3045-3054.2000; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Ikegami T, 2000, J BIOL CHEM, V275, P13654, DOI 10.1074/jbc.275.18.13654; Imai T, 1998, FEBS LETT, V432, P113, DOI 10.1016/S0014-5793(98)00845-X; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; Jeuniaux C., 1966, METHOD ENZYMOL, V8, P644, DOI [DOI 10.1016/0076-6879(66)08117-5, 10.1016/0076-6879(66)08117-5]; Koivula A, 1998, FEBS LETT, V429, P341, DOI 10.1016/S0014-5793(98)00596-1; Koivula A, 1999, FEBS LETT, V447, P334, DOI 10.1016/S0014-5793(99)00213-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsumoto T, 1999, P JPN ACAD B-PHYS, V75, P269, DOI 10.2183/pjab.75.269; Mattinen ML, 1997, PROTEIN SCI, V6, P294; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; Ohno T, 1996, J BACTERIOL, V178, P5065, DOI 10.1128/jb.178.17.5065-5070.1996; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1997, FOLD DES, V2, P291, DOI 10.1016/S1359-0278(97)00040-0; Simpson HD, 1999, J BACTERIOL, V181, P4611, DOI 10.1128/JB.181.15.4611-4616.1999; Sugiyama J, 1999, J MOL BIOL, V286, P247, DOI 10.1006/jmbi.1998.2458; Suzuki K, 1998, BIOSCI BIOTECH BIOCH, V62, P128, DOI 10.1271/bbb.62.128; Suzuki K, 1999, BIOCHEM J, V343, P587, DOI 10.1042/0264-6021:3430587; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; Watanabe T, 2001, FEBS LETT, V494, P74, DOI 10.1016/S0014-5793(01)02317-1; Watanabe T, 1997, J BACTERIOL, V179, P7111, DOI 10.1128/jb.179.22.7111-7117.1997; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; YAMADA H, 1981, CARBOHYD RES, V92, P160, DOI 10.1016/S0008-6215(00)85993-5; YANASE Y, 1987, ARCH BIOCHEM BIOPHYS, V253, P168, DOI 10.1016/0003-9861(87)90649-7	35	152	156	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41343	41349		10.1074/jbc.M103610200	http://dx.doi.org/10.1074/jbc.M103610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522778	hybrid			2022-12-25	WOS:000171925600128
J	Wilson, MP; Sun, Y; Cao, L; Majerus, PW				Wilson, MP; Sun, Y; Cao, L; Majerus, PW			Inositol 1,3,4-trisphosphate 5/6-kinase is a protein kinase that phosphorylates the transcription factors c-Jun and ATF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; SIGNAL-TRANSDUCTION; COP9 COMPLEX; ENTAMOEBA-HISTOLYTICA; LIGHT CONTROL; LIPID KINASE; IN-VITRO; POLYPHOSPHATES; ARABIDOPSIS; INHIBITION	Phosphorylation of inositol 1,3,4-trisphosphate by inositol 1,3,4-trisphosphate 5/6-kinase is the first committed step in the formation of higher phosphorylated forms of inositol. We have shown that the eight proteins called the COP9 signalosome complex copurify with calf brain 5/6-kinase. Because the complex has been shown to phosphorylate c-Jun an vitro, we tested both the complex and 5/6-kinase and found that both are able to phosphorylate c-Jun and ATF-2 on serine/threonine residues. These findings establish a link between two major signal transduction systems: the inositol phosphates and the stress response system.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, 660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672, R01HL016634, R37HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672, HL 16634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA T, 1987, J BIOL CHEM, V262, P9952; BALLA T, 1987, BIOCHEM BIOPH RES CO, V148, P199, DOI 10.1016/0006-291X(87)91095-3; BECK KA, 1991, J BIOL CHEM, V266, P4442; Bondev A, 1999, BIOL CHEM, V380, P1337, DOI 10.1515/BC.1999.171; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; Field J, 2000, MOL BIOCHEM PARASIT, V108, P119, DOI 10.1016/S0166-6851(00)00197-3; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUGHES PJ, 1994, BBA-MOL CELL RES, V1223, P57, DOI 10.1016/0167-4889(94)90073-6; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Itoh T, 2000, J BIOL CHEM, V275, P19389, DOI 10.1074/jbc.M000426200; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KING WG, 1990, BIOCHEM J, V270, P125, DOI 10.1042/bj2700125; LAM K, 1994, J BIOL CHEM, V269, P20648; Larsson O, 1997, SCIENCE, V278, P471, DOI 10.1126/science.278.5337.471; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin JB, 2000, J BIOL CHEM, V275, P10134, DOI 10.1074/jbc.275.14.10134; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHEARS SB, 1990, SYM SOC EXP BIOL, V44, P181; SHEARS SB, 1987, BIOCHEM J, V246, P139, DOI 10.1042/bj2460139; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; Spain BH, 1996, MOL CELL BIOL, V16, P6698; TOKER A, 1994, J BIOL CHEM, V269, P33258; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642	49	56	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40998	41004		10.1074/jbc.M106605200	http://dx.doi.org/10.1074/jbc.M106605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11533064	hybrid			2022-12-25	WOS:000171925600084
J	Zhao, F; Satoda, M; Licht, JD; Hayashizaki, Y; Gelb, BD				Zhao, F; Satoda, M; Licht, JD; Hayashizaki, Y; Gelb, BD			Cloning and characterization of a novel mouse AP-2 transcription factor, Ap-2 gamma, with unique DNA binding and transactivation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; EPITHELIAL-CELLS; FAMILY; EMBRYOGENESIS; AP-2-ALPHA; AP-2-BETA; PROTEINS; PROMOTER; MEMBERS; CANCER	AP-2 transcription factors are sequence-specific DNA-binding proteins expressed in neural crest and other tissues during mammalian development. Three mammalian genes, AP-2 alpha, AP-2 beta, and AP-2 gamma, have been reported previously. A partial predicted AP-2 gene was identified in tandem with AP-2 beta on human chromosome 6p12p21.1. The orthologous mouse gene, which we named Ap-2 delta, was identified from a fetal mouse head cDNA library. Northern analysis revealed two transcripts in embryonic and newborn mouse brain, with markedly higher steady-state levels in the former. The predicted Ap-2 delta protein comprised 452 amino acids and was highly similar to other AP-2 proteins across the DNA-binding and dimerization domains. Ap-2 delta formed homodimers and heterodimers in vitro, bound an optimized AP-2 consensus DNA sequence, and transactivated gene expression in eukaryotic cells. Ap-2 delta dimers bound poorly to an AP-2 binding sequence from the human metallothionein IIa promoter in vitro, revealing a sequence specificity not previously observed among other AP-2 proteins. The PY motif and critical residues in the transactivation domain, which are highly conserved in the AP-2 family and believed necessary for transactivation, were divergent in Ap-2 delta. The unique protein sequence and functional features of Ap-2 delta suggest mechanisms, besides tissue-specific AP-2 gene expression, for specific control of target gene activation.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY USA; Mt Sinai Sch Med, Dept Med, New York, NY USA; Mt Sinai Sch Med, Derald H Ruttenberg Ctr, New York, NY USA; RIKEN, Genome Sci Lab, Yokohama, Kanagawa 2300045, Japan	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; RIKEN	Gelb, BD (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave Levy Pl,Box 1498, New York, NY 10029 USA.	gelbb01@doc.mssm.edu	Hayashizaki, Yoshihide/N-6590-2015; Licht, Jonathan/L-4239-2019	Satoda, Masahiko/0000-0003-0804-860X; Licht, Jonathan/0000-0002-3942-1369	NICHD NIH HHS [HD38018] Funding Source: Medline; PHS HHS [A59998] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038018] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anttila MA, 2000, BRIT J CANCER, V82, P1974; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Bisgrove DA, 1997, MOL CELL BIOL, V17, P5935, DOI 10.1128/MCB.17.10.5935; Bosher JM, 1996, ONCOGENE, V13, P1701; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Ebert SN, 1998, J NEUROCHEM, V70, P2286; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Maconochie M, 1999, DEVELOPMENT, V126, P1483; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SNAPE AM, 1991, DEVELOPMENT, V113, P283; Turner BC, 1998, CANCER RES, V58, P5466; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	29	123	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40755	40760		10.1074/jbc.M106284200	http://dx.doi.org/10.1074/jbc.M106284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522791	hybrid			2022-12-25	WOS:000171925600052
J	Kozaki, AK; Mayumi, K; Sasaki, Y				Kozaki, AK; Mayumi, K; Sasaki, Y			Thiol-disulfide exchange between nuclear-encoded and chloroplast-encoded subunits of pea acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; REDOX; LIGHT; IDENTIFICATION; MUTAGENESIS; ACTIVATION; PLANTS; FORMS	Fatty acid synthesis in pea chloroplasts is regulated by light/dark. The regulatory enzyme acetyl-CoA carboxylase is modulated by light/dark, presumably under redox regulation. Acetyl-CoA carboxylase is a multienzyme complex composed of biotin carboxylase and carboxyltransferase (CT). To demonstrate the redox regulation of CT, composed of the nuclear-encoded a and the chloroplast-encoded beta subunits, we identified the cysteine residues involved in such regulation. We expressed the recombinant CT in Escherichia coli and found that the partly deleted CT was, like the full-length CT, sensitive to a redox state. Site-directed mutagenesis of the deleted CT showed that replacement by alanine of the cysteine residue 267 in the a polypeptide or 442 in the beta polypeptide resulted in redox-insensitive CT and broke the intermolecular disulfide bond between the a and beta polypeptides. Similar results were confirmed in the full-length CT. These results indicate that the two cysteines in recombinant CT are involved in redox regulation by intermolecular disulfide-dithiol exchange between the alpha and beta subunits. Immunoblots of extract from plants incubated in the light or dark supported that such a disulfide-dithiol exchange is relevant in vivo. A covalent bond between a nuclear-encoded polypeptide and a chloroplast-encoded polypeptide probably regulates the enzyme activity in response to light.	Nagoya Univ, Grad Sch Agr Sci, Lab Plant Mol Biol, Nagoya, Aichi 4648601, Japan	Nagoya University	Sasaki, Y (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Lab Plant Mol Biol, Nagoya, Aichi 4648601, Japan.	sasaki@agr.nagoya-u.ac.jp						Anderson LE, 1996, PLANT J, V10, P553, DOI 10.1046/j.1365-313X.1996.10030553.x; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; Hunter SC, 1998, ARCH BIOCHEM BIOPHYS, V359, P170, DOI 10.1006/abbi.1998.0900; INAKA K, 1991, J BIOL CHEM, V266, P12599; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; JACQUOT JP, 1995, EUR J BIOCHEM, V229, P675, DOI 10.1111/j.1432-1033.1995.tb20513.x; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KONISHI T, 1994, P NATL ACAD SCI USA, V91, P3598, DOI 10.1073/pnas.91.9.3598; Konishi T, 1996, PLANT CELL PHYSIOL, V37, P117, DOI 10.1093/oxfordjournals.pcp.a028920; Kozaki A, 1999, BIOCHEM J, V339, P541, DOI 10.1042/0264-6021:3390541; Kozaki A, 2000, J BIOL CHEM, V275, P10702, DOI 10.1074/jbc.275.14.10702; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SASAKI Y, 1995, PLANT PHYSIOL, V108, P445, DOI 10.1104/pp.108.2.445; SASAKI Y, 1993, J BIOL CHEM, V268, P25118; Sasaki Y, 1997, P NATL ACAD SCI USA, V94, P11096, DOI 10.1073/pnas.94.20.11096; Sasaki Y, 2001, J BIOL CHEM, V276, P3937, DOI 10.1074/jbc.M008166200; SAUER A, 1984, Z NATURFORSCH C, V39, P268; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519	23	41	50	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39919	39925		10.1074/jbc.M103525200	http://dx.doi.org/10.1074/jbc.M103525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546765	hybrid			2022-12-25	WOS:000171789200057
J	Tassi, E; Al-Attar, A; Aigner, A; Swift, MR; McDonnell, K; Karavanov, A; Wellstein, A				Tassi, E; Al-Attar, A; Aigner, A; Swift, MR; McDonnell, K; Karavanov, A; Wellstein, A			Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FACTOR RECEPTOR-1; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; KINASE; INHIBITION; DIFFERENTIATION; ANGIOGENESIS; EXPRESSION	Fibroblast growth factor-binding protein (FGF-BP) I is a secreted protein that can bind fibroblast growth factors (FGFs) 1 and 2. These FGFs are typically stored on heparan sulfate proteoglycans in the extracellular matrix in an inactive form, and it has been proposed that FGF-BP1 functions as a chaperone molecule that can mobilize locally stored FGF and present the growth factor to its tyrosine kinase receptor. FGF-BP1 is upregulated in squamous cell, colon, and breast cancers and can act as an angiogenic switch during malignant progression of epithelial cells. For the present studies, we focused on FGF-1 and -2 and investigated interactions with recombinant human FGF-BP1 protein as well as effects on signal transduction, cell proliferation, and angiogenesis. We show that recombinant FGF-BP1 specifically binds FGF-2 and that this binding is inhibited by FGF-1, heparan sulfate, and heparinoids. Furthermore, FGF-BP1 enhances FGF-1- and FGF-2-dependent proliferation of NIH-3T3 fibroblasts and FGF-2-induced extracellular signal-regulated kinase 2 phosphorylation. Finally, in the chicken chorioallantoic membrane angiogenesis assay, FGF-BP1 synergizes with exogenously added FGF-2. We conclude that FGF-BP1 binds directly to FGF-1 and FGF-2 and positively modulates the biological activities of these growth factors.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Ciphergen Biosyst, Palo Alto, CA 94306 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Bldg E311,3970 Reservoir Rd,NW, Washington, DC 20007 USA.	wellstea@georgetown.edu	Aigner, Achim/R-4429-2017; Tassi, Enrico/K-3958-2015; Tassi, Enrico/AAJ-9661-2020	Aigner, Achim/0000-0002-2778-6256; Tassi, Enrico/0000-0002-3335-6500; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA 71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; Dove AQ, 1999, NAT BIOTECHNOL, V17, P233, DOI 10.1038/6972; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2000, J BIOL CHEM, V275, P39801; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; LANDGREN E, 1995, ONCOGENE, V10, P2027; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Liu XH, 2001, KIDNEY INT, V59, P1717, DOI 10.1046/j.1523-1755.2001.0590051717.x; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; MOSCATELLI DA, 1986, ANTICANCER RES, V6, P861; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Wellstein A, 1996, BREAST CANCER RES TR, V38, P109, DOI 10.1007/BF01803789; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WU DQ, 1991, J BIOL CHEM, V266, P16778; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZUGMAIER G, 1992, J NATL CANCER I, V84, P1716, DOI 10.1093/jnci/84.22.1716	52	109	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40247	40253		10.1074/jbc.M104933200	http://dx.doi.org/10.1074/jbc.M104933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509569	hybrid			2022-12-25	WOS:000171789200098
J	Langelier, MF; Forget, D; Rojas, A; Porlier, Y; Burton, ZF; Coulombe, B				Langelier, MF; Forget, D; Rojas, A; Porlier, Y; Burton, ZF; Coulombe, B			Structural and functional interactions of transcription factor (TF) IIA with TFIIE and TFIIF in transcription initiation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GENERAL TRANSCRIPTION; CARBOXYL-TERMINAL-DOMAIN; BOX-BINDING PROTEIN; TOPOLOGICAL LOCALIZATION; IMMEDIATELY UPSTREAM; YEAST TRANSCRIPTION; CRYSTAL-STRUCTURE; PROMOTER DNA; COMPLEX; TBP	A topological model for transcription initiation by RNA polymerase II (RNAPII has recently been proposed. This model stipulates that wrapping of the promoter DNA around RNAPII and the general initiation factors TBP, TFIIB, TFIIE, TFIIF and TFIIH induces a torsional strain in the DNA double helix that facilitates strand separation and open complex formation. In this report, we show that TFIIA, a factor previously shown to both stimulate basal transcription and have co-activator functions, is located near the cross-point of the DNA loop where it can interact with TBP, TFIIE56, TFIIE34, and the RNAPII-associated protein (RAP) 74. In addition, we demonstrate that TFIIA can stimulate basal transcription by stimulating the functions of both TFIIE34 and RAP74 during the initiation step of the transcription reaction. These results provide novel insights into mechanisms of TFIIA function.	Inst Rech Clin Montreal, Lab Gene Transcript, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Michigan State University	Coulombe, B (corresponding author), Inst Rech Clin Montreal, Lab Gene Transcript, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	coulomb@ircm.qc.ca			Canadian Institutes of Health Research [14309-2] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Coulombe Benoit, 1992, Gene Expression, V2, P99; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Douziech M, 1999, J BIOL CHEM, V274, P19868, DOI 10.1074/jbc.274.28.19868; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1992, J BIOL CHEM, V267, P2786; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; GE H, 1994, J BIOL CHEM, V269, P17136; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Lei L, 1999, MOL CELL BIOL, V19, P8372; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PAN GH, 1994, J BIOL CHEM, V269, P30101; PETERSON MG, 1991, NATURE, V354, P369; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 2000, METH MOL B, V148, P383; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SOPTA M, 1985, J BIOL CHEM, V260, P353; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; Yamamoto S, 2001, MOL CELL BIOL, V21, P1, DOI 10.1128/MCB.21.1.1-15.2001; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Yokomori K, 1998, P NATL ACAD SCI USA, V95, P6722, DOI 10.1073/pnas.95.12.6722	63	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38652	38657		10.1074/jbc.M106422200	http://dx.doi.org/10.1074/jbc.M106422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509574	Green Accepted, hybrid			2022-12-25	WOS:000171673200044
J	Nykvist, P; Tasanen, K; Viitasalo, T; Kapyla, J; Jokinen, J; Bruckner-Tuderman, L; Heino, J				Nykvist, P; Tasanen, K; Viitasalo, T; Kapyla, J; Jokinen, J; Bruckner-Tuderman, L; Heino, J			The cell adhesion domain of type XVII collagen promotes integrin-mediated cell spreading by a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIII-COLLAGEN; I-DOMAIN; A-DOMAIN; BINDING; KERATINOCYTES; EXPRESSION; RECEPTOR; CLONING; SUBUNIT; ALPHA(1)BETA(1)	Type XVII collagen (BP180) is a keratinocyte transmembrane protein that exists as the full-length protein in hemidesmosomes and as a 120-kDa shed ectodomain in the extracellular matrix. The largest collagenous domain of type XVII collagen, COL15, has been described previously as a cell adhesion domain (Tasanen, K., Eble, J. A., Aumailley, M., Schumann, H., Baetge, J, Tu, H., Bruckner, P., and Bruckner-Tuderman, L. (2000) J: Biol Chem. 275, 3093-3099). In the present work, the integrin binding of triple helical, human recombinant COL15 was tested. Solid phase binding assays using recombinant integrin alpha I-1, alpha I-2, and alpha I-10 domains and cell spreading assays with alpha (1)beta (1)- and alpha (2)beta (1)-expressing Chinese hamster ovary cells showed that, unlike other collagens, COL15 was not recognized by the collagen receptors. Denaturation of the COL15 domain increased the spreading of human HaCaT keratinocytes, which could migrate on the denatured COL15 domain as effectively as on fibronectin. Spreading of HaCaT cells on the COL15 domain was mediated by alpha (5)beta (1) and alpha (v)beta (1) integrins, and it could be blocked by RGD peptides. The collagen alpha -chains in the COL15 domain do not contain RGD motifs but, instead, contain 12 closely related KGD motifs, four in each of the three alpha -chains. Twenty-two overlapping, synthetic peptides corresponding to the entire COL15 domain were tested; three peptides, all containing the KGD motif, inhibited the spreading of HaCaT cells on denatured COL15 domain. Furthermore, this effect was lost by mutation from D to E (KGE instead of KGD). We suggest that the COL15 domain of type XVII collagen represents a specific collagenous structure, unable to interact with the cellular receptors for other collagens. After being shed from the cell surface, it may support keratinocyte spreading and migration.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Oulu, Dept Dermatol, FIN-90220 Oulu, Finland; Univ Munster, Dept Dermatol, D-48149 Munster, Germany	University of Jyvaskyla; University of Turku; University of Turku; University of Oulu; University of Munster	Heino, J (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.			Tasanen, Kaisa/0000-0001-8056-5949; Kapyla, Jarmo/0000-0003-3036-713X				Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BRUCKNERTUDERMA.L, 2001, IN PRESS CONNECTIVE; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hirako Y, 1998, J BIOL CHEM, V273, P9711, DOI 10.1074/jbc.273.16.9711; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Oshikawa K, 1999, J BIOCHEM, V125, P31, DOI 10.1093/oxfordjournals.jbchem.a022264; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SAELMAN EUM, 1994, BLOOD, V83, P1244; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	35	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38673	38679		10.1074/jbc.M102589200	http://dx.doi.org/10.1074/jbc.M102589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514543	hybrid			2022-12-25	WOS:000171673200047
J	Poligone, B; Baldwin, AS				Poligone, B; Baldwin, AS			Positive and negative regulation of NF-kappa B by COX-2-Roles of different prostaglandins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COLON-CANCER CELLS; TRANSCRIPTIONAL ACTIVITY; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); PROSTANOID RECEPTORS; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; CYCLOOXYGENASE-2; APOPTOSIS	The prostaglandin H synthases (PGHS) catalyze the conversion of arachidonic acid to prostaglandin H-2, the committed step in prostanoid synthesis. Two forms of PGHS exist, PGHS-1 (COX-1) and PGHS-2 (COX-2). The gene encoding the latter form is known to be inducible by a number of stimuli including several inflammatory mediators. Recent evidence indicates that the inducible cyclooxygenase may have both pro- and anti-inflammatory properties through the generation of different prostaglandins. Previous reports indicate that the transcription factor NF-kappaB can function upstream of COX-2 to control transcription of this gene and that the cyclopentenone prostaglandins can inhibit NF-kappaB activation via the inhibition of the I kappaB kinase. Thus, it is suggested that cyclopentenones feed back to inhibit continued nuclear accumulation of NF-kappaB. In this report we demonstrate COX-2 expression inhibits nuclear translocation of NF-kappaB, and we confirm that the cyclopentenone prostaglandins inhibit NF-kappaB. In addition, we show that prostaglandin E-2 and its analogs promote the inherent transcriptional activity of the p65/RelA subunit of NF-kappaB in a manner independent of induced nuclear accumulation. Consistent with this evidence, prostaglandin E2 strongly synergizes with the inflammatory cytokine tumor necrosis factor-a to promote NF-kappaB-dependent transcription and gene expression. The data provide a molecular rationale to explain both the pro- and anti-inflammatory nature of COX-2.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Mol Biol & Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA75080, CA72771] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072771, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098, R37AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Baggiolini M, 1995, Clin Exp Immunol, V101 Suppl 1, P5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GILSTON V, 1997, BIOCHEM SOC T, V25, P518; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hendel J, 1997, AM J GASTROENTEROL, V92, P1170; Jobin C, 1998, IMMUNOLOGY, V95, P537; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Parker J, 1997, EXP CELL RES, V236, P321, DOI 10.1006/excr.1997.3741; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wu KK, 1996, ANNU REV MED, V47, P315; YOSHIMURA T, 1987, J IMMUNOL, V139, P788; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	55	199	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38658	38664		10.1074/jbc.M106599200	http://dx.doi.org/10.1074/jbc.M106599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509575	hybrid			2022-12-25	WOS:000171673200045
J	Xu, N; Ekstrom, U; Nilsson-Ehle, P				Xu, N; Ekstrom, U; Nilsson-Ehle, P			ACTH decreases the expression and secretion of apolipoprotein B in HepG2 cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APO-B; MCA-RH7777 CELLS; MESSENGER-RNA; G2 CELLS; HEMODIALYSIS-PATIENTS; CHOLESTEROL EFFLUX; LDL-RECEPTOR; PROTEIN; CORTICOTROPIN	Administration of adrenocorticotropic hormone (ACTH) has been shown to decrease plasma concentrations of apolipoprotein B (apoB) containing lipoproteins, including lipoprotein(a), in man. However, the mechanism behind this hypolipidemic effect is unknown. This study aimed at distinguishing between the main possibilities (increased elimination or decreased production of lipoproteins) using HepG2 cell cultures. Addition of ACTH to the cell culture medium selectively downregulated apoB mRNA expression and apoB secretion in a dose-dependent manner. At 100 pmol/liter ACTH, the apoB mRNA level was about 40% lower than in the untreated cells, and the secretion of apoB into the medium was decreased to a similar extent. The expression and secretion of other apolipoproteins (apoA-I, apoE, and apoM), however, were not affected by ACTH. Under normal culture conditions the level of secretion of apoB from HepG2 cells is quite low. In the presence of 0.4 mmol/liter oleic acid secretion of apoB increased 3-fold, but this phenomenon was not seen in ACTH-treated cells. Binding and internalization of radiolabeled low density lipoprotein (LDL) by HepG2 cell, as well as LDL-receptor mRNA and scavenger receptor B-I mRNA levels, were not influenced by ACTH. In conclusion, ACTH directly and selectively down-regulated the production and secretion of apoB in HepG2 cell cultures, suggesting that a principal mechanism behind the cholesterol-lowering effect of ACTH in vivo may be a decreased production rate of apoB-containing lipoproteins from the liver.	Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden	Lund University; Skane University Hospital	Nilsson-Ehle, P (corresponding author), Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden.	peter.nilsson-ehle@klinkem.lu.se						AKGUN S, 1969, ENDOCRINOLOGY, V84, P926, DOI 10.1210/endo-84-4-926; ALAUPOVIC P, 1986, ARCH BIOCHEM BIOPHYS, V244, P226, DOI 10.1016/0003-9861(86)90112-8; ALFANO J, 1983, CAN J BIOCHEM CELL B, V61, P708, DOI 10.1139/o83-089; AlRayyes O, 1996, HEPATOLOGY, V24, P613; Arnadottir M, 1999, METABOLISM, V48, P342, DOI 10.1016/S0026-0495(99)90083-5; Arnadottir M, 1997, KIDNEY INT, V52, P1651, DOI 10.1038/ki.1997.498; Arnadottir M, 2001, SCAND J CLIN LAB INV, V61, P301; BABIAK J, 1987, BAILLIERE CLIN ENDOC, V1, P515, DOI 10.1016/S0950-351X(87)80022-8; Bartens W, 1997, METABOLISM, V46, P726, DOI 10.1016/S0026-0495(97)90113-X; Berg AL, 1999, KIDNEY INT, V56, P1534, DOI 10.1046/j.1523-1755.1999.00675.x; BERG AL, 1991, J INTERN MED, V229, P201, DOI 10.1111/j.1365-2796.1991.tb00332.x; Berg AL, 1996, KIDNEY INT, V50, P538, DOI 10.1038/ki.1996.346; BERG AL, 1994, METABOLISM, V43, P90, DOI 10.1016/0026-0495(94)90162-7; BOREN J, 1993, BIOCHEM SOC T, V21, P487, DOI 10.1042/bst0210487; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BRECKENRIDGE WC, 1985, CAN J BIOCHEM CELL B, V63, P890, DOI 10.1139/o85-110; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DORY L, 1978, BIOCHIM BIOPHYS ACTA, V528, P161, DOI 10.1016/0005-2760(78)90191-1; EISENBERG S, 1983, KLIN WOCHENSCHR, V61, P119, DOI 10.1007/BF01486366; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; KEMPEN HJ, 1995, J LIPID RES, V36, P1796; KRAFT HG, 1992, DNA CELL BIOL, V11, P291, DOI 10.1089/dna.1992.11.291; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; TENG BB, 1994, J BIOL CHEM, V269, P29395; Tietz NW, 1995, CLIN GUIDE LAB TESTS, V3rd; Vu H, 1997, BBA-LIPID LIPID MET, V1349, P97, DOI 10.1016/S0005-2760(97)00125-2; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Xu N, 1999, J BIOL CHEM, V274, P31286, DOI 10.1074/jbc.274.44.31286; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665	39	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38680	38684		10.1074/jbc.M104659200	http://dx.doi.org/10.1074/jbc.M104659200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514556	hybrid			2022-12-25	WOS:000171673200048
J	Yang, WB; Hong, YH; Shen, XQ; Frankowski, C; Camp, HS; Leff, T				Yang, WB; Hong, YH; Shen, XQ; Frankowski, C; Camp, HS; Leff, T			Regulation of transcription by AMP-activated protein kinase - Phosphorylation of p300 blocks its interaction with nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIF; CELL; COACTIVATORS; COMPLEXES; CBP/P300; ROLES	AMP-activated protein kinase (AMP-kinase) modulates many metabolic processes in response to fluctuations in cellular energy status. Although most of its known targets are metabolic enzymes, it has been proposed that AMP-kinase might also regulate gene expression. Here we demonstrate that the transcriptional coactivator p300 is a substrate of AMP-kinase. Phosphorylation of p300 at serine 89 by AMP-kinase dramatically reduced its interaction, in vitro and in vivo, with the nuclear receptors peroxisome proliferator-activated receptor gamma, thyroid receptor, retinoic acid receptor, and retinoid X receptor, but did not affect its interaction with the non-nuclear receptor transcription factors Ela, p53, or GATA4. These findings indicate that the AMP-kinase signaling pathway selectively modulates a subset of p300 activities and represent the first example of a transcriptional component regulated by AMP-kinase. Our results suggest a direct link between cellular energy metabolism and gene expression.	Pfizer Global Res & Dev, Dept Mol Sci, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Leff, T (corresponding author), Wayne State Univ, Sch Med, Ctr Integrat Metab & Endocrine Res, 540 E Canfield, Detroit, MI 48201 USA.	tleff@med.wayne.edu	Leff, Todd/U-9084-2018	Leff, Todd/0000-0001-6923-3900				Buchbinder JL, 1997, BIOCHEMISTRY-US, V36, P8039, DOI 10.1021/bi9704820; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen SY, 2000, J BIOL CHEM, V275, P3733, DOI 10.1074/jbc.275.6.3733; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Goodman RH, 2000, GENE DEV, V14, P1553; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	21	169	179	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38341	38344		10.1074/jbc.C100316200	http://dx.doi.org/10.1074/jbc.C100316200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11518699	hybrid			2022-12-25	WOS:000171673200003
J	Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R				Saito, Y; Ochiai, Y; Kodama, Y; Tamura, Y; Togashi, T; Kosugi-Okano, H; Miyazawa, T; Wakabayashi, Y; Hatakeyama, K; Wakana, S; Niwa, O; Kominami, R			Genetic loci controlling susceptibility to gamma-ray-induced thymic lymphoma	ONCOGENE			English	Article						susceptibility gene; genetic mapping; gamma-ray radiation; mouse thymic lymphoma; congenic mouse	INTESTINAL NEOPLASIA; CANCER SUSCEPTIBILITY; SUPPRESSOR GENE; DEFICIENT MICE; COMPLEX TRAITS; MAJOR MODIFIER; COLON-CANCER; MOUSE; RESISTANCE; TUMORS	BALB/c is a susceptible strain for the development of gamma -ray induced mouse thymic lymphoma whereas MSM shows resistance. Association analysis of 220 backcross mice between the two strains using 67 markers was carried out to identify loci involved in the control of susceptibility. The genotype of mice with lymphoma showed excess heterozygosity relative to MSM homozygosity at D2Mit15 and D4Mit12 and was skewed toward MSM-derived alleles at D5Mit5. The P values in Mantel-Cox test were 0.0048 (D2Mit15), 0.0034 (D4Mit12) and 0.0048 (D5Mit5), suggesting association at the three loci in the susceptibility. Cooperative effect on lymphomagenesis was also observed among the three loci. To obtain independent evidence for linkage at D4Mit12, we made partially congenic mice in which a D4Mit12 region in BALB/c was replaced by MSM-derived homolog. Examination for the lymphoma susceptibility in 78 progeny of the congenic mice confirmed the effect of the locus near D4Mit12 (P=0.0037). The result, together with the linkage analysis, shows that the locus near D4Mit12 is regarded as a confirmed linkage but the other two loci as marginally suggestive.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Surg 1, Niigata 9518122, Japan; Kyoto Univ, Inst Phys, Kyoto, Japan; Kyoto Univ, Chem Res Genome Sci Ctr, Kyoto, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 606, Japan	Niigata University; Niigata University; Kyoto University; Kyoto University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 9518122, Japan.							Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Baross-Francis A, 2000, CARCINOGENESIS, V21, P1259, DOI 10.1093/carcin/21.6.1259; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; MERUELO D, 1981, J EXP MED, V154, P1201, DOI 10.1084/jem.154.4.1201; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; OKUMOTO M, 1990, CANCER RES, V50, P3848; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Shisa H, 1996, JPN J CANCER RES, V87, P258, DOI 10.1111/j.1349-7006.1996.tb00214.x; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; van Wezel T, 1999, CANCER RES, V59, P4216; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590	28	27	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5243	5247		10.1038/sj.onc.1204675	http://dx.doi.org/10.1038/sj.onc.1204675			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526516				2022-12-25	WOS:000170464000021
J	Latif, R; Graves, P; Davies, TF				Latif, R; Graves, P; Davies, TF			Oligomerization of the human thyrotropin receptor - Fluorescent protein-tagged hTSHR reveals post-translational complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING HORMONE-RECEPTOR; TSH RECEPTOR; EXTRACELLULAR DOMAIN; DISULFIDE-ISOMERASE; GRAVES-DISEASE; LIVING CELLS; CLEAVAGE; INTERNALIZATION; IDENTIFICATION; AUTOANTIBODIES	To examine thyrotropin (TSH) receptor homophilic interactions we fused the human TSH receptor (hTSHR) carboxyl terminus to green fluorescent protein (GFP) and the corresponding chimeric cDNA was expressed in Chinese hamster ovary cells. Fluorescent TSH receptors on the plasma membrane were functional as assessed by TSH-induced cAMP synthesis. The binding of TSH, as well as TSHR autoantibodies, induced time- and dose-dependent receptor capping. Fluorescence resonance energy transfer between receptors differentially tagged with GFP variants (RFP and YFP) provided evidence for the close proximity of individual receptor molecules. This was consistent with previous studies demonstrating the presence of TSHR dimers and oligomers in thyroid tissue. Co-immunoprecipitation of GFP-tagged and Myc-tagged receptor complexes was performed using doubly transfected cells with Myc antibody. Western blotting of the immunoprecipitated complex revealed the absence of noncleaved TSH holoreceptors. This further suggested that cleavage of the holoreceptor into its two-subunit structure, comprising disulfide-linked TSHR-alpha and TSHR-beta subunits, was required for the formation of TSHR dimers and higher order complexes.	CUNY Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Latif, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1Gustave L Levy Pl, New York, NY 10029 USA.	rauf.latif@mssm.edu	Latif, Rauf/ABH-4394-2020; latif, rauf/AAR-1634-2020	Latif, Rauf/0000-0002-4226-3728; 	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045011, R01DK052464, R01DK035764] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR9145-01] Funding Source: Medline; NIDDK NIH HHS [DK45011, DK52464, DK35764] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1533, DOI 10.1177/36.12.3192937; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; AVIVI A, 1982, MOL CELL ENDOCRINOL, V25, P55, DOI 10.1016/0303-7207(82)90169-1; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; de Bernard S, 1999, J BIOL CHEM, V274, P101, DOI 10.1074/jbc.274.1.101; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Graves P, 1999, J CLIN ENDOCR METAB, V84, P2177, DOI 10.1210/jc.84.6.2177; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GRAVES PN, 1995, ENDOCRINOLOGY, V136, P521, DOI 10.1210/en.136.2.521; Graves PN, 2000, ENDOCRIN METAB CLIN, V29, P267, DOI 10.1016/S0889-8529(05)70131-6; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOOVER RL, 1983, J CELL BIOL, V97, P73, DOI 10.1083/jcb.97.1.73; Horvat RD, 1999, BIOCHEM BIOPH RES CO, V255, P382, DOI 10.1006/bbrc.1999.0185; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; John SA, 1998, J PHYSIOL-LONDON, V510, P333, DOI 10.1111/j.1469-7793.1998.333bk.x; Kakinuma A, 1997, J BIOL CHEM, V272, P28296, DOI 10.1074/jbc.272.45.28296; Kita M, 1999, ENDOCRINOLOGY, V140, P1392, DOI 10.1210/en.140.3.1392; Kwiatkowska K, 1999, CELL MOTIL CYTOSKEL, V42, P298, DOI 10.1002/(SICI)1097-0169(1999)42:4<298::AID-CM4>3.0.CO;2-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latif R, 2000, THYROID, V10, P407, DOI 10.1089/thy.2000.10.407; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MARTIN A, 1988, MOL CELL ENDOCRINOL, V60, P233, DOI 10.1016/0303-7207(88)90183-9; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Misrahi M, 1997, EUR J ENDOCRINOL, V137, P599, DOI 10.1530/eje.0.1370599; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; Oda Y, 2000, THYROID, V10, P1051, DOI 10.1089/thy.2000.10.1051; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PODESTA EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3986, DOI 10.1073/pnas.80.13.3986; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; Sanders J, 1997, BAILLIERE CLIN ENDOC, V11, P451, DOI 10.1016/S0950-351X(97)80693-3; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; Tanaka K, 2000, ENDOCRINOLOGY, V141, P3573, DOI 10.1210/en.141.10.3573; Tanaka K, 1999, J BIOL CHEM, V274, P2093, DOI 10.1074/jbc.274.4.2093; Tarasova NI, 1997, CELL TISSUE RES, V287, P325, DOI 10.1007/s004410050757; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	48	94	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45217	45224		10.1074/jbc.M103727200	http://dx.doi.org/10.1074/jbc.M103727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11535591	hybrid			2022-12-25	WOS:000172406700115
J	Cahan, R; Axelrad, I; Safrin, M; Ohman, DE; Kessler, E				Cahan, R; Axelrad, I; Safrin, M; Ohman, DE; Kessler, E			A secreted aminopeptidase of Pseudomonas aeruginosa - Identification, primary structure, and relationship to other aminopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-GRISEUS AMINOPEPTIDASE; AEROMONAS-CAVIAE T-64; INTRAMOLECULAR CHAPERONE; VIBRIO-PROTEOLYTICUS; MOLECULAR-CLONING; ELASTASE ACTIVITY; SENSITIVE METHOD; GENE; PURIFICATION; LASA	Using leucine-p-nitroanilide (Leu-pNA) as a substrate, we demonstrated aminopeptidase activity in the culture filtrates of several Pseudomonas aeruginosa strains. The aminopeptidase was partially purified by DEAE-cellulose chromatography and found to be heat stable. The apparent molecular mass of the enzyme was similar to 56 kDa; hence, it was designated AP(56). Heating (70 degreesC) of the partially purified aminopeptidase preparations led to the conversion of AP56 to a similar to 28-kDa protein (AP(28)) that retained enzyme activity, a reaction that depended on elastase (LasB). The pH optimum for Leu-pNA hydrolysis by AP(28) was 8.5. This activity was inhibited by Zn chelators but not by inhibitors of serine- or thiol-proteases, suggesting that AP(28) is a Zn-dependent enzyme. Of several amino acid p-nitroanilide derivatives examined, Leu-pNA was the preferred substrate. The sequences of the first 20 residues of AP(56), and AP(28) were determined. A search of the P. aeruginosa genomic data base revealed a perfect match of these sequences with positions 39-58 and 273-291, respectively, in a 536-amino acid residue open reading frame predicted to encode an aminopeptidase. A search for sequence similarities with other proteins revealed 52% identity with Streptomyces griseus aminopeptidase, similar to 35% identity with Saccharomyces cerevisiae aminopeptidase Y and a hypothetical aminopeptidase from Bacillus subtilis, and 29-32% with Aeromonas caviae, Vibrio proteolyticus, and Vibrio cholerae aminopeptidases. The residues potentially involved in zinc coordination were conserved in all these proteins. Thus, P. aeruginosa aminopeptidase may belong to the same family (M28) of metalloproteases.	Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; McGuire Dept Vet Affairs Med Ctr, Richmond, VA 23249 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center	Kessler, E (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel.			Cahan, Rivka/0000-0001-9783-4033	NIAID NIH HHS [AI 26187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AWAD WM, 1998, HDB PROTEOLYTIC ENZY, P1431; BENMEIR D, 1993, EUR J BIOCHEM, V212, P107, DOI 10.1111/j.1432-1033.1993.tb17639.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun P, 1998, J BACTERIOL, V180, P3467, DOI 10.1128/JB.180.13.3467-3469.1998; Caballero AR, 2001, ANAL BIOCHEM, V290, P330, DOI 10.1006/abio.2001.4999; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; CHEVRIER B, 1998, HDB PROTEOLYTIC ENZY, P1433; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; Engel LS, 1998, J BIOL CHEM, V273, P16792, DOI 10.1074/jbc.273.27.16792; Filloux A, 1998, FEMS MICROBIOL REV, V22, P177, DOI 10.1016/S0168-6445(98)00013-8; Folders J, 2000, J BACTERIOL, V182, P1257, DOI 10.1128/JB.182.5.1257-1263.2000; GOLDBERG JB, 1987, J BACTERIOL, V169, P4532, DOI 10.1128/jb.169.10.4532-4539.1987; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; Greenblatt HM, 1997, J MOL BIOL, V265, P620, DOI 10.1006/jmbi.1996.0729; GUENET C, 1992, J BIOL CHEM, V267, P8390; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; Izawa N, 1996, J FERMENT BIOENG, V82, P544, DOI 10.1016/S0922-338X(97)81249-4; Izawa N, 1997, J AGR FOOD CHEM, V45, P4897, DOI 10.1021/jf970453w; KANAYAMA N, 1995, J LEUKOCYTE BIOL, V57, P129, DOI 10.1002/jlb.57.1.129; KESSLER E, 1993, J BIOL CHEM, V268, P7503; Kessler E, 1997, J BIOL CHEM, V272, P9884; KESSLER E, 1988, J BACTERIOL, V170, P1215, DOI 10.1128/jb.170.3.1215-1219.1988; Kessler E, 1998, HDB PROTEOLYTIC ENZY, P1476; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA H, 1995, METHOD ENZYMOL, V248, P395; Maeda H, 1996, BIOL CHEM H-S, V377, P217; Maras B, 1996, EUR J BIOCHEM, V236, P843, DOI 10.1111/j.1432-1033.1996.00843.x; McIver KS, 1995, MOL MICROBIOL, V18, P877, DOI 10.1111/j.1365-2958.1995.18050877.x; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; MORIHARA K, 1998, HDB PROTEOLYTIC ENZY, P1150; Nirasawa S, 1999, BBA-PROTEIN STRUCT M, V1433, P335, DOI 10.1016/S0167-4838(99)00158-2; Nirasawa S, 1999, BIOCHEM J, V341, P25, DOI 10.1042/0264-6021:3410025; NISHIZAWA M, 1994, J BIOL CHEM, V269, P13651; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHMAN DE, 1980, J BACTERIOL, V142, P836, DOI 10.1128/JB.142.3.836-842.1980; PARK S, 1995, MOL MICROBIOL, V16, P263, DOI 10.1111/j.1365-2958.1995.tb02298.x; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; PETERS JE, 1992, MOL MICROBIOL, V6, P1155, DOI 10.1111/j.1365-2958.1992.tb01554.x; Pollack M, 1998, INFECT DIS, P1824; Prescott J M, 1976, Methods Enzymol, V45, P530; PRESCOTT JM, 1966, ARCH BIOCHEM BIOPHYS, V117, P328, DOI 10.1016/0003-9861(66)90420-6; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P1412; SPUNGIN A, 1989, EUR J BIOCHEM, V183, P471, DOI 10.1111/j.1432-1033.1989.tb14952.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Toma C, 1996, INFECT IMMUN, V64, P4495, DOI 10.1128/IAI.64.11.4495-4500.1996; Van Delden C, 1998, INFECT IMMUN, V66, P4499; VANHEEKE G, 1992, BIOCHIM BIOPHYS ACTA, V1131, P337, DOI 10.1016/0167-4781(92)90037-Z; Vessillier S, 2001, EUR J BIOCHEM, V268, P1049, DOI 10.1046/j.1432-1327.2001.01967.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAGNER FW, 1972, J BIOL CHEM, V247, P1208; Zhang ZZ, 2000, BIOCHEM J, V350, P671, DOI 10.1042/0264-6021:3500671; Zhang ZZ, 2001, BIOSCI BIOTECH BIOCH, V65, P420, DOI 10.1271/bbb.65.420	57	52	54	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43645	43652		10.1074/jbc.M106950200	http://dx.doi.org/10.1074/jbc.M106950200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11533066	hybrid			2022-12-25	WOS:000172297700023
J	Reis, M; Farage, M; de Souza, ACL; de Meis, L				Reis, M; Farage, M; de Souza, ACL; de Meis, L			Correlation between uncoupled ATP hydrolysis and heat production by the sarcoplasmic reticulum Ca2+-ATPase - Coupling effect of fluoride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; TIGHT-BINDING; ENERGY INTERCONVERSION; FUNCTIONAL-STATES; REACTION CYCLE; TRANSPORT; CA2+; MAGNESIUM; PHOSPHORYLATION; THERMOGENESIS	The sarcoplasmic reticulum Ca2+-ATPase transports Ca2+ using the chemical energy derived from ATP hydrolysis. Part of the chemical energy is used to translocate Ca2+ through the membrane (work) and part is dissipated as heat. The amount of heat produced during catalysis increases after formation of the Ca2+ gradient across the vesicle membrane. In the absence of gradient (leaky vesicles) the amount of heat produced/mol of ATP cleaved is half of that measured in the presence of the gradient. After formation of the gradient, part of the ATPase activity is not coupled to Ca2+ transport. We now show that NaF can impair the uncoupled ATPase activity with discrete effect on the ATPase activity coupled to Ca2+ transport. For the control vesicles not treated with NaF, after formation of the gradient only 20% of the ATP cleaved is coupled to Ca2+ transport, and the caloric yield of the total ATPase activity (coupled plus uncoupled) is 22.8 kcal released/mol of ATP cleaved. In contrast, the vesicles treated with NaF consume only the ATP needed to maintain the gradient, and the caloric yield of ATP hydrolysis is 3.1 kcal/mol of ATP. The slow ATPase activity measured in vesicles treated with NaF has the same Ca2+ dependence as the control vesicles. This demonstrates unambiguously that the uncoupled activity is an actual pathway of the Ca2+-ATPase rather than a contaminating phosphatase. We conclude that when ATP hydrolysis occurs without coupled biological work most of the chemical energy is dissipated as heat. Thus, uncoupled ATPase activity appears to be the mechanistic feature underlying the ability of the Ca2+ ATPase to modulated heat production.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@biqmed.ufrj.br	Reis, Marcelo Martins/H-9370-2012	Reis, Marcelo Martins/0000-0002-4706-1041				CHIESI M, 1979, J BIOL CHEM, V254, P370; CLAUSEN T, 1991, PHYSIOL REV, V71, P733, DOI 10.1152/physrev.1991.71.3.733; COLL RJ, 1992, J BIOL CHEM, V267, P21584; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; De Meis L, 2000, AN ACAD BRAS CIENC, V72, P365, DOI 10.1590/S0001-37652000000300010; de Meis L, 2000, BIOCHEM BIOPH RES CO, V276, P35, DOI 10.1006/bbrc.2000.3418; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DUCHAMP C, 1993, AM J PHYSIOL, V265, pR1076, DOI 10.1152/ajpregu.1993.265.5.R1076; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GOULD GW, 1987, J BIOL CHEM, V262, P7676; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1976, BIOCHEMISTRY-US, V15, P5293, DOI 10.1021/bi00669a015; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; MAKINOSE M, 1965, BIOCHEM Z, V343, P360; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; SCWARTZENBACH G, 1957, HELVETIA CHIMICA ACT, V40, P1886; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; TANFORD C, 1984, FEBS LETT, V166, P1, DOI 10.1016/0014-5793(84)80033-2; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; WALTER H, 1973, EUR J BIOCHEM, V36, P110, DOI 10.1111/j.1432-1033.1973.tb02890.x; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	49	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42793	42800		10.1074/jbc.M107625200	http://dx.doi.org/10.1074/jbc.M107625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544263	hybrid			2022-12-25	WOS:000172169300022
J	Nakanishi, K; Maruyama, M; Shibata, T; Morishima, N				Nakanishi, K; Maruyama, M; Shibata, T; Morishima, N			Identification of a caspase-9 substrate and detection of its cleavage in programmed cell death during mouse development.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; NERVOUS-SYSTEM; APOPTOTIC PATHWAYS; ACTIVATION; VIMENTIN; EMBRYO; PROTEIN; FAS; REQUIREMENT; EXPRESSION	The caspase family of proteases represents the main machinery by which apoptosis occurs. In vitro studies have revealed that upstream caspases are activated in response to apoptotic stimuli, and the active caspases in turn process downstream effector caspases that are involved in the destruction of cellular structure. Caspase-9 is an upstream caspase that can become active in response to cellular damage, including deprivation of growth factors and exposure to oxidative stress in vitro. Little is known, however, about how activation of caspase-9 is temporally and spatially regulated in vivo, e.g. during development. We have identified vimentin as the first example of a caspase-9 substrate that is not a downstream procaspase. Immunohistochemical analysis, using a specific antibody against the vimentin fragments generated by caspase-9, showed that caspase-9 cleaves vimentin in apoptotic cells in the embryonic nervous system and the interdigital regions. This result is consistent with observations that gene knockouts of caspase-9 and its activator, Apaf-1, result in developmental defects in these tissues. Our results show that the specific antibody is useful for in situ detection of caspase-9 activation in programmed cell death.	RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Mol & Cellular Biol Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Dept Mol Biol, Fac Sci & Engn, Urawa, Saitama 3388570, Japan; NEDO New Energy & Ind Technol Dev Org, Tokyo 1706028, Japan	RIKEN; RIKEN; Saitama University	Morishima, N (corresponding author), RIKEN, Inst Phys & Chem Res, Bioarchitect Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Nakanishi, Keiko/B-9963-2013; Morishima, Nobuhiro/D-3946-2017					ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; Belichenko I, 2001, ARCH BIOCHEM BIOPHYS, V390, P57, DOI 10.1006/abbi.2001.2365; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; COCHARD P, 1984, J NEUROSCI, V4, P2080; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Frade JM, 1996, NATURE, V383, P166; FUHS E, 1994, ANNU REV BIOCHEM, V63, P345; Fujita E, 2000, DEV BRAIN RES, V122, P135, DOI 10.1016/S0165-3806(00)00066-3; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; MILLER BE, 1995, J IMMUNOL, V154, P1331; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OSBORN M, 1984, EUR J CELL BIOL, V34, P137; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; RAVIZADEH S, 1993, SCIENCE, V261, P345; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; Theiler K, 1989, HOUSE MOUSE ATLAS EM, DOI 10.1007/978-3-642-88418-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WRIDE MA, 1994, INT J DEV BIOL, V38, P673; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; ZAKERI ZF, 1994, BIOCHEM CELL BIOL, V72, P603, DOI 10.1139/o94-080; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	50	72	73	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41237	41244		10.1074/jbc.M105648200	http://dx.doi.org/10.1074/jbc.M105648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514563	hybrid			2022-12-25	WOS:000171925600115
J	Quellhorst, GJ; Allen, CM; Wessling-Resnick, M				Quellhorst, GJ; Allen, CM; Wessling-Resnick, M			Modification of Rab5 with a photoactivatable analog of geranylgeranyl diphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; FARNESYL-PROTEIN TRANSFERASE; SMALL GTPASE RAB5; MEMBRANE ASSOCIATION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; GDP/GTP EXCHANGE; ENDOSOME FUSION; HIGH-AFFINITY; BOVINE BRAIN	A photoprobe analog of geranylgeranyl diphosphate (2-diazo-3,3,3-trifluoropropionyloxy-farnesyl diphosphate or DATFP-FPP) inhibits mevalonate-dependent prenylation of in vitro translated Rab5 in rabbit reticulocyte lysate, suggesting that it competes for lipid binding to the Rab geranylgeranyl transferase. Modification of Rab5 with DATFP-FPP, demonstrated by gel mobility shift and Triton X-114 phase separation experiments, confirms that the enzyme uses the analog as a substrate. The sedimentation of DATFP-modified Rab5 as a larger mass complex on sucrose density gradients indicates that it binds to other factors in rabbit reticulocyte lysate. Most importantly, DATFP-Rab5 cross-links to these soluble factors upon exposure to UV light. Immunoprecipitation with antibodies raised against proteins known to interact with Rab5 reveals that the crosslinked complexes contain Rab escort protein and GDI-1. DATFP-Rab5 also associates with membranes in a guanosine-5'-O-(3-thiotriphosphate)-stimulated manner. However, although prenylated Rab5 can be crosslinked to two unknown membrane-associated factors by the chemical cross-linker disuccinimidyl suberate, these proteins fail to be W cross-linked to membrane-bound DATFP-Rab5. These results strongly suggest that membrane-associated factors bind Rab5 through protein-protein interactions rather than protein-prenyl interactions. The modification of Rab5 with DATFP-FPP establishes a novel photoaffinity technique for the characterization of prenyl-binding sites.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Univ Florida, J Hillis Miller Hlth Ctr, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	Harvard University; Harvard T.H. Chan School of Public Health; State University System of Florida; University of Florida	Quellhorst, GJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019894] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM19894] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTRONG J, 2000, INT J BIOCHEM CELL B, V32, P303; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Chiariello M, 1999, FEBS LETT, V453, P20, DOI 10.1016/S0014-5793(99)00686-9; Edelstein RL, 1997, BIOCHEM BIOPH RES CO, V235, P377, DOI 10.1006/bbrc.1997.6792; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; GARRETT MD, 1993, FEBS LETT, V331, P233, DOI 10.1016/0014-5793(93)80343-S; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HOFFENBERG S, 1995, J BIOL CHEM, V270, P5048, DOI 10.1074/jbc.270.10.5048; HORI Y, 1991, ONCOGENE, V6, P515; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Jones AT, 1999, J CELL SCI, V112, P3477; Kilic F, 1997, J BIOL CHEM, V272, P5298, DOI 10.1074/jbc.272.8.5298; LI GP, 1993, J BIOL CHEM, V268, P24475; Luan P, 1999, J BIOL CHEM, V274, P14806, DOI 10.1074/jbc.274.21.14806; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SANFORD JC, 1995, ANAL BIOCHEM, V224, P547, DOI 10.1006/abio.1995.1086; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	45	11	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40727	40733		10.1074/jbc.M104398200	http://dx.doi.org/10.1074/jbc.M104398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11522782	hybrid			2022-12-25	WOS:000171925600048
J	Rossi, V; Cseh, S; Bally, I; Thielens, NM; Jensenius, JC; Arlaud, GJ				Rossi, V; Cseh, S; Bally, I; Thielens, NM; Jensenius, JC; Arlaud, GJ			Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; COMPLEMENT-SYSTEM; CATALYTIC REGION; SUB-COMPONENTS; PROTEIN; PURIFICATION; ACTIVATION; C1S; PATHWAY; C1BARS	Mannan-binding lectin (MBL)-associated serine proteases-1 and 2 (MASP-1 and MASP-2) are homologous modular proteases that each interact with MBL, an oligomeric serum lectin involved in innate immunity. To precisely determine their substrate specificity, human MASP-1 and MASP-2, and fragments from their catalytic regions were expressed using a baculovirus/insect cells system. Recombinant MASP-2 displayed a rather wide, Cls-like esterolytic activity, and specifically cleaved complement proteins C2 and C4, with relative efficiencies 3- and 23-fold higher, respectively, than human Cls. MASP-2 also showed very weak C3 cleaving activity. Recombinant MASP-1 had a lower and more restricted esterolytic activity. It showed marginal activity toward C2 and C3, and no activity on C4. The enzymic activity of both MASP-1 and MASP-2 was specifically titrated by C1 inhibitor, and abolished at a 1:1 C1 inhibitor:protease ratio. Taken together with previous findings, these and other data strongly support the hypothesis that MASP-2 is the protease that, in association with MBL, triggers complement activation via the AML pathway, through combined self-activation and proteolytic properties devoted to C1r and Cls in the C1 complex. In view of the very low activity of MASP-1 on C3 and C2, our data raise questions about the implication of this protease in complement activation.	CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble 1, France; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Aarhus University	Arlaud, GJ (corresponding author), CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Thielens, Nicole M/F-2512-2013	Thielens, Nicole M/0000-0002-7354-0302				ALSALIHI A, 1982, FEBS LETT, V150, P238, DOI 10.1016/0014-5793(82)81342-2; ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; Arlaud GJ, 1998, ADV IMMUNOL, V69, P249, DOI 10.1016/S0065-2776(08)60609-4; ARLAUD GJ, 1979, BIOCHIM BIOPHYS ACTA, V576, P151, DOI 10.1016/0005-2795(79)90494-X; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1995, TRENDS BIOCH SCI S, V20, pC3; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Endo Y, 1998, J IMMUNOL, V161, P4924; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; ISENMAN DE, 2000, COMPLEMENT FACTSBOOK, P95; Ji X, 1997, P NATL ACAD SCI USA, V94, P6340, DOI 10.1073/pnas.94.12.6340; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LACROIX MB, 1989, BIOCHEM J, V257, P885, DOI 10.1042/bj2570885; Matsushita M, 2000, J IMMUNOL, V165, P2637, DOI 10.4049/jimmunol.165.5.2637; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MATSUSHITA M, 1995, IMMUNOBIOLOGY, V194, P443, DOI 10.1016/S0171-2985(11)80110-5; Matsushita M, 1998, IMMUNOBIOLOGY, V199, P340, DOI 10.1016/S0171-2985(98)80038-7; MCRAE BJ, 1981, J BIOL CHEM, V256, P2362; Petersen SV, 1998, MOL IMMUNOL, V35, P409, DOI 10.1016/S0161-5890(98)90848-3; PETILLOT Y, 1995, FEBS LETT, V358, P323, DOI 10.1016/0014-5793(94)01429-5; REBOUL A, 1977, FEBS LETT, V79, P45, DOI 10.1016/0014-5793(77)80347-5; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; SIM RB, 1979, BIOCHEM J, V179, P449, DOI 10.1042/bj1790449a; Stover CM, 1999, J IMMUNOL, V162, P3481; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TERAI I, 1995, INT IMMUNOL, V7, P1579, DOI 10.1093/intimm/7.10.1579; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; THIELENS NM, 1994, BIOCHEM J, V301, P509, DOI 10.1042/bj3010509; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; THIELENS NM, 1982, FEBS LETT, V141, P19, DOI 10.1016/0014-5793(82)80006-9; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; Turner M W, 2000, Rev Immunogenet, V2, P305; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; VORUPJENSEN T, 2000, THESIS U AARHUS; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Wong NKH, 1999, MOL IMMUNOL, V36, P853, DOI 10.1016/S0161-5890(99)00106-6; Xu Y., 2000, COMPLEMENT FACTSBOOK, P73; Zhang Y, 1998, MOL IMMUNOL, V35, P390, DOI 10.1016/S0161-5890(98)90771-4	49	127	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40880	40887		10.1074/jbc.M105934200	http://dx.doi.org/10.1074/jbc.M105934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527969	hybrid			2022-12-25	WOS:000171925600068
J	Wright, CF; Oswald, BW; Dellis, S				Wright, CF; Oswald, BW; Dellis, S			Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LATE PROMOTER; INTERMEDIATE GENE; RNA-SYNTHESIS; LUNG-CANCER; IN-VITRO; PROTEIN; BINDING; SPERMATOGENESIS; OVEREXPRESSION	Vaccinia virus gene expression is temporally regulated, and three gene classes have been identified: early, intermediate, and late. Several virus-encoded proteins and an activity designated VLTF-X are required for maximum transcription in vitro of a template containing a late promoter. VLTF-X is present in both cytoplasmic and nuclear extracts prepared from uninfected mammalian cells and co-purifies with a late promoter DNA-binding activity. Here, extensive purification of VLTF-X has revealed that heterogeneous nuclear ribonucleoproteins A2/B1 and RBM3 co-purified with in vitro late transcription stimulation. Overexpression and purification of these proteins from Escherichia coli demonstrated that they both complemented for VLTF-X activity in in vitro transcription reactions. These studies identify two host cell factors potentially contributing to poxvirus replication in vivo.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Coll Charleston, Dept Biol, Charleston, SC 29424 USA	Medical University of South Carolina; College of Charleston	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, POB 250908, Charleston, SC 29425 USA.			Wright, Cynthia/0000-0003-0442-1665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043329] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43329] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1996, CURRENT PROTOCOLS MO; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; DAVISON AJ, 1989, J MOL BIOL, V210, P771, DOI 10.1016/0022-2836(89)90108-3; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; Hubbs AE, 1996, J VIROL, V70, P327, DOI 10.1128/JVI.70.1.327-331.1996; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; KECK JG, 1993, J VIROL, V67, P5749, DOI 10.1128/JVI.67.10.5749-5753.1993; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MORRISON DK, 1986, CELL, V44, P587, DOI 10.1016/0092-8674(86)90268-0; Passarelli AL, 1996, J VIROL, V70, P4444, DOI 10.1128/JVI.70.7.4444-4450.1996; PEDLEY S, 1984, J GEN VIROL, V65, P1687, DOI 10.1099/0022-1317-65-10-1687; PIOOLROMA S, 1992, NATURE, V355, P730; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Shen XL, 2001, P NATL ACAD SCI USA, V98, P2717, DOI 10.1073/pnas.031424298; Shi ST, 2000, EMBO J, V19, P4701, DOI 10.1093/emboj/19.17.4701; Sueoka E, 1999, CANCER RES, V59, P1404; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; WEIR JP, 1987, J VIROL, V61, P75, DOI 10.1128/JVI.61.1.75-80.1987; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; Wright CF, 1998, J VIROL, V72, P1446, DOI 10.1128/JVI.72.2.1446-1451.1998; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; WRIGHT CF, 1991, J VIROL, V65, P3715, DOI 10.1128/JVI.65.7.3715-3720.1991	39	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40680	40686		10.1074/jbc.M102399200	http://dx.doi.org/10.1074/jbc.M102399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11546759	hybrid			2022-12-25	WOS:000171925600041
J	Xiao, XL; Tang, YS; Mackins, JY; Sun, XL; Jayaram, HN; Hansen, DK; Antony, AC				Xiao, XL; Tang, YS; Mackins, JY; Sun, XL; Jayaram, HN; Hansen, DK; Antony, AC			Isolation and characterization of a folate receptor mRNA-binding trans-factor from human placenta - Evidence favoring identity with heterogeneous nuclear ribonucleoprotein E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL-TUBE DEFECTS; KH-DOMAIN PROTEINS; MESSENGER-RNA; MOLECULAR-CLONING; GENE-EXPRESSION; IDENTIFICATION; REGION; INVITRO; COMPLEX; TRANSLATION	The interaction of an 18-base cis-element in the 5'-untranslated region of human folate receptor (FR)-alpha mRNA with a cytosolic trans-factor protein is critical for the translation of FR (Sun, X.-L., and Antony, A. C. (1996) J. Biol. Chem. 271, 25539-25547). This trans-factor was isolated to apparent homogeneity as a 43- and 38-kDa doublet from human placenta using poly(U)-Sepharose, followed by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electro-elution as major purification steps. Amino acid microsequencing of two cyanogen bromide-generated peptide fragments of the 43-kDa trans-factor revealed complete identity with 43-kDa heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1). Purified specific rabbit anti-hnRNP E1 peptide antibodies (generated against a synthetic oligopeptide that was not represented in microsequenced peptides of the trans-factor) also recognized the purified trans-factor on Western blots. Conversely, the 18-base FR RNA cis-element also bound hnRNP E1 protein on Northwestern blots. Moreover, a 19-base RNA cis-element in the 3'-untranslated region of 15-lipoxygenase mRNA that is known to bind hnRNP E1 also interacted with placental 43-kDa trans-factor. In addition, several murine tissues containing a hnRNP E1-related protein (also known as alpha CP-1) readily interacted with the 18-base FR RNA cis-element. Finally, anti-hnRNP El antibodies specifically inhibited translation of FR in vitro in a dose-dependent manner, and the antibody effect could be reversed in a dose-dependent manner by either purified trans-factor or hnRNP E1. Collectively, the data favor identity of the FR mRNA-binding trans-factor and hnRNP E1, confirm its critical role in the translation of FR, and highlight yet another role of multifunctional hnRNP E1 in eukaryotic mRNA regulation.	Indiana Univ, Sch Med, Indiana Canc Res Inst, Dept Med,Div Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; US FDA, Natl Ctr Toxicol Res, Div Genet & Reprod Toxicol, Jefferson, AR 72079 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; US Food & Drug Administration (FDA)	Antony, AC (corresponding author), Indiana Univ, Sch Med, Indiana Canc Res Inst, Dept Med,Div Hematol Oncol, R4-266,1044 W Walnut St, Indianapolis, IN 46202 USA.				NCI NIH HHS [R01CA58919] Funding Source: Medline; NICHD NIH HHS [R01 HD39295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039295] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA058919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antony A.C., 2000, HEMATOLOGY BASIC PRI, P446; ANTONY AC, 1992, BLOOD, V79, P2807; ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; Antony AC, 2000, TERATOLOGY, V62, P42, DOI 10.1002/1096-9926(200007)62:1&lt;42::AID-TERA9&gt;3.0.CO;2-U; ANTONY AC, 2000, P 19 ANN CONV IND AS; Barber RC, 1998, AM J MED GENET, V76, P310, DOI 10.1002/(SICI)1096-8628(19980401)76:4<310::AID-AJMG6>3.0.CO;2-T; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; Funke B, 1996, NUCLEIC ACIDS RES, V24, P3821, DOI 10.1093/nar/24.19.3821; Gamarnik AV, 1997, RNA, V3, P882; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Hansen D. K., 2001, Teratology, V63, P292; Hansen D. K., 1999, Teratology, V59, P385; Heil SG, 1999, EUR J HUM GENET, V7, P393, DOI 10.1038/sj.ejhg.5200305; HENDERSON GI, 1995, J LAB CLIN MED, V126, P184; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Piedrahita JA, 1999, NAT GENET, V23, P228, DOI 10.1038/13861; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Sun XL, 1996, J BIOL CHEM, V271, P25539; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yang XY, 1996, J BIOL CHEM, V271, P11493, DOI 10.1074/jbc.271.19.11493	40	35	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41510	41517		10.1074/jbc.M106824200	http://dx.doi.org/10.1074/jbc.M106824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527973	hybrid			2022-12-25	WOS:000171925600149
J	Johnson, MA; Macdonald, TL; Mannick, JB; Conaway, MR; Gaston, B				Johnson, MA; Macdonald, TL; Mannick, JB; Conaway, MR; Gaston, B			Accelerated S-nitrosothiol breakdown by amyotrophic lateral sclerosis mutant copper,zinc-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; DOPAMINE NEURONS; MOTOR-NEURONS; RAT; GLUTATHIONE; APOPTOSIS; NITROSOGLUTATHIONE; INHIBITION	Mutations in copper,zinc-superoxide dismutase (SOD) have been implicated in familial amyotrophic lateral sclerosis (FALS). We have investigated the breakdown of S-nitrosothiols by wild-type (WT) SOD and two common FALS mutants, alanine-4 valine (A4V) SOD and glycine-37 arginine (G37R) SOD. In the presence of glutathione, A4V SOD and G37R SOD catalyzed S-nitrosoglutathione breakdown three times more efficiently than WT SOD. Indeed, A4V SOD catabolized GSNO more efficiently than WT SOD throughout the physiological range of GSH concentrations. Moreover, a variety of additional S-nitrosothiols were catabolized more readily by A4V SOD than by WT SOD. Initial rate data for fully reduced WT SOD and A4V SOD, and data using ascorbic acid as the reductant, suggest that FALS mutations in SOD may influence the efficiency of reduction of the copper center by glutathione. We have identified a potentially toxic gain of function of two common FALS mutations that may contribute to neurodegeneration in FALS.	Univ Virginia, Div Pulm Med, Dept Pediat, Hlth Syst, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Massachusetts, Sch Med, Shrewsbury, MA USA; Univ Virginia, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Hlth Syst, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Massachusetts System; University of Virginia	Gaston, B (corresponding author), Univ Virginia, Div Pulm Med, Dept Pediat, Hlth Syst, Charlottesville, VA 22908 USA.	BMG3G@Virginia.edu		Johnson, Michael/0000-0001-5078-9896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL059337, R01HL059337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59337] Funding Source: Medline; NINDS NIH HHS [NS 34678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BANNENBERG G, 1995, J PHARMACOL EXP THER, V272, P1238; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BOTOLINA V, 1994, NATURE, V368, P850; Brown RH, 1997, ARCH NEUROL-CHICAGO, V54, P1246, DOI 10.1001/archneur.1997.00550220050013; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; CLARK AG, 1988, BIOCHEM PHARMACOL, V37, P3199, DOI 10.1016/0006-2952(88)90321-8; Crow JP, 1997, J NEUROCHEM, V69, P1945; Crow JP, 1997, J NEUROCHEM, V69, P1936; Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; EMERY CJ, 1995, PHYSIOL RES, V44, P19; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAN J, 1996, BIOL NITRIC OXIDE, V4; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V361, P323, DOI 10.1006/abbi.1998.1010; Kamosinska B, 1997, AM J PHYSIOL-LUNG C, V272, pL1098, DOI 10.1152/ajplung.1997.272.6.L1098; KashibaIwatsuki M, 1996, FEBS LETT, V389, P149, DOI 10.1016/0014-5793(96)00560-1; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1998, J IMMUNOL, V161, P4122; Kluge I, 1997, J NEUROCHEM, V69, P2599; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; LIPTON AJ, 2000, AM J CRIT CARE MED, V161, pA483; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu ZG, 1998, J PHARMACOL EXP THER, V284, P526; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Ogawa Y, 1997, BIOCHEM BIOPH RES CO, V241, P251, DOI 10.1006/bbrc.1997.7804; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Park JW, 1996, BIOCHEM BIOPH RES CO, V220, P31, DOI 10.1006/bbrc.1996.0351; Pocernich CB, 2000, NEUROCHEM INT, V36, P185, DOI 10.1016/S0197-0186(99)00126-6; Polticelli F, 1998, PROTEIN SCI, V7, P2354, DOI 10.1002/pro.5560071112; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rauhala P, 1998, FASEB J, V12, P165, DOI 10.1096/fasebj.12.2.165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Seber GAF, 1989, NONLINEAR REGRESSION, DOI [10.1002/0471725315, DOI 10.1002/0471725315]; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; ZHANG J, 2000, STAT 21 CENT METH AP	65	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39872	39878		10.1074/jbc.M102781200	http://dx.doi.org/10.1074/jbc.M102781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518706	hybrid			2022-12-25	WOS:000171789200050
J	Worm, J; Kirkin, AF; Dzhandzhugazyan, KN; Guldberg, P				Worm, J; Kirkin, AF; Dzhandzhugazyan, KN; Guldberg, P			Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HISTONE DEACETYLASE COMPLEX; ACUTE LYMPHOCYTIC-LEUKEMIA; ORGANIC ANION TRANSPORTER; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; ANTIFOLATE RESISTANCE; DNA METHYLATION; TUMOR-CELLS; REPRESS TRANSCRIPTION	The molecular basis of methotrexate resistance was studied in human MDA-MB-231 breast cancer cells, which are inherently defective in methotrexate uptake and lack expression of the reduced folate carrier (RFC). Transfection of MDA-MB-231 cells with RFC cDNA restored methotrexate uptake and increased methotrexate sensitivity by similar to 50-fold. A CpG island in the promoter region of RFC was found to be methylated in MDA-MB-231 cells, but was unmethylated in RFC expressing, methotrexate-sensitive MCF-7 breast cancer cells. Chromatin immunoprecipitation with antibodies against acetylated histories H3 and H4 showed that the RFC promoter was enriched for acetylated histories on expressed, unmethylated alleles only. Treatment of MDA-MB-231 cells with 5-aza-2'-deoxycytidine restored RFC expression but also led to increased methotrexate efflux and did not reverse methotrexate resistance. This suggests that 5-aza-2'-deoxycytidine up-regulates both methotrexate uptake and some methotrexate-resistance mechanism(s). Reverse transcription-polymerase chain reaction analysis showed increased expression levels of several ATP-dependent efflux pumps in response to 5-aza-2'-deoxycytidine treatment, including P-glycoprotein and members of the multidrug resistance-associated protein family. Up-regulation of P-glycoprotein in response to 5-aza-2'-deoxycytidine was associated with demethylation of a CpG island in the MDR1 promoter, whereas the mechanism(s) for 5-aza-2'-deoxycytidine-induced up-regulation of multidrug resistance-associated proteins is probably indirect. Dipyridamole inhibited methotrexate efflux and reversed methotrexate resistance in 5-aza-2'-deoxycytidine-treated MDA-MB-231 cells.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.							ASOH K, 1989, JPN J CANCER RES, V80, P475, DOI 10.1111/j.1349-7006.1989.tb02339.x; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; CABRAL S, 1984, P NATL ACAD SCI-BIOL, V81, P3200, DOI 10.1073/pnas.81.10.3200; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Chen C, 2001, J BIOL CHEM, V276, P320, DOI 10.1074/jbc.M007096200; CHEN HX, 1993, CANCER RES, V53, P1974; Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; DeGraaf D, 1996, P NATL ACAD SCI USA, V93, P1238, DOI 10.1073/pnas.93.3.1238; Ding BC, 2001, J BIOL CHEM, V276, P8713, DOI 10.1074/jbc.M005248200; DIXON KH, 1994, J BIOL CHEM, V269, P17; Dressel U, 2000, ANTICANCER RES, V20, P1017; Drori S, 2000, J BIOL CHEM, V275, P30855, DOI 10.1074/jbc.M003988200; FERGUSON AT, 1995, CANCER RES, V55, P2279; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Gifford AJ, 1998, INT J CANCER, V78, P176, DOI 10.1002/(SICI)1097-0215(19981005)78:2<176::AID-IJC10>3.3.CO;2-F; GOEL R, 1992, NEW DRUGS CONCEPTS R, P19; Gollapudi S, 1997, CANCER CHEMOTH PHARM, V40, P150, DOI 10.1007/s002800050640; Gong MK, 1999, GENE, V233, P21, DOI 10.1016/S0378-1119(99)00166-3; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Guo W, 1999, CLIN CANCER RES, V5, P621; HENDERSON GB, 1985, BIOCHEM PHARMACOL, V34, P1725, DOI 10.1016/0006-2952(85)90641-0; Hooijberg JH, 1999, CANCER RES, V59, P2532; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kantharidis P, 1997, CLIN CANCER RES, V3, P2025; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KENNEDY DG, 1986, BIOCHEM PHARMACOL, V35, P3053, DOI 10.1016/0006-2952(86)90385-0; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Ma DQ, 2000, BIOCHEM BIOPH RES CO, V279, P891, DOI 10.1006/bbrc.2000.4019; Masuda M, 1997, CANCER RES, V57, P3506; Moscow JA, 1998, LEUKEMIA LYMPHOMA, V30, P215; MOSCOW JA, 1995, CANCER RES, V55, P3790; Moscow JA, 1997, INT J CANCER, V72, P184, DOI 10.1002/(SICI)1097-0215(19970703)72:1<184::AID-IJC26>3.0.CO;2-I; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nedergaard T, 1997, INT J CANCER, V71, P364, DOI 10.1002/(SICI)1097-0215(19970502)71:3<364::AID-IJC10>3.0.CO;2-G; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Norris MD, 1996, INT J CANCER, V65, P613; Pinard MF, 1996, CANCER CHEMOTH PHARM, V38, P281, DOI 10.1007/s002800050483; Plumb JA, 2000, CANCER RES, V60, P6039; RHEE MS, 1993, CANCER RES, V53, P2227; Roy K, 1997, J BIOL CHEM, V272, P5587, DOI 10.1074/jbc.272.9.5587; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Sadlish H, 2000, BIOCHEM J, V346, P509, DOI 10.1042/0264-6021:3460509; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SIROTNAK FM, 1981, CANCER RES, V41, P966; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TRIPPETT T, 1992, BLOOD, V80, P1158; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; vanTriest B, 1997, BIOCHEM PHARMACOL, V53, P1855, DOI 10.1016/S0006-2952(97)82448-3; Volk EL, 2000, CANCER RES, V60, P3514; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Yang XW, 2000, CANCER RES, V60, P6890; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	80	113	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39990	40000		10.1074/jbc.M103181200	http://dx.doi.org/10.1074/jbc.M103181200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509559	hybrid			2022-12-25	WOS:000171789200067
J	Tobe, K; Suzuki, R; Aoyama, M; Yamauchi, T; Kamon, J; Kubota, N; Terauchi, Y; Matsui, J; Akanuma, Y; Kimura, S; Tanaka, J; Abe, M; Ohsumi, J; Nagai, R; Kadowaki, T				Tobe, K; Suzuki, R; Aoyama, M; Yamauchi, T; Kamon, J; Kubota, N; Terauchi, Y; Matsui, J; Akanuma, Y; Kimura, S; Tanaka, J; Abe, M; Ohsumi, J; Nagai, R; Kadowaki, T			Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PROTEIN; TRANSCRIPTION FACTOR; GLUCOSE-HOMEOSTASIS; DIABETES-MELLITUS; TRANSGENIC MICE; CULTURED-CELLS; RESISTANCE; IRS-2; DISRUPTION; REPRODUCTION	Insulin receptor substrate (IRS)-2(-/-) mice develop diabetes because of insulin resistance in the liver and failure to undergo beta -cell hyperplasia. Here we show by DNA chip microarray analysis that expression of the sterol regulatory element-binding protein (SREBP)-1 gene, a downstream target of insulin, was paradoxically increased in 16-week-old IRS-2(-/-) mouse liver, where insulin-mediated intracellular signaling events were substantially attenuated. The expression of SREBP-1 downstream genes, such as the spot 14, ATP citrate-lyase, and fatty acid synthase genes, was also increased. Increased liver triglyceride content in IRS-2(-/-) mice assures the physiological importance of SREBP-1 gene induction. IRS-2(-/-) mice showed leptin resistance; low dose leptin administration, enough to reduce food intake and body weight in wild-type mice, failed to do so in IRS-2(-/-) mice. Interestingly, high dose leptin administration reduced SREBP-1 expression in IRS-2(-/-) mouse liver. Thus, IRS-2 gene disruption results in leptin resistance, causing an SREBP-1 gene induction, obesity, fatty liver, and diabetes.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 1000005, Japan; Sankyo Corp Ltd, Biomed Res Labs, Tokyo 1408710, Japan	University of Tokyo; Asahi Life Foundation	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Ohsumi, Jun/L-3095-2017; Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; 				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	41	107	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38337	38340		10.1074/jbc.C100160200	http://dx.doi.org/10.1074/jbc.C100160200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11546755	hybrid			2022-12-25	WOS:000171673200002
J	Xiao, Z; Watson, N; Rodriguez, C; Lodish, HF				Xiao, Z; Watson, N; Rodriguez, C; Lodish, HF			Nucleocytoplasmic shuttling of Smad1 conferred by its nuclear localization and nuclear export signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; PROTEIN; TRANSLOCATION; SMAD4/DPC4; SEQUENCE; ELEMENT; KINASE	Smad1 mediates signaling by bone morphogenetic proteins (BMPs). In the resting state, Smad1 is found in both the nucleus and cytosol. BMP addition triggers Smad1 serine phosphorylation, binding of Smad4, and its accumulation in the nucleus. Mutations in the Smad1 N-terminal basic nuclear localization signal (NLS)-like motif, conserved among all Smad proteins, eliminated its ligand-induced nuclear translocation without affecting its other functions, including DNA binding and complex formation with Smad4. Addition of leptomycin B, an inhibitor of nuclear export, induced rapid nuclear accumulation of Smad1, whereas overexpression of CRM1, the receptor for nuclear export, resulted in Smad1 re-localization to the cytoplasm and inhibition of BMP-induced nuclear accumulation. Thus, in addition to the NLS, Smad1 also contains a functional nuclear export signal (NES). We identified a leucine-rich NES motif in the C terminus of Smad1; its disruption led to constitutive Smad1 nuclear distribution. Reporter gene activation assays demonstrated that both the NLS and NES are required for optimal transcriptional activation by Smad1. Despite its constitutive nuclear accumulation, a Smad1 NES mutant did not display higher basal reporter gene activity. We conclude that Smad1 is under constant nucleocytoplasmic shuttling conferred by its NLS and NES; nuclear accumulation after ligand-induced phosphorylation represents a change in the balance of the activities of these opposing signals and is essential for transcriptional activation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			rodriguez, carlos/0000-0001-9593-8680	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mattison CP, 2000, GENE DEV, V14, P1229; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200	21	91	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39404	39410		10.1074/jbc.M103117200	http://dx.doi.org/10.1074/jbc.M103117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11509558	hybrid			2022-12-25	WOS:000171673200140
J	Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK				Chernova, OB; Hunyadi, A; Malaj, E; Pan, HQ; Crooks, C; Roe, B; Cowell, JK			A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells	ONCOGENE			English	Article						brain tumors; gene cloning; WD40 repeat; translocation; chromosome 10	TUMOR-SUPPRESSOR GENE; MARINER TRANSPOSON; PROTEIN FAMILY; HUMAN GLIOMAS; LOW-GRADE; DELETION; BRAIN; SEQUENCE; 19Q; ASTROCYTOMAS	Allelic deletions of 10q25-26 and 19q13.3-13.4 are the most common genetic alterations in glial tumors. We have identified a balanced t(10;19) reciprocal translocation in the A172 glioblastoma cell line which involves both critical regions on chromosomes 10 and 19. In addition, loss of an entire copy of chromosome 10 has occurred in this cell line suggesting that the translocation event may provide a highly specific critical inactivating event in a gene responsible for tumorigenesis. Positional cloning of this translocation breakpoint resulted in the identification of a novel chromosome 10 gene, WDR11, which is a member of the WD-repeat gene family. The WDR11 gene is ubiquitously expressed, including normal brain and glial tumors. WDR11 is composed of 29 exons distributed over 58 kilobases and oriented towards the telomere. The translocation resulted in deletion of exon 5 and consequently fusion of intron 4 of WDR11 to the 3' untranslated region of a novel member, ZNF320, of the Kruppel-like zinc finger gene family. Since ZNF320 is oriented toward the centromere of chromosome 19, both genes appeared on the same derivative chromosome der(10). The chimeric transcript encodes the WDR11 polypeptide, which is truncated after the second of six WD-repeats. ZNF320 is also expressed in A172 cells, although it is not clear if the translocation affects the expression of the altered gene because of the presence of another unrearranged gene on chromosome 19. We suggest that, because of its localization in a region frequently showing LOH and the observation of inactivation of this gene in glioblastoma cells, WDR11 is a candidate gene for the frequently proposed tumor suppressor gene in 10q25-26 which is involved in tumorigenesis of glial and other tumors showing frequent alterations in the distal 10q region.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Koculi, Eda/0000-0001-9477-555X; Cowell, John/0000-0002-2079-5950; Pan, Huaqin/0000-0002-7166-108X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELLO MJ, 1995, INT J CANCER, V64, P207; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng Y, 1999, HUM PATHOL, V30, P1284, DOI 10.1016/S0046-8177(99)90057-6; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Herbst RA, 1999, ARCH DERMATOL RES, V291, P567, DOI 10.1007/s004030050456; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; KARLBOM AE, 1993, HUM GENET, V92, P169; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kiyosawa H, 1996, HUM MOL GENET, V5, P745, DOI 10.1093/hmg/5.6.745; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nakamura M, 2000, J NEUROPATH EXP NEUR, V59, P539, DOI 10.1093/jnen/59.6.539; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; OOSUMI T, 1995, NATURE, V378, P672, DOI 10.1038/378672a0; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Robertson HM, 1997, GENE, V205, P219, DOI 10.1016/S0378-1119(97)00471-X; ROE BA, 1996, DNA ISOLATION SEQUEN; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Saxena A, 1999, ONCOGENE, V18, P1385, DOI 10.1038/sj.onc.1202440; Shannon M, 1998, DNA SEQUENCE, V8, P303, DOI 10.3109/10425179809034075; SIPKINS SB, 1998, GYNECOL ONCOL, V3, P391; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Suminaga R, 2000, J HUM GENET, V45, P331, DOI 10.1007/s100380070003; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xu Y, 1994, Genet Eng (N Y), V16, P241; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243	75	42	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5378	5392		10.1038/sj.onc.1204694	http://dx.doi.org/10.1038/sj.onc.1204694			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536051				2022-12-25	WOS:000170575500014
J	Reese, JS; Allay, E; Gerson, SL				Reese, JS; Allay, E; Gerson, SL			Overexpression of human O-6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice	ONCOGENE			English	Article						MGMT; p53; MNU; lymphomagenesis	TRANSGENIC MICE; N-METHYLNITROSOUREA; THYMIC LYMPHOMAS; KNOCKOUT MICE; HUMAN MGMT; GENE; MUTATIONS; EXPRESSION; REPAIR; TUMORS	O-6-alkylguanine DNA alkyltransferase (AGT) is a key mechanism in the prevention against MNU induced malignant transformation by removal of O-6 methyl guanine (O(6)mG) adducts. We asked whether heterozygous p53 deficient mice (p53+/-) would be more susceptible to MNU induced lymphomas than wild type mice, and whether O(6)mG adducts were responsible for this susceptibility. To determine whether MGMT overexpression would be protective, p53+/- mice were bred to human MGMT transgenic mice (MGMT+) and treated with 50 mg/kg MNU. MNU increased the incidence of thymic lymphomas in non-transgenic p53 + / - mice from 23% (n = 13) to 68% (n = 22) and decreased the mean latency from 433 to 106 days (P=0.01 compared to untreated mice). Wild type mice had an incidence of 30% (n = 38) and a mean latency of 135 days after MNU. Overexpression of MGMT in the thymus of p53 + / - mice significantly reduced the lymphoma incidence from 68 to 28% (n = 17) and increased the latency from 106 to 167 days (P=0.003). Similarly, the lymphoma incidence in MGMT + /wild type mice decreased from 30 to 8% (n = 12) and the latency increased to 297 days (P=0.2). Loss of the wild type allele was found in only 2/17 lymphomas occurring in p53 + / - mice and there were no significant point mutations in exons 5-8 of p53. Furthermore, there was no loss of p53 function in these mice. These data demonstrate that unrepaired O(6)mG lesions act cooperatively with the reduced p53 dose and lead to lymphomagenesis in p53+/- mice, but AGT overexpression and rapid removal of O(6)mG adducts is protective.	Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, BRB-3,10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [CA63193] Funding Source: Medline; NIEHS NIH HHS [ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1999, ONCOGENE, V18, P3783, DOI 10.1038/sj.onc.1202697; Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; GOODROW TL, 1992, MOL CARCINOGEN, V5, P9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LIU LL, 1994, CANCER RES, V54, P4648; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NEALE GAM, 1995, BLOOD, V86, P3060; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, CANCER RES, V61, P88; Ohgaki H, 2000, MOL CARCINOGEN, V28, P97, DOI 10.1002/1098-2744(200006)28:2<97::AID-MC5>3.0.CO;2-O; PEGG AE, 1990, CANCER RES, V50, P6119; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; SAYLORS RL, 1991, CANCER RES, V51, P4721; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215	23	23	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5258	5263		10.1038/sj.onc.1204700	http://dx.doi.org/10.1038/sj.onc.1204700			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536039				2022-12-25	WOS:000170575500002
J	Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT				Tang, QB; Chen, WX; Gonzales, MS; Finch, J; Inoue, H; Bowden, GT			Role of cyclic AMP responsive element in the UVB induction of cyclooxygenase-2 transcription in human keratinocytes	ONCOGENE			English	Article						UVB; CREB; p38; COX-2; transcription	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATOR PROTEIN-1 ACTIVATION; SYNTHASE-2 GENE-EXPRESSION; MESSENGER-RNA STABILITY; GROWTH-FACTOR-ALPHA; COLON-CANCER CELLS; P38 MAP KINASE; NUCLEAR FACTOR; PHORBOL ESTER; ENDOTHELIAL-CELLS	It has been shown that UVB irradiation induces expression of COX-2 and up-regulation of COX-2 plays a functional role in UVB tumor promotion. In this study, we examined the cis-elements in the human COX-2 promoter that may be responsible for the UVB induction of COX-2. Analyses with the COX-2 promoter region revealed that the cyclic AMP responsive element near the TATA box was essential for both basal and UVB induced COX-2 expression. This was further supported by studies using a dominant negative mutant of CREB, which strongly inhibited the activity of COX-2 promoter. Electrophoretic mobility shift assays indicated that CREB and ATF-I were the major proteins binding to the COX-2 CRE. CREB and ATF-I were phosphorylated upon UVB treatment, and SB202190, a p38 MAPK inhibitor, decreased the phosphorylation of CREB/ATF-1 and suppressed COX-2 promoter activity. In contrast, treatment with forskolin, an activator of adenylyl cyclase, led to phosphorylation of CREB and ATF-I and activation of COX-2 promoter. Finally, enhanced binding of phospho-CREB/ATF-1 to the COX-2 CRE was observed after UVB induction. Thus, one signaling pathway for UVB induction of human COX-2 involves activation of p38, subsequent phosphorylation of CREB/ATF-1, and activation of the COX-2 CRE through enhanced binding of phosphorylated CREB/ATF-1.	Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, Tucson, AZ 85724 USA; Natl Cardiovasc Ctr, Dept Pharmacol, Inst Res, Suita, Osaka 5658565, Japan	University of Arizona; National Cerebral & Cardiovascular Center - Japan	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Ctr Canc, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Boolbol SK, 1996, CANCER RES, V56, P2556; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN W, 2001, IN PRESS ONCOGENE; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang M, 1998, CANCER RES, V58, P1208; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365-2044.2000.01271.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MOATTER T, 1992, J CELL PHYSIOL, V151, P571, DOI 10.1002/jcp.1041510317; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; Reddy BS, 1996, CANCER RES, V56, P4566; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Sheng HM, 1998, CANCER RES, V58, P362; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH W, 1997, ADV EXP MED BIOL, P989; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 2000, CANCER RES, V60, P2399; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	49	72	74	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5164	5172		10.1038/sj.onc.1204667	http://dx.doi.org/10.1038/sj.onc.1204667			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526505				2022-12-25	WOS:000170464000010
J	Brandenburger, Y; Jenkins, A; Autelitano, DJ; Hannan, RD				Brandenburger, Y; Jenkins, A; Autelitano, DJ; Hannan, RD			Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes	FASEB JOURNAL			English	Article						rDNA transcription; cardiomyocyte hypertrophy; antisense RNA; adenovirus	POLYMERASE-I TRANSCRIPTION; UPSTREAM BINDING-FACTOR; RDNA TRANSCRIPTION; DNA-TRANSCRIPTION; HEART-CELLS; NEONATAL CARDIOMYOCYTES; PROTEIN-SYNTHESIS; ACTIVATION; KINASE; RECEPTOR	Recent evidence suggests that increased translational efficiency of existing ribosomes alone is insufficient to account for the hypertrophic growth of cardiomyocytes and that synthesis of new functional ribosomes must occur. The rate-limiting step in ribosome accumulation is the transcription of the ribosomal 45S genes (rDNA) by RNA polymerase I. Our previous studies have demonstrated that increases in the expression of the rDNA transcription factor UBF correlated with hypertrophy of neonatal cardiomyocytes. These studies expand this observation to examine directly the hypothesis that increased UBF levels are an essential requirement for the initiation of cardiac hypertrophy. We demonstrate that the introduction of UBF antisense RNA into myocytes, using adenovirus approaches, efficiently inhibits UBF accumulation during induction of cardiomyocyte hypertrophy. Moreover, this approach results in a significant reduction in rDNA transcription, rRNA levels, and protein accumulation, which are all the hallmarks of cardiac growth. Furthermore, UBF antisense RNA expression did not alter reexpression of the fetal gene program, which confirmed that the effect was specific for transcription by RNA polymerase I. These findings demonstrate that an increase in rRNA synthesis is required for hypertrophy of cardiomyocytes and also implicate UBF as a major regulatory factor in this process. Approaches that target UBF activity may be of therapeutic use in the regression of pathophysiological cardiac hypertrophy.	Baker Med Res Inst, Mol Physiol Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Hannan, RD (corresponding author), Baker Med Res Inst, Mol Physiol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	ross.hannan@baker.edu.au	Jenkins, Alicia/N-2482-2015	Hannan, Ross/0000-0002-2166-4493				ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DROUET C, 1991, J IMMUNOL, V147, P1694; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; GLIBETIC M, 1995, J BIOL CHEM, V270, P4209, DOI 10.1074/jbc.270.9.4209; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN R, 1998, TRANSCRIPTION RIBOSO, V1, P221; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Luyken J, 1996, CIRC RES, V78, P354, DOI 10.1161/01.RES.78.3.354; MATHEWS MB, 1975, CELL, V6, P223, DOI 10.1016/0092-8674(75)90013-6; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; Morgan HECB, 1992, HEART CARDIOVASCULAR, P1505; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PAULE M, 1998, TRANSCRIPTION EUKARY; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; PETTERSSON U, 1975, CELL, V6, P1, DOI 10.1016/0092-8674(75)90066-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sheridan DJ, 2000, CARDIOVASC RES, V47, P133, DOI 10.1016/S0008-6363(00)00065-1; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Tuan JC, 1999, MOL CELL BIOL, V19, P2872; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	53	51	51	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2051	+		10.1096/fj.00-0853fje	http://dx.doi.org/10.1096/fj.00-0853fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511532				2022-12-25	WOS:000170318500018
J	Chang, WH; Pratt, S; Chen, TH; Bourguignon, L; Shoback, D				Chang, WH; Pratt, S; Chen, TH; Bourguignon, L; Shoback, D			Amino acids in the cytoplasmic C terminus of the parathyroid Ca2+-sensing receptor mediate efficient cell-surface expression and phospholipase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTORS; XENOPUS-LAEVIS OOCYTES; CHAIN BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; CLONING; HYPERCALCEMIA; AGONISTS; DOMAIN; TAIL	The C-terminal tail of the calcium receptor (CaR) regulates the affinity of the receptor for ligand, desensitization, and membrane localization. To determine the role of specific amino acids in the bovine parathyroid CaR in mediating signal transduction and cell-surface expression, we transfected truncated and mutated Call cDNAs into HEK-293 cells. The ability of high extracellular [Ca2+] ([Ca2+](o)) to increase total inositol phosphate (InsP) production, an index of phospholipase C (PLC) activation, was determined. Receptor expression was assessed by immunoblotting and immunocytochemistry. In cells transiently or stably expressing receptors with the C-terminal tail truncated after residue 895 (CaR-(1-895)) or 929 (CaR-(1-929)), raising [Ca2+](o) increased InsPs to levels comparable with those of cells expressing wild-type Calls. There were no PLC responses to high [Ca2+](o) (up to 30 mM) in cells expressing CaRs with C-terminal tails of only 3 residues (CaR-(1-866)), even though these receptors were expressed in the membrane. We scanned the residues between Ser(866) and Val(895) using tandem-Ala and single-site mutagenesis. Two point mutants (His(880) --> Ala and Phe(882) --> Ala CaR) showed 50-70% reductions in high [Ca2+](o)-induced InsP production. The levels of expression and glycosylation of these mutants were comparable with wild-type Calls, but both receptors were profoundly retained in intracellular organelles and co-localized with the endoplasmic reticulum marker BiP. This suggested that the signaling defects of these receptors were likely because of defective trafficking of receptors to the cell surface. Modeling of the C-terminal domain of the CaR indicated that His(880) and Phe(882) are situated in a putative alpha -helical structure of 15 amino acids between residues 877 and 891 in the C-terminal tail. Our studies support the idea that specific amino acids, and possibly a unique secondary structure in the C-terminal tail, are required for the efficient targeting of the CaR to the cell surface required for PLC activation.	Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Shoback, D (corresponding author), Univ Calif San Francisco, Dept Med, Dept Vet Affairs Med Ctr, Endocrine Res Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055846] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43400, DK55846] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1998, METABOLIC BONE DIS, P479; Cao YX, 1998, P NATL ACAD SCI USA, V95, P11987, DOI 10.1073/pnas.95.20.11987; Carling T, 2000, J CLIN ENDOCR METAB, V85, P2042, DOI 10.1210/jc.85.5.2042; Chang W, 1999, MOL CELL ENDOCRINOL, V158, P13, DOI 10.1016/S0303-7207(99)00189-6; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; Chang WH, 1998, AM J PHYSIOL-ENDOC M, V275, pE213, DOI 10.1152/ajpendo.1998.275.2.E213; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Flor PJ, 1996, J NEUROCHEM, V67, P58; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; Lienhardt A, 2000, J CLIN ENDOCR METAB, V85, P1695, DOI 10.1210/jc.85.4.1695; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SHOBACK DM, 1988, ENDOCRINOLOGY, V122, P2833, DOI 10.1210/endo-122-6-2833; Ye CP, 1996, BIOCHEM BIOPH RES CO, V224, P271, DOI 10.1006/bbrc.1996.1019	31	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44129	44136		10.1074/jbc.M104834200	http://dx.doi.org/10.1074/jbc.M104834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11535593	hybrid			2022-12-25	WOS:000172297700083
J	Whitney, KD; Watson, MA; Goodwin, B; Galardi, CM; Maglich, JM; Wilson, JG; Willson, TM; Collins, JL; Kliewer, SA				Whitney, KD; Watson, MA; Goodwin, B; Galardi, CM; Maglich, JM; Wilson, JG; Willson, TM; Collins, JL; Kliewer, SA			Liver X receptor (LXR) regulation of the LMR alpha gene in human macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; BILE-ACID BIOSYNTHESIS; TANGIER-DISEASE; NUCLEAR RECEPTOR; CHOLESTEROL EFFLUX; RESPONSE PATHWAY; PLASMA-MEMBRANE; ABC1 GENE; APOA-I; ACTIVATION	The nuclear oxysterol receptors LXR alpha (NR1H3) and LXR beta (NR1H2) coordinately regulate the expression of genes involved in the transport and catabolism of cholesterol. In macrophages, LXR stimulates the transcription of genes encoding transporters involved in cholesterol efflux, which may limit the transformation of these cells into foam cells in response to lipid loading. Here, we report that natural and synthetic LXR ligands induce the expression of the LXRa gene in primary human macrophages and differentiated THP-1 macrophages. This regulation was not observed in primary human adipocytes or hepatocytes, a human intestinal cell line, or in any mouse tissue or cell line examined. The human LXRa gene was isolated, and the transcription initiation site delineated. Analysis of the LXR alpha promoter revealed a functional LXR/RXR binding site similar to2.9 kb upstream of the transcription initiation site. We conclude that LXRa regulates its own expression in human macrophages and that this response is likely to amplify the effects of oxysterols on reverse cholesterol transport. These findings underscore the importance of LXR as a potential therapeutic target for the treatment of atherosclerosis.	GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA	GlaxoSmithKline	Kliewer, SA (corresponding author), GlaxoSmithKline, Res & Dev, 5 Moore Dr, Res Triangle Pk, NC USA.		feinstein, doug/M-9414-2019					Alberti S, 2000, GENE, V243, P93, DOI 10.1016/S0378-1119(99)00555-7; Aouizerat BE, 1999, AM J HUM GENET, V65, P397, DOI 10.1086/302490; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Costet P, 2000, J BIOL CHEM, V275, P28240; Fayard E, 2001, CURR OPIN LIPIDOL, V12, P113, DOI 10.1097/00041433-200104000-00004; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schachter M, 1997, INT J CARDIOL, V62, pS3, DOI 10.1016/S0167-5273(97)00235-0; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289	40	132	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43509	43515		10.1074/jbc.M106155200	http://dx.doi.org/10.1074/jbc.M106155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11546778	hybrid			2022-12-25	WOS:000172297700006
J	Coustry, F; Hu, QH; de Crombrugghe, B; Maity, SN				Coustry, F; Hu, QH; de Crombrugghe, B; Maity, SN			CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase II alpha promoter - Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING FACTOR CBF; NF-Y; IN-VITRO; GENE PROMOTER; HIV-1 ENHANCER; HISTONE FOLD; PROTEIN; COMPLEX; EXPRESSION	To understand the role of CCAAT-binding factor (CBF) in transcription in the context of chromatin-assembled DNA, we used regularly spaced nucleosomal DNA using topoisomerase II alpha (topo II alpha) and alpha2(1) collagen promoter templates, which were subsequently reconstituted in an in vitro transcription reaction. Binding of CBF to the nucleosomal wild-type topo II alpha promoter containing four CBF-binding sites disrupted the regular nucleosomal structure not only in the promoter region containing the CBF-binding sites but also in the downstream region over the transcription start site. In contrast, no nucleosome disruption was observed in a mutant topo II alpha promoter containing mutations in all CBF-binding sites. Interestingly, CBF also activated transcription from nucleosomal wild-type topo II alpha promoter. In this experiment, a promoter containing one wild-type CBF-binding site was activated very weakly, whereas the promoter containing mutations in all sites was not activated by CBF. A truncated CBF that lacked the glutamine-rich domains did not activate transcription from nucleosomal wild-type topo II alpha promoter but disrupted the nucleosomal structure about as much as did the binding of full-length CBF. Two nucleosomal mouse a2(1) collagen promoter DNAs, one containing a single and the other containing four CBF-binding sites, were also reconstituted in an in vitro transcription reaction. None of the nucleosomal collagen promoters was activated by CBF. However, both of these collagen promoters were activated by CBF when the transcription reaction was performed using naked DNA templates. Binding of CBF to the nucleosomal collagen promoter containing four binding sites disrupted the nucleosomal structure, similarly as observed in the topo II alpha promoter. Altogether this study indicates that CBF-mediated nucleosomal disruption occurred independently of transcription activation. It also suggests that specific promoter structure may play a role in the CBF-mediated transcription activation of nucleosomal topo II alpha promoter template.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Maity, SN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NCI NIH HHS [CA16672, CA49515] Funding Source: Medline; NIAMS NIH HHS [R01 AR46264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA049515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; ARCOT SS, 1989, J BIOL CHEM, V264, P2343; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bulger M., 1994, METH MOL G, V5, P241; Caretti G, 1999, MOL CELL BIOL, V19, P8591; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Masternak K, 2000, GENE DEV, V14, P1156; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WOLFFE AP, 1993, METH MOL G, V2, P314; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WOOD WM, 1989, J BIOL CHEM, V264, P14841; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	36	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40621	40630		10.1074/jbc.M106918200	http://dx.doi.org/10.1074/jbc.M106918200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11514576	hybrid			2022-12-25	WOS:000171925600034
J	Li, SL; Jedrzejas, MJ				Li, SL; Jedrzejas, MJ			Hyaluronan binding and degradation by Streptococcus agalactiae hyaluronate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCUS; ACTION PATTERN; PNEUMONIAE; RESOLUTION; EXPRESSION; GENE; SPECIFICITY; ASSOCIATION; INFECTIONS; VIRULENCE	Streptococcus agalactiae hyaluronate lyase is a virulence factor that helps this pathogen to break through the biophysical barrier of the host tissues by the enzymatic degradation of hyaluronan and certain chondroitin sulfates at beta -1,4 glycosidic linkages. Crystal structures of the native enzyme and the enzyme-product complex were determined at 2.1- and 2.2-Angstrom resolutions, respectively. An elongated cleft transversing the middle of the molecule has been identified as the substrate-binding place. Two product molecules of hyaluronan degradation were observed bound to the cleft. The enzyme catalytic site was identified to comprise three residues: His(479), Tyr(488), and Asn(429). The highly positively charged cleft facilitates the binding of the negatively charged polymeric substrate chain. The matching between the aromatic patch of the enzyme and the hydrophobic patch of the substrate chain anchors the substrate chain into degradation position. A pair of proton exchanges between the enzyme and the substrate results in the cleavage of the beta -1,4 glycosidic linkage of the substrate chain and the unsaturation of the product. Phe(423) likely determines the size of the product at the product release side of the catalytic region. Hyaluronan chain is processively degraded from the reducing end toward the nonreducing end. The unsulfated or 6-sulfated regions of chondroitin sulfate can also be degraded in the same manner as hyaluronan.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	mjedrzejas@chori.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER CJ, 1988, ANN NY ACAD SCI, V549, P193, DOI 10.1111/j.1749-6632.1988.tb23972.x; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; Baker JR, 1997, BIOCHEM J, V327, P65, DOI 10.1042/bj3270065; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BLANCHET C, 1998, MULTIPLE PROTEIN SEQ; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; Divne C, 1998, J MOL BIOL, V275, P309, DOI 10.1006/jmbi.1997.1437; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Gase K, 1998, BBA-GENE STRUCT EXPR, V1398, P86, DOI 10.1016/S0167-4781(98)00045-1; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2000, ACTA CRYSTALLOGR D, V56, P460, DOI 10.1107/S0907444900000706; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurent TC, 1998, CHEM BIOL MED APPL H; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; LIN B, 1994, J BIOL CHEM, V269, P30113; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINKER A, 1956, J BIOL CHEM, V219, P13; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; MILLIGAN TW, 1978, INFECT IMMUN, V21, P738, DOI 10.1128/IAI.21.3.738-746.1978; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; PRICHARD DG, 2000, PROTEINS, V40, P126; QUIOCHO FA, 1999, BIOORGANIC CHEM CARB, P441; Rolland K, 1999, J CLIN MICROBIOL, V37, P1892, DOI 10.1128/JCM.37.6.1892-1898.1999; Ruijssenaars HJ, 1999, APPL ENVIRON MICROB, V65, P2446; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; Spellerberg B, 2000, MICROBES INFECT, V2, P1733, DOI 10.1016/S1286-4579(00)01328-9; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	43	76	80	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41407	41416		10.1074/jbc.M106634200	http://dx.doi.org/10.1074/jbc.M106634200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11527972	hybrid			2022-12-25	WOS:000171925600137
J	Urbauer, JL; Adelman, K; Urbauer, RJB; Simeonov, MF; Gilmore, JM; Zolkiewski, M; Brody, EN				Urbauer, JL; Adelman, K; Urbauer, RJB; Simeonov, MF; Gilmore, JM; Zolkiewski, M; Brody, EN			Conserved regions 4.1 and 4.2 of sigma(70) constitute the recognition sites for the anti-sigma factor AsiA, and AsiA is a dimer free in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; C-TERMINAL HALF; BACTERIOPHAGE-T4 ASIA; CHEMICAL-SHIFT; BINDING-SITE; DNA-BINDING; TRANSCRIPTION; PROTEIN; GENE; MOTA	The association of the bacteriophage T4-encoded AsiA protein with the sigma (70) subunit of the Escherichia coli RNA polymerase is one of the principal events governing transcription of the T4 genome. Analytical ultracentrifugation and NMR studies indicate that free AsiA is a symmetric dimer and the dimers can exchange subunits. Using NMR, the mutual recognition sites on AsiA and sigma (70) have been elucidated. Residues throughout the N-terminal half of AsiA are involved either directly or indirectly in binding to sigma (70) whereas the two highly conserved C-terminal regions of sigma (70), denoted 4.1 and 4.2, constitute the entire AsiA binding domain. Peptides corresponding to these regions bind tightly to AsiA individually and simultaneously. Simultaneous binding promotes structural changes in AsiA that mimic interaction with the complete AsiA binding determinant of sigma (70). Moreover, the results suggest that a significant rearrangement of the dimer accompanies peptide binding. Thus, both conserved regions 4.1 and 4.2 are intimately involved in recognition of AsiA by sigma (70). The interaction of AsiA with 4.1 provides a potential explanation of the differential abilities of DNA and AsiA to bind to free sigma (70) and a mechanistic alternative to models of AsiA function that rely on binding to a single site on sigma (70).	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Cornell Univ, Dept Phys, Ithaca, NY 14853 USA; Bulgarian Acad Sci, Dept Organ Chem, BU-1113 Sofia, Bulgaria; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Kansas; Cornell University; Bulgarian Academy of Sciences; Kansas State University; University of Colorado System; University of Colorado Boulder	Urbauer, JL (corresponding author), Univ Kansas, Dept Mol Biosci, 1200 Sunnyside Ave, Lawrence, KS 66045 USA.	jurbauer@ku.edu		Adelman, Karen/0000-0001-5364-334X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054998] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39806] Funding Source: Medline; NIGMS NIH HHS [GM50700, GM54998] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 1998, P NATL ACAD SCI USA, V95, P15247, DOI 10.1073/pnas.95.26.15247; Adelman K, 1997, J BIOL CHEM, V272, P27435, DOI 10.1074/jbc.272.43.27435; BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; BROWN KL, 1995, MOL MICROBIOL, V16, P397, DOI 10.1111/j.1365-2958.1995.tb02405.x; Campbell EA, 2000, J MOL BIOL, V300, P17, DOI 10.1006/jmbi.2000.3838; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Daughdrill GW, 1998, BIOCHEMISTRY-US, V37, P1076, DOI 10.1021/bi971952t; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Decatur AL, 1996, GENE DEV, V10, P2348, DOI 10.1101/gad.10.18.2348; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Foster MP, 1998, J BIOMOL NMR, V12, P51, DOI 10.1023/A:1008290631575; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Helmann JD, 1999, CURR OPIN MICROBIOL, V2, P135, DOI 10.1016/S1369-5274(99)80024-1; Hinton DM, 1996, J MOL BIOL, V256, P235, DOI 10.1006/jmbi.1996.0082; Hinton DM, 2000, J MOL BIOL, V304, P731, DOI 10.1006/jmbi.2000.4113; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Minakhin L, 2001, J MOL BIOL, V306, P631, DOI 10.1006/jmbi.2001.4445; ORSINI G, 1993, J BACTERIOL, V175, P85, DOI 10.1128/JB.175.1.85-93.1993; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P3956, DOI 10.1128/JB.176.13.3956-3965.1994; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; Sharma UK, 1999, J BACTERIOL, V181, P5855, DOI 10.1128/JB.181.18.5855-5859.1999; STEVENS A, 1977, BIOCHIM BIOPHYS ACTA, V475, P193, DOI 10.1016/0005-2787(77)90355-0; Urbauer JL, 1997, J BIOMOL NMR, V10, P205, DOI 10.1023/A:1018343223888; Wilkinson KD, 1999, J MOL BIOL, V291, P1067; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	33	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41128	41132		10.1074/jbc.M106400200	http://dx.doi.org/10.1074/jbc.M106400200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11518715	hybrid			2022-12-25	WOS:000171925600101
J	Wang, CW; Liao, JC				Wang, CW; Liao, JC			Alteration of product specificity of Rhodobacter sphaeroides phytoene desaturase by directed evolution.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS GENE-CLUSTER; ESCHERICHIA-COLI; CAROTENOID BIOSYNTHESIS; MOLECULAR EVOLUTION; FUNCTIONAL-ANALYSIS; PATHWAY; PROTEIN; LEVEL	Phytoene desaturases occurring in nature convert phytoene to either neurosporene or lycopene in most eubacteria. Approximately 10% of known phytoene desaturases, as in Rhodobacter, produce neurosporene, whereas the rest produce lycopene. These two types of enzymes, although similar in function, have relatively low similarity (below 60%) in terms of nucleotide or amino acid sequence. The mechanism controlling the product specificity of these enzymes is unclear. Here we used directed evolution to change the product of Rhodobacter sphaeroides phytoene desaturase (crtI gene product), a neurosporene-producing enzyme, to lycopene. Two generations of random mutagenesis were performed, from which three positive mutants were isolated and sequenced. We then used site-directed mutagenesis to determine the effect of each amino acid change. Gathering information from random mutagenesis, we further recombined the beneficial mutations by site-directed mutagenesis and increased the percent of lycopene production to 90%.	Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem Engn, 5531 Boelter Hall, Los Angeles, CA 90095 USA.			Liao, James/0000-0002-4580-7276				Armstrong GA, 1996, FASEB J, V10, P228, DOI 10.1096/fasebj.10.2.8641556; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Garcia-Asua G, 1998, TRENDS PLANT SCI, V3, P445, DOI 10.1016/S1360-1385(98)01329-6; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Wang CW, 2000, BIOTECHNOL PROGR, V16, P922, DOI 10.1021/bp000124f; Wang CW, 1999, BIOTECHNOL BIOENG, V62, P235, DOI 10.1002/(SICI)1097-0290(19990120)62:2<235::AID-BIT14>3.0.CO;2-U	20	31	43	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41161	41164		10.1074/jbc.M105786200	http://dx.doi.org/10.1074/jbc.M105786200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11526111	hybrid			2022-12-25	WOS:000171925600105
J	Bald, D; Noji, H; Yoshida, M; Hirono-Hara, Y; Hisabori, T				Bald, D; Noji, H; Yoshida, M; Hirono-Hara, Y; Hisabori, T			Redox regulation of the rotation of F-1-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ATP SYNTHASE; ADENOSINE-TRIPHOSPHATASE; DISULFIDE BOND; WILD-TYPE; F1-ATPASE; ACTIVATION; RESOLUTION; BACTERIUM; EXCHANGE	In F-1-ATPase, the smallest known motor enzyme, unidirectional rotation of the central axis subunit gamma is coupled to ATP hydrolysis. In the present study, we report the redox switching of the rotation of this enzyme. For this purpose, the switch region from the gamma subunit of the redox-sensitive chloroplast F-1-ATPase was introduced into the bacterial F-1-ATPase. The ATPase activity of the obtained complex was increased up to 3-fold upon reduction (Bald, D., Noji, H., Stumpp, M. T., Yoshida, M. & Hisabori, T. (2000) J. Biol. Chem. 275,12757-12762). Here, we successfully observed the modulation of rotation of gamma in this chimeric complex by changes in the redox conditions. In addition we revealed that the suppressed enzymatic activity of the oxidized F-1-ATPase complex was characterized by more frequent long pauses in the rotation of the gamma subunit. These findings obtained by the single molecule analysis therefore provide new insights into the mechanisms of enzyme regulation.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Tokyo Inst Technol, PRESTO, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Teikyo University	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Baalmann E, 1995, ARCH BIOCHEM BIOPHYS, V324, P201, DOI 10.1006/abbi.1995.0031; Bald D, 2000, J BIOL CHEM, V275, P12757, DOI 10.1074/jbc.275.17.12757; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CADET F, 1987, BIOCHEM J, V241, P71, DOI 10.1042/bj2410071; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; VASILYEVA EA, 1992, BIOCHEM J, V202, P9; WOLOSIUK RA, 1978, ARCH BIOCHEM BIOPHYS, V189, P97, DOI 10.1016/0003-9861(78)90119-4; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	27	61	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39505	39507		10.1074/jbc.C100436200	http://dx.doi.org/10.1074/jbc.C100436200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11518700	hybrid, Green Published			2022-12-25	WOS:000171789200002
J	Leduc, J; Thorsteinsson, MV; Gaal, T; Roberts, GP				Leduc, J; Thorsteinsson, MV; Gaal, T; Roberts, GP			Mapping CooA center dot RNA polymerase interactions - Identification of activating regions 2 and 3 in CooA, the co-sensing transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; AMP RECEPTOR PROTEIN; IRON-SULFUR PROTEIN; RHODOSPIRILLUM-RUBRUM; TERMINAL DOMAIN; CONTACT SITE; HISTIDINE 77; HEME; FNR; HYDROGENASE	CooA is a CO-sensing protein that activates the transcription of genes encoding the CO-oxidation (coo) regulon, whose polypeptide products are required for utilizing CO as an energy source in Rhodospirillum rubrum. CooA binds to a position overlapping the -35 element of the P-cooF promoter, similar to the arrangement of class II CRP (cAMP receptor protein)- and FNR (fumarate and nitrate reductase activator protein)-dependent promoters when expressed in Escherichia coli. Gain-of-function CooA variants were isolated in E. coli following mutagenesis of the portion of cooA encoding the effector-binding domain. Some of the mutations affect regions of CooA that are homologous to the activating regions (AR2 and AR3) previously identified in CRP and FNR, whereas others affect residues that lie in a region of CooA between AR2 and ARS. These CooA variants are comparable to wild-type (WT) CooA in DNA binding affinity in response to CO but differ in transcription activation, presumably because of altered interactions with E. coli RNA polymerase. Based on predictions of similarity to CRP and FNR, loss-of-function CooA variants were obtained in the AR2 and AR3 regions that have minimal transcriptional activity, yet have WT-like DNA binding affinities in response to CO. This study demonstrates that WT CooA contains AR2- and AR3-like surfaces that are required for optimal transcription activation.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	groberts@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BELL A, 1994, MOL MICROBIOL, V11, P383, DOI 10.1111/j.1365-2958.1994.tb00318.x; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; ENSIGN SA, 1991, J BIOL CHEM, V266, P18395; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; He YP, 1999, J BIOL CHEM, V274, P10840, DOI 10.1074/jbc.274.16.10840; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Li B, 1998, NUCLEIC ACIDS RES, V26, P2075, DOI 10.1093/nar/26.9.2075; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Rhodius VA, 2000, J MOL BIOL, V299, P295, DOI 10.1006/jmbi.2000.3736; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; VOGEL AM, 1994, MOL MICROBIOL, V12, P811, DOI 10.1111/j.1365-2958.1994.tb01067.x; WILLIAMS R, 1991, NUCLEIC ACIDS RES, V19, P6705, DOI 10.1093/nar/19.24.6705; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028	33	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39968	39973		10.1074/jbc.M105758200	http://dx.doi.org/10.1074/jbc.M105758200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11522788	hybrid			2022-12-25	WOS:000171789200063
J	Pummill, PE; Kempner, ES; DeAngelis, PL				Pummill, PE; Kempner, ES; DeAngelis, PL			Functional molecular mass of a vertebrate hyaluronan synthase as determined by radiation inactivation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; LEUCONOSTOC-MESENTEROIDES; CHITIN OLIGOSACCHARIDES; SYNTHESIZE HYALURONAN; PASTEURELLA-MULTOCIDA; TARGET ANALYSIS; DG42 GENE; IN-VITRO; XENOPUS; PROTEIN	Hyaluronan (RA), a linear polysaccharide composed of N-acetylglucosamine-glucuronic acid repeats, is found in the extracellular matrix of vertebrate tissues as well as the capsule of several pathogenic bacteria. The HA synthases (HASs) are dual-action glycosyltransferases that catalyze the addition of two different sugars from UDP-linked precursors to the growing HA chain. The prototypical vertebrate hyaluronan synthase, x1-HAS1 (or DG42) from Xenopus laevis, is a 588-residue membrane protein. Recently, the streptococcal enzyme was found to function as a monomer of protein with similar to 16 lipid molecules. The vertebrate enzymes are larger than the streptococcal enzymes; based on the vertebrate HAS deduced amino acid sequence, two additional membrane-associated regions at the carboxyl terminus are predicted. We have utilized radiation inactivation to measure the target size of yeast-derived recombinant x1HAS1. The target size of HAS activity was confirmed using two internal standards. First, samples were spiked with glucose-6-phosphate dehydrogenase, an enzyme of known molecular weight. Second, parallel samples of native x1HAS1 and a x1HAS1-green fluorescent protein fusion (833 residues) were compared; substantial confidence was gained by using this novel internal standard. Our test also corroborated the basic tenets of radiation inactivation theory. We found that the vertebrate HAS protein functions catalytically as a monomer.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; NIAMSD, Phys Biol Lab, NIH, Bethesda, MD 20892 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.				NIGMS NIH HHS [GM 56497] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; ARONSON DL, 1962, RADIAT RES, V16, P138, DOI 10.2307/3571193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; Kempner ES, 1999, ANAL BIOCHEM, V276, P113, DOI 10.1006/abio.1999.4362; KEMPNER ES, 1982, J BIOL CHEM, V257, P8919; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE WT, 1991, J BIOL CHEM, V266, P13028; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Tlapak-Simmons VL, 1998, J BIOL CHEM, V273, P26100, DOI 10.1074/jbc.273.40.26100; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	37	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39832	39835		10.1074/jbc.M105489200	http://dx.doi.org/10.1074/jbc.M105489200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11517224	hybrid			2022-12-25	WOS:000171789200044
J	Zhao, HB; Laitala-Leinonen, T; Parikka, V; Vaananen, HK				Zhao, HB; Laitala-Leinonen, T; Parikka, V; Vaananen, HK			Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUFFLED BORDER MEMBRANE; VACUOLAR H+-ATPASE; RESORBING OSTEOCLASTS; PLASMA-MEMBRANE; BINDING PROTEIN; PROTON PUMP; CATHEPSIN-K; LOCALIZATION; CELLS; OLIGONUCLEOTIDES	During skeletal growth and remodeling the mineralized bone matrix is resorted by osteoclasts through the constant secretion of protons and proteases to the bone surface. This relies on the formation of specialized plasma membrane domains, the sealing zone and the ruffled border, and vectorial transportation of intracellular vesicles in bone-resorting osteoclasts. Here we show that Rab7, a small GTPase that is associated with late endosomes, is highly expressed and is predominantly localized at the ruffled border in bone-resorting osteoclasts. The decreased expression of Rab7 in cultured osteoclasts by antisense oligodeoxynucleotides disrupted the polarization of the osteoclasts and the targeting of vesicles to the ruffled border. These impairments caused a significant inhibition of bone resorption in vitro. The results indicate that the late endocytotic pathway is involved in the osteoclast polarization and bone resorption and underscore the importance of Rab7 in osteoclast function.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland	University of Turku	Zhao, HB (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Barnes Jewish Hosp N, Mailstop 90-31-649,216 S Kingshighway Blvd, St Louis, MO 63110 USA.		Zhao, Haibo/ABG-9729-2021	Parikka, Vilhelmiina/0000-0002-9281-8154; ZHAO, HAIBO/0000-0003-0836-7555				Abu-Amer Y, 1999, J BONE MINER RES, V14, P1855, DOI 10.1359/jbmr.1999.14.11.1855; AKAMINE A, 1993, HISTOCHEMISTRY, V100, P101, DOI 10.1007/BF00572895; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GAO WY, 1992, MOL PHARMACOL, V41, P223; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; HASS A, 1995, EMBO J, V14, P5258; HUBER LA, 1995, METHOD ENZYMOL, V257, P302; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; Masuda ES, 2000, FEBS LETT, V470, P61, DOI 10.1016/S0014-5793(00)01288-6; MERESSE S, 1995, J CELL SCI, V108, P3349; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Palokangas H, 1997, J CELL SCI, V110, P1767; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SALO J, 1996, J CELL SCI, V106, P301; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SELANDER K, 1994, CALCIFIED TISSUE INT, V55, P368, DOI 10.1007/BF00299317; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Vaananen HK, 2000, J CELL SCI, V113, P377; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Villanova I, 1999, J BONE MINER RES, V14, P1867, DOI 10.1359/jbmr.1999.14.11.1867; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756-3282(98)00138-0; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	46	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					39295	39302		10.1074/jbc.M010999200	http://dx.doi.org/10.1074/jbc.M010999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11514537	hybrid			2022-12-25	WOS:000171673200128
J	Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST				Chan, TL; Curtis, LC; Leung, SY; Farrington, SM; Ho, JWC; Chan, ASY; Lam, PWY; Tse, CW; Dunlop, MG; Wyllie, AH; Yuen, ST			Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes	ONCOGENE			English	Article						early-onset colorectal cancer; chromosomal instability; DNA ploidy; microsatellite instability	COMPARATIVE GENOMIC HYBRIDIZATION; YOUNG-PATIENTS; GENETIC INSTABILITY; COLON-CANCER; TUMORS; P53; MUTATIONS; CARCINOGENESIS; CHECKPOINT; CARCINOMAS	Colorectal cancer has been described in terms of genetic instability selectively affecting either microsatellite sequences (MIN) or chromosome number and structure (CIN). A subgroup with apparently stable, near-diploid chromosomes and stable microsatellites (MACS) also exists. These distinctions are important, partly because of their value in highlighting different pathways of carcinogenesis, and partly because of their direct relevance to prognosis. Study of early-onset cancer has often proved a fruitful resource for the identification of the nature and function of cancer susceptibility genes. In a study of colorectal cancer with stable microsatellite DNA, we describe 22 early-onset tumours (mean age = 33), compared with 16 late-onset tumours (mean age = 68). Both groups contained carcinomas with the MACS phenotype, characterized by near diploid DNA content, as defined by flow cytometry, and minimal chromosome arm deletion or amplification (six or less events per genome), determined by comparative genomic hybridization (CGH). Minimal chromosome imbalance correlated strongly with diploid DNA content (P<0.001). The proportion of MACS cancers was significantly greater in early-onset as compared to late-onset tumours (64 vs 13%, P=0.005). Of the chromosome arm imbalances commonly observed in late-onset tumours, only 18q- was observed more than twice amongst the 14 early-onset MACS tumours. Seventy-nine per cent of these MACS tumours were located in the distal colon, and 69% were at advanced clinico-pathological stages (with lymph node or distant metastasis). A positive family history of colorectal or other cancers was elicited in seven patients in the MACS early-onset group, and one additional patient in this group had a metachronous ovarian cancer. The results suggest that MACS cancer may have a genetic basis different from either MIN or CIN, and further studies of these cancers may lead to discovery of new mechanisms of colorectal carcinogenesis and cancer susceptibility.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Oncol, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China	University of Cambridge; University of Hong Kong; University of Hong Kong; University of Edinburgh; University of Edinburgh	Wyllie, AH (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		Yuen, Siu/K-6311-2014; Dunlop, Malcolm G/F-1973-2011; Leung, Suet Yi/C-4340-2009; Farrington, Susan M/Q-2710-2019; Farrington, Susan M/C-7319-2013; Leung, Suet Yi/T-9620-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389; Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; CLARKE AR, 1994, ONCOGENE, V9, P1767; Cottu PH, 1996, ONCOGENE, V13, P2727; Curtis LJ, 2000, J PATHOL, V192, P440; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAWN MT, 1995, CANCER RES, V55, P3721; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung SY, 2000, ONCOGENE, V19, P4079, DOI 10.1038/sj.onc.1203740; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTHE RA, 1993, CANCER RES, V53, P5849; MERRITT AJ, 1994, CANCER RES, V54, P614; Miyazaki M, 1999, CANCER RES, V59, P5283; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; SCHLEGEL J, 1995, CANCER RES, V55, P6002; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	35	62	65	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4871	4876		10.1038/sj.onc.1204653	http://dx.doi.org/10.1038/sj.onc.1204653			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521198				2022-12-25	WOS:000170271800011
J	Chung, JY; Park, JO; Phyu, H; Dong, ZG; Yang, CS				Chung, JY; Park, JO; Phyu, H; Dong, ZG; Yang, CS			Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3 '-digallate	FASEB JOURNAL			English	Article						tea polyphenols; MAP kinases; Erk1/2 activity; MEK1/2; Raf-1	ACTIVATOR PROTEIN-1 ACTIVITY; PROLINE-RICH PROTEINS; NITRIC-OXIDE SYNTHASE; I-KAPPA-B; BLACK TEA; GREEN TEA; LUNG TUMORIGENESIS; CANCER CELLS; GROWTH; INDUCTION	Our previous study showed that tea polyphenols inhibited MAP kinase and AP-1 activities in mouse epidermal JB6 cells and the corresponding H-ras-transformed cell line 30.7b Ras 12. The present study investigated the mechanisms of this inhibition. The cells were incubated with (-)-epigallocatechin-3-gallate (EGCG) or theaflavin-3,3'-digallate (TFdiG) (20 muM) for different times, and the cell lysate was analyzed by immunoblotting. EGCG treatment decreased the levels of phospho-Erk1/2 and -MEK1/2 time-dependently (by 60% at 60 min). TFdiG lowered their levels by 38%-50% at 15 min. TFdiG effectively decreased total Raf-1 protein levels, most likely through lysosomal degradation. EGCG did not affect protein levels or the activity of Raf-1 significantly but decreased its association with MEK1 as determined by co-immunoprecipitation. In addition, EGCG and TFdiG (10 muM) inhibited the phosphorylation of Elk-1 by isolated phospho-Erk1/2 in vitro. This inhibition of Erk1/2 activity is Elk-1 concentration-dependent and ATP concentration-independent, which suggests that EGCG and TFdiG interfere with the binding of the protein substrate to the kinase. The presently demonstrated specific mechanisms of inhibition of MAP kinases by EGCG and TFdiG may help us to understand the effects of tea consumption on cancer, inflammatory diseases, and cardiovascular diseases.	Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08854 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Rutgers State University New Brunswick; University of Minnesota System	Yang, CS (corresponding author), Rutgers State Univ, Coll Pharm, Canc Res Lab, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	csyang@rci.rutgers.edu						ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; Baxter NJ, 1997, BIOCHEMISTRY-US, V36, P5566, DOI 10.1021/bi9700328; Blot WJ, 1997, CRIT REV FOOD SCI, V37, P739, DOI 10.1080/10408399709527800; Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Charlton AJ, 1996, FEBS LETT, V382, P289, DOI 10.1016/0014-5793(96)00186-X; Chung JY, 1999, CANCER RES, V59, P4610; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICE JF, 1992, ANN NY ACAD SCI, V674, P58, DOI 10.1111/j.1749-6632.1992.tb27477.x; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Hibasami H, 1998, INT J MOL MED, V1, P725; Hibasami H, 1998, ONCOL REP, V5, P527; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang MT, 1997, CANCER RES, V57, P2623; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Katiyar SK, 1996, INT J ONCOL, V8, P221; Kohlmeier L, 1997, NUTR CANCER, V27, P1, DOI 10.1080/01635589709514494; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Lin YL, 1999, EUR J PHARMACOL, V367, P379, DOI 10.1016/S0014-2999(98)00953-4; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Lu YP, 1997, CARCINOGENESIS, V18, P2163, DOI 10.1093/carcin/18.11.2163; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCarty MF, 1998, MED HYPOTHESES, V50, P511, DOI 10.1016/S0306-9877(98)90273-0; MEHANSHO H, 1987, ANNU REV NUTR, V7, P423, DOI 10.1146/annurev.nu.07.070187.002231; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SCHULZ B, 1996, CURR TRENDS POLYM SC, V1, P1; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yang CS, 1999, P SOC EXP BIOL MED, V220, P213, DOI 10.1046/j.1525-1373.1999.d01-36.x; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409; YANG CS, 1999, CURR PRACT MED, V2, P163; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 1997, CANCER RES, V57, P1889; Yang GY, 1997, CARCINOGENESIS, V18, P2361, DOI 10.1093/carcin/18.12.2361	56	143	152	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2022	+		10.1096/fj.01-0031fje	http://dx.doi.org/10.1096/fj.01-0031fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511526				2022-12-25	WOS:000170318500020
J	Huang, SM; Bisogno, T; Petros, TJ; Chang, SY; Zavitsanos, PA; Zipkin, RE; Sivakumar, R; Coop, A; Maeda, DY; De Petrocellis, L; Burstein, S; Di Marzo, V; Walker, JM				Huang, SM; Bisogno, T; Petros, TJ; Chang, SY; Zavitsanos, PA; Zipkin, RE; Sivakumar, R; Coop, A; Maeda, DY; De Petrocellis, L; Burstein, S; Di Marzo, V; Walker, JM			Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE N-ACYLTRANSFERASE; FORMALIN-INDUCED ACTIVITY; COENZYME-A SYNTHETASE; DORSAL HORN NEURONS; ACYL-COA ESTERS; CANNABINOID RECEPTOR; HUMAN-LIVER; ANANDAMIDE; RAT; PURIFICATION	In mammals, specific lipids and amino acids serve as crucial signaling molecules. In bacteria, conjugates of lipids and amino acids (referred to as lipoamino acids) have been identified and found to possess biological activity. Here, we report that mammals also produce lipoamino acids, specifically the arachidonyl amino acids. We show that the conjugate of arachidonic acid and glycine (N-arachidonylglycine (NAGly)) is present in bovine and rat brain as well as other tissues and that it suppresses tonic inflammatory pain. The biosynthesis of NAGly and its degradation by the enzyme fatty acid amide hydrolase can be observed in rat brain tissue. In addition to NAGly, bovine brain produces at least two other arachidonyl amino acids: N-arachidonyl gamma -aminobutyric acid (NAGABA) and N-arachidonylalanine. Like NAGly, NAGABA inhibits pain. These findings open the door to the identification of other members of this new class of biomolecules, which may be integral to pain regulation and a variety of functions in mammals.	Brown Univ, Alan M Schrier Res Lab, Dept Psychol, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA; CNR, Ist Cibernet, Endocannabinoid Res Grp, I-80072 Naples, Italy; Agilent Technol, Wilmington, DE 19808 USA; Appl Biosyst Inc, Framingham, MA 01701 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA	Brown University; Brown University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Agilent Technologies; Thermo Fisher Scientific; Applied Biosystems; University System of Maryland; University of Maryland Baltimore; University of Massachusetts System; University of Massachusetts Worcester	Walker, JM (corresponding author), Brown Univ, Alan M Schrier Res Lab, Dept Psychol, 89 Waterman St,POB 1853, Providence, RI 02912 USA.		Maeda, Dean/AAB-8973-2020; Di Marzo, Vincenzo/AAD-7742-2019; Bisogno, Tiziana/B-7891-2015; Petros, Timothy/U-3299-2019	Maeda, Dean/0000-0002-9304-6846; Di Marzo, Vincenzo/0000-0002-1490-3070; Petros, Timothy/0000-0002-8943-546X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012178, R01DA013012, K02DA000375] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13012, K02DA00375, DA12178] Funding Source: Medline; NINDS NIH HHS [NS33247] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abram SE, 1997, ANESTHESIOLOGY, V86, P1015, DOI 10.1097/00000542-199705000-00001; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Burstein SH, 2000, PROSTAG OTH LIPID M, V61, P29, DOI 10.1016/S0090-6980(00)00053-8; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEBUISSON D, 1977, PAIN, V4, P161; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; DICKENSON AH, 1987, NEUROSCI LETT, V83, P207, DOI 10.1016/0304-3940(87)90242-4; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; GREGERSEN N, 1986, BIOCHEM MED METAB B, V35, P210, DOI 10.1016/0885-4505(86)90076-9; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; KAWAI Y, 1988, EUR J BIOCHEM, V171, P73, DOI 10.1111/j.1432-1033.1988.tb13760.x; KAWAZOE R, 1991, J BACTERIOL, V173, P5470, DOI 10.1128/jb.173.17.5470-5475.1991; KOLVRAA S, 1986, BIOCHEM MED METAB B, V36, P98, DOI 10.1016/0885-4505(86)90112-X; LEROUGE P, 1988, CHEM PHYS LIPIDS, V49, P161, DOI 10.1016/0009-3084(88)90003-5; Maurelli S, 1995, FEBS LETT, V377, P82, DOI 10.1016/0014-5793(95)01311-3; MAWAL YR, 1994, BIOCHEM BIOPH RES CO, V205, P1373, DOI 10.1006/bbrc.1994.2817; MORISAKI N, 1983, BIOCHIM BIOPHYS ACTA, V752, P301; NANDI DL, 1979, J BIOL CHEM, V254, P7230; NGAN F, 1991, J CHROMATOGR SCI, V29, P8, DOI 10.1093/chromsci/29.1.8; Puig S, 1996, PAIN, V64, P345, DOI 10.1016/0304-3959(95)00121-2; REDDY TS, 1983, ARCH BIOCHEM BIOPHYS, V226, P125, DOI 10.1016/0003-9861(83)90277-1; SCHACHTER D, 1953, J BIOL CHEM, V203, P925; SCHACHTER D, 1954, J BIOL CHEM, V208, P263; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; TAYLOR BK, 1995, J NEUROSCI, V15, P7575; WILSON DB, 1982, J BIOL CHEM, V257, P3510; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	31	257	288	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42639	42644		10.1074/jbc.M107351200	http://dx.doi.org/10.1074/jbc.M107351200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11518719	hybrid			2022-12-25	WOS:000172169300003
J	Mitchell, DC; Niu, SL; Litman, BJ				Mitchell, DC; Niu, SL; Litman, BJ			Optimization of receptor-G protein coupling by bilayer lipid composition I - Kinetics of rhodopsin-transducin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHODOPSIN-II; PHOTORECEPTOR-MEMBRANES; LATERAL DIFFUSION; CRYSTAL-STRUCTURE; BOVINE RHODOPSIN; MOLECULAR ORDER; DISK MEMBRANES; CHOLESTEROL; PHOSPHOLIPIDS; LUMIRHODOPSIN	The role of membrane composition in modulating the rate of G protein-receptor complex formation was examined using rhodopsin and transducin (G(t)) as a model system. Metarhodopsin II (MII) and MII-G(t) complex formation rates were measured, in the absence of GTP, via flash photolysis for rhodopsin reconstituted in 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0,18:1PC) and 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0,22:6PC) bilayers, with and without 30 mol% cholesterol. Variation in bilayer lipid composition altered the lifetime of MII-G(t) formation to a greater extent than the lifetime of MII. MII-G(t) formation was fastest in 18:0,22:6PC and slowest in 18:0,18:1PC/30 mol% cholesterol. At 37 degreesC and a G(t) to photolyzed rhodopsin ratio of 1:1 in 18:0,22: 6PC bilayers, MII-G(t) formed with a lifetime of 0.6 +/-0.06 ms, which was not significantly different from the lifetime for MII formation. Incorporation of 30 mol% cholesterol slowed the rate of MII-G(t) complex formation by about 400% in 18:0,18:1PC, but by less than 25% in 18:0,22:6PC bilayers. In 18:0,22:6PC, with or without cholesterol, MII-G(t) formed rapidly after MII formed. In contrast, cholesterol in 18:0,18:IPC induced a considerable lag time in MII-G(t) formation after MII formed. These results demonstrate that membrane composition is a critical factor in determining the temporal response of a G protein-coupled signaling system.	NIAAA, Sect Fluorescence Studies, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), NIAAA, Sect Fluorescence Studies, Lab Membrane Biochem & Biophys, Pk 5,Rm 158,12420 Parklawn Dr, Rockville, MD 20852 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000080, ZIAAA000080, Z01AA000105, Z01AA000072] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BARTLETT GR, 1959, J BIOL CHEM, V234, P596; BENNETT N, 1982, EUR J BIOCHEM, V127, P97, DOI 10.1111/j.1432-1033.1982.tb06842.x; BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365; BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; Borst JW, 2000, BBA-MOL CELL BIOL L, V1487, P61, DOI 10.1016/S1388-1981(00)00084-6; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; Dickopf S, 1998, BIOCHEMISTRY-US, V37, P16888, DOI 10.1021/bi981879m; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; Jager S, 1998, BIOCHEMISTRY-US, V37, P6998, DOI 10.1021/bi9728194; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Ladha S, 1996, BIOPHYS J, V71, P1364, DOI 10.1016/S0006-3495(96)79339-6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; LEWIS JW, 1981, PHOTOCHEM PHOTOBIOL, V34, P375, DOI 10.1111/j.1751-1097.1981.tb09012.x; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LITMAN BJ, 1996, LIPIDS S, V31, P193; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MILLER JL, 1987, BIOCHIM BIOPHYS ACTA, V898, P81, DOI 10.1016/0005-2736(87)90111-8; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Neuringer M, 2000, AM J CLIN NUTR, V71, p256S, DOI 10.1093/ajcn/71.1.256S; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; OBRIEN DF, 1977, BIOCHEMISTRY-US, V16, P1295, DOI 10.1021/bi00626a009; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; STINSON AM, 1991, EXP EYE RES, V52, P218; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; Tachibanaki S, 1997, BIOCHEMISTRY-US, V36, P14173, DOI 10.1021/bi970932o; THORGEIRSSON TE, 1993, BIOCHEMISTRY-US, V32, P13861, DOI 10.1021/bi00213a015	45	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42801	42806		10.1074/jbc.M105772200	http://dx.doi.org/10.1074/jbc.M105772200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544258	hybrid			2022-12-25	WOS:000172169300023
J	Reymond, N; Fabre, S; Lecocq, E; Adelaide, J; Dubreuil, P; Lopez, M				Reymond, N; Fabre, S; Lecocq, E; Adelaide, J; Dubreuil, P; Lopez, M			Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with Nectin1/PRR1 through V domain interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; CELL-CELL JUNCTIONS; ADHERENS JUNCTIONS; ADHESION MOLECULE; BINDING PROTEIN; AF-6 INTERACTS; MURINE HOMOLOG; GLYCOPROTEIN-D; ENTRY	Nectins are adhesion molecules that participate in the organization of epithelial and endothelial junctions and serve as receptors for herpes simplex virus entry. They belong to the immunoglobulin superfamily, are homologues of the poliovirus receptor (PVR/CD155), and were also named poliovirus receptor-related (PRR) proteins. We identify a new member of the nectin family named nectin4. Peptide sequences of human and murine nectin4 share 92% identity, and as for other members, the ectodomain is made of three immunoglobulin-like domains of V, C, C types. In contrast to other nectin molecules, detection of nectin4 transcripts is mainly restricted to placenta in human tissues. Expression is broader in mouse, and interestingly nectin4 is detected at days 11, 15, and 17 during murine embryogenesis. Nectin4 interacts with afadin, a F-actin-associated molecule, via its carboxyl-terminal cytoplasmic sequence. Both molecules co-localize at cadherin-based adherens junctions in the MDCKII epithelial cell line. Nectins are homophilic adhesion molecules, and recently heterophilic interactions have been described between nectin3/nectin1 and nectin3/nectin2. We confirmed these trans-interactions and also described nectin3 as the PVR/CD155 ligand. By means of several approaches, we report on the identification of nectin4 as a new ligand for nectin1. First, a soluble chimeric recombinant nectin4 ectodomain (nectin4-Fc) trans-interacts with cells expressing nectin1 but not with cells expressing nectin2, nectin3, or PVR/CD155. Conversely, nectin1-Fc binds to cells expressing nectin4. Second, nectin1-Fc precipitates nectin4 expressed in COS cells. Third, reciprocal in vitro physical interactions were detected between nectin4-Fc and nectin1-Fc. The nectin4-Fc/nectin4-Fc interaction was detected suggesting that nectin4 exhibits both homophilic and heterophilic properties. Using the same approaches we demonstrate, for the first time, that the V domain of nectin1 acts as a major functional region involved in trans-heterointeraction with nectin4 and also nectin3.	INSERM, U119, Inst Cancerol & Immunol Marseille, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lopez, M (corresponding author), INSERM, U119, Inst Cancerol & Immunol Marseille, 27 Bd Lei Roure, F-13009 Marseille, France.		Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011; ADELAIDE, José JA/O-4390-2017	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; ADELAIDE, José JA/0000-0003-4364-9857				Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Cocchi F, 2001, J VIROL, V75, P7987, DOI 10.1128/JVI.75.17.7987-7994.2001; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Lopez M, 2001, J VIROL, V75, P5684, DOI 10.1128/JVI.75.12.5684-5691.2001; LOPEZ M, 1997, LEUKOCYTE TYPING, V6, P1081; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Menotti L, 2000, P NATL ACAD SCI USA, V97, P4867, DOI 10.1073/pnas.97.9.4867; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Watari Y, 1998, GENE, V224, P53, DOI 10.1016/S0378-1119(98)00527-7; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	35	226	240	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43205	43215		10.1074/jbc.M103810200	http://dx.doi.org/10.1074/jbc.M103810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11544254	hybrid			2022-12-25	WOS:000172169300075
J	Gao, XL; Satoh, T; Liao, YH; Song, CH; Hu, CD; Kariya, K; Kataoka, T				Gao, XL; Satoh, T; Liao, YH; Song, CH; Hu, CD; Kariya, K; Kataoka, T			Identification and characterization of RA-GEF-2, a Rap guanine nucleotide exchange factor that serves as a downstream target of M-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT ACTIVATION; KINASE ACTIVATION; ADENYLYL-CYCLASE; MAP KINASE; HA-RAS; FAMILY; INTERACTS; PROTEINS; DOMAIN	The Ras family small GTPase Rap is regulated by an array of specific guanine nucleotide exchange factors (GEFs) in response to upstream stimuli. RA-GEF-1 was identified as a novel Rap GEF, which possesses a Ras/Rap1-associating (RA) domain. Here we report a protein closely related to RA-GEF-1, named RA-GEF-2. Like RA-GEF-1, a putative cyclic nucleotide monophosphate-binding domain, a Ras exchanger motif, a PSD-95/D1gA/ZO-1 domain, and an RA domain in addition to the GEF catalytic domain are found in RA-GEF-2. However, RA-GEF-2 displays a different tissue distribution profile from that of RA-GEF-1. RA-GEF-2 stimulates guanine nucleotide exchange of both Rap1 and Rap2, but not Ha-Ras. The RA domain of RA-GEF-2 binds to M-Ras in a GTP-dependent manner, but not to other Ras family GTPases tested, including Ha-Ras, N-Ras, Rap1A, Rap2A, R-Ras, Ra1A, Rin, Rit, and Rheb, in contrast to the RA domain of RA-GEF-1, which specifically binds to Rap1. In accordance with this, RA-GEF-2 colocalizes with activated M-Ras in the plasma membrane in COS-7 cells, suggesting a role of RA-GEF-2 in the regulation of Rap1 and Rap2, particularly in the plasma membrane. In fact, an increase in the level of the GTP-bound form of plasma membrane-located Rap1 was observed when coexpressed with RA-GEF-2 and activated M-Ras. Thus, RA-GEF-2 acts as a GEF for Rap1 and Rap2 downstream of M-Ras in the plasma membrane, whereas RA-GEF-1 exerts Rap GEF function in perinuclear compartments including the Golgi apparatus.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,CHuo Ku, Kobe, Hyogo 6500017, Japan; Univ Ryukyus, Sch Med, Dept Biochem 2, Nishihara, Okinawa 9030215, Japan	Kobe University; University of the Ryukyus	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,CHuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Shima F, 2000, MOL CELL BIOL, V20, P26, DOI 10.1128/MCB.20.1.26-33.2000; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wienecke R, 1996, ONCOGENE, V13, P913; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	79	83	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42219	42225		10.1074/jbc.M105760200	http://dx.doi.org/10.1074/jbc.M105760200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11524421	hybrid			2022-12-25	WOS:000172450400091
J	Grahammer, F; Warth, R; Barhanin, J; Bleich, M; Hug, MJ				Grahammer, F; Warth, R; Barhanin, J; Bleich, M; Hug, MJ			The small conductance K+ channel, KCNQ1 - Expression, function, and subunit composition in murine trachea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CL SECRETION; POTASSIUM CHANNEL; EPITHELIAL-CELLS; AIRWAY EPITHELIA; MEMBRANE-PROTEIN; APICAL MEMBRANE; ION-TRANSPORT; RABBIT COLON; RAT; CALCIUM	The gene KCNQ1 encodes a K+ channel a-subunit important for cardiac repolarization, formerly known as K,LQT1. In large and small intestine a channel complex consisting of KCNQ1 and the beta -subunit KCNE3 (MiRP2) is known to mediate the cAMP-activated basolateral K+ current, which is essential for luminal Cl- secretion. Northern blot experiments revealed an expression of both subunits in lung tissue. However, previous reports suggested a role of KCNE1 (minK, Isk) but not KCNE3 in airway epithelial cells. Here we give evidence that KCNE1 is not detected in murine tracheal epithelial cells and that Cl- secretion by these cells is not reduced by the knock-out of the KCNE1 gene. In contrast we show that a complex consisting of KCNQ1 and KCNE3 probably forms a basolateral K+ channel in murine tracheal epithelial cells. As described for colonic epithelium, the current through KCNQ1 complexes in murine trachea is specifically inhibited by the chromanol 293B. A 293B-sensitive current was present after stimulation with forskolin and agonists that increase Ca2+ as well as after administration of the pharmacological K+ channel activator, 1-EBIO. A 293B-inhibitable current was already present under control conditions and reduced after administration of amiloride indicating a role of this K+ channel not only for Cl- secretion but also for Na+ reabsorption. We conclude that at least in mice a KCNQ1 channel complex seems to be the dominant basolateral K+ conductance in tracheal epithelial cells.	Univ Munster, Abt Vegetat Physiol, Inst Physiol, D-48149 Munster, Germany; Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Aventis Pharma Deutsch GmbH, D-65926 Frankfurt, Germany	University of Munster; University of Freiburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis	Hug, MJ (corresponding author), Univ Munster, Abt Vegetat Physiol, Inst Physiol, Robert Koch Str 27A, D-48149 Munster, Germany.	hugma@uni-muenster.de	Warth, Richard/N-7119-2014; Bleich, Markus/A-2812-2010; Grahammer, Florian/ABB-7775-2021	Warth, Richard/0000-0001-6084-0659; Bleich, Markus/0000-0002-1745-2295; 				Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Adeagbo ASO, 1999, EUR J PHARMACOL, V379, P151, DOI 10.1016/S0014-2999(99)00489-6; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Arrighi I, 2001, P NATL ACAD SCI USA, V98, P8792, DOI 10.1073/pnas.141233398; Bleich M, 2000, PFLUG ARCH EUR J PHY, V440, P202, DOI 10.1007/s004240000257; Bleich M, 1997, PFLUG ARCH EUR J PHY, V434, P499, DOI 10.1007/s004240050427; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; ECKE D, 1995, CELL PHYSIOL BIOCHEM, V5, P204, DOI 10.1159/000154755; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Greger R, 1996, PFLUG ARCH EUR J PHY, V432, P579, DOI 10.1007/s004240050173; Greger R, 2000, ANNU REV PHYSIOL, V62, P467, DOI 10.1146/annurev.physiol.62.1.467; GREGER R, 1983, B MT DESERT ISL BIOL, V23, P8; Grubb BR, 2001, AM J PHYSIOL-CELL PH, V281, pC615, DOI 10.1152/ajpcell.2001.281.2.C615; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Hwang TH, 1996, J MEMBRANE BIOL, V154, P251, DOI 10.1007/s002329900149; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; JORIS L, 1989, PFLUG ARCH EUR J PHY, V415, P118, DOI 10.1007/BF00373149; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LI DC, 2000, AM J PHYSIOL, V279, pL14; Lock H, 2000, J BIOL CHEM, V275, P34849, DOI 10.1074/jbc.C000633200; LOHRMANN E, 1995, PFLUG ARCH EUR J PHY, V429, P517, DOI 10.1007/BF00704157; MacVinish LJ, 1998, J PHYSIOL-LONDON, V510, P237, DOI 10.1111/j.1469-7793.1998.237bz.x; Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Suessbrich H, 1999, Rev Physiol Biochem Pharmacol, V137, P191; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Vallon V, 2001, J AM SOC NEPHROL, V12, P2003, DOI 10.1681/ASN.V12102003; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Warth R, 1996, PFLUG ARCH EUR J PHY, V432, P81, DOI 10.1007/s004240050108; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	44	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42268	42275		10.1074/jbc.M105014200	http://dx.doi.org/10.1074/jbc.M105014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11527966	hybrid			2022-12-25	WOS:000172450400097
J	Wang, X; Yeh, SY; Wu, G; Hsu, CL; Wang, L; Chiang, TY; Yang, Y; Guo, YL; Chang, CS				Wang, X; Yeh, SY; Wu, G; Hsu, CL; Wang, L; Chiang, TY; Yang, Y; Guo, YL; Chang, CS			Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SET DOMAIN; DROSOPHILA-TRITHORAX; TUMOR-SUPPRESSOR; GROWTH-CONTROL; DU145 CELLS; COACTIVATOR; GENE; PROTEIN; CLONING; TRANSACTIVATION	The androgen receptor (AR) is a member of the steroid receptor superfamily that binds to the androgen response element to regulate target gene transcription. AR may need to interact with some selected coregulators for maximal or proper androgen function. Here we report the isolation of a new AR coregulator with a calculated molecular mass of 267 kDa named the androgen receptor-associated protein 267-alpha (ARA267-alpha). ARA267-alpha contains 2427 amino acids, including one Su(var)3-9, Enhancer-of-zeste, and Trithorax (SET) domain, two LXXLL motifs, three nuclear translocation signal (NLS) sequences, and four plant homodomain (PHD) finger domains. Northern blot analyses reveal that ARA267-alpha is expressed predominantly in the lymph node as 13- and 10-kilobase transcripts. HepG2 is the only cell line tested that does not express ARA267-alpha. Yeast two-hybrid and glutathione S-transferase pull-down assays show that both the N and C terminus of ARA267-alpha interact with the AR DNA- and ligand-binding domains. Unlike other coregulators, such as CBP, which enhance the interaction between the N and C terminus of AR, we found that ARA267-alpha had little influence on the interaction between the N and C terminus of AR. Luciferase and chloramphenicol acetyltransferase assays show that ARA267-alpha can enhance AR transactivation in a dihydrotestosterone-dependent manner in PC-3 and H1299 cells. ARA267-alpha can also enhance AR transactivation with other coregulators, such as ARA24 or PCAF, a histone acetylase, in an additive manner. Together, our data demonstrate that ARA267-alpha is a new AR coregulator containing the SET domain with an exceptionally large molecular mass that can enhance AR transactivation in prostate cancer cells.	Univ Rochester, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, Rochester, NY 14642 USA; Peking Univ, Hosp 1, Beijing 100034, Peoples R China; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; Peking University; University of Rochester	Chang, CS (corresponding author), Univ Rochester, George Whipple Lab Canc Res, Rochester, NY 14642 USA.				NCI NIH HHS [CA71570] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AGOULNIK I, 2000, KEYST STER S STEAMB; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Hsing AW, 2000, CANCER RES, V60, P5111; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; Truica CI, 2000, CANCER RES, V60, P4709; Yeh S, 2000, J FORMOS MED ASSOC, V99, P885; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	38	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40417	40423		10.1074/jbc.M104765200	http://dx.doi.org/10.1074/jbc.M104765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11509567	hybrid			2022-12-25	WOS:000171925600010
J	Ackermann, M; Padmanabhan, R				Ackermann, M; Padmanabhan, R			De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HEPATITIS-C VIRUS; STEM-LOOP STRUCTURE; YELLOW-FEVER VIRUS; PUTATIVE METHYLTRANSFERASE DOMAIN; RIBONUCLEIC-ACID POLYMERASE; FLAVIVIRUS GENOMIC RNA; PROTEIN 5B POLYMERASE; IN-VITRO; POLIOVIRUS RNA; SECONDARY STRUCTURE	Replication of positive strand flaviviruses is mediated by the viral RNA-dependent RNA polymerases (RdRP). To study replication of dengue virus (DEN), a flavivirus family member, an in vitro RdRP assay was established using cytoplasmic extracts of DEN-infected mosquito cells and viral subgenomic RNA templates containing 5'-and 3'-terminal regions (TRs). Evidence supported that an interaction between the TRs containing conserved stem-loop, cyclization motifs, and pseudoknot structural elements is required for RNA synthesis. Two RNA products, a template size and a hairpin, twice that of the template, were formed. To isolate the function of the viral RdRP (NS5) from that of other host or viral factors present in the cytoplasmic extracts, the NS5 protein was expressed and purified from Escherichia coli. In this study, we show that the purified NS5 alone is sufficient for the synthesis of the two products and that the template-length RNA is the product of de novo initiation. Furthermore, the incubation temperature during initiation, but not elongation phase of RNA synthesis modulates the relative amounts of the hairpin and de novo RNA products. A model is proposed that a specific conformation of the viral polymerase and/or structure at the 3' end of the template RNA is required for de novo initiation.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rpadmana@kumc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078, R01AI045623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-45623, AI-32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BARTHOLOMEUSZ AI, 1993, ARCH VIROL, V128, P111, DOI 10.1007/BF01309792; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; BLACKWELL JL, 1995, J VIROL, V69, P5650, DOI 10.1128/JVI.69.9.5650-5658.1995; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BLUMENTHAL T, 1980, J BIOL CHEM, V255, P1713; BRINTON MA, 1986, VIROLOGY, V153, P113, DOI 10.1016/0042-6822(86)90012-7; BRINTON MA, 1988, VIROLOGY, V162, P290, DOI 10.1016/0042-6822(88)90468-0; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; CLEAVES GR, 1981, VIROLOGY, V111, P73, DOI 10.1016/0042-6822(81)90654-1; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; DYNAN WS, 1979, BIOCHEMISTRY-US, V18, P4581, DOI 10.1021/bi00588a019; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; Gluick TC, 1997, BIOCHEMISTRY-US, V36, P16173, DOI 10.1021/bi971362v; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRUN JB, 1986, J VIROL, V60, P1113, DOI 10.1128/JVI.60.3.1113-1124.1986; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAHN CS, 1987, J MOL BIOL, V198, P33, DOI 10.1016/0022-2836(87)90455-4; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; HEY TD, 1987, J VIROL, V61, P802, DOI 10.1128/JVI.61.3.802-811.1987; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hsue B, 1998, ADV EXP MED BIOL, V440, P297; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kadare G, 1997, J VIROL, V71, P2583; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Kautner I, 1997, J PEDIATR-US, V131, P516, DOI 10.1016/S0022-3476(97)70054-4; Khromykh AA, 2001, J VIROL, V75, P6719, DOI 10.1128/JVI.75.14.6719-6728.2001; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LUBINSKI JM, 1987, J VIROL, V61, P2997, DOI 10.1128/JVI.61.10.2997-3003.1987; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; MOHAN PM, 1991, GENE, V108, P185, DOI 10.1016/0378-1119(91)90433-C; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; NAKHASI HL, 1991, J VIROL, V65, P5961, DOI 10.1128/JVI.65.11.5961-5967.1991; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Osman TAM, 1996, J VIROL, V70, P6227, DOI 10.1128/JVI.70.9.6227-6234.1996; PARDIGON N, 1992, J VIROL, V66, P1007, DOI 10.1128/JVI.66.2.1007-1015.1992; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; QUADT R, 1993, P NATL ACAD SCI USA, V90, P1498, DOI 10.1073/pnas.90.4.1498; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; SANKAR S, 1991, J VIROL, V65, P2993, DOI 10.1128/JVI.65.6.2993-3000.1991; Schuppli D, 1998, J MOL BIOL, V283, P585, DOI 10.1006/jmbi.1998.2123; Shi PY, 1996, BIOCHEMISTRY-US, V35, P4222, DOI 10.1021/bi952398v; Singh RN, 1997, VIROLOGY, V233, P430, DOI 10.1006/viro.1997.8621; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P8792, DOI 10.1073/pnas.91.19.8792; SONG CZ, 1995, J MOL BIOL, V254, P6, DOI 10.1006/jmbi.1995.0594; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Stewart SR, 1998, NUCLEIC ACIDS RES, V26, P5318, DOI 10.1093/nar/26.23.5318; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; WU SX, 1991, VIROLOGY, V183, P392, DOI 10.1016/0042-6822(91)90153-3; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; You S, 1999, J BIOL CHEM, V274, P33714, DOI 10.1074/jbc.274.47.33714; You SY, 2001, J BIOL CHEM, V276, P15581, DOI 10.1074/jbc.M010923200; Zeng LL, 1998, J VIROL, V72, P7510, DOI 10.1128/JVI.72.9.7510-7522.1998; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	112	245	257	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39926	39937		10.1074/jbc.M104248200	http://dx.doi.org/10.1074/jbc.M104248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546770	hybrid			2022-12-25	WOS:000171789200058
J	Manna, T; Sarkar, T; Poddar, A; Roychowdhury, M; Das, KP; Bhattacharyya, B				Manna, T; Sarkar, T; Poddar, A; Roychowdhury, M; Das, KP; Bhattacharyya, B			Chaperone-like activity of tubulin - Binding and reactivation of unfolded substrate enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; CYTOPLASMIC CHAPERONIN; ESCHERICHIA-COLI; PROTEIN; GROEL; AGGREGATION; POLYMERIZATION	The eukaryotic cytoskeletal protein tubulin is a heterodimer of two subunits, alpha and beta, and is a building block unit of microtubules. In a previous communication we demonstrated that tubulin possesses chaperone-like activities by preventing the stress-induced aggregation of various proteins (Guha, S., Manna, T. K., Das, K. P., and Bhattacharyya, B. (1998) J. Biol. Chem. 273, 30077-30080). As an extension of this observation, we explored whether tubulin, like other known chaperones, also protected biological activity of proteins against thermal stress or increased the yields of active proteins during refolding from a denatured state. We show here that tubulin not only prevents the thermal aggregation of alcohol dehydrogenase and malic dehydrogenase but also protects them from loss of activity. We also show that tubulin prevents the aggregation of substrates during their refolding from a denatured state and forms a stable complex with denatured substrate. The activity of malic dehydrogenase, a-glucosidase, and lactate dehydrogenase during their refolding from urea or guanidium hydrochloride denatured states increased significantly in presence of tubulin compared with that without tubulin. These results suggest that tubulin, in addition to its role in mitosis, cell motility, and other cellular events, might be implicated in protein folding and protection from stress.	Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India; Bose Inst, Dept Chem, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute	Bhattacharyya, B (corresponding author), Bose Inst, Dept Biochem, Centenary Campus,P-1-12 CIT Scheme VIIM, Kolkata 700054, W Bengal, India.	bablu@boseinst.ernet.in		Manna, Tapas/0000-0002-2213-6246; Das, Kali/0000-0001-7686-9077				BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; Bhattacharyya J, 1999, J BIOL CHEM, V274, P15505, DOI 10.1074/jbc.274.22.15505; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHATTOPADHYAY S, 1994, BIOCHEM J, V300, P717, DOI 10.1042/bj3000717; Ellis RJ, 1996, SCIENCE, V272, P1448; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; GNAGLIARDI A, 1995, J BIOL CHEM, V270, P28126; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; HAMEL E, 1981, ARCH BIOCHEM BIOPHYS, V209, P29, DOI 10.1016/0003-9861(81)90253-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JACOB U, 1995, J BIOL CHEM, V270, P7288; JACOB U, 1994, TRENDS BIOCHEM SCI, V19, P205; JACOB U, 1993, J BIOL CHEM, V268, P1517; JAENICKE R, 1990, PROTEIN STRUCTURE PR, P191; KOPETZKI E, 1989, MOL GEN GENET, V216, P149, DOI 10.1007/BF00332244; LOWRY OH, J BIOL CHEM, V193, P265; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Pal S, 1999, J BIOL CHEM, V274, P32771, DOI 10.1074/jbc.274.46.32771; PONTINGEL H, 1983, J SUBMICR CYTOL PATH, V15, P359; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Szebeni A, 1999, PROTEIN SCI, V8, P905; TAGUCHI H, 1994, J BIOL CHEM, V269, P8529; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WARD LD, 1994, BIOCHEMISTRY-US, V33, P11891, DOI 10.1021/bi00205a027; WEICH H, 1992, NATURE, V358, P169; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	39	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39742	39747		10.1074/jbc.M104061200	http://dx.doi.org/10.1074/jbc.M104061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11509563	hybrid			2022-12-25	WOS:000171789200032
J	Nagaike, T; Suzuki, T; Tomari, Y; Takemoto-Hori, C; Negayama, F; Watanabe, K; Ueda, T				Nagaike, T; Suzuki, T; Tomari, Y; Takemoto-Hori, C; Negayama, F; Watanabe, K; Ueda, T			Identification and characterization of mammalian mitochondrial tRNA nucleotidyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RIBONUCLEIC-ACID; TANDEM-MASS-SPECTROMETRY; ESCHERICHIA-COLI; PROTEIN-COMPONENTS; RIBOSOMAL-RNA; ACTIVE-SITE; 3' TERMINUS; SEQUENCE; GENE; PURIFICATION	The CCA-adding enzyme (ATP:tRNA adenylyltransferase or CTP:tRNA cytidylyltransferase (EC 2.7.7.25)) generates the conserved CCA sequence responsible for the attachment of amino acid at the 3' terminus of tRNA molecules. It was shown that enzymes from various organisms strictly recognize the elbow region of tRNA formed by the conserved D- and T-loops. However, most of the mammalian mitochondrial (mt) tRNAs lack consensus sequences in both D- and T-loops. To characterize the mammalian mt CCA-adding enzymes, we have partially purified the enzyme from bovine liver mitochondria and determined cDNA sequences from human and mouse dbESTs by mass spectrometric analysis. The identified sequences contained typical amino-terminal peptides for mitochondrial protein import and had characteristics of the class II nucleotidyltransferase superfamily that includes eukaryotic and eubacterial CCA-adding enzymes. The human recombinant enzyme was overexpressed in Escherichia coli, and its CCA-adding activity was characterized using several int tRNAs as substrates. The results clearly show that the human mt CCA-adding enzyme can efficiently repair mt tRNAs that are poor substrates for the E. coli enzyme although both enzymes work equally well on cytoplasmic tRNAs. This suggests that the mammalian mt enzymes have evolved so as to recognize mt tRNAs with unusual structures.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Kashiwa, Chiba 2778562, Japan; RIKEN, Genom Sci Ctr, Tsurumi Ku, Kanagawa 2300045, Japan	University of Tokyo; University of Tokyo; RIKEN	Suzuki, T (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bldg FSB-301,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	t-suzuki@k.u-tokyo.ac.jp	Tomari, Yukihide/A-8009-2009; Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Tomari, Yukihide/0000-0001-8442-0851; Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; CHUNG HKJ, 1990, J BIOL CHEM, V265, P21000; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Deng XY, 2000, YEAST, V16, P945; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P450; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; KEITH G, 1974, BIOCHEMISTRY-US, V13, P3601, DOI 10.1021/bi00714a031; KUMAZAWA Y, 1991, J BIOCHEM, V109, P421, DOI 10.1093/oxfordjournals.jbchem.a123397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li ZL, 1996, BIOCHEM J, V314, P49, DOI 10.1042/bj3140049; Liu JCH, 1998, RNA, V4, P639, DOI 10.1017/S1355838298980013; MARCHFELDER A, 1994, PLANT PHYSIOL, V105, P1247, DOI 10.1104/pp.105.4.1247; MASIAKOWSKI P, 1980, J BIOL CHEM, V255, P1233; MASIAKOWSKI P, 1980, J BIOL CHEM, V255, P1240; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; MUKERJI SK, 1972, J BIOL CHEM, V247, P481; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Raynal LC, 1999, MOL MICROBIOL, V32, P765, DOI 10.1046/j.1365-2958.1999.01394.x; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; SPACCIAPOLI P, 1989, J BIOL CHEM, V264, P3799; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; TAMURA K, 1994, J BIOL CHEM, V269, P22173; Tolkunova E, 2000, J BIOL CHEM, V275, P35063, DOI 10.1074/jbc.M006265200; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; Yue DX, 1996, RNA, V2, P895	44	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40041	40049		10.1074/jbc.M106202200	http://dx.doi.org/10.1074/jbc.M106202200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11504732	hybrid			2022-12-25	WOS:000171789200073
J	Oram, JF; Vaughan, AM; Stocker, R				Oram, JF; Vaughan, AM; Stocker, R			ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tecopherol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOCOPHEROL TRANSFER PROTEIN; TANGIER-DISEASE; DENSITY-LIPOPROTEIN; VITAMIN-E; CHOLESTEROL EFFLUX; II PNEUMOCYTES; CELLS; MACROPHAGES; MUTATIONS; RECEPTOR	Alpha -Tocopherol (alpha -TOH) is associated with plasma lipoproteins and accumulates in cell membranes throughout the body, suggesting that lipoproteins play a role in transporting alpha -TOH between tissues. Here we show that secretion of alpha -TOH from cultured cells is mediated in part by ABCA1, an ATP-binding cassette protein that transports cellular cholesterol and phospholipids to lipid-poor high density lipoprotein (HDL) apolipoproteins such as apoA-i. Treatment of human fibroblasts and murine RAW264 macrophages with cholesterol and/or 8-bromo-cyclic AMP, which induces ABCA1 expression, enhanced apoA-1-mediated alpha -TOH efflux. ApoA-I lacked the ability to remove alpha -TOH from Tangier disease fibroblasts that have a nonfunctional ABCA1 BHK cells that lack an active ABCA1 pathway markedly increased secretion of alpha -TOH to apoA-1 when forced to express ABCA1 ABCA1 also mediated a fraction of the alpha -TOH efflux promoted by lipid-containing HDL particles, indicating that HDL promotes alpha -TOH efflux by both ABCA1-dependent and -independent processes. Exposing apoA-1 to ABCA1-expressing cells did not enhance its ability to remove alpha -TOH from cells lacking ABCA1, consistent with this transporter participating directly in the translocation of alpha -TOH to apolipoproteins. These studies provide evidence that ABCA1 mediates secretion of cellular alpha -TOH into the HDL metabolic pathway, a process that may facilitate vitamin transport between tissues and influence lipid oxidation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Heart Res Inst, Biochem Grp, Sydney, NSW 2050, Australia	University of Washington; University of Washington Seattle; University of Sydney; Heart Research Institute	Oram, JF (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.		Stocker, Roland/AAV-4489-2021		NHLBI NIH HHS [HL 18645, HL 55362] Funding Source: Medline; NIDDK NIH HHS [DK 02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL055362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arita M, 1997, P NATL ACAD SCI USA, V94, P12437, DOI 10.1073/pnas.94.23.12437; Asmis R, 2000, ARTERIOSCL THROM VAS, V20, P2078, DOI 10.1161/01.ATV.20.9.2078; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CATIGNANI GL, 1977, BIOCHIM BIOPHYS ACTA, V497, P349, DOI 10.1016/0304-4165(77)90192-1; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Goti D, 1998, BIOCHEM J, V332, P57, DOI 10.1042/bj3320057; Guthmann F, 1997, EUR J CELL BIOL, V74, P197; KAYDEN HJ, 1993, J LIPID RES, V34, P343; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Nakamura T, 1998, LIPIDS, V33, P1001, DOI 10.1007/s11745-998-0298-3; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; Oram J F, 1986, Methods Enzymol, V129, P645; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Witt W, 2000, J LIPID RES, V41, P2009	32	146	149	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					39898	39902		10.1074/jbc.M106984200	http://dx.doi.org/10.1074/jbc.M106984200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11546785	hybrid			2022-12-25	WOS:000171789200054
J	Mehta, PB; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Robson, CN; Neal, DE; Leung, HY			Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells	ONCOGENE			English	Article						fibroblast growth factor; mitogen-activated protein kinase; Elk-1; MEF2A; actin; prostate	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; KINASE PATHWAYS; PROTEIN-KINASES; POINT MUTATION; FGF RECEPTORS; EXPRESSION; TRANSCRIPTION; CANCER; PROLIFERATION	FGF7/Keratinocyte growth factor (KGF) regulates the differentiation and development of the prostate epithelium, while over-expression of FGF8 and FGF1 are implicated in carcinogenesis of the prostate. We tested the hypothesis that different members of the FGF family function through different signalling molecules. In prostate DU145 cells, both FGF1 and FGF2 activated ERK1/2 potently and p38 moderately. KGF was however most efficient in inducing p38 activities but had no effect on ERK1/2 function. JNK and STAT activities were not induced by FGFs in prostate cells. fn vitro expression of the transcription factors Elk-1 and MEF2A (substrates for ERK1/2 and p38, respectively) for functional quantification, confirmed the pattern of FGF-induced MAPK activations in COS-7 cells. Furthermore, KGF was more efficient than FGF1 and FGF2 in inducing actin stress fibres, and the specific p38 inhibitor SB202190 completely abolished this in a dose-dependent manner. The MEK1/2 inhibitor, U0126, had no effect on FGF-induced stress fibre formation. This study demonstrates the selective activation of MAPK family members by FGFs resulting in activation of transcription factors and stress fibre formation. As multiple FGFs are overexpressed in human prostate cancer, characterization of the distinct signalling pathway by FGFs may reveal new specific targets for therapy.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Carstens RP, 1997, J AM SOC NEPHROL, V8, pA1849; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Feng SJ, 1997, CANCER RES, V57, P5369; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Matsubara A, 1998, CANCER RES, V58, P1509; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Velmuri GS, 1996, BIOCHEM J, V314, P805, DOI 10.1042/bj3140805; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	36	37	37	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5359	5365		10.1038/sj.onc.1204688	http://dx.doi.org/10.1038/sj.onc.1204688			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536048				2022-12-25	WOS:000170575500011
J	Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG				Janicke, RU; Engels, IH; Dunkern, T; Kaina, B; Schulze-Osthoff, K; Porter, AG			Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells	ONCOGENE			English	Article						apoptosis; intrinsic death pathway; DNA; damage; cell cycle arrest	CYTOCHROME-C RELEASE; ETOPOSIDE-INDUCED APOPTOSIS; HUMAN LYMPHOMA-CELLS; CASPASE ACTIVATION; TUMOR-CELLS; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; THYMOCYTE APOPTOSIS; DEPENDENT APOPTOSIS; SIGNALING COMPLEX	There is considerable evidence that ionizing radiation (IR) and chemotherapeutic drugs mediate apoptosis through the intrinsic death pathway via the release of mitochondrial cytochrome c and activation of caspases-9 and -3. Here we show that MCF-7 cells that lack caspase-3 undergo a caspase-dependent apoptotic cell death in the absence of DNA fragmentation and x-fodrin cleavage following treatment with etoposide or doxorubicin, but not after exposure to IR. Re-expression of caspase-3 restored DNA fragmentation and a-fodrin cleavage following drug treatment, but it did not alter the radiation-resistant phenotype of these cells. In contrast to the anticancer drugs, IR failed to induce the intrinsic death pathway in MCF-7/casp-3 cells, an event readily observed in IR-induced apoptosis of HeLa cells. Although IR-induced DNA double-strand breaks were repaired with similar efficiencies in all cell lines, cell cycle analyses revealed a persistent G2/M arrest in the two MCF-7 cell lines, but not in HeLa cells. Together, our data demonstrate that caspase-3 is required for DNA fragmentation and a-fodrin cleavage in drug-induced apoptosis and that the intrinsic death pathway is fully functional in MCF-7 cells. Furthermore, they show that the radiation-resistant phenotype of MCF-7 cells is not due to the lack of caspase-3, but is caused by the failure of IR to activate the intrinsic death pathway. We propose (1) different signaling pathways are induced by anticancer drugs and IR, and (2) IR-induced G2/M arrest prevents the generation of an apoptotic signal required for the activation of the intrinsic death pathway.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Munster; Johannes Gutenberg University of Mainz; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Janicke, RU (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fuchs EJ, 1997, CANCER RES, V57, P2550; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Heenan M, 1996, CYTOTECHNOLOGY, V19, P237, DOI 10.1007/BF00744218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; LEHNERT S, 1989, RADIAT RES, V118, P568, DOI 10.2307/3577414; Levenson AS, 1997, CANCER RES, V57, P3071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OSHITA F, 1992, J CANCER RES CLIN, V119, P28, DOI 10.1007/BF01209484; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Schmitt CA, 1999, J PATHOL, V187, P127; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yu YJ, 1998, CANCER RES, V58, P4277; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	64	69	72	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5043	5053		10.1038/sj.onc.1204659	http://dx.doi.org/10.1038/sj.onc.1204659			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526489				2022-12-25	WOS:000170439800014
J	Garcia-Martinez, C; Sibille, B; Solanes, G; Darimont, C; Mace, K; Villarroya, F; Gomez-Foix, AM				Garcia-Martinez, C; Sibille, B; Solanes, G; Darimont, C; Mace, K; Villarroya, F; Gomez-Foix, AM			Overexpression of UCP3 in cultured human muscle lowers mitochondrial membrane potential, raises ATP/ADP ratio, and favors fatty acid versus glucose oxidation	FASEB JOURNAL			English	Article						oleate; glycolytic rate; nutrient oxidation; glycolysis	UNCOUPLING PROTEIN-3 GENE; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; EXPRESSION; HEPATOCYTES; OBESITY; 2,4-DINITROPHENOL; THERMOGENESIS; ACTIVATION; TRANSPORT	The skeletal muscle mitochondrial uncoupling protein-3 (UCP3) promotes substrate oxidation, but direct evidence for its metabolic role is lacking. Here, we show that UCP3 overexpression in cultured human muscle cells decreased mitochondrial membrane potential (Delta Psim). Despite this, the ATP content was not significantly decreased compared with control cells, whereas ADP content was reduced and thus the ATP/ADP ratio raised. This finding was in contrast with the effect caused by the chemical protonophoric uncoupler, CCCP, which lowered Delta Psim, ATP, and the ATP/ADP ratio. UCP3-overexpression enhanced oxidation of oleate, regardless of the presence of glucose, whereas etomoxir, which blocks fatty acid entry to mitochondria, suppressed the UCP3 effect. Glucose oxidation was stimulated in UCP3-overexpressing cells, but this effect was inhibited by oleate. UCP3 caused weak increase of both 2-Deoxyglucose uptake and glycolytic rate, which differed from the marked stimulation by CCCP. We concluded that UCP3 promoted nutrient oxidation by lowering Delta Psim and enhanced fatty acid-dependent inhibition of glucose oxidation. Unlike the uncoupler CCCP, however, UCP3 raised the ATP/ADP ratio and modestly increased glucose uptake and glycolysis. We propose that this differential effect provides a biological significance to UCP3, which is up-regulated in metabolic stress situations where it could be involved in nutrient partitioning.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Lyon 1, Lab Physiol & Regulat Energet Cellulaires & Mol, F-69622 Villeurbanne, France	University of Barcelona; Nestle SA; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gomez-Foix, AM (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.	anamaria@sun.bq.ub.es	Sibille, Brigitte/Q-8240-2016; Martinez, Celia Garcia/G-9536-2017; Villarroya, Francesc/K-4357-2014	Sibille, Brigitte/0000-0001-6806-0454; Martinez, Celia Garcia/0000-0002-5267-0191; Villarroya, Francesc/0000-0003-1266-9142				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Askanas V, 1992, HDB CLIN NEUROL, P85; Bao S, 1998, DIABETES, V47, P1935, DOI 10.2337/diabetes.47.12.1935; Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Brun S, 1999, FEBS LETT, V453, P205, DOI 10.1016/S0014-5793(99)00722-X; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; MA SW, 1986, CAN J PHYSL PHARM, V9, P1252; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; MUOIO DM, 2000, KEYST S MOL CONTR AD, P143; Otabe S, 2000, DIABETOLOGIA, V43, P245, DOI 10.1007/s001250050037; Otabe S, 1999, DIABETES, V48, P206; Pierrat B, 2000, EUR J BIOCHEM, V267, P2680, DOI 10.1046/j.1432-1327.2000.01285.x; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RIGOULET M, 1989, BIOCHIM BIOPHYS ACTA, V975, P325, DOI 10.1016/S0005-2728(89)80339-1; Samec S, 1999, PFLUG ARCH EUR J PHY, V438, P452, DOI 10.1007/s004240051061; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SIBILLE B, 1995, EUR J BIOCHEM, V231, P498, DOI 10.1111/j.1432-1033.1995.tb20724.x; Solanes G, 2000, FASEB J, V14, P2141; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; WINTER CG, 1994, ARCH BIOCHEM BIOPHYS, V314, P17, DOI 10.1006/abbi.1994.1406	38	85	90	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					2033	+		10.1096/fj.00-0828fje	http://dx.doi.org/10.1096/fj.00-0828fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11511517				2022-12-25	WOS:000170318500012
